{
 "cells": [
  {
   "attachments": {},
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Clinical Text Representation\n",
    "\n",
    "`What is clinical text?`\n",
    "* Clinical text are words and sentences from clinical narratives \n",
    "* Narratives such as case notes, family history, laboratory reports \n",
    "* Can be electronic or handwritten format\n",
    "\n",
    "`What is different about clinical text?`\n",
    "* Domain nuances\n",
    "* Notations and abbreviations \n",
    "* Making sense of this text is important in designing pipeplines and how data pre-processing is done.\n",
    "\n",
    "`Types of text representation`\n",
    "\n",
    "There are different techniques for text representation. The decision on which to apply is dependent on:\n",
    "* Practicality\n",
    "* Team experience \n",
    "* Availability\n",
    "* Cost of computation\n",
    "\n",
    "Techniques used:\n",
    "* One-hot encoding: based on binary vectors\n",
    "* Count vectors: based on frequency, such as BoW and TF-IDF\n",
    "* Embedding: encodes context for words and sentences "
   ]
  },
  {
   "attachments": {},
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "This notebook explores entering custom fast text models on clinical data. \n",
    "\n",
    "Sample data from `STI Treatment Guidelines`"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "import nltk\n",
    "# nltk.download('punkt')\n",
    "from pprint import pprint\n",
    "from gensim.models import FastText\n",
    "import fasttext\n",
    "from nltk import word_tokenize\n",
    "import tika\n",
    "from tika import parser\n",
    "import string\n",
    "from sklearn.decomposition import PCA\n",
    "import matplotlib.pyplot as plt"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "2023-01-26 09:52:03,943 [MainThread  ] [WARNI]  Failed to see startup log message; retrying...\n"
     ]
    }
   ],
   "source": [
    "raw_text = parser.from_file('data/STI-Guidelines-2021.pdf')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "<class 'dict'>\n"
     ]
    }
   ],
   "source": [
    "# tika parser returns a dictionary\n",
    "print(type(raw_text))\n",
    "\n",
    "# Returned dictionary contains metadata and content \n",
    "# print(raw_text.items())"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "23392\n",
      "follow-up titer should not be repeated until approximately \n"
     ]
    }
   ],
   "source": [
    "# Here i will pre-process the data by lowering the case and strip-\n",
    "# punctuations and then convert it back to string from the list format. \n",
    "rawtext_list = raw_text['content'].splitlines()\n",
    "rawtext_list = [item.lower() for item in rawtext_list if item.strip()]\n",
    "\n",
    "print(len(rawtext_list))\n",
    "\n",
    "# sample sentence \n",
    "print(rawtext_list[5000])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "1294718"
      ]
     },
     "execution_count": 5,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# Join list of sentences into a string \n",
    "sti_str = ' '.join(rawtext_list)\n",
    "for c in string.punctuation:\n",
    "    # remove punctuations \n",
    "    sti_str = sti_str.replace(c, \"\")\n",
    "len(sti_str)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "('sexually transmitted infections treatment guidelines 2021 morbidity and '\n",
      " 'mortality weekly report recommendations and reports  vol 70  no 4 july 23 '\n",
      " '2021  sexually transmitted infections treatment  guidelines 2021 us '\n",
      " 'department of health and human services centers for disease control and '\n",
      " 'prevention the mmwr series of publications is published by the center for '\n",
      " 'surveillance epidemiology and laboratory services centers for disease '\n",
      " 'control and prevention cdc  us department of health and human services '\n",
      " 'atlanta ga 303294027 suggested citation author names first three then et al '\n",
      " 'if more than six title mmwr recomm rep 202170no rrinclusive page numbers '\n",
      " 'centers for disease control and prevention rochelle p walensky md mph '\n",
      " 'director debra houry md mph acting principal deputy director daniel b '\n",
      " 'jernigan md mph acting deputy director for public health science and '\n",
      " 'surveillance rebecca bunnell phd med director office of science jennifer '\n",
      " 'layden md phd deputy director office of science michael f iademarco md mph '\n",
      " 'director center for surveillance epidemiology and laboratory services  mmwr '\n",
      " 'editorial and production staff serials charlotte k kent phd mph editor in '\n",
      " 'chief  christine g casey md editor mary dott md mph online editor terisa f '\n",
      " 'rutledge managing editor david c johnson lead technical writereditor marella '\n",
      " 'meadows project editor martha f boyd lead visual information specialist '\n",
      " 'alexander j gottardy maureen a leahy julia c martinroe stephen r spriggs '\n",
      " 'tong yang visual information specialists quang m doan mba phyllis h king  '\n",
      " 'terraye m starr moua yang information technology specialists  mmwr editorial '\n",
      " 'board timothy f jones md chairman matthew l boulton md mph carolyn brooks '\n",
      " 'scd ma  jay c butler md  virginia a caine md  jonathan e fielding md mph mba '\n",
      " 'david w fleming md  william e halperin md drph mph jewel mullen md mph mpa '\n",
      " 'jeff niederdeppe phd celeste philip md mph patricia quinlisk md mph  patrick '\n",
      " 'l remington md mph  carlos roig ms ma william schaffner md  nathaniel smith '\n",
      " 'md mph morgan bobb swanson bs abbigail tumpey mph ian branam ma acting '\n",
      " 'lead   health communication specialist shelton bartley mph lowery johnson '\n",
      " 'amanda ray  jacqueline n sanchez ms health communication specialists will '\n",
      " 'yang ma visual information specialist recommendations and reports contents '\n",
      " 'introduction 1 methods 1 clinical prevention guidance 2 sti detection among '\n",
      " 'special populations  11 hiv infection  24 diseases characterized by genital '\n",
      " 'anal or perianal ulcers  27 syphilis  39 management of persons who have a '\n",
      " 'history of penicillin allergy  56 diseases characterized by urethritis and '\n",
      " 'cervicitis  60 chlamydial infections  65 gonococcal infections  71 '\n",
      " 'mycoplasma genitalium  80 diseases characterized by vulvovaginal itching '\n",
      " 'burning irritation  odor or discharge  82 pelvic inflammatory disease  94 '\n",
      " 'epididymitis  98 human papillomavirus infections 100 viral hepatitis 113 '\n",
      " 'proctitis proctocolitis and enteritis 124 ectoparasitic infections 126 '\n",
      " 'sexual assault and abuse and stis 128 references 135 recommendations and '\n",
      " 'reports mmwr  july 23 2021  vol 70  no 4 1us department of health and human '\n",
      " 'servicescenters for disease control and prevention sexually transmitted '\n",
      " 'infections treatment guidelines 2021 kimberly a workowski md12 laura h '\n",
      " 'bachmann md1 philip a chan md13 christine m johnston md14 christina a muzny '\n",
      " 'md15   ina park md16 hilary reno md17 jonathan m zenilman md18 gail a bolan '\n",
      " 'md1 1division of std prevention national center for hivaids viral hepatitis '\n",
      " 'std and tb prevention cdc atlanta georgia 2emory university atlanta georgia  '\n",
      " '3brown university providence rhode island 4university of washington seattle '\n",
      " 'washington 5university of alabama at birmingham birmingham alabama   '\n",
      " '6university of california san francisco san francisco california 7washington '\n",
      " 'university st louis missouri 8johns hopkins university baltimore maryland '\n",
      " 'summary these guidelines for the treatment of persons who have or are at '\n",
      " 'risk for sexually transmitted infections stis were updated by  cdc after '\n",
      " 'consultation with professionals knowledgeable in the field of stis who met '\n",
      " 'in atlanta georgia june 11–14 2019  the information in this report updates '\n",
      " 'the 2015 guidelines these guidelines discuss 1 updated recommendations for '\n",
      " 'treatment of  neisseria gonorrhoeae chlamydia trachomatis and trichomonas '\n",
      " 'vaginalis 2 addition of metronidazole to the recommended  treatment regimen '\n",
      " 'for pelvic inflammatory disease 3 alternative treatment options for '\n",
      " 'bacterial vaginosis 4 management of  mycoplasma genitalium 5 human '\n",
      " 'papillomavirus vaccine recommendations and counseling messages 6 expanded '\n",
      " 'risk factors  for syphilis testing among pregnant women 7 onetime testing '\n",
      " 'for hepatitis c infection 8 evaluation of men who have sex with  men after '\n",
      " 'sexual assault and 9 twostep testing for serologic diagnosis of genital '\n",
      " 'herpes simplex virus physicians and other health  care providers can use '\n",
      " 'these guidelines to assist in prevention and treatment of stis corresponding '\n",
      " 'preparer kimberly a workowski md division of  std prevention national center '\n",
      " 'for hivaids viral hepatitis  std and tb prevention cdc telephone 4046391898 '\n",
      " 'email  kgw2cdcgov introduction the term “sexually transmitted infection” sti '\n",
      " 'refers to  a pathogen that causes infection through sexual contact  whereas '\n",
      " 'the term “sexually transmitted disease” std refers  to a recognizable '\n",
      " 'disease state that has developed from an  infection physicians and other '\n",
      " 'health care providers have a  crucial role in preventing and treating stis '\n",
      " 'these guidelines  are intended to assist with that effort although the '\n",
      " 'guidelines  emphasize treatment prevention strategies and diagnostic  '\n",
      " 'recommendations also are discussed this report updates sexually transmitted '\n",
      " 'diseases treatment  guidelines 2015 1 and should be regarded as a source of  '\n",
      " 'clinical guidance rather than prescriptive standards health care  providers '\n",
      " 'should always consider the clinical circumstances of  each person in the '\n",
      " 'context of local disease prevalence these  guidelines are applicable to any '\n",
      " 'patient care setting that serves  persons at risk for stis including family '\n",
      " 'planning clinics  hiv care clinics correctional health care settings '\n",
      " 'private  physicians’ offices federally qualified health centers clinics  for '\n",
      " 'adolescent care and other primary care facilities these  guidelines are '\n",
      " 'focused on treatment and counseling and do  not address other community '\n",
      " 'services and interventions that  are essential to sti and hiv prevention '\n",
      " 'efforts these sti treatment guidelines complement recommendations  for '\n",
      " 'providing quality sexually transmitted diseases clinical  services 2020 2 '\n",
      " 'regarding quality clinical services for stis  in primary care and std '\n",
      " 'specialty care settings this guidance  specifies operational determinants of '\n",
      " 'quality services in various  clinical settings describes onsite treatment '\n",
      " 'and partner  services and indicates when stirelated conditions should be  '\n",
      " 'managed through consultation with or referral to a specialist methods these '\n",
      " 'guidelines were developed by cdc staff who worked  with subject matter '\n",
      " 'experts with expertise in sti clinical  management from other federal '\n",
      " 'agencies nongovernmental  academic and research institutions and '\n",
      " 'professional medical  organizations cdc staff identified governmental and  '\n",
      " 'nongovernmental subject matter experts on the basis of their  expertise and '\n",
      " 'assisted them in developing questions to guide  individual literature '\n",
      " 'reviews cdc staff informed the subject  matter experts that they were being '\n",
      " 'consulted to exchange  information and observations and to obtain their '\n",
      " 'individual  input all subject matter experts disclosed potential conflicts  '\n",
      " 'of interest sti treatment guidelines 2021 work group  members are listed at '\n",
      " 'the end of this report in 2018 cdc staff identified key questions about '\n",
      " 'treatment  and clinical management to guide an update of the 2015  std '\n",
      " 'treatment guidelines 1 to answer these questions  and synthesize new '\n",
      " 'information available since publication  of the 2015 guidelines subject '\n",
      " 'matter experts and cdc staff  mailtokgw2cdcgov recommendations and reports 2 '\n",
      " 'mmwr  july 23 2021  vol 70  no 4 us department of health and human '\n",
      " 'servicescenters for disease control and prevention collaborated to conduct '\n",
      " 'systematic literature reviews by using  an extensive medline database '\n",
      " 'evidencebased approach for  each section of the 2015 guidelines eg using '\n",
      " 'englishlanguage  published abstracts and peer reviewed journal articles '\n",
      " 'these  systematic reviews were focused on four principal outcomes  of sti '\n",
      " 'therapy for each disease or infection 1 treatment  of infection on the basis '\n",
      " 'of microbiologic eradication  2 alleviation of signs and symptoms 3 '\n",
      " 'prevention of sequelae  and 4 prevention of transmission including '\n",
      " 'advantages eg  costeffectiveness singledose formulations and directly  '\n",
      " 'observed therapy and disadvantages eg adverse effects  of specific regimens '\n",
      " 'the outcome of the literature reviews  guided development of background '\n",
      " 'materials including tables  of evidence from peerreviewed publications '\n",
      " 'summarizing  the type of study eg randomized controlled trial or case  '\n",
      " 'series study population and setting treatments or other  interventions '\n",
      " 'outcome measures assessed reported findings  and weaknesses and biases in '\n",
      " 'study design and analysis in june 2019 the subject matter experts presented '\n",
      " 'their  assessments of the literature reviews at an inperson meeting  of '\n",
      " 'governmental and nongovernmental participants each  key question was '\n",
      " 'discussed and pertinent publications were  reviewed in terms of strengths '\n",
      " 'weaknesses and relevance  participants evaluated the quality of evidence '\n",
      " 'provided their  input and discussed findings in the context of the modified  '\n",
      " 'rating system used by the us preventive services task force  uspstf the '\n",
      " 'discussions were informal and not structured  to reach consensus cdc staff '\n",
      " 'also reviewed the publications  from other professional organizations '\n",
      " 'including the american  college of obstetricians and gynecologists acog '\n",
      " 'uspstf  the american cancer society acs the american society  for colposcopy '\n",
      " 'and cervical pathology asccp and the  advisory committee on immunization '\n",
      " 'practices acip  the discussion culminated in a list of participants’ '\n",
      " 'opinions  on all the key sti topic areas for consideration by cdc  more '\n",
      " 'detailed descriptions of the key questions search terms  systematic search '\n",
      " 'evidence tables and review process are  available at '\n",
      " 'httpswwwcdcgovstdtreatmentguidelines defaulthtm cdc staff then independently '\n",
      " 'reviewed the tables of evidence  prepared by the subject matter experts '\n",
      " 'individual comments  from the participants and professional organizations '\n",
      " 'and existing  guidelines from other organizations to determine whether  '\n",
      " 'revisions to the 2015 std treatment guidelines were warranted  cdc staff '\n",
      " 'ranked evidence as high medium and low on the  basis of each study’s '\n",
      " 'strengths and weaknesses according to the  uspstf ratings '\n",
      " 'httpswwwuspreventiveservicestaskforce '\n",
      " 'orguspstfuspreventiveservicestaskforceratings cdc staff  then developed '\n",
      " 'draft recommendations that were peer reviewed  by public health and clinical '\n",
      " 'experts as defined by the office of  management and budget for influential '\n",
      " 'scientific information  a public webinar was held to provide an overview of '\n",
      " 'the draft  recommendations and invite questions and comments on the  draft '\n",
      " 'recommendations the peer review comments webinar  questions and responses '\n",
      " 'were considered by cdc staff in  developing the final recommendations for '\n",
      " 'the updated sti  treatment guidelines recommendations for hiv hepatitis c  '\n",
      " 'cervical cancer screening sti screening in pregnancy human  papillomavirus '\n",
      " 'hpv testing and hepatitis a virus hav and  hepatitis b virus hbv vaccination '\n",
      " 'were developed after cdc  staff reviewed existing published recommendations '\n",
      " 'the english language literature was searched periodically by cdc staff to  '\n",
      " 'identify subsequently published articles warranting consideration throughout '\n",
      " 'this report the evidence used as the basis for  specific recommendations is '\n",
      " 'discussed briefly publication  of comprehensive annotated discussions of '\n",
      " 'such evidence  is planned in a supplemental issue of the journal clinical  '\n",
      " 'infectious diseases after publication of the treatment guidelines  when more '\n",
      " 'than one therapeutic regimen is recommended  and the listed regimens have '\n",
      " 'similar efficacy and similar  rates of intolerance or toxicity the '\n",
      " 'recommendations are  listed alphabetically if differences are specified '\n",
      " 'regimens are  prioritized on the basis of these differences recommended  '\n",
      " 'regimens should be used primarily alternative regimens can be  considered in '\n",
      " 'instances of notable drug allergy or other medical  contraindications to the '\n",
      " 'recommended regimens alternative  regimens are considered inferior to '\n",
      " 'recommended regimens on  the basis of available evidence regarding the '\n",
      " 'principal outcomes  and disadvantages of the regimens clinical prevention '\n",
      " 'guidance prevention and control of stis are based on the following  five '\n",
      " 'major strategies 3 1 accurate risk assessment and education and counseling  '\n",
      " 'of persons at risk regarding ways to avoid stis through  changes in sexual '\n",
      " 'behaviors and use of recommended  prevention services 2 preexposure '\n",
      " 'vaccination for vaccinepreventable stis 3 identification of persons with an '\n",
      " 'asymptomatic  infection and persons with symptoms associated with  an sti 4 '\n",
      " 'effective diagnosis treatment counseling and follow up of persons who are '\n",
      " 'infected with an sti 5 evaluation treatment and counseling of sex partners  '\n",
      " 'of persons who are infected with an sti '\n",
      " 'httpswwwcdcgovstdtreatmentguidelinesdefaulthtm '\n",
      " 'httpswwwcdcgovstdtreatmentguidelinesdefaulthtm '\n",
      " 'httpswwwuspreventiveservicestaskforceorguspstfuspreventiveservicestaskforceratings '\n",
      " 'httpswwwuspreventiveservicestaskforceorguspstfuspreventiveservicestaskforceratings '\n",
      " 'recommendations and reports mmwr  july 23 2021  vol 70  no 4 3us department '\n",
      " 'of health and human servicescenters for disease control and prevention sti '\n",
      " 'and hiv infection risk assessment primary prevention of stis includes '\n",
      " 'assessment of behavioral  risk ie assessing the sexual behaviors that can '\n",
      " 'place persons  at risk for infection and biologic risk ie testing for risk  '\n",
      " 'markers for sti and hiv acquisition or transmission as part  of the clinical '\n",
      " 'encounter health care providers should routinely  obtain sexual histories '\n",
      " 'from their patients and address risk  reduction as indicated in this report '\n",
      " 'guidance for obtaining  a sexual history is available at the division of std '\n",
      " 'prevention  resource page httpswwwcdcgovstdtreatmentresources htm and in the '\n",
      " 'curriculum provided by the national network  of std clinical prevention '\n",
      " 'training centers httpswww nnptcorg effective interviewing and counseling '\n",
      " 'skills  characterized by respect compassion and a nonjudgmental  attitude '\n",
      " 'toward all patients are essential to obtaining a  thorough sexual history '\n",
      " 'and delivering effective prevention  messages effective techniques for '\n",
      " 'facilitating rapport with  patients include using openended questions eg '\n",
      " '“tell me  about any new sex partners you’ve had since your last visit” and  '\n",
      " '“what has your experience with using condoms been like”  understandable '\n",
      " 'nonjudgmental language eg “what gender  are your sex partners”and “have you '\n",
      " 'ever had a sore or scab  on your penis” and normalizing language eg “some of '\n",
      " 'my  patients have difficulty using a condom with every sex act how  is it '\n",
      " 'for you” the “five p’s” approach to obtaining a sexual  history is one '\n",
      " 'strategy for eliciting information about the key  areas of interest box 1 in '\n",
      " 'addition health care professionals  can consider assessing sexual history by '\n",
      " 'asking patients such  questions as “do you have any questions or concerns '\n",
      " 'about  your sexual health” additional information about gaining  cultural '\n",
      " 'competency when working with certain populations  eg gay bisexual or other '\n",
      " 'men who have sex with men  msm women who have sex with women wsw or with  '\n",
      " 'women and men wswm or transgender men and women  or adolescents is available '\n",
      " 'in sections of these guidelines related  to these populations in addition to '\n",
      " 'obtaining a behavioral risk assessment a  comprehensive sti and hiv risk '\n",
      " 'assessment should include  sti screening as recommended in these guidelines '\n",
      " 'because  stis are biologic markers of risk particularly for hiv  acquisition '\n",
      " 'and transmission among certain msm in most  clinical settings sti screening '\n",
      " 'is an essential and underused  component of an sti and hiv risk assessment '\n",
      " 'persons  seeking treatment or evaluation for a particular sti should be  '\n",
      " 'screened for hiv and other stis as indicated by community  prevalence and '\n",
      " 'individual risk factors see chlamydial  infections gonococcal infections '\n",
      " 'syphilis persons should  be informed about all the tests for stis they are '\n",
      " 'receiving and  notified about tests for common stis eg genital herpes  box 1 '\n",
      " 'the five p’s approach for health care providers obtaining sexual histories '\n",
      " 'partners practices protection from sexually  transmitted infections past '\n",
      " 'history of sexually transmitted infections and pregnancy intention 1 '\n",
      " 'partners • “are you currently having sex of any kind” • “what is the genders '\n",
      " 'of your partners” 2 practices • “to understand any risks for sexually '\n",
      " 'transmitted  infections stis i need to ask more specific questions  about '\n",
      " 'the kind of sex you have had recently” • “what kind of sexual contact do you '\n",
      " 'have or have you had”  ű “do you have vaginal sex meaning ‘penis in vagina’ '\n",
      " 'sex”  ű “do you have anal sex meaning ‘penis in rectumanus’  sex”  ű “do you '\n",
      " 'have oral sex meaning ‘mouth on penisvagina’” 3 protection from stis • “do '\n",
      " 'you and your partners discuss prevention of stis  and human immunodeficiency '\n",
      " 'virus hiv” • “do you and your partners discuss getting tested” • for '\n",
      " 'condoms  ű “what protection methods do you use in what  situations do you '\n",
      " 'use condoms” 4 past history of stis • “have you ever been tested for stis '\n",
      " 'and hiv” • “have you ever been diagnosed with an sti in the past” • “have '\n",
      " 'any of your partners had an sti” additional questions for identifying hiv '\n",
      " 'and viral  hepatitis risk • “have you or any of your partners ever injected '\n",
      " 'drugs” • “is there anything about your sexual health that you  have '\n",
      " 'questions about” 5 pregnancy intention • “do you think you would like to '\n",
      " 'have more children  in the future” •  “how important is it to you to prevent '\n",
      " 'pregnancy  until then” • “are you or your partner using contraception or  '\n",
      " 'practicing any form of birth control” • “would you like to talk about ways '\n",
      " 'to prevent  pregnancy” httpswwwcdcgovstdtreatmentresourceshtm '\n",
      " 'httpswwwcdcgovstdtreatmentresourceshtm httpswwwnnptcorg httpswwwnnptcorg '\n",
      " 'recommendations and reports 4 mmwr  july 23 2021  vol 70  no 4 us department '\n",
      " 'of health and human servicescenters for disease control and prevention '\n",
      " 'trichomoniasis mycoplasma genitalium and hpv that are  available but not '\n",
      " 'being performed and reasons why they are  not always indicated persons '\n",
      " 'should be informed of their test  results and recommendations for future '\n",
      " 'testing efforts should  be made to ensure that all persons receive sti care '\n",
      " 'regardless  of personal circumstances eg ability to pay citizenship  or '\n",
      " 'immigration status gender identity language spoken or  specific sex '\n",
      " 'practices sti and hiv infection  prevention counseling after obtaining a '\n",
      " 'sexual history from their patients all  providers should encourage risk '\n",
      " 'reduction by offering  prevention counseling prevention counseling is most '\n",
      " 'effective  if provided in a nonjudgmental and empathetic manner  appropriate '\n",
      " 'to the patient’s culture language sex and gender  identity sexual '\n",
      " 'orientation age and developmental level  prevention counseling for stis and '\n",
      " 'hiv should be offered  to all sexually active adolescents and to all adults '\n",
      " 'who have  received an sti diagnosis have had an sti during the  previous '\n",
      " 'year or have had multiple sex partners uspstf  recommends intensive '\n",
      " 'behavioral counseling for all sexually  active adolescents and for adults at '\n",
      " 'increased risk for stis and  hiv 4 such interactive counseling which can be '\n",
      " 'resource  intensive is directed at a person’s risk the situations in which  '\n",
      " 'risk occurs and the use of personalized goalsetting strategies  one such '\n",
      " 'approach known as clientcentered sti and hiv  prevention counseling involves '\n",
      " 'tailoring a discussion of risk  reduction to the person’s situation although '\n",
      " 'one large study in  sti clinics project respect demonstrated that this '\n",
      " 'approach  was associated with lower acquisition of curable stis eg  '\n",
      " 'trichomoniasis chlamydia gonorrhea and syphilis 5 another  study conducted '\n",
      " '10 years later in the same settings but different  contexts project aware '\n",
      " 'did not replicate this result 6 with the challenges that intensive '\n",
      " 'behavioral counseling poses  health care professionals might find brief '\n",
      " 'prevention messages  and those delivered through video or in a group session '\n",
      " 'to be  more accessible for the client a review of 11 studies evaluated  '\n",
      " 'brief prevention messages delivered by providers and health  counselors and '\n",
      " 'reported them to be feasible and to decrease  subsequent stis in std clinic '\n",
      " 'settings 7 and hiv care  settings 8 other approaches use motivational '\n",
      " 'interviewing  to move clients toward achievable riskreduction goals client '\n",
      " 'centered counseling and motivational interviewing can be used  effectively '\n",
      " 'by clinicians and staff trained in these approaches  cdc provides additional '\n",
      " 'information on these and other  effective behavioral interventions at '\n",
      " 'httpswwwcdcgov stdprograminterventionshtm training in clientcentered  '\n",
      " 'counseling and motivational interviewing is available through  the std '\n",
      " 'national network of prevention training centers  httpswwwnnptcorg in '\n",
      " 'addition to oneonone sti and hiv prevention  counseling videos and large '\n",
      " 'group presentations can provide  explicit information concerning stis and '\n",
      " 'reducing disease  transmission eg how to use condoms consistently and  '\n",
      " 'correctly and the importance of routine screening group based strategies '\n",
      " 'have been effective in reducing the occurrence  of stis among persons at '\n",
      " 'risk including those attending  std clinics 9 brief online '\n",
      " 'electroniclearning modules for  young msm have been reported to be effective '\n",
      " 'in reducing  incident stis and offer a convenient client platform for  '\n",
      " 'effective interventions 10 because the incidence of certain  stis most '\n",
      " 'notably syphilis is higher among persons with  hiv infection use of '\n",
      " 'clientcentered sti counseling for  persons with hiv continues to be '\n",
      " 'encouraged by public health  agencies and other health organizations '\n",
      " 'httpswwwcdcgov stdstatistics2019defaulthtm a 2014 guideline from cdc  the '\n",
      " 'health resources and services administration and the  national institutes of '\n",
      " 'health recommends that clinical and  nonclinical providers assess a person’s '\n",
      " 'behavioral and biologic  risks for acquiring or transmitting stis and hiv '\n",
      " 'including  having sex without condoms having recent stis and having  '\n",
      " 'partners recently treated for stis httpsstackscdcgov viewcdc44064 that '\n",
      " 'federal guideline is for clinical and  nonclinical providers to offer or '\n",
      " 'make referral for regular  screening for multiple stis onsite sti treatment '\n",
      " 'when  indicated and riskreduction interventions tailored to the  person’s '\n",
      " 'risks brief riskreduction counseling delivered by  medical providers during '\n",
      " 'hiv primary care visits coupled  with routine sti screening has been '\n",
      " 'reported to reduce sti  incidence among persons with hiv infection 8 other  '\n",
      " 'specific methods have been designed for the hiv care setting  '\n",
      " 'httpswwwcdcgovhiveffectiveinterventionsindexhtml primary prevention methods '\n",
      " 'preexposure vaccination preexposure vaccination is one of the most effective '\n",
      " 'methods  for preventing transmission of hpv hav and hbv all  of which can be '\n",
      " 'sexually transmitted hpv vaccination is  recommended routinely for males and '\n",
      " 'females aged 11 or  12 years and can be administered beginning at age 9 '\n",
      " 'years  hpv vaccination is recommended through age 26 years for  those not '\n",
      " 'previously vaccinated 11 sharing clinical decision making about hpv '\n",
      " 'vaccination is recommended for certain  adults aged 27–45 years who are not '\n",
      " 'adequately vaccinated  in accordance with existing guidance httpswwwcdcgov '\n",
      " 'vaccineshcpaciprecsvaccspecifichpvhtml '\n",
      " 'httpswwwcdcgovstdprograminterventionshtm '\n",
      " 'httpswwwcdcgovstdprograminterventionshtm httpswwwnnptcorg '\n",
      " 'httpsstackscdcgovviewcdc44064 httpsstackscdcgovviewcdc44064 '\n",
      " 'httpswwwcdcgovhiveffectiveinterventionsindexhtml '\n",
      " 'httpswwwcdcgovvaccineshcpaciprecsvaccspecifichpvhtml '\n",
      " 'httpswwwcdcgovvaccineshcpaciprecsvaccspecifichpvhtml recommendations and '\n",
      " 'reports mmwr  july 23 2021  vol 70  no 4 5us department of health and human '\n",
      " 'servicescenters for disease control and prevention hepatitis b vaccination '\n",
      " 'is recommended for all unvaccinated  uninfected persons who are sexually '\n",
      " 'active with more than  one partner or are being evaluated or treated for an '\n",
      " 'sti 12  in addition hepatitis a and b vaccines are recommended for  msm '\n",
      " 'persons who inject drugs persons with chronic liver  disease and persons '\n",
      " 'with hiv or hepatitis c infections who  have not had hepatitis a or '\n",
      " 'hepatitis b 12 hav vaccine is  also recommended for persons who are homeless '\n",
      " '13 details  regarding hav and hbv vaccination including routine  childhood '\n",
      " 'vaccination are available at httpswwwcdcgov hepatitis and at the acip '\n",
      " 'website httpswwwcdcgov vaccineshcpaciprecsvaccspecificindexhtml condoms '\n",
      " 'external condoms when used consistently and correctly external latex  '\n",
      " 'condoms also known as male condoms are effective in  preventing the sexual '\n",
      " 'transmission of hiv infection http '\n",
      " 'wwwashasexualhealthorgpdfsmaleandfemalecondoms pdf in heterosexual hiv '\n",
      " 'mixedstatus relationships ie those  involving one infected and one '\n",
      " 'uninfected partner in which  condoms were used consistently hivnegative '\n",
      " 'partners were  71–80 less likely to become infected with hiv compared  with '\n",
      " 'persons in similar relationships in which condoms were  not used 1415 two '\n",
      " 'analyses of msm mixedstatus couple  studies estimated the protective effect '\n",
      " 'of condom use to be 70  and 91 respectively 1617 moreover studies '\n",
      " 'demonstrate  that consistent condom use reduces the risk for other stis  '\n",
      " 'including chlamydia gonorrhea hepatitis b and trichomoniasis  18–21 by '\n",
      " 'limiting lower genital tract infections condoms  also might reduce the risk '\n",
      " 'for pelvic inflammatory disease  pid among women 22 in addition consistent '\n",
      " 'and correct  use of latex condoms reduces the risk for hpv infection  and '\n",
      " 'hpvassociated diseases genital herpes syphilis and  chancroid when the '\n",
      " 'infected area or site of potential exposure  is covered 23–27 additional '\n",
      " 'information is available at  httpswwwcdcgovcondomeffectivenessindexhtml and  '\n",
      " 'wwwfactsaboutcondomscomprofessionalphp condoms  are regulated as medical '\n",
      " 'devices and are subject to random  sampling and testing by the food and drug '\n",
      " 'administration  fda each latex condom manufactured in the united states  is '\n",
      " 'tested electronically for holes before packaging the rate of  condom '\n",
      " 'breakage during sexual intercourse and withdrawal in  the united states is '\n",
      " 'approximately two broken condoms per  100 condoms rates of breakage and '\n",
      " 'slippage might be slightly  higher during anal intercourse 2829 the failure '\n",
      " 'of condoms  to protect against stis or unintended pregnancy usually results  '\n",
      " 'from inconsistent or incorrect use rather than condom breakage  30 users '\n",
      " 'should check the expiration or manufacture date  on the box or individual '\n",
      " 'package latex condoms should not  be used beyond their expiration date or 5 '\n",
      " 'years after the  manufacturing date condoms made of materials other than  '\n",
      " 'latex are available in the united states and can be classified  into two '\n",
      " 'general categories 1 polyurethane polyisoprene or  other synthetic condoms '\n",
      " 'and 2 natural membrane condoms polyurethane external condoms provide '\n",
      " 'protection against  stis and hiv and pregnancy comparable to that of latex  '\n",
      " 'condoms 2031 these can be substituted for latex condoms  by persons with '\n",
      " 'latex sensitivity are typically more resistant to  deterioration and are '\n",
      " 'compatible with use of both oilbased  and waterbased lubricants the '\n",
      " 'effectiveness of other synthetic  external condoms to prevent stis has not '\n",
      " 'been extensively  studied and fda labeling restricts their recommended use  '\n",
      " 'to persons who are sensitive to or allergic to latex natural  membrane '\n",
      " 'condoms frequently called natural skin condoms  or incorrectly lambskin '\n",
      " 'condoms are made from lamb cecum  and can have pores up to 1500 nm in '\n",
      " 'diameter although  these pores do not allow the passage of sperm they are '\n",
      " 'more  than 10 times the diameter of hiv and more than 25 times  that of hbv '\n",
      " 'moreover laboratory studies demonstrate that  sexual transmission of viruses '\n",
      " 'including hbv herpes simplex  virus hsv and hiv can occur with natural '\n",
      " 'membrane  condoms 31 therefore natural membrane condoms are not  recommended '\n",
      " 'for prevention of stis and hiv providers should advise that condoms must be '\n",
      " 'used  consistently and correctly to be effective in preventing stis and  hiv '\n",
      " 'while noting that any condom use is better than no condom  use providing '\n",
      " 'instructions about the correct use of condoms  can be useful communicating '\n",
      " 'the following recommendations  can help ensure that patients use external '\n",
      " 'condoms correctly • use a new condom with each sex act ie oral vaginal  and '\n",
      " 'anal • carefully handle the condom to avoid damaging it with  fingernails '\n",
      " 'teeth or other sharp objects • put the condom on after the penis is erect '\n",
      " 'and before any  genital oral or anal contact with the partner • use only '\n",
      " 'waterbased or siliconebased lubricants eg  ky jelly astroglide aqualube or '\n",
      " 'glycerin with latex  condoms oilbased lubricants eg petroleum jelly  '\n",
      " 'shortening mineral oil massage oils body lotions or  cooking oil can weaken '\n",
      " 'latex and should not be used  however oilbased lubricants typically can be '\n",
      " 'used with  polyurethane or other synthetic condoms • ensure adequate '\n",
      " 'lubrication during vaginal and anal sex  which might require using exogenous '\n",
      " 'waterbased  lubricants • hold the condom firmly against the base of the '\n",
      " 'penis  during withdrawal and withdraw while the penis is still  erect to '\n",
      " 'prevent the condom from slipping off '\n",
      " 'httpswwwcdcgovvaccineshcpaciprecsvaccspecificindexhtml '\n",
      " 'httpswwwcdcgovvaccineshcpaciprecsvaccspecificindexhtml '\n",
      " 'httpwwwashasexualhealthorgpdfsmaleandfemalecondomspdf '\n",
      " 'httpwwwashasexualhealthorgpdfsmaleandfemalecondomspdf '\n",
      " 'httpwwwashasexualhealthorgpdfsmaleandfemalecondomspdf '\n",
      " 'httpswwwcdcgovcondomeffectivenessindexhtml '\n",
      " 'httpwwwfactsaboutcondomscomprofessionalphp recommendations and reports 6 '\n",
      " 'mmwr  july 23 2021  vol 70  no 4 us department of health and human '\n",
      " 'servicescenters for disease control and prevention additional information '\n",
      " 'about external condoms is available  at httpswwwcdcgovcondomeffectiveness '\n",
      " 'internal condoms condoms for internal vaginal use also known as female  '\n",
      " 'condoms are available worldwide eg the fc2 female  condom reddy condom cupid '\n",
      " 'female condom and woman’s  condom 3132 use of internal condoms can provide  '\n",
      " 'protection from acquisition and transmission of stis although  data are '\n",
      " 'limited internal condoms are more costly compared  with external condoms '\n",
      " 'however they offer the advantage of  being controlled by the receptive '\n",
      " 'partner as an sti and hiv  prevention method and the newer versions might be '\n",
      " 'acceptable  to all persons although the internal condom also has been used  '\n",
      " 'during receptive anal intercourse efficacy associated with this  practice '\n",
      " 'remains unknown 33 additional information about  the internal condom is '\n",
      " 'available at httpwwwashasexualhealth orgpdfsmaleandfemalecondomspdf cervical '\n",
      " 'diaphragms in observational studies diaphragm use has been  demonstrated to '\n",
      " 'protect against cervical gonorrhea chlamydia  and trichomoniasis 34 however '\n",
      " 'a trial examining the effect  of a diaphragm plus lubricant on hiv '\n",
      " 'acquisition among  women in africa reported no additional protective effect '\n",
      " 'when  compared with the use of male condoms alone likewise no  difference by '\n",
      " 'study arm in the rate of acquisition of chlamydia  gonorrhea or herpes '\n",
      " 'occurred 3536 diaphragms should  not be relied on as the sole source of '\n",
      " 'protection against hiv  and other stis multipurpose prevention technologies '\n",
      " 'methods that combine sti and hiv prevention  with pregnancy prevention are '\n",
      " 'known as multipurpose  prevention technologies mpts 37 httpswwwwhoint '\n",
      " 'reproductivehealthtopicslinkagesmptsen internal and  external condoms are '\n",
      " 'both examples of mpts because they are  effective prevention measures when '\n",
      " 'used correctly for sti and  hiv transmission or pregnancy prevention the '\n",
      " 'multicenter  evidence for contraception options and hiv outcomes  echo trial '\n",
      " 'observed no statistically significant differences in  hiv incidence rates '\n",
      " 'among women randomly assigned to one  of three contraceptive methods depot '\n",
      " 'medroxyprogesterone  acetate dmpa levonorgestrel implant and copper '\n",
      " 'containing intrauterine device iud however rates of hiv  infection were high '\n",
      " 'in all groups indicating a need for mpts  38 development of mpts is complex '\n",
      " 'and ongoing products  under study include microbicides with contraceptive '\n",
      " 'devices  eg tenofovir with a vaginal ring contraceptive delivery  package '\n",
      " 'and other innovative methods 39 topical microbicides and spermicides '\n",
      " 'nonspecific topical microbicides are ineffective for  preventing hiv '\n",
      " 'infection 40–45 tenofovir gel has been  studied for prevention of herpes '\n",
      " 'simplex virus 2 hsv2  and hiv infections 4647 adherence can be low 48 and  '\n",
      " 'prevention of hiv infection especially among women has not  been '\n",
      " 'demonstrated 4749vaginal rings containing dapivirine  have provided some '\n",
      " 'reduction in hiv infection 5051 for  men and transgender women who have anal '\n",
      " 'intercourse  tenofovir gel appears safe when applied before and after anal  '\n",
      " 'sex 52 spermicides containing nonoxynol9 n9 might  disrupt genital or rectal '\n",
      " 'epithelium and have been associated  with an increased risk for hiv '\n",
      " 'infection condoms with n9  are no more effective than condoms without n9 '\n",
      " 'therefore  n9 alone or in a condom is not recommended for sti and  hiv '\n",
      " 'prevention 40 n9 use also has been associated with  an increased risk for '\n",
      " 'bacterial urinary tract infections among  women 5354 nonbarrier '\n",
      " 'contraception female surgical  sterilization and hysterectomy contraceptive '\n",
      " 'methods that are not mechanical barriers  offer no protection against hiv or '\n",
      " 'other stis the echo  study observed no differences in hiv incidence rates '\n",
      " 'among  women randomly assigned to dmpa levonorgestrel implant  or '\n",
      " 'coppercontaining iud contraceptive methods 38 a  systematic review of '\n",
      " 'epidemiologic evidence reported that the  majority of studies demonstrated '\n",
      " 'no association between use  of oral contraceptives and hiv acquisition among '\n",
      " 'women  55 whether hormonal contraception alters a woman’s risk  for other '\n",
      " 'stis is uncertain 5657 sexually active women who use contraceptive methods  '\n",
      " 'other than condoms should be counseled about sti and hiv  infection '\n",
      " 'prevention measures these include preexposure  prophylaxis prep and '\n",
      " 'postexposure prophylaxis pep  limiting the number of sex partners and '\n",
      " 'correct and consistent  use of condoms emergency contraception unprotected '\n",
      " 'intercourse exposes women to risks for stis  and unplanned pregnancy '\n",
      " 'providers should offer counseling  about the option of emergency '\n",
      " 'contraception if pregnancy  is not desired options for emergency '\n",
      " 'contraception in the  united states include coppercontaining iuds and '\n",
      " 'emergency  contraceptive pills ecps 5859 more information is available  at '\n",
      " 'httpswwwacogorgclinicalclinicalguidancepractice '\n",
      " 'bulletinarticles201509emergencycontraceptionutm '\n",
      " 'sourceredirectutmmediumwebutmcampaignotn  ecps are available in the '\n",
      " 'following formulations ulipristal  httpswwwcdcgovcondomeffectiveness '\n",
      " 'httpwwwashasexualhealthorgpdfsmaleandfemalecondomspdf '\n",
      " 'httpwwwashasexualhealthorgpdfsmaleandfemalecondomspdf '\n",
      " 'httpswwwwhointreproductivehealthtopicslinkagesmptsen '\n",
      " 'httpswwwwhointreproductivehealthtopicslinkagesmptsen '\n",
      " 'httpswwwacogorgclinicalclinicalguidancepracticebulletinarticles201509emergencycontraceptionutmsourceredirectutmmediumwebutmcampaignotn '\n",
      " 'httpswwwacogorgclinicalclinicalguidancepracticebulletinarticles201509emergencycontraceptionutmsourceredirectutmmediumwebutmcampaignotn '\n",
      " 'httpswwwacogorgclinicalclinicalguidancepracticebulletinarticles201509emergencycontraceptionutmsourceredirectutmmediumwebutmcampaignotn '\n",
      " 'recommendations and reports mmwr  july 23 2021  vol 70  no 4 7us department '\n",
      " 'of health and human servicescenters for disease control and prevention '\n",
      " 'acetate in a single dose 30 mg available by prescription  levonorgestrel in '\n",
      " 'a single dose 15 mg available over the  counter or by prescription or a '\n",
      " 'combined estrogen and  progestin pill regimen insertion of a '\n",
      " 'coppercontaining  iud ≤5 days after unprotected sex can reduce pregnancy '\n",
      " 'risk  from a sex act by approximately 99 60 ecps are most  efficacious when '\n",
      " 'initiated as soon as possible after unprotected  sex ulipristal acetate is '\n",
      " 'effective ≤5 days after unprotected sex  and levonorgestrel is most '\n",
      " 'effective ≤3 days after unprotected  sex but has some efficacy at ≤5 days '\n",
      " 'ecps are ineffective  but not harmful if the woman is already pregnant 61 a  '\n",
      " '2019 cochrane review summarized the efficacy safety and  convenience of '\n",
      " 'different emergency contraception methods 61 more information about '\n",
      " 'emergency contraception is  available in contraceptive technology 21st '\n",
      " 'edition 31 in the  2016 us selected practice recommendations us spr  for '\n",
      " 'contraceptive use emergency contraception available  at '\n",
      " 'httpswwwcdcgovreproductivehealthcontraception mmwrspremergencyhtml and in '\n",
      " 'the 2016 us medical  eligibility criteria us mec for contraceptive use '\n",
      " 'copper  iuds for emergency contraception available at https '\n",
      " 'wwwcdcgovreproductivehealthcontraceptionmmwrmec appendixjhtml providers '\n",
      " 'should educate males and females about emergency  contraception especially '\n",
      " 'if other methods of contraception  were used incorrectly or not at all and '\n",
      " 'pregnancy is not desired  62 an advance supply of ecps can be provided or '\n",
      " 'prescribed  so that ecps will be available when needed 59 male circumcision '\n",
      " 'male circumcision reduces the risk for hiv infection and  certain stis among '\n",
      " 'heterosexual men three randomized  controlled trials performed in regions of '\n",
      " 'subsaharan africa  where generalized hiv epidemics involving predominantly  '\n",
      " 'heterosexual transmission were occurring demonstrated that  male '\n",
      " 'circumcision reduces the risk for hiv acquisition among  men by 50–60 63–65 '\n",
      " 'in those trials circumcision  also was protective against other stis '\n",
      " 'including highrisk  genital hpv infection and genital herpes 66–68 followup  '\n",
      " 'studies have demonstrated sustained benefit of circumcision  for hiv '\n",
      " 'prevention 69 and that the effect is not mediated  solely through a '\n",
      " 'reduction in hsv2 infection or genital ulcer  disease gud 70 the world '\n",
      " 'health organization who and the joint  united nations programme on hivaids '\n",
      " 'unaids  recommend that male circumcision efforts be scaled up as an  '\n",
      " 'effective intervention for preventing heterosexually acquired hiv  infection '\n",
      " '71 in countries with hyperendemic and generalized  hiv epidemics within the '\n",
      " 'context of ensuring universal access  to comprehensive hiv prevention '\n",
      " 'treatment care and support  '\n",
      " 'httpswwwafrowhointpublicationsvoluntarymedicalmale circumcisionhivprevention '\n",
      " 'in the united states the american  academy of pediatrics aap recommends that '\n",
      " 'newborn male  circumcision be available to families that desire it because '\n",
      " 'the  benefits of the procedure including prevention of penile cancers  '\n",
      " 'urinary tract infections gud and hiv infection outweigh the  risks acog has '\n",
      " 'also endorsed aap’s policy statement in light  of these benefits the '\n",
      " 'american urological association states  that male circumcision should be '\n",
      " 'considered an option for risk  reduction among other strategies 72 '\n",
      " 'additional information  for providers counseling male patients and parents '\n",
      " 'regarding  male circumcision for preventing hiv stis and other adverse  '\n",
      " 'health outcomes is available at httpswwwcdcgovhivrisk malecircumcisionhtml '\n",
      " 'no definitive data exist to determine whether male  circumcision reduces hiv '\n",
      " 'acquisition among msm although  one metaanalysis of 62 observational studies '\n",
      " 'reported that  circumcision was protective against hiv acquisition in low '\n",
      " 'to  middleincome countries but not in highincome countries  73 further '\n",
      " 'studies are needed to confirm any potential  benefit of male circumcision '\n",
      " 'for this population preexposure prophylaxis for hiv daily oral '\n",
      " 'antiretroviral prep with a fixeddose combination  of emtricitabine ftc and '\n",
      " 'either tenofovir disoproxil fumarate  tdf or tenofovir alafenamide taf have '\n",
      " 'demonstrated  safety 74 and a substantial reduction in the rate of hiv  '\n",
      " 'acquisition for msm 75 tdfftc has demonstrated  safety and efficacy for '\n",
      " 'mixedstatus heterosexual couples 76  and heterosexual men and women '\n",
      " 'recruited individually  77 however no evidence is yet available regarding '\n",
      " 'taf ftc among heterosexually active women in addition one  clinical trial '\n",
      " 'involving persons who inject drugs 78 and one  involving heterosexual '\n",
      " 'mixedstatus couples 76 demonstrated  substantial efficacy and safety of '\n",
      " 'daily oral prep with tdf  alone high adherence to oral prep was strongly '\n",
      " 'associated  with protection from hiv infection studies conducted with  msm '\n",
      " 'have demonstrated that taking prep at specific times  before and after '\n",
      " 'sexual intercourse was effective in preventing  hiv however less experience '\n",
      " 'exits with this regimen it is  not fda cleared and it has not been studied '\n",
      " 'among other  populations 79 comprehensive clinical practice guidelines are '\n",
      " 'available  for providers in prescribing prep to reduce the risk for hiv  '\n",
      " 'infection 80 among hivnegative sexually active men  and women bacterial stis '\n",
      " 'are key indicators of risk for  hiv acquisition studies have documented the '\n",
      " 'risk for hiv  acquisition among msm within 1 year after infection with  '\n",
      " 'rectal gonorrhea or chlamydia one in 15 men primary  or secondary syphilis '\n",
      " 'one in 18 and among men with no  '\n",
      " 'httpswwwcdcgovreproductivehealthcontraceptionmmwrspremergencyhtml '\n",
      " 'httpswwwcdcgovreproductivehealthcontraceptionmmwrspremergencyhtml '\n",
      " 'httpswwwcdcgovreproductivehealthcontraceptionmmwrmecappendixjhtml '\n",
      " 'httpswwwcdcgovreproductivehealthcontraceptionmmwrmecappendixjhtml '\n",
      " 'httpswwwcdcgovreproductivehealthcontraceptionmmwrmecappendixjhtml '\n",
      " 'httpswwwafrowhointpublicationsvoluntarymedicalmalecircumcisionhivprevention '\n",
      " 'httpswwwafrowhointpublicationsvoluntarymedicalmalecircumcisionhivprevention '\n",
      " 'httpswwwcdcgovhivriskmalecircumcisionhtml '\n",
      " 'httpswwwcdcgovhivriskmalecircumcisionhtml recommendations and reports 8 '\n",
      " 'mmwr  july 23 2021  vol 70  no 4 us department of health and human '\n",
      " 'servicescenters for disease control and prevention rectal sti or syphilis '\n",
      " 'infection one in 53 81–83 sexually  active adults and adolescents should be '\n",
      " 'screened for stis  eg chlamydia gonorrhea and syphilis in accordance with  '\n",
      " 'recommendations and persons with infection should be  offered prep the '\n",
      " 'uspstf recommends that persons at risk  for hiv acquisition be offered prep '\n",
      " '84 persons at risk for  hiv acquisition include hivnegative persons whose '\n",
      " 'sexual  partner or partners have hiv infection especially if viral load  is '\n",
      " 'detectable or unknown persons who have had gonorrhea  or syphilis during the '\n",
      " 'previous 6 months and injecting drug  users who share injection equipment 84 '\n",
      " 'clinical practice  guidelines recommend sti screening for persons taking '\n",
      " 'prep  80 because increased rates of sti acquisition have been  described '\n",
      " '85–87 preexposure prophylaxis for stis providing hsv treatment to persons '\n",
      " 'with hiv and hsv  infection has not demonstrated benefit in reducing hiv  '\n",
      " 'acquisition among uninfected partners a large randomized  controlled trial '\n",
      " 'evaluated mixedstatus heterosexual couples  among the partners with hiv '\n",
      " 'infection who also were  seropositive for hsv2 88 use of acyclovir had no '\n",
      " 'effect  on hiv transmission these findings are consistent with a  previous '\n",
      " 'trial that reported no benefit of acyclovir in preventing  hiv acquisition '\n",
      " 'among persons seropositive for hsv2 89 doxycycline prophylaxis has been '\n",
      " 'examined for preventing  bacterial stis in a pilot study 30 msm living with '\n",
      " 'hiv with  previous syphilis two or more episodes since hiv diagnosis  were '\n",
      " 'randomly assigned to doxycycline 100 mg for 48 weeks  versus a financial '\n",
      " 'incentive–based behavioral intervention 90  that study demonstrated a 73 '\n",
      " 'reduction in any bacterial sti  at any site without substantial differences '\n",
      " 'in sexual behavior  additional studies examining doxycycline prophylaxis '\n",
      " 'are  under way or in development 91 postexposure prophylaxis for hiv and '\n",
      " 'stis guidelines for using pep aimed at preventing hiv and other  stis as a '\n",
      " 'result of sexual exposure are available at httpswww '\n",
      " 'cdcgovhivpdfprogramresourcescdchivnpepguidelines pdf sexually active persons '\n",
      " 'seeking hiv pep should be  evaluated for prep after completing their pep '\n",
      " 'course and  testing negative for hiv hiv pep is also discussed elsewhere  in '\n",
      " 'this report see sexual assault and abuse and stis genital  hygiene methods '\n",
      " 'eg vaginal washing and douching after  sexual exposure are ineffective in '\n",
      " 'protecting against hiv and  stis and might increase the risk for bacterial '\n",
      " 'vaginosis bv  certain stis and hiv infection 92 sti pep in the form of '\n",
      " 'doxycycline 200 mg taken after  unprotected anal sex has been studied among '\n",
      " 'msm and  transgender women results demonstrated reduction in incident  '\n",
      " 'chlamydia and syphilis by 70 and 73 respectively but no  effect on gonorrhea '\n",
      " '93 other studies are under way or in  development regarding doxycycline '\n",
      " 'prophylaxis for bacterial  stis 91 no longterm data are available regarding '\n",
      " 'the impact  of sti pep on antimicrobial resistance and the microbiome  '\n",
      " 'further studies are needed to determine whether sti pep is  an effective and '\n",
      " 'beneficial strategy for sti prevention hiv treatment as prevention '\n",
      " 'antiretroviral  treatment of persons with hiv to prevent hiv  among partners '\n",
      " 'in 2011 the randomized controlled trial hptn 052  demonstrated that among '\n",
      " 'hiv mixedstatus heterosexual  couples hiv antiretroviral therapy art for the '\n",
      " 'infected  partner decreased the risk for transmission to the uninfected  '\n",
      " 'partner by 96 94 therefore art not only is beneficial to  the health of '\n",
      " 'persons with hiv infection it also reduces the  risk for transmission '\n",
      " 'additional studies of hiv mixedstatus  couples heterosexual and msm couples '\n",
      " 'partner study  and msm couples opposites attract and partners2  studies '\n",
      " 'reported that patients with hiv taking art who  maintain an undetectable '\n",
      " 'viral load demonstrate no risk for  transmitting hiv to their hivnegative '\n",
      " 'sex partners 95–97  for those reasons art should be offered to all persons '\n",
      " 'with  hiv infection to obtain viral suppression detailed guidance  regarding '\n",
      " 'art regimens is available in the us department of  health and human '\n",
      " 'services’ hiv treatment guidelines 98 hiv seroadaptive strategies '\n",
      " 'seroadaptive strategies for hiv prevention have largely  originated within '\n",
      " 'communities of msm they are predicated  on knowledge of self and partner hiv '\n",
      " 'status one specific  seroadaptive practice is serosorting which includes '\n",
      " 'limiting  anal sex without a condom to partners with the same hiv  status as '\n",
      " 'their own or choosing to selectively use condoms  with hiv mixedstatus '\n",
      " 'partners another practice among  mixedstatus couples is seropositioning in '\n",
      " 'which the  person with hiv infection is the receptive partner for anal  '\n",
      " 'intercourse observational studies have consistently reported  that '\n",
      " 'serosorting confers greater risk for hiv infection than  consistent condom '\n",
      " 'use but has lower risk compared with anal  intercourse without a condom and '\n",
      " 'without serosorting 99– 101 serosorting practices have been associated with '\n",
      " 'increased  risk for stis including chlamydia and gonorrhea 102103 '\n",
      " 'serosorting is not recommended for the following reasons  many msm who have '\n",
      " 'hiv infection do not know they  have hiv because they have not been tested '\n",
      " 'recently men’s  assumptions about the hiv status of their partners might be  '\n",
      " 'wrong and some men with hiv infection might not disclose or  might '\n",
      " 'misrepresent their hiv status all of these factors increase  '\n",
      " 'httpswwwcdcgovhivpdfprogramresourcescdchivnpepguidelinespdf '\n",
      " 'httpswwwcdcgovhivpdfprogramresourcescdchivnpepguidelinespdf '\n",
      " 'httpswwwcdcgovhivpdfprogramresourcescdchivnpepguidelinespdf recommendations '\n",
      " 'and reports mmwr  july 23 2021  vol 70  no 4 9us department of health and '\n",
      " 'human servicescenters for disease control and prevention the risk that '\n",
      " 'serosorting can lead to hiv infection serosorting  has not been studied '\n",
      " 'among heterosexually active persons abstinence and reduction of number of  '\n",
      " 'sex partners abstinence from oral vaginal and anal sex and participating  in '\n",
      " 'a longterm mutually monogamous relationship with a  partner known to be '\n",
      " 'uninfected are prevention approaches to  avoid transmission of stis for '\n",
      " 'persons who are being treated  for an sti or whose partners are undergoing '\n",
      " 'treatment  counseling that encourages abstinence from sexual intercourse  '\n",
      " 'until completion of the entire course of medication is vital  for preventing '\n",
      " 'reinfection a trial conducted among women  regarding the effectiveness of '\n",
      " 'counseling messages when  patients have cervicitis or vaginal discharge '\n",
      " 'demonstrated  that women whose sex partners have used condoms might  benefit '\n",
      " 'from a hierarchical message that includes condoms  but women without such '\n",
      " 'experience might benefit more from  an abstinenceonly message 104 a more '\n",
      " 'comprehensive  discussion of abstinence and other sexual practices that can '\n",
      " 'help  persons reduce their risk for stis is available in contraceptive  '\n",
      " 'technology 21st edition 31 partner services the term “partner services” '\n",
      " 'refers to a continuum of clinical  evaluation counseling diagnostic testing '\n",
      " 'and treatment  designed to increase the number of infected persons brought '\n",
      " 'to  treatment and to reduce transmission among sexual networks  this '\n",
      " 'continuum includes efforts of health departments  medical providers and '\n",
      " 'patients themselves the term “public  health partner services” refers to '\n",
      " 'efforts by public health  departments to identify the sex and needlesharing '\n",
      " 'partners  of infected persons to ensure their medical evaluation and  '\n",
      " 'treatment health departments are increasingly incorporating  referral to '\n",
      " 'additional services as indicated into the partner services  continuum aside '\n",
      " 'from the general benefit to patients and partners  service referrals and '\n",
      " 'linkage can mitigate the circumstances that  increase risk for future sti '\n",
      " 'and hiv acquisition the types and comprehensiveness of public health '\n",
      " 'partner  services and the specific stis for which they are offered vary  by '\n",
      " 'public health agency their resources and the geographic  prevalence of stis '\n",
      " 'in most areas of the united states health  departments routinely attempt to '\n",
      " 'provide partner services to  all persons with infectious syphilis primary or '\n",
      " 'secondary  and persons with a new diagnosis of hiv infection health  '\n",
      " 'departments should provide partner services for persons who  might have '\n",
      " 'cephalosporinresistant gonorrhea in contrast  relatively few us health '\n",
      " 'departments routinely provide  sti partner services to persons with '\n",
      " 'gonorrhea chlamydia  trichomoniasis or other stis 105 because sti diagnoses  '\n",
      " 'often can serve as risk markers for hiv acquisition 83 public  health '\n",
      " 'services might include followup of msm with an sti  to offer hiv prep public '\n",
      " 'health services can also include hiv  and sti prevention interventions '\n",
      " 'including hiv and sti  testing linkage and relinkage of persons with hiv '\n",
      " 'infection  to hiv care clinics and referral of partners of persons with  '\n",
      " 'stis or hiv infection to hiv prep as indicated 106–109  clinicians should '\n",
      " 'familiarize themselves with public health  practices in their area however '\n",
      " 'in most instances providers  should understand that responsibility for '\n",
      " 'discussing the  treatment of partners of persons with stis rests with the  '\n",
      " 'diagnosing provider and the patient state laws require a good  faith effort '\n",
      " 'by the provider to inform partners and providers  should familiarize '\n",
      " 'themselves with public health laws clinicians who do not notify partners of '\n",
      " 'patients directly  can still provide partner services by counseling infected '\n",
      " 'persons  and providing them with written information and medication  to give '\n",
      " 'to their partners if recommended and allowable by  state law directly '\n",
      " 'evaluating and treating sex partners and  cooperating with state and local '\n",
      " 'health departments clinicians’  efforts to ensure treatment of patients’ sex '\n",
      " 'partners can reduce  the risk for reinfection and potentially diminish '\n",
      " 'transmission  of stis 110 therefore clinicians should encourage all  persons '\n",
      " 'with stis to notify their sex partners and urge them  to seek medical '\n",
      " 'evaluation and treatment exceptions to this  practice include circumstances '\n",
      " 'posing a risk for intimate  partner violence 111 available data are limited '\n",
      " 'regarding  the rate of intimate partner violence directly attributable  to '\n",
      " 'partner notification 112113 however because of the  reported prevalence of '\n",
      " 'intimate partner violence in the general  population 114 providers should '\n",
      " 'consider the potential  risk before notifying partners of persons or '\n",
      " 'encouraging  partner notification time spent counseling patients about the  '\n",
      " 'importance of notifying partners is associated with improved  notification '\n",
      " 'outcomes 115 when possible clinicians should  advise persons to bring their '\n",
      " 'primary sex partner with them  when returning for treatment and should '\n",
      " 'concurrently treat  both persons although this approach can be effective for '\n",
      " 'a  main partner 116117 it might not be a feasible approach  for additional '\n",
      " 'sex partners evidence indicates that providing  patients with written '\n",
      " 'information to share with sex partners  can increase rates of partner '\n",
      " 'treatment 110 certain health departments now use technology eg  email '\n",
      " 'texting mobile applications and social media outlets  to facilitate partner '\n",
      " 'services for locating and notifying the  sex partners of persons with stis '\n",
      " 'including hiv 118119  patients now have the option to use internet sites to '\n",
      " 'send  anonymous email or text messages advising partners of their  exposure '\n",
      " 'to an sti 120 anonymous notification via the  recommendations and reports 10 '\n",
      " 'mmwr  july 23 2021  vol 70  no 4 us department of health and human '\n",
      " 'servicescenters for disease control and prevention internet is considered '\n",
      " 'better than no notification at all  however because the extent to which '\n",
      " 'these sites affect partner  notification and treatment is uncertain patients '\n",
      " 'should be  encouraged to notify their partners in person or by telephone  '\n",
      " 'email or text message alternatively patients can authorize a  medical '\n",
      " 'provider or public health professional to notify their  sex partners '\n",
      " 'expedited partner therapy expedited partner therapy ept is a harmreduction  '\n",
      " 'strategy and the clinical practice of treating the sex partners  of persons '\n",
      " 'with diagnosed chlamydia or gonorrhea who are  unable or unlikely to seek '\n",
      " 'timely treatment by providing  medications or prescriptions to the patient '\n",
      " 'as allowable by law  patients then provide partners with these therapies '\n",
      " 'without  the health care provider having examined the partner https '\n",
      " 'wwwcdcgovstdept unless prohibited by law or other  regulations medical '\n",
      " 'providers should routinely offer ept  to patients with chlamydia when the '\n",
      " 'provider cannot ensure  that all of a patient’s sex partners from the '\n",
      " 'previous 60 days  will seek timely treatment if the patient has not had sex  '\n",
      " 'during the 60 days before diagnosis providers should offer  ept for the '\n",
      " 'patient’s most recent sex partner because ept  must be an oral regimen and '\n",
      " 'current gonorrhea treatment  involves an injection ept for gonorrhea should '\n",
      " 'be offered  to partners unlikely to access timely evaluation after linkage  '\n",
      " 'is explored ept is legal in the majority of states but varies  by chlamydial '\n",
      " 'or gonococcal infection providers should visit  httpswwwcdcgovstdept to '\n",
      " 'obtain updated information for  their state providing patients with packaged '\n",
      " 'oral medication  is the preferred approach because the efficacy of ept '\n",
      " 'using  prescriptions has not been evaluated obstacles to ept can exist  at '\n",
      " 'the pharmacy level 121122 and many persons especially  adolescents do not '\n",
      " 'fill the prescriptions provided to them by  a sex partner 123124 medication '\n",
      " 'or prescriptions provided  for ept should be accompanied by educational '\n",
      " 'materials for  the partner including treatment instructions warnings about  '\n",
      " 'taking medications eg if the partner is pregnant or has an  allergy to the '\n",
      " 'medication general health counseling and a  statement advising that partners '\n",
      " 'seek medical evaluation as  soon as possible for hiv infection and any '\n",
      " 'symptoms of stis  particularly pid evidence supporting ept is based on three '\n",
      " 'us clinical  trials involving heterosexual men and women with chlamydia  or '\n",
      " 'gonorrhea 125–127 all three trials reported that more  partners were treated '\n",
      " 'when patients were offered ept two  reported statistically significant '\n",
      " 'decreases in the rate of  reinfection and one observed a lower risk for '\n",
      " 'persistent or  recurrent infection that was statistically nonsignificant a  '\n",
      " 'fourth trial in the united kingdom did not demonstrate a  difference in the '\n",
      " 'risk for reinfection or in the numbers of  partners treated between persons '\n",
      " 'offered ept and those  advised to notify their sex partners 128 us trials '\n",
      " 'and a  metaanalysis of ept revealed that the magnitude of reduction  in '\n",
      " 'reinfection of index patients compared with patient referral  differed '\n",
      " 'according to the sti and the sex of the index patient  110125–127 however '\n",
      " 'across trials reductions in chlamydia  prevalence at followup were '\n",
      " 'approximately 20 and  reductions in gonorrhea were approximately 50 at '\n",
      " 'followup existing data indicate that ept also might have a role in  partner '\n",
      " 'management for trichomoniasis however no partner  management intervention '\n",
      " 'has been reported to be more  effective than any other in reducing '\n",
      " 'trichomoniasis reinfection  rates 129130 no data support use of ept in the '\n",
      " 'routine  management of patients with syphilis data are limited regarding use '\n",
      " 'of ept for gonococcal  or chlamydial infections among msm compared with  '\n",
      " 'heterosexuals 131132 published studies including recent  data regarding '\n",
      " 'extragenital testing indicated that male partners  of msm with diagnosed '\n",
      " 'gonorrhea or chlamydia might have  other bacterial stis gonorrhea or '\n",
      " 'syphilis or hiv 133–135  studies have reported that 5 of msm have a new '\n",
      " 'diagnosis  of hiv when evaluated as partners of men with gonococcal  or '\n",
      " 'chlamydial infections 133134 however more recent data  indicate that in '\n",
      " 'certain settings the frequency of hiv infection  is much lower 135 '\n",
      " 'considering limited data and potential  for other bacterial stis among msm '\n",
      " 'partners shared clinical  decisionmaking regarding ept is recommended all '\n",
      " 'persons  who receive bacterial sti diagnoses and their sex partners  '\n",
      " 'particularly msm should be tested for hiv and those at risk  for hiv '\n",
      " 'infection should be offered hiv prep httpswww '\n",
      " 'cdcgovhivpdfriskprepcdchivprepguidelines2017pdf  reporting and '\n",
      " 'confidentiality accurate and timely reporting of stis is integral to public  '\n",
      " 'health efforts in assessing morbidity trends allocating limited  resources '\n",
      " 'and assisting local health authorities with partner  notification and '\n",
      " 'treatment sti and hivaids cases should  be reported in accordance with state '\n",
      " 'and local statutory  requirements syphilis including congenital syphilis  '\n",
      " 'gonorrhea chlamydia chancroid and hiv are reportable  diseases in every '\n",
      " 'state because the requirements for reporting  other stis differ by state '\n",
      " 'clinicians should be familiar with the  reporting requirements applicable '\n",
      " 'within their jurisdictions reporting can be provider based laboratory based '\n",
      " 'or  both clinicians who are unsure of state and local reporting  '\n",
      " 'requirements should seek advice from state or local health  department sti '\n",
      " 'programs sti and hiv reports are kept  confidential in most jurisdictions '\n",
      " 'such reports are protected  httpswwwcdcgovstdept httpswwwcdcgovstdept '\n",
      " 'httpswwwcdcgovstdept httpswwwcdcgovhivpdfriskprepcdchivprepguidelines2017pdf '\n",
      " 'httpswwwcdcgovhivpdfriskprepcdchivprepguidelines2017pdf recommendations and '\n",
      " 'reports mmwr  july 23 2021  vol 70  no 4 11us department of health and human '\n",
      " 'servicescenters for disease control and prevention by statute or regulation '\n",
      " 'before conducting a followup  of a person with a positive sti test result '\n",
      " 'public health  professionals should consult the patient’s health care '\n",
      " 'provider  if possible to inform them of the purpose of the public health  '\n",
      " 'visit verify the diagnosis determine the treatments received  and ascertain '\n",
      " 'the best approaches to patient followup retesting after treatment to detect  '\n",
      " 'repeat infections retesting 3 months after diagnosis of chlamydia gonorrhea  '\n",
      " 'or trichomoniasis can detect repeat infection and potentially  can be used '\n",
      " 'to enhance populationbased prevention 136137  any person who has a positive '\n",
      " 'test for chlamydia or gonorrhea  along with women who have a positive test '\n",
      " 'for trichomonas  should be rescreened 3 months after treatment any person  '\n",
      " 'who receives a syphilis diagnosis should undergo followup  serologic '\n",
      " 'syphilis testing per current recommendations  and followup testing for hiv '\n",
      " 'see syphilis additional  information regarding retesting is available '\n",
      " 'elsewhere in this  report see chlamydial infections gonococcal infections  '\n",
      " 'syphilis trichomoniasis sti detection among special  populations pregnant '\n",
      " 'women intrauterine or perinatally transmitted stis can have  debilitating '\n",
      " 'effects on pregnant women their fetuses and their  partners all pregnant '\n",
      " 'women and their sex partners should be  asked about stis counseled about the '\n",
      " 'possibility of perinatal  infections and provided access to recommended '\n",
      " 'screening and  treatment if needed recommendations for screening pregnant '\n",
      " 'women for  stis to detect asymptomatic infections are based on disease  '\n",
      " 'severity and sequelae prevalence among the population costs  medicolegal '\n",
      " 'considerations eg state laws and other factors  the following screening '\n",
      " 'recommendations for pregnant  women summarize clinical guidelines from '\n",
      " 'federal agencies  and medical professional organizations screening '\n",
      " 'recommendations hiv infection  all pregnant women in the united states '\n",
      " 'should be tested  for hiv at the first prenatal visit even if they have '\n",
      " 'been  previously tested 138 testing pregnant women for hiv  and prompt '\n",
      " 'linkage to care of women with hiv infection are  vital for women’s health '\n",
      " 'and reducing perinatal transmission of  hiv through art and obstetrical '\n",
      " 'interventions hiv testing  should be offered as part of the routine panel of '\n",
      " 'prenatal tests  ie optout testing for women who decline hiv testing  '\n",
      " 'providers should address their concerns and when appropriate  continue to '\n",
      " 'encourage testing partners of pregnant patients  should be offered hiv '\n",
      " 'testing if their status is unknown 139 retesting in the third trimester '\n",
      " 'preferably before 36 weeks’  gestation is recommended for women at high risk '\n",
      " 'for  acquiring hiv infection examples of women at high risk  include those '\n",
      " 'who inject drugs have stis during pregnancy  have multiple sex partners '\n",
      " 'during pregnancy have a new  sex partner during pregnancy or have partners '\n",
      " 'with hiv  infection those who are receiving care in health care facilities  '\n",
      " 'in settings with hiv incidence ≥1 per 1000 women per year  those who are '\n",
      " 'incarcerated those who live in areas with high  rates of hiv infection or '\n",
      " 'those who have signs or symptoms  of acute hiv infection eg fever '\n",
      " 'lymphadenopathy skin  rash myalgia arthralgia headache oral ulcers '\n",
      " 'leukopenia  thrombocytopenia or transaminase elevation 140 rapid hiv testing '\n",
      " 'should be performed for any woman in labor  who has not been tested for hiv '\n",
      " 'during pregnancy or whose hiv  status is unknown unless she declines if a '\n",
      " 'rapid hiv test result  is positive art should be administered without '\n",
      " 'waiting for the  results of confirmatory testing '\n",
      " 'httpsclinicalinfohivgovsites defaultfilesinlinefilesperinatalglpdf syphilis '\n",
      " 'during 2012–2019 congenital syphilis rates in the united  states increased '\n",
      " 'from 84 to 485 cases per 100000 births  a 4774 increase 141 at least 45 '\n",
      " 'states have a prenatal  syphilis testing requirement with high variability '\n",
      " 'among those  requirements 142 in the united states all pregnant women  '\n",
      " 'should be screened for syphilis at the first prenatal visit even  if they '\n",
      " 'have been tested previously 143 prenatal screening  for syphilis has been '\n",
      " 'reported to be suboptimal in the united  states 144145 testing in the third '\n",
      " 'trimester and at delivery  can prevent congenital syphilis cases 146147 '\n",
      " 'partners of  pregnant women with syphilis should be evaluated tested  and '\n",
      " 'treated when access to prenatal care is not optimal a stat rapid  plasma '\n",
      " 'reagin rpr card test and treatment if that test is  reactive should be '\n",
      " 'administered at the time that a pregnancy  is confirmed or when the '\n",
      " 'pregnancy test is performed if  followup is uncertain pregnant women should '\n",
      " 'be retested  for syphilis at 28 weeks’ gestation and at delivery if the '\n",
      " 'mother  lives in a community with high syphilis rates or is at risk for  '\n",
      " 'syphilis acquisition during pregnancy eg misuses drugs or  has an sti during '\n",
      " 'pregnancy having multiple sex partners  having a new sex partner or having a '\n",
      " 'sex partner with an sti  neonates should not be discharged from the hospital '\n",
      " 'unless  httpsclinicalinfohivgovsitesdefaultfilesinlinefilesperinatalglpdf '\n",
      " 'httpsclinicalinfohivgovsitesdefaultfilesinlinefilesperinatalglpdf '\n",
      " 'recommendations and reports 12 mmwr  july 23 2021  vol 70  no 4 us '\n",
      " 'department of health and human servicescenters for disease control and '\n",
      " 'prevention the syphilis serologic status of the mother has been determined  '\n",
      " 'at least once during pregnancy any woman who delivers a  stillborn infant '\n",
      " 'should be tested for syphilis hepatitis b all pregnant women should be '\n",
      " 'routinely tested for hepatitis  b surface antigen hbsag at the first '\n",
      " 'prenatal visit even if they  have been previously vaccinated or tested 148 '\n",
      " 'women who  are hbsag positive should be provided with or referred for  '\n",
      " 'counseling and medical management women who are hbsag  negative but at risk '\n",
      " 'for hbv infection should be vaccinated  women who were not screened '\n",
      " 'prenatally those who engage  in behaviors that put them at high risk for '\n",
      " 'infection eg  having had more than one sex partner during the previous  6 '\n",
      " 'months having been evaluated or treated for an sti  having had recent or '\n",
      " 'current injection drug use or having an  hbsagpositive sex partner and those '\n",
      " 'with clinical hepatitis  should be tested at the time of admission to the '\n",
      " 'hospital  for delivery to avoid misinterpreting a transient positive  hbsag '\n",
      " 'result during the 21 days after vaccination hbsag  testing should be '\n",
      " 'performed before vaccine administration  all laboratories that conduct hbsag '\n",
      " 'tests should test initially  reactive specimens with a licensed neutralizing '\n",
      " 'confirmatory  test when pregnant women are tested for hbsag at the time  of '\n",
      " 'admission for delivery shortened testing protocols can be  used and '\n",
      " 'initially reactive results should prompt expedited  administration of '\n",
      " 'immunoprophylaxis to neonates 148  pregnant women who are hbsag positive '\n",
      " 'should be reported  to the local or state health department to ensure that '\n",
      " 'they  are entered into a casemanagement system and that timely  and '\n",
      " 'ageappropriate prophylaxis is provided to their infants  information '\n",
      " 'concerning the pregnant woman’s hbsag status  should be provided to the '\n",
      " 'hospital where delivery is planned  and to the health care provider who will '\n",
      " 'care for the newborn  in addition household and sexual contacts of women who '\n",
      " 'are  hbsag positive should be vaccinated chlamydia all pregnant women aged '\n",
      " '25 years as well as older women  at increased risk for chlamydia eg those '\n",
      " 'aged ≥25 years who  have a new sex partner more than one sex partner a sex '\n",
      " 'partner  with concurrent partners or a sex partner who has an sti  should be '\n",
      " 'routinely screened for chlamydia trachomatis at the first  prenatal visit '\n",
      " '149 pregnant women who remain at increased  risk for chlamydial infection '\n",
      " 'also should be retested during the  third trimester to prevent maternal '\n",
      " 'postnatal complications and  chlamydial infection in the neonate pregnant '\n",
      " 'women identified  as having chlamydia should be treated immediately and have '\n",
      " 'a  test of cure to document chlamydial eradication by a nucleic acid  '\n",
      " 'amplification test naat 4 weeks after treatment all persons  diagnosed with '\n",
      " 'a chlamydial infection should be rescreened  3 months after treatment '\n",
      " 'gonorrhea all pregnant women aged 25 years as well as women aged  ≥25 years '\n",
      " 'at increased risk for gonorrhea eg those with other  stis during pregnancy '\n",
      " 'or those with a new sex partner more  than one sex partner a sex partner '\n",
      " 'with concurrent partners  or a sex partner who has an sti or is exchanging '\n",
      " 'sex for money  or drugs should be screened for neisseria gonorrhoeae at the  '\n",
      " 'first prenatal visit 149 pregnant women who remain at high  risk for '\n",
      " 'gonococcal infection also should be retested during the  third trimester to '\n",
      " 'prevent maternal postnatal complications and  gonococcal infection in the '\n",
      " 'neonate clinicians should consider  the communities they serve and might '\n",
      " 'choose to consult local  public health authorities for guidance on '\n",
      " 'identifying groups  that are more vulnerable to gonorrhea acquisition on the '\n",
      " 'basis  of local disease prevalence gonococcal infection in particular  is '\n",
      " 'concentrated among specific geographic locations and  communities '\n",
      " 'httpswwwcdcgovstdstatistics2019default htm pregnant women identified as '\n",
      " 'having gonorrhea should  be treated immediately all persons diagnosed with '\n",
      " 'gonorrhea  should be rescreened 3 months after treatment hepatitis c virus '\n",
      " 'the rate of hepatitis c virus hcv infection has increased  among pregnant '\n",
      " 'women in recent years 150–153 hcv  screening should be performed for all '\n",
      " 'pregnant women  during each pregnancy except in settings where the hcv  '\n",
      " 'infection hcv positivity rate is 01 154–156 the most  important risk factor '\n",
      " 'for hcv infection is past or current  injecting drug use 157 additional risk '\n",
      " 'factors include having  had a blood transfusion or organ transplantation '\n",
      " 'before july  1992 having received clotting factor concentrates produced  '\n",
      " 'before 1987 having received an unregulated tattoo having  been on longterm '\n",
      " 'hemodialysis having other percutaneous  exposures or having hiv infection '\n",
      " 'all women with hcv  infection should receive counseling supportive care and  '\n",
      " 'linkage to care httpswwwhcvguidelinesorg no vaccine  is available for '\n",
      " 'preventing hcv transmission cervical cancer pregnant women should undergo '\n",
      " 'cervical cancer screening  and at the same frequency as nonpregnant women '\n",
      " 'however  management differs slightly during pregnancy 158  colposcopy is '\n",
      " 'recommended for the same indications during  pregnancy as for nonpregnant '\n",
      " 'women however biopsies  may be deferred and endocervical sampling should '\n",
      " 'not  be performed treatment should not be performed during  pregnancy unless '\n",
      " 'cancer is detected httpswwwcdcgovstdstatistics2019defaulthtm '\n",
      " 'httpswwwcdcgovstdstatistics2019defaulthtm httpswwwhcvguidelinesorg '\n",
      " 'recommendations and reports mmwr  july 23 2021  vol 70  no 4 13us department '\n",
      " 'of health and human servicescenters for disease control and prevention '\n",
      " 'bacterial vaginosis trichomoniasis and  genital herpes evidence does not '\n",
      " 'support routine screening for bv among  asymptomatic pregnant women at high '\n",
      " 'risk for preterm  delivery 159 symptomatic women should be evaluated  and '\n",
      " 'treated see bacterial vaginosis evidence does not  support routine screening '\n",
      " 'for trichomonas vaginalis among  asymptomatic pregnant women women who '\n",
      " 'report symptoms  should be evaluated and treated see trichomoniasis in  '\n",
      " 'addition evidence does not support routine hsv2 serologic  screening among '\n",
      " 'asymptomatic pregnant women however  typespecific serologic tests might be '\n",
      " 'useful for identifying  pregnant women at risk for hsv2 infection and for '\n",
      " 'guiding  counseling regarding the risk for acquiring genital herpes  during '\n",
      " 'pregnancy routine serial cultures for hsv are not  indicated for women in '\n",
      " 'the third trimester who have a history  of recurrent genital herpes for more '\n",
      " 'detailed discussions of sti screening and treatment  among pregnant women '\n",
      " 'refer to the following references  screening for hiv infection us preventive '\n",
      " 'services task force  recommendation statement 138 recommendations for the '\n",
      " 'use  of antiretroviral drugs in pregnant women with hiv infection  and '\n",
      " 'interventions to reduce perinatal hiv transmission in  the united states '\n",
      " 'httpsclinicalinfohivgovsitesdefault filesinlinefilesperinatalglpdf  '\n",
      " 'guidelines for perinatal  care 160 prevention of hepatitis b virus infection '\n",
      " 'in the  united states recommendations of the advisory committee  on '\n",
      " 'immunization practices 12 screening for chlamydia and  gonorrhea us '\n",
      " 'preventive services task force recommendation  statement 149 screening for '\n",
      " 'bacterial vaginosis in pregnant  persons to prevent preterm delivery us '\n",
      " 'preventive services  task force recommendation statement 159 screening for  '\n",
      " 'syphilis infection in pregnant women us preventive services  task force '\n",
      " 'recommendation statement 161 serologic screening  for genital herpes '\n",
      " 'infection us preventive services task force  recommendation statement 162 '\n",
      " 'screening for hiv infection  in pregnant women a systematic review for the '\n",
      " 'us preventive  services task force 163 screening for hepatitis b in '\n",
      " 'pregnant  women updated evidence report and systematic review  for the us '\n",
      " 'preventive services task force 164 and cdc  recommendations for hepatitis c '\n",
      " 'screening among adults —  united states 2020 156 adolescents in the united '\n",
      " 'states prevalence rates of certain stis are  highest among adolescents and '\n",
      " 'young adults 141 for  example reported rates of chlamydia and gonorrhea are '\n",
      " 'highest  among females during their adolescent and young adult years  and '\n",
      " 'many persons acquire hpv infection during that time persons who initiate sex '\n",
      " 'early in adolescence are at higher risk  for stis as are adolescents living '\n",
      " 'in detention facilities those  receiving services at std clinics those who '\n",
      " 'are involved in  commercial sex exploitation or survival sex and are '\n",
      " 'exchanging  sex for drugs money food or housing young males who  have sex '\n",
      " 'with males ymsm transgender youths and youths  with disabilities substance '\n",
      " 'misuse or mental health disorders  factors contributing to increased '\n",
      " 'vulnerability to stis during  adolescence include having multiple sex '\n",
      " 'partners having  sequential sex partnerships of limited duration or '\n",
      " 'concurrent  partnerships failing to use barrier protection consistently  and '\n",
      " 'correctly having lower socioeconomic status and facing  multiple obstacles '\n",
      " 'to accessing health care 141165 all 50 states and the district of columbia '\n",
      " 'explicitly allow  minors to consent for their own sti services no state '\n",
      " 'requires  parental consent for sti care although the age at which a  minor '\n",
      " 'can provide consent for specified health care services  ie hpv vaccination '\n",
      " 'and hiv testing and treatment varies  among states in 2019 a total of 18 '\n",
      " 'states allowed but did not  require physicians to notify parents of a '\n",
      " 'minor’s receipt of sti  services including states where minors can legally '\n",
      " 'provide their  own consent to the service httpswwwcdcgovhivpolicies '\n",
      " 'lawstatesminorshtml protecting confidentiality for sti care particularly '\n",
      " 'for  adolescents enrolled in private health insurance plans presents  '\n",
      " 'multiple problems after a claim has been submitted many  states mandate that '\n",
      " 'health plans provide a written statement  to the beneficiary indicating the '\n",
      " 'service performed the charges  covered what the insurer allows and the '\n",
      " 'amount for which the  patient is responsible ie explanation of benefits eob '\n",
      " '166– 169 in addition federal laws obligate notices to beneficiaries  when '\n",
      " 'claims are denied including alerting beneficiaries who  need to pay for care '\n",
      " 'until the allowable deductible is reached  for sti testing and '\n",
      " 'treatmentrelated care an eob or  medical bill that is received by a parent '\n",
      " 'might disclose services  provided and list sti laboratory tests performed or '\n",
      " 'treatment  administered some states have instituted mechanisms for  '\n",
      " 'protecting adolescents’ confidentiality and limiting eobs  additional risks '\n",
      " 'to confidentiality breaches can inadvertently  occur through electronic '\n",
      " 'health records although technology  continues to evolve to assist with '\n",
      " 'ensuring confidential care  aap and the society for adolescent health and '\n",
      " 'medicine  sahm have published guidance on strategies to address  emerging '\n",
      " 'risks for confidentiality breaches associated with  health information '\n",
      " 'technology 169 aap and the sahm recommend that providers have  time alone '\n",
      " 'with their adolescent patients that includes  assessment for sexual behavior '\n",
      " 'the aap recommendations  are available at httpsservicesaaporgennewsroom '\n",
      " 'campaignsandtoolkitsadolescenthealthcare and the sahm  '\n",
      " 'httpsclinicalinfohivgovsitesdefaultfilesinlinefilesperinatalglpdf '\n",
      " 'httpsclinicalinfohivgovsitesdefaultfilesinlinefilesperinatalglpdf '\n",
      " 'httpswwwcdcgovhivpolicieslawstatesminorshtml '\n",
      " 'httpswwwcdcgovhivpolicieslawstatesminorshtml '\n",
      " 'httpsservicesaaporgennewsroomcampaignsandtoolkitsadolescenthealthcare '\n",
      " 'httpsservicesaaporgennewsroomcampaignsandtoolkitsadolescenthealthcare '\n",
      " 'recommendations and reports 14 mmwr  july 23 2021  vol 70  no 4 us '\n",
      " 'department of health and human servicescenters for disease control and '\n",
      " 'prevention recommendations are available at httpswwwadolescenthealth '\n",
      " 'orgmysahmloginorcreateanaccountaspxreturnurl '\n",
      " '2fresources2fclinicalcareresources2fconfidentiality aspx discussions '\n",
      " 'concerning sexual behavior should be tailored  for the patient’s '\n",
      " 'developmental level and be aimed at identifying  risk behaviors eg multiple '\n",
      " 'partners oral anal or vaginal  sex or drug misuse behaviors careful '\n",
      " 'nonjudgmental and  thorough counseling is particularly vital for adolescents '\n",
      " 'who  might not feel comfortable acknowledging their engagement in  behaviors '\n",
      " 'that make them more vulnerable to acquiring stis screening recommendations '\n",
      " 'recommendations for screening adolescents for stis to  detect asymptomatic '\n",
      " 'infections are based on disease severity  and sequelae prevalence among the '\n",
      " 'population costs  medicolegal considerations eg state laws and other '\n",
      " 'factors  routine laboratory screening for common stis is indicated  for all '\n",
      " 'sexually active adolescents the following screening  recommendations '\n",
      " 'summarize published clinical prevention  guidelines for sexually active '\n",
      " 'adolescents from federal agencies  and medical professional organizations '\n",
      " 'chlamydia routine screening for c trachomatis infection on an annual  basis '\n",
      " 'is recommended for all sexually active females aged  25 years 149 rectal '\n",
      " 'chlamydial testing can be considered  for females on the basis of reported '\n",
      " 'sexual behaviors and  exposure through shared clinical decisionmaking '\n",
      " 'between the  patient and the provider 170171 evidence is insufficient  to '\n",
      " 'recommend routine screening for c trachomatis among  sexually active young '\n",
      " 'males on the basis of efficacy and cost effectiveness however screening of '\n",
      " 'sexually active young males  should be considered in clinical settings '\n",
      " 'serving populations  of young men with a high prevalence of chlamydial '\n",
      " 'infections  eg adolescent service clinics correctional facilities and std  '\n",
      " 'clinics chlamydia screening including pharyngeal or rectal  testing should '\n",
      " 'be offered to all ymsm at least annually on  the basis of sexual behavior '\n",
      " 'and anatomic site of exposure see  men who have sex with men gonorrhea '\n",
      " 'routine screening for n gonorrhoeae on an annual basis is  recommended for '\n",
      " 'all sexually active females aged 25 years  149 extragenital gonorrhea '\n",
      " 'screening pharyngeal or rectal  can be considered for females on the basis '\n",
      " 'of reported sexual  behaviors and exposure through shared clinicaldecision  '\n",
      " 'between the patient and the provider 170171 gonococcal  infection is more '\n",
      " 'prevalent among certain geographic  locations and communities 141 clinicians '\n",
      " 'should consider  the communities they serve and consult local public health  '\n",
      " 'authorities for guidance regarding identifying groups that are  more '\n",
      " 'vulnerable to gonorrhea acquisition on the basis of local  disease '\n",
      " 'prevalence evidence is insufficient to recommend  routine screening on the '\n",
      " 'basis of efficacy and costeffectiveness  for n gonorrhoeae among '\n",
      " 'asymptomatic sexually active young  males who have sex with females only '\n",
      " 'screening for gonorrhea  including pharyngeal or rectal testing should be '\n",
      " 'offered to  ymsm at least annually see men who have sex with men providers '\n",
      " 'might consider optout chlamydia and gonorrhea  screening ie the patient is '\n",
      " 'notified that testing will be  performed unless the patient declines '\n",
      " 'regardless of reported  sexual activity for adolescent and young adult '\n",
      " 'females during  clinical encounters costeffectiveness analyses indicate '\n",
      " 'that  optout chlamydia screening among adolescent and young  adult females '\n",
      " 'might substantially increase screening be cost saving 172 and identify '\n",
      " 'infections among patients who do  not disclose sexual behavior 173 hiv '\n",
      " 'infection hiv screening should be discussed and offered to all  adolescents '\n",
      " 'frequency of repeat screenings should be based on  the patient’s sexual '\n",
      " 'behaviors and the local disease prevelance  138 persons with hiv infection '\n",
      " 'should receive prevention  counseling and linkage to care before leaving the '\n",
      " 'testing site cervical cancer guidelines from uspstf and acog recommend that  '\n",
      " 'cervical cancer screening begin at age 21 years 174175 this  recommendation '\n",
      " 'is based on the low incidence of cervical  cancer and limited usefulness of '\n",
      " 'screening for cervical cancer  among adolescents 176 in contrast the 2020 '\n",
      " 'acs guidelines  recommend that cervical cancer screening begin at age 25 '\n",
      " 'years  with hpv testing this change is recommended because the  incidence of '\n",
      " 'invasive cervical cancer in women aged 25 years  is decreasing because of '\n",
      " 'vaccination 177 adolescents  with hiv infection who have initiated sexual '\n",
      " 'intercourse  should have cervical screening cytology in accordance with  '\n",
      " 'hivaids guidelines httpsclinicalinfohivgoven '\n",
      " 'guidelinesadultandadolescentopportunisticinfection '\n",
      " 'humanpapillomavirusdiseaseviewfull other sexually transmitted infections '\n",
      " 'ymsm and pregnant females should be routinely screened  for syphilis see '\n",
      " 'pregnant women men who have sex with  men local disease prevalence can help '\n",
      " 'guide decision making regarding screening for t vaginalis especially among  '\n",
      " 'adolescent females in certain areas routine screening of  adolescents and '\n",
      " 'young adults who are asymptomatic for certain  stis eg syphilis '\n",
      " 'trichomoniasis bv hsv hav and hbv  is not typically recommended  '\n",
      " 'httpswwwadolescenthealthorgmysahmloginorcreateanaccountaspxreturnurl2fresources2fclinicalcareresources2fconfidentialityaspx '\n",
      " 'httpswwwadolescenthealthorgmysahmloginorcreateanaccountaspxreturnurl2fresources2fclinicalcareresources2fconfidentialityaspx '\n",
      " 'httpswwwadolescenthealthorgmysahmloginorcreateanaccountaspxreturnurl2fresources2fclinicalcareresources2fconfidentialityaspx '\n",
      " 'httpswwwadolescenthealthorgmysahmloginorcreateanaccountaspxreturnurl2fresources2fclinicalcareresources2fconfidentialityaspx '\n",
      " 'httpsclinicalinfohivgovenguidelinesadultandadolescentopportunisticinfectionhumanpapillomavirusdiseaseviewfull '\n",
      " 'httpsclinicalinfohivgovenguidelinesadultandadolescentopportunisticinfectionhumanpapillomavirusdiseaseviewfull '\n",
      " 'httpsclinicalinfohivgovenguidelinesadultandadolescentopportunisticinfectionhumanpapillomavirusdiseaseviewfull '\n",
      " 'recommendations and reports mmwr  july 23 2021  vol 70  no 4 15us department '\n",
      " 'of health and human servicescenters for disease control and prevention '\n",
      " 'primary prevention recommendations primary prevention and anticipatory '\n",
      " 'guidance for recognizing  symptoms and behaviors associated with stis are '\n",
      " 'strategies that  should be incorporated into all types of health care visits '\n",
      " 'for  adolescents and young adults the following recommendations  for primary '\n",
      " 'prevention of stis ie vaccination and  counseling are based on published '\n",
      " 'clinical guidelines for  sexually active adolescents and young adults from '\n",
      " 'federal  agencies and medical professional organizations • hpv vaccination '\n",
      " 'is recommended through age 26 years  for those not vaccinated previously at '\n",
      " 'the routine age of  11 or 12 years httpswwwcdcgovvaccineshcpacip '\n",
      " 'recsvaccspecifichpvhtml • the hbv vaccination series is recommended for all '\n",
      " 'adolescents  and young adults who have not previously received the '\n",
      " 'universal  hbv vaccine series during childhood 12 • the hav vaccination '\n",
      " 'series should be offered to  adolescents and young adults as well as those '\n",
      " 'who have  not previously received the universal hav vaccine series  during '\n",
      " 'childhood httpswwwcdcgovvaccines scheduleshcpimzchildindicationshtmlnotehepa '\n",
      " '• information regarding hiv transmission prevention testing  and '\n",
      " 'implications of infection should be regarded as an essential  component of '\n",
      " 'the anticipatory guidance provided to all  adolescents and young adults as '\n",
      " 'part of routine health care • cdc and uspstf recommend offering hiv prep to  '\n",
      " 'adolescents weighing ≥35 kg and adults who are hiv  negative and at '\n",
      " 'substantial risk for hiv infection 80178  ymsm should be offered prep in '\n",
      " 'youthfriendly settings  with tailored adherence support eg text messaging '\n",
      " 'and  visits per existing guidelines indications for prep initial  and '\n",
      " 'followup prescribing guidance and laboratory testing  recommendations are '\n",
      " 'the same for adolescents and adults  httpswwwcdcgovhivriskprep • medical '\n",
      " 'providers who care for adolescents and young  adults should integrate '\n",
      " 'sexuality education into clinical  practice health care providers should '\n",
      " 'counsel adolescents  about the sexual behaviors that are associated with '\n",
      " 'risk for  acquiring stis and should educate patients regarding  '\n",
      " 'evidencebased prevention strategies which includes a  discussion about '\n",
      " 'abstinence and other riskreduction  behaviors eg consistent and correct '\n",
      " 'condom use and  reduction in the number of sex partners including  '\n",
      " 'concurrent partners interactive counseling approaches  eg patientcentered '\n",
      " 'counseling and motivational  interviewing are effective sti and hiv '\n",
      " 'prevention  strategies and are recommended by uspstf educational  materials '\n",
      " 'eg handouts pamphlets and videos can  reinforce officebased educational '\n",
      " 'efforts children management of children who have stis requires close  '\n",
      " 'cooperation among clinicians laboratorians and child protection authorities '\n",
      " 'official investigations when indicated  should be initiated promptly certain '\n",
      " 'diseases eg gonorrhea  syphilis hiv chlamydia and trichomoniasis if acquired '\n",
      " 'after  the neonatal period strongly indicate sexual contact for other  '\n",
      " 'diseases eg hsv hpv and anogenital warts and vaginitis  the association with '\n",
      " 'sexual contact is not as clear see sexual  assault and abuse and stis men '\n",
      " 'who have sex with men msm comprise a diverse group in terms of behaviors  '\n",
      " 'identities and health care needs 179 the term “msm” often  is used '\n",
      " 'clinically to refer to sexual behavior alone regardless of  sexual '\n",
      " 'orientation eg a person might identify as heterosexual  but still be '\n",
      " 'classified as msm sexual orientation is  independent of gender identity '\n",
      " 'classification of msm can vary  in the inclusion of transgender men and '\n",
      " 'women on the basis  of whether men are defined by sex at birth ie '\n",
      " 'transgender  women included or current gender identity ie transgender  men '\n",
      " 'included therefore sexual orientation as well as gender  identity of '\n",
      " 'individual persons and their sex partners should be  obtained during health '\n",
      " 'care visits msm might be at increased  risk for hiv and other stis because '\n",
      " 'of their sexual network or  behavioral or biologic factors including number '\n",
      " 'of concurrent  partners condomless sex anal sex or substance use 180–182  '\n",
      " 'these factors along with sexual network or higher community  disease '\n",
      " 'prevalence can increase the risk for stis among msm  compared with other '\n",
      " 'groups 183184 performing a detailed and comprehensive sexual history is  the '\n",
      " 'first step in identifying vulnerability and providing tailored  counseling '\n",
      " 'and care 3 factors associated with increased  vulnerability to sti '\n",
      " 'acquisition among msm include having  multiple partners anonymous partners '\n",
      " 'and concurrent  partners 185186 repeat syphilis infections are common and  '\n",
      " 'might be associated with hiv infection substance use eg  methamphetamines '\n",
      " 'black race and multiple sex partners  187 similarly gonorrhea incidence has '\n",
      " 'increased among msm  and might be more likely to display antimicrobial '\n",
      " 'resistance  compared with other groups 188189 gonococcal infection  among '\n",
      " 'msm has been associated with similar risk factors to  syphilis including '\n",
      " 'having multiple anonymous partners and  substance use especially '\n",
      " 'methamphetamines 190 disparities  in gonococcal infection are also more '\n",
      " 'pronounced among certain  racial and ethnic groups of msm 141 '\n",
      " 'httpswwwcdcgovvaccineshcpaciprecsvaccspecifichpvhtml '\n",
      " 'httpswwwcdcgovvaccineshcpaciprecsvaccspecifichpvhtml '\n",
      " 'httpswwwcdcgovvaccinesscheduleshcpimzchildindicationshtmlnotehepa '\n",
      " 'httpswwwcdcgovvaccinesscheduleshcpimzchildindicationshtmlnotehepa '\n",
      " 'httpswwwcdcgovhivriskprep recommendations and reports 16 mmwr  july 23 2021  '\n",
      " 'vol 70  no 4 us department of health and human servicescenters for disease '\n",
      " 'control and prevention hiv risk among men who have sex with men msm are '\n",
      " 'disproportionately at risk for hiv infection in  the united states the '\n",
      " 'estimated lifetime risk for hiv infection  among msm is one in six compared '\n",
      " 'with heterosexual men at  one in 524 and heterosexual women at one in 253 '\n",
      " '191 these  disparities are further exacerbated by race and ethnicity with  '\n",
      " 'african americanblack and hispaniclatino msm having a  one in two and a one '\n",
      " 'in four lifetime risk for hiv infection  respectively for hiv transmission '\n",
      " 'occurs much more readily  through receptive anal sex compared with '\n",
      " 'penilevaginal sex  192 similar to other stis multiple partners anonymous  '\n",
      " 'partners condomless sex and substance use are all associated  with hiv '\n",
      " 'infection 193–196 importantly other stis  also might significantly increase '\n",
      " 'the risk for hiv infection  197–199 an estimated 10 of new hiv infections '\n",
      " 'were  attributable to chlamydial or gonococcal infection 81 a  substantial '\n",
      " 'number of msm remain unaware of their hiv  diagnosis 200 clinical care '\n",
      " 'involving msm including  those who have hiv infection should involve asking '\n",
      " 'about  stirelated risk factors and routine sti testing clinicians  should '\n",
      " 'routinely ask msm about their sexual behaviors and  symptoms consistent with '\n",
      " 'common stis including urethral  discharge dysuria ulcers rash '\n",
      " 'lymphadenopathy and  anorectal symptoms that might be consistent with '\n",
      " 'proctitis  eg discharge rectal bleeding pain on defecation or pain  during '\n",
      " 'anal sex however certain stis are asymptomatic  especially at rectal and '\n",
      " 'pharyngeal sites and routine testing  is recommended in addition clinicians '\n",
      " 'should provide  education and counseling regarding evidencebased safersex  '\n",
      " 'approaches that have demonstrated effectiveness in reducing  sti incidence '\n",
      " 'see hiv infection detection counseling  and referral preexposure prophylaxis '\n",
      " 'for hiv prevention prep is the use of medications for preventing an '\n",
      " 'infection  before exposure studies have demonstrated that a daily oral  '\n",
      " 'medication tdfftc is effective in preventing hiv acquisition  and '\n",
      " 'specifically among msm 7475201 prep guidelines  provide information '\n",
      " 'regarding sexually active persons who are at  substantial risk for acquiring '\n",
      " 'hiv infection having had anal or  vaginal sex during the previous 6 months '\n",
      " 'with either a partner  with hiv infection a bacterial sti in the past 6 '\n",
      " 'months or  inconsistent or no condom use with a sex partner or persons  who '\n",
      " 'inject drugs injecting partner with hiv infection or sharing  injection '\n",
      " 'equipment 80 those guidelines provide information  regarding daily prep use '\n",
      " 'for either tdfftc men or women  or tenofovir alafenamide and emtricitabine '\n",
      " 'for msm screening  for bacterial stis should occur at least every 6 months '\n",
      " 'for all  sexually active patients and every 3 months among msm or  among '\n",
      " 'patients with ongoing risk behaviors msm taking prep  might compensate for '\n",
      " 'decreased hiv acquisition risk by using  condoms less frequently or '\n",
      " 'modifying their behavior in other ways  202203 although data regarding this '\n",
      " 'behavior are inconsistent  studies have reported that msm taking prep have '\n",
      " 'high rates of  stis and frequent screening is warranted 204–206 importance '\n",
      " 'of rectal and pharyngeal testing rectal and pharyngeal testing by naat for '\n",
      " 'gonorrhea  and chlamydia is recognized as an important sexual health  '\n",
      " 'consideration for msm rectal gonorrhea and chlamydia are  associated with '\n",
      " 'hiv infection 82207 and men with repeat  rectal infections can be at '\n",
      " 'substantially higher risk for hiv  acquisition 208 pharyngeal infections '\n",
      " 'with gonorrhea or  chlamydia might be a principal source of urethral '\n",
      " 'infections  209–211 studies have demonstrated that among msm  prevalence of '\n",
      " 'rectal gonorrhea and chlamydia ranges from  02 to 24 and 21 to 23 '\n",
      " 'respectively and prevalence  of pharyngeal gonorrhea and chlamydia ranges '\n",
      " 'from 05 to  165 and 0 to 36 respectively 171 approximately  70 of gonococcal '\n",
      " 'and chlamydial infections might be  missed if urogenitalonly testing is '\n",
      " 'performed among msm  212–216 because most pharyngeal and rectal infections '\n",
      " 'are  asymptomatic selfcollected swabs have been reported to be  an '\n",
      " 'acceptable means of collection for pharyngeal and rectal  specimens 217–219 '\n",
      " 'which can enhance patient comfort  and reduce clinical workloads a detailed '\n",
      " 'sexual history should be taken for all msm to  identify anatomic locations '\n",
      " 'exposed to infection for screening  clinics that provide services for msm at '\n",
      " 'high risk should  consider implementing routine extragenital screening for  '\n",
      " 'n gonorrhoeae and c trachomatis infections and screening is  likely to be '\n",
      " 'costeffective 220 screening recommendations sti screening among msm has been '\n",
      " 'reported to be  suboptimal in a crosssectional sample of msm in the united  '\n",
      " 'states approximately one third reported not having had an  sti test during '\n",
      " 'the previous 3 years and msm with multiple  sex partners reported less '\n",
      " 'frequent screening 221 msm  living with hiv infection and engaged in care '\n",
      " 'also experience  suboptimal rates of sti testing 222223 limited data exist  '\n",
      " 'regarding the optimal frequency of screening for gonorrhea  chlamydia and '\n",
      " 'syphilis among msm with the majority of  evidence derived from mathematical '\n",
      " 'modeling models from  australia have demonstrated that increasing syphilis '\n",
      " 'screening  frequency from two times a year to four times a year resulted  in '\n",
      " 'a relative decrease of 84 from peak prevalence 224 in  a compartmental model '\n",
      " 'applied to different populations in  canada quarterly syphilis screening '\n",
      " 'averted more than twice  recommendations and reports mmwr  july 23 2021  vol '\n",
      " '70  no 4 17us department of health and human servicescenters for disease '\n",
      " 'control and prevention the number of syphilis cases compared with '\n",
      " 'semiannual  screening 225 furthermore msm screening coverage  needed for '\n",
      " 'eliminating syphilis among a population is  substantially reduced from 62 '\n",
      " 'with annual screening to 23  with quarterly screening 226227 in an msm '\n",
      " 'transmission  model that explored the impact of hiv prep use on sti  '\n",
      " 'prevalence quarterly chlamydia and gonorrhea screening was  associated with '\n",
      " 'an 83 reduction in incidence 205 the only  empiric data available that '\n",
      " 'examined the impact of screening  frequency come from an observational '\n",
      " 'cohort of msm using  hiv prep in which quarterly screening identified more  '\n",
      " 'bacterial stis and semiannual screening would have resulted  in delayed '\n",
      " 'treatment of 35 of total identified sti infections  206 in addition '\n",
      " 'quarterly screening was reported to have  prevented sti exposure in a median '\n",
      " 'of three sex partners  per sti infection 206 on the basis of available '\n",
      " 'evidence  quarterly screening for gonorrhea chlamydia and syphilis for  '\n",
      " 'certain sexually active msm can improve case finding which  can reduce the '\n",
      " 'duration of infection at the population level  reduce ongoing transmission '\n",
      " 'and ultimately prevalence among  this population 228 preventive screening '\n",
      " 'for common stis is indicated for all  msm the following screening '\n",
      " 'recommendations summarize  published federal agency and uspstf clinical '\n",
      " 'prevention  guidelines for msm and should be performed at least annually hiv '\n",
      " 'infection hiv serologic testing is indicated if hiv status is unknown  or if '\n",
      " 'hiv negative and the patient or their sex partner has had  more than one sex '\n",
      " 'partner since the most recent hiv test syphilis syphilis serologic testing '\n",
      " 'is indicated to establish whether  persons with reactive tests have '\n",
      " 'untreated syphilis have partially  treated syphilis or are manifesting a '\n",
      " 'slow or inadequate  serologic response to recommended previous therapy '\n",
      " 'gonorrhea and chlamydia the following testing is recommended for msm • a '\n",
      " 'test for urethral infection with n gonorrhoeae and  c trachomatis among men '\n",
      " 'who have had insertive  intercourse during the preceding year urine naat  is '\n",
      " 'preferred • a test for rectal infection with n gonorrhoeae and  c '\n",
      " 'trachomatis among men who have had receptive anal  intercourse during the '\n",
      " 'preceding year rectal naat  is preferred  regardless of condom use during '\n",
      " 'exposure • a test for pharyngeal infection with n gonorrhoeae among  men who '\n",
      " 'have had receptive oral intercourse during the  preceding year pharyngeal '\n",
      " 'naat is preferred • testing for c trachomatis pharyngeal infection is not  '\n",
      " 'recommended basing screening practices solely on history might be  '\n",
      " 'suboptimal because providers might feel uncomfortable  taking a detailed '\n",
      " 'sexual history 229 men might also feel  uncomfortable sharing personal '\n",
      " 'sexual information with  their provider and rectal and pharyngeal infections '\n",
      " 'can be  identified even in the absence of reported risk behaviors 171  '\n",
      " 'furthermore the role of saliva kissing and rimming ie  oralrectal contact in '\n",
      " 'the transmission of n gonorrhoeae and  c trachomatis has not been well '\n",
      " 'studied 230–232 rectal and pharyngeal testing providercollected or self '\n",
      " 'collected specimens should be performed for all msm who  report exposure at '\n",
      " 'these sites testing can be offered to msm  who do not report exposure at '\n",
      " 'these sites after a detailed  explanation due to known underreporting of '\n",
      " 'risk behaviors  all msm with hiv infection entering care should be screened  '\n",
      " 'for gonorrhea and chlamydia at appropriate anatomic sites of  exposure as '\n",
      " 'well as for syphilis more frequent sti screening ie for syphilis gonorrhea  '\n",
      " 'and chlamydia at 3 to 6month intervals is indicated for  msm including those '\n",
      " 'taking prep and those with hiv  infection if risk behaviors persist or if '\n",
      " 'they or their sex partners  have multiple partners in addition providers can '\n",
      " 'consider  the benefits of offering more frequent hiv screening eg  every 3–6 '\n",
      " 'months to msm at increased risk for acquiring  hiv infection hepatitis b '\n",
      " 'virus all msm should be screened with hbsag hbv core  antibody and hbv '\n",
      " 'surface antibody testing to detect hbv  infection 233 vaccination against '\n",
      " 'both hav and hbv  is recommended for all msm for whom previous infection  or '\n",
      " 'vaccination cannot be documented serologic testing can  be considered before '\n",
      " 'vaccinating if the patient’s vaccination  history is unknown however '\n",
      " 'vaccination should not be  delayed vaccinating persons who have had previous '\n",
      " 'infection  or vaccination does not increase the risk for vaccinerelated  '\n",
      " 'adverse events see hepatitis a virus hepatitis b virus hepatitis c virus cdc '\n",
      " 'recommends hcv screening at least once for all  adults aged ≥18 years except '\n",
      " 'in settings where the prevalence  of hcv infection hcv rna positivity is 01 '\n",
      " '156  the american association for the study of liver diseases infectious '\n",
      " 'diseases society of america guidelines recommend  all msm with hiv infection '\n",
      " 'be screened for hcv during the  recommendations and reports 18 mmwr  july 23 '\n",
      " '2021  vol 70  no 4 us department of health and human servicescenters for '\n",
      " 'disease control and prevention initial hiv evaluation and at least annually '\n",
      " 'thereafter https wwwhcvguidelinesorg more frequent screening depends  on '\n",
      " 'ongoing risk behaviors highrisk sexual behavior and  concomitant ulcerative '\n",
      " 'stis or stirelated proctitis sexual  transmission of hcv can occur and is '\n",
      " 'most common among  msm with hiv infection 234–237 screening for hcv in  this '\n",
      " 'setting is costeffective 238239 screening should be  performed by using hcv '\n",
      " 'antibody assays followed by hcv  rna testing for those with a positive '\n",
      " 'antibody test suspicion  for acute hcv infection eg clinical evidence of '\n",
      " 'hepatitis and  risk behaviors should prompt consideration for hcv rna  '\n",
      " 'testing despite a negative antibody test human papillomavirus hpv infection '\n",
      " 'and associated conditions eg anogenital  warts and anal squamous '\n",
      " 'intraepithelial lesions are highly  prevalent among msm the hpv vaccination '\n",
      " 'is recommended  for all men including msm and transgender persons or  '\n",
      " 'immunocompromised males including those with hiv  infection through age 26 '\n",
      " 'years 11 more information is  available at httpswwwcdcgovhpvdownloads9vhpv '\n",
      " 'guidancepdf a digital anorectal examination dare should be  performed to '\n",
      " 'detect early anal cancer among persons with hiv  and msm without hiv but who '\n",
      " 'have a history of receptive  anal intercourse data are insufficient to '\n",
      " 'recommend routine  anal cancer screening with anal cytology in populations '\n",
      " 'at risk  for anal cancer see anal cancer health centers that initiate a  '\n",
      " 'cytologybased screening program should only do so if referrals  to '\n",
      " 'highresolution anoscopy hra and biopsy are available herpes simplex virus2 '\n",
      " 'evaluation for hsv2 infection with typespecific serologic  tests also can be '\n",
      " 'considered if infection status is unknown  among persons with previously '\n",
      " 'undiagnosed genital tract  infection see genital herpes postexposure '\n",
      " 'prophylaxis and preexposure  prophylaxis for sti prevention studies have '\n",
      " 'reported that a benefit might be derived  from sti pep and prep for sti '\n",
      " 'prevention one study  demonstrated that monthly oral administration of a 1g '\n",
      " 'dose  of azithromycin reduced infection with n gonorrhoeae and  c '\n",
      " 'trachomatis but did not decrease the incidence of hiv  transmission 240 '\n",
      " 'among msm doxycycline taken as pep in  a single oral dose ≤24 hours after '\n",
      " 'sex decreased infection with  treponema pallidum and c trachomatis however '\n",
      " 'no substantial  effect was observed for infection with n gonorrhoeae 93  '\n",
      " 'doxycycline taken as sti prep as 100 mg orally once daily  also demonstrated '\n",
      " 'a substantial reduction in gonorrhea  chlamydia and syphilis among msm 90 '\n",
      " 'however these  studies had limitations because of small sample size short  '\n",
      " 'duration of therapy and concerns about antibiotic resistance  specifically '\n",
      " 'regarding n gonorrhoeae 241 further study is  needed to determine the '\n",
      " 'effectiveness of using antimicrobials  for sti prep or pep counseling and '\n",
      " 'education approaches different counseling and sti prevention strategies are  '\n",
      " 'needed to effectively engage different groups of msm  outreach efforts '\n",
      " 'should be guided by local surveillance efforts  and community input engaging '\n",
      " 'msm at risk through social  media specifically online hookup sites is an '\n",
      " 'important  outreach effort to consider hookup sites are internet sites  and '\n",
      " 'mobile telephone applications that men might use for  meeting other men for '\n",
      " 'sex internet use might facilitate sexual  encounters and sti transmission '\n",
      " 'among msm and many  men report using hookup sites to meet partners 242–245  '\n",
      " 'the ease and accessibility of meeting partners online might  reduce stigma '\n",
      " 'and barriers of meeting partners through  other settings moreover these '\n",
      " 'sites offer an opportunity for  effective sti prevention messaging 246 '\n",
      " 'although the cost  might be limiting 247 different groups of msm might use  '\n",
      " 'different hookup sites and efforts should be guided by local  community '\n",
      " 'input studies have demonstrated the acceptability  and feasibility of '\n",
      " 'reaching msm through these hookup sites  to promote sti prevention efforts '\n",
      " '248249 enteric infections among men who have sex  with men the importance of '\n",
      " 'sexual transmission of enteric pathogens  among msm has been recognized '\n",
      " 'since the 1970s after the  first report of msmassociated shigellosis was '\n",
      " 'reported in  san francisco 250251 global increases in the incidence  of '\n",
      " 'shigellosis among adult msm have been more recently  observed 252–256 '\n",
      " 'sporadic outbreaks of shigella sonnei  and shigella flexneri have been '\n",
      " 'reported among msm  257–262 transmission occurs through oralanal contact  or '\n",
      " 'sexual contact and transmission efficiency is enhanced by  both biologic or '\n",
      " 'host and behavioral factors hiv without  viral suppression can be an '\n",
      " 'independent risk factor that  can contribute to transmission by increasing '\n",
      " 'shedding of  the enteric pathogen increasing susceptibility of the host  or '\n",
      " 'both 255263 surveillance data in england during  2004–2015 demonstrated that '\n",
      " '21 of nontravelassociated  shigella diagnoses among msm were among persons '\n",
      " 'with  hiv infection 255 other enteric organisms might also cause disease '\n",
      " 'among  msm through sexual activities leading to oralanal contact  including '\n",
      " 'bacteria such as escherichia coli 264 and  httpswwwhcvguidelinesorg '\n",
      " 'httpswwwhcvguidelinesorg httpswwwcdcgovhpvdownloads9vhpvguidancepdf '\n",
      " 'httpswwwcdcgovhpvdownloads9vhpvguidancepdf recommendations and reports mmwr  '\n",
      " 'july 23 2021  vol 70  no 4 19us department of health and human '\n",
      " 'servicescenters for disease control and prevention campylobacter jejuni or '\n",
      " 'campylobacter coli 265266 viruses  such as hav 267 and parasites such as '\n",
      " 'giardia lamblia or  entamoeba histolytica 268269 behavioral characteristics  '\n",
      " 'associated with the sexual transmission of enteric infections  are broadly '\n",
      " 'similar to those associated with other stis eg  gonorrhea syphilis and '\n",
      " 'lymphogranuloma venereum lgv  this includes multiple sex partners and online '\n",
      " 'hookup sites  that increase opportunities for sexual mixing which might  '\n",
      " 'create dense sexual networks that facilitate sti transmission  among msm 270 '\n",
      " 'specific behaviors associated with sexually  transmitted enteric infections '\n",
      " 'among msm involve attendance  at sex parties and recreational drug use '\n",
      " 'including chem sex  ie using crystal methamphetamine gammabutyrolactone  or '\n",
      " 'mephedrone before or during sex which might facilitate  condomless sex group '\n",
      " 'sex fisting use of sex toys and scat play  253271 the growing number of '\n",
      " 'sexually transmitted enteric  infections might be attributable in part to '\n",
      " 'the emergence of  antimicrobial resistance this is well reported regarding '\n",
      " 'shigella  species for which rapid intercontinental dissemination of a  s '\n",
      " 'flexneri 3a lineage with highlevel resistance to azithromycin  through '\n",
      " 'sexual transmission among msm 272 and clusters  of multidrug resistant '\n",
      " 'shigella cases among msm have recently  been reported 273 multidrugresistant '\n",
      " 'campylobacter species  have also been documented 266274 for msm patients '\n",
      " 'with  diarrhea clinicians should request laboratory examinations  including '\n",
      " 'stool culture provide counseling about the risk for  infection with enteric '\n",
      " 'pathogens during sexual activity oral anal oralgenital analgenital and '\n",
      " 'digitalanal contact that  could expose them to enteric pathogens and choose '\n",
      " 'treatment  when needed according to antimicrobial drug susceptibility women '\n",
      " 'who have sex with women and  women who have sex with  women and men wsw and '\n",
      " 'wswm comprise diverse groups with variations  in sexual identity practices '\n",
      " 'and risk behaviors studies  indicate that certain wsw particularly '\n",
      " 'adolescents young  women and wswm might be at increased risk for stis  and '\n",
      " 'hiv on the basis of reported risk behaviors 275–280  studies have '\n",
      " 'highlighted the diversity of sexual practices and  examined use of '\n",
      " 'protective or riskreduction strategies among  wsw populations 281–283 use of '\n",
      " 'barrier protection with  female partners eg gloves during digitalgenital sex '\n",
      " 'external  condoms with sex toys and latex or plastic barriers also known  as '\n",
      " 'dental dams for oralgenital sex was infrequent in all  studies although '\n",
      " 'health organizations have online materials  directed to patients few '\n",
      " 'comprehensive and reliable resources  of sexual health information for wsw '\n",
      " 'are available 284 recent studies regarding sti rates among wsw and  wswm '\n",
      " 'indicate that wswm experience higher rates of stis  than wsw with rates '\n",
      " 'comparable with women who have sex  with men wsm in all studies reviewed '\n",
      " '279285286 these  studies indicate that wsw might experience stis at lower  '\n",
      " 'rates than wswm and wsm although still at significant  rates 287 one study '\n",
      " 'reported higher sexualrisk behaviors  among adolescent wswm and wsw than '\n",
      " 'among adolescent  wsm 280 wsw report reduced knowledge of sti risks  288 and '\n",
      " 'both wsw and wswm experience barriers to care  especially black wsw and wswm '\n",
      " '289290 in addition a  continuum of sexual behaviors reported by wsw and '\n",
      " 'wswm  indicates the need for providers to not assume lower risk for  wsw '\n",
      " 'highlighting the importance of an open discussion  about sexual health few '\n",
      " 'data are available regarding the risk for stis conferred  by sex between '\n",
      " 'women however transmission risk probably  varies by the specific sti and '\n",
      " 'sexual practice eg oralgenital  sex vaginal or anal sex using hands fingers '\n",
      " 'or penetrative  sex items and oralanal sex 291292 practices involving  '\n",
      " 'digitalvaginal or digitalanal contact particularly with shared  penetrative '\n",
      " 'sex items present a possible means for transmission  of infected '\n",
      " 'cervicovaginal or anal secretions this possibility  is most directly '\n",
      " 'supported by reports of shared trichomonas  infections 293294 and by '\n",
      " 'concordant drugresistance  genotype testing and phylogenetic linkage '\n",
      " 'analysis identifying  hiv transmitted sexually between women 295296 the  '\n",
      " 'majority of wsw 53–97 have had sex with men in the  past and continue to do '\n",
      " 'so with 5–28 of wsw reporting  male partners during the previous year '\n",
      " '292297–300 hpv can be transmitted through skintoskin contact  and sexual '\n",
      " 'transmission of hpv likely occurs between wsw  301–303 hpv dna has been '\n",
      " 'detected through polymerase  chain reaction pcr–based methods from the '\n",
      " 'cervix vagina  and vulva among 13–30 of wsw 301302 and can  persist on '\n",
      " 'fomites including sex toys 304 among wsw  who report no lifetime history of '\n",
      " 'sex with men 26 had  antibodies to hpv16 and 42 had antibodies to hpv6  301 '\n",
      " 'highgrade squamous intraepithelial lesions hsil and  lowgrade squamous '\n",
      " 'intraepithelial lesions lsil have been  detected on papanicolaou smears pap '\n",
      " 'tests among wsw  who reported no previous sex with men 301302 wswm  are at '\n",
      " 'risk for acquiring hpv from both their female partners  and male partners '\n",
      " 'and thus are at risk for cervical cancer  therefore routine cervical cancer '\n",
      " 'screening should be offered  to all women regardless of sexual orientation '\n",
      " 'or practices  and young adult wsw and wswm should be offered hpv  '\n",
      " 'vaccination in accordance with recommendations 11 https '\n",
      " 'wwwcdcgovvaccineshcpaciprecsvaccspecifichpvhtml '\n",
      " 'httpswwwcdcgovvaccineshcpaciprecsvaccspecifichpvhtml '\n",
      " 'httpswwwcdcgovvaccineshcpaciprecsvaccspecifichpvhtml recommendations and '\n",
      " 'reports 20 mmwr  july 23 2021  vol 70  no 4 us department of health and '\n",
      " 'human servicescenters for disease control and prevention genital '\n",
      " 'transmission of hsv2 between female sex partners  is inefficient but can '\n",
      " 'occur a us populationbased survey  among women aged 18–59 years demonstrated '\n",
      " 'an hsv2  seroprevalence of 30 among women reporting samesex  partners during '\n",
      " 'the previous year 36 among women  reporting samesex partners in their '\n",
      " 'lifetime and 24 among  women reporting no lifetime samesex behavior 299 '\n",
      " 'hsv2  seroprevalence among women selfidentifying as homosexual  or lesbian '\n",
      " 'was 8 similar to a previous clinicbased study of  wsw 299305 but was 26 '\n",
      " 'among black wsw in one  study 287 the relatively frequent practice of '\n",
      " 'orogenital sex  among wsw and wswm might place them at higher risk  for '\n",
      " 'genital infection with hsv1 a hypothesis supported by  the recognized '\n",
      " 'association between hsv1 seropositivity and  previous number of female '\n",
      " 'partners thus sexual transmission  of hsv1 and hsv2 can occur between female '\n",
      " 'sex partners  this information should be communicated to women as part  of '\n",
      " 'sexual health counseling trichomonas is a relatively common infection among '\n",
      " 'wsw  and wswm with prevalence rates higher than for chlamydia  or gonorrhea '\n",
      " '306307 and direct transmission of trichomonas  between female partners has '\n",
      " 'been demonstrated 293294 limited information is available regarding '\n",
      " 'transmission  of bacterial stis between female partners transmission of  '\n",
      " 'syphilis between female sex partners probably through oral  sex has been '\n",
      " 'reported although the rate of transmission of  c trachomatis or n '\n",
      " 'gonorrhoeae between women is unknown  infection also might be acquired from '\n",
      " 'past or current male  partners data indicate that c trachomatis infection '\n",
      " 'among  wsw can occur 275286308309 data are limited  regarding gonorrhea '\n",
      " 'rates among wsw and wswm 170  reports of samesex behavior among women should '\n",
      " 'not deter  providers from offering and providing screening for stis  '\n",
      " 'including chlamydia according to guidelines bv is common among women and '\n",
      " 'even more so among  women with female partners 310–312 epidemiologic data  '\n",
      " 'strongly demonstrate that bv is sexually transmitted among  women with '\n",
      " 'female partners evidence continues to support  the association of such '\n",
      " 'sexual behaviors as having a new partner  having a partner with bv having '\n",
      " 'receptive oral sex and having  digitalvaginal and digitalanal sex with '\n",
      " 'incident bv 313314  a study including monogamous couples demonstrated  that '\n",
      " 'female sex partners frequently share identical genital  lactobacillus '\n",
      " 'strains 315 within a communitybased  cohort of wsw extravaginal ie oral and '\n",
      " 'rectal reservoirs  of bvassociated bacteria were a risk factor for incident '\n",
      " 'bv  316 studies have examined the impact of specific sexual  practices on '\n",
      " 'the vaginal microflora 306317–319 and on  recurrent 320 or incident 321322 '\n",
      " 'bv among wsw a  bv pathogenesis study in wsw reported that prevotella bivia  '\n",
      " 'gardnerella vaginalis and atopobium vaginae might have  substantial roles in '\n",
      " 'development of incident bv 323 these  studies have continued to support '\n",
      " 'although have not proven  the hypothesis that sexual behaviors specific '\n",
      " 'bvassociated  bacteria and possibly exchange of vaginal or extravaginal  '\n",
      " 'microbiota eg oral bacterial communities between partners  might be involved '\n",
      " 'in the pathogenesis of bv among wsw although bv is common among wsw routine '\n",
      " 'screening  for asymptomatic bv is not recommended results of one  randomized '\n",
      " 'trial used a behavioral intervention to reduce  persistent bv among wsw '\n",
      " 'through reduced sharing of vaginal  fluid on hands or sex toys women '\n",
      " 'randomly assigned to the  intervention were 50 less likely to report '\n",
      " 'receptive digital vaginal contact without gloves than control subjects and '\n",
      " 'they  reported sharing sex toys infrequently however these women  had no '\n",
      " 'reduction in persistent bv at 1 month posttreatment  and no reduction in '\n",
      " 'incident episodes of recurrent bv 324  trials have not been reported '\n",
      " 'examining the benefits of treating  female partners of women with bv '\n",
      " 'recurrent bv among  wsw is associated with having a samesex partner and a '\n",
      " 'lack of  condom use 325 increasing awareness of signs and symptoms  of bv '\n",
      " 'among women and encouraging healthy sexual practices  eg avoiding shared sex '\n",
      " 'toys cleaning shared sex toys and  using barriers might benefit women and '\n",
      " 'their partners sexually active women are at risk for acquiring bacterial  '\n",
      " 'viral and protozoal stis from current and previous partners  both male and '\n",
      " 'female wsw should not be presumed to be at  low or no risk for stis on the '\n",
      " 'basis of their sexual orientation  report of samesex behavior among women '\n",
      " 'should not deter  providers from considering and performing screening for '\n",
      " 'stis  and cervical cancer according to guidelines effective screening  '\n",
      " 'requires that care providers and their female patients engage in  a '\n",
      " 'comprehensive and open discussion of sexual and behavioral  risks that '\n",
      " 'extends beyond sexual identity transgender and gender diverse persons '\n",
      " 'transgender persons often experience high rates of stigma and  socioeconomic '\n",
      " 'and structural barriers to care that negatively  affect health care usage '\n",
      " 'and increase susceptibility to hiv and  stis 326–332 persons who are '\n",
      " 'transgender have a gender  identity that differs from the sex that they were '\n",
      " 'assigned at birth  333334 transgender women also known as trans women  '\n",
      " 'transfeminine persons or women of transgender experience  are women who were '\n",
      " 'assigned male sex at birth born with  male anatomy transgender men also '\n",
      " 'known as trans men  transmasculine persons or men of transgender experience  '\n",
      " 'are men who were assigned female sex at birth ie born with  female anatomy '\n",
      " 'in addition certain persons might identify  outside the gender binary of '\n",
      " 'male or female or move back and  recommendations and reports mmwr  july 23 '\n",
      " '2021  vol 70  no 4 21us department of health and human servicescenters for '\n",
      " 'disease control and prevention forth between different gender identities and '\n",
      " 'use such terms  as “gender nonbinary” “genderqueer” or “gender fluid” to  '\n",
      " 'describe themselves persons who use terms such as “agender”  or “null '\n",
      " 'gender” do not identify with having any gender the  term “cisgender” is used '\n",
      " 'to describe persons who identify with  their assigned sex at birth '\n",
      " 'prevalence studies of transgender  persons among the overall population have '\n",
      " 'been limited and  often are based on small convenience samples gender '\n",
      " 'identity is independent of sexual orientation sexual  orientation identities '\n",
      " 'among transgender persons are diverse  persons who are transgender or gender '\n",
      " 'diverse might have sex  with cisgender men cisgender women or other '\n",
      " 'transgender  or gender nonbinary persons clinical environment assessment '\n",
      " 'providers should create welcoming environments that  facilitate disclosure '\n",
      " 'of gender identity and sexual orientation  clinics should document gender '\n",
      " 'identity and sex assigned  at birth for all patients to improve sexual '\n",
      " 'health care for  transgender and gender nonbinary persons assessment of  '\n",
      " 'gender identity and sex assigned at birth has been validated  among diverse '\n",
      " 'populations has been reported to be acceptable  335336 and might result in '\n",
      " 'increased patients identifying  as transgender 337 lack of medical provider '\n",
      " 'knowledge and other barriers to care  eg discrimination in health care '\n",
      " 'settings or denial of services  often result in transgender and gender '\n",
      " 'nonbinary persons  avoiding or delaying preventive care services 338–340 '\n",
      " 'and  incurring missed opportunities for hiv and sti prevention  services '\n",
      " 'genderinclusive and traumaguided health care  might increase the number of '\n",
      " 'transgender patients who seek  sexual health services including sti testing '\n",
      " '341 because  transgender persons are at high risk for sexual violence 342 '\n",
      " 'primary care providers should take a comprehensive sexual  history including '\n",
      " 'a discussion of sti screening hiv prep  and pep behavioral health and social '\n",
      " 'determinants of sexual  health clinicians can improve the experience of '\n",
      " 'sexual health  screening and counseling for transgender persons by asking '\n",
      " 'for  their choice of terminology or modifying language eg asking  patients '\n",
      " 'their gender pronouns to be used during clinic visits  and history taking '\n",
      " 'and examination 343 options for fertility  preservation pregnancy potential '\n",
      " 'and contraception options  should also be discussed if indicated for '\n",
      " 'transgender persons  who retain a uterus and ovaries ovulation might '\n",
      " 'continue in  the presence of testosterone therapy and pregnancy potential  '\n",
      " 'exists httpstranscareucsfedu transgender women a systematic review and '\n",
      " 'metaanalysis of hiv infection  among transgender women estimated that hiv '\n",
      " 'prevalence in  the united states is 14 among transgender women with the  '\n",
      " 'highest prevalence among black 44 and hispanic 26  transgender women 344 '\n",
      " 'data also demonstrate high rates of  hiv infection among transgender women '\n",
      " 'worldwide 345  bacterial sti prevalence varies among transgender women and  '\n",
      " 'is based largely on convenience samples despite limited data  international '\n",
      " 'and us studies have indicated elevated incidence  and prevalence of '\n",
      " 'gonorrhea and chlamydia among transgender  women similar to rates among '\n",
      " 'cisgender msm 346–348 a  recent study using data from the std surveillance '\n",
      " 'network  revealed that the proportions of transgender women with  '\n",
      " 'extragenital chlamydial or gonococcal infections were similar  to those of '\n",
      " 'cisgender msm 349 providers caring for transgender women should have  '\n",
      " 'knowledge of their patients’ current anatomy and patterns  of sexual '\n",
      " 'behavior before counseling them about sti and  hiv prevention the majority '\n",
      " 'of transgender women have  not undergone genitalaffirmation surgery and '\n",
      " 'therefore  might retain a functional penis in these instances they  might '\n",
      " 'engage in insertive oral vaginal or anal sex as well as  receptive oral or '\n",
      " 'anal sex in the us transgender survey 12  of transgender women had undergone '\n",
      " 'vaginoplasty surgery  and approximately 50 more were considering surgical  '\n",
      " 'intervention 350 providers should have knowledge about  the type of tissue '\n",
      " 'used to construct the neovagina which  can affect future sti and hiv '\n",
      " 'preventive care and screening  recommendations the majority of vaginoplasty '\n",
      " 'surgeries  conducted in the united states use penile and scrotal tissue  to '\n",
      " 'create the neovagina 351 other surgical techniques  use intestinal tissue eg '\n",
      " 'sigmoid colon graft or splitskin  grafts 352 although these surgeries '\n",
      " 'involve penectomy and  orchiectomy the prostate remains intact transgender '\n",
      " 'women  who have had a vaginoplasty might engage in receptive vaginal  oral '\n",
      " 'or anal sex neovaginal stis have infrequently been reported in  the '\n",
      " 'literature and include hsv and hpvgenital warts in  penileinversion '\n",
      " 'vaginoplasty c trachomatis in procedures  that involved penile skin and '\n",
      " 'grafts with urethra mucosa or  abdominal peritoneal lining 353 and n '\n",
      " 'gonorrhoeae in  both penileinversion and colovaginoplasty 354–359 if  the '\n",
      " 'vaginoplasty used an intestinal graft a risk also exists for  bowelrelated '\n",
      " 'disease eg adenocarcinoma inflammatory  bowel disease diversion colitis and '\n",
      " 'polyps 360–362 transgender men the few studies of hiv prevalence among '\n",
      " 'transgender men  indicated that they have a lower prevalence of hiv '\n",
      " 'infection  than transgender women a recent estimate of hiv prevalence  among '\n",
      " 'transgender men was 2 344 however transgender  men who have sex with '\n",
      " 'cisgender men might be at elevated  httpstranscareucsfedu recommendations '\n",
      " 'and reports 22 mmwr  july 23 2021  vol 70  no 4 us department of health and '\n",
      " 'human servicescenters for disease control and prevention risk for hiv '\n",
      " 'infection 332363364 data are limited  regarding sti prevalence among '\n",
      " 'transgender men and the  majority of studies have used clinicbased data or '\n",
      " 'convenience  sampling recent data from the std surveillance network  '\n",
      " 'demonstrated higher prevalence of gonorrhea and chlamydia  among transgender '\n",
      " 'men similar to rates reported among  cisgender msm 365 the us transgender '\n",
      " 'survey indicated that the proportion  of transgender men and gender diverse '\n",
      " 'persons assigned  female sex at birth who have undergone genderaffirmation  '\n",
      " 'genital surgery is low providers should consider the anatomic  diversity '\n",
      " 'among transgender men because a person can undergo  a metoidioplasty a '\n",
      " 'procedure to increase the length of the  clitoris with or without urethral '\n",
      " 'lengthening and might not  have a hysterectomy and oophorectomy and '\n",
      " 'therefore be at risk  for bacterial stis hpv hsv hiv and cervical cancer '\n",
      " '366  for transgender men using genderaffirming hormone therapy  the decrease '\n",
      " 'in estradiol levels caused by exogenous testosterone  can lead to vaginal '\n",
      " 'atrophy 367368 and is associated with a  high prevalence of unsatisfactory '\n",
      " 'sample acquisition 369 the  impact of these hormonal changes on mucosal '\n",
      " 'susceptibility  to hiv and stis is unknown transgender men who have not '\n",
      " 'chosen to undergo  hysterectomy with removal of the cervix remain at risk '\n",
      " 'for  cervical cancer these persons often avoid cervical cancer  screening '\n",
      " 'because of multiple factors including discomfort  with medical examinations '\n",
      " 'and fear of discrimination  338370 providers should be aware that conducting '\n",
      " 'a  speculum examination can be technically difficult after  metoidioplasty '\n",
      " 'surgery because of narrowing of the introitus  in these situations highrisk '\n",
      " 'hpv testing using a swab can  be considered selfcollected swabs for highrisk '\n",
      " 'hpv testing  has been reported to be an acceptable option for transgender  '\n",
      " 'men 371 screening recommendations the following are screening '\n",
      " 'recommendations for  transgender and gender diverse persons • because of the '\n",
      " 'diversity of transgender persons regarding  surgical genderaffirming '\n",
      " 'procedures hormone use and  their patterns of sexual behavior providers '\n",
      " 'should remain  aware of symptoms consistent with common stis and  screen for '\n",
      " 'asymptomatic infections on the basis of the  patient’s sexual practices and '\n",
      " 'anatomy • genderbased screening recommendations should be  adapted on the '\n",
      " 'basis of anatomy eg routine screening  for c trachomatis and n gonorrhoeae '\n",
      " 'as recommended  for all sexually active females aged 25 years on an annual  '\n",
      " 'basis and should be extended to transgender men and  nonbinary persons with '\n",
      " 'a cervix among this age group • hiv screening should be discussed and '\n",
      " 'offered to all  transgender persons frequency of repeat screenings should  '\n",
      " 'be based on level of risk • for transgender persons with hiv infection who '\n",
      " 'have sex  with cisgender men and transgender women sti  screening should be '\n",
      " 'conducted at least annually including  syphilis serology hcv testing and '\n",
      " 'urogenital and  extragenital naat for gonorrhea and chlamydia • transgender '\n",
      " 'women who have had vaginoplasty surgery  should undergo routine sti '\n",
      " 'screening for all exposed sites  eg oral anal or vaginal no data are '\n",
      " 'available regarding  the optimal screening method urine or vaginal swab for  '\n",
      " 'bacterial stis of the neovagina the usual techniques for  creating a '\n",
      " 'neovagina do not result in a cervix therefore  no rationale exists for '\n",
      " 'cervical cancer screening 368 • if transgender men have undergone '\n",
      " 'metoidioplasty surgery  with urethral lengthening and have not had a '\n",
      " 'vaginectomy  assessment of genital bacterial stis should include a  cervical '\n",
      " 'swab because a urine specimen will be inadequate  for detecting cervical '\n",
      " 'infections • cervical cancer screening for transgender men and  nonbinary '\n",
      " 'persons with a cervix should follow current  screening guidelines see human '\n",
      " 'papillomavirus infections persons in correctional facilities multiple '\n",
      " 'studies have demonstrated that persons entering  correctional facilities '\n",
      " 'have a high prevalence of stis hiv and  viral hepatitis especially those '\n",
      " 'aged ≤35 years 141372373  risk behaviors for acquiring stis eg having '\n",
      " 'condomless  sex having multiple sex partners substance misuse and  engaging '\n",
      " 'in commercial survival or coerced sex are common  among incarcerated '\n",
      " 'populations before their incarceration  many persons have had limited access '\n",
      " 'to medical care other  social determinants of health eg insufficient social '\n",
      " 'and  economic support or living in communities with high local  sti '\n",
      " 'prevalence are common addressing stis in correctional  settings is vital for '\n",
      " 'addressing the overall sti impact among  affected populations growing '\n",
      " 'evidence demonstrates the usefulness of expanded  sti screening and '\n",
      " 'treatment services in correctional settings  including shortterm facilities '\n",
      " 'jails longterm institutions  prisons and juvenile detention centers for '\n",
      " 'example in  jurisdictions with comprehensive targeted jail screening more  '\n",
      " 'chlamydial infections among females and males if screened  are detected and '\n",
      " 'subsequently treated in the correctional setting  than in any other single '\n",
      " 'reporting source 141374 and might  represent the majority of reported cases '\n",
      " 'in certain jurisdictions  375 screening in the jail setting has the '\n",
      " 'potential to reach  recommendations and reports mmwr  july 23 2021  vol 70  '\n",
      " 'no 4 23us department of health and human servicescenters for disease control '\n",
      " 'and prevention substantially more persons at risk than screening among the  '\n",
      " 'prison population alone both males and females aged ≤35 years in juvenile '\n",
      " 'and adult  detention facilities have been reported to have higher rates of  '\n",
      " 'chlamydia and gonorrhea than nonincarcerated persons in  the community '\n",
      " '141374376 syphilis seroprevalence rates  which can indicate previously '\n",
      " 'treated or current infection are  considerably higher among incarcerated '\n",
      " 'adult men and women  than among adolescents which is consistent with the '\n",
      " 'overall  national syphilis trends 141374 detection and treatment  of early '\n",
      " 'syphilis in correctional facilities might affect rates  of transmission '\n",
      " 'among adults and prevention of congenital  syphilis 377 in jails '\n",
      " 'approximately half of entrants are released back  into the community within '\n",
      " '48 hours as a result treatment  completion rates for those screened for stis '\n",
      " 'and who receive  sti diagnoses in shortterm facilities might not be optimal  '\n",
      " 'however because of the mobility of incarcerated populations  in and out of '\n",
      " 'the community the impact of screening in  correctional facilities on the '\n",
      " 'prevalence of infections among  detainees and subsequent transmission in the '\n",
      " 'community  after release might be considerable 378 moreover treatment  '\n",
      " 'completion rates of ≥95 in shortterm facilities can be  achieved by offering '\n",
      " 'screening at or shortly after intake  thus facilitating earlier receipt of '\n",
      " 'test results and if needed  followup of untreated persons can be conducted '\n",
      " 'through  public health outreach universal optout screening for chlamydia and '\n",
      " 'gonorrhea  among females aged ≤35 years entering juvenile and adult  '\n",
      " 'correctional facilities is recommended 379 males aged  30 years entering '\n",
      " 'juvenile and adult correctional facilities  should also be screened for '\n",
      " 'chlamydia and gonorrhea 380  optout screening has the potential to '\n",
      " 'substantially increase  the number tested and the number of chlamydia and '\n",
      " 'gonorrhea  infections detected 381–385 pointofcare poc naat  might also be '\n",
      " 'considered if the tests have demonstrated  sufficient sensitivity and '\n",
      " 'specificity studies have demonstrated  high prevalence of trichomoniasis '\n",
      " 'among incarcerated  females 386–392 screening recommendations chlamydia and '\n",
      " 'gonorrhea females aged ≤35 years and males aged 30 years housed  in '\n",
      " 'correctional facilities should be screened for chlamydia and  gonorrhea this '\n",
      " 'screening should be conducted at intake and  offered as optout screening '\n",
      " 'trichomonas females aged ≤35 years housed in correctional facilities  should '\n",
      " 'be screened for trichomonas this screening should be  conducted at intake '\n",
      " 'and offered as optout screening syphilis optout screening for incarcerated '\n",
      " 'persons should be  conducted on the basis of the local area and '\n",
      " 'institutional  prevalence of early primary secondary or early latent  '\n",
      " 'infectious syphilis correctional facilities should stay apprised  of local '\n",
      " 'syphilis prevalence in shortterm facilities screening  at entry might be '\n",
      " 'indicated viral hepatitis all persons housed in juvenile and adult '\n",
      " 'correctional facilities  should be screened at entry for viral hepatitis '\n",
      " 'including hav  hbv and hcv depending on local prevalence and the  person’s '\n",
      " 'vaccination status vaccination for hav and hbv  should be offered if the '\n",
      " 'person is susceptible cervical cancer women and transgender men who are '\n",
      " 'housed in correctional  facilities should be screened for cervical cancer as '\n",
      " 'for women  who are not incarcerated 393394 see cervical cancer hiv infection '\n",
      " 'all persons being housed in juvenile and adult correctional  facilities '\n",
      " 'should be screened at entry for hiv infection  screening should be offered '\n",
      " 'as optout screening for those  identified as being at risk for hiv infection '\n",
      " 'eg with  diagnosed gonorrhea or syphilis or persons who inject drugs  and '\n",
      " 'being released into the community starting hiv prep  or providing linkage to '\n",
      " 'a community clinic for hiv prep  for hiv prevention should be considered '\n",
      " '395396 persons  are likely to engage in highrisk activities immediately '\n",
      " 'after  release from incarceration 397 for those identified with  hiv '\n",
      " 'infection treatment should be initiated those persons  receiving prep or hiv '\n",
      " 'treatment should have linkage to  care established before release '\n",
      " 'correctional settings should  consider implementing other sti prevention '\n",
      " 'approaches  both during incarceration and upon release which might  include '\n",
      " 'educational and behavioral counseling interventions  398–401 vaccination eg '\n",
      " 'for hpv 402403 condom  distribution 404405 ept 125 and prep to prevent hiv  '\n",
      " 'infection see primary prevention methods recommendations and reports 24 '\n",
      " 'mmwr  july 23 2021  vol 70  no 4 us department of health and human '\n",
      " 'servicescenters for disease control and prevention hiv infection detection '\n",
      " 'counseling and referral infection with hiv causes an acute but brief and '\n",
      " 'nonspecific  influenzalike retroviral syndrome that can include fever  '\n",
      " 'malaise lymphadenopathy pharyngitis arthritis or skin  rash most persons '\n",
      " 'experience at least one symptom however  some might be asymptomatic or have '\n",
      " 'no recognition of illness  406–409 acute infection transitions to a '\n",
      " 'multiyear chronic  illness that progressively depletes cd4 t lymphocytes '\n",
      " 'crucial  for maintenance of effective immune function ultimately  persons '\n",
      " 'with untreated hiv infection experience symptomatic  lifethreatening '\n",
      " 'immunodeficiency ie aids effective art that suppresses hiv replication to '\n",
      " 'undetectable  levels reduces morbidity provides a nearnormal lifespan and  '\n",
      " 'prevents sexual transmission of hiv to others 95–97410– 412 early diagnosis '\n",
      " 'of hiv and rapid linkage to care are  essential for achieving these goals '\n",
      " 'guidelines from both the  us department of health and human services and '\n",
      " 'the  international aids society–usa panel recommend that all  persons with '\n",
      " 'hiv infection be offered effective art as soon  as possible both to reduce '\n",
      " 'morbidity and mortality and to  prevent hiv transmission 413 std specialty '\n",
      " 'or sexual health clinics are a vital partner in  reducing hiv infections in '\n",
      " 'the united states these clinics  provide safety net services to vulnerable '\n",
      " 'populations in need  of hiv prevention services who are not served by the '\n",
      " 'health  care system and hiv partner service organizations diagnosis  of an '\n",
      " 'sti is a biomarker for hiv acquisition especially among  persons with '\n",
      " 'primary or secondary syphilis or among msm  rectal gonorrhea or chlamydia '\n",
      " '197 std clinics perform only  approximately 20 of all federally funded hiv '\n",
      " 'tests nationally  but identify approximately 30 of all new infections 414  '\n",
      " 'among testing venues std clinics are high performing in  terms of linkage to '\n",
      " 'hiv care within 90 days of diagnosis  during 2013–2017 the percentage of '\n",
      " 'persons with a new  diagnosis in an std clinic and linked to care within 90 '\n",
      " 'days  increased from 55 to 90 415415 screening recommendations the following '\n",
      " 'recommendations apply to testing for hiv • hiv testing is recommended for '\n",
      " 'all persons seeking sti  evaluation who are not already known to have hiv '\n",
      " 'infection  testing should be routine at the time of the sti evaluation  '\n",
      " 'regardless of whether the patient reports any specific behavioral  risks for '\n",
      " 'hiv testing for hiv should be performed at the time  of sti diagnosis and '\n",
      " 'treatment if not performed at the initial  sti evaluation and screening '\n",
      " '82195416 • cdc and uspstf recommend hiv screening at least  once for all '\n",
      " 'persons aged 15–65 years 417 • persons at higher risk for hiv acquisition '\n",
      " 'including  sexually active gay bisexual and other msm should be  screened '\n",
      " 'for hiv at least annually providers can consider  the benefits of offering '\n",
      " 'more frequent screening eg every  3–6 months among msm at increased risk for '\n",
      " 'acquiring  hiv 418419 • all pregnant women should be tested for hiv during '\n",
      " 'the  first prenatal visit a second test during the third trimester  '\n",
      " 'preferably at 36 weeks’ gestation should be considered  and is recommended '\n",
      " 'for women who are at high risk for  acquiring hiv infection women who '\n",
      " 'receive health care  in jurisdictions with high rates of hiv and women  '\n",
      " 'examined in clinical settings in which hiv incidence  is  ≥1 per 1000 women '\n",
      " 'screened per year 138140  • hiv screening should be voluntary and free from '\n",
      " 'coercion  patients should not be tested without their knowledge • optout hiv '\n",
      " 'screening notifying the patient that an hiv  test will be performed unless '\n",
      " 'the patient declines is  recommended in all health care settings cdc also  '\n",
      " 'recommends that consent for hiv screening be  incorporated into the general '\n",
      " 'informed consent for  medical care in the same manner as other screening or  '\n",
      " 'diagnostic tests • requirement of specific signed consent for hiv testing '\n",
      " 'is  not recommended general informed consent for medical  care is considered '\n",
      " 'sufficient to encompass informed  consent for hiv testing • providers should '\n",
      " 'use a laboratorybased antigenantibody  agab combination assay as the first '\n",
      " 'test for hiv unless  persons are unlikely to follow up with a provider to '\n",
      " 'receive  their hiv test results in those cases screening with a rapid  poc '\n",
      " 'test can be useful • preliminary positive screening tests for hiv should be  '\n",
      " 'followed by supplemental testing to establish the diagnosis • providing '\n",
      " 'prevention counseling as part of hiv screening  programs or in conjunction '\n",
      " 'with hiv diagnostic testing is  not required 6 however persons might be more '\n",
      " 'likely to  think about hiv and consider their riskrelated behavior  when '\n",
      " 'undergoing an hiv test hiv testing gives providers  an opportunity to '\n",
      " 'conduct sti and hiv prevention  counseling and communicate riskreduction '\n",
      " 'messages • acute hiv infection can occur among persons who report  recent '\n",
      " 'sexual or needlesharing behavior or who have had  an sti diagnosis • '\n",
      " 'providers should test for hiv rna if initial testing according  to the hiv '\n",
      " 'testing algorithm recommended by cdc is  negative or indeterminate when '\n",
      " 'concerned about acute hiv  infection httpsstackscdcgovviewcdc50872 '\n",
      " 'httpsstackscdcgovviewcdc50872 recommendations and reports mmwr  july 23 '\n",
      " '2021  vol 70  no 4 25us department of health and human servicescenters for '\n",
      " 'disease control and prevention • providers should not assume that a '\n",
      " 'laboratory report of a  negative hiv agab or antibody test indicates that '\n",
      " 'the requisite  hiv rna testing for acute hiv infection has been conducted  '\n",
      " 'they should consider explicitly requesting hiv rna testing  when concerned '\n",
      " 'about early acute hiv infection • providers should assess eligibility of all '\n",
      " 'persons seeking  sti services for hiv prep and pep for persons with  '\n",
      " 'substantial risk whose results are hiv negative providers  should offer or '\n",
      " 'provide referral for prep services unless  the last potential hiv exposure '\n",
      " 'occurred 72 hours in  which case pep might be indicated diagnostic '\n",
      " 'considerations hiv infection can be diagnosed by hiv 12 agab  combination '\n",
      " 'immunoassays all fdacleared hiv tests are  highly sensitive and specific '\n",
      " 'available serologic tests can  detect all known subtypes of hiv1 the '\n",
      " 'majority also detect  hiv2 and uncommon variants of hiv1 eg group o and  '\n",
      " 'group n according to an algorithm for hiv diagnosis cdc  recommends that hiv '\n",
      " 'testing begin with a laboratory based hiv1hiv2 agab combination assay which '\n",
      " 'if  repeatedly reactive is followed by a laboratorybased assay  with a '\n",
      " 'supplemental hiv1hiv2 antibody differentiation  assay '\n",
      " 'httpsstackscdcgovviewcdc50872 this algorithm  confers an additional '\n",
      " 'advantage because it can detect hiv2  antibodies after the initial '\n",
      " 'immunoassay although hiv2 is  uncommon in the united states accurate '\n",
      " 'identification is  vital because monitoring and therapy for hiv2 differs '\n",
      " 'from  that for hiv1 420 rna testing should be performed  on all specimens '\n",
      " 'with reactive immunoassay but negative  supplemental antibody test results '\n",
      " 'to determine whether the  discordance represents acute hiv infection rapid '\n",
      " 'poc hiv tests can enable clinicians to make a  preliminary diagnosis of hiv '\n",
      " 'infection in 20 minutes the  majority of rapid antibody assays become '\n",
      " 'reactive later in the  course of hiv infection than conventional '\n",
      " 'laboratorybased  assays and thus can produce negative results among persons  '\n",
      " 'recently infected eg acutely infected persons furthermore  hiv hometest kits '\n",
      " 'only detect hiv antibodies and therefore  will not detect acute hiv '\n",
      " 'infection if early or acute infection  is suspected and a rapid hiv antibody '\n",
      " 'assay is negative  confirmatory testing with combined laboratorybased assays '\n",
      " 'or  rna testing should be performed cdc recommends that all  persons with '\n",
      " 'reactive rapid tests be assessed with a laboratory based agab assay '\n",
      " 'additional details about interpretation of  results by using the hiv testing '\n",
      " 'algorithm recommended by  cdc are available at httpsstackscdcgovviewcdc48472 '\n",
      " 'acute hiv infection providers serving persons at risk for stis are in a '\n",
      " 'position  to diagnose hiv infection during its acute phase diagnosing  hiv '\n",
      " 'infection during the acute phase is particularly important  because persons '\n",
      " 'with acute hiv have highly infectious  disease due to the concentration of '\n",
      " 'virus in plasma and  genital secretions which is extremely elevated during '\n",
      " 'that  stage of infection 421422 httpsclinicalinfohivgoven '\n",
      " 'guidelinesadultandadolescentarvacuteandrecentearly hivinfectionviewfull art '\n",
      " 'during acute hiv infection  is recommended because it substantially reduces '\n",
      " 'infection  transmission to others improves laboratory markers of  disease '\n",
      " 'might decrease severity of acute disease lowers viral  setpoint reduces the '\n",
      " 'size of the viral reservoir decreases  the rate of viral mutation by '\n",
      " 'suppressing replication and  preserves immune function '\n",
      " 'httpsclinicalinfohivgoven guidelinesadultandadolescentarvacuteandrecentearly '\n",
      " 'hivinfectionviewfull persons who receive an acute hiv  diagnosis should be '\n",
      " 'referred immediately to an hiv clinical  care provider provided prevention '\n",
      " 'counseling eg advised to  reduce the number of partners and to use condoms '\n",
      " 'correctly  and consistently and screened for stis information should be  '\n",
      " 'provided regarding availability of pep for sexual and injecting  drug use '\n",
      " 'partners not known to have hiv infection if the  most recent contact was 72 '\n",
      " 'hours preceding hiv diagnosis when providers test by using the cdc algorithm '\n",
      " 'specimens  collected during acute infection might give indeterminate or  '\n",
      " 'negative results because insufficient antihiv antibodies and  potentially '\n",
      " 'insufficient antigen are present to be reactive on  agab combination assays '\n",
      " 'and supplemental hiv1hiv2  antibody differentiation assays whenever acute '\n",
      " 'hiv infection  is suspected eg initial testing according to the cdc '\n",
      " 'algorithm  is negative or indeterminate after a possible sexual exposure to  '\n",
      " 'hiv within the previous few days to weeks especially if the  person has '\n",
      " 'symptoms or has primary or secondary syphilis  gonorrhea or chlamydia '\n",
      " 'additional testing for hiv rna  is recommended if this additional testing '\n",
      " 'for hiv rna is  also negative repeat testing in a few weeks is recommended  '\n",
      " 'to rule out very early acute infection when hiv rna might  not be detectable '\n",
      " 'a more detailed discussion of testing in  the context of acute hiv infection '\n",
      " 'is available at https clinicalinfohivgovenguidelinesadultandadolescentarv '\n",
      " 'initiationantiretroviraltherapyviewfull treatment art should be initiated as '\n",
      " 'soon as possible for all persons with  hiv infection regardless of cd4 tcell '\n",
      " 'count both for individual  health and to prevent hiv transmission '\n",
      " 'httpsclinicalinfohiv govsitesdefaultfilesinlinefilesadultandadolescentglpdf  '\n",
      " 'httpsstackscdcgovviewcdc50872 httpsstackscdcgovviewcdc48472 '\n",
      " 'httpsclinicalinfohivgovenguidelinesadultandadolescentarvacuteandrecentearlyhivinfectionviewfull '\n",
      " 'httpsclinicalinfohivgovenguidelinesadultandadolescentarvacuteandrecentearlyhivinfectionviewfull '\n",
      " 'httpsclinicalinfohivgovenguidelinesadultandadolescentarvacuteandrecentearlyhivinfectionviewfull '\n",
      " 'httpsclinicalinfohivgovenguidelinesadultandadolescentarvacuteandrecentearlyhivinfectionviewfull '\n",
      " 'httpsclinicalinfohivgovenguidelinesadultandadolescentarvacuteandrecentearlyhivinfectionviewfull '\n",
      " 'httpsclinicalinfohivgovenguidelinesadultandadolescentarvacuteandrecentearlyhivinfectionviewfull '\n",
      " 'httpsclinicalinfohivgovenguidelinesadultandadolescentarvinitiationantiretroviraltherapyviewfull '\n",
      " 'httpsclinicalinfohivgovenguidelinesadultandadolescentarvinitiationantiretroviraltherapyviewfull '\n",
      " 'httpsclinicalinfohivgovenguidelinesadultandadolescentarvinitiationantiretroviraltherapyviewfull '\n",
      " 'httpsclinicalinfohivgovsitesdefaultfilesinlinefilesadultandadolescentglpdf '\n",
      " 'httpsclinicalinfohivgovsitesdefaultfilesinlinefilesadultandadolescentglpdf '\n",
      " 'recommendations and reports 26 mmwr  july 23 2021  vol 70  no 4 us '\n",
      " 'department of health and human servicescenters for disease control and '\n",
      " 'prevention persons with hiv infection who achieve and maintain a viral load  '\n",
      " 'suppressed to 200 copiesml with art have effectively no risk  for sexually '\n",
      " 'transmitting hiv 95–97421 early hiv diagnosis  and treatment is thus not '\n",
      " 'only vital for individual health but also as  a public health intervention '\n",
      " 'to prevent new infections knowledge  of the prevention benefit of treatment '\n",
      " 'can help reduce stigma and  increase the person’s commitment to start and '\n",
      " 'remain adherent  to art 423 the importance of adherence should be stressed  '\n",
      " 'as well as the fact that art does not protect against other stis  that can '\n",
      " 'be prevented by using condoms interventions to assist  persons to remain '\n",
      " 'adherent to their prescribed hiv treatment to  otherwise reduce the '\n",
      " 'possibility of transmission to others and to  protect themselves against '\n",
      " 'stis have been developed for diverse  populations at risk 424 '\n",
      " 'httpsclinicalinfohivgovsitesdefault filesinlinefilesadultandadolescentglpdf '\n",
      " 'comprehensive hiv treatment and care services might not  be available in '\n",
      " 'facilities focused primarily on sti treatment  providers in such settings '\n",
      " 'should be knowledgeable about hiv  treatment and care options available in '\n",
      " 'their communities  and promptly link persons who have newly diagnosed hiv  '\n",
      " 'infection and any persons with hiv infection who are not  engaged in ongoing '\n",
      " 'effective care to a health care provider  or facility experienced in caring '\n",
      " 'for persons living with hiv  '\n",
      " 'httpsclinicalinfohivgovsitesdefaultfilesinlinefiles adultandadolescentglpdf  '\n",
      " 'other hiv management considerations behavioral and psychosocial services are '\n",
      " 'integral to caring for  persons with hiv infection providers should expect '\n",
      " 'persons  to be distressed when first informed that they have hiv they  face '\n",
      " 'multiple adaptive challenges including coping with the  reactions of others '\n",
      " 'to a stigmatizing illness developing and  adopting strategies to maintain '\n",
      " 'physical and emotional health  initiating changes in behavior to prevent hiv '\n",
      " 'transmission to  others and reducing the risk for acquiring additional stis  '\n",
      " 'many persons will require assistance gaining access to health  care and '\n",
      " 'other support services and coping with changes in  personal relationships '\n",
      " 'persons with hiv infection might have additional needs  eg referral for '\n",
      " 'substance use or mental health disorders  others require assistance to '\n",
      " 'secure and maintain employment  and housing persons capable of reproduction '\n",
      " 'might require  family planning counseling information about reproductive  '\n",
      " 'health choices and referral for reproductive health care the following '\n",
      " 'recommendations apply to managing persons  with diagnosed hiv infection • '\n",
      " 'link persons with hiv infection to care and start them  on art as soon as '\n",
      " 'possible • report cases in accordance with local requirements to  public '\n",
      " 'health and initiate partner services • provide prevention counseling to '\n",
      " 'persons with diagnosed  hiv infection • ensure all persons with hiv '\n",
      " 'infection are informed that  if they achieve and maintain a suppressed viral '\n",
      " 'load they  have effectively no risk for transmitting hiv stress that  a '\n",
      " 'suppressed viral load is not a substitute for condoms and  behavioral '\n",
      " 'modifications because art does not protect  persons with hiv against other '\n",
      " 'stis • provide additional counseling either onsite or through  referral '\n",
      " 'about the psychosocial and medical implications  of having hiv infection • '\n",
      " 'assess the need for immediate medical care and  psychosocial support • link '\n",
      " 'persons with diagnosed hiv infection to services  provided by health care '\n",
      " 'personnel experienced in managing  hiv infection additional services that '\n",
      " 'might be needed  include substance misuse counseling and treatment  '\n",
      " 'treatment for mental health disorders or emotional distress  reproductive '\n",
      " 'counseling riskreduction counseling and  case management providers should '\n",
      " 'follow up to ensure  that patients have received services for any identified '\n",
      " 'needs • persons with hiv infection should be educated about the  importance '\n",
      " 'of ongoing medical care and what to expect  from these services sti '\n",
      " 'screening of persons with hiv infection in hiv  care settings at the initial '\n",
      " 'hiv care visit providers should screen all  sexually active persons for '\n",
      " 'syphilis gonorrhea and chlamydia  and perform screening for these infections '\n",
      " 'at least annually  during the course of hiv care 425 specific testing  '\n",
      " 'includes syphilis serology and naat for n gonorrhoeae and  c trachomatis at '\n",
      " 'the anatomic site of exposure women should  also be screened for '\n",
      " 'trichomoniasis at the initial visit and  annually thereafter women should be '\n",
      " 'screened for cervical  cancer precursor lesions per existing guidelines 98 '\n",
      " 'more frequent screening for syphilis gonorrhea and  chlamydia eg every 3 or '\n",
      " '6 months should be tailored  to individual risk and the local prevalence of '\n",
      " 'specific stis  certain stis can be asymptomatic their diagnosis might  '\n",
      " 'prompt referral for partner services might identify sexual and  '\n",
      " 'needlesharing partners who can benefit from early diagnosis  and treatment '\n",
      " 'of hiv and might prompt reengagement in  care or hiv prevention services eg '\n",
      " 'pep or prep 8 more  detailed information on screening testing and treatment '\n",
      " 'is  provided in pathogenspecific sections of this report '\n",
      " 'httpsclinicalinfohivgovsitesdefaultfilesinlinefilesadultandadolescentglpdf '\n",
      " 'httpsclinicalinfohivgovsitesdefaultfilesinlinefilesadultandadolescentglpdf '\n",
      " 'httpsclinicalinfohivgovsitesdefaultfilesinlinefilesadultandadolescentglpdf '\n",
      " 'httpsclinicalinfohivgovsitesdefaultfilesinlinefilesadultandadolescentglpdf '\n",
      " 'recommendations and reports mmwr  july 23 2021  vol 70  no 4 27us department '\n",
      " 'of health and human servicescenters for disease control and prevention '\n",
      " 'partner services and reporting partner notification is a key component in '\n",
      " 'the evaluation  of persons with hiv infection early diagnosis and treatment  '\n",
      " 'of hiv among all potentially exposed sexual and injecting  drug sharing '\n",
      " 'partners can improve their health and reduce  new infections for those '\n",
      " 'partners without hiv infection  partner services also provide an opportunity '\n",
      " 'for offering hiv  prevention services including prep or pep if exposure was  '\n",
      " '72 hours previous and sti testing and treatment health care providers should '\n",
      " 'inform persons with diagnosed  hiv infection about any legal obligations of '\n",
      " 'providers to report  cases of hiv to public health the local confidential '\n",
      " 'processes  for managing partner services including that a public health  '\n",
      " 'department still might be in contact to follow up in their care  and partner '\n",
      " 'services and the benefits and risks of partner  notification and services '\n",
      " 'health care providers should also  encourage persons with a new hiv '\n",
      " 'diagnosis to notify their  partners and provide them with referral '\n",
      " 'information for their  partners about hiv testing partner notification for '\n",
      " 'exposure  to hiv should be confidential health care providers can assist  in '\n",
      " 'the partner notification process either directly or by referral  to health '\n",
      " 'department partner notification programs health  department staff are '\n",
      " 'trained to use public health investigation  strategies for confidentially '\n",
      " 'locating persons who can benefit  from hiv treatment care or prevention '\n",
      " 'services guidance  regarding spousal notification varies by jurisdiction '\n",
      " 'detailed  recommendations for notification evaluation and treatment of  '\n",
      " 'exposed partners are available in recommendations for partner  services '\n",
      " 'programs for hiv infection syphilis gonorrhea and  chlamydial infections 111 '\n",
      " 'special considerations pregnancy all pregnant women should be tested for hiv '\n",
      " 'during the  first prenatal visit a second test during the third trimester  '\n",
      " 'preferably at 36 weeks’ gestation should be considered and  is recommended '\n",
      " 'for women who are at high risk for acquiring  hiv women who receive health '\n",
      " 'care in jurisdictions with high  rates of hiv infection and women served in '\n",
      " 'clinical settings  in which prenatal screening identifies ≥1 pregnant woman  '\n",
      " 'with hiv per 1000 women screened 138 diagnostic  algorithms for hiv for '\n",
      " 'pregnant women do not differ from  those for nonpregnant women see sti '\n",
      " 'detection among  special populations pregnant women should be informed  that '\n",
      " 'hiv testing will be performed as part of the routine panel  of prenatal '\n",
      " 'tests 138 for women who decline hiv testing  providers should address '\n",
      " 'concerns that pose obstacles discuss  the benefits of testing eg early hiv '\n",
      " 'detection treatment and  care for improving health of the mother and '\n",
      " 'reducing perinatal  transmission of hiv and encourage testing at subsequent  '\n",
      " 'prenatal visits women who decline testing because they have  had a previous '\n",
      " 'negative hiv test result should be informed  about the importance of '\n",
      " 'retesting during each pregnancy  women with no prenatal care should be '\n",
      " 'tested for hiv at the  time of delivery testing pregnant women is crucial '\n",
      " 'because knowledge of  infection status can help maintain the woman’s health '\n",
      " 'and  it enables receipt of interventions ie art or specialized  obstetrical '\n",
      " 'care that can substantially reduce the risk for  perinatal transmission of '\n",
      " 'hiv pregnant women with  diagnosed hiv infection should be educated about '\n",
      " 'the benefits  of art for their own health and for reducing the risk for hiv  '\n",
      " 'transmission to their infant in the absence of art a mother’s  risk for '\n",
      " 'transmitting hiv to her neonate is approximately  30 however risk can be '\n",
      " 'reduced to 2 through art  obstetrical interventions ie elective cesarean '\n",
      " 'delivery at  38 weeks’ pregnancy and breastfeeding avoidance https '\n",
      " 'clinicalinfohivgovsitesdefaultfilesinlinefilesperinatalgl pdf  pregnant '\n",
      " 'women with hiv infection should be linked  to an hiv care provider '\n",
      " 'experienced in managing hiv in  pregnancy and provided antenatal and '\n",
      " 'postpartum treatment  and advice detailed and regularly updated '\n",
      " 'recommendations  for managing pregnant patients with hiv infection are  '\n",
      " 'available at httpsclinicalinfohivgovsitesdefaultfilesinline '\n",
      " 'filesperinatalglpdf hiv infection among neonates infants and children '\n",
      " 'diagnosis of hiv infection in a pregnant woman indicates  the need for '\n",
      " 'evaluating and managing the hivexposed  neonate and considering whether the '\n",
      " 'woman’s other children  if any might be infected detailed recommendations '\n",
      " 'regarding  diagnosis and management of hiv infection among neonates  and '\n",
      " 'children of mothers with hiv are beyond the scope of  these guidelines but '\n",
      " 'are available at httpsclinicalinfohiv govenguidelines exposed neonates and '\n",
      " 'children with hiv  infection should be referred to physicians with expertise '\n",
      " 'in  neonatal and pediatric hiv management diseases characterized by genital  '\n",
      " 'anal or perianal ulcers in the united states the majority of young sexually '\n",
      " 'active  patients who have genital anal or perianal ulcers have either  '\n",
      " 'genital herpes or syphilis the frequency of each condition  differs by '\n",
      " 'geographic area and population however genital  herpes is the most prevalent '\n",
      " 'of these diseases more than one  etiologic agent eg herpes and syphilis can '\n",
      " 'be present in  any genital anal or perianal ulcer less common infectious  '\n",
      " 'httpsclinicalinfohivgovsitesdefaultfilesinlinefilesperinatalglpdf '\n",
      " 'httpsclinicalinfohivgovsitesdefaultfilesinlinefilesperinatalglpdf '\n",
      " 'httpsclinicalinfohivgovsitesdefaultfilesinlinefilesperinatalglpdf '\n",
      " 'httpsclinicalinfohivgovsitesdefaultfilesinlinefilesperinatalglpdf '\n",
      " 'httpsclinicalinfohivgovsitesdefaultfilesinlinefilesperinatalglpdf '\n",
      " 'recommendations and reports 28 mmwr  july 23 2021  vol 70  no 4 us '\n",
      " 'department of health and human servicescenters for disease control and '\n",
      " 'prevention causes of genital anal or perianal ulcers include chancroid  lgv '\n",
      " 'and granuloma inguinale donovanosis guds eg  syphilis herpes and lgv might '\n",
      " 'also present as oral ulcers  genital herpes syphilis chlamydia gonorrhea and '\n",
      " 'chancroid  have been associated with an increased risk for hiv acquisition  '\n",
      " 'and transmission genital anal or perianal lesions can also be  associated '\n",
      " 'with infectious and noninfectious conditions that  are not sexually '\n",
      " 'transmitted eg yeast trauma carcinoma  aphthae or behcet’s disease fixed '\n",
      " 'drug eruption or psoriasis a diagnosis based only on medical history and '\n",
      " 'physical  examination frequently can be inaccurate therefore all  persons '\n",
      " 'who have genital anal or perianal ulcers should be  evaluated specific '\n",
      " 'evaluation of genital anal or perianal ulcers  includes syphilis serology '\n",
      " 'tests and darkfield examination  from lesion exudate or tissue or naat if '\n",
      " 'available naat  or culture for genital herpes type 1 or 2 and serologic '\n",
      " 'testing  for typespecific hsv antibody in settings where chancroid is  '\n",
      " 'prevalent a naat or culture for haemophilus ducreyi should  be performed no '\n",
      " 'fdacleared naat for diagnosing syphilis is available  in the united states '\n",
      " 'however multiple fdacleared naats  are available for diagnosing hsv1 and '\n",
      " 'hsv2 in genital  specimens certain clinical laboratories have developed '\n",
      " 'their  own syphilis and hsv naats and have conducted clinical  laboratory '\n",
      " 'improvement amendment clia verification  studies with genital specimens '\n",
      " 'typespecific serology for  hsv2 might aid in identifying persons with '\n",
      " 'genital herpes  see genital herpes in addition biopsy of ulcers with  '\n",
      " 'immunohistochemistry can help identify the cause of ulcers  that are unusual '\n",
      " 'or that do not respond to initial therapy hiv  testing should be performed '\n",
      " 'on all persons not known to have  hiv infection who present with genital '\n",
      " 'anal or perianal ulcers  see diagnostic considerations in diseasespecific '\n",
      " 'sections  naat testing at extragenital sites should be considered for  cases '\n",
      " 'in which guds are suspected eg oral manifestations  of syphilis herpes or '\n",
      " 'lgv commercially available naats  have not been cleared by fda for these '\n",
      " 'indications however  they can be used by laboratories that have met '\n",
      " 'regulatory  requirements for an offlabel procedure because early syphilis '\n",
      " 'treatment decreases transmission  possibility public health standards '\n",
      " 'require health care  providers to presumptively treat any patient with a '\n",
      " 'suspected  case of infectious syphilis at the initial visit even before '\n",
      " 'test  results are available presumptive treatment of a patient with a  '\n",
      " 'suspected first episode of genital herpes also is recommended  because hsv '\n",
      " 'treatment benefits depend on prompt therapy  initiation the clinician should '\n",
      " 'choose the presumptive  treatment on the basis of the clinical presentation '\n",
      " 'ie hsv  lesions begin as vesicles and primary syphilis as a papule and  '\n",
      " 'epidemiologic circumstances eg high incidence of disease  among populations '\n",
      " 'and communities and travel history for  example syphilis is so common among '\n",
      " 'msm that any male  who has sex with men presenting with a genital ulcer '\n",
      " 'should be  presumptively treated for syphilis at the initial visit after '\n",
      " 'syphilis  and hsv tests are performed after a complete diagnostic  '\n",
      " 'evaluation 25 of patients who have genital ulcers might  not have a '\n",
      " 'laboratoryconfirmed diagnosis 426 chancroid chancroid prevalence has '\n",
      " 'declined in the united states  141 when infection does occur it is usually '\n",
      " 'associated  with sporadic outbreaks worldwide chancroid appears to  have '\n",
      " 'decreased as well although infection might still occur in  certain africa '\n",
      " 'regions and the caribbean chancroid is a risk  factor in hiv transmission '\n",
      " 'and acquisition 197 diagnostic considerations a definitive diagnosis of '\n",
      " 'chancroid requires identifying  h ducreyi on special culture media that is '\n",
      " 'not widely  available from commercial sources even when these media  are '\n",
      " 'used sensitivity is 80 427 no fdacleared naat  for h ducreyi is available in '\n",
      " 'the united states however  such testing can be performed by clinical '\n",
      " 'laboratories that  have developed their own naat and have conducted clia  '\n",
      " 'verification studies on genital specimens the combination of one or more '\n",
      " 'deep and painful  genital ulcers and tender suppurative inguinal adenopathy  '\n",
      " 'indicates the chancroid diagnosis inguinal lymphadenitis  typically occurs '\n",
      " 'in 50 of cases 428 for both clinical and  surveillance purposes a probable '\n",
      " 'diagnosis of chancroid can  be made if all of the following four criteria '\n",
      " 'are met 1 the  patient has one or more painful genital ulcers 2 the '\n",
      " 'clinical  presentation appearance of genital ulcers and if present  regional '\n",
      " 'lymphadenopathy are typical for chancroid 3 the  patient has no evidence of '\n",
      " 't pallidum infection by darkfield  examination or naat ie ulcer exudate or '\n",
      " 'serous fluid or  by serologic tests for syphilis performed at least 7–14 '\n",
      " 'days  after onset of ulcers and 4 hsv1 or hsv2 naat or hsv  culture '\n",
      " 'performed on the ulcer exudate or fluid are negative treatment successful '\n",
      " 'antimicrobial treatment for chancroid cures  the infection resolves the '\n",
      " 'clinical symptoms and prevents  transmission to others in advanced cases '\n",
      " 'genital scarring and  rectal or urogenital fistulas from suppurative buboes '\n",
      " 'can result  despite successful therapy recommendations and reports mmwr  '\n",
      " 'july 23 2021  vol 70  no 4 29us department of health and human '\n",
      " 'servicescenters for disease control and prevention recommended regimens for '\n",
      " 'chancroid azithromycin 1 g orally in a single dose or ceftriaxone 250 mg im '\n",
      " 'in a single dose or ciprofloxacin 500 mg orally 2 timesday for 3 days or '\n",
      " 'erythromycin base 500 mg orally 3 timesday for 7 days azithromycin and '\n",
      " 'ceftriaxone offer the advantage of  singledose therapy 429 worldwide several '\n",
      " 'isolates with  intermediate resistance to either ciprofloxacin or '\n",
      " 'erythromycin  have been reported however because cultures are not routinely  '\n",
      " 'performed and chancroid is uncommon data are limited  regarding prevalence '\n",
      " 'of h ducreyi antimicrobial resistance other management considerations men '\n",
      " 'who are uncircumcised and persons with hiv infection  do not respond as well '\n",
      " 'to treatment as persons who are  circumcised or are hiv negative 430 '\n",
      " 'patients should be  tested for hiv at the time chancroid is diagnosed if the '\n",
      " 'initial  hiv test results were negative the provider can consider the  '\n",
      " 'benefits of offering more frequent testing and hiv prep to  persons at '\n",
      " 'increased risk for hiv infection followup patients should be reexamined 3–7 '\n",
      " 'days after therapy  initiation if treatment is successful ulcers usually '\n",
      " 'improve  symptomatically within 3 days and objectively within 7 days  after '\n",
      " 'therapy if no clinical improvement is evident the clinician  should consider '\n",
      " 'whether the diagnosis is correct another sti  is present the patient has hiv '\n",
      " 'infection the treatment was  not used as instructed or the h ducreyi strain '\n",
      " 'causing the  infection is resistant to the prescribed antimicrobial the '\n",
      " 'time  required for complete healing depends on the size of the ulcer  large '\n",
      " 'ulcers might require 2 weeks in addition healing can  be slower for '\n",
      " 'uncircumcised men who have ulcers under the  foreskin clinical resolution of '\n",
      " 'fluctuant lymphadenopathy is  slower than that of ulcers and might require '\n",
      " 'needle aspiration  or incision and drainage despite otherwise successful '\n",
      " 'therapy  although needle aspiration of buboes is a simpler procedure  '\n",
      " 'incision and drainage might be preferred because of reduced  need for '\n",
      " 'subsequent drainage procedures management of sex partners regardless of '\n",
      " 'whether disease symptoms are present sex  partners of patients with '\n",
      " 'chancroid should be examined and  treated if they had sexual contact with '\n",
      " 'the patient during the  10 days preceding the patient’s symptom onset '\n",
      " 'special considerations pregnancy data indicate ciprofloxacin presents a low '\n",
      " 'risk to the  fetus during pregnancy but has potential for toxicity during  '\n",
      " 'breastfeeding 431 alternative drugs should be used if the  patient is '\n",
      " 'pregnant or lactating no adverse effects of chancroid  on pregnancy outcome '\n",
      " 'have been reported hiv infection persons with hiv infection who have '\n",
      " 'chancroid infection  should be monitored closely because they are more '\n",
      " 'likely to  experience chancroid treatment failure and to have ulcers  that '\n",
      " 'heal slowly 430432 persons with hiv might require  repeated or longer '\n",
      " 'courses of therapy and treatment failures  can occur with any regimen data '\n",
      " 'are limited concerning  the therapeutic efficacy of the recommended '\n",
      " 'singledose  azithromycin and ceftriaxone regimens among persons with  hiv '\n",
      " 'infection children because sexual contact is the major primary transmission '\n",
      " 'route  among us patients diagnosis of chancroid ulcers among infants  and '\n",
      " 'children especially in the genital or perineal region is highly  suspicious '\n",
      " 'of sexual abuse however h ducreyi is recognized as a  major cause of '\n",
      " 'nonsexually transmitted cutaneous ulcers among  children in tropical regions '\n",
      " 'and specifically countries where  yaws is endemic 433–435 acquisition of a '\n",
      " 'lowerextremity  ulcer attributable to h ducreyi in a child without genital '\n",
      " 'ulcers  and reported travel to a region where yaws is endemic should  not be '\n",
      " 'considered evidence of sexual abuse genital herpes  genital herpes is a '\n",
      " 'chronic lifelong viral infection two types  of hsv can cause genital herpes '\n",
      " 'hsv1 and hsv2 most  cases of recurrent genital herpes are caused by hsv2 '\n",
      " 'and  119 of persons aged 14–49 years are estimated to be infected  in the '\n",
      " 'united states 436 however an increasing proportion  of anogenital herpetic '\n",
      " 'infections have been attributed to  hsv1 which is especially prominent among '\n",
      " 'young women  and msm 186437438 the majority of persons infected with hsv2 '\n",
      " 'have not  had the condition diagnosed many of whom have mild or  '\n",
      " 'unrecognized infections but shed virus intermittently in the  anogenital '\n",
      " 'area consequently most genital herpes infections  are transmitted by persons '\n",
      " 'unaware that they have the  infection or who are asymptomatic when '\n",
      " 'transmission occurs  management of genital hsv should address the chronic '\n",
      " 'nature  of the infection rather than focusing solely on treating acute  '\n",
      " 'episodes of genital lesions recommendations and reports 30 mmwr  july 23 '\n",
      " '2021  vol 70  no 4 us department of health and human servicescenters for '\n",
      " 'disease control and prevention diagnostic considerations clinical diagnosis '\n",
      " 'of genital herpes can be difficult because the  selflimited recurrent '\n",
      " 'painful and vesicular or ulcerative lesions  classically associated with hsv '\n",
      " 'are absent in many infected persons  at the time of clinical evaluation if '\n",
      " 'genital lesions are present  clinical diagnosis of genital herpes should be '\n",
      " 'confirmed by type specific virologic testing from the lesion by naat or '\n",
      " 'culture 186  recurrences and subclinical shedding are much more frequent '\n",
      " 'for  hsv2 genital herpes infection than for hsv1 genital herpes  439440 '\n",
      " 'therefore prognosis and counseling depend on which  hsv type is present '\n",
      " 'typespecific serologic tests can be used to  aid in the diagnosis of hsv '\n",
      " 'infection in the absence of genital  lesions both typespecific virologic and '\n",
      " 'typespecific serologic tests  for hsv should be available in clinical '\n",
      " 'settings that provide care  to persons with or at risk for stis hsv2 genital '\n",
      " 'herpes infection  increases the risk for acquiring hiv twofold to threefold '\n",
      " 'therefore  all persons with genital herpes should be tested for hiv 441 '\n",
      " 'virologic tests hsv naat assays are the most sensitive tests because  they '\n",
      " 'detect hsv from genital ulcers or other mucocutaneous  lesions these tests '\n",
      " 'are increasingly available 442–444  although multiple fdacleared assays '\n",
      " 'exist for hsv detection  these tests vary in sensitivity from 909 to 100 '\n",
      " 'however  they are considered highly specific 445–447 pcr is also  the test '\n",
      " 'of choice for diagnosing hsv infections affecting the  central nervous '\n",
      " 'system cns and systemic infections eg  meningitis encephalitis and neonatal '\n",
      " 'herpes hsv pcr  of the blood should not be performed to diagnose genital  '\n",
      " 'herpes infection except in cases in which concern exists for  disseminated '\n",
      " 'infection eg hepatitis in certain settings viral  culture is the only '\n",
      " 'available virologic test the sensitivity of viral  culture is low especially '\n",
      " 'for recurrent lesions and decreases  rapidly as lesions begin to heal 443448 '\n",
      " 'viral culture  isolates and pcr amplicons should be typed to determine  '\n",
      " 'whether hsv1 or hsv2 is causing the infection failure to  detect hsv by naat '\n",
      " 'or culture especially in the presence  of older lesions or the absence of '\n",
      " 'active lesions does not  indicate an absence of hsv infection because viral '\n",
      " 'shedding  is intermittent similarly random or blind genital swabs in  the '\n",
      " 'absence of lesions should not be used to diagnose genital  hsv infection '\n",
      " 'because sensitivity is low and a negative result  does not exclude the '\n",
      " 'presence of hsv infection cytologic detection of cellular changes associated '\n",
      " 'with hsv  infection is an insensitive and nonspecific method of diagnosing  '\n",
      " 'genital lesions ie tzanck preparation and therefore should  not be relied on '\n",
      " 'although a direct immunofluorescence  assay using fluoresceinlabeled '\n",
      " 'monoclonal antibodies is also  available for detecting hsv antigen from '\n",
      " 'genital specimens  this assay lacks sensitivity and is not recommended 449 '\n",
      " 'typespecific serologic tests both typespecific and typecommon antibodies to '\n",
      " 'hsv  develop during the first weeks after infection and persist  '\n",
      " 'indefinitely the majority of available accurate type specific hsv serologic '\n",
      " 'assays are based on the hsvspecific  glycoprotein g2 gg2 hsv2 and '\n",
      " 'glycoprotein g1 gg1  hsv1 typecommon antibody tests do not distinguish  '\n",
      " 'between hsv1 and hsv2 infection therefore typespecific  serologic assays '\n",
      " 'should be requested 450–452 both laboratorybased assays and poc tests that '\n",
      " 'provide  results for hsv2 antibodies from capillary blood or serum  during a '\n",
      " 'clinic visit are available the sensitivity of glycoprotein  g typespecific '\n",
      " 'tests for detecting hsv2 antibody varies from  80 to 98 falsenegative '\n",
      " 'results might be more frequent  at early stages of infection 451453454 '\n",
      " 'therefore in  cases of recent suspected hsv2 acquisition repeat type '\n",
      " 'specific antibody testing 12 weeks after the presumed time  of acquisition '\n",
      " 'is indicated the most commonly used test  herpeselect hsv2 enzyme '\n",
      " 'immunoassay eia often is  falsely positive at low index values 11–30 457–457 '\n",
      " 'one  study reported an overall specificity of 574 with a specificity  of 398 '\n",
      " 'for index values of 11–29 458 because of the  poor specificity of '\n",
      " 'commercially available typespecific eias  particularly with low index values '\n",
      " '30 a confirmatory test  biokit or western blot with a second method should '\n",
      " 'be  performed before test interpretation use of confirmatory  testing with '\n",
      " 'the biokit or the western blot assays have been  reported to improve '\n",
      " 'accuracy of hsv2 serologic testing 459  the herpeselect hsv2 immunoblot '\n",
      " 'should not be used for  confirmation because it uses the same antigen as the '\n",
      " 'hsv2  eia if confirmatory tests are unavailable patients should be  '\n",
      " 'counseled about the limitations of available testing before  obtaining '\n",
      " 'serologic tests and health care providers should  be aware that '\n",
      " 'falsepositive results occur immunoglobulin  m igm testing for hsv1 or hsv2 '\n",
      " 'is not useful because  igm tests are not type specific and might be positive '\n",
      " 'during  recurrent genital or oral episodes of herpes 460 therefore  hsv igm '\n",
      " 'testing is not recommended because approximately all hsv2 infections are '\n",
      " 'sexually  acquired presence of typespecific hsv2 antibody implies  '\n",
      " 'anogenital infection in this instance education and counseling  for persons '\n",
      " 'with genital hsv infections should be provided  the presence of hsv1 '\n",
      " 'antibody alone is more difficult  to interpret hsv1 serologic testing does '\n",
      " 'not distinguish  between oral and genital infection and typically should '\n",
      " 'not  be performed for diagnosing genital hsv1 infection persons  with hsv1 '\n",
      " 'antibodies often have oral hsv infection acquired  during childhood which '\n",
      " 'might be asymptomatic lack of  symptoms in a person who is hsv1 seropositive '\n",
      " 'does not  recommendations and reports mmwr  july 23 2021  vol 70  no 4 31us '\n",
      " 'department of health and human servicescenters for disease control and '\n",
      " 'prevention distinguish anogenital from orolabial or cutaneous infection  and '\n",
      " 'regardless of site of infection these persons remain at risk  for acquiring '\n",
      " 'hsv2 in addition hsv1 serologic testing  has low sensitivity for detection '\n",
      " 'of hsv1 antibody 458  however acquisition of hsv1 genital herpes is '\n",
      " 'increasing  and hsv1 genital herpes also can be asymptomatic 437– 439461462 '\n",
      " 'diagnosis of hsv1 infection is confirmed by  virologic tests from genital '\n",
      " 'lesions typespecific hsv2 serologic assays for diagnosing  hsv2 are useful '\n",
      " 'in the following scenarios recurrent or  atypical genital symptoms or '\n",
      " 'lesions with a negative hsv  pcr or culture result clinical diagnosis of '\n",
      " 'genital herpes  without laboratory confirmation and a patient’s partner has  '\n",
      " 'genital herpes hsv2 serologic screening among the general  population is not '\n",
      " 'recommended patients who are at higher  risk for infection eg those '\n",
      " 'presenting for an sti evaluation  especially for persons with ≥10 lifetime '\n",
      " 'sex partners and  persons with hiv infection might need to be assessed for '\n",
      " 'a  history of genital herpes symptoms followed by typespecific  hsv '\n",
      " 'serologic assays to diagnose genital herpes for those with  genital symptoms '\n",
      " 'genital herpes management antiviral medication offers clinical benefits to '\n",
      " 'symptomatic  patients and is the mainstay of management the goals for  use '\n",
      " 'of antiviral medications to treat genital herpes infection  are to treat or '\n",
      " 'prevent symptomatic genital herpes recurrences  and improve quality of life '\n",
      " 'and suppress the virus to prevent  transmission to sexual partners '\n",
      " 'counseling regarding the  natural history of genital herpes risks for sexual '\n",
      " 'and perinatal  transmission and methods for reducing transmission is also  '\n",
      " 'integral to clinical management systemic antiviral drugs can partially '\n",
      " 'control the signs and  symptoms of genital herpes when used to treat first '\n",
      " 'clinical and  recurrent episodes or when used as daily suppressive therapy  '\n",
      " 'however these drugs neither eradicate latent virus nor affect  the risk '\n",
      " 'frequency or severity of recurrences after the drug  is discontinued '\n",
      " 'randomized trials have indicated that three  fdaapproved antiviral '\n",
      " 'medications provide clinical benefit  for genital herpes acyclovir '\n",
      " 'valacyclovir and famciclovir  463–471 valacyclovir is the valine ester of '\n",
      " 'acyclovir and has  enhanced absorption after oral administration allowing '\n",
      " 'for  less frequent dosing than acyclovir famciclovir also has high  oral '\n",
      " 'bioavailability topical therapy with antiviral drugs offers  minimal '\n",
      " 'clinical benefit and is discouraged first clinical episode of genital herpes '\n",
      " 'newly acquired genital herpes can cause a prolonged  clinical illness with '\n",
      " 'severe genital ulcerations and neurologic  involvement even persons with '\n",
      " 'firstepisode herpes who have  mild clinical manifestations initially can '\n",
      " 'experience severe or  prolonged symptoms during recurrent infection '\n",
      " 'therefore  all patients with first episodes of genital herpes should '\n",
      " 'receive  antiviral therapy recommended regimens for first clinical episode '\n",
      " 'of genital  herpes acyclovir† 400 mg orally 3 timesday for 7–10 days or '\n",
      " 'famciclovir 250 mg orally 3 timesday for 7–10 days or valacyclovir 1 g '\n",
      " 'orally 2 timesday for 7–10 days  treatment can be extended if healing is '\n",
      " 'incomplete after 10 days of therapy † acyclovir 200 mg orally 5 timesday is '\n",
      " 'also effective but is not  recommended because of the frequency of dosing '\n",
      " 'recurrent hsv2 genital herpes almost all persons with symptomatic '\n",
      " 'firstepisode hsv2  genital herpes subsequently experience recurrent episodes '\n",
      " 'of  genital lesions intermittent asymptomatic shedding occurs  among persons '\n",
      " 'with hsv2 genital herpes infection even  those with longstanding clinically '\n",
      " 'silent infection antiviral  therapy for recurrent genital herpes can be '\n",
      " 'administered either  as suppressive therapy to reduce the frequency of '\n",
      " 'recurrences  or episodically to ameliorate or shorten the duration of '\n",
      " 'lesions  certain persons including those with mild or infrequent  recurrent '\n",
      " 'outbreaks benefit from antiviral therapy therefore  options for treatment '\n",
      " 'should be discussed many persons prefer  suppressive therapy which has the '\n",
      " 'additional advantage of  decreasing the risk for transmitting hsv2 genital '\n",
      " 'herpes to  susceptible partners 472473 suppressive therapy for recurrent '\n",
      " 'hsv2  genital herpes suppressive therapy reduces frequency of genital '\n",
      " 'herpes  recurrences by 70–80 among patients who have frequent  recurrences '\n",
      " '469–472 persons receiving such therapy  often report having experienced no '\n",
      " 'symptomatic outbreaks  suppressive therapy also is effective for patients '\n",
      " 'with less  frequent recurrences longterm safety and efficacy have  been '\n",
      " 'documented among patients receiving daily acyclovir  valacyclovir and '\n",
      " 'famciclovir 474 quality of life is improved  for many patients with frequent '\n",
      " 'recurrences who receive  suppressive therapy rather than episodic treatment '\n",
      " '475  providers should discuss with patients on an annual basis  whether they '\n",
      " 'want to continue suppressive therapy because  frequency of genital hsv2 '\n",
      " 'recurrence diminishes over time  for many persons however neither treatment '\n",
      " 'discontinuation  nor laboratory monitoring is necessary because adverse '\n",
      " 'events  and development of hsv antiviral resistance related to long term '\n",
      " 'antiviral use are uncommon recommendations and reports 32 mmwr  july 23 '\n",
      " '2021  vol 70  no 4 us department of health and human servicescenters for '\n",
      " 'disease control and prevention treatment with valacyclovir 500 mg daily '\n",
      " 'decreases the rate  of hsv2 transmission for discordant heterosexual '\n",
      " 'couples  in which a partner has a history of genital hsv2 infection  473 '\n",
      " 'such couples should be encouraged to consider  suppressive antiviral therapy '\n",
      " 'as part of a strategy for preventing  transmission in addition to consistent '\n",
      " 'condom use and  avoidance of sexual activity during recurrences suppressive  '\n",
      " 'antiviral therapy for persons with a history of symptomatic  genital herpes '\n",
      " 'also is likely to reduce transmission when used  by those who have multiple '\n",
      " 'partners hsv2 seropositive  persons without a history of symptomatic genital '\n",
      " 'herpes  have a 50 decreased risk for genital shedding compared  with those '\n",
      " 'with symptomatic genital herpes 476 no data  are available regarding '\n",
      " 'efficacy of suppressive therapy for  preventing hsv2 transmission among '\n",
      " 'discordant couples in  which a partner has a history of asymptomatic hsv2 '\n",
      " 'infection  identified by a positive hsv2 serologic test among hsv2  '\n",
      " 'seropositive persons without hiv infection oral tdfftc  and intravaginal '\n",
      " 'tenofovir are ineffective at reducing the risk  for hsv2 shedding or '\n",
      " 'recurrences 477 recommended regimens for suppression of recurrent hsv2  '\n",
      " 'genital herpes acyclovir 400 mg orally 2 timesday or valacyclovir 500 mg '\n",
      " 'orally once a day or valacyclovir 1 g orally once a day or famciclovir 250 '\n",
      " 'mg orally 2 timesday  valacyclovir 500 mg once a day might be less effective '\n",
      " 'than other  valacyclovir or acyclovir dosing regimens for persons who have '\n",
      " 'frequent  recurrences ie ≥10 episodesyear famciclovir appears somewhat less '\n",
      " 'effective for suppression of  viral shedding 478 ease of administration and '\n",
      " 'cost also are  key considerations for prolonged treatment recurrent hsv1 '\n",
      " 'genital herpes recurrences are less frequent after the first episode of '\n",
      " 'hsv1  genital herpes compared with genital hsv2 genital herpes  and genital '\n",
      " 'shedding rapidly decreases during the first year of  infection 479 no data '\n",
      " 'are available regarding the efficacy  of suppressive therapy for preventing '\n",
      " 'transmission among  persons with hsv1 genital herpes infection because of  '\n",
      " 'the decreased risk for recurrences and shedding suppressive  therapy for '\n",
      " 'hsv1 genital herpes should be reserved for those  with frequent recurrences '\n",
      " 'through shared clinical decision making between the patient and the provider '\n",
      " 'episodic therapy for recurrent hsv2 genital herpes episodic treatment of '\n",
      " 'recurrent herpes is most effective if  therapy is initiated within 1 day of '\n",
      " 'lesion onset or during the  prodrome that precedes some outbreaks the '\n",
      " 'patient should  be provided with a supply of drug or a prescription for the  '\n",
      " 'medication with instructions to initiate treatment immediately  when '\n",
      " 'symptoms begin acyclovir famciclovir and valacyclovir  appear equally '\n",
      " 'effective for episodic treatment of genital herpes  466–470 recommended '\n",
      " 'regimens for episodic therapy for recurrent  hsv2 genital herpes acyclovir '\n",
      " '800 mg orally 2 timesday for 5 days or acyclovir 800 mg orally 3 timesday '\n",
      " 'for 2 days or famciclovir 1 g orally 2 timesday for 1 day or famciclovir 500 '\n",
      " 'mg orally once followed by 250 mg 2 timesday for  2 days or famciclovir 125 '\n",
      " 'mg orally 2 timesday for 5 days or valacyclovir 500 mg orally 2 timesday for '\n",
      " '3 days or valacyclovir 1 g orally once daily for 5 days  acyclovir 400 mg '\n",
      " 'orally 3 timesday for 5 days is also effective but is not  recommended '\n",
      " 'because of frequency of dosing severe disease intravenous iv acyclovir '\n",
      " 'therapy 5–10 mgkg body weight  iv every 8 hours should be provided for '\n",
      " 'patients who have severe  hsv disease or complications that necessitate '\n",
      " 'hospitalization  eg disseminated infection pneumonitis or hepatitis or  cns '\n",
      " 'complications eg meningitis or encephalitis hsv2  meningitis is a rare '\n",
      " 'complication of hsv2 genital herpes  infection that affects women more than '\n",
      " 'men 480 iv therapy  should be considered until clinical improvement followed '\n",
      " 'by  oral antiviral therapy to complete 10 days of total therapy  longer '\n",
      " 'duration is recommended for cns complications  hsv2 meningitis is '\n",
      " 'characterized clinically by signs of  headache photophobia fever meningismus '\n",
      " 'and cerebrospinal  fluid csf lymphocytic pleocytosis accompanied by mildly  '\n",
      " 'elevated protein and normal glucose 481 optimal therapies  for hsv2 '\n",
      " 'meningitis have not been well studied 482  however acyclovir 5–10 mgkg body '\n",
      " 'weight iv every 8 hours  until clinical improvement is observed followed by '\n",
      " 'highdose  oral antiviral therapy valacyclovir 1 g 3 timesday to complete  a '\n",
      " '10 to 14day course of total therapy is recommended  for patients with '\n",
      " 'previous episodes of documented hsv2  meningitis oral valacyclovir may be '\n",
      " 'used for the entire  course during episodes of recurrent hsv2 meningitis a  '\n",
      " 'randomized clinical trial indicated that suppressive therapy  valacyclovir '\n",
      " '500 mg 2 timesday did not prevent recurrent  hsv2 meningitis episodes '\n",
      " 'however the dose might not  have been sufficient for cns penetration 483 '\n",
      " 'valacyclovir  recommendations and reports mmwr  july 23 2021  vol 70  no 4 '\n",
      " '33us department of health and human servicescenters for disease control and '\n",
      " 'prevention 500 mg 2 timesday is not recommended for suppression of  hsv2 '\n",
      " 'meningitis higher doses have not been studied in  clinical trials hsv '\n",
      " 'meningitis should be distinguished from  encephalitis which requires a '\n",
      " 'longer course 14–21 days of  iv therapy impaired renal function warrants an '\n",
      " 'adjustment  in acyclovir dosage hepatitis hepatitis is a rare manifestation '\n",
      " 'of disseminated hsv  infection often reported among pregnant women who  '\n",
      " 'acquire hsv during pregnancy 484 pregnant women in  any trimester can '\n",
      " 'present with fever and hepatitis markedly  elevated transaminases but might '\n",
      " 'not have any genital or skin  lesions hsv hepatitis is associated with '\n",
      " 'fulminant liver failure  and high mortality 25 therefore a high index of '\n",
      " 'suspicion  for hsv is necessary with a confirmatory diagnosis by hsv  pcr '\n",
      " 'from blood 485 among pregnant women with fever  and unexplained severe '\n",
      " 'hepatitis disseminated hsv infection  should be considered and empiric iv '\n",
      " 'acyclovir should be  initiated pending confirmation 484 prevention '\n",
      " 'consistent and correct condom use has been reported  in multiple studies to '\n",
      " 'decrease but not eliminate the risk  for hsv2 transmission from men to women '\n",
      " '486–488  condoms are less effective for preventing transmission from  women '\n",
      " 'to men 489 two randomized clinical trials of  medical male circumcision mmc '\n",
      " 'demonstrated a decreased  risk for hsv2 acquisition among men in uganda and  '\n",
      " 'south africa 6668 results from a third trial conducted  in kenya did not '\n",
      " 'demonstrate a substantial difference in  hsv2 acquisition among men who '\n",
      " 'received mmc 490  a systematic review indicated high consistency for '\n",
      " 'decreased  risk for hsv2 acquisition among women with a male partner  who '\n",
      " 'underwent mmc 491 these data indicate that mmc  can be associated with '\n",
      " 'decreased risk for hsv2 acquisition  among adult heterosexual men and with '\n",
      " 'decreased risk for  hsv2 transmission from male to female partners '\n",
      " 'randomized clinical trials have demonstrated that prep with  daily oral '\n",
      " 'tdfftc decreases the risk for hsv2 acquisition  by 30 in heterosexual '\n",
      " 'partnerships 492 pericoital  intravaginal tenofovir 1 gel also decreases the '\n",
      " 'risk for hsv2  acquisition among heterosexual women 493 among msm  and '\n",
      " 'transgender women daily oral tdfftc decreases the  risk for severe ulcers '\n",
      " 'with symptomatic genital hsv2 infection  but not for hsv2 acquisition 494 '\n",
      " 'insufficient evidence  exists that tdfftc use among those who are not at '\n",
      " 'risk for  hiv acquisition will prevent hsv2 infection and it should  not be '\n",
      " 'used for that sole purpose oral tdf does not prevent  hsv2 acquisition among '\n",
      " 'persons with hiv infection who  are taking tdf as part of their art regimen '\n",
      " '495 no data  indicate that antivirals acyclovir valacyclovir or famciclovir  '\n",
      " 'can be taken as prep by persons without hsv2 to prevent  its acquisition '\n",
      " 'counseling counseling of persons with genital herpes and their sex  partners '\n",
      " 'is crucial for management the goals of counseling  include helping patients '\n",
      " 'cope with the infection and preventing  sexual and perinatal transmission '\n",
      " 'although initial counseling  can be provided at the first visit patients '\n",
      " 'often benefit from  learning about the chronic aspects of the disease after '\n",
      " 'the acute  illness subsides multiple resources including internet sites and  '\n",
      " 'printed materials are available to assist patients their partners  and '\n",
      " 'clinicians who provide counseling 496497 httpswww ashasexualhealthorg and '\n",
      " 'httpswwwcdcgovstdherpes although the psychological effect of a serologic '\n",
      " 'diagnosis of  hsv2 infection in a person with asymptomatic or unrecognized  '\n",
      " 'genital herpes appears minimal and transient 498499 certain  persons with '\n",
      " 'hsv infection might express anxiety concerning  genital herpes that does not '\n",
      " 'reflect the actual clinical severity  of their disease the psychological '\n",
      " 'effect of hsv infection can  be substantial common concerns about genital '\n",
      " 'herpes include  the severity of initial clinical manifestations recurrent '\n",
      " 'episodes  sexual relationships and transmission to sex partners and ability  '\n",
      " 'to bear healthy children symptomatic hsv2 genital herpes when counseling '\n",
      " 'persons with symptomatic hsv2 genital  herpes infection the provider should '\n",
      " 'discuss the following • the natural history of the disease with emphasis on '\n",
      " 'the  potential for recurrent episodes asymptomatic viral  shedding and the '\n",
      " 'attendant risks for sexual transmission  of hsv to occur during asymptomatic '\n",
      " 'periods  asymptomatic viral shedding is most frequent during the  first 12 '\n",
      " 'months after acquiring hsv2 • the effectiveness of daily suppressive '\n",
      " 'antiviral therapy for  preventing symptomatic recurrent episodes of genital  '\n",
      " 'herpes for persons experiencing a first episode or recurrent  genital herpes '\n",
      " '• the effectiveness of daily use of valacyclovir in reducing  risk for '\n",
      " 'transmission of hsv2 among persons without  hiv 473 and use of episodic '\n",
      " 'therapy to shorten the  duration of recurrent episodes • the importance of '\n",
      " 'informing current sex partners about  genital herpes and informing future '\n",
      " 'partners before  initiating a sexual relationship • the importance of '\n",
      " 'abstaining from sexual activity with  uninfected partners when lesions or '\n",
      " 'prodromal symptoms  are present httpswwwashasexualhealthorg '\n",
      " 'httpswwwashasexualhealthorg httpswwwcdcgovstdherpes recommendations and '\n",
      " 'reports 34 mmwr  july 23 2021  vol 70  no 4 us department of health and '\n",
      " 'human servicescenters for disease control and prevention • the effectiveness '\n",
      " 'of male latex condoms which when used  consistently and correctly can reduce '\n",
      " 'but not eliminate  the risk for genital herpes transmission 486–488 • the '\n",
      " 'typespecific serologic testing of partners of persons  with symptomatic hsv2 '\n",
      " 'genital herpes to determine  whether such partners are already hsv '\n",
      " 'seropositive or  whether risk for acquiring hsv exists • the low risk for '\n",
      " 'neonatal hsv except when genital herpes  is acquired late in pregnancy or if '\n",
      " 'prodrome or lesions are  present at delivery • the increased risk for hiv '\n",
      " 'acquisition among hsv2  seropositive persons who are exposed to hiv 76471  • '\n",
      " 'the lack of effectiveness of episodic or suppressive therapy  among persons '\n",
      " 'with hiv infection to reduce risk for  transmission to partners who might be '\n",
      " 'at risk for  hsv2 acquisition asymptomatic hsv2 genital herpes when '\n",
      " 'counseling persons with asymptomatic hsv2 genital  herpes infection the '\n",
      " 'provider should consider the following • asymptomatic persons who receive a '\n",
      " 'diagnosis of hsv2  by typespecific serologic testing with confirmatory '\n",
      " 'testing  if needed should receive education about the symptoms of  genital '\n",
      " 'herpes infection see diagnostic considerations • episodic and suppressive '\n",
      " 'antiviral therapies are used  predominantly to treat recurrences prevent '\n",
      " 'recurrences  and prevent transmission to sex partners of persons with  '\n",
      " 'symptomatic hsv2 infection • for patients with serological evidence of hsv2 '\n",
      " 'with  combination testing if needed without symptomatic  recurrences neither '\n",
      " 'episodic nor suppressive therapy is  indicated for prevention of recurrences '\n",
      " 'see diagnostic  considerations • among persons with asymptomatic infection '\n",
      " 'the efficacy  of suppressive therapy to prevent hsv2 transmission to  sex '\n",
      " 'partners has not been studied • because of the decreased risk for shedding '\n",
      " 'among those  with asymptomatic hsv2 genital herpes the benefit of  '\n",
      " 'suppressive therapy for preventing transmission is  unknown among this '\n",
      " 'population hsv1 genital herpes when counseling persons with hsv1 genital '\n",
      " 'herpes  infection the provider should consider the following • persons with '\n",
      " 'virologic laboratorydocumented  symptomatic hsv1 genital herpes infection '\n",
      " 'should be  educated that the risk for recurrent genital herpes and  genital '\n",
      " 'shedding is lower with hsv1 infection compared  with hsv2 infection • '\n",
      " 'because of the decreased risk for recurrences and shedding  suppressive '\n",
      " 'therapy for hsv1 genital herpes should be  reserved for those with frequent '\n",
      " 'recurrences • for patients with frequently recurring hsv1 genital  herpes '\n",
      " 'suppressive therapy might be considered  suppressive therapy to prevent hsv1 '\n",
      " 'transmission to sex  partners has not been studied for persons with '\n",
      " 'symptomatic hsv1 genital herpes or  asymptomatic hsv2 genital herpes '\n",
      " 'suppressive therapy can  be considered for those who have substantial '\n",
      " 'psychosocial  distress caused by the diagnosis of genital herpes for women  '\n",
      " 'who have genital herpes the providers who care for them  during pregnancy '\n",
      " 'and those who will care for their newborn  infant should be informed of '\n",
      " 'their infection see genital  herpes during pregnancy management of sex '\n",
      " 'partners the sex partners of persons who have symptomatic  genital herpes '\n",
      " 'can benefit from evaluation and counseling  symptomatic sex partners should '\n",
      " 'be evaluated and treated in  the same manner as patients who have '\n",
      " 'symptomatic genital  herpes asymptomatic sex partners of patients who have  '\n",
      " 'symptomatic genital herpes should be asked about a history  of genital '\n",
      " 'symptoms and offered typespecific serologic testing  for hsv2 for partners '\n",
      " 'without genital herpes no data are  available on which to base a '\n",
      " 'recommendation for pep or  prep with antiviral medications or that they '\n",
      " 'would prevent  acquisition and this should not be offered to patients as a  '\n",
      " 'prevention strategy special considerations drug allergy intolerance or '\n",
      " 'adverse reactions allergic and other adverse reactions to oral acyclovir  '\n",
      " 'valacyclovir and famciclovir are rare desensitization to  acyclovir has been '\n",
      " 'described 500 hiv infection immunocompromised patients can have prolonged or '\n",
      " 'severe  episodes of genital perianal or oral herpes lesions caused by  hsv '\n",
      " 'are common among persons with hiv infection and  might be severe painful and '\n",
      " 'atypical 501 hsv shedding is  increased among persons with hiv infection 502 '\n",
      " 'whereas  art reduces the severity and frequency of symptomatic genital  '\n",
      " 'herpes frequent subclinical shedding still occurs 503504  clinical '\n",
      " 'manifestations of genital herpes might worsen during  immune reconstitution '\n",
      " 'early after initiation of art hsv2  typespecific serologic testing can be '\n",
      " 'considered for persons  with hiv infection during their initial evaluation '\n",
      " 'particularly  among those with a history of genital symptoms indicative of  '\n",
      " 'hsv infection recommendations and reports mmwr  july 23 2021  vol 70  no 4 '\n",
      " '35us department of health and human servicescenters for disease control and '\n",
      " 'prevention recommended therapy for firstepisode genital herpes is  the same '\n",
      " 'as for persons without hiv infection although  treatment courses might need '\n",
      " 'to be extended for lesion  resolution suppressive or episodic therapy with '\n",
      " 'oral antiviral  agents is effective in decreasing the clinical '\n",
      " 'manifestations of  hsv infection among persons with hiv 503504 the risk  for '\n",
      " 'gud increases during the first 6 months after starting  art especially among '\n",
      " 'persons who have a cd4 tcell count  200 cellmm3 suppressive antiviral '\n",
      " 'therapy reduces the risk  for gud among this population and can be continued '\n",
      " 'for  6 months after art initiation 504 when the risk for gud  returns to '\n",
      " 'baseline levels suppressive antiviral therapy among  persons with hiv and '\n",
      " 'hsv infection does not reduce the  risk for either hiv transmission or hsv2 '\n",
      " 'transmission to  susceptible sex partners 88505 suppressive antiviral '\n",
      " 'therapy  does not delay hiv disease progression and is not associated  with '\n",
      " 'decreased risk for hivrelated inflammation among  persons taking art 506 for '\n",
      " 'severe hsv disease initiating  therapy with acyclovir 5–10 mgkg iv every 8 '\n",
      " 'hours might  be necessary recommended regimens for daily suppression of '\n",
      " 'genital  herpes among persons with hiv infection acyclovir 400–800 mg orally '\n",
      " '2–3 timesday or famciclovir 500 mg orally 2 timesday or valacyclovir 500 mg '\n",
      " 'orally 2 timesday recommended regimens for episodic genital herpes '\n",
      " 'infection  among persons with hiv infection acyclovir 400 mg orally 3 '\n",
      " 'timesday for 5–10 days or famciclovir 500 mg orally 2 timesday for 5–10 days '\n",
      " 'or valacyclovir 1 g orally 2 timesday for 5–10 days antiviralresistant hsv '\n",
      " 'infection if lesions persist or recur in a patient receiving antiviral  '\n",
      " 'treatment acyclovir resistance should be suspected and a viral  culture '\n",
      " 'obtained for phenotypic sensitivity testing 507  molecular testing for '\n",
      " 'acyclovir resistance is not available  such persons should be managed in '\n",
      " 'consultation with an  infectious disease specialist and alternative therapy '\n",
      " 'should be  administered all acyclovirresistant strains are also resistant  '\n",
      " 'to valacyclovir and the majority are resistant to famciclovir  foscarnet '\n",
      " '40–80 mgkg body weight iv every 8 hours until  clinical resolution is '\n",
      " 'attained is the treatment of choice for  acyclovirresistant genital herpes '\n",
      " '508509 intravenous  cidofovir 5 mgkg body weight once weekly might also be  '\n",
      " 'effective foscarnet and cidofovir are nephrotoxic medications  that require '\n",
      " 'intensive laboratory monitoring and infectious  disease specialist '\n",
      " 'consultation imiquimod 5 applied to the lesion  for 8 hours 3 timesweek '\n",
      " 'until clinical resolution is an alternative  that has been reported to be '\n",
      " 'effective 510511 topical cidofovir  gel 1 can be applied to lesions 2–4 '\n",
      " 'times daily however cidofovir  must be compounded at a pharmacy 512 '\n",
      " 'prevention of antiviral resistance remains challenging among  persons with '\n",
      " 'hiv infection experience with another group  of immunocompromised persons eg '\n",
      " 'hematopoietic stem cell recipients demonstrated that persons receiving '\n",
      " 'daily  suppressive antiviral therapy were less likely to experience  '\n",
      " 'acyclovirresistant hsv infection compared with those who  received episodic '\n",
      " 'therapy for outbreaks 513 genital herpes during pregnancy prevention of '\n",
      " 'neonatal herpes depends both on preventing  acquisition of genital herpes '\n",
      " 'during late pregnancy and  avoiding exposure of the neonate to herpetic '\n",
      " 'lesions and viral  shedding during delivery mothers of newborns who acquire  '\n",
      " 'neonatal herpes often lack histories of clinically evident genital  herpes '\n",
      " '514515 the risk for transmission to the neonate from  an infected mother is '\n",
      " 'high 30–50 among women who  acquire genital herpes near the time of delivery '\n",
      " 'and low 1  among women with prenatal histories of recurrent herpes or  who '\n",
      " 'acquire genital herpes during the first half of pregnancy  516517 women who '\n",
      " 'acquire hsv in the second half of  pregnancy should be managed in '\n",
      " 'consultation with maternal fetal medicine and infectious disease specialists '\n",
      " 'all pregnant women should be asked whether they have  a history of genital '\n",
      " 'herpes or genital symptoms concerning  for hsv infection at the onset of '\n",
      " 'labor all women should  be questioned thoroughly about symptoms of genital '\n",
      " 'herpes  including prodromal symptoms eg pain or burning at site  before '\n",
      " 'appearance of lesion and all women should be examined  thoroughly for '\n",
      " 'herpetic lesions women without symptoms or  signs of genital herpes or its '\n",
      " 'prodrome can deliver vaginally  although cesarean delivery does not '\n",
      " 'eliminate the risk for hsv  transmission to the neonate 517 women with '\n",
      " 'recurrent genital  herpetic lesions at the onset of labor should have a '\n",
      " 'cesarean  delivery to reduce the risk for neonatal hsv infection routine '\n",
      " 'hsv2 serologic screening of pregnant women is not  recommended women without '\n",
      " 'known genital herpes should  be counseled to abstain from vaginal '\n",
      " 'intercourse during the  third trimester with partners known to have or '\n",
      " 'suspected of  having genital herpes in addition to prevent hsv1 genital  '\n",
      " 'herpes pregnant women without known orolabial herpes  should be advised to '\n",
      " 'abstain from receptive oral sex during the  third trimester with partners '\n",
      " 'known to have or suspected to  have orolabial herpes typespecific serologic '\n",
      " 'tests can be useful  for identifying pregnant women at risk for hsv '\n",
      " 'infection and  for guiding counseling regarding the risk for acquiring '\n",
      " 'genital  recommendations and reports 36 mmwr  july 23 2021  vol 70  no 4 us '\n",
      " 'department of health and human servicescenters for disease control and '\n",
      " 'prevention herpes during pregnancy for example such testing might be  '\n",
      " 'offered to a woman with no history of genital herpes whose  sex partner has '\n",
      " 'hsv infection many fetuses are exposed to  acyclovir each year and the '\n",
      " 'medication is believed to be safe  for use during all trimesters of '\n",
      " 'pregnancy a casecontrol study  reported an increased risk for the rare '\n",
      " 'neonatal outcome of  gastroschisis among women who used antiviral '\n",
      " 'medications  between the month before conception and the third month of  '\n",
      " 'pregnancy 518 acyclovir is also believed to be safe during  breastfeeding '\n",
      " '431519 although data regarding prenatal  exposure to valacyclovir and '\n",
      " 'famciclovir are limited data from  animal trials indicate that these drugs '\n",
      " 'also pose a low risk  among pregnant women 520 acyclovir can be '\n",
      " 'administered  orally to pregnant women with firstepisode genital herpes or  '\n",
      " 'recurrent herpes and should be administered iv to pregnant  women with '\n",
      " 'severe hsv see genital herpes hepatitis  suppressive acyclovir treatment '\n",
      " 'starting at 36 weeks’ gestation  reduces the frequency of cesarean delivery '\n",
      " 'among women who  have recurrent genital herpes by diminishing the frequency '\n",
      " 'of  recurrences at term 521–523 however such treatment might  not protect '\n",
      " 'against transmission to neonates in all cases 524  no data support use of '\n",
      " 'antiviral therapy among asymptomatic  hsvseropositive women without a '\n",
      " 'history of genital herpes  in addition the effectiveness of antiviral '\n",
      " 'therapy among sex  partners with a history of genital herpes to decrease the '\n",
      " 'risk  for hsv transmission to a pregnant woman has not been  studied '\n",
      " 'additional information on the clinical management  of genital herpes in '\n",
      " 'pregnancy is available through existing  guidelines 525 recommended regimen '\n",
      " 'for suppression of recurrent genital  herpes among pregnant women acyclovir '\n",
      " '400 mg orally 3 timesday or valacyclovir 500 mg orally 2 timesday  treatment '\n",
      " 'recommended starting at 36 weeks’ gestation neonatal herpes newborn infants '\n",
      " 'exposed to hsv during birth as  documented by virologic testing of maternal '\n",
      " 'lesions at delivery  or presumed by observation of maternal lesions should '\n",
      " 'be  followed clinically in consultation with a pediatric infectious  disease '\n",
      " 'specialist detailed guidance is available regarding  management of neonates '\n",
      " 'who are delivered vaginally in the  presence of maternal genital herpes '\n",
      " 'lesions and is beyond the  scope of these guidelines more information is '\n",
      " 'available from  the aap httpsredbooksolutionsaaporg surveillance  cultures '\n",
      " 'or pcr of mucosal surfaces of the neonate to detect  hsv infection might be '\n",
      " 'considered before the development of  clinical signs of neonatal herpes to '\n",
      " 'guide treatment initiation  in addition administration of acyclovir might be '\n",
      " 'considered  for neonates born to women who acquired hsv near term  because '\n",
      " 'the risk for neonatal herpes is high for these newborn  infants all newborn '\n",
      " 'infants who have neonatal herpes should  be promptly evaluated and treated '\n",
      " 'with systemic acyclovir  the recommended regimen for infants treated for '\n",
      " 'known or  suspected neonatal herpes is acyclovir 20 mgkg body weight  iv '\n",
      " 'every 8 hours for 14 days if disease is limited to the skin and  mucous '\n",
      " 'membranes or for 21 days for disseminated disease  and disease involving the '\n",
      " 'cns granuloma inguinale donovanosis granuloma inguinale donovanosis is a '\n",
      " 'genital ulcerative  disease caused by the intracellular gramnegative '\n",
      " 'bacterium  klebsiella granulomatis formerly known as calymmatobacterium  '\n",
      " 'granulomatis the disease occurs rarely in the united states  however '\n",
      " 'sporadic cases have been described in india south  africa and south america '\n",
      " '526–535 although granuloma  inguinale was previously endemic in australia it '\n",
      " 'is now  extremely rare 536537 clinically the disease is characterized  as '\n",
      " 'painless slowly progressive ulcerative lesions on the genitals  or perineum '\n",
      " 'without regional lymphadenopathy subcutaneous  granulomas pseudobuboes also '\n",
      " 'might occur the lesions  are highly vascular ie beefy red appearance and can '\n",
      " 'bleed  extragenital infection can occur with infection extension to  the '\n",
      " 'pelvis or it can disseminate to intraabdominal organs  bones or the mouth '\n",
      " 'the lesions also can develop secondary  bacterial infection and can coexist '\n",
      " 'with other sexually  transmitted pathogens diagnostic considerations the '\n",
      " 'causative organism of granuloma inguinale is difficult  to culture and '\n",
      " 'diagnosis requires visualization of darkstaining  donovan bodies on tissue '\n",
      " 'crush preparation or biopsy  although no fdacleared molecular tests for the '\n",
      " 'detection of  k granulomatis dna exist molecular assays might be useful  for '\n",
      " 'identifying the causative agent treatment multiple antimicrobial regimens '\n",
      " 'have been effective  however only a limited number of controlled trials '\n",
      " 'have  been published 538 treatment has been reported to halt  progression of '\n",
      " 'lesions and healing typically proceeds inward  from the ulcer margins '\n",
      " 'prolonged therapy is usually required to  permit granulation and '\n",
      " 'reepithelialization of the ulcers relapse  can occur 6–18 months after '\n",
      " 'apparently effective therapy httpsredbooksolutionsaaporg recommendations and '\n",
      " 'reports mmwr  july 23 2021  vol 70  no 4 37us department of health and human '\n",
      " 'servicescenters for disease control and prevention recommended regimen for '\n",
      " 'granuloma inguinale donovanosis azithromycin 1 g orally onceweek or 500 mg '\n",
      " 'daily for 3 weeks and  until all lesions have completely healed alternative '\n",
      " 'regimens doxycycline 100 mg orally 2 timesday for at least 3 weeks and until '\n",
      " 'all  lesions have completely healed or erythromycin base 500 mg orally 4 '\n",
      " 'timesday for 3 weeks and until all  lesions have completely healed or '\n",
      " 'trimethoprimsulfamethoxazole one doublestrength 160 mg800  mg tablet orally '\n",
      " '2 timeday for 3 weeks and until all lesions have  completely healed the '\n",
      " 'addition of another antibiotic to these regimens can be  considered if '\n",
      " 'improvement is not evident within the first few  days of therapy other '\n",
      " 'management considerations patients should be followed clinically until signs '\n",
      " 'and  symptoms have resolved all persons who receive a diagnosis  of '\n",
      " 'granuloma inguinale should be tested for hiv followup patients should be '\n",
      " 'followed clinically until signs and  symptoms resolve management of sex '\n",
      " 'partners persons who have had sexual contact with a patient who has  '\n",
      " 'granuloma inguinale within the 60 days before onset of the  patient’s '\n",
      " 'symptoms should be examined and offered therapy  however the value of '\n",
      " 'empiric therapy in the absence of clinical  signs and symptoms has not been '\n",
      " 'established special considerations pregnancy use of doxycycline in pregnancy '\n",
      " 'might be associated  with discoloration of teeth however the risk is not '\n",
      " 'well  defined doxycycline is compatible with breastfeeding 431  sulfonamides '\n",
      " 'can be associated with neonatal kernicterus  among those with '\n",
      " 'glucose6phospate dehydrogenase  deficiency and should be avoided during the '\n",
      " 'third trimester  and while breastfeeding 431 for these reasons pregnant and  '\n",
      " 'lactating women with granuloma inguinale should be treated  with a macrolide '\n",
      " 'regimen erythromycin or azithromycin hiv infection persons with granuloma '\n",
      " 'inguinale and hiv infection should  receive the same regimens as those who '\n",
      " 'do not have hiv lymphogranuloma venereum lgv is caused by c trachomatis '\n",
      " 'serovars l1 l2 or l3  539540 lgv can cause severe inflammation and invasive  '\n",
      " 'infection in contrast with c trachomatis serovars a–k that  cause mild or '\n",
      " 'asymptomatic infection clinical manifestations  of lgv can include gud '\n",
      " 'lymphadenopathy or proctocolitis  rectal exposure among msm or women can '\n",
      " 'result in  proctocolitis which is the most common presentation of  lgv '\n",
      " 'infection 541 and can mimic inflammatory bowel  disease with clinical '\n",
      " 'findings of mucoid or hemorrhagic  rectal discharge anal pain constipation '\n",
      " 'fever or tenesmus  542543 outbreaks of lgv proctocolitis have been  reported '\n",
      " 'among msm with high rates of hiv infection  544–547 lgv proctocolitis can be '\n",
      " 'an invasive systemic  infection and if it is not treated early can lead to '\n",
      " 'chronic  colorectal fistulas and strictures reactive arthropathy has also  '\n",
      " 'been reported however reports indicate that rectal lgv can  also be '\n",
      " 'asymptomatic 548 a common clinical manifestation  of lgv among heterosexuals '\n",
      " 'is tender inguinal or femoral  lymphadenopathy that is typically unilateral '\n",
      " 'a selflimited  genital ulcer or papule sometimes occurs at the site of '\n",
      " 'inoculation  however by the time persons seek care the lesions have often  '\n",
      " 'disappeared lgvassociated lymphadenopathy can be severe  with bubo formation '\n",
      " 'from fluctuant or suppurative inguinal or  femoral lymphadenopathy oral '\n",
      " 'ulceration can occur and might  be associated with cervical adenopathy '\n",
      " '549–551 persons with  genital or colorectal lgv lesions can also experience '\n",
      " 'secondary  bacterial infection or can be infected with other sexually and  '\n",
      " 'nonsexually transmitted pathogens diagnostic considerations a definitive lgv '\n",
      " 'diagnosis can be made only with lgv specific molecular testing eg pcrbased '\n",
      " 'genotyping these  tests can differentiate lgv from non–lgv c trachomatis in  '\n",
      " 'rectal specimens however these tests are not widely available  and results '\n",
      " 'are not typically available in a time frame that  would influence clinical '\n",
      " 'management therefore diagnosis is  based on clinical suspicion epidemiologic '\n",
      " 'information and a  c trachomatis naat at the symptomatic anatomic site '\n",
      " 'along  with exclusion of other etiologies for proctocolitis inguinal  '\n",
      " 'lymphadenopathy or genital oral or rectal ulcers 551552  genital or oral '\n",
      " 'lesions rectal specimens and lymph node  specimens ie lesion swab or bubo '\n",
      " 'aspirate can be tested  for c trachomatis by naat or culture naat is the '\n",
      " 'preferred  approach for testing because it can detect both lgv strains and  '\n",
      " 'non–lgv c trachomatis strains 553 therefore all persons  presenting with '\n",
      " 'proctocolitis should be tested for chlamydia  with a naat performed on '\n",
      " 'rectal specimens severe symptoms  of proctocolitis eg bloody discharge '\n",
      " 'tenesmus and rectal  recommendations and reports 38 mmwr  july 23 2021  vol '\n",
      " '70  no 4 us department of health and human servicescenters for disease '\n",
      " 'control and prevention ulcers indicate lgv a rectal gram stain with 10 '\n",
      " 'white  blood cells wbcs has also been associated with rectal lgv  545554555 '\n",
      " 'chlamydia  se ro logy  complement  f ixa t ion  or  microimmunofluorescence '\n",
      " 'should not be used routinely as a  diagnostic tool for lgv because the '\n",
      " 'utility of these serologic  methods has not been established interpretation '\n",
      " 'has not been  standardized and validation for clinical proctitis '\n",
      " 'presentation  has not been done it might support an lgv diagnosis in  cases '\n",
      " 'of isolated inguinal or femoral lymphadenopathy for  which diagnostic '\n",
      " 'material for c trachomatis naat cannot  be obtained treatment at the time of '\n",
      " 'the initial visit before diagnostic naats  for chlamydia are available '\n",
      " 'persons with a clinical syndrome  consistent with lgv should be '\n",
      " 'presumptively treated  presumptive treatment for lgv is indicated among '\n",
      " 'patients  with symptoms or signs of proctocolitis eg bloody  discharge '\n",
      " 'tenesmus or ulceration in cases of severe inguinal  lymphadenopathy with '\n",
      " 'bubo formation particularly if the  patient has a recent history of a '\n",
      " 'genital ulcer or in the presence  of a genital ulcer if other etiologies '\n",
      " 'have been ruled out the  goal of treatment is to cure infection and prevent '\n",
      " 'ongoing tissue  damage although tissue reaction to the infection can result '\n",
      " 'in  scarring buboes might require aspiration through intact skin  or '\n",
      " 'incision and drainage to prevent formation of inguinal or  femoral '\n",
      " 'ulcerations recommended regimen for lymphogranuloma venereum doxycycline 100 '\n",
      " 'mg orally 2 timesday for 21 days alternative regimens azithromycin 1 g '\n",
      " 'orally once weekly for 3 weeks or erythromycin base 500 mg orally 4 timesday '\n",
      " 'for 21 days  because this regimen has not been validated a test of cure with '\n",
      " 'c trachomatis  naat 4 weeks after completion of treatment can be considered '\n",
      " 'the optimal treatment duration for symptomatic lgv has  not been studied in '\n",
      " 'clinical trials the recommended 21day  course of doxycycline is based on '\n",
      " 'longstanding clinical practice  and is highly effective with an estimated '\n",
      " 'cure rate of 985  555556 shorter courses of doxycycline might be effective  '\n",
      " 'on the basis of a small retrospective study of msm with rectal  lgv 50 of '\n",
      " 'whom were symptomatic who received a 7 to  14day course of doxycycline and '\n",
      " 'had a 97 cure rate 558  randomized prospective studies of shortercourse '\n",
      " 'doxycycline  for treating lgv are needed longer courses of therapy might  be '\n",
      " 'required in the setting of fistulas buboes and other forms  of severe '\n",
      " 'disease 559 a small nonrandomized study from spain involving patients  with '\n",
      " 'rectal lgv demonstrated cure rates of 97 with a  regimen of azithromycin 1 g '\n",
      " 'once weekly for 3 weeks 560  pharmacokinetic data support this dosing '\n",
      " 'strategy 561  however this regimen has not been validated fluoroquinolone '\n",
      " 'based treatments also might be effective however the optimal  duration of '\n",
      " 'treatment has not been evaluated the clinical  significance of asymptomatic '\n",
      " 'lgv is unknown and it is  effectively treated with a 7day course of '\n",
      " 'doxycycline 562  other management considerations patients should be followed '\n",
      " 'clinically until signs and  symptoms have resolved persons who receive an '\n",
      " 'lgv diagnosis  should be tested for other stis especially hiv gonorrhea and  '\n",
      " 'syphilis those whose hiv test results are negative should be  offered hiv '\n",
      " 'prep followup all persons who have been treated for lgv should be retested  '\n",
      " 'for chlamydia approximately 3 months after treatment if  retesting at 3 '\n",
      " 'months is not possible providers should retest  at the patient’s next visit '\n",
      " 'for medical care within the 12month  period after initial treatment '\n",
      " 'management of sex partners persons who have had sexual contact with a '\n",
      " 'patient who  has lgv within the 60 days before onset of the patient’s  '\n",
      " 'symptoms should be evaluated examined and tested for  chlamydial infection '\n",
      " 'depending on anatomic site of exposure  asymptomatic partners should be '\n",
      " 'presumptively treated with  a chlamydia regimen doxycycline 100 mg orally 2 '\n",
      " 'timesday  for 7 days special considerations pregnancy use of doxycycline in '\n",
      " 'pregnancy might be associated with  discoloration of teeth however the risk '\n",
      " 'is not well defined  563 doxycycline is compatible with breastfeeding 431  '\n",
      " 'azithromycin might prove useful for lgv treatment during  pregnancy at a '\n",
      " 'presumptive dose of 1 g weekly for 3 weeks  no published data are available '\n",
      " 'regarding an effective dose and  duration of treatment pregnant and '\n",
      " 'lactating women with  lgv can be treated with erythromycin although this '\n",
      " 'regimen  is associated with frequent gastrointestinal side effects pregnant  '\n",
      " 'women treated for lgv should have a test of cure performed  4 weeks after '\n",
      " 'the initial c trachomatis naatpositive test recommendations and reports '\n",
      " 'mmwr  july 23 2021  vol 70  no 4 39us department of health and human '\n",
      " 'servicescenters for disease control and prevention hiv infection persons '\n",
      " 'with lgv and hiv infection should receive the  same regimens as those who do '\n",
      " 'not have hiv prolonged  therapy might be required because a delay in '\n",
      " 'resolution of  symptoms might occur syphilis syphilis is a systemic disease '\n",
      " 'caused by t pallidum the  disease has been divided into stages on the basis '\n",
      " 'of clinical  findings which guide treatment and followup persons who  have '\n",
      " 'syphilis might seek treatment for signs or symptoms  primary syphilis '\n",
      " 'classically presents as a single painless ulcer  or chancre at the site of '\n",
      " 'infection but can also present with  multiple atypical or painful lesions '\n",
      " '564 secondary syphilis  manifestations can include skin rash mucocutaneous '\n",
      " 'lesions  and lymphadenopathy tertiary syphilis can present with  cardiac '\n",
      " 'involvement gummatous lesions tabes dorsalis and  general paresis latent '\n",
      " 'infections ie those lacking clinical manifestations  are detected by '\n",
      " 'serologic testing latent syphilis acquired  within the preceding year is '\n",
      " 'referred to as early latent syphilis  all other cases of latent syphilis are '\n",
      " 'classified as late latent  syphilis or latent syphilis of unknown duration t '\n",
      " 'pallidum can infect the cns which can occur at any stage  of syphilis and '\n",
      " 'result in neurosyphilis early neurologic clinical  manifestations or '\n",
      " 'syphilitic meningitis eg cranial nerve  dysfunction meningitis '\n",
      " 'meningovascular syphilis stroke  and acute altered mental status are usually '\n",
      " 'present within  the first few months or years of infection late neurologic  '\n",
      " 'manifestations eg tabes dorsalis and general paresis occur  10 to 30 years '\n",
      " 'after infection infection of the visual system ocular syphilis or auditory  '\n",
      " 'system otosyphilis can occur at any stage of syphilis but is  commonly '\n",
      " 'identified during the early stages and can present  with or without '\n",
      " 'additional cns involvement ocular syphilis  often presents as panuveitis but '\n",
      " 'can involve structures in  both the anterior and posterior segment of the '\n",
      " 'eye including  conjunctivitis anterior uveitis posterior interstitial '\n",
      " 'keratitis  optic neuropathy and retinal vasculitis ocular syphilis can  '\n",
      " 'result in permanent vision loss otosyphilis typically presents  with '\n",
      " 'cochleovestibular symptoms including tinnitus vertigo  and sensorineural '\n",
      " 'hearing loss hearing loss can be unilateral or  bilateral have a sudden '\n",
      " 'onset and progress rapidly otosyphilis  can result in permanent hearing loss '\n",
      " 'diagnostic considerations darkfield examinations and molecular tests for '\n",
      " 'detecting  t pallidum directly from lesion exudate or tissue are  the '\n",
      " 'definitive methods for diagnosing early syphilis and  congenital syphilis '\n",
      " '565 although no t pallidum direct detection molecular naats are commercially '\n",
      " 'available  certain laboratories provide locally developed and validated  pcr '\n",
      " 'tests for detecting t pallidum dna a presumptive  diagnosis of syphilis '\n",
      " 'requires use of two laboratory serologic  tests a nontreponemal test ie '\n",
      " 'venereal disease research  laboratory vdrl or rapid plasma reagin rpr test  '\n",
      " 'and a treponemal test ie the t pallidum passive particle  agglutination tppa '\n",
      " 'assay various eias chemiluminescence  immunoassays cias and immunoblots or '\n",
      " 'rapid treponemal  assays 566–568 at least 18 treponemalspecific tests are  '\n",
      " 'cleared for use in the united states use of only one type of  serologic test '\n",
      " 'nontreponemal or treponemal is insufficient  for diagnosis and can result in '\n",
      " 'falsenegative results among  persons tested during primary syphilis and '\n",
      " 'falsepositive results  among persons without syphilis or previously treated '\n",
      " 'syphilis nontreponemal tests and traditional algorithm falsepositive '\n",
      " 'nontreponemal test results can be associated  with multiple medical '\n",
      " 'conditions and factors unrelated to  syphilis including other infections eg '\n",
      " 'hiv autoimmune  conditions vaccinations injecting drug use pregnancy  and '\n",
      " 'older age 566569 therefore persons with a reactive  nontreponemal test '\n",
      " 'should always receive a treponemal test  to confirm the syphilis diagnosis '\n",
      " 'ie traditional algorithm  nontreponemal test antibody titers might correlate '\n",
      " 'with disease  activity and are used for monitoring treatment response serum  '\n",
      " 'should be diluted to identify the highest titer and results should  be '\n",
      " 'reported quantitatively a fourfold change in titer equivalent  to a change '\n",
      " 'of two dilutions eg from 116 to 14 or from 18  to 132 is considered '\n",
      " 'necessary for demonstrating a clinically  significant difference between two '\n",
      " 'nontreponemal test results  obtained by using the same serologic test '\n",
      " 'preferably from the  same manufacturer to avoid variation in results '\n",
      " 'sequential  serologic tests for a patient should be performed using the  '\n",
      " 'same testing method vdrl or rpr preferably by the same  laboratory vdrl and '\n",
      " 'rpr are equally valid assays however  quantitative results from the two '\n",
      " 'tests cannot be compared  directly with each other because the methods are '\n",
      " 'different  and rpr titers frequently are slightly higher than vdrl titers '\n",
      " 'nontreponemal test titers usually decrease after treatment  and might become '\n",
      " 'nonreactive with time however for certain  persons nontreponemal antibodies '\n",
      " 'might decrease less than  fourfold after treatment ie inadequate serologic '\n",
      " 'response  or might decline appropriately but fail to serorevert and  '\n",
      " 'recommendations and reports 40 mmwr  july 23 2021  vol 70  no 4 us '\n",
      " 'department of health and human servicescenters for disease control and '\n",
      " 'prevention persist for a long period atypical nontreponemal serologic  test '\n",
      " 'results eg unusually high unusually low or fluctuating  titers might occur '\n",
      " 'regardless of hiv status when serologic  tests do not correspond with '\n",
      " 'clinical findings indicative of  primary secondary or latent syphilis '\n",
      " 'presumptive treatment is  recommended for persons with risk factors for '\n",
      " 'syphilis and use  of other tests eg biopsy for histology and immunostaining  '\n",
      " 'and pcr of lesion should be considered for the majority  of persons with hiv '\n",
      " 'infection serologic tests are accurate  and reliable for diagnosing syphilis '\n",
      " 'and evaluating response  to treatment treponemal tests and reverse  sequence '\n",
      " 'algorithm the majority of patients who have reactive treponemal tests  will '\n",
      " 'have reactive tests for the remainder of their lives regardless  of adequate '\n",
      " 'treatment or disease activity however 15–25  of patients treated during the '\n",
      " 'primary stage revert to being  serologically nonreactive after 2–3 years 570 '\n",
      " 'treponemal  antibody titers do not predict treatment response and therefore  '\n",
      " 'should not be used for this purpose clinical laboratories sometimes screen '\n",
      " 'syphilis serologic  samples by using automated treponemal immunoassays  '\n",
      " 'typically by eia or cia 571–573 this reverse sequence  algorithm for '\n",
      " 'syphilis testing can identify persons previously  treated for syphilis those '\n",
      " 'with untreated or incompletely  treated syphilis and those with '\n",
      " 'falsepositive results that can  occur with a low likelihood of infection 574 '\n",
      " 'persons with  a positive treponemal screening test should have a standard  '\n",
      " 'quantitative nontreponemal test with titer performed  reflexively by the '\n",
      " 'laboratory to guide patient management  decisions if the nontreponemal test '\n",
      " 'is negative the laboratory  should perform a treponemal test different from '\n",
      " 'the one used  for initial testing preferably tppa or treponemal assay based  '\n",
      " 'on different antigens than the original test to adjudicate the  results of '\n",
      " 'the initial test if a second treponemal test is positive eg eia reactive  '\n",
      " 'rpr nonreactive or tppa reactive persons with a history  of previous '\n",
      " 'treatment will require no further management  unless sexual history '\n",
      " 'indicates a reexposure in this instance a  repeat nontreponemal test 2–4 '\n",
      " 'weeks after a confirmed medical  history and physical examination is '\n",
      " 'recommended to evaluate  for early infection those without a history of '\n",
      " 'treatment for  syphilis should be offered treatment unless a medical '\n",
      " 'history  or results of a physical examination indicate a recent infection  '\n",
      " 'previously untreated persons should be treated for syphilis of  unknown '\n",
      " 'duration or late latent syphilis if the second treponemal test is negative '\n",
      " 'eg eia reactive  rpr nonreactive tppa nonreactive and the epidemiologic  '\n",
      " 'risk and clinical probability for syphilis are low further  evaluation or '\n",
      " 'treatment is not indicated multiple studies demonstrate that high '\n",
      " 'quantitative index  values or high signaltocutoff ratio from treponemal eia  '\n",
      " 'or cia tests correlate with tppa positivity which might  eliminate the need '\n",
      " 'for additional confirmatory testing  however the range of index values '\n",
      " 'varies among different  treponemal immunoassays and the values that '\n",
      " 'correspond to  high levels of reactivity with confirmatory testing might '\n",
      " 'differ  by immunoassay 567575–582 cerebrospinal fluid evaluation further '\n",
      " 'testing with csf evaluation is warranted for  persons with clinical signs of '\n",
      " 'neurosyphilis eg cranial nerve  dysfunction meningitis stroke acute or '\n",
      " 'chronic altered mental  status or loss of vibration sense all patients with '\n",
      " 'ocular  symptoms and reactive syphilis serology need a full ocular  '\n",
      " 'examination including cranial nerve evaluation if cranial nerve  dysfunction '\n",
      " 'is present a csf evaluation is needed among  persons with isolated ocular '\n",
      " 'symptoms ie no cranial nerve  dysfunction or other neurologic abnormalities '\n",
      " 'confirmed  ocular abnormalities on examination and reactive syphilis  '\n",
      " 'serology a csf examination is unnecessary before treatment  csf analysis can '\n",
      " 'be helpful in evaluating persons with ocular  symptoms and reactive syphilis '\n",
      " 'serology who do not have ocular  findings or cranial nerve dysfunction on '\n",
      " 'examination among  patients with isolated auditory abnormalities and '\n",
      " 'reactive  syphilis serology csf evaluation is likely to be normal and is  '\n",
      " 'unnecessary before treatment 583584 laboratory testing is helpful in '\n",
      " 'supporting the diagnosis of  neurosyphilis however no single test can be '\n",
      " 'used to diagnose  neurosyphilis in all instances diagnosis of neurosyphilis  '\n",
      " 'depends on a combination of csf tests eg csf cell count  protein or reactive '\n",
      " 'csfvdrl in the presence of reactive  serologic test nontreponemal and '\n",
      " 'treponemal results and  neurologic signs and symptoms csf laboratory '\n",
      " 'abnormalities  are common for persons with early syphilis and are of  '\n",
      " 'unknown medical significance in the absence of neurologic  signs or symptoms '\n",
      " '585 csfvdrl is highly specific but  insensitive for a person with neurologic '\n",
      " 'signs or symptoms a  reactive csfvdrl in the absence of blood contamination  '\n",
      " 'is considered diagnostic of neurosyphilis when csfvdrl is negative despite '\n",
      " 'clinical signs of  neurosyphilis reactive serologic tests results '\n",
      " 'lymphocytic  pleocytosis or protein neurosyphilis should be considered  in '\n",
      " 'that instance additional evaluation by using fluorescent  treponemalantibody '\n",
      " 'absorption ftaabs or tppa testing  on csf might be warranted the csf ftaabs '\n",
      " 'test is less  specific for neurosyphilis than the csfvdrl but is highly  '\n",
      " 'sensitive fewer data are available regarding csf tppa  recommendations and '\n",
      " 'reports mmwr  july 23 2021  vol 70  no 4 41us department of health and human '\n",
      " 'servicescenters for disease control and prevention however the sensitivity '\n",
      " 'and specificity appear similar to the  csf ftaabs 586 neurosyphilis is '\n",
      " 'highly unlikely with  a negative csf ftaabs or tppa test especially among  '\n",
      " 'persons with nonspecific neurologic signs and symptoms 587 among persons '\n",
      " 'with hiv infection csf leukocyte count  can be elevated 5 wbcsmm3 the '\n",
      " 'association with csf  leukocyte count and plasma hiv viral suppression has '\n",
      " 'not been  well characterized using a higher cutoff 20 wbcsmm3  might improve '\n",
      " 'the specificity of neurosyphilis diagnosis among  this population 588 '\n",
      " 'treatment penicillin g administered parenterally is the preferred drug  for '\n",
      " 'treating patients in all stages of syphilis the preparation  used ie '\n",
      " 'benzathine aqueous procaine or aqueous  crystalline dosage and length of '\n",
      " 'treatment depend on the  stage and clinical manifestations of the disease '\n",
      " 'treatment for  late latent syphilis 1 years’ duration and tertiary syphilis  '\n",
      " 'requires a longer duration of therapy because organisms  theoretically might '\n",
      " 'be dividing more slowly the validity of this  rationale has not been '\n",
      " 'assessed longer treatment duration is  required for persons with latent '\n",
      " 'syphilis of unknown duration  to ensure that those who did not acquire '\n",
      " 'syphilis within the  preceding year are adequately treated selection of the '\n",
      " 'appropriate penicillin preparation is  important because t pallidum can '\n",
      " 'reside in sequestered sites  eg the cns and aqueous humor that are poorly '\n",
      " 'accessed  by certain forms of penicillin combinations of benzathine  '\n",
      " 'penicillin procaine penicillin and oral penicillin preparations  are not '\n",
      " 'considered appropriate for syphilis treatment reports  have indicated that '\n",
      " 'practitioners have inadvertently prescribed  combination long and '\n",
      " 'shortacting benzathineprocaine  penicillin bicillin cr instead of the '\n",
      " 'standard benzathine  penicillin product bicillin la recommended in the '\n",
      " 'united  states for treating primary secondary and latent syphilis  '\n",
      " 'practitioners pharmacists and purchasing agents should be  aware of the '\n",
      " 'similar names of these two products to avoid  using the incorrect '\n",
      " 'combination therapy agent for treating  syphilis 589 penicillin’s '\n",
      " 'effectiveness for treating syphilis was well  established through clinical '\n",
      " 'experience even before the value of  randomized controlled clinical trials '\n",
      " 'was recognized therefore  approximately all recommendations for treating '\n",
      " 'syphilis are  based not only on clinical trials and observational studies '\n",
      " 'but  on many decades of clinical experience special considerations pregnancy '\n",
      " 'parenteral penicillin g is the only therapy with documented  efficacy for '\n",
      " 'syphilis during pregnancy pregnant women with  syphilis at any stage who '\n",
      " 'report penicillin allergy should be  desensitized and treated with '\n",
      " 'penicillin see management of  persons who have a history of penicillin '\n",
      " 'allergy jarischherxheimer reaction the jarischherxheimer reaction is an '\n",
      " 'acute febrile reaction  frequently accompanied by headache myalgia and fever '\n",
      " 'that  can occur within the first 24 hours after the initiation of any  '\n",
      " 'syphilis therapy it is a reaction to treatment and not an allergic  reaction '\n",
      " 'to penicillin patients should be informed about this  possible adverse '\n",
      " 'reaction and how to manage it if it occurs the  jarischherxheimer reaction '\n",
      " 'occurs most frequently among  persons who have early syphilis presumably '\n",
      " 'because bacterial  loads are higher during these stages antipyretics can be '\n",
      " 'used  to manage symptoms however they have not been proven to  prevent this '\n",
      " 'reaction the jarischherxheimer reaction might  induce early labor or cause '\n",
      " 'fetal distress in pregnant women  however this should not prevent or delay '\n",
      " 'therapy 590 see  syphilis during pregnancy management of sex partners sexual '\n",
      " 'transmission of t pallidum is thought to occur only  when mucocutaneous '\n",
      " 'syphilitic lesions are present such  manifestations are uncommon after the '\n",
      " 'first year of infection  persons exposed through sexual contact with a '\n",
      " 'person who  has primary secondary or early latent syphilis should be  '\n",
      " 'evaluated clinically and serologically and treated according to  the '\n",
      " 'following recommendations • persons who have had sexual contact with a '\n",
      " 'person who  receives a diagnosis of primary secondary or early latent  '\n",
      " 'syphilis 90 days before the diagnosis should be treated  presumptively for '\n",
      " 'early syphilis even if serologic test results  are negative • persons who '\n",
      " 'have had sexual contact with a person who  receives a diagnosis of primary '\n",
      " 'secondary or early latent  syphilis 90 days before the diagnosis should be '\n",
      " 'treated  presumptively for early syphilis if serologic test results are  not '\n",
      " 'immediately available and the opportunity for  followup is uncertain if '\n",
      " 'serologic tests are negative no  treatment is needed if serologic tests are '\n",
      " 'positive  treatment should be based on clinical and serologic  evaluation '\n",
      " 'and syphilis stage • in certain areas or among populations with high '\n",
      " 'syphilis  infection rates health departments recommend notification  and '\n",
      " 'presumptive treatment of sex partners of persons with  recommendations and '\n",
      " 'reports 42 mmwr  july 23 2021  vol 70  no 4 us department of health and '\n",
      " 'human servicescenters for disease control and prevention syphilis of unknown '\n",
      " 'duration who have high nontreponemal  serologic test titers ie 132 because '\n",
      " 'high titers might  be indicative of early syphilis these partners should be  '\n",
      " 'managed as if the index patient had early syphilis • longterm sex partners '\n",
      " 'of persons who have late latent  syphilis should be evaluated clinically and '\n",
      " 'serologically for  syphilis and treated on the basis of the evaluation’s '\n",
      " 'findings • the following sex partners of persons with syphilis are  '\n",
      " 'considered at risk for infection and should be confidentially  notified of '\n",
      " 'the exposure and need for evaluation partners  who have had sexual contact '\n",
      " 'within 3 months plus the  duration of symptoms for persons who receive a '\n",
      " 'diagnosis  of primary syphilis within 6 months plus duration of  symptoms '\n",
      " 'for those with secondary syphilis and within  1 year for persons with early '\n",
      " 'latent syphilis primary and secondary syphilis treatment parenteral '\n",
      " 'penicillin g has been used effectively for achieving  clinical resolution ie '\n",
      " 'the healing of lesions and prevention of  sexual transmission and for '\n",
      " 'preventing late sequelae however  no comparative trials have been conducted '\n",
      " 'to guide selection  of an optimal penicillin regimen substantially fewer '\n",
      " 'data are  available for nonpenicillin regimens recommended regimen for '\n",
      " 'primary and secondary syphilis  among adults benzathine penicillin g 24 '\n",
      " 'million units im in a single dose  recommendations for treating syphilis '\n",
      " 'among persons with hiv infection  and pregnant women are discussed elsewhere '\n",
      " 'in this report see syphilis  among persons with hiv infection syphilis '\n",
      " 'during pregnancy available data demonstrate that use of additional doses of  '\n",
      " 'benzathine penicillin g amoxicillin or other antibiotics do  not enhance '\n",
      " 'efficacy of this recommended regimen when used  to treat primary and '\n",
      " 'secondary syphilis regardless of hiv  status 591–593 recommended regimen for '\n",
      " 'syphilis among infants and  children  benzathine penicillin g 50000 unitskg '\n",
      " 'body weight im up to the adult  dose of 24 million units in a single dose '\n",
      " 'infants and children aged ≥1 month who receive a syphilis  diagnosis should '\n",
      " 'have birth and maternal medical records  reviewed to assess whether they '\n",
      " 'have congenital or acquired  syphilis see congenital syphilis infants and '\n",
      " 'children aged  ≥1 month with primary and secondary syphilis should be  '\n",
      " 'managed by a pediatric infectious disease specialist and  evaluated for '\n",
      " 'sexual abuse eg through consultation with child  protective services see '\n",
      " 'sexual assault or abuse of children other management considerations all '\n",
      " 'persons who have primary and secondary syphilis should  be tested for hiv at '\n",
      " 'the time of diagnosis and treatment those  persons whose hiv test results '\n",
      " 'are negative should be offered  hiv prep in geographic areas in which hiv '\n",
      " 'prevalence is  high persons who have primary or secondary syphilis should  '\n",
      " 'be offered prep and retested for hiv in 3 months if the initial  hiv test '\n",
      " 'result was negative persons who have syphilis and symptoms or signs '\n",
      " 'indicating  neurologic disease eg cranial nerve dysfunction meningitis  '\n",
      " 'stroke or altered mental state should have an evaluation  that includes csf '\n",
      " 'analysis persons with syphilis who have  symptoms or signs of ocular '\n",
      " 'syphilis eg uveitis iritis  neuroretinitis or optic neuritis should have a '\n",
      " 'thorough cranial  nerve examination and ocular slitlamp and ophthalmologic  '\n",
      " 'examinations csf evaluation is not always needed for persons  with ocular '\n",
      " 'syphilis if no evidence of cranial nerves 2 3 4  5 and 6 dysfunction or '\n",
      " 'other evidence of neurologic disease  exists if symptoms and signs of otic '\n",
      " 'syphilis are present then  an otologic examination is needed csf evaluation '\n",
      " 'in persons  with otic syphilis does not aid in the clinical management  and '\n",
      " 'therefore is not recommended see cerebrospinal fluid  evaluation treatment '\n",
      " 'should be guided by the results of these  evaluations invasion of csf by t '\n",
      " 'pallidum accompanied  by csf laboratory abnormalities is common among '\n",
      " 'adults  who have primary or secondary syphilis but has unknown  medical '\n",
      " 'significance 585 in the absence of clinical  neurologic findings no evidence '\n",
      " 'supports variation from the  recommended treatment regimen for primary or '\n",
      " 'secondary  syphilis symptomatic neurosyphilis after treatment with the  '\n",
      " 'penicillin regimens recommended for primary and secondary  syphilis is rare '\n",
      " 'therefore unless clinical signs or symptoms of  neurologic or ophthalmic '\n",
      " 'involvement are present routine csf  analysis is not recommended for persons '\n",
      " 'who have primary or  secondary syphilis followup clinical and serologic '\n",
      " 'evaluation should be performed at  6 and 12 months after treatment more '\n",
      " 'frequent evaluation  might be prudent if opportunity for followup is '\n",
      " 'uncertain  or if repeat infection is a clinical concern serologic response  '\n",
      " 'ie titer should be compared with the titer at the time of  treatment however '\n",
      " 'assessing serologic response to treatment  can be difficult and definitive '\n",
      " 'criteria for cure or failure by  serologic criteria have not been well '\n",
      " 'established in addition  nontreponemal test titers might decrease more '\n",
      " 'slowly for  persons previously treated for syphilis 594595 persons who have '\n",
      " 'signs or symptoms that persist or recur  and those with at least a fourfold '\n",
      " 'increase in nontreponemal  recommendations and reports mmwr  july 23 2021  '\n",
      " 'vol 70  no 4 43us department of health and human servicescenters for disease '\n",
      " 'control and prevention test titer persisting for 2 weeks likely were '\n",
      " 'reinfected or  experienced treatment failure among persons who have  '\n",
      " 'neurologic findings or persons with no neurologic findings  without any '\n",
      " 'reported sexual exposure during the previous  3–6 months indicating that '\n",
      " 'treatment failure might be possible  a csf examination is recommended with '\n",
      " 'treatment guided  by csf findings these persons should also be reevaluated '\n",
      " 'for  hiv infection among persons with no neurologic findings after a '\n",
      " 'thorough  neurologic examination and who are sexually active reinfection  is '\n",
      " 'likely and repeat treatment for early syphilis is recommended  these persons '\n",
      " 'should also be reevaluated for hiv infection failure of nontreponemal test '\n",
      " 'titers to decrease fourfold  within 12 months after therapy for primary or '\n",
      " 'secondary  syphilis inadequate serologic response might be indicative  of '\n",
      " 'treatment failure however clinical trial data have  demonstrated that 10–20 '\n",
      " 'of persons with primary and  secondary syphilis treated with the recommended '\n",
      " 'therapy  will not achieve the fourfold decrease in nontreponemal titer  '\n",
      " 'within 12 months after treatment 591596597 serologic  response to treatment '\n",
      " 'appears to be associated with multiple  factors including the person’s '\n",
      " 'syphilis stage earlier stages are  more likely to decrease fourfold and '\n",
      " 'become nonreactive  initial nontreponemal antibody titers titers 18 are less '\n",
      " 'likely  to decline fourfold than higher titers and age titers among  older '\n",
      " 'patients might be less likely to decrease fourfold than  those of younger '\n",
      " 'patients 596–598 optimal management  of persons who have an inadequate '\n",
      " 'serologic response after  syphilis treatment is unclear at a minimum these '\n",
      " 'persons  should receive additional neurologic examinations clinical  and '\n",
      " 'serologic followup annually and reevaluation for hiv  infection if '\n",
      " 'neurologic symptoms or signs are identified  a csf evaluation is recommended '\n",
      " 'with findings guiding  management if additional followup cannot be ensured  '\n",
      " 'retreatment is recommended because treatment failure might  be the result of '\n",
      " 'unrecognized cns infection csf examination  can be considered in situations '\n",
      " 'in which followup is uncertain for retreatment weekly injections of '\n",
      " 'benzathine penicillin  g 24 million units intramuscularly im for 3 weeks is  '\n",
      " 'recommended unless csf examination indicates that  neurosyphilis is present '\n",
      " 'see neurosyphilis ocular syphilis  and otosyphilis serologic titers might '\n",
      " 'not decrease despite  a negative csf examination and a repeated 3week '\n",
      " 'therapy  course 599 in these circumstances the benefit of additional  '\n",
      " 'therapy or repeated csf examinations is unclear and it is not  typically '\n",
      " 'recommended serologic and clinical monitoring at  least annually should '\n",
      " 'continue to monitor for any sustained  increases in nontreponemal titer '\n",
      " 'management of sex partners see syphilis management of sex partners special '\n",
      " 'considerations penicillin allergy data to support use of alternatives to '\n",
      " 'penicillin in treating  primary and secondary syphilis are limited however '\n",
      " 'multiple  therapies might be effective for nonpregnant persons with  '\n",
      " 'penicillin allergy who have primary or secondary syphilis  doxycycline 100 '\n",
      " 'mg orally 2 timesday for 14 days 600601  and tetracycline 500 mg orally 4 '\n",
      " 'timesday for 14 days have  been used for years and can be effective '\n",
      " 'compliance is likely to  be better with doxycycline than tetracycline '\n",
      " 'because tetracycline  can cause more gastrointestinal side effects and '\n",
      " 'requires more  frequent dosing limited clinical studies along with biologic  '\n",
      " 'and pharmacologic evidence indicate that ceftriaxone 1 g daily  either im or '\n",
      " 'iv for 10 days is effective for treating primary  and secondary syphilis '\n",
      " 'however the optimal dose and duration  of ceftriaxone therapy have not been '\n",
      " 'defined 602603  azithromycin as a single 2g oral dose has been effective  '\n",
      " 'for treating primary and secondary syphilis among certain  populations '\n",
      " '602604605 however because of t pallidum  chromosomal mutations associated '\n",
      " 'with azithromycin and  other macrolide resistance and documented treatment '\n",
      " 'failures  in multiple us geographic areas azithromycin should not be  used '\n",
      " 'as treatment for syphilis 606–608 thorough clinical  and serologic followup '\n",
      " 'of persons receiving any alternative  therapy is essential persons with a '\n",
      " 'penicillin allergy whose compliance with  therapy or followup cannot be '\n",
      " 'ensured should be desensitized  and treated with benzathine penicillin g '\n",
      " 'skin testing for  penicillin allergy might be useful in circumstances in '\n",
      " 'which  the reagents and expertise are available for performing the test  '\n",
      " 'adequately see management of persons who have a history  of penicillin '\n",
      " 'allergy pregnancy pregnant women with primary or secondary syphilis who  are '\n",
      " 'allergic to penicillin should be desensitized and treated  with penicillin g '\n",
      " 'skin testing or oral graded penicillin dose  challenge might be helpful in '\n",
      " 'identifying women at risk for  acute allergic reactions see management of '\n",
      " 'persons who have  a history of penicillin allergy syphilis during pregnancy '\n",
      " 'hiv infection persons with hiv infection who have primary or secondary  '\n",
      " 'syphilis should be treated similarly to those without hiv see  syphilis '\n",
      " 'among persons with hiv infection recommendations and reports 44 mmwr  july '\n",
      " '23 2021  vol 70  no 4 us department of health and human servicescenters for '\n",
      " 'disease control and prevention latent syphilis latent syphilis is defined as '\n",
      " 'syphilis characterized by  seroreactivity without other evidence of primary '\n",
      " 'secondary  or tertiary disease persons who have latent syphilis and who  '\n",
      " 'acquired syphilis during the preceding year are classified as  having early '\n",
      " 'latent syphilis early nonprimary nonsecondary  persons can receive a '\n",
      " 'diagnosis of early latent syphilis if during  the year preceding the '\n",
      " 'diagnosis they had a documented  seroconversion or a sustained 2 weeks '\n",
      " 'fourfold or greater  increase in nontreponemal test titers in a previously '\n",
      " 'treated  person unequivocal symptoms of primary or secondary  syphilis or a '\n",
      " 'sex partner documented to have primary  secondary or early latent syphilis '\n",
      " 'in addition for persons  with reactive nontreponemal and treponemal tests '\n",
      " 'whose only  possible exposure occurred during the previous 12 months  early '\n",
      " 'latent syphilis can be assumed in the absence of these conditions associated '\n",
      " 'with latent  syphilis an asymptomatic person should be considered to  have '\n",
      " 'latent syphilis of unknown duration or late latent syphilis  1 year’s '\n",
      " 'duration nontreponemal serologic titers usually are  higher early in the '\n",
      " 'course of syphilis infection however early  latent syphilis cannot be '\n",
      " 'reliably diagnosed solely on the basis  of nontreponemal titers all persons '\n",
      " 'with latent syphilis should  have careful examination of all accessible '\n",
      " 'mucosal surfaces to  evaluate for mucosal lesions primary or secondary '\n",
      " 'syphilis  before making a latent syphilis diagnosis physical examination  '\n",
      " 'should include the oral cavity perianal area perineum rectum  and genitals '\n",
      " 'vagina and cervix for women scrotum penis and  underneath the foreskin for '\n",
      " 'uncircumcised men treatment because latent syphilis is not transmitted '\n",
      " 'sexually the  objective of treating persons in this disease stage is to '\n",
      " 'prevent  medical complications of syphilis latent syphilis can also be  '\n",
      " 'vertically transmitted to a fetus therefore the goal of treating  a pregnant '\n",
      " 'woman is to prevent congenital syphilis although  clinical experience '\n",
      " 'supports the effectiveness of penicillin in  achieving this goal limited '\n",
      " 'evidence is available for guiding  choice of specific regimens or duration '\n",
      " 'available data  demonstrate that additional doses of benzathine penicillin '\n",
      " 'g  amoxicillin or other antibiotics in early latent syphilis do not  enhance '\n",
      " 'efficacy regardless of hiv status 592593609 recommended regimens for latent '\n",
      " 'syphilis among adults early latent syphilis benzathine penicillin g 24 '\n",
      " 'million units im in a  single dose late latent syphilis benzathine '\n",
      " 'penicillin g 72 million units total  administered as 3 doses of 24 million '\n",
      " 'units im each at 1week intervals  recommendations for treating syphilis in '\n",
      " 'persons with hiv and pregnant  women are discussed elsewhere in this report '\n",
      " 'see syphilis among  persons with hiv infection syphilis during pregnancy '\n",
      " 'infants and children aged ≥1 month with diagnosed latent  syphilis should be '\n",
      " 'managed by a pediatric infectious disease  specialist and receive a csf '\n",
      " 'examination in addition birth  and maternal medical records should be '\n",
      " 'reviewed to assess  whether these infants and children have congenital or '\n",
      " 'acquired  syphilis for those with congenital syphilis treatment should  be '\n",
      " 'undertaken as described see congenital syphilis those  with acquired '\n",
      " 'syphilis should be evaluated for sexual abuse  eg through consultation with '\n",
      " 'child protection services see  sexual assault or abuse of children these '\n",
      " 'regimens are for  children who are not allergic to penicillin who have '\n",
      " 'acquired  syphilis and who have normal csf examinations other management '\n",
      " 'considerations all persons who have latent syphilis should be tested for '\n",
      " 'hiv  at the time of diagnosis or treatment those persons whose  hiv test '\n",
      " 'results are negative should be offered hiv prep in  geographic areas in '\n",
      " 'which the prevalence of hiv infection is  high or among populations '\n",
      " 'vulnerable to hiv acquisition  persons who have early latent or late latent '\n",
      " 'syphilis should be  offered prep and retested for hiv in 3 months if the '\n",
      " 'first hiv  test result was negative persons who receive a diagnosis of '\n",
      " 'latent syphilis and have  neurologic or ocular signs and symptoms eg '\n",
      " 'cognitive  dysfunction motor or sensory deficits ophthalmic or auditory  '\n",
      " 'symptoms cranial nerve palsies or symptoms or signs of  meningitis or stroke '\n",
      " 'should be evaluated for neurosyphilis ocular  syphilis or otosyphilis '\n",
      " 'according to their clinical presentation  see neurosyphilis ocular syphilis '\n",
      " 'and otosyphilis if a person receives a delayed dose of penicillin in a '\n",
      " 'course of  weekly therapy for late latent syphilis or syphilis of unknown  '\n",
      " 'duration the course of action that should be recommended  is unclear '\n",
      " 'clinical experience indicates that an interval of  10–14 days between doses '\n",
      " 'of benzathine penicillin for latent  syphilis might be acceptable before '\n",
      " 'restarting the sequence of  injections ie if dose 1 is administered on day 0 '\n",
      " 'dose 2 is  administered on days 10–14 pharmacologic considerations  indicate '\n",
      " 'that an interval of 7–9 days between doses if feasible  might be preferred '\n",
      " '610–612 delayed doses are not optimal  for pregnant women receiving therapy '\n",
      " 'for latent syphilis 613  pregnant women who have delays in any therapy dose '\n",
      " '9 days  between doses should repeat the full course of therapy followup '\n",
      " 'quantitative nontreponemal serologic tests should be  repeated at 6 12 and '\n",
      " '24 months these serologic titers should  be compared with the titer at the '\n",
      " 'time of treatment persons  with at least a fourfold sustained increase in '\n",
      " 'nontreponemal  test titer persisting for 2 weeks or who experienced signs  '\n",
      " 'or symptoms attributable to primary or secondary syphilis  recommendations '\n",
      " 'and reports mmwr  july 23 2021  vol 70  no 4 45us department of health and '\n",
      " 'human servicescenters for disease control and prevention were likely '\n",
      " 'reinfected or experienced treatment failure these  persons should be '\n",
      " 'retreated and reevaluated for hiv infection  among persons who have '\n",
      " 'neurologic findings after a thorough  neurologic examination or among '\n",
      " 'persons with no neurologic  findings and no sexual exposure during the '\n",
      " 'previous year a csf  examination is recommended treatment should be guided '\n",
      " 'by  csf findings among persons with no neurologic findings after  neurologic '\n",
      " 'examination and who are sexually active treatment  with weekly injections of '\n",
      " 'benzathine penicillin g 24 million  units im for 3 weeks is recommended '\n",
      " 'optimal management of persons who have less than a  fourfold decrease in '\n",
      " 'titers 24 months after treatment ie an  inadequate serologic response is '\n",
      " 'unclear especially if the initial  titer was 18 at a minimum these persons '\n",
      " 'should receive  additional clinical and serologic followup and be evaluated '\n",
      " 'for  hiv infection if neurologic symptoms or signs are identified  a csf '\n",
      " 'evaluation is recommended with the findings guiding  management if '\n",
      " 'additional followup cannot be ensured or if  an initially high titer 132 '\n",
      " 'does not decrease at least fourfold  24 months after treatment retreatment '\n",
      " 'with weekly injections  of benzathine penicillin g 24 million units im for 3 '\n",
      " 'weeks is  recommended because treatment failure might be the result  of '\n",
      " 'unrecognized cns infection csf examination can be  considered in such '\n",
      " 'situations where followup is uncertain or  initial high titers do not '\n",
      " 'decrease after 24 months if the csf examination is negative repeat treatment '\n",
      " 'for  latent syphilis is recommended serologic titers might not  decrease '\n",
      " 'despite a negative csf examination and a repeated  course of therapy '\n",
      " 'especially if the initial nontreponemal titer  is low 18 in these '\n",
      " 'circumstances the need for additional  therapy or repeated csf examinations '\n",
      " 'is unclear but is usually  not recommended serologic and clinical monitoring '\n",
      " 'at  least annually should continue to monitor for any sustained  increases '\n",
      " 'in nontreponemal titer management of sex partners see syphilis management of '\n",
      " 'sex partners special considerations penicillin allergy  the effectiveness of '\n",
      " 'alternatives to penicillin in treating  latent syphilis has not been well '\n",
      " 'documented nonpregnant  patients allergic to penicillin who have clearly '\n",
      " 'defined early  latent syphilis should respond to antibiotics recommended as  '\n",
      " 'alternatives to penicillin for treating primary and secondary  syphilis see '\n",
      " 'primary and secondary syphilis the only  acceptable alternatives for '\n",
      " 'treating late latent syphilis or  syphilis of unknown duration are '\n",
      " 'doxycycline 100 mg orally  2 timesday or tetracycline 500 mg orally 4 '\n",
      " 'timesday  each for 28 days the efficacy of these alternative regimens  among '\n",
      " 'persons with hiv infection has not been well studied  these therapies should '\n",
      " 'be used only in conjunction with close  serologic and clinical followup '\n",
      " 'especially among persons  with hiv infection on the basis of biologic '\n",
      " 'plausibility and  pharmacologic properties ceftriaxone might be effective '\n",
      " 'for  treating latent syphilis however the optimal dose and duration  of '\n",
      " 'ceftriaxone therapy have not been defined treatment  decisions should be '\n",
      " 'discussed in consultation with a specialist  persons with a penicillin '\n",
      " 'allergy whose compliance with  therapy or followup cannot be ensured should '\n",
      " 'be desensitized  and treated with benzathine penicillin g skin testing for  '\n",
      " 'penicillin allergy might be useful in circumstances in which  the reagents '\n",
      " 'and expertise are available for performing the test  adequately see '\n",
      " 'management of persons who have a history  of penicillin allergy pregnancy '\n",
      " 'pregnant women who are allergic to penicillin should be  desensitized and '\n",
      " 'treated with penicillin g skin testing for  penicillin allergy might be '\n",
      " 'useful in circumstances in which  the reagents and expertise are available '\n",
      " 'for performing the test  adequately see management of persons who have a '\n",
      " 'history  of penicillin allergy syphilis during pregnancy hiv infection '\n",
      " 'persons with hiv infection who have latent syphilis should  be treated '\n",
      " 'similarly to persons who do not have hiv see  syphilis among persons with '\n",
      " 'hiv infection tertiary syphilis tertiary syphilis refers to gummas '\n",
      " 'cardiovascular syphilis  psychiatric manifestations eg memory loss or '\n",
      " 'personality  changes or late neurosyphilis guidelines for all forms of  '\n",
      " 'neurosyphilis eg early or late neurosyphilis are discussed  elsewhere in '\n",
      " 'these recommendations see neurosyphilis  ocular syphilis and otosyphilis '\n",
      " 'persons with gummas  and cardiovascular syphilis who are not allergic to '\n",
      " 'penicillin  and have no evidence of neurosyphilis by clinical and csf  '\n",
      " 'examination should be treated with the following regimen recommended regimen '\n",
      " 'for tertiary syphilis among adults  tertiary syphilis with normal csf '\n",
      " 'examination benzathine penicillin  g 72 million units total administered as '\n",
      " '3 doses of 24 million units im  each at 1week intervals other management '\n",
      " 'considerations all persons who have tertiary syphilis should receive a csf  '\n",
      " 'examination before therapy is initiated and have an hiv test  '\n",
      " 'recommendations and reports 46 mmwr  july 23 2021  vol 70  no 4 us '\n",
      " 'department of health and human servicescenters for disease control and '\n",
      " 'prevention those persons whose hiv test results are negative should be  '\n",
      " 'offered hiv prep persons with csf abnormalities should be  treated with a '\n",
      " 'neurosyphilis regimen certain providers treat all  persons who have '\n",
      " 'cardiovascular syphilis with a neurosyphilis  regimen these persons should '\n",
      " 'be managed in consultation  with an infectious disease specialist limited '\n",
      " 'information is  available concerning clinical response and followup of '\n",
      " 'persons  who have tertiary syphilis management of sex partners see syphilis '\n",
      " 'management of sex partners special considerations penicillin allergy any '\n",
      " 'person allergic to penicillin should be treated in  consultation with an '\n",
      " 'infectious disease specialist pregnancy pregnant women who are allergic to '\n",
      " 'penicillin should be  desensitized and treated with penicillin g skin '\n",
      " 'testing or oral  graded penicillin dose challenge might be helpful in '\n",
      " 'identifying  women at risk for acute allergic reactions see management  of '\n",
      " 'persons who have a history of penicillin allergy syphilis  during pregnancy '\n",
      " 'hiv infection persons with hiv infection who have tertiary syphilis should  '\n",
      " 'be treated as described for persons without hiv see syphilis  among persons '\n",
      " 'with hiv infection neurosyphilis ocular syphilis and  otosyphilis treatment '\n",
      " 'cns involvement can occur during any stage of syphilis  and csf laboratory '\n",
      " 'abnormalities are common among  persons with early syphilis even in the '\n",
      " 'absence of clinical  neurologic findings no evidence exists to support '\n",
      " 'variation  from recommended diagnosis and treatment for syphilis at  any '\n",
      " 'stage for persons without clinical neurologic findings  except tertiary '\n",
      " 'syphilis if clinical evidence of neurologic  involvement is observed eg '\n",
      " 'cognitive dysfunction motor or  sensory deficits cranial nerve palsies or '\n",
      " 'symptoms or signs of  meningitis or stroke a csf examination should be '\n",
      " 'performed  before treatment syphilitic uveitis or other ocular syphilis '\n",
      " 'manifestations  eg neuroretinitis and optic neuritis can occur at any stage  '\n",
      " 'of syphilis and can be isolated abnormalities or associated with  '\n",
      " 'neurosyphilis all persons with ocular symptoms and reactive  syphilis '\n",
      " 'serology need a full ocular examination including  cranial nerve evaluation '\n",
      " 'if cranial nerve dysfunction is present  a csf evaluation is needed among '\n",
      " 'persons with isolated ocular  symptoms no cranial nerve dysfunction or other '\n",
      " 'neurologic  abnormalities reactive syphilis serology and confirmed ocular  '\n",
      " 'abnormalities on examination csf examination is unnecessary  before '\n",
      " 'treatment csf analysis might be helpful in evaluating  persons with ocular '\n",
      " 'symptoms and reactive syphilis serology  who do not have ocular findings on '\n",
      " 'examination if ocular  syphilis is suspected immediate referral to and '\n",
      " 'management  in collaboration with an ophthalmologist is crucial ocular  '\n",
      " 'syphilis should be treated similarly to neurosyphilis even if a  csf '\n",
      " 'examination is normal hearing loss and other otologic symptoms can occur at '\n",
      " 'any  stage of syphilis and can be isolated abnormalities or associated  with '\n",
      " 'neurosyphilis especially of cranial nerve 8 however  among persons with '\n",
      " 'isolated auditory symptoms normal  neurologic examination and reactive '\n",
      " 'syphilis serology csf  examination is likely to be normal and is not '\n",
      " 'recommended  before treatment otosyphilis should be managed in  '\n",
      " 'collaboration with an otolaryngologist and treated by using  the same '\n",
      " 'regimen as for neurosyphilis recommended regimen for neurosyphilis ocular '\n",
      " 'syphilis or  otosyphilis among adults  aqueous crystalline penicillin g '\n",
      " '18–24 million units per day  administered as 3–4 million units iv every 4 '\n",
      " 'hours or continuous  infusion for 10–14 days if compliance with therapy can '\n",
      " 'be ensured the following  alternative regimen might be considered '\n",
      " 'alternative regimen procaine penicillin g 24 million units im once daily '\n",
      " 'plus probenecid 500 mg orally 4 timesday both for 10–14 days the durations '\n",
      " 'of the recommended and alternative regimens  for neurosyphilis are shorter '\n",
      " 'than the duration of the regimen  used for latent syphilis therefore '\n",
      " 'benzathine penicillin  24 million units im once per week for 1–3 weeks can '\n",
      " 'be  considered after completion of these neurosyphilis treatment  regimens '\n",
      " 'to provide a comparable total duration of therapy other management '\n",
      " 'considerations the following are other considerations in the management  of '\n",
      " 'persons who have neurosyphilis • all persons who have neurosyphilis ocular '\n",
      " 'syphilis or  otosyphilis should be tested for hiv at the time of  diagnosis '\n",
      " 'those whose hiv test results are negative  should be offered hiv prep '\n",
      " 'recommendations and reports mmwr  july 23 2021  vol 70  no 4 47us department '\n",
      " 'of health and human servicescenters for disease control and prevention • '\n",
      " 'although systemic steroids are used frequently as  adjunctive therapy for '\n",
      " 'otosyphilis and for ocular syphilis  such drugs have not been proven to be '\n",
      " 'beneficial followup data from two studies indicate that among '\n",
      " 'immunocompetent  persons and persons with hiv infection who are on '\n",
      " 'effective  art normalization of the serum rpr titer predicts  normalization '\n",
      " 'of abnormal csf parameters after neurosyphilis  treatment 614615 therefore '\n",
      " 'repeated csf examinations  are unnecessary for persons without hiv infection '\n",
      " 'or persons  with hiv infection who are on art and who exhibit serologic  and '\n",
      " 'clinical responses after treatment management of sex partners see syphilis '\n",
      " 'management of sex partners special considerations penicillin allergy limited '\n",
      " 'data indicate that ceftriaxone 1–2 g daily either im  or iv for 10–14 days '\n",
      " 'can be used as an alternative treatment  for persons with neurosyphilis '\n",
      " '603616617 crosssensitivity  between ceftriaxone and penicillin can occur '\n",
      " 'however the  risk for penicillin crossreactivity between thirdgeneration  '\n",
      " 'cephalosporins is negligible 618–621 see management of  persons who have a '\n",
      " 'history of penicillin allergy if concern  exists regarding ceftriaxone '\n",
      " 'safety for a patient with neurosyphilis  skin testing should be performed to '\n",
      " 'confirm penicillin allergy  and if necessary penicillin desensitization in '\n",
      " 'consultation with  a specialist is recommended other regimens have not been  '\n",
      " 'adequately evaluated for treatment of neurosyphilis pregnancy pregnant women '\n",
      " 'who are allergic to penicillin should be  desensitized and treated with '\n",
      " 'penicillin g skin testing or oral  graded penicillin dose challenge might be '\n",
      " 'helpful in identifying  women at risk for acute allergic reactions see '\n",
      " 'management of  persons who have a history of penicillin allergy hiv '\n",
      " 'infection persons with hiv infection who have neurosyphilis should  be '\n",
      " 'treated as described for persons without hiv see syphilis  among persons '\n",
      " 'with hiv infection syphilis among persons with hiv infection diagnostic '\n",
      " 'considerations interpretation of treponemal and nontreponemal serologic  '\n",
      " 'tests for persons with hiv infection is the same as for persons  without hiv '\n",
      " 'although rare unusual serologic responses have  been observed among persons '\n",
      " 'with hiv infection who have  syphilis the majority of reports have involved '\n",
      " 'posttreatment  serologic titers that were higher than expected ie high '\n",
      " 'serofast  or fluctuated and falsenegative serologic test results and '\n",
      " 'delayed  appearance of seroreactivity have also been reported 622 when '\n",
      " 'clinical findings are indicative of syphilis but serologic  tests are '\n",
      " 'nonreactive or their interpretation is unclear alternative  tests eg biopsy '\n",
      " 'of a lesion darkfield examination or pcr of  lesion material might be useful '\n",
      " 'for diagnosis neurosyphilis  ocular syphilis and otosyphilis should be '\n",
      " 'considered in the  differential diagnosis of neurologic ocular and other '\n",
      " 'signs  and symptoms among persons with hiv infection treatment persons with '\n",
      " 'hiv infection who have early syphilis might  be at increased risk for '\n",
      " 'neurologic complications 623 and  might have higher rates of inadequate '\n",
      " 'serologic response  with recommended regimens the magnitude of these risks '\n",
      " 'is  not defined precisely but is likely small although longterm  1 year '\n",
      " 'comparative data are lacking no treatment regimens  for syphilis have been '\n",
      " 'demonstrated to be more effective in  preventing neurosyphilis among persons '\n",
      " 'with hiv infection  than the syphilis regimens recommended for persons '\n",
      " 'without  hiv 609 careful followup after therapy is essential using  art per '\n",
      " 'current hiv guidelines might improve clinical  outcomes among persons '\n",
      " 'coinfected with hiv and syphilis  concerns regarding adequate treatment of '\n",
      " 'syphilis among  persons with hiv infection might not apply to those with  '\n",
      " 'hiv virologic suppression 624625 primary and secondary syphilis among '\n",
      " 'persons  with hiv infection recommended regimen for primary and secondary '\n",
      " 'syphilis  among persons with hiv infection benzathine penicillin g 24 '\n",
      " 'million units im in a single dose available data demonstrate that additional '\n",
      " 'doses of  benzathine penicillin g amoxicillin or other antibiotics in  '\n",
      " 'primary and secondary syphilis among persons with hiv  infection do not '\n",
      " 'result in enhanced efficacy 592593609 other management considerations the '\n",
      " 'majority of persons with hiv infection respond  appropriately to the '\n",
      " 'recommended benzathine penicillin g  treatment regimen for primary and '\n",
      " 'secondary syphilis 626  csf abnormalities eg mononuclear pleocytosis and '\n",
      " 'elevated  protein levels can be common among persons with hiv even  those '\n",
      " 'without syphilis the clinical and prognostic significance  of such csf '\n",
      " 'laboratory abnormalities among persons with  primary and secondary syphilis '\n",
      " 'who lack neurologic symptoms  recommendations and reports 48 mmwr  july 23 '\n",
      " '2021  vol 70  no 4 us department of health and human servicescenters for '\n",
      " 'disease control and prevention is unknown certain studies have demonstrated '\n",
      " 'that among  persons with hiv infection and syphilis csf abnormalities  are '\n",
      " 'associated with a cd4 tcell count of ≤350 cellsml or  an rpr titer of ≥132 '\n",
      " '614627 however csf examination  followed by treatment for neurosyphilis on '\n",
      " 'the basis of  laboratory abnormalities has not been associated with '\n",
      " 'improved  clinical outcomes in the absence of neurologic signs and  symptoms '\n",
      " 'all persons with hiv infection and primary and  secondary syphilis should '\n",
      " 'have a thorough neurologic ocular  and otic examination 614622625 csf '\n",
      " 'examination should  be reserved for those with an abnormal neurologic '\n",
      " 'examination followup persons with hiv infection and primary or secondary  '\n",
      " 'syphilis should be evaluated clinically and serologically for  possible '\n",
      " 'treatment failure at 3 6 9 12 and 24 months after  therapy those who meet '\n",
      " 'the criteria for treatment failure  ie signs or symptoms that persist or '\n",
      " 'recur or a sustained  2 weeks fourfold or greater increase in titer should '\n",
      " 'be  managed in the same manner as persons without hiv infection  ie '\n",
      " 'depending on history of sexual activity and on findings of  neurologic '\n",
      " 'examination either repeat treatment with weekly  injections of benzathine '\n",
      " 'penicillin g 24 million units im for  3 weeks or csf examination and repeat '\n",
      " 'treatment guided by  csf findings see primary and secondary syphilis  in '\n",
      " 'addition csf examination and retreatment can be  considered for persons '\n",
      " 'whose nontreponemal test titers do  not decrease fourfold within 24 months '\n",
      " 'of therapy if csf  examination is normal treatment with benzathine '\n",
      " 'penicillin  g administered as 24 million units im at weekly intervals for  3 '\n",
      " 'weeks is recommended serologic titers might not decrease  despite a negative '\n",
      " 'csf examination and a repeated 3week  course of therapy 599 especially if '\n",
      " 'the initial nontreponemal  titer is low 18 in these circumstances the '\n",
      " 'benefit of  additional therapy or repeated csf examinations is unclear but  '\n",
      " 'is not usually recommended serologic and clinical monitoring  at least '\n",
      " 'annually should continue to monitor for any sustained  increases in '\n",
      " 'nontreponemal titer management of sex partners see syphilis management of '\n",
      " 'sex partners special considerations penicillin allergy persons with hiv '\n",
      " 'infection who are allergic to penicillin  and have primary or secondary '\n",
      " 'syphilis should be managed  according to the recommendations for persons '\n",
      " 'without hiv  who are allergic to penicillin see primary and secondary  '\n",
      " 'syphilis persons with penicillin allergy whose compliance  with alternative '\n",
      " 'therapy or followup cannot be ensured should  be desensitized and treated '\n",
      " 'with penicillin g see management  of persons who have a history of '\n",
      " 'penicillin allergy using  penicillin alternatives has not been well studied '\n",
      " 'among persons  with hiv infection azithromycin is not recommended for  '\n",
      " 'persons with hiv and primary or secondary syphilis infection  alternative '\n",
      " 'therapies should be used only in conjunction with  close serologic and '\n",
      " 'clinical followup persons with hiv and  latent syphilis should be treated '\n",
      " 'similarly to persons who do  not have hiv see latent syphilis latent '\n",
      " 'syphilis among persons with hiv infection recommended regimen for early '\n",
      " 'latent syphilis among  persons with hiv infection benzathine penicillin g 24 '\n",
      " 'million units im in a single dose recommended regimen for late latent '\n",
      " 'syphilis or latent  syphilis of unknown duration among persons with hiv  '\n",
      " 'infection benzathine penicillin g 72 million units total administered as 3 '\n",
      " 'doses  of 24 million units im at 1week intervals other management '\n",
      " 'considerations all persons with hiv and latent syphilis infection should  '\n",
      " 'undergo a thorough neurologic ocular and otic examination  those with '\n",
      " 'neurologic symptoms or signs should undergo  immediate csf examination in '\n",
      " 'the absence of neurologic  symptoms or signs csf examination has not been '\n",
      " 'associated  with improved clinical outcomes and therefore is not  '\n",
      " 'recommended those with ocular or otic symptoms or  signs should be evaluated '\n",
      " 'for ocular syphilis and otosyphilis  according to those clinical '\n",
      " 'presentations see neurosyphilis  ocular syphilis and otosyphilis followup '\n",
      " 'patients with hiv and latent syphilis infection should  be evaluated '\n",
      " 'clinically and serologically at 6 12 18 and  24 months after therapy those '\n",
      " 'persons who meet the criteria  for treatment failure ie signs or symptoms '\n",
      " 'that persist or  recur or a sustained 2 weeks fourfold or greater increase  '\n",
      " 'in titer should be managed in the same manner as persons  without hiv ie '\n",
      " 'depending on history of sexual activity and  on findings of neurologic '\n",
      " 'examination either repeat treatment  with weekly injections of benzathine '\n",
      " 'penicillin g 24 million  units im for 3 weeks or csf examination and repeat '\n",
      " 'treatment  guided by csf findings see latent syphilis in addition csf '\n",
      " 'examination and retreatment can be  considered for persons whose '\n",
      " 'nontreponemal test titers do  not decrease fourfold within 24 months of '\n",
      " 'therapy if csf  examination is normal treatment with benzathine penicillin  '\n",
      " 'g administered as 24 million units im at weekly intervals for  '\n",
      " 'recommendations and reports mmwr  july 23 2021  vol 70  no 4 49us department '\n",
      " 'of health and human servicescenters for disease control and prevention 3 '\n",
      " 'weeks is recommended serologic titers might not decrease  despite a negative '\n",
      " 'csf examination and a repeated 3week  course of therapy 599 especially if '\n",
      " 'the initial nontreponemal  titer is low 18 in these circumstances the '\n",
      " 'benefit of  additional therapy or repeated csf examinations is unclear but  '\n",
      " 'is not usually recommended serologic and clinical monitoring  at least '\n",
      " 'annually should continue to ensure nontreponemal  titers remain stable '\n",
      " 'without any sustained titer increases management of sex partners see '\n",
      " 'syphilis management of sex partners special considerations penicillin '\n",
      " 'allergy the efficacy of alternative nonpenicillin regimens for latent  '\n",
      " 'syphilis for persons living with hiv infection has not been well  studied '\n",
      " 'and these therapies should be used only in conjunction  with close serologic '\n",
      " 'and clinical followup patients with  penicillin allergy whose compliance '\n",
      " 'with alternative therapy  or followup cannot be ensured should be '\n",
      " 'desensitized and  treated with penicillin g see management of persons who  '\n",
      " 'have a history of penicillin allergy neurosyphilis ocular syphilis and otic '\n",
      " 'syphilis  among persons with hiv infection all persons with hiv and syphilis '\n",
      " 'infection should receive a  careful neurologic ocular and otic examination '\n",
      " 'persons with  hiv infection and neurosyphilis should be treated according  '\n",
      " 'to the recommendations for persons with neurosyphilis and  without hiv '\n",
      " 'infection see neurosyphilis ocular syphilis  and otosyphilis followup '\n",
      " 'persons with hiv and neurosyphilis infection should be  managed according to '\n",
      " 'the recommendations for persons without  hiv infection serum rpr can be '\n",
      " 'followed for necessary  treatment success rather than following csf '\n",
      " 'parameters see  neurosyphilis ocular syphilis and otosyphilis limited data  '\n",
      " 'indicate that changes in csf parameters might occur more  slowly among '\n",
      " 'persons with hiv infection especially those  with more advanced '\n",
      " 'immunosuppression 588624 management of sex partners see syphilis management '\n",
      " 'of sex partners special considerations penicillin allergy persons with hiv '\n",
      " 'who are allergic to penicillin and have  neurosyphilis infection should be '\n",
      " 'managed according to the  recommendations for persons without hiv infection '\n",
      " 'with  neurosyphilis who are allergic to penicillin see neurosyphilis  ocular '\n",
      " 'syphilis and otosyphilis small observational studies  conducted among '\n",
      " 'persons with hiv and neurosyphilis report  that ceftriaxone 1–2 g iv daily '\n",
      " 'for 10–14 days might be  effective as an alternative agent 628–630 the '\n",
      " 'possibility  of crosssensitivity between ceftriaxone and penicillin exists  '\n",
      " 'however the risk for penicillin crossreactivity between  thirdgeneration '\n",
      " 'cephalosporins is negligible 619–621631  see management of persons who have '\n",
      " 'a history of penicillin  allergy if concern exists regarding the safety of '\n",
      " 'ceftriaxone  for a person with hiv and neurosyphilis skin testing should  be '\n",
      " 'performed to confirm penicillin allergy and if necessary  penicillin '\n",
      " 'desensitization in consultation with a specialist is  recommended other '\n",
      " 'regimens have not been adequately  evaluated for treatment of neurosyphilis '\n",
      " 'syphilis during pregnancy all women should be screened serologically for '\n",
      " 'syphilis  at the first prenatal care visit 174 which is mandated by  the '\n",
      " 'majority of states 142 among populations for whom  receipt of prenatal care '\n",
      " 'is not optimal serologic screening and  treatment if serologic test is '\n",
      " 'reactive should be performed at  the time of pregnancy testing 632 '\n",
      " 'antepartum screening can  be performed by manual nontreponemal antibody '\n",
      " 'testing eg  rpr by using the traditional syphilis screening algorithm or  by '\n",
      " 'treponemal antibody testing eg immunoassays using the  reverse sequence '\n",
      " 'algorithm pregnant women with positive treponemal screening tests  eg eia '\n",
      " 'cia or immunoblot should have additional  quantitative nontreponemal testing '\n",
      " 'because titers are essential  for monitoring treatment response serologic '\n",
      " 'testing should  also be performed twice during the third trimester at 28 '\n",
      " 'weeks’  gestation and at delivery for pregnant women who live in  '\n",
      " 'communities with high rates of syphilis and for women who  have been at risk '\n",
      " 'for syphilis acquisition during pregnancy maternal risk factors for syphilis '\n",
      " 'during pregnancy include  sex with multiple partners sex in conjunction with '\n",
      " 'drug  use or transactional sex late entry to prenatal care ie first  visit '\n",
      " 'during the second trimester or later or no prenatal  care methamphetamine or '\n",
      " 'heroine use incarceration of the  woman or her partner and unstable housing '\n",
      " 'or homelessness  174633–636 moreover as part of the management of  pregnant '\n",
      " 'women who have syphilis providers should obtain  information concerning '\n",
      " 'ongoing risk behaviors and treatment  of sex partners to assess the risk for '\n",
      " 'reinfection any woman who has a fetal death after 20 weeks’ gestation  '\n",
      " 'should be tested for syphilis no mother or neonate should  leave the '\n",
      " 'hospital without maternal serologic status having been  recommendations and '\n",
      " 'reports 50 mmwr  july 23 2021  vol 70  no 4 us department of health and '\n",
      " 'human servicescenters for disease control and prevention documented at least '\n",
      " 'once during pregnancy any woman who at  the time of delivery has no prenatal '\n",
      " 'care history or has been at  risk for syphilis acquisition during pregnancy '\n",
      " 'eg misuses drugs  has had another sti during pregnancy or has had multiple '\n",
      " 'sex  partners a new partner or a partner with an sti should have the  '\n",
      " 'results of a syphilis serologic test documented before discharge diagnostic '\n",
      " 'considerations pregnant women seropositive for syphilis should be  '\n",
      " 'considered infected unless an adequate treatment history is  clearly '\n",
      " 'documented in the medical records and sequential  serologic antibody titers '\n",
      " 'have decreased as recommended for  the syphilis stage the risk for '\n",
      " 'antepartum fetal infection or  congenital syphilis at delivery is related to '\n",
      " 'the syphilis stage  during pregnancy with the highest risk occurring during  '\n",
      " 'the primary and secondary stages quantitative maternal  nontreponemal titer '\n",
      " 'especially if 18 might be a marker of  early infection and bacteremia '\n",
      " 'however risk for fetal infection  is still substantial among pregnant women '\n",
      " 'with late latent  syphilis and low titers pregnant women with stable '\n",
      " 'serofast  low nontreponemal titers who have previously been treated  for '\n",
      " 'syphilis might not require additional treatment however  increasing or high '\n",
      " 'antibody titers in a pregnant woman  previously treated might indicate '\n",
      " 'reinfection or treatment  failure and treatment should be offered if an '\n",
      " 'automated treponemal test eg eia or cia is used for  antepartum syphilis '\n",
      " 'screening all positive tests should be reflexed  to a quantitative '\n",
      " 'nontreponemal test eg rpr or vdrl if  the nontreponemal test is negative the '\n",
      " 'results are considered  discrepant and a second treponemal test tppa is '\n",
      " 'preferred  should be performed preferably on the same specimen if the second '\n",
      " 'treponemal test is positive eg eia positive  rpr negative or tppa positive '\n",
      " 'current or previous syphilis  infection can be confirmed for women with a '\n",
      " 'history of  adequately treated syphilis who do not have ongoing risk no  '\n",
      " 'further treatment is necessary women without a history of  treatment should '\n",
      " 'have the syphilis stage determined and should  be treated accordingly with a '\n",
      " 'recommended penicillin regimen if the second treponemal test is negative eg '\n",
      " 'eia positive  rpr negative or tppa negative the positive eia or cia is  more '\n",
      " 'likely to represent a falsepositive test result for women  who are living in '\n",
      " 'communities with low rates of syphilis have  a partner who is uninfected and '\n",
      " 'have no history of treated  syphilis 637638 if the woman is at low risk for '\n",
      " 'syphilis  lacks signs or symptoms of primary syphilis has a partner  with no '\n",
      " 'clinical or serologic evidence of syphilis and is likely  to follow up with '\n",
      " 'clinical care repeat serologic testing within 4  weeks can be considered to '\n",
      " 'determine whether the eia or cia  remains positive or if the rpr vdrl or '\n",
      " 'tppa result becomes  positive if both the rpr and tppa remain negative no '\n",
      " 'further  treatment is necessary if followup is not likely women with an  '\n",
      " 'isolated reactive treponemal test and without a history of treated  syphilis '\n",
      " 'should be treated according to the syphilis stage treatment penicillin g is '\n",
      " 'the only known effective antimicrobial for  treating fetal infection and '\n",
      " 'preventing congenital syphilis  639 evidence is insufficient to determine '\n",
      " 'the optimal  penicillin regimen during pregnancy 640 recommended regimen for '\n",
      " 'syphilis during pregnancy pregnant women should be treated with the '\n",
      " 'recommended penicillin  regimen for their stage of infection other '\n",
      " 'management considerations the following recommendations should be considered '\n",
      " 'for  pregnant women with syphilis infection • certain evidence indicates '\n",
      " 'that additional therapy is  beneficial for pregnant women to prevent '\n",
      " 'congenital  syphilis for women who have primary secondary or early  latent '\n",
      " 'syphilis a second dose of benzathine penicillin g  24 million units im can '\n",
      " 'be administered 1 week after the  initial dose 641–643 • when syphilis is '\n",
      " 'diagnosed during the second half of  pregnancy management should include a '\n",
      " 'sonographic fetal  evaluation for congenital syphilis however this '\n",
      " 'evaluation  should not delay therapy sonographic signs of fetal or  '\n",
      " 'placental syphilis eg hepatomegaly ascites hydrops fetal  anemia or a '\n",
      " 'thickened placenta indicate a greater risk for  fetal treatment failure 644 '\n",
      " 'cases accompanied by these  signs should be managed in consultation with '\n",
      " 'obstetric  specialists a second dose of benzathine penicillin g  24 million '\n",
      " 'units im after the initial dose might be beneficial  for fetal treatment in '\n",
      " 'these situations • women treated for syphilis during the second half of  '\n",
      " 'pregnancy are at risk for premature labor or fetal distress  if the '\n",
      " 'treatment precipitates the jarischherxheimer  reaction 590 these women '\n",
      " 'should be advised to seek  obstetric attention after treatment if they '\n",
      " 'notice any fever  contractions or decrease in fetal movements stillbirth is  '\n",
      " 'a rare complication of treatment however concern for  this complication '\n",
      " 'should not delay necessary treatment  no data are available to support that '\n",
      " 'corticosteroid  treatment alters the risk for treatmentrelated '\n",
      " 'complications  during pregnancy • missed doses 9 days between doses are not '\n",
      " 'acceptable for  pregnant women receiving therapy for late latent syphilis  '\n",
      " '613 an optimal interval between doses is 7 days for  pregnant women if a '\n",
      " 'pregnant woman does not return  for the next dose on day 7 every effort '\n",
      " 'should be made  recommendations and reports mmwr  july 23 2021  vol 70  no 4 '\n",
      " '51us department of health and human servicescenters for disease control and '\n",
      " 'prevention to contact her and link her to immediate treatment within  2 days '\n",
      " 'to avoid retreatment pregnant women who miss a  dose of therapy should '\n",
      " 'repeat the full course of therapy • all women who have syphilis should be '\n",
      " 'offered testing for  hiv at the time of diagnosis followup coordinated '\n",
      " 'prenatal care and treatment are vital because  providers should document '\n",
      " 'that women are adequately  treated for the syphilis stage and ensure that '\n",
      " 'the clinical and  antibody responses are appropriate for the patient’s '\n",
      " 'disease  stage if syphilis is diagnosed and treated at or before 24 weeks’  '\n",
      " 'gestation serologic titers should not be repeated before 8 weeks  after '\n",
      " 'treatment eg at 32 weeks’ gestation but should be  repeated again at '\n",
      " 'delivery titers should be repeated sooner  if reinfection or treatment '\n",
      " 'failure is suspected for syphilis  diagnosed and treated after 24 weeks’ '\n",
      " 'gestation serologic titers  should be repeated at delivery a majority of '\n",
      " 'women will not achieve a fourfold decrease  in titers before delivery '\n",
      " 'although this does not indicate  treatment failure 645 however a fourfold '\n",
      " 'increase in titer  after treatment eg from 18 to 132 that is sustained for  '\n",
      " '2 weeks is concerning for reinfection or treatment failure  nontreponemal '\n",
      " 'titers can increase immediately after treatment  presumably related to the '\n",
      " 'treatment response therefore unless  symptoms and signs exist of primary or '\n",
      " 'secondary syphilis  followup titer should not be repeated until '\n",
      " 'approximately  8 weeks after treatment inadequate maternal treatment is  '\n",
      " 'likely if delivery occurs within 30 days of therapy clinical signs  of '\n",
      " 'infection are present at delivery or the maternal antibody  titer at '\n",
      " 'delivery is fourfold higher than the pretreatment titer management of sex '\n",
      " 'partners see syphilis management of sex partners special considerations '\n",
      " 'penicillin allergy no proven alternatives to penicillin are available for  '\n",
      " 'treatment of syphilis during pregnancy pregnant women who  have a history of '\n",
      " 'penicillin allergy should be desensitized and  treated with penicillin g '\n",
      " 'skin testing or oral graded penicillin  dose challenge might be helpful in '\n",
      " 'identifying women at risk  for acute allergic reactions see management of '\n",
      " 'persons who  have a history of penicillin allergy tetracycline and '\n",
      " 'doxycycline are to be avoided in the second  and third trimesters of '\n",
      " 'pregnancy 431 erythromycin and  azithromycin should not be used because '\n",
      " 'neither reliably cures  maternal infection nor treats an infected fetus 640 '\n",
      " 'data are  insufficient to recommend ceftriaxone or other cephalosporins  for '\n",
      " 'treatment of maternal infection and prevention of  congenital syphilis '\n",
      " '646647 hiv infection placental inflammation from congenital syphilis '\n",
      " 'infection  might increase the risk for perinatal transmission of hiv all  '\n",
      " 'women with hiv infection should be evaluated for syphilis and  receive a '\n",
      " 'penicillin regimen appropriate for the syphilis stage  data are insufficient '\n",
      " 'to recommend any alternative regimens  for pregnant women with syphilis and '\n",
      " 'hiv infection see  syphilis among persons with hiv congenital syphilis the '\n",
      " 'rate of reported congenital syphilis in the united states  has increased '\n",
      " 'dramatically since 2012 during 2019 a total of  1870 cases of congenital '\n",
      " 'syphilis were reported including 94  stillbirths and 34 infant deaths 141 '\n",
      " 'the 2019 national rate  of 485 cases per 100000 live births represents a 41 '\n",
      " 'increase  relative to 2018 343 cases per 100000 live births and a 477  '\n",
      " 'increase relative to 2012 84 cases per 100000 live births  during 2015–2019 '\n",
      " 'the rate of congenital syphilis increased  2911 124 to 485 per 100000 live '\n",
      " 'births which mirrors  increases in the rate of primary and secondary '\n",
      " 'syphilis among  females aged 15–44 years a 1719 increase from 32 to 87  per '\n",
      " '100000 females effective prevention and detection of congenital syphilis  '\n",
      " 'depend on identifying syphilis among pregnant women and  therefore on the '\n",
      " 'routine serologic screening of pregnant  women during the first prenatal '\n",
      " 'visit and at 28 weeks’ gestation  and at delivery for women who live in '\n",
      " 'communities with high  rates of syphilis women with hiv infection or those '\n",
      " 'who  are at increased risk for syphilis acquisition certain states  have '\n",
      " 'recommended screening three times during pregnancy  for all women clinicians '\n",
      " 'should screen according to their  state’s guidelines maternal risk factors '\n",
      " 'for syphilis during pregnancy include  sex with multiple partners sex in '\n",
      " 'conjunction with drug  use or transactional sex late entry to prenatal care '\n",
      " 'ie first  visit during the second trimester or later or no prenatal  care '\n",
      " 'methamphetamine or heroine use incarceration of the  woman or her partner '\n",
      " 'and unstable housing or homelessness  174633–636 moreover as part of the '\n",
      " 'management of  pregnant women who have syphilis providers should obtain  '\n",
      " 'information concerning ongoing risk behaviors and treatment  of sex partners '\n",
      " 'to assess the risk for reinfection routine screening of neonatal sera or '\n",
      " 'umbilical cord blood  is not recommended because diagnosis at that time does '\n",
      " 'not  prevent congenital syphilis in certain newborns no mother  or newborn '\n",
      " 'infant should leave the hospital without maternal  recommendations and '\n",
      " 'reports 52 mmwr  july 23 2021  vol 70  no 4 us department of health and '\n",
      " 'human servicescenters for disease control and prevention serologic status '\n",
      " 'having been documented at least once during  pregnancy any woman who had no '\n",
      " 'prenatal care before  delivery or is considered at increased risk for '\n",
      " 'syphilis acquisition  during pregnancy should have the results of a syphilis '\n",
      " 'serologic  test documented before she or her neonate is discharged a  '\n",
      " 'quantitative rpr is needed at the time of delivery to compare  with the '\n",
      " 'neonate’s nontreponemal test result if a stat rpr  is unavailable and a '\n",
      " 'rapid treponemal test is performed at  delivery the results should be '\n",
      " 'confirmed by using standard  syphilis serologic laboratory tests eg rpr and '\n",
      " 'treponemal  test and algorithms evaluation and treatment of neonates '\n",
      " 'diagnosis of congenital syphilis can be difficult because  maternal '\n",
      " 'nontreponemal and treponemal immunoglobulin g  igg antibodies can be '\n",
      " 'transferred through the placenta to the  fetus complicating the '\n",
      " 'interpretation of reactive serologic tests  for syphilis among neonates '\n",
      " 'infants aged 30 days therefore  treatment decisions frequently must be made '\n",
      " 'on the basis of  identification of syphilis in the mother adequacy of '\n",
      " 'maternal  treatment presence of clinical laboratory or radiographic  '\n",
      " 'evidence of syphilis in the neonate and comparison of maternal  at delivery '\n",
      " 'and neonatal nontreponemal serologic titers eg  rpr or vdrl by using the '\n",
      " 'same test preferably conducted  by the same laboratory any neonate at risk '\n",
      " 'for congenital  syphilis should receive a full evaluation and testing for '\n",
      " 'hiv all neonates born to mothers who have reactive nontreponemal  and '\n",
      " 'treponemal test results should be evaluated with a  quantitative '\n",
      " 'nontreponemal serologic test rpr or vdrl  performed on the neonate’s serum '\n",
      " 'because umbilical cord blood  can become contaminated with maternal blood '\n",
      " 'and yield a  falsepositive result and wharton’s jelly within the umbilical  '\n",
      " 'cord can yield a falsenegative result the nontreponemal  test performed on '\n",
      " 'the neonate should be the same type of  nontreponemal test performed on the '\n",
      " 'mother conducting a treponemal test eg tppa immunoassay eia cia or microbead '\n",
      " 'immunoassay on neonatal serum is  not recommended because it is difficult to '\n",
      " 'interpret as passively  transferred maternal antibodies can persist for 15 '\n",
      " 'months  commercially available igm tests are not recommended all neonates '\n",
      " 'born to women who have reactive nontreponemal  serologic tests for syphilis '\n",
      " 'at delivery should be examined  thoroughly for evidence of congenital '\n",
      " 'syphilis eg nonimmune  hydrops conjugated or direct hyperbilirubinemia† or  '\n",
      " 'cholestatic jaundice or cholestasis hepatosplenomegaly  rhinitis skin rash '\n",
      " 'or pseudoparalysis of an extremity  pathologic examination of the placenta '\n",
      " 'or umbilical cord using  specific staining eg silver or a t pallidum pcr '\n",
      " 'test using  † direct hyperbilirubinemia is direct bilirubin level 2 mgdl 34 '\n",
      " 'umoll or  20 of the total bilirubin level a cliavalidated test should be '\n",
      " 'considered direct fluorescence  antibody dfatp reagents are unavailable 565 '\n",
      " 'darkfield  microscopic examination or pcr testing of suspicious lesions  or '\n",
      " 'body fluids eg bullous rash or nasal discharge also should  be performed in '\n",
      " 'addition to these tests for stillborn infants  skeletal survey demonstrating '\n",
      " 'typical osseous lesions might aid  in the diagnosis of congenital syphilis '\n",
      " 'because these  abnormalities are not detected on fetal ultrasound the '\n",
      " 'following scenarios describe the recommended  congenital syphilis evaluation '\n",
      " 'and treatment of neonates born  to women who had reactive nontreponemal and '\n",
      " 'treponemal  serologic tests for syphilis during pregnancy eg rpr reactive  '\n",
      " 'tppa reactive or eia reactive rpr reactive and have a  reactive '\n",
      " 'nontreponemal test at delivery eg rpr reactive  maternal history of '\n",
      " 'infection with t pallidum and treatment  for syphilis should be considered '\n",
      " 'when evaluating and treating  the neonate for congenital syphilis in most '\n",
      " 'scenarios except  when congenital syphilis is proven or highly probable '\n",
      " 'scenario 1 confirmed proven or highly probable  congenital syphilis any '\n",
      " 'neonate with  • an abnormal physical examination that is consistent with  '\n",
      " 'congenital syphilis  • a serum quantitative nontreponemal serologic titer '\n",
      " 'that is  fourfold§ or greater higher than the mother’s titer at  delivery eg '\n",
      " 'maternal titer  12 neonatal titer ≥18 or  maternal titer\\xa0\\xa018 neonatal '\n",
      " 'titer ≥132¶ or • a positive darkfield test or pcr of placenta cord lesions '\n",
      " 'or  body fluids or a positive silver stain of the placenta or cord '\n",
      " 'recommended evaluation • csf analysis for vdrl cell count and protein  § one '\n",
      " 'dilution is within the test performance of nontreponemal tests and is not  a '\n",
      " 'significant change  ¶ the absence of a fourfold or greater titer for a '\n",
      " 'neonate does not exclude  congenital syphilis   interpretation of csf test '\n",
      " 'results requires a nontraumatic lumbar puncture  ie a csf sample that is not '\n",
      " 'contaminated with blood csf test results  obtained during the neonatal '\n",
      " 'period can be difficult to interpret normal values  differ by gestational '\n",
      " 'age and are higher among preterm infants studies indicate  that 95 of '\n",
      " 'healthy neonates have values of ≤16–19 wbcsmm3 or protein  levels of '\n",
      " '≤115–118 mgdl on csf examination during the second month  of life 95 of '\n",
      " 'healthy infants have ≤9–11 wbcsmm3 or protein levels of  ≤89–91 mgdl lower '\n",
      " 'values ie 5 wbcsmm3 and protein level of 40 mg dl might be considered the '\n",
      " 'upper limits of normal for older infants other  causes of elevated values '\n",
      " 'should be considered when an infant is being evaluated  for congenital '\n",
      " 'syphilis sources kestenbaum la ebberson j zorc jj  hodinka rl shah ss '\n",
      " 'defining cerebrospinal fluid white blood cell count  reference values in '\n",
      " 'neonates and young infants pediatrics 2010125257–64  shah ss ebberson j '\n",
      " 'kestenbaum la hodinka rl zorc jj agespecific  reference values for '\n",
      " 'cerebrospinal fluid protein concentration in neonates and  young infants j '\n",
      " 'hosp med 2011622–7 thomson j sucharew h cruz at  et al pediatric emergency '\n",
      " 'medicine collaborative research committee pem  crc hsv study group '\n",
      " 'cerebrospinal fluid reference values for young  infants undergoing lumbar '\n",
      " 'puncture pediatrics 2018141e20173405 recommendations and reports mmwr  july '\n",
      " '23 2021  vol 70  no 4 53us department of health and human servicescenters '\n",
      " 'for disease control and prevention • complete blood count cbc and '\n",
      " 'differential and  platelet count • longbone radiographs • other tests as '\n",
      " 'clinically indicated eg chest radiograph  liver function tests neuroimaging '\n",
      " 'ophthalmologic  examination and auditory brain stem response recommended '\n",
      " 'regimens confirmed or highly probable  congenital syphilis aqueous '\n",
      " 'crystalline penicillin g 100000–150000 unitskgbody  weightday administered '\n",
      " 'as 50000 unitskg body weightdose iv every  12 hours during the first 7 days '\n",
      " 'of life and every 8 hours thereafter for a  total of 10 days or procaine '\n",
      " 'penicillin g 50000 unitskg body weightdose im in a single  daily dose for 10 '\n",
      " 'days if 1 day of therapy is missed the entire course should  be restarted '\n",
      " 'data are insufficient regarding use of other  antimicrobial agents eg '\n",
      " 'ampicillin when possible a full  10day course of penicillin is preferred '\n",
      " 'even if ampicillin was  initially provided for possible sepsis 648–650 using '\n",
      " 'agents  other than penicillin requires close serologic followup for  '\n",
      " 'assessing therapy adequacy scenario 2 possible congenital syphilis any '\n",
      " 'neonate who has a normal physical examination and a  serum quantitative '\n",
      " 'nontreponemal serologic titer equal to or  less than fourfold of the '\n",
      " 'maternal titer at delivery eg maternal  titer\\xa0\\xa018 neonatal titer ≤116 '\n",
      " 'and one of the following • the mother was not treated was inadequately '\n",
      " 'treated or  has no documentation of having received treatment • the mother '\n",
      " 'was treated with erythromycin or a regimen  other than those recommended in '\n",
      " 'these guidelines ie a  nonpenicillin g regimen†† • the mother received the '\n",
      " 'recommended regimen but  treatment was initiated 30 days before delivery '\n",
      " 'recommended evaluation • csf analysis for vdrl cell count and protein • cbc '\n",
      " 'differential and platelet count • longbone radiographs this evaluation is '\n",
      " 'not necessary if a 10day course of  parenteral therapy is administered '\n",
      " 'although such evaluations  might be useful for instance a lumbar puncture '\n",
      " 'might  document csf abnormalities that would prompt close  followup other '\n",
      " 'tests eg cbc platelet count and long bone radiographs can be performed to '\n",
      " 'further support a  diagnosis of congenital syphilis  †† a women treated with '\n",
      " 'a regimen other than recommended in these guidelines  should be considered '\n",
      " 'untreated recommended regimens possible congenital syphilis aqueous '\n",
      " 'crystalline penicillin g 100000–150000 unitskg body  weightday administered '\n",
      " 'as 50000 unitskg body weightdose iv every  12 hours during the first 7 days '\n",
      " 'of life and every 8 hours thereafter for a  total of 10 days or procaine '\n",
      " 'penicillin g 50000 unitskg body weightdose im in a single  daily dose for 10 '\n",
      " 'days or benzathine penicillin g 50000 unitskg body weightdose im in a  '\n",
      " 'single dose before using the singledose benzathine penicillin g regimen  the '\n",
      " 'recommended evaluation ie csf examination long bone radiographs and cbc with '\n",
      " 'platelets should be normal  and followup should be certain if any part of '\n",
      " 'the neonate’s  evaluation is abnormal or not performed if the csf analysis  '\n",
      " 'is uninterpretable because of contamination with blood or  if followup is '\n",
      " 'uncertain a 10day course of penicillin g  is required if the neonate’s '\n",
      " 'nontreponemal test is nonreactive and  the provider determines that the '\n",
      " 'mother’s risk for untreated  syphilis is low treatment of the neonate with a '\n",
      " 'single im  dose of benzathine penicillin g 50000 unitskg body weight  for '\n",
      " 'possible incubating syphilis can be considered without  an evaluation '\n",
      " 'neonates born to mothers with untreated  early syphilis at the time of '\n",
      " 'delivery are at increased risk for  congenital syphilis and the 10day course '\n",
      " 'of penicillin g  should be considered even if the neonate’s nontreponemal  '\n",
      " 'test is nonreactive the complete evaluation is normal and  followup is '\n",
      " 'certain scenario 3 congenital syphilis less likely any neonate who has a '\n",
      " 'normal physical examination and a  serum quantitative nontreponemal '\n",
      " 'serologic titer equal or less  than fourfold of the maternal titer at '\n",
      " 'delivery eg maternal  titer\\xa0\\xa018 neonatal titer ≤116 and both of the '\n",
      " 'following  are true • the mother was treated during pregnancy treatment was  '\n",
      " 'appropriate for the infection stage and the treatment  regimen was initiated '\n",
      " '≥30 days before delivery • the mother has no evidence of reinfection or '\n",
      " 'relapse recommended evaluation no evaluation is recommended recommended '\n",
      " 'regimen congenital syphilis less likely benzathine penicillin g 50000 '\n",
      " 'unitskg body weightdose im in a  single dose  another approach involves not '\n",
      " 'treating the newborn if followup is  certain but providing close serologic '\n",
      " 'followup every 2–3 months for 6  months for infants whose mothers’ '\n",
      " 'nontreponemal titers decreased at  least fourfold after therapy for early '\n",
      " 'syphilis or remained stable for low titer latent syphilis eg vdrl 12 or rpr '\n",
      " '14 recommendations and reports 54 mmwr  july 23 2021  vol 70  no 4 us '\n",
      " 'department of health and human servicescenters for disease control and '\n",
      " 'prevention scenario 4 congenital syphilis unlikely any neonate who has a '\n",
      " 'normal physical examination and a  serum quantitative nontreponemal '\n",
      " 'serologic titer equal to or  less than fourfold of the maternal titer at '\n",
      " 'delivery§ and both  of the following are true • the mother’s treatment was '\n",
      " 'adequate before pregnancy • the mother’s nontreponemal serologic titer '\n",
      " 'remained low  and stable ie serofast before and during pregnancy and  at '\n",
      " 'delivery eg vdrl ≤12 or rpr ≤14 recommended evaluation no evaluation is '\n",
      " 'recommended recommended regimen congenital syphilis unlikely no treatment is '\n",
      " 'required however any neonate with reactive  nontreponemal tests should be '\n",
      " 'followed serologically to ensure the  nontreponemal test returns to negative '\n",
      " 'see followup benzathine  penicillin g 50000 unitskg body weight as a single '\n",
      " 'im injection might  be considered particularly if followup is uncertain and '\n",
      " 'the neonate has  a reactive nontreponemal test the following situations '\n",
      " 'describe management of neonates  born to women screened during pregnancy by '\n",
      " 'using the reverse  sequence algorithm with reactive treponemal serologic '\n",
      " 'tests  and a nonreactive nontreponemal serologic test reactive maternal '\n",
      " 'treponemal serologies with a  nonreactive nontreponemal serology eg eia '\n",
      " 'reactive  rpr nonreactive or tppa reactive during pregnancy  syphilis is '\n",
      " 'highly unlikely for neonates born to mothers with  a nonreactive '\n",
      " 'nontreponemal test after adequate treatment  for syphilis during pregnancy '\n",
      " 'or documentation of adequate  treatment before pregnancy with no evidence of '\n",
      " 'reinfection  of relapse if testing is performed again at delivery and 1 the  '\n",
      " 'maternal nontreponemal test remains nonreactive and 2 the  neonate has a '\n",
      " 'normal physical examination and nonreactive  nontreponemal test eg rpr '\n",
      " 'nonreactive the provider  should consider managing similarly to scenario 4 '\n",
      " 'without  a laboratory evaluation and with no treatment required  benzathine '\n",
      " 'penicillin g 50000 unitskg body weight as a  single im injection might be '\n",
      " 'considered if syphilis exposure  is possible within 1 month of delivery and '\n",
      " 'followup of the  mother and infant is uncertain isolated reactive maternal '\n",
      " 'treponemal serology eg  eia reactive rpr nonreactive or tppa nonreactive  '\n",
      " 'during pregnancy syphilis is unlikely for neonates born to  mothers screened '\n",
      " 'with the reverse sequence algorithm with  isolated reactive maternal '\n",
      " 'treponemal serology among low prevalence populations these are likely '\n",
      " 'falsepositive results and  might become nonreactive with repeat testing 638 '\n",
      " 'if these  neonates have a normal physical examination and the risk for  '\n",
      " 'syphilis is low in the mother no evaluation and treatment are  recommended '\n",
      " 'for the neonate if syphilis exposure is possible  or unknown in the mother '\n",
      " 'or the mother desires further  evaluation to definitively rule out syphilis '\n",
      " 'repeat serology  within 4 weeks is recommended to evaluate for early '\n",
      " 'infection  see syphilis during pregnancy isolated reactive maternal '\n",
      " 'treponemal serology eg rapid  treponemal test at delivery for mothers with '\n",
      " 'late or no  prenatal care with a reactive rapid treponemal test at delivery  '\n",
      " 'confirmatory laboratorybased testing should be performed  however results '\n",
      " 'should not delay evaluation and treatment of  the neonate these neonates '\n",
      " 'should be evaluated and treated  with a 10day course of penicillin as '\n",
      " 'recommended in scenario  1 and consultation with a specialist is recommended '\n",
      " 'followup all neonates with reactive nontreponemal tests should receive  '\n",
      " 'thorough followup examinations and serologic testing ie rpr  or vdrl every '\n",
      " '2–3 months until the test becomes nonreactive for a neonate who was not '\n",
      " 'treated because congenital syphilis  was considered less likely or unlikely '\n",
      " 'nontreponemal antibody  titers should decrease by age 3 months and be '\n",
      " 'nonreactive  by age 6 months indicating that the reactive test result was  '\n",
      " 'caused by passive transfer of maternal igg antibody at age  6 months if the '\n",
      " 'nontreponemal test is nonreactive no further  evaluation or treatment is '\n",
      " 'needed if the nontreponemal test is  still reactive the infant is likely '\n",
      " 'infected and should be treated treated neonates who exhibit persistent '\n",
      " 'nontreponemal test  titers by age 6–12 months should be reevaluated through '\n",
      " 'csf  examination and managed in consultation with an expert  retreatment '\n",
      " 'with a 10day course of a penicillin g regimen  might be indicated neonates '\n",
      " 'with a negative nontreponemal test at birth and  whose mothers were '\n",
      " 'seroreactive at delivery should be retested  at age 3 months to rule out '\n",
      " 'serologically negative incubating  congenital syphilis at the time of birth '\n",
      " 'treponemal tests should  not be used to evaluate treatment response because '\n",
      " 'the results  are qualitative and passive transfer of maternal igg '\n",
      " 'treponemal  antibody might persist for 15 months neonates whose initial csf '\n",
      " 'evaluations are abnormal do  not need repeat lumbar puncture unless they '\n",
      " 'exhibit persistent  nontreponemal serologic test titers at age 6–12 months  '\n",
      " 'persistent nontreponemal titers and csf abnormalities should  be managed in '\n",
      " 'consultation with an expert special considerations penicillin allergy '\n",
      " 'neonates who require treatment for congenital syphilis  but who have a '\n",
      " 'history of penicillin allergy or develop an  allergic reaction presumed '\n",
      " 'secondary to penicillin should  recommendations and reports mmwr  july 23 '\n",
      " '2021  vol 70  no 4 55us department of health and human servicescenters for '\n",
      " 'disease control and prevention be desensitized and then treated with '\n",
      " 'penicillin g see  management of persons who have a history of penicillin  '\n",
      " 'allergy skin testing remains unavailable for neonates because  the procedure '\n",
      " 'has not been standardized for this age group  data are insufficient '\n",
      " 'regarding use of other antimicrobial agents  eg ceftriaxone for congenital '\n",
      " 'syphilis among neonates if  a nonpenicillin g agent is used close clinical '\n",
      " 'and serologic  followup is required in consultation with an expert repeat  '\n",
      " 'csf examination should be performed if the initial csf  examination was '\n",
      " 'abnormal penicillin shortage during periods when the availability of aqueous '\n",
      " 'crystalline  penicillin g is compromised the following is recommended  '\n",
      " 'httpswwwcdcgovstdtreatmentdrugnoticeshtm • for neonates with clinical '\n",
      " 'evidence of congenital syphilis  see scenario 1 check local sources for '\n",
      " 'aqueous crystalline  penicillin g potassium or sodium and notify cdc and  '\n",
      " 'fda of limited supply if iv penicillin g is limited  substitute some or all '\n",
      " 'daily doses with procaine penicillin g  50000 unitskg body weightdose imday '\n",
      " 'in a single  daily dose for 10 days  • if aqueous or procaine penicillin g '\n",
      " 'is unavailable  ceftriaxone 50–75 mgkg body weightday iv every  24 hours can '\n",
      " 'be considered with thorough clinical and  serologic followup and in '\n",
      " 'consultation with an expert  because evidence is insufficient to support '\n",
      " 'using ceftriaxone  for treating congenital syphilis ceftriaxone should be '\n",
      " 'used  with caution in neonates with jaundice • for neonates without any '\n",
      " 'clinical evidence of congenital  syphilis see scenario 2 and scenario 3 use  '\n",
      " 'ű procaine penicillin g 50000 unitskg body weight doseday im in a single '\n",
      " 'dose for 10 days or  ű benzathine penicillin g 50000 unitskg body weight  im '\n",
      " 'as a single dose • if any part of the evaluation for congenital syphilis is  '\n",
      " 'abnormal or was not performed csf examination is not  interpretable or '\n",
      " 'followup is uncertain procaine penicillin  g is recommended a single dose of '\n",
      " 'ceftriaxone is  inadequate therapy • for premature neonates who have no '\n",
      " 'clinical evidence of  congenital syphilis see scenario 2 and scenario 3 and  '\n",
      " 'might not tolerate im injections because of decreased  muscle mass iv '\n",
      " 'ceftriaxone can be considered with  thorough clinical and serologic followup '\n",
      " 'and in  consultation with an expert ceftriaxone dosing should  be adjusted '\n",
      " 'according to birthweight hiv infection evidence is insufficient to determine '\n",
      " 'whether neonates who  have congenital syphilis and hiv infection or whose '\n",
      " 'mothers  have hiv require different therapy or clinical management  than is '\n",
      " 'recommended for all neonates all neonates with  congenital syphilis should '\n",
      " 'be managed similarly regardless of  hiv status evaluation and treatment of '\n",
      " 'infants and children  with congenital syphilis infants and children aged ≥1 '\n",
      " 'month who are identified as  having reactive serologic tests for syphilis eg '\n",
      " 'rpr reactive  tppa reactive or eia reactive rpr reactive should be  examined '\n",
      " 'thoroughly and have maternal serology and records  reviewed to assess '\n",
      " 'whether they have congenital or acquired  syphilis see primary and secondary '\n",
      " 'syphilis latent syphilis  sexual assault or abuse of children in the case of '\n",
      " 'extremely  early or incubating syphilis at the time of delivery all '\n",
      " 'maternal  serologic tests might have been negative thus infection might  be '\n",
      " 'undetected until a diagnosis is made later in the infant or  child any '\n",
      " 'infant or child at risk for congenital syphilis should  receive a full '\n",
      " 'evaluation and testing for hiv infection international adoptee immigrant or '\n",
      " 'refugee children from  countries where treponemal infections eg yaws or '\n",
      " 'pinta are  endemic might have reactive nontreponemal and treponemal  '\n",
      " 'serologic tests which cannot distinguish between syphilis and  other '\n",
      " 'subspecies of t pallidum 651 these children might  also have syphilis t '\n",
      " 'pallidum subspecies pallidum and should  be evaluated for congenital '\n",
      " 'syphilis recommended evaluation the following evaluations should be '\n",
      " 'performed • csf analysis for vdrl cell count and protein • cbc differential '\n",
      " 'and platelet count • other tests as clinically indicated eg longbone  '\n",
      " 'radiographs chest radiograph liver function tests  abdominal ultrasound '\n",
      " 'ophthalmologic examination  neuroimaging and auditory brainstem response '\n",
      " 'recommended regimen for congenital syphilis among infants  and children '\n",
      " 'aqueous crystalline penicillin g 200000–300000 unitskg body  weightday iv '\n",
      " 'administered as 50000 unitskg body weight every 4–6  hours for 10 days if '\n",
      " 'the infant or child has no clinical manifestations of  congenital syphilis '\n",
      " 'and the evaluation including the csf  examination is normal treatment with 3 '\n",
      " 'weekly doses of  benzathine penicillin g 50000 unitskg body weight im  can '\n",
      " 'be considered a single dose of benzathine penicillin  g 50000 unitskg body '\n",
      " 'weight im up to the adult dose of  httpswwwcdcgovstdtreatmentdrugnoticeshtm '\n",
      " 'recommendations and reports 56 mmwr  july 23 2021  vol 70  no 4 us '\n",
      " 'department of health and human servicescenters for disease control and '\n",
      " 'prevention 24 million units in a single dose can be considered after the  '\n",
      " '10day course of iv aqueous penicillin g to provide more  comparable duration '\n",
      " 'for treatment in those who have no  clinical manifestations and normal csf '\n",
      " 'all of these treatment  regimens should also be adequate for children who '\n",
      " 'might have  other treponemal infections followup thorough followup '\n",
      " 'examinations and serologic testing ie  rpr or vdrl of infants and children '\n",
      " 'treated for congenital  syphilis after the neonatal period aged 30 days '\n",
      " 'should be  performed every 3 months until the test becomes nonreactive  or '\n",
      " 'the titer has decreased fourfold the serologic response  after therapy might '\n",
      " 'be slower for infants and children than  neonates if these titers increase '\n",
      " 'at any point 2 weeks or do  not decrease fourfold after 12–18 months the '\n",
      " 'infant or child  should be evaluated eg csf examination treated with  a '\n",
      " '10day course of parenteral penicillin g and managed in  consultation with an '\n",
      " 'expert treponemal tests eg eia cia  or tppa should not be used to evaluate '\n",
      " 'treatment response  because the results are qualitative and persist after '\n",
      " 'treatment  and passive transfer of maternal igg treponemal antibody  might '\n",
      " 'persist for 15 months after delivery infants or children  whose initial csf '\n",
      " 'evaluations are abnormal do not need repeat  lumbar puncture unless their '\n",
      " 'serologic titers do not decrease  fourfold after 12–18 months after 18 '\n",
      " 'months of followup  abnormal csf indices that persist and cannot be '\n",
      " 'attributed to  other ongoing illness indicate that retreatment is needed '\n",
      " 'for  possible neurosyphilis and should be managed in consultation  with an '\n",
      " 'expert special considerations penicillin allergy infants and children who '\n",
      " 'require treatment for congenital  syphilis but who have a history of '\n",
      " 'penicillin allergy or develop  an allergic reaction presumed secondary to '\n",
      " 'penicillin should be  desensitized and treated with penicillin g see '\n",
      " 'management  of persons who have a history of penicillin allergy skin  '\n",
      " 'testing remains unavailable for infants and children because the  procedure '\n",
      " 'has not been standardized for this age group data  are insufficient '\n",
      " 'regarding use of other antimicrobial agents eg  ceftriaxone for congenital '\n",
      " 'syphilis among infants and children  if a nonpenicillin g agent is used '\n",
      " 'close clinical serologic and  csf followup is required in consultation with '\n",
      " 'an expert penicillin shortage during periods when availability of penicillin '\n",
      " 'g is  compromised management options are similar to options  for the neonate '\n",
      " 'see evaluation and treatment of neonates • for infants and children with '\n",
      " 'clinical evidence of  congenital syphilis if iv penicillin is limited after '\n",
      " 'checking  local sources and notifying cdc and fda about limited  supplies '\n",
      " 'procaine penicillin g 50000 unitskg body  weightdose im up to the adult dose '\n",
      " 'of 24 million units  a day in a single daily dose for 10 days is recommended '\n",
      " '• if procaine penicillin g is not available ceftriaxone in doses  for age '\n",
      " 'and weight can be considered with thorough clinical  and serologic followup '\n",
      " 'infants and children receiving  ceftriaxone should be managed in '\n",
      " 'consultation with an expert  because evidence is insufficient to support use '\n",
      " 'of ceftriaxone  for treatment of congenital syphilis among infants or '\n",
      " 'children  for infants aged ≥30 days use ceftriaxone 75 mgkg body  weightday '\n",
      " 'iv or im in a single daily dose for 10–14 days  dose adjustment might be '\n",
      " 'necessary on the basis of current  weight for children ceftriaxone 100 mgkg '\n",
      " 'body weight day in a single daily dose is recommended • for infants and '\n",
      " 'children without any clinical evidence of  infection see scenario 2 and '\n",
      " 'scenario 3 use  ű procaine penicillin g 50000 unitskg body weightdose  im up '\n",
      " 'to the adult dose of 24 million units a day in a  single dose for 10 days '\n",
      " 'or  ű benzathine penicillin g 50000 unitskg body weight  im up to the adult '\n",
      " 'dose of 24 million units as a  single dose • if any part of the evaluation '\n",
      " 'for congenital syphilis is  abnormal or not performed csf examination is '\n",
      " 'not  interpretable or followup is uncertain procaine penicillin  g is '\n",
      " 'recommended in these scenarios a single dose of  ceftriaxone is inadequate '\n",
      " 'therapy hiv infection evidence is insufficient to determine whether infants '\n",
      " 'and  children who have congenital syphilis and hiv infection or  whose '\n",
      " 'mothers have hiv require different therapy or clinical  management than what '\n",
      " 'is recommended for all infants and  children all infants and children with '\n",
      " 'congenital syphilis  should be managed similarly regardless of hiv status '\n",
      " 'management of persons who have a  history of penicillin allergy penicillin '\n",
      " 'and other ßlactam antibiotics have a crucial  role in treating stis '\n",
      " 'penicillin is recommended for all  clinical stages of syphilis and no proven '\n",
      " 'alternatives exist for  treating neurosyphilis congenital syphilis or '\n",
      " 'syphilis during  pregnancy ceftriaxone a thirdgeneration cephalosporin is  '\n",
      " 'recommended for gonorrhea treatment for extragenital site  infections '\n",
      " 'especially pharyngeal failure rates of nonceftriaxone  recommendations and '\n",
      " 'reports mmwr  july 23 2021  vol 70  no 4 57us department of health and human '\n",
      " 'servicescenters for disease control and prevention regimens can be '\n",
      " 'substantial in most clinical settings patients  who report a penicillin '\n",
      " 'allergy are not treated with ßlactam  antimicrobials for patients with a '\n",
      " 'diagnosis of gonorrhea and  a concomitant reported allergy to penicillin '\n",
      " 'ceftriaxone is often  avoided even though the crossreactivity between '\n",
      " 'penicillin  allergy and thirdgeneration cephalosporins is low 652–654 '\n",
      " 'prevalence of reported allergy to penicillin is approximately  10 among the '\n",
      " 'us population and higher among hospital  inpatients and residents in health '\n",
      " 'care–related facilities 655– 658 one large study in an sti clinic revealed '\n",
      " 'that 83 of  patients reported penicillin or another ßlactam antibiotic  '\n",
      " 'allergy 659 penicillin allergy is often overreported with the  majority of '\n",
      " 'patients who report penicillin allergy able to tolerate  the medication 660 '\n",
      " 'the prevalence of reported penicillin  allergy in lowincome countries is '\n",
      " 'unknown however limited  data indicate that penicillin is one of the most '\n",
      " 'frequently  reported antibiotic allergies 661 patients often are incorrectly '\n",
      " 'labeled as allergic to penicillin  and are therefore denied the benefit of a '\n",
      " 'ßlactam therapy  the presence of a penicillin allergy label considerably '\n",
      " 'reduces  prescribing options for affected patients moreover penicillin  '\n",
      " 'allergy labels lead to the use of more expensive and less effective  drugs '\n",
      " 'and can result in adverse consequences including longer  length of hospital '\n",
      " 'stay and increased risk for infection multiple  studies have described that '\n",
      " 'persons with reported penicillin or  another ßlactam antibiotic allergy have '\n",
      " 'higher rates of surgical site infections methicillinresistant staphylococcus '\n",
      " 'aureus  infections and higher medical care usage 653662–664 the overreported '\n",
      " 'prevalence of penicillin allergy is  secondary to imprecise use of the term '\n",
      " '“allergy” by families  and clinicians and lack of clarity to differentiate '\n",
      " 'between  immunoglobulin e igemediated hypersensitivity reactions  drug '\n",
      " 'intolerances and other idiosyncratic reactions that can  occur days after '\n",
      " 'exposure approximately 80 of patients  with a true igemediated allergic '\n",
      " 'reaction to penicillin have  lost the sensitivity after 10 years 658 thus '\n",
      " 'patients with  recent reactions are more likely to be allergic than '\n",
      " 'patients  with remote reactions and patients who had allergic reactions  in '\n",
      " 'the distant past might no longer be reactive in a baltimore maryland sti '\n",
      " 'clinic study only 71 of  the patients who reported allergy to penicillin or '\n",
      " 'to another  ßlactam antibiotic had an objective positive test for '\n",
      " 'penicillin  allergy 659 moreover in studies that have incorporated  '\n",
      " 'penicillin skin testing and graded oral challenge among persons  with '\n",
      " 'reported penicillin allergy the true rates of allergy are low  ranging from '\n",
      " '15 to 61 665–667 studies in preoperative  surgical patients with reported '\n",
      " 'penicillin allergy evaluated  for cardiovascular surgery 668 or orthopedics '\n",
      " '669 have  rates of skin test positivity 85 however when patients  with '\n",
      " 'highrisk penicillin allergy histories are excluded 99  of patients could '\n",
      " 'receive ßlactams in hospitalized patients  and other populations with '\n",
      " 'comorbidities the typical rates of  validated penicillin allergy among '\n",
      " 'patients who report a history  of penicillin allergy are 25–90 670–673 '\n",
      " 'crossreactivity with cephalosporins penicillin and cephalosporins both '\n",
      " 'contain a ßlactam ring  this structural similarity has led to considerable '\n",
      " 'confusion  regarding crossreactivity of these drugs and the risks for  '\n",
      " 'allergic reactions from cephalosporins among penicillin allergic patients in '\n",
      " 'most clinical settings patients with  reported penicillin allergy are '\n",
      " 'precluded from treatment  with such cephalosporin antibiotics as ceftriaxone '\n",
      " 'third generation cephalosporins eg ceftriaxone and cefixime have  lower '\n",
      " 'crossreactivity with igemediated penicillinallergic  patients 1 compared '\n",
      " 'with first and secondgeneration  cephalosporins range 1–8 moreover '\n",
      " 'anaphylaxis  secondary to cephalosporins is extremely rare among persons  '\n",
      " 'who report a penicillin allergy and is estimated to occur at a rate  of one '\n",
      " 'per 52000 persons 652 data from the kaiser health  care system reported that '\n",
      " 'among 3313 patients with self reported cephalosporin allergy who received a '\n",
      " 'cephalosporin  mostly first generation no cases of anaphylaxis were '\n",
      " 'reported  652 use of third and fourthgeneration cephalosporins  and '\n",
      " 'carbapenems is safe for patients without a history of any  igemediated '\n",
      " 'symptoms eg anaphylaxis or urticaria from  penicillin during the preceding '\n",
      " '10 years validating penicillin or another ßlactam  antibiotic allergy '\n",
      " 'evaluating a patient who reports a penicillin or another  ßlactam antibiotic '\n",
      " 'allergy involves three steps 1 obtaining  a thorough medical history '\n",
      " 'including previous exposures to  penicillin or other ßlactam antibiotics 658 '\n",
      " '2 performing  a skin test evaluation by using the penicillin major and '\n",
      " 'minor  determinants and 3 among those who have a negative  penicillin skin '\n",
      " 'test performing an observed oral challenge with  250 mg amoxicillin before '\n",
      " 'proceeding directly to treatment  with the indicated ßlactam therapy 667675 '\n",
      " 'for persons who have a positive skin test reactive to penicillin  either to '\n",
      " 'the major or minor determinants treatment with a  ßlactam antibiotic is not '\n",
      " 'usually advised and other effective  antimicrobials should be used 656658 '\n",
      " 'for persons among  whom the only therapy option is a penicillin antibiotic '\n",
      " 'eg a  patient with neurosyphilis or a pregnant woman with syphilis  and '\n",
      " 'among whom a penicillin skin test is positive induction  of penicillin '\n",
      " 'tolerance also referred to as desensitization is  required 675 '\n",
      " 'desensitization protocols to penicillin should  recommendations and reports '\n",
      " '58 mmwr  july 23 2021  vol 70  no 4 us department of health and human '\n",
      " 'servicescenters for disease control and prevention be performed by '\n",
      " 'allergists and they require a monitored  inpatient environment penicillin '\n",
      " 'skin testing penicillin skin testing with a major determinant  analog '\n",
      " 'penicilloylpolylysine and minor determinants  benzylpenicilloate '\n",
      " 'benzylpenilloate or benzylpenicillin  isomers of penicillin are used for '\n",
      " 'skin test evaluation for  igedependent penicillin allergy and can reliably '\n",
      " 'identify  persons at high risk for igemediated reactions to penicillin  '\n",
      " '658660676 until recently penicillin skin testing in the  united states only '\n",
      " 'included the major determinant benzyl  penicillin polyllysine prepen in '\n",
      " 'addition to penicillin  g this test identifies approximately 90–99 of the '\n",
      " 'ige mediated penicillinallergic patients because the remaining  1–10 of '\n",
      " 'penicillinallergic patients who are not captured  by this penicillin skin '\n",
      " 'test are due to minor determinants ige  antibodies the standard practice is '\n",
      " 'to follow skin testing with  an observed oral challenge of amoxicillin 250 '\n",
      " 'mg with 1 hour  of observation if the skin test and oral challenge are both  '\n",
      " 'negative the risk for igemediated anaphylaxis approaches zero  and is '\n",
      " 'equivalent to that of a person who has never reported  an allergy to '\n",
      " 'penicillin a revised version of the penicillin skin test kit which includes  '\n",
      " 'the major determinant reagent prepen minor determinants  and amoxicillin is '\n",
      " 'being evaluated by fda this penicillin  skin test kit has been evaluated '\n",
      " 'among 455 patients 677  with previous allergy history and has a negative '\n",
      " 'predictive  value of 98 if approved this kit might eliminate the need  for '\n",
      " 'oral challenge penicillin skin testing has become a clinically significant  '\n",
      " 'element in antibiotic stewardship programs and the  procedure has been '\n",
      " 'increasingly used by hospitalbased  pharmacists hospitalists and infectious '\n",
      " 'disease physicians  670672673678679 as part of overall antibiotic '\n",
      " 'stewardship  interventions when integrated into stewardship the rates of  '\n",
      " 'ßlactam antibiotic use increased substantially 670 recommendations persons '\n",
      " 'with a history of severe adverse cutaneous  reaction eg stevensjohnson '\n",
      " 'syndrome or toxic epidermal  necrolysis and other severe non–igemediated '\n",
      " 'reactions eg  interstitial nephritis or hemolytic anemia are not candidates  '\n",
      " 'for penicillin skin testing or challenge penicillin and any  other ßlactam '\n",
      " 'antibiotics should be avoided indefinitely  among these patients who should '\n",
      " 'be referred to an allergy  center for further evaluation similarly patients '\n",
      " 'who deny  penicillin allergy but who report previous igetype reactions  to '\n",
      " 'cephalosporins should be referred to an allergist for specific  '\n",
      " 'cephalosporin testing in a time of increasing antimicrobial resistance '\n",
      " 'following  recommended use of antibiotic treatments is crucial sti  programs '\n",
      " 'and clinicians should promote increased access to  penicillin allergy '\n",
      " 'testing allergy testing is being provided by  clinicians in primary care and '\n",
      " 'hospital settings if appropriate  sti programs and ambulatory settings '\n",
      " 'should consider  developing expanded access to penicillin or ßlactam '\n",
      " 'allergy  assessment persons with highrisk symptom histories eg anaphylaxis  '\n",
      " 'within the previous 10 years should not be administered  penicillin or a '\n",
      " 'ßlactam antibiotic in an ambulatory setting  furthermore these persons with '\n",
      " 'highrisk symptoms should  not receive penicillin skin testing or amoxicillin '\n",
      " 'oral challenge  in an ambulatory sti setting and should be referred to an  '\n",
      " 'allergist for further evaluation highrisk symptom histories include '\n",
      " 'development of  the following after penicillin or ßlactam administration  '\n",
      " 'anaphylaxis within 6 hours or severe adverse cutaneous reaction  eg '\n",
      " 'eosinophilia and systemic symptoms stevensjohnson  syndrome toxic epidermal '\n",
      " 'necrolysis or acute generalized  exanthematous pustulosis and other severe '\n",
      " 'non–igemediated  reactions eg kidney or hepatic injury hemolytic anemia or  '\n",
      " 'thrombocytopenia direct treatment approach for ceftriaxone among persons '\n",
      " 'with confirmed igemediated penicillin  allergy the level of crossreactivity '\n",
      " 'with thirdgeneration  cephalosporins is low 652680681 if a patient has a low '\n",
      " 'risk history for an igemediated penicillin allergy ambulatory  settings '\n",
      " 'often treat with thirdgeneration cephalosporins  without further testing '\n",
      " 'lowrisk history includes one  nonspecific symptom eg gastrointestinal '\n",
      " 'intolerance  headache fatigue or nonurticarial rash box 2 in addition  a '\n",
      " 'family history of penicillin or ßlactam allergy alone is not a  '\n",
      " 'contraindication for treatment with ßlactam antibiotics this  practice is '\n",
      " 'increasingly being used in ambulatory settings and  for preoperative '\n",
      " 'prophylaxis 658663680682–684 box 2 lowrisk history in patients who report '\n",
      " 'penicillin allergy gastrointestinal symptoms headache pruritis without rash '\n",
      " 'localized rash delayed onset rash 24 hours symptoms unknown family history '\n",
      " 'of penicillin or another drug allergy patient denies allergy but it is on '\n",
      " 'the medical record recommendations and reports mmwr  july 23 2021  vol 70  '\n",
      " 'no 4 59us department of health and human servicescenters for disease control '\n",
      " 'and prevention patients at low risk for oral challenge if the patient gives '\n",
      " 'only a lowrisk history of igemediated  penicillin allergy that includes '\n",
      " 'symptoms such gastrointestinal  intolerance headache fatigue or nonspecific '\n",
      " 'pruritus or gives  a family history only an oral challenge can be '\n",
      " 'administered  to document the absence of allergy box 2 if the reaction  '\n",
      " 'occurred in the distant past 10 years the likelihood is  reduced even '\n",
      " 'further 653658663682683685686 the  risk for severe amoxicillinmediated '\n",
      " 'anaphylaxis has decreased  over time and is rare in the united kingdom '\n",
      " 'during 1972– 2007 one fatal case of amoxicillinmedicated anaphylaxis was  '\n",
      " 'reported 684  skin testing for penicillin allergy skin testing for '\n",
      " 'penicillin allergy should be performed if  any indication exists that the '\n",
      " 'symptoms were secondary to an  igemediated hypersensitivity testing is also '\n",
      " 'indicated as a  potential diagnostic procedure to definitively rule out '\n",
      " 'penicillin  allergy and document a negative allergy status in the medical  '\n",
      " 'record ie delabeling because penicillin allergy testing  does not test for '\n",
      " 'multiple minor determinants a person with  a negative skin test should '\n",
      " 'follow up with an oral challenge to  confirm the negative status persons '\n",
      " 'with negative results of a penicillin skin test followed by  an amoxicillin '\n",
      " 'oral challenge can receive conventional penicillin  therapy safely if needed '\n",
      " 'persons with positive skin test results and  for whom no other clinical '\n",
      " 'options exist eg neurosyphilis and  syphilis in a pregnant woman should be '\n",
      " 'referred to an allergist  and desensitized before initiating treatment '\n",
      " 'testing procedures penicillin skin testing includes use of skin test '\n",
      " 'reagents for  identifying persons at risk for adverse reactions box 3 '\n",
      " 'followed  by initial pinprick screening with penicillin major determinants  '\n",
      " 'prepen and penicillin g followed by intradermal testing if  pinprick results '\n",
      " 'are negative penicillin testing procedures are  performed in accordance with '\n",
      " 'the prepen test kit instructions  '\n",
      " 'httpspenallergytestcomwpcontentuploadsprepen packageinsertpdf  saline '\n",
      " 'negative controls and histamine  positive controls are an integral part of '\n",
      " 'the procedure penicillin  skin testing should not be performed for patients '\n",
      " 'who have  taken antihistamines within the past 7 days skin testing can be '\n",
      " 'safely performed by trained  nonallergists and has been implemented as an '\n",
      " 'antimicrobial  stewardship intervention by internal medicine physicians  '\n",
      " 'pharmacists hospitalists and infectious disease physicians  670673678679 '\n",
      " 'patients tested should also receive  documentation of status and the results '\n",
      " 'should be entered in  the medical record penicillin skin testing during '\n",
      " 'pregnancy is considered safe  for pregnant persons who report a penicillin '\n",
      " 'or ßlactam  allergy penicillin allergy is an important consideration in  '\n",
      " 'treating syphilis during pregnancy and the potential for group  b '\n",
      " 'streptococcal infection and preoperative prophylaxis if a  cesarean delivery '\n",
      " 'is required however oral challenges should  not be performed unless in a '\n",
      " 'setting where additional support  services are available managing persons '\n",
      " 'being tested patients who have a positive skin test should not receive  '\n",
      " 'ßlactam drugs in the ambulatory setting and should be  referred to an '\n",
      " 'allergist or penicillin allergy expert for further  evaluation the allergy '\n",
      " 'testing results should be documented  in the medical record patients who '\n",
      " 'test negative should be  informed that their risk for anaphylaxis is '\n",
      " 'extremely low and is  equivalent to a person who does not report an allergy '\n",
      " 'history if  treatment with penicillin or ceftriaxone is indicated it can be  '\n",
      " 'administered safely documentation of testing results should  be provided to '\n",
      " 'the patient desensitization desensitization is required for persons who have '\n",
      " 'a  documented penicillin allergy and for whom no therapeutic  alternatives '\n",
      " 'exist eg syphilis during pregnancy and persons  with neurosyphilis modified '\n",
      " 'protocols might be considered  box 3 skin test reagents for identifying '\n",
      " 'persons at risk for  adverse reactions to penicillin major determinant • '\n",
      " 'benzylpenicilloyl polylysine injection prepen  allerquest 6 × 105m minor '\n",
      " 'determinant precursors • benzylpenicillin g 102m 33 mgml 10000 unitsml • '\n",
      " 'benzylpenicilloate 102m 33 mgml • benzylpenicilloate or penicilloyl '\n",
      " 'propylamine  102m 33 mgml aged penicillin is not an adequate source of '\n",
      " 'minor  determinants penicillin g should either be freshly  prepared or come '\n",
      " 'from a freshfrozen source positive control • commercial histamine for '\n",
      " 'scratch testing 10 mgml negative control • diluent usually saline or '\n",
      " 'allergen diluent source adapted from saxon a beall gn rohr as adelman dc '\n",
      " 'immediate  hypersensitivity reactions to betalactam antibiotics ann intern '\n",
      " 'med  1987107204−15 '\n",
      " 'httpspenallergytestcomwpcontentuploadsprepenpackageinsertpdf '\n",
      " 'httpspenallergytestcomwpcontentuploadsprepenpackageinsertpdf recommendations '\n",
      " 'and reports 60 mmwr  july 23 2021  vol 70  no 4 us department of health and '\n",
      " 'human servicescenters for disease control and prevention on the basis of the '\n",
      " 'clinical syndrome drug of choice and route  of administration 687–690 '\n",
      " 'patients might require referral  to a specialty center where desensitization '\n",
      " 'can be performed allergy referral resources with increased access to skin '\n",
      " 'testing kits and the need to  better target therapy for gonorrhea and '\n",
      " 'syphilis programs  should identify local allergy consultant resources '\n",
      " 'diseases characterized by urethritis  and cervicitis urethritis urethritis '\n",
      " 'as characterized by urethral inflammation can  result from either infectious '\n",
      " 'or noninfectious conditions  symptoms if present include dysuria urethral '\n",
      " 'pruritis  and mucoid mucopurulent or purulent discharge signs of  urethral '\n",
      " 'discharge on examination can also be present among  persons without symptoms '\n",
      " 'although n gonorrhoeae and c  trachomatis are well established as clinically '\n",
      " 'important infectious  causes of urethritis m genitalium has been strongly '\n",
      " 'associated  with urethritis and less commonly prostatitis 691–697 if  poc '\n",
      " 'diagnostic tools eg gram methylene blue mb or  gentian violet gv stain '\n",
      " 'microscopy are unavailable drug  regimens effective against both gonorrhea '\n",
      " 'and chlamydia  should be administered further testing to determine the  '\n",
      " 'specific etiology is recommended for preventing complications  reinfection '\n",
      " 'and transmission because a specific diagnosis might  improve treatment '\n",
      " 'compliance delivery of riskreduction  interventions and partner services '\n",
      " 'both chlamydia and  gonorrhea are reportable to health departments naats '\n",
      " 'are  preferred for detecting c trachomatis and n gonorrhoeae and  urine is '\n",
      " 'the preferred specimen for males 553 naatbased  tests for diagnosing t '\n",
      " 'vaginalis among men with urethritis  have not been cleared by fda however '\n",
      " 'laboratories have  performed the cliacompliant validation studies 698  '\n",
      " 'needed to provide such testing etiology multiple organisms can cause '\n",
      " 'infectious urethritis the  presence of gramnegative intracellular diplococci '\n",
      " 'gnid  or purple intracellular diplococci mb or gv on urethral  smear is '\n",
      " 'indicative of presumed gonococcal infection  which is frequently accompanied '\n",
      " 'by chlamydial infection  nongonococcal urethritis ngu which is diagnosed '\n",
      " 'when  microscopy of urethral secretions indicate inflammation  without gnid '\n",
      " 'or mb or gv purple intracellular diplococci  is caused by c trachomatis in '\n",
      " '15–40 of cases however  prevalence varies by age group with a lower '\n",
      " 'proportion of  disease occurring among older men 699 documentation  of '\n",
      " 'chlamydial infection as ngu etiology is essential because  of the need for '\n",
      " 'partner referral for evaluation and treatment  to prevent complications of '\n",
      " 'chlamydia especially for female  partners complications of c '\n",
      " 'trachomatis–associated ngu  among males include epididymitis prostatitis and '\n",
      " 'reactive  arthritis m genitalium is associated with symptoms of urethritis '\n",
      " 'and  urethral inflammation and accounts for 15–25 of ngu  cases in the '\n",
      " 'united states 691–693696697700 among  men with symptoms of urethritis m '\n",
      " 'genitalium was detected  in 11 of those with urethritis in australia 701 '\n",
      " '12–15  in the united kingdom 702–704 15 in south africa 696  19 in china 705 '\n",
      " '21 in korea 22 in japan 706 and  287 in the united states range 204–388 697 '\n",
      " 'data  are inconsistent regarding other mycoplasma and ureaplasma  species as '\n",
      " 'etiologic agents of urethritis 707 the majority  of men with ureaplasma '\n",
      " 'infections do not have overt disease  unless a high organism load is present '\n",
      " 't vaginalis can cause urethritis among heterosexual  men however the '\n",
      " 'prevalence varies substantially by us  geographic region age and sexual '\n",
      " 'behavior and within specific  populations studies among men with and without '\n",
      " 'overt  urethritis in developed countries document relatively low  rates of t '\n",
      " 'vaginalis in the netherlands 05 708 japan  13 706709 the united states 24 '\n",
      " '710 and the  united kingdom 36 703 studies in other countries have  '\n",
      " 'documented higher rates such as in croatia 82 711 and  zimbabwe 84 712 '\n",
      " 'particularly among symptomatic  patients neisseria meningitidis can colonize '\n",
      " 'mucosal surfaces and  cause urethritis 713 urogenital n meningitidis rates  '\n",
      " 'and duration of carriage prevalence of asymptomatic and  symptomatic '\n",
      " 'infection and modes of transmission have  not been systematically described '\n",
      " 'however studies indicate  that n meningitidis can be transmitted through '\n",
      " 'oral penile contact ie fellatio 714–716 n meningitidis  has similar colony '\n",
      " 'morphology appearance on culture and  cannot be distinguished from n '\n",
      " 'gonorrhoeae on gram stain  identification of n meningitidis as the etiologic '\n",
      " 'agent with  presumed gonococcal urethritis on the basis of gram stain  but '\n",
      " 'negative naat for gonorrhea requires a confirmation  by culture '\n",
      " 'meningococcal urethritis is treated with the same  antimicrobial regimens as '\n",
      " 'gonococcal urethritis although  evidence is limited regarding the risk for '\n",
      " 'sexual transmission or  recurrent infections with meningococcal urethritis '\n",
      " 'treatment  of sex partners of patients with meningococcal urethritis with  '\n",
      " 'the same antimicrobial regimens as for exposure to gonococcal  infection can '\n",
      " 'be considered no indication exists for treating  recommendations and reports '\n",
      " 'mmwr  july 23 2021  vol 70  no 4 61us department of health and human '\n",
      " 'servicescenters for disease control and prevention persons with n '\n",
      " 'meningitidis identified in their oropharynx  when not also associated with '\n",
      " 'symptomatic urethritis in other instances ngu can be caused by hsv epstein '\n",
      " 'barr virus and adenovirus 699 acquired by fellatio ie oral penile contact in '\n",
      " 'a retrospective review of 80 cases of hsv  urethritis in australia 717 the '\n",
      " 'majority of infections were  associated with hsv1 with clinical findings of '\n",
      " 'meatitis 62  genital ulceration 37 and dysuria 20 adenovirus can  present '\n",
      " 'with dysuria meatal inflammation and conjunctivitis  718 enteric bacteria '\n",
      " 'have been identified as an uncommon  cause of ngu and might be associated '\n",
      " 'with insertive anal  intercourse 699 other bacterial pathogens have been '\n",
      " 'implicated as potential  causes of clinical urethritis either in clustered '\n",
      " 'case series or as  sporadic cases such as haemophilus influenzae and '\n",
      " 'haemophilus  parainfluenzae 719–723 haemophilus was identified in 126  of '\n",
      " 'cases among 413 men mostly msm reporting insertive oral  sex 724 and high '\n",
      " 'rates of azithromycin resistance 395  were identified among haemophilus '\n",
      " 'urethritis patients 725  individual case reports have linked ngu to multiple '\n",
      " 'bacterial  species including corynebacterium propinquum 726 kurthia  '\n",
      " 'gibsonii 727 corynebacterium glucuronolyticum 728729  corynebacterium '\n",
      " 'striatrium 730 aerococcus urinae 731  and neisseria elongata 732 diagnostic '\n",
      " 'testing and treatment  for lesscommon organisms are reserved for situations '\n",
      " 'in  which these infections are suspected eg sexual partner with  '\n",
      " 'trichomoniasis urethral lesions or severe dysuria and meatitis  or when ngu '\n",
      " 'is not responsive to recommended therapy even in settings that provide '\n",
      " 'comprehensive diagnostic  testing etiology can remain obscure in half of '\n",
      " 'cases idiopathic  ngu was reported in 772 59 of 1295 first presentations  of '\n",
      " 'ngu among men seeking sexual health services in australia  701 in a '\n",
      " 'casecontrol study of 211 men with ngu  symptoms in denmark no identifiable '\n",
      " 'pathogen was identified  in 24 of acute cases and 33 of chronic cases 733 '\n",
      " 'ngu’s  importance if not caused by a defined pathogen is uncertain  neither '\n",
      " 'complications eg urethral stricture or epididymitis  nor adverse outcomes '\n",
      " 'among sex partners have been identified  in these cases associations between '\n",
      " 'ngu and insertive anal and oral  exposure have been reported 734 as have '\n",
      " 'higher rates  of bvassociated leptotrichia or sneathia species among  '\n",
      " 'heterosexual men with urethritis 735 these studies increase  concern for '\n",
      " 'possible undetected infectious rectal or vaginal  pathogens or alternatively '\n",
      " 'a transient reactive dysbiosis after  exposure to a new microbiome or even a '\n",
      " 'noninfectious reactive  etiology 736 diagnostic considerations clinicians '\n",
      " 'should attempt to obtain objective evidence of  urethral inflammation if poc '\n",
      " 'diagnostic tests eg gram  stain or mb or gv microscopy are unavailable '\n",
      " 'urethritis  can be documented on the basis of any of the following signs  or '\n",
      " 'laboratory tests • mucoid mucopurulent or purulent discharge on examination '\n",
      " '• gram stain is a poc diagnostic test for evaluating  urethritis that is '\n",
      " 'highly sensitive and specific for  documenting both urethritis and the '\n",
      " 'presence or absence  of gonococcal infection mb or gv stain of urethral  '\n",
      " 'secretions is an alternative poc diagnostic test with  performance '\n",
      " 'characteristics similar to gram stain thus  the cutoff number for wbcs per '\n",
      " 'oil immersion field  should be the same 737  ű presumed gonococcal infection '\n",
      " 'is established by  documenting the presence of wbcs containing gnid  in gram '\n",
      " 'stain or intracellular purple diplococci in mb  or gv smears men should be '\n",
      " 'tested for c trachomatis  and n gonorrhoeae by naats and presumptively '\n",
      " 'treated  and managed accordingly for gonococcal infection see  gonococcal '\n",
      " 'infections  ű if no intracellular gramnegative or purple diplococci  are '\n",
      " 'present men should receive naats for c trachomatis  and n gonorrhoeae and '\n",
      " 'can be managed for ngu as  recommended see nongonococcal urethritis  ű gram '\n",
      " 'stain of urethral secretions exist that demonstrate  ≥2 wbcs per oil '\n",
      " 'immersion field 738 the microscopy  diagnostic cutoff might vary depending '\n",
      " 'on background  prevalence ≥2 wbcshigh power field hpf in high prevalence '\n",
      " 'settings sti clinics or ≥5 wbcshpf in  lowerprevalence settings§§ §§ for '\n",
      " 'urethral microscopy the cutoff for diagnosing urethritis is ≥2 wbcshpf  '\n",
      " 'sources rietmeijer ca mettenbrink cj recalibrating the gram stain  diagnosis '\n",
      " 'of male urethritis in the era of nucleic acid amplification testing sex  '\n",
      " 'transm dis 20123918–20 rietmeijer ca mettenbrink cj the diagnosis  of '\n",
      " 'nongonococcal urethritis in men can there be a universal standard sex  '\n",
      " 'transm dis 201744195–6 an additional evaluation supported this cutoff  by '\n",
      " 'demonstrating ngu sensitivity of 926 for cutoff of ≥2 versus 556  '\n",
      " 'sensitivity for cutoff of ≥5 source sarier m sepin n duman i et al  '\n",
      " 'microscopy of gramstained urethral smear in the diagnosis of urethritis '\n",
      " 'which  threshold value should be selected andrologia 201850e13143 '\n",
      " 'diagnostic  cutoffs for 369 symptomatic and asymptomatic heterosexual men '\n",
      " 'seeking sti  care in seattle revealed a maximal sensitivity and specificity '\n",
      " 'achieved with a  cutoff of ≥5 wbcshpf using a lower cutoff of ≥2 wbcshpf '\n",
      " 'would miss  13 of c trachomatis and m genitalium and overtreat 45 of persons '\n",
      " 'who  have negative tests source leipertz g chambers l lowens s et al p796  '\n",
      " 'reassessing the gram stain smear gss polymorphonuclear leukocyte pmn  cutoff '\n",
      " 'for diagnosing nongonococcal urethritis ngu sex transm infect  201995suppl '\n",
      " '1a339 another study discussed that the wbchpf cutoff  value should '\n",
      " 'discriminate on the basis of the prevalence of chlamydia  mycoplasma and '\n",
      " 'gonorrhea among a clinic population source moi h  hartgill u skullerud kh '\n",
      " 'reponen ej syvertsen l moghaddam a  microscopy of stained urethral smear in '\n",
      " 'male urethritis which cutoff should  be used sex transm dis 201744189–94 '\n",
      " 'recommendations and reports 62 mmwr  july 23 2021  vol 70  no 4 us '\n",
      " 'department of health and human servicescenters for disease control and '\n",
      " 'prevention • positive leukocyte esterase test on firstvoid urine or  '\n",
      " 'microscopic examination of sediment from a spun first void urine '\n",
      " 'demonstrating ≥10 wbcshpf men evaluated in settings in which gram stain or '\n",
      " 'mb or  gv smear is unavailable who meet at least one criterion for  '\n",
      " 'urethritis ie urethral discharge positive leukocyte esterase  test on first '\n",
      " 'void urine or microscopic examination of first void urine sediment with ≥10 '\n",
      " 'wbcshpf should be tested  for c trachomatis and n gonorrhoeae by naats and '\n",
      " 'treated  with regimens effective against gonorrhea and chlamydia if symptoms '\n",
      " 'are present but no evidence of urethral  inflammation is present naats for c '\n",
      " 'trachomatis and  n gonorrhoeae might identify infections 739 persons  with '\n",
      " 'chlamydia or gonorrhea should receive recommended  treatment and sex '\n",
      " 'partners should be referred for evaluation  and treatment if none of these '\n",
      " 'clinical criteria are present  empiric treatment of men with symptoms of '\n",
      " 'urethritis is  recommended only for those at high risk for infection who '\n",
      " 'are  unlikely to return for a followup evaluation or test results such  men '\n",
      " 'should be treated with drug regimens effective against  gonorrhea and '\n",
      " 'chlamydia nongonococcal urethritis ngu is a nonspecific diagnosis that can '\n",
      " 'have various  infectious etiologies c trachomatis has been well established  '\n",
      " 'as an ngu etiology however prevalence varies across  populations and '\n",
      " 'accounts for 50 of overall cases 712740– 742 m genitalium is estimated to '\n",
      " 'account for 10–25 of  cases 696697701703704706733743 and t vaginalis  for '\n",
      " '1–8 of cases depending on population and location  703706708710712 other '\n",
      " 'etiologies include different  bacteria such as haemophilus species 724725 n '\n",
      " 'meningitidis  713716 hsv 706717 and adenovirus 744 however  even when '\n",
      " 'extensive testing is performed no pathogens are  identified in approximately '\n",
      " 'half of cases 701733 diagnostic considerations clinical presentation can '\n",
      " 'include urethral discharge  irritation dysuria or meatal pruritus 697743745 '\n",
      " 'ngu is  confirmed for symptomatic men when diagnostic evaluation of  '\n",
      " 'urethral secretions indicates inflammation without evidence  of diplococci '\n",
      " 'by gram mb or gv smear on microscopy  712746747 visible discharge or '\n",
      " 'secretions can be collected  by a swab without inserting it into the urethra '\n",
      " 'if no visible  secretions the swab can be inserted into the urethral meatus  '\n",
      " 'and rotated making contact with the urethral wall before  removal if '\n",
      " 'microscopy is unavailable urine testing for  leukocyte esterase can be '\n",
      " 'performed on firstvoid urine and  microscopic examination of sediment from a '\n",
      " 'spun firstvoid  urine demonstrating ≥10 wbcshpf has a high negative  '\n",
      " 'predictive value all men who have suspected or confirmed ngu should  be '\n",
      " 'tested for chlamydia and gonorrhea by using naats  a specific diagnosis can '\n",
      " 'potentially reduce complications  reinfection and transmission m genitalium '\n",
      " 'testing should be  performed for men who have persistent or recurrent '\n",
      " 'symptoms  after initial empiric treatment testing for t vaginalis should  be '\n",
      " 'considered in areas or among populations with high  prevalence in cases '\n",
      " 'where a partner is known to be infected  or for men who have persistent or '\n",
      " 'recurrent symptoms after  initial empiric treatment treatment ideally '\n",
      " 'treatment should be pathogen based however  diagnostic information might not '\n",
      " 'be immediately available  presumptive treatment should be initiated at ngu '\n",
      " 'diagnosis  doxycycline is highly effective for chlamydial urethral  '\n",
      " 'infections and is also effective for chlamydial infections of  the rectum it '\n",
      " 'also has some activity against m genitalium  in contrast reports have '\n",
      " 'increased of azithromycin treatment  failures for chlamydial infection '\n",
      " '748749 and the incidence  of macrolide resistance in m genitalium also has '\n",
      " 'been rapidly  rising 697702705750751 pharmacokinetic data indicate  that '\n",
      " 'changing azithromycin dosing from a singledose strategy  to a multiday '\n",
      " 'strategy might protect against inducing resistance  in m genitalium '\n",
      " 'infections 745752 see mycoplasma  genitalium recommended regimen for '\n",
      " 'nongonococcal urethritis doxycycline 100 mg orally 2 timesday for 7 days '\n",
      " 'alternative regimens azithromycin 1 g orally in a single dose or '\n",
      " 'azithromycin 500 mg orally in a single dose then 250 mg orally daily  for 4 '\n",
      " 'days to maximize compliance with recommended therapies  medications should '\n",
      " 'be dispensed onsite at the clinic and  regardless of the number of doses '\n",
      " 'involved in the regimen  the first dose should be directly observed '\n",
      " 'erythromycin is no  longer recommended for ngu because of its '\n",
      " 'gastrointestinal  side effects and dosing frequency levofloxacin is no '\n",
      " 'longer  recommended for ngu because of its inferior efficacy  especially for '\n",
      " 'm genitalium management considerations to minimize transmission and '\n",
      " 'reinfections men treated for  ngu should be instructed to abstain from '\n",
      " 'sexual intercourse  until they and their partners have been treated ie '\n",
      " 'until  recommendations and reports mmwr  july 23 2021  vol 70  no 4 63us '\n",
      " 'department of health and human servicescenters for disease control and '\n",
      " 'prevention completion of a 7day regimen and symptoms have resolved or  for 7 '\n",
      " 'days after singledose therapy men with ngu should  be tested for hiv and '\n",
      " 'syphilis followup men should be provided their testing results obtained as  '\n",
      " 'part of the ngu evaluation those with a specific diagnosis  of chlamydia '\n",
      " 'gonorrhea or trichomoniasis should be  offered partner services and '\n",
      " 'instructed to return 3 months  after treatment for repeat testing because of '\n",
      " 'high rates of  reinfection regardless of whether their sex partners were '\n",
      " 'treated  136137753754 see chlamydial infections gonococcal  infections '\n",
      " 'trichomoniasis if symptoms persist or recur after therapy completion men  '\n",
      " 'should be instructed to return for reevaluation and should be  tested for m '\n",
      " 'genitalium and t vaginalis symptoms alone  without documentation of signs or '\n",
      " 'laboratory evidence of  urethral inflammation are insufficient basis for '\n",
      " 'retreatment  providers should be alert to the possible diagnosis of chronic  '\n",
      " 'prostatitis or chronic pelvic pain syndrome in men experiencing  persistent '\n",
      " 'perineal penile or pelvic pain or discomfort  voiding symptoms pain during '\n",
      " 'or after ejaculation or new onset premature ejaculation lasting for 3 months '\n",
      " 'men with  persistent pain should be referred to a urologist with expertise  '\n",
      " 'in pelvic pain disorders management of sex partners all sex partners of men '\n",
      " 'with ngu within the preceding  60 days should be referred for evaluation and '\n",
      " 'testing and  presumptive treatment with a drug regimen effective against  '\n",
      " 'chlamydia all partners should be evaluated and treated  according to the '\n",
      " 'management section for their respective  pathogen ept could be an alternate '\n",
      " 'approach if a partner is  unable to access timely care to avoid reinfection '\n",
      " 'sex partners  should abstain from sexual intercourse until they and their  '\n",
      " 'partners are treated persistent or recurrent nongonococcal urethritis the '\n",
      " 'objective diagnosis of persistent or recurrent ngu  should be made before '\n",
      " 'considering additional antimicrobial  therapy symptomatic recurrent or '\n",
      " 'persistent urethritis might  be caused by treatment failure or reinfection '\n",
      " 'after successful  treatment among men who have persistent symptoms after  '\n",
      " 'treatment without objective signs of urethral inflammation the  value of '\n",
      " 'extending the duration of antimicrobials has not been  demonstrated '\n",
      " 'treatment failure for chlamydial urethritis has  been estimated at 6–12 755 '\n",
      " 'the most common cause  of persistent or recurrent ngu is m genitalium '\n",
      " 'especially  after doxycycline therapy 756757 treatment failure for  m '\n",
      " 'genitalium is harder to determine because certain men  achieve clinical cure '\n",
      " 'ie resolution of symptoms but can  still have detectable m genitalium in '\n",
      " 'urethral specimens 758 the initial step in recurrent urethritis is assessing '\n",
      " 'compliance  with treatment or potential reexposure to an untreated sex  '\n",
      " 'partner 697743 if the patient did not comply with the  treatment regimen or '\n",
      " 'was reexposed to an untreated partner  retreatment with the initial regimen '\n",
      " 'can be considered if  therapy was appropriately completed and no reexposure  '\n",
      " 'occurred therapy is dependent on the initial treatment  regimen ideally '\n",
      " 'diagnostic testing among men with recurrent  or persistent symptoms '\n",
      " 'including those with gonorrhea  chlamydia m genitalium and trichomoniasis '\n",
      " 'can be used to  guide further management decisions t vaginalis is also known '\n",
      " 'to cause urethritis among men who  have sex with women in areas where t '\n",
      " 'vaginalis is prevalent  men who have sex with women with persistent or '\n",
      " 'recurrent  urethritis should be tested for t vaginalis and presumptively  '\n",
      " 'treated with metronidazole 2 g orally in a single dose or  tinidazole 2 g '\n",
      " 'orally in a single dose their partners should be  referred for evaluation '\n",
      " 'and treatment if needed if t vaginalis is unlikely msm with ngu or negative  '\n",
      " 't vaginalis naat men with recurrent ngu should be tested  for m genitalium '\n",
      " 'by using an fdacleared naat treatment  for m genitalium includes a twostage '\n",
      " 'approach ideally using  resistanceguided therapy if m genitalium resistance '\n",
      " 'testing is  available it should be performed and the results should be used  '\n",
      " 'to guide therapy see mycoplasma genitalium if m genitalium  resistance '\n",
      " 'testing is not available doxycycline 100 mg orally  2 timesday for 7 days '\n",
      " 'followed by moxifloxacin 400 mg orally  once daily for 7 days should be used '\n",
      " 'the rationale for this  approach is that although not curative doxycycline '\n",
      " 'decreases  the m genitalium bacterial load thereby increasing likelihood  of '\n",
      " 'moxifloxacin success 759 higher doses of azithromycin  have not been '\n",
      " 'effective for m genitalium after azithromycin  treatment failures men with '\n",
      " 'persistent or recurrent ngu after  treatment for m genitalium or t vaginalis '\n",
      " 'should be referred  to an infectious disease or urology specialist special '\n",
      " 'considerations hiv infection ngu might facilitate hiv transmission 760 '\n",
      " 'persons with  ngu and hiv infection should receive the same treatment  '\n",
      " 'regimen as those who do not have hiv cervicitis two major diagnostic signs '\n",
      " 'characterize cervicitis 1 a  purulent or mucopurulent endocervical exudate '\n",
      " 'visible in  the endocervical canal or on an endocervical swab specimen  '\n",
      " 'commonly referred to as mucopurulent cervicitis and  recommendations and '\n",
      " 'reports 64 mmwr  july 23 2021  vol 70  no 4 us department of health and '\n",
      " 'human servicescenters for disease control and prevention 2 sustained '\n",
      " 'endocervical bleeding easily induced by gentle  passage of a cotton swab '\n",
      " 'through the cervical os either or both  signs might be present cervicitis '\n",
      " 'frequently is asymptomatic  however certain women might report an abnormal '\n",
      " 'vaginal  discharge and intermenstrual vaginal bleeding eg especially  after '\n",
      " 'sexual intercourse the criterion of using an increased  number of wbcs on '\n",
      " 'endocervical gram stain in the diagnosis  of cervicitis has not been '\n",
      " 'standardized it is not sensitive  has a low positive predictive value for c '\n",
      " 'trachomatis and  n gonorrhoeae infections and is not available in most '\n",
      " 'clinical  settings 297761 leukorrhea defined as 10 wbcshpf on  microscopic '\n",
      " 'examination of vaginal fluid might be a sensitive  indicator of cervical '\n",
      " 'inflammation with a high negative  predictive value ie cervicitis is '\n",
      " 'unlikely in the absence of  leukorrhea 762763 finally although the presence '\n",
      " 'of gram negative intracellular diplococci on gram stain of endocervical  '\n",
      " 'exudate might be specific for diagnosing gonococcal cervical  infection when '\n",
      " 'evaluated by an experienced laboratorian it is  not a sensitive indicator of '\n",
      " 'infection 764 etiology c trachomatis or n gonorrhoeae is the most common '\n",
      " 'etiology  of cervicitis defined by diagnostic testing trichomoniasis  '\n",
      " 'genital herpes especially primary hsv2 infection or  m genitalium 761765–768 '\n",
      " 'also have been associated  with cervicitis however in many cases of '\n",
      " 'cervicitis no  organism is isolated especially among women at relatively  '\n",
      " 'low risk for recent acquisition of these stis eg women aged  30 years 769 '\n",
      " 'limited data indicate that bv and frequent  douching might cause cervicitis '\n",
      " '770–772 the majority  of persistent cases of cervicitis are not caused by '\n",
      " 'reinfection  with c trachomatis or n gonorrhoeae other factors might  be '\n",
      " 'involved eg persistent abnormality of vaginal flora  m genitalium douching '\n",
      " 'or exposure to other types of chemical  irritants dysplasia or idiopathic '\n",
      " 'inflammation in the zone of  ectopy available data do not indicate an '\n",
      " 'association between  group b streptococcus colonization and cervicitis '\n",
      " '773774  no specific evidence exists for a role for ureaplasma parvum or  '\n",
      " 'ureaplasma urealyticum in cervicitis 707761765775776 diagnostic '\n",
      " 'considerations because cervicitis might be a sign of upper genital tract  '\n",
      " 'infection eg endometritis women should be assessed for  signs of pid and '\n",
      " 'tested for c trachomatis and n gonorrhoeae  with naat on vaginal cervical or '\n",
      " 'urine samples 553 see  chlamydial infections gonococcal infections women  '\n",
      " 'with cervicitis also should be evaluated for concomitant bv  and '\n",
      " 'trichomoniasis because sensitivity of microscopy for  detecting t vaginalis '\n",
      " 'is relatively low approximately 50  symptomatic women with cervicitis and '\n",
      " 'negative wetmount  microscopy for trichomonads should receive further '\n",
      " 'testing  ie naat culture or other fdacleared diagnostic test  see '\n",
      " 'trichomoniasis testing for m genitalium with the fda cleared naat can be '\n",
      " 'considered although hsv2 infection  has been associated with cervicitis the '\n",
      " 'utility of specific testing  ie pcr or culture for hsv2 is unknown testing '\n",
      " 'for  u parvum u urealyticum mycoplasma hominis or genital  culture for group '\n",
      " 'b streptococcus is not recommended treatment multiple factors should affect '\n",
      " 'the decision to provide  presumptive therapy for cervicitis presumptive '\n",
      " 'treatment with  antimicrobials for c trachomatis and n gonorrhoeae should  '\n",
      " 'be provided for women at increased risk eg those aged  25 years and women '\n",
      " 'with a new sex partner a sex partner  with concurrent partners or a sex '\n",
      " 'partner who has an sti if  followup cannot be ensured or if testing with '\n",
      " 'naat is not  possible trichomoniasis and bv should be treated if detected  '\n",
      " 'see bacterial vaginosis trichomoniasis for women at lower  risk for stis '\n",
      " 'deferring treatment until results of diagnostic  tests are available is an '\n",
      " 'option if treatment is deferred and  c trachomatis and n gonorrhoeae naats '\n",
      " 'are negative a  followup visit to determine whether the cervicitis has '\n",
      " 'resolved  can be considered recommended regimen for cervicitis doxycycline '\n",
      " '100 mg orally 2 timesday for 7 days   consider concurrent treatment for '\n",
      " 'gonococcal infection if the patient is  at risk for gonorrhea or lives in a '\n",
      " 'community where the prevalence of  gonorrhea is high see gonococcal '\n",
      " 'infections alternative regimen azithromycin 1 g orally in a single dose '\n",
      " 'other management considerations to minimize transmission and reinfection '\n",
      " 'women treated  for cervicitis should be instructed to abstain from sexual  '\n",
      " 'intercourse until they and their partners have been treated  ie until '\n",
      " 'completion of a 7day regimen or for 7 days after  singledose therapy and '\n",
      " 'symptoms have resolved women  who receive a cervicitis diagnosis should be '\n",
      " 'tested for syphilis  and hiv in addition to other recommended diagnostic '\n",
      " 'tests followup women receiving treatment should return to their provider  '\n",
      " 'for a followup visit to determine whether cervicitis has  resolved for women '\n",
      " 'who are untreated a followup visit gives  providers an opportunity to '\n",
      " 'communicate test results obtained  as part of the cervicitis evaluation '\n",
      " 'providers should treat on  the basis of any positive test results and '\n",
      " 'determine whether  recommendations and reports mmwr  july 23 2021  vol 70  '\n",
      " 'no 4 65us department of health and human servicescenters for disease control '\n",
      " 'and prevention cervicitis has resolved women with a specific diagnosis of  '\n",
      " 'chlamydia gonorrhea or trichomoniasis should be offered  partner services '\n",
      " 'and instructed to return in 3 months after  treatment for repeat testing '\n",
      " 'because of high rates of reinfection  regardless of whether their sex '\n",
      " 'partners were treated 753 if  symptoms persist or recur women should be '\n",
      " 'instructed to  return for reevaluation management of sex partners management '\n",
      " 'of sex partners of women treated for cervicitis  should be tailored for the '\n",
      " 'specific infection identified or  suspected all sex partners during the '\n",
      " 'previous 60 days should  be referred for evaluation testing and presumptive '\n",
      " 'treatment  if chlamydia gonorrhea or trichomoniasis was identified ept  and '\n",
      " 'other effective partner referral strategies are alternative  approaches for '\n",
      " 'treating male partners of women who have  chlamydial or gonococcal infection '\n",
      " '125–127 see partner  services to avoid reinfection sex partners should '\n",
      " 'abstain  from sexual intercourse until they and their partners are treated '\n",
      " 'persistent or recurrent cervicitis women with persistent or recurrent '\n",
      " 'cervicitis despite  antimicrobial therapy should be reevaluated for '\n",
      " 'possible  reexposure or treatment failure if relapse or reinfection with  a '\n",
      " 'specific infection has been excluded bv is not present and  sex partners '\n",
      " 'have been evaluated and treated management  options for persistent '\n",
      " 'cervicitis are undefined in addition  the usefulness of repeated or '\n",
      " 'prolonged administration of  antimicrobial therapy for persistent '\n",
      " 'symptomatic cervicitis  remains unknown the etiology of persistent '\n",
      " 'cervicitis  including the potential role of m genitalium 777 is unclear  m '\n",
      " 'genitalium might be considered for cases of cervicitis that  persist after '\n",
      " 'azithromycin or doxycycline therapy in which  reexposure to an infected '\n",
      " 'partner or medical nonadherence is  unlikely among women with persistent '\n",
      " 'cervicitis who were  previously treated with doxycycline or azithromycin '\n",
      " 'testing  for m genitalium can be considered and treatment initiated on  the '\n",
      " 'basis of results of diagnostic testing 318 see mycoplasma  genitalium for '\n",
      " 'women with persistent symptoms that are  clearly attributable to cervicitis '\n",
      " 'referral to a gynecologic  specialist can be considered for evaluation of '\n",
      " 'noninfectious  causes eg cervical dysplasia or polyps 778 special '\n",
      " 'considerations hiv infection women with cervicitis and hiv infection should '\n",
      " 'receive  the same treatment regimen as those who do not have hiv  cervicitis '\n",
      " 'can increase cervical hiv shedding and treatment  reduces hiv shedding from '\n",
      " 'the cervix and thereby might  reduce hiv transmission to susceptible sex '\n",
      " 'partners 779–783 pregnancy diagnosis and treatment of cervicitis for '\n",
      " 'pregnant women  does not differ from that for women who are not pregnant '\n",
      " 'see  diagnostic considerations treatment contraceptive management according '\n",
      " 'to us medical eligibility criteria for contraceptive  use 2016 leaving an '\n",
      " 'iud in place during treatment for  cervicitis is advisable 58 however '\n",
      " 'current recommendations  specify that an iud should not be placed if active '\n",
      " 'cervicitis  is diagnosed 59 chlamydial infections chlamydial infection '\n",
      " 'among  adolescents and adults chlamydial infection is the most frequently '\n",
      " 'reported  bacterial infectious disease in the united states and prevalence  '\n",
      " 'is highest among persons aged ≤24 years 141784 multiple  sequelae can result '\n",
      " 'from c trachomatis infection among  women the most serious of which include '\n",
      " 'pid ectopic  pregnancy and infertility certain women who receive a  '\n",
      " 'diagnosis of uncomplicated cervical infection already have  subclinical '\n",
      " 'upper genital tract infection asymptomatic infection is common among both '\n",
      " 'men and  women to detect chlamydial infection health care providers  '\n",
      " 'frequently rely on screening tests annual screening of all  sexually active '\n",
      " 'women aged 25 years is recommended as is  screening of older women at '\n",
      " 'increased risk for infection eg  women aged ≥25 years who have a new sex '\n",
      " 'partner more  than one sex partner a sex partner with concurrent partners  '\n",
      " 'or a sex partner who has an sti 149 in a community based cohort of female '\n",
      " 'college students incident chlamydial  infection was also associated with bv '\n",
      " 'and highrisk hpv  infection 785 although chlamydia incidence might be '\n",
      " 'higher  among certain women aged ≥25 years in certain communities  overall '\n",
      " 'the largest proportion of infection is among women  aged 25 years 141 '\n",
      " 'chlamydia screening programs have been demonstrated  to reduce pid rates '\n",
      " 'among women 786787 although  evidence is insufficient to recommend routine '\n",
      " 'screening for  c trachomatis among sexually active young men because of  '\n",
      " 'certain factors ie feasibility efficacy and costeffectiveness  screening of '\n",
      " 'sexually active young men should be considered  in clinical settings with a '\n",
      " 'high prevalence of chlamydia eg  adolescent clinics correctional facilities '\n",
      " 'or std specialty  recommendations and reports 66 mmwr  july 23 2021  vol 70  '\n",
      " 'no 4 us department of health and human servicescenters for disease control '\n",
      " 'and prevention clinics or for populations with a high burden of infection  '\n",
      " 'eg msm 149788 among women the primary focus of  chlamydia screening should '\n",
      " 'be to detect and treat chlamydia  prevent complications and test and treat '\n",
      " 'their partners  whereas targeted chlamydia screening for men should be  '\n",
      " 'considered only when resources permit prevalence is high and  such screening '\n",
      " 'does not hinder chlamydia screening efforts for  women 789–791 more frequent '\n",
      " 'screening than annual for  certain women eg adolescents or certain men eg '\n",
      " 'msm  might be indicated on the basis of risk behaviors diagnostic '\n",
      " 'considerations for women c trachomatis urogenital infection can be  '\n",
      " 'diagnosed by vaginal or cervical swabs or firstvoid urine for  men c '\n",
      " 'trachomatis urethral infection can be diagnosed by  testing firstvoid urine '\n",
      " 'or a urethral swab naats are the most  sensitive tests for these specimens '\n",
      " 'and are the recommended  test for detecting c trachomatis infection 553 '\n",
      " 'naats that  are fda cleared for use with vaginal swab specimens can be  '\n",
      " 'collected by a clinician or patient in a clinical setting patient collected '\n",
      " 'vaginal swab specimens are equivalent in sensitivity  and specificity to '\n",
      " 'those collected by a clinician using naats  792793 and this screening '\n",
      " 'strategy is highly acceptable  among women 794795 optimal urogenital '\n",
      " 'specimen  types for chlamydia screening by using naat include first catch '\n",
      " 'urine for men and vaginal swabs for women 553  recent studies have '\n",
      " 'demonstrated that among men naat  performance on selfcollected meatal swabs '\n",
      " 'is comparable  to patientcollected urine or providercollected urethral  '\n",
      " 'swabs 796–798 patient collection of a meatal swab for  c trachomatis testing '\n",
      " 'might be a reasonable approach for men  who are either unable to provide '\n",
      " 'urine or prefer to collect their  own meatal swab over providing urine '\n",
      " 'previous evidence  indicates that the liquidbased cytology specimens '\n",
      " 'collected for  pap smears might be acceptable specimens for naat although  '\n",
      " 'test sensitivity using these specimens might be lower than that  associated '\n",
      " 'with use of cervical or vaginal swab specimens 799  regardless certain naats '\n",
      " 'have been cleared by fda for use  on liquidbased cytology specimens rectal '\n",
      " 'and oropharyngeal c trachomatis infection among  persons engaging in '\n",
      " 'receptive anal or oral intercourse can be  diagnosed by testing at the '\n",
      " 'anatomic exposure site naats have  been demonstrated to have improved '\n",
      " 'sensitivity and specificity  compared with culture for detecting c '\n",
      " 'trachomatis at rectal  and oropharyngeal sites 553800–804 and certain naat  '\n",
      " 'platforms have been cleared by fda for these anatomic sites  805 data '\n",
      " 'indicate that naat performance on selfcollected  rectal swabs is comparable '\n",
      " 'to cliniciancollected rectal swabs  and this specimen collection strategy '\n",
      " 'for rectal c trachomatis  screening is highly acceptable among men 217806  '\n",
      " 'selfcollected rectal swabs are a reasonable alternative to  '\n",
      " 'cliniciancollected rectal swabs for c trachomatis screening by  naat '\n",
      " 'especially when clinicians are not available or when self collection is '\n",
      " 'preferred over clinician collection annual screening  for rectal c '\n",
      " 'trachomatis infection should be performed among  men who report sexual '\n",
      " 'activity at the rectal site extragenital  chlamydial testing at the rectal '\n",
      " 'site can be considered for  females on the basis of reported sexual '\n",
      " 'behaviors and exposure  through shared clinical decisionmaking bythe patient '\n",
      " 'and the  provider the majority of persons with c trachomatis detected  at '\n",
      " 'oropharyngeal sites do not have oropharyngeal symptoms  the clinical '\n",
      " 'significance of oropharyngeal c trachomatis  infection is unclear and '\n",
      " 'prevalence is low even among  populations at high risk however when '\n",
      " 'gonorrhea testing  is performed at the oropharyngeal site chlamydia test '\n",
      " 'results  might be reported because certain naats detect both bacteria  from '\n",
      " 'a single specimen poc tests for c trachomatis among asymptomatic persons  '\n",
      " 'can expedite treatment of infected persons and their sex  partners among '\n",
      " 'symptomatic patients poc tests for  c trachomatis can optimize treatment by '\n",
      " 'limiting unnecessary  presumptive treatment at the time of clinical '\n",
      " 'decisionmaking  and improve antimicrobial stewardship thus using a poc  test '\n",
      " 'will likely be a costeffective diagnostic strategy for  c trachomatis '\n",
      " 'infection 807 newer naatbased poc tests  have promising performance and are '\n",
      " 'becoming commercially  available 807–809 treatment treating persons with c '\n",
      " 'trachomatis prevents adverse  reproductive health complications and '\n",
      " 'continued sexual  transmission furthermore treating their sex partners  can '\n",
      " 'prevent reinfection and infection of other partners  treating pregnant women '\n",
      " 'usually prevents transmission of  c trachomatis to neonates during birth '\n",
      " 'treatment should be  provided promptly for all persons with chlamydial '\n",
      " 'infection  treatment delays have been associated with complications eg  pid '\n",
      " 'in a limited proportion of women 810 recommended regimen for chlamydial '\n",
      " 'infection among  adolescents and adults doxycycline 100 mg orally 2 timesday '\n",
      " 'for 7 days alternative regimens azithromycin 1 g orally in a single dose or '\n",
      " 'levofloxacin 500 mg orally once daily for 7 days a metaanalysis and a '\n",
      " 'cochrane systematic review evaluated  data from randomized clinical trials '\n",
      " 'of azithromycin versus  doxycycline for treating urogenital chlamydial '\n",
      " 'infection  recommendations and reports mmwr  july 23 2021  vol 70  no 4 67us '\n",
      " 'department of health and human servicescenters for disease control and '\n",
      " 'prevention determined that microbiologic treatment failure among men  was '\n",
      " 'higher for azithromycin than for doxycycline 748749  observational studies '\n",
      " 'have also demonstrated that doxycycline  is more efficacious for rectal c '\n",
      " 'trachomatis infection for men  and women than azithromycin 748811 a '\n",
      " 'randomized trial  for the treatment of rectal chlamydia infection among msm  '\n",
      " 'reported microbiologic cure was 100 with doxycycline and  74 with '\n",
      " 'azithromycin 812 a published review reported  that c trachomatis was '\n",
      " 'detected at the anorectal site among  33–83 of women who had urogenital c '\n",
      " 'trachomatis  infection and its detection was not associated with report of  '\n",
      " 'receptive anorectal sexual activity 813 although the clinical significance '\n",
      " 'of oropharyngeal  c trachomatis infection is unclear and routine '\n",
      " 'oropharyngeal  screening is not recommended oropharyngeal c trachomatis  can '\n",
      " 'be sexually transmitted to genital sites 211814 therefore  if c trachomatis '\n",
      " 'is identified from an oropharyngeal specimen  while screening for pharyngeal '\n",
      " 'gonorrhea it should be treated  evidence is limited regarding the efficacy '\n",
      " 'of antimicrobial  regimens for oropharyngeal chlamydia however a recently  '\n",
      " 'published observational study indicates doxycycline might  be more '\n",
      " 'efficacious than azithromycin for oropharyngeal  chlamydia 815 available '\n",
      " 'evidence supports that doxycycline is efficacious  for c trachomatis '\n",
      " 'infections of urogenital rectal and  oropharyngeal sites although '\n",
      " 'azithromycin maintains high  efficacy for urogenital c trachomatis infection '\n",
      " 'among women  concern exists regarding effectiveness of azithromycin for  '\n",
      " 'concomitant rectal c trachomatis infection which can occur  commonly among '\n",
      " 'women and cannot be predicted by reported  sexual activity inadequately '\n",
      " 'treated rectal c trachomatis  infection among women who have urogenital '\n",
      " 'chlamydia  can increase the risk for transmission and place women at  risk '\n",
      " 'for repeat urogenital c trachomatis infection through  autoinoculation from '\n",
      " 'the anorectal site 816 doxycycline is  also available in a delayedrelease '\n",
      " '200mg tablet formulation  which requires oncedaily dosing for 7 days and is '\n",
      " 'as effective  as doxycycline 100 mg twice daily for 7 days for treating  '\n",
      " 'urogenital c trachomatis infection in men and women it is  more costly but '\n",
      " 'also has lower frequency of gastrointestinal  side effects 817 levofloxacin '\n",
      " 'is an effective treatment  alternative but is more expensive erythromycin is '\n",
      " 'no longer  recommended because of the frequency of gastrointestinal side  '\n",
      " 'effects which can result in nonadherence when nonadherence  to doxycycline '\n",
      " 'regimen is a substantial concern azithromycin  1 g regimen is an alternative '\n",
      " 'treatment option but might  require posttreatment evaluation and testing '\n",
      " 'because it has  demonstrated lower treatment efficacy among persons with  '\n",
      " 'rectal infection among persons receiving multidose regimens medication  '\n",
      " 'should be dispensed with all doses involved onsite and in  the clinic and '\n",
      " 'the first dose should be directly observed to  maximize adherence with '\n",
      " 'recommended therapies onsite  directly observed singledose therapy with '\n",
      " 'azithromycin should  always be available for persons for whom adherence '\n",
      " 'with  multiday dosing is a considerable concern other management '\n",
      " 'considerations to minimize disease transmission to sex partners persons  '\n",
      " 'treated for chlamydia should be instructed to abstain from  sexual '\n",
      " 'intercourse for 7 days after singledose therapy or until  completion of a '\n",
      " '7day regimen and resolution of symptoms if  present to minimize risk for '\n",
      " 'reinfection patients also should  be instructed to abstain from sexual '\n",
      " 'intercourse until all of their  sex partners have been treated persons who '\n",
      " 'receive a diagnosis  of chlamydia should be tested for hiv gonorrhea and '\n",
      " 'syphilis  msm who are hiv negative with a rectal chlamydia diagnosis  should '\n",
      " 'be offered hiv prep followup test of cure to detect therapeutic failure ie '\n",
      " 'repeat testing  4 weeks after completing therapy is not advised for '\n",
      " 'nonpregnant  persons treated with the recommended or alternative regimens  '\n",
      " 'unless therapeutic adherence is in question symptoms persist  or reinfection '\n",
      " 'is suspected moreover using chlamydial naats  at 4 weeks after completion of '\n",
      " 'therapy is not recommended  because the continued presence of nonviable '\n",
      " 'organisms  553818819 can lead to falsepositive results a high prevalence of '\n",
      " 'c trachomatis infection has been  observed among women and men who were '\n",
      " 'treated  for chlamydial infection during the preceding months  753755820–822 '\n",
      " 'the majority of posttreatment infections  do not result from treatment '\n",
      " 'failure but rather from reinfection  caused by failure of sex partners to '\n",
      " 'receive treatment or  initiation of sexual activity with a new infected '\n",
      " 'partner 823  indicating a need for improved education and treatment of  sex '\n",
      " 'partners repeat infections confer an elevated risk for pid  and other '\n",
      " 'complications among women men and women  who have been treated for chlamydia '\n",
      " 'should be retested  approximately 3 months after treatment regardless of '\n",
      " 'whether  they believe their sex partners were treated scheduling the  '\n",
      " 'followup visit at the time of treatment is encouraged 753  if retesting at 3 '\n",
      " 'months is not possible clinicians should retest  whenever persons next seek '\n",
      " 'medical care 12 months after  initial treatment management of sex partners '\n",
      " 'sex partners should be referred for evaluation testing and  presumptive '\n",
      " 'treatment if they had sexual contact with the  recommendations and reports '\n",
      " '68 mmwr  july 23 2021  vol 70  no 4 us department of health and human '\n",
      " 'servicescenters for disease control and prevention partner during the 60 '\n",
      " 'days preceding the patient’s onset of  symptoms or chlamydia diagnosis '\n",
      " 'although the exposure  intervals defining identification of sex partners at '\n",
      " 'risk are  based on limited data the most recent sex partner should be  '\n",
      " 'evaluated and treated even if the time of the last sexual contact  was 60 '\n",
      " 'days before symptom onset or diagnosis if health department partner '\n",
      " 'management strategies eg  disease intervention specialists are impractical '\n",
      " 'or unavailable  for persons with chlamydia and if a provider is concerned  '\n",
      " 'that sex partners are unable to promptly access evaluation and  treatment '\n",
      " 'services ept should be considered as permitted by  law see partner services '\n",
      " 'compared with standard patient  referral of partners this approach to '\n",
      " 'therapy which involves  delivering the medication itself or a prescription '\n",
      " 'by the  patient or collaborating pharmacy has been associated with  '\n",
      " 'decreased rates of persistent or recurrent chlamydia among  women 125–127 '\n",
      " 'providers should provide patients with  written educational materials to '\n",
      " 'give to their partners about  chlamydia which should include notification '\n",
      " 'that partners  have been exposed and information about the importance  of '\n",
      " 'treatment these materials also should inform partners  about potential '\n",
      " 'therapyrelated allergies and adverse effects  along with symptoms indicative '\n",
      " 'of complications eg  testicular pain among men and pelvic or abdominal pain  '\n",
      " 'among women educational materials for female partners  should include '\n",
      " 'information about the importance of seeking  medical evaluation especially '\n",
      " 'if pid symptoms are present  undertreatment of pid among female partners and '\n",
      " 'missed  opportunities for diagnosing other stis among women  are concerning '\n",
      " 'msm with chlamydia have a high risk for  coexisting infections especially '\n",
      " 'undiagnosed hiv among  their partners and might have partners without hiv '\n",
      " 'who  could benefit from hiv prep data are also limited regarding  '\n",
      " 'effectiveness of ept in reducing persistent or recurrent  chlamydia among '\n",
      " 'msm 123133134 thus shared clinical  decisionmaking regarding ept for msm is '\n",
      " 'recommended  having partners accompany patients when they return for  '\n",
      " 'treatment is another strategy that has been used successfully  for ensuring '\n",
      " 'partner treatment see partner services to avoid  reinfection sex partners '\n",
      " 'should be instructed to abstain from  condomless sexual intercourse until '\n",
      " 'they and their sex partners  have been treated ie after completion of a 7day '\n",
      " 'regimen  and any symptoms have resolved special considerations pregnancy '\n",
      " 'clinical experience and published studies indicate that  azithromycin is '\n",
      " 'safe and effective during pregnancy 824–826  doxycycline is contraindicated '\n",
      " 'during the second and third  trimesters of pregnancy because of risk for '\n",
      " 'tooth discoloration  human data reveal that levofloxacin presents a low risk '\n",
      " 'to the  fetus during pregnancy but has potential for toxicity during  '\n",
      " 'breastfeeding however data from animal studies increase  concerns regarding '\n",
      " 'cartilage damage to neonates 431 test of cure ie repeat testing after '\n",
      " 'completion of therapy  to document chlamydial eradication preferably by '\n",
      " 'naat  at approximately 4 weeks after therapy completion during  pregnancy is '\n",
      " 'recommended because severe sequelae can occur  among mothers and neonates if '\n",
      " 'the infection persists in  addition all pregnant women who have chlamydial '\n",
      " 'infection  diagnosed should be retested 3 months after treatment  detection '\n",
      " 'of c trachomatis infection during the third semester  is not uncommon among '\n",
      " 'adolescent and young adult women  including those without c trachomatis '\n",
      " 'detected at the time of  initial prenatal screening 827 women aged 25 years '\n",
      " 'and  those at increased risk for chlamydia ie those who have a  new sex '\n",
      " 'partner more than one sex partner a sex partner with  concurrent partners or '\n",
      " 'a sex partner who has an sti should  be screened at the first prenatal visit '\n",
      " 'and rescreened during the  third trimester to prevent maternal postnatal '\n",
      " 'complications  and chlamydial infection in the infant 149 recommended '\n",
      " 'regimen for chlamydial infection during  pregnancy azithromycin 1 g orally '\n",
      " 'in a single dose  alternative regimen amoxicillin 500 mg orally 3 timesday '\n",
      " 'for 7 days because of concerns regarding chlamydia persistence  after '\n",
      " 'exposure to penicillinclass antibiotics that has been  demonstrated in '\n",
      " 'animal and in vitro studies amoxicillin is  listed as an alternative therapy '\n",
      " 'for c trachomatis for pregnant  women 828829 erythromycin is no longer '\n",
      " 'recommended  because of the frequency of gastrointestinal side effects that '\n",
      " 'can  result in therapy nonadherence in addition systematic reviews  and '\n",
      " 'metaanalyses have noted an association with macrolide  antimicrobials '\n",
      " 'especially erythromycin during pregnancy and  adverse child outcomes '\n",
      " 'indicating cautious use in pregnancy  830–831 hiv infection persons who have '\n",
      " 'chlamydia and hiv infection should  receive the same treatment regimen as '\n",
      " 'those who do not  have hiv chlamydial infection among neonates prenatal '\n",
      " 'screening and treatment of pregnant women is  the best method for preventing '\n",
      " 'chlamydial infection among  recommendations and reports mmwr  july 23 2021  '\n",
      " 'vol 70  no 4 69us department of health and human servicescenters for disease '\n",
      " 'control and prevention neonates c trachomatis infection of neonates results '\n",
      " 'from  perinatal exposure to the mother’s infected cervix initial  c '\n",
      " 'trachomatis neonatal infection involves the mucous  membranes of the eye '\n",
      " 'oropharynx urogenital tract and  rectum although infection might be '\n",
      " 'asymptomatic in these  locations instead c trachomatis infection among '\n",
      " 'neonates  is most frequently recognized by conjunctivitis that develops  '\n",
      " '5–12 days after birth c trachomatis also can cause a subacute  afebrile '\n",
      " 'pneumonia with onset at ages 1–3 months although  c trachomatis has been the '\n",
      " 'most frequent identifiable  infectious cause of ophthalmia neonatorum '\n",
      " 'neonatal  chlamydial infections including ophthalmia and pneumonia  have '\n",
      " 'occurred less frequently since institution of widespread  prenatal screening '\n",
      " 'and treatment of pregnant women neonates  born to mothers at high risk for '\n",
      " 'chlamydial infection with  untreated chlamydia or with no or unconfirmed '\n",
      " 'prenatal care  are at high risk for infection however presumptive treatment  '\n",
      " 'of the neonate is not indicated because the efficacy of such  treatment is '\n",
      " 'unknown infants should be monitored to ensure  prompt and ageappropriate '\n",
      " 'treatment if symptoms develop  processes should be in place to ensure '\n",
      " 'communication between  physicians and others caring for the mother and the '\n",
      " 'newborn  to ensure thorough monitoring of the newborn after birth ophthalmia '\n",
      " 'neonatorum caused by  c trachomatis a chlamydial etiology should be '\n",
      " 'considered for all infants aged  ≤30 days who experience conjunctivitis '\n",
      " 'especially if the mother  has a history of chlamydial infection these '\n",
      " 'infants should receive  evaluation and ageappropriate care and treatment '\n",
      " 'preventing ophthalmia neonatorum caused by  c trachomatis neonatal ocular '\n",
      " 'prophylaxis with erythromycin the only  agent available in the united states '\n",
      " 'for this purpose is  ineffective against chlamydial ophthalmia neonatorum '\n",
      " 'or  pneumonia 833 as an alternative prevention efforts should  focus on '\n",
      " 'prenatal screening for c trachomatis including • screening pregnant women at '\n",
      " 'risk for c trachomatis  infection at the first prenatal visit eg women aged  '\n",
      " '25 years and those aged ≥25 years who have a new sex  partner more than one '\n",
      " 'sex partner a sex partner with  concurrent partners or a sex partner who has '\n",
      " 'an sti • treating all pregnant women with c trachomatis during  pregnancy '\n",
      " 'and performing a test of cure 4 weeks after  treatment to verify chlamydial '\n",
      " 'eradication these women  should also be retested 3 months after treatment '\n",
      " 'and again  in the third trimester or at time of delivery and their  partners '\n",
      " 'should also be tested and treated • retesting pregnant women during the '\n",
      " 'third trimester who  initially tested negative but remained at increased '\n",
      " 'risk for  acquiring infection eg women aged 25 years and those  aged ≥25 '\n",
      " 'years who have a new sex partner more than one  sex partner a sex partner '\n",
      " 'with concurrent partners or a  sex partner who has an sti and • screening at '\n",
      " 'delivery those pregnant women who were not  screened for c trachomatis '\n",
      " 'during pregnancy if at risk or  who had no prenatal care physicians and '\n",
      " 'others caring  for the mother and the newborn should communicate to  ensure '\n",
      " 'followup on the results of laboratory tests  performed at delivery and if '\n",
      " 'positive prompt and age appropriate treatment for the newborn and the mother '\n",
      " 'neonates born to mothers for whom prenatal chlamydia  screening has been '\n",
      " 'confirmed and the results are negative are  not at high risk for infection '\n",
      " 'diagnostic considerations sensitive and specific methods for diagnosing '\n",
      " 'chlamydial  ophthalmia in the neonate include both tissue culture and  '\n",
      " 'nonculture tests eg dfa tests and naats dfa is the  only nonculture '\n",
      " 'fdacleared test for detecting chlamydia  from conjunctival swabs naats are '\n",
      " 'not cleared by fda for  detecting chlamydia from conjunctival swabs and '\n",
      " 'clinical  laboratories should verify the procedure according to clia  '\n",
      " 'regulations specimens for culture isolation and nonculture  tests should be '\n",
      " 'obtained from the everted eyelid by using a  dacron duponttipped swab or the '\n",
      " 'swab specified by the  manufacturer’s test kit for culture and dfa specimens '\n",
      " 'must  contain conjunctival cells not exudate alone ocular specimens  from '\n",
      " 'neonates being evaluated for chlamydial conjunctivitis  also should be '\n",
      " 'tested for n gonorrhoeae see ophthalmia  neonatorum caused by n gonorrhoeae '\n",
      " 'treatment recommended regimen for chlamydial infection among  neonates '\n",
      " 'erythromycin base or ethyl succinate 50 mgkg body weightday  orally divided '\n",
      " 'into 4 doses daily for 14 days  an association between oral erythromycin and '\n",
      " 'azithromycin and infantile  hypertrophic pyloric stenosis ihps has been '\n",
      " 'reported among infants  aged 6 weeks infants treated with either of these '\n",
      " 'antimicrobials should  be followed for ihps signs and symptoms although data '\n",
      " 'regarding use of azithromycin for treating  neonatal chlamydial infection '\n",
      " 'are limited available data  demonstrate that a short therapy course might be '\n",
      " 'effective  834 topical antibiotic therapy alone is inadequate for  treating '\n",
      " 'ophthalmia neonatorum caused by chlamydia and is  unnecessary when systemic '\n",
      " 'treatment is administered recommendations and reports 70 mmwr  july 23 2021  '\n",
      " 'vol 70  no 4 us department of health and human servicescenters for disease '\n",
      " 'control and prevention followup because the efficacy of erythromycin '\n",
      " 'treatment for  ophthalmia neonatorum is approximately 80 a second  course of '\n",
      " 'therapy might be required 834835 data regarding  the efficacy of '\n",
      " 'azithromycin for ophthalmia neonatorum are  limited therefore followup of '\n",
      " 'infants is recommended to  determine whether the initial treatment was '\n",
      " 'effective the  possibility of concomitant chlamydial pneumonia should be  '\n",
      " 'considered see infant pneumonia caused by c trachomatis management of '\n",
      " 'mothers and their sex partners mothers of infants who have ophthalmia caused '\n",
      " 'by chlamydia  and the sex partners of these women should be evaluated and  '\n",
      " 'presumptively treated for chlamydia see chlamydial infection  among '\n",
      " 'adolescents and adults infant pneumonia caused by c trachomatis chlamydial '\n",
      " 'pneumonia among infants typically occurs at age  1–3 months and is a '\n",
      " 'subacute pneumonia characteristic signs  of chlamydial pneumonia among '\n",
      " 'infants include a repetitive  staccato cough with tachypnea and '\n",
      " 'hyperinflation and bilateral  diffuse infiltrates on a chest radiograph in '\n",
      " 'addition peripheral  eosinophilia ≥400 cellsmm3 occurs frequently because  '\n",
      " 'clinical presentations differ all infants aged 1–3 months  suspected of '\n",
      " 'having pneumonia especially those whose  mothers have a history of are at '\n",
      " 'risk for eg aged 25 years  and those aged ≥25 years who have a new sex '\n",
      " 'partner more  than one sex partner a sex partner with concurrent partners  '\n",
      " 'or a sex partner who has an sti or suspected of having a  chlamydial '\n",
      " 'infection should be tested for c trachomatis and  treated if infected '\n",
      " 'diagnostic considerations specimens for chlamydial testing should be '\n",
      " 'collected from  the nasopharynx tissue culture is the definitive standard  '\n",
      " 'diagnostic test for chlamydial pneumonia nonculture  tests eg dfa and naat '\n",
      " 'can be used dfa is the only  nonculture fdacleared test for detecting c '\n",
      " 'trachomatis from  nasopharyngeal specimens however dfa of nasopharyngeal  '\n",
      " 'specimens has a lower sensitivity and specificity than culture  naats are '\n",
      " 'not cleared by fda for detecting chlamydia from  nasopharyngeal specimens '\n",
      " 'and clinical laboratories should  verify the procedure according to clia '\n",
      " 'regulations 553  tracheal aspirates and lung biopsy specimens if collected  '\n",
      " 'should be tested for c trachomatis treatment because test results for '\n",
      " 'chlamydia often are unavailable at the  time initial treatment decisions are '\n",
      " 'being made treatment for  c trachomatis pneumonia frequently is based on '\n",
      " 'clinical and  radiologic findings age of the infant ie 1–3 months and  risk '\n",
      " 'for chlamydia in the mother ie aged 25 years history  of chlamydial '\n",
      " 'infection multiple sex partners a sex partner  with a concurrent partner or '\n",
      " 'a sex partner with a history of  an sti in the absence of laboratory results '\n",
      " 'in a situation  with a high degree of suspicion of chlamydial infection and  '\n",
      " 'the mother is unlikely to return with the infant for followup  exposed '\n",
      " 'infants can be presumptively treated with the shorter course regimen of '\n",
      " 'azithromycin 20 mgkg body weightday  orally 1 dose daily for 3 days '\n",
      " 'recommended regimen for chlamydial pneumonia among  infants erythromycin '\n",
      " 'base or ethyl succinate 50 mgkg body weightday orally  divided into 4 doses '\n",
      " 'daily for 14 days alternative regimen azithromycin suspension 20 mgkgday '\n",
      " 'orally 1 dose daily for 3 days followup because erythromycin effectiveness '\n",
      " 'in treating pneumonia  caused by c trachomatis is approximately 80 a second  '\n",
      " 'course of therapy might be required 836 data regarding  effectiveness of '\n",
      " 'azithromycin in treating chlamydial pneumonia  are limited followup of '\n",
      " 'infants is recommended to determine  whether the pneumonia has resolved '\n",
      " 'although certain infants  with chlamydial pneumonia continue to have '\n",
      " 'abnormal  pulmonary function tests later during childhood management of '\n",
      " 'mothers and their sex partners mothers of infants who have chlamydial '\n",
      " 'pneumonia and the  sex partners of these women should be evaluated tested '\n",
      " 'and  presumptively treated for chlamydia see chlamydial infection  among '\n",
      " 'adolescents and adults chlamydial infection among infants and  children '\n",
      " 'sexual abuse should be considered a cause of chlamydial  infection among '\n",
      " 'infants and children however perinatally  transmitted c trachomatis '\n",
      " 'infection of the nasopharynx  urogenital tract and rectum can persist for '\n",
      " '2–3 years see  sexual assault or abuse of children diagnostic considerations '\n",
      " 'naats can be used to test vaginal and urine specimens  from girls and urine '\n",
      " 'in boys see sexual assault or abuse  of children data are lacking regarding '\n",
      " 'use of naats for  specimens from extragenital sites rectum and pharynx '\n",
      " 'among  boys and girls 553 other nonculture tests eg dfa are  recommendations '\n",
      " 'and reports mmwr  july 23 2021  vol 70  no 4 71us department of health and '\n",
      " 'human servicescenters for disease control and prevention not recommended '\n",
      " 'because of specificity concerns although  data regarding naats for specimens '\n",
      " 'from extragenital sites for  children are more limited and performance is '\n",
      " 'test dependent  553 no evidence supports that naat performance  for '\n",
      " 'detecting c trachomatis for extragenital sites among  children would differ '\n",
      " 'from that among adults because of  the implications of a diagnosis of c '\n",
      " 'trachomatis infection in  a child only cliavalidated fdacleared naat should '\n",
      " 'be  used for extragenital site specimens 837 recommended regimens for '\n",
      " 'chlamydial infection among  infants and children for infants and children '\n",
      " 'weighing 45 kg erythromycin base or ethyl  succinate 50 mgkg body weightday '\n",
      " 'orally divided into 4 doses daily  for 14 days data are limited regarding '\n",
      " 'the effectiveness and optimal dose of  azithromycin for treating chlamydial '\n",
      " 'infection among infants and  children weighing 45 kg for children weighing '\n",
      " '≥45 kg but aged 8 years azithromycin 1 g  orally in a single dose for '\n",
      " 'children aged ≥8 years azithromycin 1 g orally in a single dose or '\n",
      " 'doxycycline 100 mg orally 2 timesday for 7 days other management '\n",
      " 'considerations see sexual assault or abuse of children followup a test of '\n",
      " 'cure to detect therapeutic failure ensures treatment  effectiveness and '\n",
      " 'should be obtained at a followup visit  approximately 4 weeks after '\n",
      " 'treatment is completed gonococcal infections gonococcal infection among  '\n",
      " 'adolescents and adults in the united states an estimated 1568000 new  n '\n",
      " 'gonorrhoeae infections occur each year 141838 and  gonorrhea is the second '\n",
      " 'most commonly reported bacterial  communicable disease urethral infections '\n",
      " 'caused by  n gonorrhoeae can produce symptoms among men that cause  them to '\n",
      " 'seek curative treatment soon enough to prevent  sequelae but often not soon '\n",
      " 'enough to prevent transmission  to others among women gonococcal infections '\n",
      " 'are commonly  asymptomatic or might not produce recognizable symptoms  until '\n",
      " 'complications eg pid have occurred pid can result in  tubal scarring that '\n",
      " 'can lead to infertility or ectopic pregnancy annual screening for n '\n",
      " 'gonorrhoeae infection is recommended  for all sexually active women aged 25 '\n",
      " 'years and for older  women at increased risk for infection eg those aged ≥25 '\n",
      " 'years  who have a new sex partner more than one sex partner a sex  partner '\n",
      " 'with concurrent partners or a sex partner who has  an sti 149 additional '\n",
      " 'risk factors for gonorrhea include  inconsistent condom use among persons '\n",
      " 'who are not in  mutually monogamous relationships previous or coexisting  '\n",
      " 'stis and exchanging sex for money or drugs clinicians  should consider the '\n",
      " 'communities they serve and consult local  public health authorities for '\n",
      " 'guidance regarding identifying  groups at increased risk gonococcal '\n",
      " 'infection in particular is  concentrated in specific geographic locations '\n",
      " 'and communities  msm at high risk for gonococcal infection eg those with  '\n",
      " 'multiple anonymous partners or substance abuse or those at  risk for hiv '\n",
      " 'acquisition should be screened at all anatomic  sites of exposure every 3–6 '\n",
      " 'months see men who have sex  with men at least annual screening is '\n",
      " 'recommended for all  msm screening for gonorrhea among heterosexual men and  '\n",
      " 'women aged 25 years who are at low risk for infection is  not recommended '\n",
      " '149 a recent travel history with sexual  contacts outside the united states '\n",
      " 'should be part of any  gonorrhea evaluation diagnostic considerations '\n",
      " 'specific microbiologic diagnosis of n gonorrhoeae infection  should be '\n",
      " 'performed for all persons at risk for or suspected of  having gonorrhea a '\n",
      " 'specific diagnosis can potentially reduce  complications reinfections and '\n",
      " 'transmission culture naat  and poc naat such as genexpert cepheid are '\n",
      " 'available  for detecting genitourinary infection with n gonorrhoeae  149 '\n",
      " 'culture requires endocervical women or urethral  men swab specimens culture '\n",
      " 'is also available for detecting  rectal oropharyngeal and conjunctival '\n",
      " 'gonococcal infection  naats and poc naats allow for the widest variety of  '\n",
      " 'fdacleared specimen types including endocervical and  vaginal swabs and '\n",
      " 'urine for women urethral swabs and urine  for men and rectal swabs and '\n",
      " 'pharyngeal swabs for men and  women '\n",
      " 'wwwaccessdatafdagovcdrhdocsreviewsk121710 pdf  however product inserts for '\n",
      " 'each naat manufacturer  should be consulted carefully because collection '\n",
      " 'methods  and specimen types vary certain naats that have been  demonstrated '\n",
      " 'to detect commensal neisseria species might  have comparable low specificity '\n",
      " 'when testing oropharyngeal  specimens for n gonorrhoeae 553 naat sensitivity '\n",
      " 'for  detecting n gonorrhoeae from urogenital and nongenital  anatomic sites '\n",
      " 'is superior to culture but varies by naat type  553800–803 for urogenital '\n",
      " 'infections optimal specimen  types for gonorrhea screening using naats '\n",
      " 'include firstvoid  urine for men and vaginal swab specimens for women 553  '\n",
      " 'patientcollected samples can be used in place of provider collected samples '\n",
      " 'in clinical settings when testing by naat  '\n",
      " 'httpswwwaccessdatafdagovcdrhdocsreviewsk121710pdf '\n",
      " 'httpswwwaccessdatafdagovcdrhdocsreviewsk121710pdf recommendations and '\n",
      " 'reports 72 mmwr  july 23 2021  vol 70  no 4 us department of health and '\n",
      " 'human servicescenters for disease control and prevention for urine men and '\n",
      " 'women vaginal swabs rectal swabs and  oropharyngeal swabs after patient '\n",
      " 'instructions have been  provided 209806839–842 patientcollected specimens  '\n",
      " 'are reasonable alternatives to providercollected swabs for  gonorrhea '\n",
      " 'screening by naat in cases of suspected or documented treatment failure  '\n",
      " 'clinicians should perform both culture and antimicrobial  susceptibility '\n",
      " 'testing because naats cannot provide  antimicrobial susceptibility results '\n",
      " 'because n gonorrhoeae  has demanding nutritional and environmental growth  '\n",
      " 'requirements optimal recovery rates are achieved when  specimens are '\n",
      " 'inoculated directly and when the growth  medium is promptly incubated in an '\n",
      " 'increased carbon dioxide  co2 environment 553 nonnutritive swab transport  '\n",
      " 'systems are available that might maintain gonococcal viability  for 48 hours '\n",
      " 'in ambient temperatures 843–845 because of its high specificity 99 and '\n",
      " 'sensitivity  95 a gram stain of urethral discharge or secretions that  '\n",
      " 'demonstrate polymorphonuclear leukocytes with intracellular  gramnegative '\n",
      " 'diplococci can be considered diagnostic for  infection with n gonorrhoeae '\n",
      " 'among symptomatic men  however because of lower sensitivity a negative gram '\n",
      " 'stain  should not be considered sufficient for ruling out infection  among '\n",
      " 'asymptomatic men infection detection by using  gram stain of endocervical '\n",
      " 'pharyngeal and rectal specimens  also is insensitive and is not recommended '\n",
      " 'mb or gv stain  of urethral secretions is an alternative poc diagnostic '\n",
      " 'test  with performance characteristics similar to gram stain  gonococcal '\n",
      " 'infection is diagnosed among symptomatic men by  documenting the presence of '\n",
      " 'a wbccontaining intracellular  purple diplococci in mb or gv smears '\n",
      " 'antimicrobialresistant n gonorrhoeae gonorrhea treatment is complicated by '\n",
      " 'the ability of  n gonorrhoeae to develop resistance to antimicrobials  '\n",
      " '846–848 in 1986 the gonococcal isolate surveillance  project gisp a national '\n",
      " 'sentinel surveillance system was  established to monitor trends in '\n",
      " 'antimicrobial susceptibilities  of urethral n gonorrhoeae strains in the '\n",
      " 'united states  849 the epidemiology of antimicrobial resistance guides  '\n",
      " 'decisions about gonococcal treatment recommendations  and has evolved '\n",
      " 'because of shifts in antimicrobial resistance  patterns during 2007 '\n",
      " 'emergence of fluoroquinolone resistant n gonorrhoeae in the united states '\n",
      " 'prompted cdc  to cease recommending fluoroquinolones for gonorrhea  '\n",
      " 'treatment leaving cephalosporins as the only remaining  class of '\n",
      " 'antimicrobials available for gonorrhea treatment in  the united states 850 '\n",
      " 'reflecting concern about emerging  gonococcal resistance cdc’s 2010 std '\n",
      " 'treatment guidelines  recommended dual therapy for gonorrhea with a '\n",
      " 'cephalosporin  plus either azithromycin or doxycycline even if naat for  c '\n",
      " 'trachomatis was negative at the time of treatment 851  however during '\n",
      " '2006–2011 the minimum concentrations of  cefixime needed to inhibit in vitro '\n",
      " 'growth of the n gonorrhoeae  strains circulating in the united states and '\n",
      " 'other countries  increased demonstrating that cefixime effectiveness might '\n",
      " 'be  waning 851 in addition treatment failures with cefixime or  other oral '\n",
      " 'cephalosporins were reported in asia 852–855  europe 856–860 south africa '\n",
      " '861 and canada 862863  during that time case reports of ceftriaxone '\n",
      " 'treatment failures  for pharyngeal infections reported in australia 864865  '\n",
      " 'japan 866 and europe were concerning 856867  consequently cdc no longer '\n",
      " 'recommends cefixime as a  firstline regimen for gonorrhea treatment in the '\n",
      " 'united  states 868 since 2013 the proportion of gisp isolates  that '\n",
      " 'demonstrate reduced susceptibility minimal inhibitory  concentration mic ≥20 '\n",
      " 'µgml to azithromycin has  increased almost tenfold to 51 in 2019 141 unlike '\n",
      " 'the  appearance of ciprofloxacin resistance in the early 2000s and  cefixime '\n",
      " 'reducedsusceptibility isolates during 2010–2011  emergence of azithromycin '\n",
      " 'resistance is not concentrated  among certain populations eg msm in the '\n",
      " 'western united  states azithromycin has unique pharmacokinetic properties  '\n",
      " 'that might predispose to resistance due to its prolonged halflife  869870 '\n",
      " 'with the exception of a small cluster of gonorrhea  strains with '\n",
      " 'azithromycin resistance and reduced susceptibility  to cefixime and '\n",
      " 'ceftriaxone among seven patients during 2016  all gonorrhea strains '\n",
      " 'identified by gisp are susceptible to  either or both azithromycin and '\n",
      " 'ceftriaxone or cefixime in  addition since 2013 antimicrobial stewardship '\n",
      " 'has become  an urgent public health concern in the united states as  '\n",
      " 'described in antimicrobial resistant threats in the united states  871 '\n",
      " 'emergence of azithromycin resistance is not isolated to  n gonorrhoeae it '\n",
      " 'has also been demonstrated in m genitalium  and such enteric pathogens as '\n",
      " 'shigella and campylobacter see  mycoplasma genitalium proctitis '\n",
      " 'proctocolitis and enteritis  finally concern exists regarding azithromycin '\n",
      " 'treatment  efficacy for chlamydia see chlamydial infections dual therapy for '\n",
      " 'gonococcal infection with ceftriaxone  and azithromycin recommended in '\n",
      " 'previous guidance  might have mitigated emergence of reduced susceptibility '\n",
      " 'to  ceftriaxone in n gonorrhoeae however concerns regarding  potential harm '\n",
      " 'to the microbiome and the effect on other  pathogens diminishes the benefits '\n",
      " 'of maintaining dual therapy  consequently only ceftriaxone is recommended '\n",
      " 'for treating  gonorrhea in the united states 872 clinicians remaining  '\n",
      " 'vigilant for treatment failures is paramount and cdc plans  to continue to '\n",
      " 'monitor for changing ceftriaxone mics  until additional antimicrobials or a '\n",
      " 'vaccine is available in  cases in which chlamydial infection has not been '\n",
      " 'excluded  recommendations and reports mmwr  july 23 2021  vol 70  no 4 73us '\n",
      " 'department of health and human servicescenters for disease control and '\n",
      " 'prevention patients should also receive antichlamydial therapy cdc  and '\n",
      " 'state health departments participate in cdcsupported  gonorrhea surveillance '\n",
      " 'activities httpswwwcdcgovstd gisp and can provide the most current '\n",
      " 'information regarding  gonococcal susceptibility criteria for resistance to '\n",
      " 'cefixime and ceftriaxone have not  been defined by the clinical and '\n",
      " 'laboratory standards institute  clsi however isolates with cefixime or '\n",
      " 'ceftriaxone mics  ≥05 µgml are considered to have decreased susceptibility  '\n",
      " '873 in the united states the proportion of isolates in  gisp demonstrating '\n",
      " 'decreased susceptibility to ceftriaxone  or cefixime has remained low during '\n",
      " '2019 01 of isolates  with decreased susceptibility mic ≥05 µgml to '\n",
      " 'ceftriaxone  or cefixime were identified 141 because increasing mics  might '\n",
      " 'predict resistance emergence gisp established lower  cephalosporin mic '\n",
      " 'threshold values that are lower than the  susceptibility breakpoints set by '\n",
      " 'clsi to provide greater  sensitivity in detecting decreasing gonococcal '\n",
      " 'susceptibility  for surveillance purposes the percentage of isolates with  '\n",
      " 'cefixime mics ≥025 µgml increased from 01 during  2006 to 14 during 2011 '\n",
      " '851874 and declined to  03 during 2019 141 the percentage of isolates with  '\n",
      " 'ceftriaxone mics ≥0125 µgml increased from 01 in  2006 to 04 in 2011 and '\n",
      " 'decreased to 01 in 2019 141  isolates with highlevel cefixime and '\n",
      " 'ceftriaxone mics mics   15–80 µgml and mics  15–40 µgml respectively  have '\n",
      " 'been identified in japan 866 france 867875 spain  876877 the united kingdom '\n",
      " 'and australia 878879  decreased susceptibility of n gonorrhoeae to '\n",
      " 'cephalosporins  and other antimicrobials is expected to continue state and  '\n",
      " 'local surveillance for antimicrobial resistance is crucial for  guiding '\n",
      " 'local therapy recommendations 846847 although  approximately 3 of all us men '\n",
      " 'who have gonococcal  infections are sampled through gisp surveillance by '\n",
      " 'clinicians  also is crucial clinicians who diagnose n gonorrhoeae infection  '\n",
      " 'in a person with suspected cephalosporin treatment failure  should perform '\n",
      " 'culture and ast of relevant clinical specimens  consult an infectious '\n",
      " 'disease specialist or an std clinical  expert httpswwwstdccnorgrenderpublic '\n",
      " 'for guidance  in clinical management and report the case to cdc through  '\n",
      " 'state and local public health authorities within 24 hours  isolates should '\n",
      " 'be saved and sent to cdc through local and  state public health laboratory '\n",
      " 'mechanisms health departments  should prioritize notification and culture '\n",
      " 'evaluation for sexual  partners of persons with n gonorrhoeae infection '\n",
      " 'thought  to be associated with cephalosporin treatment failure or  persons '\n",
      " 'whose isolates demonstrate decreased susceptibility  to cephalosporin agar '\n",
      " 'dilution is the reference standard  and preferred method of antimicrobial '\n",
      " 'susceptibility testing  with n gonorrhoeae antibiotic gradient strips such '\n",
      " 'as etest  biomérieux can be used and are considered an acceptable  '\n",
      " 'alternative for quantitative antimicrobial susceptibility testing with  n '\n",
      " 'gonorrhoeae when manufacturer instructions are followed disc  diffusion only '\n",
      " 'provides qualitative susceptibility results uncomplicated gonococcal '\n",
      " 'infection of the  cervix urethra or rectum recommended regimen for '\n",
      " 'uncomplicated gonococcal  infection of the cervix urethra or rectum among '\n",
      " 'adults and  adolescents ceftriaxone 500 mg im in a single dose for persons '\n",
      " 'weighing 150 kg if chlamydial infection has not been excluded treat for '\n",
      " 'chlamydia with  doxycycline 100 mg orally 2 timesday for 7 days  for persons '\n",
      " 'weighing ≥150 kg 1 g ceftriaxone should be administered although clinical '\n",
      " 'data confirm that a single injection  of ceftriaxone 250 mg is 99 95 '\n",
      " 'confidence interval  ci\\xa0976–997 effective in curing anogenital gonorrhea  '\n",
      " 'of circulating isolates mic  003 µgml a higher dose is  likely necessary for '\n",
      " 'isolates with elevated mics 880881  effective treatment of uncomplicated '\n",
      " 'urogenital gonorrhea with  ceftriaxone requires concentrations higher than '\n",
      " 'the strain mic  for approximately 24 hours although individual variability  '\n",
      " 'exists in the pharmacokinetics of ceftriaxone a 500mg dose  of ceftriaxone '\n",
      " 'is expected to achieve in approximately 50 hours  mic 003 µgml 880881 the '\n",
      " 'pharmacokinetics of  ceftriaxone might be different in the pharynx with '\n",
      " 'longer times  higher than the strain mic likely needed to prevent selection  '\n",
      " 'of mutant strains in the pharynx 882 singledose injectable cephalosporin '\n",
      " 'regimens other than  ceftriaxone that are safe and have been effective '\n",
      " 'against  uncomplicated urogenital and anorectal gonococcal infections  in '\n",
      " 'the past include ceftizoxime 500 mg im cefoxitin 2 g im  with probenecid 1 g '\n",
      " 'orally and cefotaxime 500 mg im  none of these injectable cephalosporins '\n",
      " 'offer any advantage  over ceftriaxone 250 mg for urogenital infection and '\n",
      " 'efficacy  for pharyngeal infection is less certain 883884 because the  '\n",
      " 'ceftriaxone dose has been increased and the pharmacokinetics  of other '\n",
      " 'cephalosporins have not been evaluated these dosing  regimens might be at a '\n",
      " 'disadvantage over ceftriaxone 500 mg  alternative regimens if ceftriaxone is '\n",
      " 'not available gentamicin 240 mg im in a single dose plus azithromycin 2 g '\n",
      " 'orally in a single dose or cefixime 800 mg orally in a single dose  if '\n",
      " 'chlamydial infection has not been excluded providers should treat for  '\n",
      " 'chlamydia with doxycycline 100 mg orally 2 timesday for 7 days '\n",
      " 'httpswwwcdcgovstdgisp httpswwwcdcgovstdgisp httpswwwstdccnorgrenderpublic '\n",
      " 'recommendations and reports 74 mmwr  july 23 2021  vol 70  no 4 us '\n",
      " 'department of health and human servicescenters for disease control and '\n",
      " 'prevention in one clinical trial dual treatment with single doses of  im '\n",
      " 'gentamicin 240 mg plus oral azithromycin 2 g cured  100 of cases lower '\n",
      " 'onesided 95 ci bound\\xa0985 and  can be considered an alternative to '\n",
      " 'ceftriaxone for persons  with cephalosporin allergy 885 this trial was not '\n",
      " 'powered  enough to provide reliable estimates of the efficacy of these  '\n",
      " 'regimens for treatment of rectal or pharyngeal infection  however this '\n",
      " 'regimen cured the few extragenital infections  among study participants '\n",
      " 'notably gastrointestinal adverse  events primarily vomiting 1 hour after '\n",
      " 'dosing occurred  among 3–4 of persons treated with gentamicin plus  '\n",
      " 'azithromycin necessitating retreatment with ceftriaxone  and azithromycin a '\n",
      " 'similar trial that studied gentamicin  240 mg plus azithromycin 1 g '\n",
      " 'determined lower cure rates at  extragenital sites 80 95 ci\\xa072–88 of '\n",
      " 'pharyngeal  and 90 95 ci\\xa084–95 of rectal infections were cured  with this '\n",
      " 'regimen 886 gemifloxacin plus azithromycin has  been studied and is no '\n",
      " 'longer recommended as an alternative  regimen because of limited '\n",
      " 'availability cost and antimicrobial  stewardship concerns 885 an 800mg oral '\n",
      " 'dose of cefixime should be considered only  as an alternative cephalosporin '\n",
      " 'regimen because it does not  provide as high nor as sustained bactericidal '\n",
      " 'blood levels as a  500mg im dose of ceftriaxone furthermore it demonstrates  '\n",
      " 'limited efficacy for treatment of pharyngeal gonorrhea 923  cure 95 ci\\xa0 '\n",
      " '749–991 in older clinical studies  cefixime cured 975 of uncomplicated '\n",
      " 'urogenital and  anorectal gonococcal infections 95 ci\\xa0 954–998  883884 '\n",
      " 'the increase in the prevalence of isolates obtained  through gisp with '\n",
      " 'elevated cefixime mics might indicate  early stages of development of '\n",
      " 'clinically significant gonococcal  resistance to cephalosporins changes in '\n",
      " 'cefixime mics can  result in decreasing effectiveness of cefixime for '\n",
      " 'treating  urogenital gonorrhea furthermore as cefixime becomes  less '\n",
      " 'effective continued used of cefixime might hasten the  development of '\n",
      " 'resistance to ceftriaxone a safe welltolerated  injectable cephalosporin and '\n",
      " 'the last antimicrobial known to  be highly effective in a single dose for '\n",
      " 'treatment of gonorrhea  at all anatomic infection sites other oral '\n",
      " 'cephalosporins eg  cefpodoxime and cefuroxime are not recommended because '\n",
      " 'of  inferior efficacy and less favorable pharmacodynamics 883 monotherapy '\n",
      " 'with azithromycin 2 g orally as a single  dose has been demonstrated to be '\n",
      " '992 effective against  uncomplicated urogenital gonorrhea 95 ci\\xa0973–999  '\n",
      " '883 however monotherapy is not recommended because  of concerns about the '\n",
      " 'ease with which n gonorrhoeae can  develop resistance to macrolides the high '\n",
      " 'proportion of isolates  with azithromycin decreased susceptibility and '\n",
      " 'documented  azithromycin treatment failures 859 strains of n gonorrhoeae  '\n",
      " 'circulating in the united states are not adequately susceptible  to '\n",
      " 'penicillin tetracycline and older macrolides eg  erythromycin and thus use '\n",
      " 'of these antimicrobials cannot  be recommended spectinomycin is effective '\n",
      " '982 in curing uncomplicated  urogenital and anorectal gonococcal infections '\n",
      " 'but has poor  efficacy for pharyngeal infections 883887 it is unavailable  '\n",
      " 'in the united states and the gentamicin alternative regimen  has replaced '\n",
      " 'the need for spectinomycin if a cephalosporin  allergy exists in the united '\n",
      " 'states uncomplicated gonococcal infection of  the pharynx the majority of '\n",
      " 'gonococcal infections of the pharynx are  asymptomatic and can be relatively '\n",
      " 'common among certain  populations 800801888–890 although these infections  '\n",
      " 'rarely cause complications they have been reported to be a  major source of '\n",
      " 'community transmission and might be a driver  of antimicrobial resistance '\n",
      " '891892 gonococcal infections  of the pharynx are more difficult to eradicate '\n",
      " 'than infections  at urogenital and anorectal sites 862 few antimicrobial  '\n",
      " 'regimens reliably cure 90 of gonococcal pharyngeal  infections 883884 '\n",
      " 'providers should ask their patients with  urogenital or rectal gonorrhea '\n",
      " 'about oral sexual exposure if  reported pharyngeal testing should be '\n",
      " 'performed recommended regimen for uncomplicated gonococcal  infection of the '\n",
      " 'pharynx among adolescents and adults ceftriaxone 500 mg im in a single dose '\n",
      " 'for persons weighing 150 kg  for persons weighing ≥150 kg 1 g ceftriaxone '\n",
      " 'should be administered if chlamydial infection is identified when '\n",
      " 'pharyngeal  gonorrhea testing is performed treat for chlamydia with  '\n",
      " 'doxycycline 100 mg orally 2 timesday for 7 days no reliable  alternative '\n",
      " 'treatments are available for pharyngeal gonorrhea  for persons with an '\n",
      " 'anaphylactic or other severe reaction  eg stevens johnson syndrome to '\n",
      " 'ceftriaxone consult  an infectious disease specialist for an alternative '\n",
      " 'treatment  recommendation other management considerations to maximize '\n",
      " 'adherence with recommended therapies  and reduce complications and '\n",
      " 'transmission medication  for gonococcal infection should be provided onsite '\n",
      " 'and  directly observed if medications are unavailable when  treatment is '\n",
      " 'indicated linkage to an sti treatment facility  should be provided for '\n",
      " 'sameday treatment to minimize  disease transmission persons treated for '\n",
      " 'gonorrhea should  be instructed to abstain from sexual activity for 7 days '\n",
      " 'after  treatment and until all sex partners are treated 7 days after  '\n",
      " 'receiving treatment and resolution of symptoms if present  recommendations '\n",
      " 'and reports mmwr  july 23 2021  vol 70  no 4 75us department of health and '\n",
      " 'human servicescenters for disease control and prevention all persons who '\n",
      " 'receive a diagnosis of gonorrhea should be  tested for other stis including '\n",
      " 'chlamydia syphilis and hiv  those persons whose hiv test results are '\n",
      " 'negative should be  offered hiv prep followup a test of cure ie repeat '\n",
      " 'testing after completion of  therapy is unnecessary for persons who receive '\n",
      " 'a diagnosis of  uncomplicated urogenital or rectal gonorrhea who are '\n",
      " 'treated  with any of the recommended or alternative regimens any  person '\n",
      " 'with pharyngeal gonorrhea should return 7–14 days  after initial treatment '\n",
      " 'for a test of cure by using either culture or  naat however testing at 7 '\n",
      " 'days might result in an increased  likelihood of falsepositive tests if the '\n",
      " 'naat is positive effort  should be made to perform a confirmatory culture '\n",
      " 'before  retreatment especially if a culture was not already collected all  '\n",
      " 'positive cultures for test of cure should undergo antimicrobial  '\n",
      " 'susceptibility testing symptoms that persist after treatment  should be '\n",
      " 'evaluated by culture for n gonorrhoeae with or  without simultaneous naat '\n",
      " 'and antimicrobial susceptibility  persistent urethritis cervicitis or '\n",
      " 'proctitis also might be caused  by other organisms see urethritis cervicitis '\n",
      " 'proctitis a high prevalence of n gonorrhoeae infection has been  observed '\n",
      " 'among men and women previously treated for  gonorrhea 137753754893 the '\n",
      " 'majority of these infections  result from reinfection caused by failure of '\n",
      " 'sex partners to  receive treatment or the initiation of sexual activity with '\n",
      " 'a  new infected partner indicating a need for improved patient  education '\n",
      " 'and treatment of sex partners men or women who  have been treated for '\n",
      " 'gonorrhea should be retested 3 months  after treatment regardless of whether '\n",
      " 'they believe their sex  partners were treated scheduling the followup visit '\n",
      " 'at the  time of treatment is encouraged if retesting at 3 months is not  '\n",
      " 'possible clinicians should retest whenever persons next seek  medical care '\n",
      " '12 months after initial treatment management of sex partners recent sex '\n",
      " 'partners ie persons having sexual contact with  the infected patient 60 days '\n",
      " 'preceding onset of symptoms or  gonorrhea diagnosis should be referred for '\n",
      " 'evaluation testing  and presumptive treatment if the patient’s last '\n",
      " 'potential sexual  exposure was 60 days before onset of symptoms or '\n",
      " 'diagnosis  the most recent sex partner should be treated if health '\n",
      " 'department partnermanagement strategies eg  disease intervention specialists '\n",
      " 'are impractical or unavailable  for persons with gonorrhea and partners’ '\n",
      " 'access to prompt  clinical evaluation and treatment is limited ept can be  '\n",
      " 'delivered to the partner by the patient or a collaborating  pharmacy as '\n",
      " 'permitted by law see partner services treatment  of the sexual partner with '\n",
      " 'cefixime 800 mg as a single dose  is recommended provided that concurrent '\n",
      " 'chlamydial  infection has been excluded if a chlamydia test result has not  '\n",
      " 'been documented the partner may be treated with a single  dose of oral '\n",
      " 'cefixime 800 mg plus oral doxycycline 100 mg  2 timesday for 7 days if '\n",
      " 'adherence with multiday dosing is  a considerable concern azithromycin 1 g '\n",
      " 'can be considered  but has lower treatment efficacy among persons with '\n",
      " 'rectal  chlamydia see chlamydial infections provision of medication  by ept '\n",
      " 'should be accompanied by written materials 125127  for educating partners '\n",
      " 'about gonorrhea their exposure to  gonorrhea and the importance of therapy '\n",
      " 'these materials  should also educate partners about seeking clinical '\n",
      " 'evaluation  for adverse reactions or complications and general followup  '\n",
      " 'when able educational materials for female partners should  include '\n",
      " 'information about the importance of seeking medical  evaluation for pid '\n",
      " 'especially if symptomatic undertreatment  of pid among female partners and '\n",
      " 'missed opportunities for  diagnosing other stis among women are of concern '\n",
      " 'msm  with gonorrhea have a high risk for coexisting infections  especially '\n",
      " 'undiagnosed hiv among their partners and they  might have partners without '\n",
      " 'hiv who could benefit from  prep data are also limited regarding the '\n",
      " 'effectiveness of ept  in reducing persistent or recurrent gonorrhea among '\n",
      " 'msm  133135 thus shared clinical decisionmaking regarding  ept for msm is '\n",
      " 'recommended see partner services to avoid  reinfection sex partners should '\n",
      " 'be instructed to abstain from  condomless sexual intercourse for 7 days '\n",
      " 'after they and their  sex partners have completed treatment and after '\n",
      " 'resolution of  symptoms if present suspected cephalosporin treatment failure '\n",
      " 'cephalosporin treatment failure is the persistence of  n gonorrhoeae '\n",
      " 'infection despite recommended cephalosporin  treatment such failure is '\n",
      " 'indicative of infection with  cephalosporinresistant gonorrhea among persons '\n",
      " 'whose  partners were treated and whose risk for reinfection is  low '\n",
      " 'suspected treatment failure has been reported among  persons receiving oral '\n",
      " 'and injectable cephalosporins 852– 855857859861863864867875894 treatment '\n",
      " 'failure  should be considered for persons whose symptoms do not  resolve '\n",
      " 'within 3–5 days after recommended treatment and  report no sexual contact '\n",
      " 'during the posttreatment followup  period and persons with a positive test '\n",
      " 'of cure ie positive  culture 72 hours or positive naat 7 days after '\n",
      " 'receiving  recommended treatment when no sexual contact is reported  during '\n",
      " 'the posttreatment followup period 874 treatment  failure should also be '\n",
      " 'considered for persons who have a  positive culture on test of cure if '\n",
      " 'obtained if evidence exists  of decreased susceptibility to cephalosporins '\n",
      " 'on antimicrobial  recommendations and reports 76 mmwr  july 23 2021  vol 70  '\n",
      " 'no 4 us department of health and human servicescenters for disease control '\n",
      " 'and prevention susceptibility testing regardless of whether sexual contact '\n",
      " 'is  reported during the posttreatment followup period the majority of '\n",
      " 'suspected treatment failures in the united  states are likely to be '\n",
      " 'reinfections rather than actual treatment  failures 137753754894 however in '\n",
      " 'cases in which  reinfection is unlikely and treatment failure is suspected  '\n",
      " 'before retreatment relevant clinical specimens should be  obtained for '\n",
      " 'culture preferably with simultaneous naat  and antimicrobial susceptibility '\n",
      " 'testing if n gonorrhoeae is  isolated phenotypic antimicrobial '\n",
      " 'susceptibility testing should  be performed by using etest or agar dilution '\n",
      " 'all isolates  of suspected treatment failures should be sent to cdc for  '\n",
      " 'antimicrobial susceptibility testing by agar dilution local  laboratories '\n",
      " 'should store isolates for possible further testing if  needed testing or '\n",
      " 'storage of specimens or isolates should be  facilitated by the state or '\n",
      " 'local health department according to  local public health protocol '\n",
      " 'instructions for shipping isolates  to cdc are available at '\n",
      " 'httpswwwcdcgovstdgonorrhea argspecimenshippinginstructions12908pdf for '\n",
      " 'persons with suspected cephalosporin treatment failure  the treating '\n",
      " 'clinician should consult an infectious disease  specialist the national '\n",
      " 'network of std clinical prevention  training center clinical consultation '\n",
      " 'line httpswwwstdccn orgrenderpublic the local or state health department '\n",
      " 'sti  program or cdc telephone 8002324636 for advice about  obtaining '\n",
      " 'cultures antimicrobial susceptibility testing and  treatment suspected '\n",
      " 'treatment failure should be reported to  cdc through the local or state '\n",
      " 'health department 24 hours  after diagnosis patients with suspected '\n",
      " 'treatment failures should first be  retreated routinely with the initial '\n",
      " 'regimen used ceftriaxone  500 mg im with the addition of doxycycline if '\n",
      " 'chlamydia  infection exists because reinfections are more likely than  '\n",
      " 'actual treatment failures however in situations with a higher  likelihood of '\n",
      " 'treatment failure than reinfection relevant  clinical specimens should be '\n",
      " 'obtained for culture preferably  with simultaneous naat and antimicrobial '\n",
      " 'susceptibility  testing before retreatment dual treatment with single doses  '\n",
      " 'of im gentamicin 240 mg plus oral azithromycin 2 g can be  considered '\n",
      " 'particularly when isolates are identified as having  elevated cephalosporin '\n",
      " 'mics 885886895 persons with  suspected treatment failure after treatment '\n",
      " 'with the alternative  regimen cefixime or gentamicin should be treated with  '\n",
      " 'ceftriaxone 500 mg as a single im dose or as a single dose with  or without '\n",
      " 'an antichlamydial agent on the basis of chlamydia  infection status a test '\n",
      " 'of cure at relevant clinical sites should  be obtained 7–14 days after '\n",
      " 'retreatment culture is the  recommended test preferably with simultaneous '\n",
      " 'naat and  antimicrobial susceptibility testing of n gonorrhoeae if isolated  '\n",
      " 'clinicians should ensure that the patients’ sex partners from  the preceding '\n",
      " '60 days are evaluated promptly with culture  and presumptively treated by '\n",
      " 'using the same regimen used  for the patients special considerations drug '\n",
      " 'allergy intolerance and adverse reactions the risk for penicillin '\n",
      " 'crossreactivity is highest with  firstgeneration cephalosporins but is rare '\n",
      " '1 with  thirdgeneration cephalosporins eg ceftriaxone and  cefixime '\n",
      " '631680896 clinicians should first thoroughly  assess a patient’s allergy '\n",
      " 'history including type of reaction  associated medications and previous '\n",
      " 'prescription records  if igemediated penicillin allergy is strongly '\n",
      " 'suspected dual  treatment with single doses of im gentamicin 240 mg plus '\n",
      " 'oral  azithromycin 2 g can be administered 885886 if a patient  is '\n",
      " 'asymptomatic and the treating facility is able to perform  gyrase a gyra '\n",
      " 'testing to identify ciprofloxacin susceptibility  wild type oral '\n",
      " 'ciprofloxacin 500 mg in a single dose can be  administered providers '\n",
      " 'treating persons with igemediated  cephalosporin or penicillin allergy '\n",
      " 'should refer to the section  of these guidelines regarding evaluation see '\n",
      " 'management of  persons who have a history of penicillin allergy pregnancy '\n",
      " 'pregnant women infected with n gonorrhoeae should be  treated with '\n",
      " 'ceftriaxone 500 mg in a single im dose plus  treatment for chlamydia if '\n",
      " 'infection has not been excluded  when cephalosporin allergy or other '\n",
      " 'considerations preclude  treatment with this regimen consultation with an '\n",
      " 'infectious  disease specialist or an std clinical expert is recommended  '\n",
      " 'gentamicin use is cautioned during pregnancy because of risk  for neonatal '\n",
      " 'birth defects nephrotoxicity or ototoxicity 897  '\n",
      " 'httpswwwstdccnorgrenderpublic hiv infection persons who have gonorrhea and '\n",
      " 'hiv infection should  receive the same treatment regimen as those who do '\n",
      " 'not  have hiv gonococcal conjunctivitis in the only published study of the '\n",
      " 'treatment regarding  gonococcal conjunctivitis among adults all 12 study  '\n",
      " 'participants responded to a single 1g im injection of  ceftriaxone 898 '\n",
      " 'because gonococcal conjunctivitis is  uncommon and data regarding treatment '\n",
      " 'of gonococcal  conjunctivitis among adults are limited consultation with an  '\n",
      " 'infectious disease specialist should be considered '\n",
      " 'httpswwwcdcgovstdgonorrheaargspecimenshippinginstructions12908pdf '\n",
      " 'httpswwwcdcgovstdgonorrheaargspecimenshippinginstructions12908pdf '\n",
      " 'httpswwwstdccnorgrenderpublic httpswwwstdccnorgrenderpublic '\n",
      " 'httpswwwstdccnorgrenderpublic recommendations and reports mmwr  july 23 '\n",
      " '2021  vol 70  no 4 77us department of health and human servicescenters for '\n",
      " 'disease control and prevention recommended regimen for gonococcal '\n",
      " 'conjunctivitis among  adolescents and adults ceftriaxone 1 g im in a single '\n",
      " 'dose providers should consider onetime lavage of the infected eye with  '\n",
      " 'saline solution management of sex partners patients should be instructed to '\n",
      " 'refer their sex partners  for evaluation and treatment see gonococcal '\n",
      " 'infections  management of sex partners disseminated gonococcal infection '\n",
      " 'infrequently n gonorrhoeae can cause disseminated  infection disseminated '\n",
      " 'gonococcal infection dgi frequently  results in petechial or pustular acral '\n",
      " 'skin lesions asymmetric  polyarthralgia tenosynovitis or oligoarticular '\n",
      " 'septic arthritis  899–901 rarely dgi is complicated by perihepatitis  '\n",
      " 'associated with gonococcal pid endocarditis or meningitis  certain strains '\n",
      " 'of n gonorrhoeae that cause dgi can cause  minimal genital inflammation and '\n",
      " 'urogenital or anorectal  infections are often asymptomatic among dgi '\n",
      " 'patients  if dgi is suspected naats or culture specimens from all  exposed '\n",
      " 'urogenital and extragenital sites should be collected  and processed in '\n",
      " 'addition to disseminated sites of infection  eg skin synovial fluid blood or '\n",
      " 'csf all n gonorrhoeae  isolates should be tested for antimicrobial '\n",
      " 'susceptibility  risk factors for dissemination have included female sex  '\n",
      " 'menstruation pregnancy and terminal complement deficiency  899 however '\n",
      " 'reports are increasing among men 900901  persons receiving eculizumab a '\n",
      " 'monoclonal antibody that  inhibits terminal complement activation also might '\n",
      " 'be at  higher risk for dgi 902 hospitalization and consultation with an '\n",
      " 'infectious disease  specialist are recommended for initial therapy '\n",
      " 'especially  for persons who might not comply with treatment have an  '\n",
      " 'uncertain diagnosis or have purulent synovial effusions or  other '\n",
      " 'complications examination for clinical evidence of  endocarditis and '\n",
      " 'meningitis should be performed treatment of arthritis and '\n",
      " 'arthritisdermatitis  syndrome recommended regimen for gonococcalrelated '\n",
      " 'arthritis and  arthritisdermatitis syndrome ceftriaxone 1 g im or iv every '\n",
      " '24 hours if chlamydial infection has not been excluded providers should '\n",
      " 'treat for  chlamydia with doxycycline 100 mg orally 2 timesday for 7 days '\n",
      " 'alternative regimens cefotaxime 1 g iv every 8 hours or ceftizoxime 1 g '\n",
      " 'every 8 hours if chlamydial infection has not been excluded providers should '\n",
      " 'treat for  chlamydia with doxycycline 100 mg orally 2 timesday for 7 days '\n",
      " 'when treating for the arthritisdermatitis syndrome the  provider can switch '\n",
      " 'to an oral agent guided by antimicrobial  susceptibility testing 24–48 hours '\n",
      " 'after substantial clinical  improvement for a total treatment course of 7 '\n",
      " 'days treatment of gonococcal meningitis and endocarditis recommended regimen '\n",
      " 'for gonococcal meningitis and  endocarditis ceftriaxone 1–2 g iv every 24 '\n",
      " 'hours if chlamydial infection has not been excluded providers should treat '\n",
      " 'for  chlamydia with doxycycline 100 mg orally 2 timesday for 7 days no '\n",
      " 'recent studies have been published regarding treatment  of dgi involving the '\n",
      " 'cns or cardiovascular system the  duration of treatment for dgi in these '\n",
      " 'situations has not been  systematically studied and should be determined in '\n",
      " 'consultation  with an infectious disease specialist treatment for dgi '\n",
      " 'should  be guided by the results of antimicrobial susceptibility testing  '\n",
      " 'length of treatment should be determined based on clinical  presentation '\n",
      " 'therapy for meningitis should be continued with  recommended parenteral '\n",
      " 'therapy for 10–14 days parenteral  antimicrobial therapy for endocarditis '\n",
      " 'should be administered  for 4 weeks treatment of gonococcal perihepatitis '\n",
      " 'should be  managed in accordance with the recommendations for pid  in these '\n",
      " 'guidelines management of sex partners gonococcal infection frequently is '\n",
      " 'asymptomatic among sex  partners of persons who have dgi providers should '\n",
      " 'instruct  patients to refer partners with whom they have had sexual  contact '\n",
      " 'during the previous 60 days for evaluation testing  and presumptive '\n",
      " 'treatment see gonococcal infections  management of sex partners gonococcal '\n",
      " 'infection among neonates prenatal screening and treatment of pregnant women '\n",
      " 'for  gonorrhea is the best method for preventing n gonorrhoeae  infection '\n",
      " 'among neonates gonococcal infection among  neonates results from perinatal '\n",
      " 'exposure to the mother’s infected  cervix it is usually an acute illness '\n",
      " 'that manifests 2–5 days after  birth prevalence of infection among neonates '\n",
      " 'depends on the  prevalence of infection among pregnant women and whether  '\n",
      " 'pregnant women are screened and treated for gonorrhea during  '\n",
      " 'recommendations and reports 78 mmwr  july 23 2021  vol 70  no 4 us '\n",
      " 'department of health and human servicescenters for disease control and '\n",
      " 'prevention pregnancy the most severe manifestations of n gonorrhoeae  '\n",
      " 'infection among neonates are ophthalmia neonatorum and  sepsis which can '\n",
      " 'include arthritis and meningitis less severe  manifestations include '\n",
      " 'rhinitis vaginitis urethritis and scalp  infection at sites of previous '\n",
      " 'fetal monitoring preventing ophthalmia neonatorum caused by  n gonorrhoeae '\n",
      " 'ocular prophylaxis and preventive gonorrhea screening  and treatment of '\n",
      " 'infected pregnant women are especially  important because ophthalmia '\n",
      " 'neonatorum can result in  perforation of the globe of the eye and blindness '\n",
      " '903  ocular prophylaxis for gonococcal ophthalmia neonatorum  has a long '\n",
      " 'history of preventing sightthreatening gonococcal  ocular infections cases '\n",
      " 'in the united states are uncommon  which is likely attributable to gonorrhea '\n",
      " 'screening programs  for women including pregnant women that have '\n",
      " 'contributed  substantially to reduction in ophthalmia neonatorum 904  '\n",
      " 'neonatal ocular prophylaxis with erythromycin the only agent  available in '\n",
      " 'the united states is required by law in most states  and is recommended '\n",
      " 'because of safety low cost and ease of  administration it can contribute to '\n",
      " 'preventing gonococcal  blindness because not all pregnant women are screened '\n",
      " 'for  gonorrhea the uspstf recommends ocular prophylaxis  with erythromycin '\n",
      " 'ointment for all newborns 24 hours  after birth 903 in addition to '\n",
      " 'continuing routine ocular  prophylaxis prevention should focus on prenatal '\n",
      " 'screening  for n gonorrhoeae including • screening pregnant women at risk eg '\n",
      " 'women aged  25 years and those aged ≥25 years who have a new sex  partner '\n",
      " 'more than one sex partner a sex partner with  concurrent partners a sex '\n",
      " 'partner who has an sti or live  in a community with high rates of gonorrhea '\n",
      " 'for  n gonorrhoeae infection at the first prenatal visit • treating all '\n",
      " 'pregnant women with n gonorrhoeae infection  during pregnancy and retesting '\n",
      " 'in 3 months in the third  trimester or at time of delivery sex partners '\n",
      " 'should be  tested and treated • retesting pregnant women in the third '\n",
      " 'trimester who  initially tested negative but remained at increased risk for  '\n",
      " 'acquiring infection eg women aged 25 years and those  aged ≥25 years who '\n",
      " 'have a new sex partner more than one  sex partner a sex partner with '\n",
      " 'concurrent partners a sex  partner who has an sti or live in a community '\n",
      " 'with high  rates of gonorrhea and • screening for gonorrhea at delivery for '\n",
      " 'women not tested  during pregnancy and at risk for infection eg women  aged '\n",
      " '25 years and those aged ≥25 years who have a new  sex partner more than one '\n",
      " 'sex partner a sex partner with  concurrent partners a sex partner who has an '\n",
      " 'sti or live  in a community with high rates of gonorrhea or received  no '\n",
      " 'prenatal care providers caring for the mother and the  newborn should '\n",
      " 'communicate to ensure followup on the  results of laboratory tests performed '\n",
      " 'at delivery and if  positive prompt appropriate treatment of the newborn  '\n",
      " 'and mother erythromycin is the only ophthalmic ointment recommended  for use '\n",
      " 'among neonates silver nitrate and tetracycline  ophthalmic ointments are no '\n",
      " 'longer manufactured in the  united states bacitracin is ineffective and '\n",
      " 'povidone iodine  has not been studied adequately 905906 gentamicin  '\n",
      " 'ophthalmic ointment has been associated with severe ocular  reactions 907908 '\n",
      " 'if erythromycin ointment is unavailable  infants at risk for exposure to n '\n",
      " 'gonorrhoeae especially those  born to a mother at risk for gonococcal '\n",
      " 'infection or with no  prenatal care can be administered ceftriaxone 25–50 '\n",
      " 'mgkg  body weight iv or im not to exceed 250 mg in a single dose recommended '\n",
      " 'regimen to prevent ophthalmia neonatorum  caused by n gonorrhoeae '\n",
      " 'erythromycin 05 ophthalmic ointment in each eye in a single  application at '\n",
      " 'birth erythromycin ophthalmic ointment should be instilled  into both eyes '\n",
      " 'of neonates as soon as possible after delivery  regardless of whether they '\n",
      " 'are delivered vaginally or by  cesarean delivery ideally ointment should be '\n",
      " 'applied by using  singleuse tubes or ampules rather than multipleuse tubes '\n",
      " 'if  prophylaxis is delayed ie not administered in the delivery  room a '\n",
      " 'monitoring system should be established to ensure  that all newborns receive '\n",
      " 'prophylaxis 24 hours after delivery diagnostic considerations newborns at '\n",
      " 'increased risk for gonococcal ophthalmia  include those who did not receive '\n",
      " 'ophthalmic prophylaxis  and whose mothers had no prenatal care have a '\n",
      " 'history  of stis during pregnancy or have a history of substance  misuse '\n",
      " 'gonococcal ophthalmia is strongly suspected when  intracellular gramnegative '\n",
      " 'diplococci are identified on gram  stain of conjunctival exudate justifying '\n",
      " 'presumptive treatment  for gonorrhea after appropriate cultures and '\n",
      " 'antimicrobial  susceptibility testing for n gonorrhoeae are performed  '\n",
      " 'presumptive treatment for n gonorrhoeae might be indicated  for newborns at '\n",
      " 'increased risk for gonococcal ophthalmia who  have increased wbcs no gnid in '\n",
      " 'a gramstained smear  of conjunctival exudate nongonococcal causes of '\n",
      " 'neonatal  ophthalmia include moraxella catarrhalis and other neisseria  '\n",
      " 'species which are organisms that are indistinguishable from  n gonorrhoeae '\n",
      " 'on gramstained smear but can be differentiated  in the microbiology '\n",
      " 'laboratory recommendations and reports mmwr  july 23 2021  vol 70  no 4 79us '\n",
      " 'department of health and human servicescenters for disease control and '\n",
      " 'prevention treatment of gonococcal ophthalmia neonatorum recommended regimen '\n",
      " 'for gonococcal ophthalmia  neonatorum ceftriaxone 25–50 mgkg body weight iv '\n",
      " 'or im in a single dose not to  exceed 250 mg one dose of ceftriaxone is '\n",
      " 'adequate therapy for gonococcal  ophthalmia ceftriaxone should be '\n",
      " 'administered cautiously  to neonates with hyperbilirubinemia especially '\n",
      " 'those born  prematurely cefotaxime 100 mgkg body weight iv or im as  a '\n",
      " 'single dose can be administered for those neonates unable to  receive '\n",
      " 'ceftriaxone because of simultaneous administration of  iv calcium topical '\n",
      " 'antibiotic therapy alone is inadequate and  unnecessary if systemic '\n",
      " 'treatment is administered other management considerations chlamydial testing '\n",
      " 'should be performed simultaneously from  the inverted eyelid specimen see '\n",
      " 'ophthalmia neonatorum  caused by c trachomatis newborns who have gonococcal  '\n",
      " 'ophthalmia should be evaluated for signs of disseminated  infection eg '\n",
      " 'sepsis arthritis and meningitis newborns  who have gonococcal ophthalmia '\n",
      " 'should be managed in  consultation with an infectious disease specialist '\n",
      " 'management of mothers and their sex partners mothers of newborns with '\n",
      " 'ophthalmia neonatorum caused by  n gonorrhoeae should be evaluated tested '\n",
      " 'and presumptively  treated for gonorrhea along with their sex partners see  '\n",
      " 'gonococcal infection among adolescents and adults disseminated gonococcal '\n",
      " 'infection and  gonococcal scalp abscesses among neonates dgi might present '\n",
      " 'as sepsis arthritis or meningitis and  is a rare complication of neonatal '\n",
      " 'gonococcal infection  localized gonococcal infection of the scalp can '\n",
      " 'result  from fetal monitoring through scalp electrodes detecting  gonococcal '\n",
      " 'infection among neonates who have sepsis arthritis  meningitis or scalp '\n",
      " 'abscesses requires cultures of blood csf  or joint aspirate specimens '\n",
      " 'obtained from the conjunctiva  vagina oropharynx and rectum are useful for '\n",
      " 'identifying the  primary site or sites of infection antimicrobial '\n",
      " 'susceptibility  testing of all isolates should be performed positive gram '\n",
      " 'stained smears of abscess exudate csf or joint aspirate provide  a '\n",
      " 'presumptive basis for initiating treatment for n gonorrhoeae treatment '\n",
      " 'recommended regimens for disseminated gonococcal  infection among neonates '\n",
      " 'ceftriaxone 25–50 mgkg body weightday iv or im in a single  daily dose for 7 '\n",
      " 'days with a duration of 10–14 days if meningitis is  documented or '\n",
      " 'cefotaxime 25 mgkg body weightday iv or im every 12 hours for  7 days with a '\n",
      " 'duration of 10–14 days if meningitis is documented ceftriaxone should be '\n",
      " 'administered cautiously to neonates  with hyperbilirubinemia especially '\n",
      " 'those born prematurely  cefotaxime 100 mgkg body weight iv or im as a '\n",
      " 'single  dose can be administered for those neonates unable to  receive '\n",
      " 'ceftriaxone because of simultaneous administration  of iv calcium other '\n",
      " 'management considerations chlamydial testing should be performed '\n",
      " 'simultaneously  among neonates with gonococcal infection see chlamydial  '\n",
      " 'infection among neonates neonates who have dgi should  be managed in '\n",
      " 'consultation with an infectious disease specialist management of mothers and '\n",
      " 'their sex partners mothers of newborns who have dgi or scalp abscesses '\n",
      " 'caused  by n gonorrhoeae should be evaluated tested and presumptively  '\n",
      " 'treated for gonorrhea along with their sex partners see  gonococcal '\n",
      " 'infection among adolescents and adults neonates born to mothers who have '\n",
      " 'gonococcal  infection neonates born to mothers who have untreated gonorrhea  '\n",
      " 'are at high risk for infection neonates should be tested for  gonorrhea at '\n",
      " 'exposed sites eg conjunctiva vagina rectum  and oropharynx and treated '\n",
      " 'presumptively for gonorrhea treatment in the absence of signs of gonococcal  '\n",
      " 'infection recommended regimen for neonates without signs of  gonococcal '\n",
      " 'infection ceftriaxone 20–50 mgkg body weight iv or im in a single dose not '\n",
      " 'to  exceed 250 mg other management considerations ceftriaxone should be '\n",
      " 'administered cautiously to neonates  with hyperbilirubinemia especially '\n",
      " 'those born prematurely  cefotaxime 100 mgkg body weight iv or im as a '\n",
      " 'single  dose can be administered for those neonates unable to  receive '\n",
      " 'ceftriaxone because of simultaneous administration  of iv calcium '\n",
      " 'ageappropriate chlamydial testing should be  recommendations and reports 80 '\n",
      " 'mmwr  july 23 2021  vol 70  no 4 us department of health and human '\n",
      " 'servicescenters for disease control and prevention performed simultaneously '\n",
      " 'among neonates with gonococcal  infection see chlamydial infection among '\n",
      " 'neonates  followup examination is not required management of mothers and '\n",
      " 'their sex partners mothers who have gonorrhea and their sex partners should  '\n",
      " 'be evaluated tested and presumptively treated for gonorrhea  see gonococcal '\n",
      " 'infection among adolescents and adults gonococcal infection among  infants '\n",
      " 'and children sexual abuse is the most frequent cause of gonococcal  '\n",
      " 'infection among infants and children see sexual assault or  abuse of '\n",
      " 'children for preadolescent girls vaginitis is the  most common manifestation '\n",
      " 'of this infection gonococcal associated pid after vaginal infection can be '\n",
      " 'less common  among preadolescents than adults among sexually abused  '\n",
      " 'children anorectal and pharyngeal infections with n  gonorrhoeae are '\n",
      " 'frequently asymptomatic diagnostic considerations culture can be used to '\n",
      " 'test urogenital and extragenital sites for  girls and boys naat can be used '\n",
      " 'to test for n gonorrhoeae from  vaginal and urine specimens from girls and '\n",
      " 'urine for boys see  sexual assault or abuse of children although data '\n",
      " 'regarding  naat from extragenital sites rectum and pharynx among  children '\n",
      " 'are more limited and performance is test dependent  no evidence supports '\n",
      " 'that performance of naat for detection  of n gonorrhoeae among children '\n",
      " 'differs from that among adults  553 because of the implications of a n '\n",
      " 'gonorrhoeae diagnosis  in a child only validated fdacleared naat assays '\n",
      " 'should be  used with extragenital specimens consultation with an expert  is '\n",
      " 'necessary before using naat to minimize the possibility of  crossreaction '\n",
      " 'with nongonococcal neisseria species and other  commensals eg n meningitidis '\n",
      " 'neisseria sicca neisseria  lactamica neisseria cinerea or m catarrhalis and '\n",
      " 'to ensure  correct interpretation of results gram stains are inadequate for '\n",
      " 'evaluating prepubertal children  for gonorrhea and should not be used to '\n",
      " 'diagnose or exclude  gonorrhea if evidence of dgi exists gonorrhea culture '\n",
      " 'and  antimicrobial susceptibility testing should be obtained from  relevant '\n",
      " 'clinical sites see disseminated gonococcal infection recommended regimen for '\n",
      " 'uncomplicated gonococcal  vulvovaginitis cervicitis urethritis pharyngitis '\n",
      " 'or proctitis  among infants and children weighing ≤45 kg ceftriaxone 25–50 '\n",
      " 'mgkg body weight iv or im in a single dose not to  exceed 250 mg im '\n",
      " 'recommended regimen for uncomplicated gonococcal  vulvovaginitis cervicitis '\n",
      " 'urethritis pharyngitis or proctitis  among children weighing 45 kg treat '\n",
      " 'with the regimen recommended for adults   see gonococcal infections '\n",
      " 'recommended regimen for bacteremia or arthritis among  children weighing ≤45 '\n",
      " 'kg  ceftriaxone 50 mgkg body weight maximum dose 2 g im or iv in a  single '\n",
      " 'dose daily every 24 hours for 7 days recommended regimen for bacteremia or '\n",
      " 'arthritis among  children weighing 45 kg  ceftriaxone 1 g im or iv in a '\n",
      " 'single dose daily every 24 hours for 7 days other management considerations '\n",
      " 'followup cultures are unnecessary only parenteral  cephalosporins ie '\n",
      " 'ceftriaxone are recommended for use  among children all children identified '\n",
      " 'as having gonococcal  infections should be tested for c trachomatis syphilis '\n",
      " 'and  hiv see sexual assault or abuse of children mycoplasma genitalium m '\n",
      " 'genitalium causes symptomatic and asymptomatic  urethritis among men and is '\n",
      " 'the etiology of approximately  15–20 of ngu 20–25 of nonchlamydial ngu  and '\n",
      " '40 of persistent or recurrent urethritis 697909910  infection with c '\n",
      " 'trachomatis is common in selected geographic  areas 911–913 although m '\n",
      " 'genitalium is often the sole  pathogen data are insufficient to implicate m '\n",
      " 'genitalium  infection with chronic complications among men eg  epididymitis '\n",
      " 'prostatitis or infertility the consequences  of asymptomatic infection with '\n",
      " 'm genitalium among men  are unknown among women m genitalium has been '\n",
      " 'associated with  cervicitis pid preterm delivery spontaneous abortion and  '\n",
      " 'infertility with an approximately twofold increase in the risk  for these '\n",
      " 'outcomes among women infected with m genitalium  766 m genitalium infections '\n",
      " 'among women are also  frequently asymptomatic and the consequences '\n",
      " 'associated  with asymptomatic m genitalium infection are unknown m '\n",
      " 'genitalium can be detected among 10–30 of women  with clinical cervicitis '\n",
      " '767770772914–916 the existing  evidence between m genitalium and cervicitis '\n",
      " 'is mostly  supportive of a causal association elevated proinflammatory  '\n",
      " 'cytokines have been demonstrated among women with  m genitalium with return '\n",
      " 'to baseline levels after clearance of  the pathogen 917 recommendations and '\n",
      " 'reports mmwr  july 23 2021  vol 70  no 4 81us department of health and human '\n",
      " 'servicescenters for disease control and prevention m genitalium is '\n",
      " 'identified in the cervix or endometrium  of women with pid more often than '\n",
      " 'in women without pid  918–924 prevalence of m genitalium among women with  '\n",
      " 'pid ranges from 4 to 22 925926 and was reported  as 60 in one study of women '\n",
      " 'with postabortal pid 918  the association with pid is supported by early '\n",
      " 'studies among  nonhuman primates that determined that endosalpingitis  '\n",
      " 'develops after inoculation with m genitalium 927 recent  studies evaluating '\n",
      " 'the lower and upper genital tract using  highly sensitive m genitalium naat '\n",
      " 'assays or the role of  m genitalium in histologically defined endometritis '\n",
      " 'have  reported significantly elevated risk for pid 928 however  most studies '\n",
      " 'of m genitalium and pid even those that  controlled extensively for other '\n",
      " 'infections and behavioral and  biologic risk are crosssectional the few '\n",
      " 'prospective studies  that have evaluated the role of m genitalium in '\n",
      " 'establishing  subsequent pid demonstrated increased pid risk however  these '\n",
      " 'were not statistically significant associations often  because of a lack of '\n",
      " 'statistical power no clinical trial data are  available that demonstrate '\n",
      " 'that treating m genitalium cervical  infection prevents development of pid '\n",
      " 'or endometritis  although data regarding the benefits of testing women with  '\n",
      " 'pid for m genitalium and the importance of directing  treatment against this '\n",
      " 'organism are limited the associations of  m genitalium with cervicitis and '\n",
      " 'pid in crosssectional studies  using naat testing are consistent 928 data '\n",
      " 'from casecontrol serologic studies 929–931  and a metaanalysis of clinical '\n",
      " 'studies 766 indicate a  potential role in causing infertility however '\n",
      " 'seroassays are  suboptimal and inconclusive similarly evidence for a role '\n",
      " 'for  m genitalium infection during pregnancy as a cause of perinatal  '\n",
      " 'complications including preterm delivery spontaneous  abortion or low '\n",
      " 'birthweight are conflicting because evidence is  insufficient to attribute '\n",
      " 'cause 766932–934 data are limited  regarding ectopic pregnancy and neonatal '\n",
      " 'm genitalium  infection 935936 rectal infection with m genitalium has been '\n",
      " 'reported among  1–26 of msm 937–940 and among 3 of women  941 rectal '\n",
      " 'infections often are asymptomatic although  higher prevalence of m '\n",
      " 'genitalium has been reported among  men with rectal symptoms similarly '\n",
      " 'although asymptomatic  m genitalium has been detected in the pharynx no '\n",
      " 'evidence  exists of it causing oropharyngeal symptoms or systemic disease '\n",
      " 'urogenital m genitalium infection is associated with hiv  among both men and '\n",
      " 'women 942–944 however the data  are from casecontrol and crosssectional '\n",
      " 'studies risk for hiv  infection is increased among women with m genitalium '\n",
      " 'and  evidence indicates that hiv shedding occurs more often among  persons '\n",
      " 'with m genitalium and hiv infection who are not taking  art than among '\n",
      " 'persons without m genitalium 942944 antimicrobial resistance resistance to '\n",
      " 'azithromycin has been rapidly increasing  and has been confirmed in multiple '\n",
      " 'studies prevalence of  molecular markers for macrolide resistance which '\n",
      " 'highly  correlates with treatment failure ranges from 44 to 90  in the '\n",
      " 'united states canada western europe and australia  697702945–953 treatment '\n",
      " 'with azithromycin alone  has been reported to select for resistance '\n",
      " '705954955  with treatment of macrolidesusceptible infections with a  1g dose '\n",
      " 'of azithromycin resulting in selection of resistant strain populations in '\n",
      " '10–12 of cases the prevalence of  quinolone resistance markers is much lower '\n",
      " '697956–959  the first clinical treatment failures after moxifloxacin were  '\n",
      " 'associated specifically with the s83i mutation in the parc gene  954960 '\n",
      " 'prevalence of the s83i mutation in the united  states ranges from 0 to 15 '\n",
      " '947 however correlation  with fluoroquinolone treatment failure is less '\n",
      " 'consistent than  that with mutations associated with macrolide resistance  '\n",
      " '953961962 clinically relevant quinolone resistance often  is associated with '\n",
      " 'coexistent macrolide resistance 954 diagnostic considerations m genitalium '\n",
      " 'is an extremely slowgrowing organism culture  can take up to 6 months and '\n",
      " 'technical laboratory capacity is  limited to research settings naat for m '\n",
      " 'genitalium is fda  cleared for use with urine and urethral penile meatal '\n",
      " 'endocervical  and vaginal swab samples httpswwwhologiccompackage '\n",
      " 'insertsdiagnosticproductsaptimamycoplasmagenitalium assay molecular tests '\n",
      " 'for macrolide ie azithromycin or  quinolone ie moxifloxacin resistance '\n",
      " 'markers are not  commercially available in the united states however '\n",
      " 'molecular  assays that incorporate detection of mutations associated with  '\n",
      " 'macrolide resistance are under evaluation men with recurrent ngu should be '\n",
      " 'tested for m genitalium  using an fdacleared naat if resistance testing is '\n",
      " 'available  it should be performed and the results used to guide therapy  '\n",
      " 'women with recurrent cervicitis should be tested for  m genitalium and '\n",
      " 'testing should be considered among women  with pid testing should be '\n",
      " 'accompanied with resistance  testing if available screening of asymptomatic '\n",
      " 'm genitalium  infection among women and men or extragenital testing  for m '\n",
      " 'genitalium is not recommended in clinical practice  if testing is '\n",
      " 'unavailable m genitalium should be suspected  in cases of persistent or '\n",
      " 'recurrent urethritis or cervicitis and  considered for pid '\n",
      " 'httpswwwhologiccompackageinsertsdiagnosticproductsaptimamycoplasmagenitaliumassay '\n",
      " 'httpswwwhologiccompackageinsertsdiagnosticproductsaptimamycoplasmagenitaliumassay '\n",
      " 'httpswwwhologiccompackageinsertsdiagnosticproductsaptimamycoplasmagenitaliumassay '\n",
      " 'recommendations and reports 82 mmwr  july 23 2021  vol 70  no 4 us '\n",
      " 'department of health and human servicescenters for disease control and '\n",
      " 'prevention treatment m genitalium lacks a cell wall and thus antibiotics '\n",
      " 'targeting  cellwall biosynthesis eg ßlactams including penicillins and  '\n",
      " 'cephalosporins are ineffective against this organism because  of the high '\n",
      " 'rates of macrolide resistance with treatment failures  707 and efficient '\n",
      " 'selection of additional resistance a 1g dose  of azithromycin should not be '\n",
      " 'used twostage therapy approaches ideally using resistance guided therapy are '\n",
      " 'recommended for treatment resistance guided therapy has demonstrated cure '\n",
      " 'rates of 90 and  should be used whenever possible 759963 however it  '\n",
      " 'requires access to macrolideresistance testing as part of this  approach '\n",
      " 'doxycycline is provided as initial empiric therapy  which reduces the '\n",
      " 'organism load and facilitates organism  clearance followed by '\n",
      " 'macrolidesensitive m genitalium  infections treated with highdose '\n",
      " 'azithromycin macrolide resistant infections are treated with moxifloxacin '\n",
      " '964965 recommended regimens if m genitalium resistance testing is  available '\n",
      " 'if macrolide sensitive doxycycline 100 mg orally 2 timesday for  7 days '\n",
      " 'followed by azithromycin 1 g orally initial dose followed by  500 mg orally '\n",
      " 'daily for 3 additional days 25 g total if macrolide resistant doxycycline '\n",
      " '100 mg orally 2 timesday for 7 days  followed by moxifloxacin 400 mg orally '\n",
      " 'once daily for 7 days recommended regimen if m genitalium resistance testing '\n",
      " 'is  not available if m genitalium is detected by an fdacleared naat '\n",
      " 'doxycycline  100 mg orally 2 timesday for 7 days followed by moxifloxacin '\n",
      " '400 mg  orally once daily for 7 days although the majority of m genitalium '\n",
      " 'strains are sensitive  to moxifloxacin resistance has been reported and '\n",
      " 'adverse  side effects and cost should be considered with this regimen  in '\n",
      " 'settings without access to resistance testing and when  moxifloxacin cannot '\n",
      " 'be used an alternative regimen can be  considered based on limited data '\n",
      " 'doxycycline 100 mg orally  2 timesday for 7 days followed by azithromycin 1 '\n",
      " 'g orally  on day 1 followed by 500 mg once daily for 3 days and a test  of '\n",
      " 'cure 21 days after completion of therapy 963 because of  the high prevalence '\n",
      " 'of macrolide resistance and high likelihood  of treatment failure this '\n",
      " 'regimen should be used only when  a test of cure is possible and no other '\n",
      " 'alternatives exist if  symptomatic treatment failure or a positive test of '\n",
      " 'cure occurs  after this regimen expert consultation is recommended  data are '\n",
      " 'limited regarding use of minocycline in instances of  treatment failure 966 '\n",
      " 'recommended pid treatment regimens are not effective  against m genitalium '\n",
      " 'initial empiric therapy for pid which  includes doxycycline 100 mg orally 2 '\n",
      " 'timesday for 14 days  should be provided at the time of presentation for '\n",
      " 'care if  m genitalium is detected a regimen of moxifloxacin 400 mg  orally '\n",
      " 'once daily for 14 days has been effective in eradicating the  organism '\n",
      " 'nevertheless no data have been published that assess  the benefits of '\n",
      " 'testing women with pid for m genitalium and  the importance of directing '\n",
      " 'treatment against this organism  is unknown followup test of cure is not '\n",
      " 'recommended for asymptomatic persons  who received treatment with a '\n",
      " 'recommended regimen in  settings in which m genitalium testing is available '\n",
      " 'persons  with persistent urethritis cervicitis or pid accompanied by  '\n",
      " 'detection of m genitalium should be treated with moxifloxacin management of '\n",
      " 'sex partners recent studies report a high concordance of m genitalium  among '\n",
      " 'partners of males females and msm however no  studies have determined '\n",
      " 'whether reinfection is reduced with  partner treatment 940967968 sex '\n",
      " 'partners of patients  with symptomatic m genitalium infection can be tested '\n",
      " 'and  those with a positive test can be treated to possibly reduce the  risk '\n",
      " 'for reinfection if testing the partner is not possible the  antimicrobial '\n",
      " 'regimen that was provided to the patient can  be provided special '\n",
      " 'considerations hiv infection persons who have m genitalium and hiv infection '\n",
      " 'should  receive the same treatment regimen as those persons without hiv '\n",
      " 'diseases characterized by  vulvovaginal itching burning  irritation odor or '\n",
      " 'discharge the majority of women will have a vaginal infection  characterized '\n",
      " 'by discharge itching burning or odor during  their lifetime with the '\n",
      " 'availability of complementary and  alternative therapies and overthecounter '\n",
      " 'medications for  candidiasis symptomatic women often seek these products  '\n",
      " 'before or in addition to an evaluation by a medical provider obtaining a '\n",
      " 'medical history alone has been reported to  be insufficient for accurate '\n",
      " 'diagnosis of vaginitis and can  lead to inappropriate administration of '\n",
      " 'medication 969  therefore a careful history examination and laboratory  '\n",
      " 'testing to determine the etiology of any vaginal symptoms  are warranted '\n",
      " 'information regarding sexual behaviors and  recommendations and reports '\n",
      " 'mmwr  july 23 2021  vol 70  no 4 83us department of health and human '\n",
      " 'servicescenters for disease control and prevention practices sex of sex '\n",
      " 'partners menses vaginal hygiene practices  eg douching and selftreatment '\n",
      " 'with oral and intravaginal  medications or other products should be elicited '\n",
      " 'the  infections most frequently associated with vaginal symptoms  are bv ie '\n",
      " 'replacement of the vaginal flora by an overgrowth  of anaerobic bacteria '\n",
      " 'including g vaginalis prevotella bivia  a vaginae megasphaera type 1 and '\n",
      " 'numerous other fastidious  or uncultivated anaerobes trichomoniasis and '\n",
      " 'vulvovaginal  candidiasis vvc cervicitis can also cause an abnormal  vaginal '\n",
      " 'discharge although vvc is usually not sexually  transmitted it is included '\n",
      " 'in this section because it is frequently  diagnosed among women who have '\n",
      " 'vaginal symptoms or are  being evaluated for an sti multiple diagnostic '\n",
      " 'methods are available for identifying the  etiology of vaginal symptoms '\n",
      " 'clinical laboratory testing can  identify the vaginitis cause in the '\n",
      " 'majority of women and is  discussed in detail in the sections of this report '\n",
      " 'dedicated to  each condition in the clinician’s office the cause of vaginal  '\n",
      " 'symptoms can often be determined by ph a potassium  hydroxide koh test and '\n",
      " 'microscopic examination of a wet  mount of fresh samples of vaginal '\n",
      " 'discharge the ph of the  vaginal secretions can be measured by ph paper an '\n",
      " 'elevated  ph ie 45 is common with bv or trichomoniasis although  '\n",
      " 'trichomoniasis can also be present with a normal vaginal ph  because ph '\n",
      " 'testing is not highly specific vaginal discharge  should be further examined '\n",
      " 'microscopically by first diluting  one sample in 1 or 2 drops of 09 normal '\n",
      " 'saline solution on  one slide and a second sample in 10 koh solution '\n",
      " 'samples  that emit an amine odor immediately upon application of  koh '\n",
      " 'suggest bv or trichomoniasis coverslips are then  placed on the slides and '\n",
      " 'they are examined under a microscope  at low and high power the '\n",
      " 'salinesolution specimen might  display motile trichomonads or clue cells ie '\n",
      " 'epithelial cells  with borders obscured by small anaerobic bacteria which  '\n",
      " 'are characteristic of bv the koh specimen typically is used  to identify '\n",
      " 'hyphae or blastospores observed with candidiasis  however absence of '\n",
      " 'trichomonads in saline or fungal elements  in koh samples does not rule out '\n",
      " 'these infections because the  sensitivity of microscopy is approximately 50 '\n",
      " 'compared with  naat trichomoniasis or culture yeast 670 presence of  wbcs '\n",
      " 'without evidence of trichomonads or yeast might also  indicate cervicitis '\n",
      " 'see cervicitis in settings where ph paper koh and microscopy  are '\n",
      " 'unavailable a broad range of clinical laboratory tests  described in the '\n",
      " 'diagnosis section for each disease can be  used presence of objective signs '\n",
      " 'of vulvovaginal inflammation  in the absence of vaginal pathogens after '\n",
      " 'laboratory testing  indicates the possibility of mechanical chemical '\n",
      " 'allergic or  other noninfectious causes of vulvovaginal signs or symptoms  '\n",
      " 'for women with persistent symptoms and no clear etiology  referral to a '\n",
      " 'specialist should be considered bacterial vaginosis bv is a vaginal '\n",
      " 'dysbiosis resulting from replacement of normal  hydrogen peroxide and '\n",
      " 'lacticacid–producing lactobacillus  species in the vagina with high '\n",
      " 'concentrations of anaerobic  bacteria including g vaginalis prevotella '\n",
      " 'species mobiluncus  species a vaginae and other bvassociated bacteria a '\n",
      " 'notable  feature is the appearance of a polymicrobial biofilm on vaginal  '\n",
      " 'epithelial cells 970 certain women experience transient  vaginal microbial '\n",
      " 'changes whereas others experience them for  longer intervals 971 bv is a '\n",
      " 'highly prevalent condition and  the most common cause of vaginal discharge '\n",
      " 'worldwide 972  however in a nationally representative survey the majority '\n",
      " 'of  women with bv were asymptomatic 310 bv is associated with having '\n",
      " 'multiple male sex partners  female partners sexual relationships with more '\n",
      " 'than one person  973 a new sex partner lack of condom use 974 douching  '\n",
      " '975976 and hsv2 seropositivity 977 male circumcision  reduces the risk for '\n",
      " 'bv among women 978 in addition bv  prevalence increases during menses 979980 '\n",
      " 'women who  have never been sexually active are rarely affected 981 the  '\n",
      " 'cause of the microbial alteration that precipitates bv is not  fully '\n",
      " 'understood and whether bv results from acquisition  of a single sexually '\n",
      " 'transmitted pathogen is unknown bv  prevalence has been reported to increase '\n",
      " 'among women with  coppercontaining iuds 972982 hormonal contraception  does '\n",
      " 'not increase risk for bv 983 and might protect against  bv development '\n",
      " '983984 vitamin d deficiency has not  been reported to be a risk factor for '\n",
      " 'bv 985 women with bv are at increased risk for sti acquisition  such as hiv '\n",
      " 'n gonorrhoeae c trachomatis t vaginalis  977 m genitalium 986 hpv 987 and '\n",
      " 'hsv2 988  complications after gynecologic surgery complications of  '\n",
      " 'pregnancy and recurrence of bv 971989–991 bv also  increases hiv infection '\n",
      " 'acquisition 992 because specific  bvassociated bacteria can increase '\n",
      " 'susceptibility to hiv  993994 and the risk for hiv transmission to male  sex '\n",
      " 'partners 187 evaluation of shortterm valacyclovir  suppression among women '\n",
      " 'with hsv2 did not decrease the  risk for bv despite effective suppression of '\n",
      " 'hsv2 995 although bvassociated bacteria can be identified on male  genitalia '\n",
      " '996997 treatment of male sex partners has not been  beneficial in preventing '\n",
      " 'the recurrence of bv 998 among  wsw a high level of bv concordance occurs '\n",
      " 'between sex  partners 292 however no studies have evaluated treatment  of '\n",
      " 'female sex partners of wsw to prevent bv recurrence recommendations and '\n",
      " 'reports 84 mmwr  july 23 2021  vol 70  no 4 us department of health and '\n",
      " 'human servicescenters for disease control and prevention diagnostic '\n",
      " 'considerations bv can be diagnosed by using clinical criteria ie  amsel’s '\n",
      " 'diagnostic criteria 999 or by determining the  nugent score from a vaginal '\n",
      " 'gram stain 1000 vaginal  gram stain considered the reference standard '\n",
      " 'laboratory  method for diagnosing bv is used to determine the relative  '\n",
      " 'concentration of lactobacilli ie long grampositive rods  small gramnegative '\n",
      " 'and gramvariable rods ie g vaginalis or  bacteroides and curved gramnegative '\n",
      " 'rods ie mobiluncus  characteristic of bv a nugent score of 0–3 is consistent '\n",
      " 'with  a lactobacilluspredominant vaginal microbiota 4–6 with  intermediate '\n",
      " 'microbiota emergence of g vaginalis and 7–10  with bv clinical diagnosis of '\n",
      " 'bv by amsel criteria requires at  least three of the following four symptoms '\n",
      " 'or signs • homogeneous thin discharge milklike consistency that  smoothly '\n",
      " 'coats the vaginal walls • clue cells eg vaginal epithelial cells studded '\n",
      " 'with  adherent bacteria on microscopic examination • ph of vaginal fluid 45 '\n",
      " '• a fishy odor of vaginal discharge before or after addition  of 10 koh ie '\n",
      " 'the whiff test detection of at least three amsel criteria has been '\n",
      " 'correlated  with results by gram stain 1001 the sensitivity and  specificity '\n",
      " 'of the amsel criteria are 37–70 and 94–99  respectively compared with the '\n",
      " 'nugent score 1002 in addition to the amsel criteria multiple poc tests are  '\n",
      " 'available for bv diagnosis the osom bv blue test sekisui  diagnostics '\n",
      " 'detects vaginal sialidase activity 10031004  the affirm vp iii becton '\n",
      " 'dickinson is an oligonucleotide  probe test that detects high concentrations '\n",
      " 'of g vaginalis  nucleic acids 5 x 105 cfu of g vaginalisml of vaginal  fluid '\n",
      " 'for diagnosing bv candida species and t vaginalis  this test has been '\n",
      " 'reported to be most useful for symptomatic  women in conjunction with '\n",
      " 'vaginal ph measurement and  presence of amine odor sensitivity of 97 '\n",
      " 'specificity is  81 compared with nugent finally the femexam test  card '\n",
      " 'cooper surgical measures vaginal ph presence of  trimethylamine a metabolic '\n",
      " 'byproduct of g vaginalis  and proline aminopeptidase 1005 sensitivity is 91 '\n",
      " 'and  specificity is 61 compared with nugent this test has  primarily been '\n",
      " 'studied in resourcepoor settings 1005 and  although it has been reported to '\n",
      " 'be beneficial compared with  syndromic management it is not a preferred '\n",
      " 'diagnostic method  for bv diagnosis multiple bv naats are available for bv '\n",
      " 'diagnosis among  symptomatic women 1002 these tests are based on detection  '\n",
      " 'of specific bacterial nucleic acids and have high sensitivity  and '\n",
      " 'specificity for bv ie g vaginalis a vaginae bvab2  or megasphaera type 1 '\n",
      " '1006 and certain lactobacilli ie  lactobacillus crispatus lactobacillus '\n",
      " 'jensenii and lactobacillus  gasseri they can be performed on either '\n",
      " 'clinician or self collected vaginal specimens with results available in 24 '\n",
      " 'hours  depending on the availability of the molecular diagnostic  platform '\n",
      " '1002 five quantitative multiplex pcr assays are  available max vaginal panel '\n",
      " 'becton dickinson 1007  aptima bv hologic nuswab vg labcorp 1008  oneswab bv '\n",
      " 'panel pcr with lactobacillus profiling by qpcr  medical diagnostic '\n",
      " 'laboratories 1009 and sureswab bv  quest diagnostics two of these assays are '\n",
      " 'fda cleared bd  max vaginal panel and aptima bv and the other three are  '\n",
      " 'laboratorydeveloped tests the max vaginal panel provides results by an '\n",
      " 'algorithmic  analysis of molecular dna detection of lactobacillus species  l '\n",
      " 'crispatus and l jensenii in addition to g vaginalis  a vaginae bvab2 and '\n",
      " 'megasphaera type 1 this test has  905 sensitivity and 858 specificity for bv '\n",
      " 'diagnosis  compared with amsel criteria and nugent score it also provides  '\n",
      " 'results for candida species and t vaginalis the aptima bv  detects g '\n",
      " 'vaginalis a vaginae and certain lactobacillus species  including l crispatus '\n",
      " 'l jensenii and l gasseri with sensitivity  and specificity ranging from 950 '\n",
      " 'to 973 and 858 to  896 respectively using either clinician or '\n",
      " 'patientcollected  vaginal swabs the three laboratorydeveloped tests nuswab  '\n",
      " 'vg oneswab bv panel pcr with lactobacillus profiling by  qpcr and sureswab '\n",
      " 'bv have to be internally validated before  use for patient care yet have '\n",
      " 'good sensitivity and specificity  similar to fdacleared assays bv naats '\n",
      " 'should be used  among symptomatic women only eg women with vaginal  '\n",
      " 'discharge odor or itch because their accuracy is not well  defined for '\n",
      " 'asymptomatic women despite the availability of  bv naats traditional methods '\n",
      " 'of bv diagnosis including  the amsel criteria nugent score and the affirm vp '\n",
      " 'iii assay  remain useful for diagnosing symptomatic bv because of their  '\n",
      " 'lower cost and ability to provide a rapid diagnosis culture of  g vaginalis '\n",
      " 'is not recommended as a diagnostic tool because  it is not specific cervical '\n",
      " 'pap tests have no clinical utility for  diagnosing bv because of their low '\n",
      " 'sensitivity and specificity treatment treatment for bv is recommended for '\n",
      " 'women with  symptoms established benefits of therapy among nonpregnant  '\n",
      " 'women are to relieve vaginal symptoms and signs of infection  other '\n",
      " 'potential benefits of treatment include reduction  in the risk for acquiring '\n",
      " 'c trachomatis n gonorrhoeae  t vaginalis m genitalium hiv hpv and hsv2 '\n",
      " '971986– 9889901010 no data are available that directly compare  the efficacy '\n",
      " 'of oral and topical medications for treating bv recommendations and reports '\n",
      " 'mmwr  july 23 2021  vol 70  no 4 85us department of health and human '\n",
      " 'servicescenters for disease control and prevention recommended regimens for '\n",
      " 'bacterial vaginosis metronidazole 500 mg orally 2 timesday for 7 days or '\n",
      " 'metronidazole gel 075 one full applicator 5 g intravaginally once  daily for '\n",
      " '5 days or clindamycin cream 2 one full applicator 5 g intravaginally at  '\n",
      " 'bedtime for 7 days a review regarding alcohol consumption during  '\n",
      " 'metronidazole treatment reported no in vitro studies animal  models reports '\n",
      " 'of adverse effects or clinical studies providing  convincing evidence of a '\n",
      " 'disulfiramlike interaction between  alcohol and metronidazole 1011 the '\n",
      " 'previous warning  against simultaneous use of alcohol and metronidazole was  '\n",
      " 'based on laboratory experiments and individual case histories  in which the '\n",
      " 'reported reactions were equally likely to have been  caused by alcohol alone '\n",
      " 'or by adverse effects of metronidazole metronidazole does not inhibit '\n",
      " 'acetaldehyde dehydrogenase  as occurs with disulfiram ethanol alone or '\n",
      " 'ethanol independent side effects of metronidazole might explain the  '\n",
      " 'suspicion of disulfiramlike effects thus refraining from  alcohol use while '\n",
      " 'taking metronidazole or tinidazole is  unnecessary clindamycin cream is oil '\n",
      " 'based and might weaken  latex condoms and diaphragms for 5 days after use '\n",
      " 'refer to  clindamycin product labeling for additional information women '\n",
      " 'should be advised to refrain from sexual activity  or to use condoms '\n",
      " 'consistently and correctly during the bv  treatment regimen douching might '\n",
      " 'increase the risk for  relapse and no data support use of douching for '\n",
      " 'treatment  or symptom relief alternative regimens clindamycin 300 mg orally '\n",
      " '2 timesday for 7 days or clindamycin ovules 100 mg intravaginally once at '\n",
      " 'bedtime for 3 days or secnidazole 2 g oral granules in a single dose† or '\n",
      " 'tinidazole 2 g orally once daily for 2 days or tinidazole 1 g orally once '\n",
      " 'daily for 5 days  clindamycin ovules use an oleaginous base that might '\n",
      " 'weaken latex or  rubber products eg condoms and diaphragms use of such '\n",
      " 'products  within 72 hours after treatment with clindamycin ovules is not  '\n",
      " 'recommended † oral granules should be sprinkled onto unsweetened applesauce '\n",
      " 'yogurt  or pudding before ingestion a glass of water can be taken after  '\n",
      " 'administration to aid in swallowing alternative regimens include secnidazole '\n",
      " 'oral granules  1012–1014 multiple oral tinidazole regimens 1015 or  '\n",
      " 'clindamycin oral or intravaginal 1016 in a phase 3 clinical  trial of '\n",
      " 'secnidazole 2 g oral granules versus placebo bv  clinical cure rates at days '\n",
      " '21–30 were 53 in the secnidazole  arm compared with 19 in the placebo arm '\n",
      " 'p0001  1013 secnidazole is listed as an alternative regimen due  to its '\n",
      " 'higher cost and lack of longterm outcomes compared  with recommended bv '\n",
      " 'treatments a patient savings card  for secnidazole is available at '\n",
      " 'httpswwwsoloseccom savingscard additional bv treatment regimens include '\n",
      " 'metronidazole  13 vaginal gel in a single dose 10171018 and clindamycin  '\n",
      " 'phosphate clindesse 2 vaginal cream in a single dose  1019 in a phase 3 '\n",
      " 'clinical trial of metronidazole 13 vaginal  gel versus placebo bv clinical '\n",
      " 'cure rates at day 21 were 372  in the metronidazole 13 vaginal gel arm '\n",
      " 'compared with  266 in the placebo arm p  001 1018 a patient savings  card '\n",
      " 'for metronidazole 13 vaginal gel is available at https '\n",
      " 'nuvessacomnuvessafiles19nuvessawebcard032819 pdf in a multicenter randomized '\n",
      " 'singleblind parallel group study of clindesse 2 vaginal cream single dose '\n",
      " 'versus  clindamycin 2 vaginal cream at bedtime for 7 days among  540 women '\n",
      " 'with bv no statistically significant difference  existed between groups in '\n",
      " 'clinical cure at days 21–30 643  versus 632 p  095 1019 however this study '\n",
      " 'had  methodologic problems a patient savings card for clindesse  2 vaginal '\n",
      " 'cream is available at httpswwwclindessecom pdfclindessesavingscardpdf bv '\n",
      " 'biofilm disrupting agents ie tol463 1020 are  being investigated to '\n",
      " 'determine their role in enhancing the  likelihood of bv cure relative to '\n",
      " 'approved therapies studies  have evaluated the clinical and microbiologic '\n",
      " 'efficacy of  intravaginal lactobacillus and other probiotic formulations to  '\n",
      " 'treat bv and restore normal vaginal microbiota 1021–1025  overall no studies '\n",
      " 'support these products as an adjunctive or  replacement therapy for women '\n",
      " 'with bv other management considerations all women with bv should be tested '\n",
      " 'for hiv and other stis followup followup visits are unnecessary if symptoms '\n",
      " 'resolve because  persistent or recurrent bv is common women should be '\n",
      " 'advised  to return for evaluation if symptoms recur limited data are  '\n",
      " 'available regarding optimal management strategies for women  with persistent '\n",
      " 'or recurrent bv using a different recommended  treatment regimen can be '\n",
      " 'considered for women who have a  recurrence however retreatment with the '\n",
      " 'same recommended  regimen is an acceptable approach for treating persistent '\n",
      " 'or  recurrent bv after the first occurrence 1026 for women with  multiple '\n",
      " 'recurrences after completion of a recommended regimen  either 075 '\n",
      " 'metronidazole gel or 750 mg metronidazole vaginal  suppository twice weekly '\n",
      " 'for 3 months has been reported to  reduce recurrences although this benefit '\n",
      " 'does not persist when  httpswwwsoloseccomsavingscard '\n",
      " 'httpswwwsoloseccomsavingscard httpswwwclindessecompdfclindessesavingscardpdf '\n",
      " 'httpswwwclindessecompdfclindessesavingscardpdf recommendations and reports '\n",
      " '86 mmwr  july 23 2021  vol 70  no 4 us department of health and human '\n",
      " 'servicescenters for disease control and prevention suppressive therapy is '\n",
      " 'discontinued 10271028 limited data  indicate that for women with multiple '\n",
      " 'recurrences an oral  nitroimidazole metronidazole or tinidazole 500 mg 2 '\n",
      " 'times day for 7 days followed by intravaginal boric acid 600 mg  daily for '\n",
      " '21 days and suppressive 075 metronidazole gel  twice weekly for 4–6 months '\n",
      " 'might be an option for women  with recurrent bv 1029 monthly oral '\n",
      " 'metronidazole 2 g  administered with fluconazole 150 mg has also been '\n",
      " 'evaluated  as suppressive therapy this regimen reduced the bv incidence  and '\n",
      " 'promoted colonization with normal vaginal microbiota  1030 a randomized '\n",
      " 'controlled trial of a dendrimerbased  microbicide 1 vaginal gel astodrimer '\n",
      " 'also reported favorable  results in prolonging the time to bv recurrence '\n",
      " 'compared with  placebo 1031 in addition a clinical trial of l crispatus '\n",
      " 'ctv05  lactinv administered vaginally in 4 consecutive daily doses  for 4 '\n",
      " 'days in week 1 followed by twice weekly doses for 10 weeks  after initial '\n",
      " 'treatment with 5 days of 075 vaginal metronidazole  gel reported a '\n",
      " 'substantially lower incidence of bv recurrence at  12 weeks in the lactinv '\n",
      " 'arm compared with placebo 1032  however this medication is not yet fda '\n",
      " 'cleared or commercially  available highdose vitamin d supplementation has '\n",
      " 'not been  determined to decrease bv recurrence in randomized controlled  '\n",
      " 'trials 1033 and is not recommended management of sex partners data from '\n",
      " 'earlier clinical trials indicate that a woman’s  response to therapy and the '\n",
      " 'likelihood of relapse or  recurrence are not affected by treatment of her '\n",
      " 'sex partner  998 therefore routine treatment of sex partners is not  '\n",
      " 'recommended however a pilot study reported that male  partner treatment ie '\n",
      " 'metronidazole 400 mg orally 2 times day in conjunction with 2 clindamycin '\n",
      " 'cream applied  topically to the penile skin 2 timesday for 7 days of women  '\n",
      " 'with recurrent bv had an immediate and sustained effect on  the composition '\n",
      " 'of the vaginal microbiota with an overall  decrease in bacterial diversity '\n",
      " 'at day 28 1034 male partner  treatment also had an immediate effect on the '\n",
      " 'composition of  the penile microbiota however this was not as pronounced  at '\n",
      " 'day 28 compared with that among women a phase 3  multicenter randomized '\n",
      " 'doubleblinded trial evaluating the  efficacy of a 7day oral metronidazole '\n",
      " 'regimen versus placebo  for treatment of male sex partners of women with '\n",
      " 'recurrent  bv did not find that male partner treatment reduced bv  '\n",
      " 'recurrence in female partners although women whose male  partners adhered to '\n",
      " 'multidose metronidazole were less likely  to experience treatment failure '\n",
      " '1035 special considerations drug allergy intolerance or adverse reactions '\n",
      " 'intravaginal clindamycin cream is preferred in case of allergy  or '\n",
      " 'intolerance to metronidazole or tinidazole intravaginal  metronidazole gel '\n",
      " 'can be considered for women who are not  allergic to metronidazole but do '\n",
      " 'not tolerate oral metronidazole pregnancy bv treatment is recommended for '\n",
      " 'all symptomatic pregnant  women because symptomatic bv has been associated '\n",
      " 'with  adverse pregnancy outcomes including premature rupture  of membranes '\n",
      " 'preterm birth intraamniotic infection and  postpartum endometritis '\n",
      " '9899911036 studies have been  undertaken to determine the efficacy of bv '\n",
      " 'treatment among  this population including two trials demonstrating that '\n",
      " 'oral  metronidazole was efficacious during pregnancy by using  the 250 mg 3 '\n",
      " 'timesday regimen 10371038 however oral  metronidazole administered as a 500 '\n",
      " 'mg 2 timesday regimen  can also be used one trial involving a limited number '\n",
      " 'of  participants revealed treatment with oral metronidazole  500 mg 2 '\n",
      " 'timesday for 7 days to be equally effective as  metronidazole gel 075 for 5 '\n",
      " 'days with cure rates of 70  by using amsel criteria to define cure 1039 '\n",
      " 'another trial  demonstrated a cure rate of 85 by using gramstain criteria  '\n",
      " 'after treatment with oral clindamycin 300 mg 2 timesday for  7 days '\n",
      " '1040–1043 although older studies indicated a possible link between  using '\n",
      " 'vaginal clindamycin during pregnancy and adverse  outcomes for the newborn '\n",
      " 'newer data demonstrate that  this treatment approach is safe for pregnant '\n",
      " 'women 1044  although metronidazole crosses the placenta no evidence of  '\n",
      " 'teratogenicity or mutagenic effects among infants has been  reported in '\n",
      " 'multiple crosssectional casecontrol and cohort  studies of pregnant women '\n",
      " '1041–1043 these data indicate  that metronidazole therapy poses low risk '\n",
      " 'during pregnancy  data from human studies are limited regarding the use of  '\n",
      " 'tinidazole in pregnancy however animal data demonstrate  that such therapy '\n",
      " 'poses moderate risk thus tinidazole should  be avoided during pregnancy 431 '\n",
      " 'data are insufficient  regarding efficacy and adverse effects of secnidazole '\n",
      " 'clindesse  2 vaginal cream metronidazole 13 vaginal gel and  750mg vaginal '\n",
      " 'metronidazole tablets during pregnancy thus  their use should be avoided '\n",
      " 'oral therapy has not been reported to be superior to topical  therapy for '\n",
      " 'treating symptomatic bv in effecting cure or  preventing adverse outcomes of '\n",
      " 'pregnancy pregnant women  can be treated with any of the recommended '\n",
      " 'regimens for  nonpregnant women in addition to the alternative regimens  of '\n",
      " 'oral clindamycin and clindamycin ovules recommendations and reports mmwr  '\n",
      " 'july 23 2021  vol 70  no 4 87us department of health and human '\n",
      " 'servicescenters for disease control and prevention treatment of asymptomatic '\n",
      " 'bv among pregnant women  at high risk for preterm delivery ie those with a '\n",
      " 'previous  preterm birth or late miscarriage has been evaluated by  multiple '\n",
      " 'studies which have yielded mixed results seven  trials have evaluated '\n",
      " 'treatment of pregnant women with  asymptomatic bv at high risk for preterm '\n",
      " 'delivery one revealed  harm 1045 two reported no benefit 10461047 and four  '\n",
      " 'demonstrated benefit 1037103810481049 treatment of asymptomatic bv among '\n",
      " 'pregnant women  at low risk for preterm delivery has not been reported to  '\n",
      " 'reduce adverse outcomes of pregnancy in a large multicenter  randomized '\n",
      " 'controlled trial 1050 therefore routine  screening for bv among asymptomatic '\n",
      " 'pregnant women at  high or low risk for preterm delivery for preventing '\n",
      " 'preterm  birth is not recommended metronidazole is secreted in breast milk '\n",
      " 'with maternal  oral therapy breastfed infants receive metronidazole in '\n",
      " 'doses  that are less than those used to treat infections among infants  '\n",
      " 'although the active metabolite adds to the total infant exposure  plasma '\n",
      " 'levels of the drug and metabolite are measurable  but remain less than '\n",
      " 'maternal plasma levels httpswww ncbinlmnihgovbooksnbk501922reportclassic  '\n",
      " 'although multiple reported case series identified no evidence  of '\n",
      " 'metronidazoleassociated adverse effects for breastfed  infants certain '\n",
      " 'clinicians recommend deferring breastfeeding  for 12–24 hours after maternal '\n",
      " 'treatment with a single 2g  dose of metronidazole 1051 lower doses produce a '\n",
      " 'lower  concentration in breast milk and are considered compatible  with '\n",
      " 'breastfeeding 10521053 hiv infection bv appears to recur with higher '\n",
      " 'frequency among women  who have hiv infection 1054 women with hiv infection  '\n",
      " 'and bv should receive the same treatment regimen as those  who do not have '\n",
      " 'hiv trichomoniasis trichomoniasis is estimated to be the most prevalent '\n",
      " 'nonviral  sti worldwide affecting approximately 37 million persons  in the '\n",
      " 'united states 8381055 because trichomoniasis is  not a reportable disease '\n",
      " '1056 and no recommendations are  available for general screening for t '\n",
      " 'vaginalis the epidemiology  of trichomoniasis has largely come from '\n",
      " 'populationbased and  clinicbased surveillance studies the us '\n",
      " 'populationbased  t vaginalis prevalence is 21 among females and 05 among  '\n",
      " 'males with the highest rates among black females 96  and black males 36 '\n",
      " 'compared with nonhispanic white  women 08 and hispanic women 14 10571058  '\n",
      " 'unlike chlamydia and gonorrhea t vaginalis prevalence  rates are as high '\n",
      " 'among women aged 24 years as they are  for women aged 24 years 1057 among '\n",
      " 'persons attending  nine geographically diverse std clinics the trichomonas  '\n",
      " 'prevalence was 146 among women 1059 and a study  of std clinic attendees in '\n",
      " 'birmingham alabama identified  a prevalence of 27 among women and 98 among '\n",
      " 'men  1060 symptomatic women have a four times higher rate of  infection than '\n",
      " 'asymptomatic women 26 versus 65 1061  rates are also high among incarcerated '\n",
      " 'persons of both sexes at  9–32 of incarcerated women 3863873913921062 and  '\n",
      " '32–8 of incarcerated men 388 women with a history of  incarceration are two '\n",
      " 'to five times more likely to have t vaginalis  38738810631064 other risk '\n",
      " 'factors for t vaginalis include  having two or more sex partners during the '\n",
      " 'previous year having  less than a high school education and living below the '\n",
      " 'national  poverty level 1065 women with bv are at higher risk for  t '\n",
      " 'vaginalis 1066 male partners of women with trichomoniasis  are likely to '\n",
      " 'have infection 1067 although the prevalence of  trichomoniasis among msm is '\n",
      " 'low 1791068 the majority of persons who have trichomoniasis  70–85 either '\n",
      " 'have minimal or no genital symptoms  and untreated infections might last '\n",
      " 'from months to years  13710691070 men with trichomoniasis sometimes have  '\n",
      " 'symptoms of urethritis epididymitis or prostatitis and women  with '\n",
      " 'trichomoniasis sometimes have vaginal discharge which  can be diffuse '\n",
      " 'malodorous or yellowgreen with or without  vulvar irritation and might have '\n",
      " 'a strawberryappearing cervix  which is observed more often on colposcopy '\n",
      " 'than on physical  examination 1071 although many persons might be unaware  '\n",
      " 'of their infection it is readily passed between sex partners  during '\n",
      " 'penilevaginal sex 1072 or through transmission of  infected vaginal fluids '\n",
      " 'or fomites among women who have sex  with women 275294 among persons who are '\n",
      " 'sexually active the best way to  prevent genital trichomoniasis is through '\n",
      " 'consistent and correct  use of condoms external or internal 18 partners of '\n",
      " 'men  who have been circumcised might have a somewhat reduced  risk for t '\n",
      " 'vaginalis infection 10721073 douching is not  recommended because it might '\n",
      " 'increase the risk for vaginal  infections including trichomoniasis 1074 t '\n",
      " 'vaginalis causes reproductive morbidity and has been  reported to be '\n",
      " 'associated with a 14times greater likelihood  of preterm birth premature '\n",
      " 'rupture of membranes and  infants who are small for gestational age 1075 t '\n",
      " 'vaginalis  was also determined to be associated with a 21fold increased  '\n",
      " 'risk for cervical cancer in a metaanalysis 1076 another  metaanalysis of six '\n",
      " 'studies reported a slightly elevated but  not statistically significant '\n",
      " 'association between t vaginalis and  prostate cancer 1077 '\n",
      " 'httpswwwncbinlmnihgovbooksnbk501922reportclassic '\n",
      " 'httpswwwncbinlmnihgovbooksnbk501922reportclassic recommendations and reports '\n",
      " '88 mmwr  july 23 2021  vol 70  no 4 us department of health and human '\n",
      " 'servicescenters for disease control and prevention t vaginalis infection is '\n",
      " 'associated with a 15fold increased risk  for hiv acquisition and is '\n",
      " 'associated with an increase in hiv  vaginal shedding which is reduced with t '\n",
      " 'vaginalis treatment  among women without viral suppression 10781079 among  '\n",
      " 'women with hiv infection t vaginalis infection is associated  with increased '\n",
      " 'risk for pid 1080–1082 diagnostic testing for t vaginalis should be '\n",
      " 'performed for  women seeking care for vaginal discharge annual screening  '\n",
      " 'might be considered for persons receiving care in high prevalence settings '\n",
      " 'eg std clinics and correctional facilities  and for asymptomatic women at '\n",
      " 'high risk for infection eg  multiple sex partners transactional sex drug '\n",
      " 'misuse or a  history of stis or incarceration however data are lacking  '\n",
      " 'regarding whether screening and treatment for asymptomatic  trichomoniasis '\n",
      " 'in highprevalence settings for women at high  risk can reduce any adverse '\n",
      " 'health events and health disparities  or reduce community infection burden '\n",
      " 'decisions about  screening can be guided by local epidemiology of t '\n",
      " 'vaginalis  infection routine annual screening for t vaginalis among  '\n",
      " 'asymptomatic women with hiv infection is recommended  because of these '\n",
      " 'adverse events associated with trichomoniasis  and hiv infection '\n",
      " 'extragenital t vaginalis is possible but highly uncommon  compared with '\n",
      " 'genital infections a study of 500 men in san  francisco california reported '\n",
      " 'a 06 rate of rectal t vaginalis  1083 however this might reflect deposition '\n",
      " 'of t vaginalis  dna and not necessarily active infection few studies of  '\n",
      " 'extragenital t vaginalis among women have been published  the efficacy '\n",
      " 'benefit and costeffectiveness of extragenital  screening are unknown and no '\n",
      " 'tests are fda cleared for  extragenital testing therefore rectal and oral '\n",
      " 'testing for  t vaginalis is not recommended diagnostic considerations '\n",
      " 'wetmount microscopy traditionally has been used as  the preferred diagnostic '\n",
      " 'test for t vaginalis among women  because it is inexpensive and can be '\n",
      " 'performed at the poc  however it has low sensitivity 44–68 compared with  '\n",
      " 'culture 1084–1086 to improve detection clinicians using  wet mounts should '\n",
      " 'attempt to evaluate slides immediately  after specimen collection because '\n",
      " 'sensitivity decreases quickly  to 20 within 1 hour after collection 1087 '\n",
      " 'more highly  sensitive and specific molecular diagnostic options are '\n",
      " 'available  which should be used in conjunction with a negative wet  mount '\n",
      " 'when possible naats are highly sensitive detecting more t vaginalis  '\n",
      " 'infections than wetmount microscopy among women  1060 the aptima t vaginalis '\n",
      " 'assay beckton dickinson is  fda cleared for detection of t vaginalis from '\n",
      " 'symptomatic  or asymptomatic women reliable samples include  '\n",
      " 'cliniciancollected endocervical swabs cliniciancollected  vaginal swabs '\n",
      " 'female urine specimens and liquid pap  smear specimens collected in '\n",
      " 'preservcyt solution hologic  6981088 this assay detects rna by transcription '\n",
      " 'mediated amplification with a sensitivity of 953–100  and specificity of '\n",
      " '952–100 compared with wet mount  and culture 10881089 among women vaginal '\n",
      " 'swabs and  urine specimens have 100 concordance 1084 this assay  has not '\n",
      " 'been fda cleared for use among men and should be  internally validated in '\n",
      " 'accordance with clia regulations before  use with urine or urethral swabs '\n",
      " 'from men the probe tec tv  qx amplified dna assay becton dickinson is fda '\n",
      " 'cleared  for detection of t vaginalis from vaginal patientcollected  or '\n",
      " 'cliniciancollected swabs endocervical swabs or urine  specimens from women '\n",
      " 'and has sensitivity of 983 and  specificity of 996 compared with wet mount '\n",
      " 'and culture  1090 similar to the aptima t vaginalis assay this test is only  '\n",
      " 'fda cleared for use among women and should be internally  validated for use '\n",
      " 'with men the max ctgctv2 assay becton  dickinson is also fda cleared for '\n",
      " 'detection of t vaginalis in  patientcollected or cliniciancollected vaginal '\n",
      " 'swab specimens  and male and female urine specimens with sensitivity and  '\n",
      " 'specificity of 962–100 and 991–100 respectively  depending on the specimen '\n",
      " 'type compared with wet mount  and culture 1091 genexpert tv cepheid is a '\n",
      " 'moderately  complex rapid test that can be performed in ≤1 hour and can be  '\n",
      " 'used at the poc 1092 it has been fda cleared for use with  female urine '\n",
      " 'specimens endocervical swabs patientcollected  or cliniciancollected vaginal '\n",
      " 'specimens and male urine  specimens with sensitivity and specificity of '\n",
      " '995–100  and 994–999 1007 respectively compared with wet  mount and culture '\n",
      " 'multiple fdacleared rapid tests are available for detecting  t vaginalis '\n",
      " 'with improved sensitivities and specificities  compared with wet mount the '\n",
      " 'osom trichomonas rapid  test sekisui diagnostics is an antigendetection test '\n",
      " 'that uses  immunochromatographic capillary flow dipstick technology  that '\n",
      " 'can be performed at the poc by using clinicianobtained  vaginal specimens '\n",
      " 'results are available in approximately  10–15 minutes with sensitivities of '\n",
      " '82–95 and specificity  of 97–100 compared with wet mount culture and  '\n",
      " 'transcriptionmediated amplification 108910931094 a  study of 209 women aged '\n",
      " '14–22 years reported that 99  could correctly perform and interpret a '\n",
      " 'vaginal selftest by  using the osom assay with a high correlation with '\n",
      " 'clinician  interpretation 96 agreement κ\\xa0\\xa0087 1094 the osom  test '\n",
      " 'should not be used with men because of low sensitivity  38 compared with '\n",
      " 'aptima 1095 the solana trichomonas  assay quidel is another rapid test for '\n",
      " 'the qualitative detection  of t vaginalis dna and can yield results 40 '\n",
      " 'minutes after  recommendations and reports mmwr  july 23 2021  vol 70  no 4 '\n",
      " '89us department of health and human servicescenters for disease control and '\n",
      " 'prevention specimen collection this assay is fda cleared for diagnosing  t '\n",
      " 'vaginalis from female vaginal and urine specimens from  asymptomatic and '\n",
      " 'symptomatic women with sensitivity 98  compared with naat for vaginal '\n",
      " 'specimens and 92 for  urine specimens 1096 the amplivue trichomonas assay  '\n",
      " 'quidel is another rapid test providing qualitative detection  of t vaginalis '\n",
      " 'that has been fda cleared for vaginal specimens  from symptomatic and '\n",
      " 'asymptomatic women with sensitivity  of 907 and specificity of 989 compared '\n",
      " 'with naat  1097 neither the osom assay nor the affirm vp iii test is  fda '\n",
      " 'cleared for use with specimens from men culture such as the inpouch system '\n",
      " 'biomed diagnostics  was considered the most sensitive method for diagnosing  '\n",
      " 't vaginalis infection before molecular detection methods  became available '\n",
      " 'culture has sensitivity of 44–75 and  specificity of 100 69810861098 for '\n",
      " 'women vaginal  secretions are the preferred specimen type for culture '\n",
      " 'because  urine culture is less sensitive 69810991100 for men  culture '\n",
      " 'specimens require a urethral swab urine sediment  or semen to improve '\n",
      " 'diagnostic yield multiple specimens  from men can be used to inoculate a '\n",
      " 'single culture cultures  require an incubator and are necessary for t '\n",
      " 'vaginalis drug  susceptibility testing the inpouch specimen should be  '\n",
      " 'examined daily for 5 days over a 7day period to reduce the  possibility of '\n",
      " 'false negatives 1101 although t vaginalis might be an incidental finding on '\n",
      " 'a  pap test neither conventional nor liquidbased pap smears  are considered '\n",
      " 'diagnostic tests for trichomoniasis however  women with t vaginalis '\n",
      " 'identified on a pap smear should be  retested with sensitive diagnostic '\n",
      " 'tests and treated if infection  is confirmed 11021103 treatment treatment '\n",
      " 'reduces symptoms and signs of t vaginalis  infection and might reduce '\n",
      " 'transmission treatment  recommendations for women are based on a '\n",
      " 'metaanalysis  1104 and a multicenter randomized trial of mostly  symptomatic '\n",
      " 'women without hiv infection 1105 the  study demonstrated that multidose '\n",
      " 'metronidazole 500 mg  orally 2 timesday for 7 days reduced the proportion '\n",
      " 'of  women retesting positive at a 1month test of cure visit by half  '\n",
      " 'compared with women who received the 2g single doseno  published randomized '\n",
      " 'trials are available that compare these  doses among men recommended regimen '\n",
      " 'for trichomoniasis among women  metronidazole 500 mg orally 2 timesday for 7 '\n",
      " 'days recommended regimen for trichomoniasis among men  metronidazole 2 g '\n",
      " 'orally in a single dose alternative regimen for women and men tinidazole 2 g '\n",
      " 'orally in a single dose the nitroimidazoles are the only class of '\n",
      " 'medications with  clinically demonstrated efficacy against t vaginalis '\n",
      " 'infections  tinidazole is usually more expensive reaches higher levels in  '\n",
      " 'serum and the genitourinary tract has a longer halflife than  metronidazole '\n",
      " '125 hours versus 73 hours and has fewer  gastrointestinal side effects '\n",
      " '11061107 in randomized  clinical trials recommended metronidazole regimens '\n",
      " 'have  resulted in cure rates of approximately 84–98 1108  and the '\n",
      " 'recommended tinidazole regimen has resulted in cure  rates of approximately '\n",
      " '92–100 1108–1112 randomized  controlled trials comparing single 2g doses of '\n",
      " 'metronidazole  and tinidazole indicated that tinidazole is equivalent or '\n",
      " 'superior  to metronidazole in achieving parasitologic cure and symptom  '\n",
      " 'resolution 111011131114 metronidazole gel does not reach therapeutic levels '\n",
      " 'in the  urethra and perivaginal glands because it is less efficacious  than '\n",
      " 'oral metronidazole it is not recommended other management considerations '\n",
      " 'providers should advise persons with t vaginalis infections  to abstain from '\n",
      " 'sex until they and their sex partners are treated  ie when therapy has been '\n",
      " 'completed and any symptoms  have resolved testing for other stis including '\n",
      " 'hiv syphilis  gonorrhea and chlamydia should be performed for persons  with '\n",
      " 't vaginalis followup because of the high rate of reinfection among women '\n",
      " 'treated  for trichomoniasis retesting for t vaginalis is recommended  for '\n",
      " 'all sexually active women 3 months after initial treatment  regardless of '\n",
      " 'whether they believe their sex partners were  treated 1371115 if retesting '\n",
      " 'at 3 months is not possible  clinicians should retest whenever persons next '\n",
      " 'seek medical  care 12 months after initial treatment data are insufficient  '\n",
      " 'to support retesting men after treatment management of sex partners '\n",
      " 'concurrent treatment of all sex partners is vital for  preventing '\n",
      " 'reinfections current partners should be referred  for presumptive therapy '\n",
      " 'partners also should be advised to  abstain from intercourse until they and '\n",
      " 'their sex partners  have been treated and any symptoms have resolved ept  '\n",
      " 'might have a role in partner management for trichomoniasis  1291116 and can '\n",
      " 'be used in states where permissible by law  '\n",
      " 'httpswwwcdcgovstdeptlegaldefaulthtm however no  partner management '\n",
      " 'intervention has been demonstrated to  be superior in reducing reinfection '\n",
      " 'rates 129130 although  httpswwwcdcgovstdeptlegaldefaulthtm recommendations '\n",
      " 'and reports 90 mmwr  july 23 2021  vol 70  no 4 us department of health and '\n",
      " 'human servicescenters for disease control and prevention no definitive data '\n",
      " 'exist to guide treatment for partners of  persons with persistent or '\n",
      " 'recurrent trichomoniasis among  whom nonadherence and reinfection are '\n",
      " 'unlikely partners  might benefit from being evaluated and receiving '\n",
      " 'treatment  see recurrent trichomoniasis recurrent trichomoniasis a recurrent '\n",
      " 'infection can result from treatment failure  antimicrobialresistant t '\n",
      " 'vaginalis or hostrelated problems  lack of adherence or reinfection from an '\n",
      " 'untreated sex partner  in the case of a recurrent infection the origin of '\n",
      " 'the repeat  infection should be assessed because most recurrent infections  '\n",
      " 'likely result from reinfection retesting can be considered in  cases of '\n",
      " 'persistent or recurrent trichomoniasis with culture the  preferred test if '\n",
      " 'naat is used it should not be conducted before  3 weeks after treatment '\n",
      " 'completion because of possible detection  of residual nucleic acid that is '\n",
      " 'not clinically relevant 1117 the nitroimidazoles are the only class of '\n",
      " 'antimicrobials  known to be effective against trichomonas infection  '\n",
      " 'metronidazole resistance occurs in 4–10 of cases of  vaginal trichomoniasis '\n",
      " '11161118 tinidazole resistance  is less well studied but was present in 1 of '\n",
      " 'infections in  one study 1116 overall more t vaginalis isolates have  '\n",
      " 'reported susceptibility to tinidazole than metronidazole 1119  multidose '\n",
      " 'oral metronidazole is more effective than singledose  treatment particularly '\n",
      " 'for women who are symptomatic or  have a history of t vaginalis 1120 '\n",
      " 'nitroimidazoleresistant trichomoniasis is concerning  because few '\n",
      " 'alternatives to standard therapy exist if treatment  failure occurs in a '\n",
      " 'woman after completing a regimen of  metronidazole 500 mg 2 timesday for 7 '\n",
      " 'days and she has been  reexposed to an untreated partner a repeat course of '\n",
      " 'the same  regimen is recommended if no reexposure has occurred she  should '\n",
      " 'be treated with metronidazole or tinidazole 2 g once  daily for 7 days if a '\n",
      " 'man has persistent t vaginalis after a  single 2g dose of metronidazole and '\n",
      " 'has been reexposed to  an untreated partner he should be retreated with a '\n",
      " 'single 2g  dose of metronidazole if he has not been reexposed he should  be '\n",
      " 'administered a course of metronidazole 500 mg 2 times day for 7 days for '\n",
      " 'persons who are experiencing persistent infection  not attributable to '\n",
      " 'reexposure clinicians should request a  kit from cdc to perform '\n",
      " 'drugresistance testing https wwwcdcgovlaboratoryspecimensubmissiondetail '\n",
      " 'htmlcdctestcodecdc10239 cdc is experienced with  susceptibility testing for '\n",
      " 'nitroimidazoleresistant t vaginalis  and can provide guidance regarding '\n",
      " 'treatment in cases of  drug resistance on the basis of drug resistance '\n",
      " 'testing an  alternative treatment regimen might be recommended  treatments '\n",
      " 'for infections demonstrating in vitro resistance  can include metronidazole '\n",
      " 'or tinidazole 2 g daily for 7 days  if a patient has treatment failure after '\n",
      " 'the 7day regimen of  highdose oral metronidazole or tinidazole two '\n",
      " 'additional  treatment options have been determined to have successful  '\n",
      " 'results for women the first is highdose oral tinidazole  2 g daily plus '\n",
      " 'intravaginal tinidazole 500 mg 2 timesday for  14 days 1121 if this regimen '\n",
      " 'fails highdose oral tinidazole  1 g 3 timesday plus intravaginal paromomycin '\n",
      " '4 g of 625  intravaginal paromomycin cream nightly for 14 days should  be '\n",
      " 'considered 1122 alternative regimens might be effective but have not been  '\n",
      " 'systemically evaluated therefore consultation with an infectious  disease '\n",
      " 'specialist is recommended clinical improvement has  been reported with '\n",
      " 'intravaginal boric acid 11231124 but  not with nitazoxanide 1123–1125 the '\n",
      " 'following topically  applied agents have minimal success 50 and are not  '\n",
      " 'recommended intravaginal betadine povidoneiodine  clotrimazole acetic acid '\n",
      " 'furazolidone gv nonoxynol9 and  potassium permanganate 1126 no other topical '\n",
      " 'microbicide  has been reported to be effective against trichomoniasis '\n",
      " 'special considerations drug allergy intolerance and adverse reactions '\n",
      " 'metronidazole and tinidazole are both nitroimidazoles  patients with an '\n",
      " 'igemediatedtype hypersensitivity reaction  to 5nitroimidazole antimicrobials '\n",
      " 'should be managed by  metronidazole desensitization according to published '\n",
      " 'regimens  11271128 and in consultation with an allergy specialist the  '\n",
      " 'optimal treatment for patients with t vaginalis who are unable  to be '\n",
      " 'desensitized has not been systematically investigated and is  based on case '\n",
      " 'reports some of which report using paromomycin  or boric acid for treating t '\n",
      " 'vaginalis 11231129 pregnancy t vaginalis infection among pregnant women is '\n",
      " 'associated  with adverse pregnancy outcomes particularly premature  rupture '\n",
      " 'of membranes preterm delivery and delivery of infants  who are small for '\n",
      " 'gestational age 1075 one randomized  trial of pregnant women with '\n",
      " 'asymptomatic trichomoniasis  reported no substantial difference in preterm '\n",
      " 'birth after  treatment with 2 g of metronidazole 48 hours apart during  '\n",
      " '16–23 and 24–29 weeks’ gestation compared with placebo  1130 however that '\n",
      " 'trial had multiple limitations including  use of an atypical metronidazole '\n",
      " 'regimen another multicenter  observational study of asymptomatic pregnant '\n",
      " 'women in sub sahara african the majority with hiv infection reported  '\n",
      " 'neither trichomoniasis nor its treatment appeared to influence  the risk for '\n",
      " 'preterm birth or a lowbirthweight infant 1131 '\n",
      " 'httpswwwcdcgovlaboratoryspecimensubmissiondetailhtmlcdctestcodecdc10239 '\n",
      " 'httpswwwcdcgovlaboratoryspecimensubmissiondetailhtmlcdctestcodecdc10239 '\n",
      " 'httpswwwcdcgovlaboratoryspecimensubmissiondetailhtmlcdctestcodecdc10239 '\n",
      " 'recommendations and reports mmwr  july 23 2021  vol 70  no 4 91us department '\n",
      " 'of health and human servicescenters for disease control and prevention '\n",
      " 'although metronidazole crosses the placenta data indicate  that it poses a '\n",
      " 'low risk to the developing fetus 104010421132  no evidence of teratogenicity '\n",
      " 'or mutagenic effects among  infants has been found in multiple '\n",
      " 'crosssectional and cohort  studies among pregnant women examining singledose '\n",
      " '2 g  and multidose metronidazole regimens 10401131–1135 symptomatic pregnant '\n",
      " 'women regardless of pregnancy stage  should be tested and treated treatment '\n",
      " 'of t vaginalis infection  can relieve symptoms of vaginal discharge for '\n",
      " 'pregnant women  and reduce sexual transmission to partners although '\n",
      " 'perinatal  transmission of trichomoniasis is uncommon treatment  might also '\n",
      " 'prevent respiratory or genital infection in the  newborn 11361137 clinicians '\n",
      " 'should counsel symptomatic  pregnant women with trichomoniasis about the '\n",
      " 'potential  risks and benefits of treatment and about the importance of  '\n",
      " 'partner treatment and condom use in the prevention of sexual  transmission '\n",
      " 'the benefit of routine screening for t vaginalis  in asymptomatic pregnant '\n",
      " 'women has not been established metronidazole is secreted in breast milk with '\n",
      " 'maternal oral  therapy breastfed infants receive metronidazole in doses '\n",
      " 'that  are lower than those used to treat infections among infants  although '\n",
      " 'the active metabolite adds to the total infant exposure  plasma levels of '\n",
      " 'the drug and metabolite are measurable but  remain less than maternal plasma '\n",
      " 'levels httpswwwncbinlm nihgovbooksnbk501922 although multiple reported case  '\n",
      " 'series studies demonstrated no evidence of adverse effects among  infants '\n",
      " 'exposed to metronidazole in breast milk clinicians  sometimes advise '\n",
      " 'deferring breastfeeding for 12–24 hours after  maternal treatment with '\n",
      " 'metronidazole 1051 in one study  maternal treatment with metronidazole 400 '\n",
      " 'mg 3 timesday  for 7 days produced a lower concentration in breast milk and  '\n",
      " 'was considered compatible with breastfeeding over longer  periods 1052 data '\n",
      " 'from studies involving human subjects are limited  regarding tinidazole use '\n",
      " 'during pregnancy however animal data  indicate this drug poses moderate risk '\n",
      " 'thus tinidazole should  be avoided for pregnant women and breastfeeding '\n",
      " 'should be  deferred for 72 hours after a single 2g oral dose of tinidazole  '\n",
      " 'httpswwwncbinlmnihgovbooksnbk501922 hiv infection up to 53 of women with hiv '\n",
      " 'have t vaginalis infection  11151138 t vaginalis infection among these women '\n",
      " 'is  substantially associated with pelvic inflammatory disease  1082 among '\n",
      " 'women who are not virally suppressed  treatment of trichomoniasis is '\n",
      " 'associated with decreases in  genital tract hiv viral load and viral '\n",
      " 'shedding 10791139  however no difference might occur among women who are  '\n",
      " 'virally suppressed 1140 because of the high prevalence  of t vaginalis among '\n",
      " 'women with hiv and the potential  for adverse reproductive health poor birth '\n",
      " 'outcomes and  possibly amplified hiv transmission routine screening and  '\n",
      " 'prompt treatment are recommended for all women with hiv  infection screening '\n",
      " 'should occur at entry to care and then at  least annually thereafter a '\n",
      " 'randomized clinical trial involving women with hiv  and t vaginalis '\n",
      " 'infection demonstrated that a single dose  of metronidazole 2 g orally was '\n",
      " 'less effective than 500 mg  2 timesday for 7 days 1105 factors that might '\n",
      " 'interfere  with standard singledose treatment for trichomoniasis among  '\n",
      " 'women with hiv include high rates of asymptomatic bv  infection art use '\n",
      " 'changes in vaginal ecology and impaired  immunity 1141 thus to improve cure '\n",
      " 'rates women with  hiv who receive a diagnosis of t vaginalis infection '\n",
      " 'should  be treated with metronidazole 500 mg orally 2 timesday  for 7 days '\n",
      " 'for pregnant women with hiv screening at  the first prenatal visit and '\n",
      " 'prompt treatment as needed are  recommended because t vaginalis infection is '\n",
      " 'a risk factor for  vertical transmission of hiv 1142 treatment treatment '\n",
      " 'reduces symptoms and signs of t vaginalis  infection cures infection and '\n",
      " 'might reduce transmission  likelihood of adverse outcomes among women with '\n",
      " 'hiv  infection is also reduced with t vaginalis therapy recommended regimen '\n",
      " 'for trichomonas and hiv infection  among women  metronidazole 500 mg orally '\n",
      " '2 timesday for 7 days if a woman with hiv infection experiences treatment '\n",
      " 'failure the  protocol outlined is recommended see recurrent trichomonas  '\n",
      " 'other management considerations followup and management  of sex partners '\n",
      " 'should be performed as for women without hiv  infection treatment of men '\n",
      " 'with hiv infection should follow  the same guidelines as for men without hiv '\n",
      " 'for women with hiv who receive a diagnosis of t vaginalis  infection '\n",
      " 'retesting is recommended 3 months after treatment  naat is encouraged '\n",
      " 'because of higher sensitivity of these  tests data are insufficient to '\n",
      " 'support retesting of men with  trichomonas and hiv infection vulvovaginal '\n",
      " 'candidiasis vvc usually is caused by candida albicans but can  occasionally '\n",
      " 'be caused by other candida species or yeasts  typical symptoms of vvc '\n",
      " 'include pruritus vaginal soreness  dyspareunia external dysuria and abnormal '\n",
      " 'vaginal discharge  none of these symptoms is specific for vvc an estimated  '\n",
      " '75 of women will have at least one episode of vvc and  40–45 will have two '\n",
      " 'or more episodes on the basis of  httpswwwncbinlmnihgovbooksnbk501922 '\n",
      " 'httpswwwncbinlmnihgovbooksnbk501922 httpswwwncbinlmnihgovbooksnbk501922 '\n",
      " 'recommendations and reports 92 mmwr  july 23 2021  vol 70  no 4 us '\n",
      " 'department of health and human servicescenters for disease control and '\n",
      " 'prevention clinical presentation microbiology host factors and response  to '\n",
      " 'therapy vvc can be classified as either uncomplicated or  complicated box 4 '\n",
      " 'approximately 10–20 of women  will have complicated vvc requiring special '\n",
      " 'diagnostic and  therapeutic considerations uncomplicated vulvovaginal '\n",
      " 'candidiasis diagnostic considerations a diagnosis of candida vaginitis is '\n",
      " 'clinically indicated by the  presence of external dysuria and vulvar '\n",
      " 'pruritus pain swelling  and redness signs include vulvar edema fissures '\n",
      " 'excoriations  and thick curdy vaginal discharge most healthy women with  '\n",
      " 'uncomplicated vvc have no identifiable precipitating factors  the diagnosis '\n",
      " 'can be made in a woman who has signs and  symptoms of vaginitis when either '\n",
      " 'a wet preparation saline  10 koh of vaginal discharge demonstrates budding  '\n",
      " 'yeasts hyphae or pseudohyphae or a culture or other test  yields a positive '\n",
      " 'result for a yeast species candida vaginitis is  associated with normal '\n",
      " 'vaginal ph 45 use of 10 koh  in wet preparations improves the visualization '\n",
      " 'of yeast and  mycelia by disrupting cellular material that might obscure  '\n",
      " 'the yeast or pseudohyphae examination of a wet mount with  koh preparation '\n",
      " 'should be performed for all women with  symptoms or signs of vvc and women '\n",
      " 'with a positive result  should be treated for those with negative wet mounts '\n",
      " 'but  existing signs or symptoms vaginal cultures for candida should  be '\n",
      " 'considered if candida cultures cannot be performed for  these women empiric '\n",
      " 'treatment can be considered identifying  candida by culture in the absence '\n",
      " 'of symptoms or signs is not  an indication for treatment because '\n",
      " 'approximately 10–20  of women harbor candida species and other yeasts in '\n",
      " 'the  vagina the majority of pcr tests for yeast are not fda  cleared and '\n",
      " 'providers who use these tests should be familiar  with the performance '\n",
      " 'characteristics of the specific test used  yeast culture which can identify '\n",
      " 'a broad group of pathogenic  yeasts remains the reference standard for '\n",
      " 'diagnosis treatment shortcourse topical formulations ie single dose and  '\n",
      " 'regimens of 1–3 days effectively treat uncomplicated vvc  treatment with '\n",
      " 'azoles results in relief of symptoms and negative  cultures in 80–90 of '\n",
      " 'patients who complete therapy recommended regimens for vulvovaginal '\n",
      " 'candidiasis overthecounter intravaginal agents clotrimazole 1 cream 5 g '\n",
      " 'intravaginally daily for 7–14 days or clotrimazole 2 cream 5 g '\n",
      " 'intravaginally daily for 3 days or miconazole 2 cream 5 g intravaginally '\n",
      " 'daily for 7 days or miconazole 4 cream 5 g intravaginally daily for 3 days '\n",
      " 'or miconazole 100 mg vaginal suppository one suppository daily for 7 days or '\n",
      " 'miconazole 200 mg vaginal suppository one suppository for 3 days or '\n",
      " 'miconazole 1200 mg vaginal suppository one suppository for 1 day or '\n",
      " 'tioconazole 65 ointment 5 g intravaginally in a single application '\n",
      " 'prescription intravaginal agents butoconazole 2 cream singledose bioadhesive '\n",
      " 'product 5 g  intravaginally in a single application or terconazole 04 cream '\n",
      " '5 g intravaginally daily for 7 days or terconazole 08 cream 5 g '\n",
      " 'intravaginally daily for 3 days or terconazole 80 mg vaginal suppository one '\n",
      " 'suppository daily for 3 days oral agent fluconazole 150 mg orally in a '\n",
      " 'single dose the creams and suppositories in these regimens are oil  based '\n",
      " 'and might weaken latex condoms and diaphragms  patients should refer to '\n",
      " 'condom product labeling for further  information even women who have '\n",
      " 'previously received a  diagnosis of vvc by a clinician are not necessarily '\n",
      " 'more  likely to be able to diagnose themselves therefore any woman  whose '\n",
      " 'symptoms persist after using an overthecounter  preparation or who has a '\n",
      " 'recurrence of symptoms 2 months  box 4 classification of vulvovaginal '\n",
      " 'candidiasis uncomplicated vulvovaginal candidiasis vvc • sporadic or '\n",
      " 'infrequent vvc  and • mildtomoderate vvc  and • likely to be candida '\n",
      " 'albicans  and • nonimmunocompromised women complicated vvc • recurrent vvc '\n",
      " 'three or more episodes of  symptomatic vvc in 1 year  or • severe vvc  or • '\n",
      " 'non–albicans candidiasis  or • women with diabetes immunocompromising  '\n",
      " 'conditions eg hiv infection underlying  immunodeficiency or '\n",
      " 'immunosuppressive therapy  eg corticosteroids source sobel jd faro s force '\n",
      " 'rw et al\\xa0 vulvovaginal candidiasis  epidemiologic diagnostic and '\n",
      " 'therapeutic considerations\\xa0am j obstet gynecol  1998178203–11 '\n",
      " 'recommendations and reports mmwr  july 23 2021  vol 70  no 4 93us department '\n",
      " 'of health and human servicescenters for disease control and prevention after '\n",
      " 'treatment for vvc should be evaluated clinically and  tested unnecessary or '\n",
      " 'unapproved use of overthecounter  preparations is common and can lead to a '\n",
      " 'delay in treatment  of other vulvovaginitis etiologies which can result in '\n",
      " 'adverse  outcomes no substantial evidence exists to support using  '\n",
      " 'probiotics or homeopathic medications for treating vvc followup followup '\n",
      " 'typically is not required however women with  persistent or recurrent '\n",
      " 'symptoms after treatment should be  instructed to return for followup visits '\n",
      " 'management of sex partners uncomplicated vvc is not usually acquired through '\n",
      " 'sexual  intercourse and data do not support treatment of sex partners  a '\n",
      " 'minority of male sex partners have balanitis characterized  by erythematous '\n",
      " 'areas on the glans of the penis in conjunction  with pruritus or irritation '\n",
      " 'these men benefit from treatment  with topical antifungal agents to relieve '\n",
      " 'symptoms special considerations drug allergy intolerance and adverse '\n",
      " 'reactions topical agents usually cause no systemic side effects although  '\n",
      " 'local burning or irritation might occur oral azoles occasionally  cause '\n",
      " 'nausea abdominal pain and headache therapy with the  oral azoles has rarely '\n",
      " 'been associated with abnormal elevations  of liver enzymes clinically '\n",
      " 'important interactions can occur  when oral azoles are administered with '\n",
      " 'other drugs 1141 complicated vulvovaginal candidiasis diagnostic '\n",
      " 'considerations vaginal culture or pcr should be obtained from women  with '\n",
      " 'complicated vvc to confirm clinical diagnosis and  identify non–albicans '\n",
      " 'candida candida glabrata does not  form pseudohyphae or hyphae and is not '\n",
      " 'easily recognized  on microscopy c albicans azole resistance is becoming '\n",
      " 'more  common in vaginal isolates 11441145 and non–albicans  candida is '\n",
      " 'intrinsically resistant to azoles therefore culture  and susceptibility '\n",
      " 'testing should be considered for patients  who remain symptomatic recurrent '\n",
      " 'vulvovaginal candidiasis recurrent vvc usually defined as three or more '\n",
      " 'episodes  of symptomatic vvc in 1 year affects 5 of women but  carries a '\n",
      " 'substantial economic burden 1146 recurrent vvc  can be either idiopathic or '\n",
      " 'secondary related to frequent  antibiotic use diabetes or other underlying '\n",
      " 'host factors the  pathogenesis of recurrent vvc is poorly understood and '\n",
      " 'the  majority of women with recurrent vvc have no apparent  predisposing or '\n",
      " 'underlying conditions c glabrata and other  non–albicans candida species are '\n",
      " 'observed in 10–20  of women with recurrent vvc conventional antimycotic  '\n",
      " 'therapies are not as effective against these non–albicans yeasts  as against '\n",
      " 'c albicans treatment most episodes of recurrent vvc caused by c albicans  '\n",
      " 'respond well to shortduration oral or topical azole therapy  however to '\n",
      " 'maintain clinical and mycologic control a longer  duration of initial '\n",
      " 'therapy eg 7–14 days of topical therapy  or a 100mg 150mg or 200mg oral dose '\n",
      " 'of fluconazole  every third day for a total of 3 doses days 1 4 and 7  is '\n",
      " 'recommended to attempt mycologic remission before  initiating a maintenance '\n",
      " 'antifungal regimen oral fluconazole ie a 100mg 150mg or 200mg dose  weekly '\n",
      " 'for 6 months is the indicated maintenance regimen  if this regimen is not '\n",
      " 'feasible topical treatments used  intermittently can also be considered '\n",
      " 'suppressive maintenance  therapies are effective at controlling recurrent '\n",
      " 'vvc but are  rarely curative longterm 1147 because c albicans azole  '\n",
      " 'resistance is becoming more common susceptibility tests if  available should '\n",
      " 'be obtained among symptomatic patients who  remain culture positive despite '\n",
      " 'maintenance therapy these  women should be managed in consultation with a '\n",
      " 'specialist severe vulvovaginal candidiasis severe vvc ie extensive vulvar '\n",
      " 'erythema edema  excoriation and fissure formation is associated with lower  '\n",
      " 'clinical response rates among patients treated with short courses  of '\n",
      " 'topical or oral therapy either 7–14 days of topical azole or  150 mg of '\n",
      " 'fluconazole in two sequential oral doses second dose  72 hours after initial '\n",
      " 'dose is recommended non–albicans vulvovaginal candidiasis because '\n",
      " 'approximately 50 of women with a positive culture  for non–albicans candida '\n",
      " 'might be minimally symptomatic or  have no symptoms and because successful '\n",
      " 'treatment is often  difficult clinicians should make every effort to exclude '\n",
      " 'other  causes of vaginal symptoms for women with non–albicans  yeast 1148 '\n",
      " 'the optimal treatment of non–albicans vvc  remains unknown however a longer '\n",
      " 'duration of therapy  7–14 days with a nonfluconazole azole regimen oral or  '\n",
      " 'topical is recommended if recurrence occurs 600 mg of boric  acid in a '\n",
      " 'gelatin capsule administered vaginally once daily for  3 weeks is indicated '\n",
      " 'this regimen has clinical and mycologic  eradication rates of approximately '\n",
      " '70 1149 if symptoms  recur referral to a specialist is advised '\n",
      " 'recommendations and reports 94 mmwr  july 23 2021  vol 70  no 4 us '\n",
      " 'department of health and human servicescenters for disease control and '\n",
      " 'prevention management of sex partners no data exist to support treating sex '\n",
      " 'partners of patients with  complicated vvc therefore no recommendation can '\n",
      " 'be made special considerations compromised host women with underlying '\n",
      " 'immunodeficiency those with  poorly controlled diabetes or other '\n",
      " 'immunocompromising  conditions eg hiv and those receiving immunosuppression  '\n",
      " 'therapy eg corticosteroid treatment might not respond as  well to shortterm '\n",
      " 'therapies efforts to correct modifiable  conditions should be made and more '\n",
      " 'prolonged ie  7–14 days conventional treatment is necessary pregnancy vvc '\n",
      " 'occurs frequently during pregnancy only topical  azole therapies applied for '\n",
      " '7 days are recommended for use  among pregnant women epidemiologic studies '\n",
      " 'indicate a  single 150mg dose of fluconazole might be associated with  '\n",
      " 'spontaneous abortion 1150 and congenital anomalies  therefore it should not '\n",
      " 'be used 1151 hiv infection vaginal candida colonization rates among women '\n",
      " 'with  hiv infection are higher than among women without hiv  with similar '\n",
      " 'demographic and risk behavior characteristics  and the colonization rates '\n",
      " 'correlate with increasing severity of  immunosuppression 1152 symptomatic '\n",
      " 'vvc is also more  frequent among women with hiv infection and similarly  '\n",
      " 'correlates with severity of immunodeficiency 1153 in  addition among women '\n",
      " 'with hiv systemic azole exposure  is associated with isolation of '\n",
      " 'non–albicans candida species  from the vagina treatment for uncomplicated '\n",
      " 'and complicated vvc  among women with hiv infection should not differ from  '\n",
      " 'that for women who do not have hiv although long term prophylactic therapy '\n",
      " 'with fluconazole 200 mg weekly  has been effective in reducing c albicans '\n",
      " 'colonization and  symptomatic vvc 1154 this regimen is not recommended  for '\n",
      " 'women with hiv infection in the absence of complicated  vvc 98 although vvc '\n",
      " 'is associated with increased hiv  seroconversion among hivnegative women and '\n",
      " 'increased  hiv cervicovaginal levels among women with hiv infection  the '\n",
      " 'effect of treatment for vvc on hiv acquisition and  transmission remains '\n",
      " 'unknown pelvic inflammatory disease pid comprises a spectrum of inflammatory '\n",
      " 'disorders of  the upper female genital tract including any combination  of '\n",
      " 'endometritis salpingitis tuboovarian abscess and pelvic  peritonitis '\n",
      " '1155–1157 sexually transmitted organisms  especially n gonorrhoeae and c '\n",
      " 'trachomatis often are  implicated recent studies report that the proportion '\n",
      " 'of  pid cases attributable to n gonorrhoeae or c trachomatis is  decreasing '\n",
      " 'of women who received a diagnosis of acute pid  approximately 50 have a '\n",
      " 'positive test for either of those  organisms 1158–1160 microorganisms that '\n",
      " 'comprise the  vaginal flora such as strict and facultative anaerobes 1160  '\n",
      " 'and g vaginalis h influenzae enteric gramnegative rods and  streptococcus '\n",
      " 'agalactiae have been associated with pid 1161  in addition cytomegalovirus '\n",
      " 'cmv t vaginalis m hominis  and u urealyticum might be associated with '\n",
      " 'certain pid cases  1072 data also indicate that m genitalium might have a '\n",
      " 'role  in pid pathogenesis 765928 and might be associated with  milder '\n",
      " 'symptoms 919923928 although one study failed  to demonstrate a substantial '\n",
      " 'increase in pid after detection of  m genitalium in the lower genital tract '\n",
      " '925 screening and treating sexually active women for chlamydia  and '\n",
      " 'gonorrhea reduces their risk for pid 11621163 although  bv is associated '\n",
      " 'with pid whether pid incidence can be  reduced by identifying and treating '\n",
      " 'women with bv is unclear  1161 whether screening young women for m '\n",
      " 'genitalium is  associated with a reduction in pid is unknown diagnostic '\n",
      " 'considerations acute pid is difficult to diagnose because of the '\n",
      " 'considerable  variation in symptoms and signs associated with this '\n",
      " 'condition  women with pid often have subtle or nonspecific symptoms or  are '\n",
      " 'asymptomatic delay in diagnosis and treatment probably  contributes to '\n",
      " 'inflammatory sequelae in the upper genital tract  laparoscopy can be used to '\n",
      " 'obtain a more accurate diagnosis  of salpingitis and a more complete '\n",
      " 'bacteriologic diagnosis  however this diagnostic tool frequently is not '\n",
      " 'readily available  and its use is not easily justifiable when symptoms are '\n",
      " 'mild or  vague moreover laparoscopy will not detect endometritis and  might '\n",
      " 'not detect subtle inflammation of the fallopian tubes  consequently a pid '\n",
      " 'diagnosis usually is based on imprecise  clinical findings 1164–1166 data '\n",
      " 'indicate that a clinical diagnosis of symptomatic pid  has a positive '\n",
      " 'predictive value for salpingitis of 65–90  compared with laparoscopy '\n",
      " '1167–1170 the positive  predictive value of a clinical diagnosis of acute '\n",
      " 'pid depends on  the epidemiologic characteristics of the population with '\n",
      " 'higher  positive predictive values among sexually active young women  '\n",
      " 'particularly adolescents women attending std clinics and  recommendations '\n",
      " 'and reports mmwr  july 23 2021  vol 70  no 4 95us department of health and '\n",
      " 'human servicescenters for disease control and prevention those who live in '\n",
      " 'communities with high rates of gonorrhea  or chlamydia regardless of '\n",
      " 'positive predictive value no single  historical physical or laboratory '\n",
      " 'finding is both sensitive  and specific for the diagnosis of acute pid '\n",
      " 'combinations of  diagnostic findings that improve either sensitivity ie '\n",
      " 'detect  more women who have pid or specificity ie exclude more  women who do '\n",
      " 'not have pid do so only at the expense of the  other for example requiring '\n",
      " 'two or more findings excludes  more women who do not have pid and reduces '\n",
      " 'the number  of women with pid who are identified episodes of pid often go '\n",
      " 'unrecognized although certain  cases are asymptomatic others are not '\n",
      " 'diagnosed because  the patient or the health care provider do not recognize '\n",
      " 'the  implications of mild or nonspecific symptoms or signs eg  abnormal '\n",
      " 'bleeding dyspareunia and vaginal discharge even  women with mild or '\n",
      " 'asymptomatic pid might be at risk for  infertility 1157 because of the '\n",
      " 'difficulty of diagnosis and  the potential for damage to the reproductive '\n",
      " 'health of women  health care providers should maintain a low threshold for '\n",
      " 'the  clinical diagnosis of pid 1158 the recommendations for  diagnosing pid '\n",
      " 'are intended to assist health care providers to  recognize when pid should '\n",
      " 'be suspected and when additional  information should be obtained to increase '\n",
      " 'diagnostic certainty  diagnosis and management of other causes of lower '\n",
      " 'abdominal  pain eg ectopic pregnancy acute appendicitis ovarian cyst  '\n",
      " 'ovarian torsion or functional pain are unlikely to be impaired  by '\n",
      " 'initiating antimicrobial therapy for pid presumptive  treatment for pid '\n",
      " 'should be initiated for sexually active  young women and other women at risk '\n",
      " 'for stis if they are  experiencing pelvic or lower abdominal pain if no '\n",
      " 'cause for  the illness other than pid can be identified or if one or more  '\n",
      " 'of the following three minimum clinical criteria are present  on pelvic '\n",
      " 'examination cervical motion tenderness uterine  tenderness or adnexal '\n",
      " 'tenderness more specific criteria for diagnosing pid include endometrial  '\n",
      " 'biopsy with histopathologic evidence of endometritis  transvaginal '\n",
      " 'sonography or magnetic resonance imaging  techniques demonstrating thickened '\n",
      " 'fluidfilled tubes with or  without free pelvic fluid or tuboovarian complex '\n",
      " 'or doppler  studies indicating pelvic infection eg tubal hyperemia  and '\n",
      " 'laparoscopic findings consistent with pid a diagnostic  evaluation that '\n",
      " 'includes some of these more extensive  procedures might be warranted in '\n",
      " 'certain cases endometrial  biopsy is warranted for women undergoing '\n",
      " 'laparoscopy who  do not have visual evidence of salpingitis because '\n",
      " 'endometritis  is the only sign of pid for certain women requiring that all '\n",
      " 'three minimum criteria be present  before the initiation of empiric '\n",
      " 'treatment can result in  insufficient sensitivity for a pid diagnosis after '\n",
      " 'deciding  whether to initiate empiric treatment clinicians should also  '\n",
      " 'consider the risk profile for stis more elaborate diagnostic  evaluation '\n",
      " 'frequently is needed because incorrect diagnosis  and management of pid '\n",
      " 'might cause unnecessary morbidity  for example the presence of signs of '\n",
      " 'lower genital tract  inflammation predominance of leukocytes in vaginal  '\n",
      " 'secretions cervical discharge or cervical friability in addition  to one of '\n",
      " 'the three minimum criteria increases the specificity of  the diagnosis one '\n",
      " 'or more of the following additional criteria  can be used to enhance the '\n",
      " 'specificity of the minimum clinical  criteria and support a pid diagnosis • '\n",
      " 'oral temperature 383°c 101°f • abnormal cervical mucopurulent discharge or '\n",
      " 'cervical  friability • presence of abundant numbers of wbcs on saline  '\n",
      " 'microscopy of vaginal fluid • elevated erythrocyte sedimentation rate • '\n",
      " 'elevated creactive protein • laboratory documentation of cervical infection '\n",
      " 'with  n gonorrhoeae or c trachomatis the majority of women with pid have '\n",
      " 'either mucopurulent  cervical discharge or evidence of wbcs on a '\n",
      " 'microscopic  evaluation of a saline preparation of vaginal fluid ie wet  '\n",
      " 'prep if the cervical discharge appears normal and no wbcs  are observed on '\n",
      " 'the wet prep of vaginal fluid a pid diagnosis  is unlikely and alternative '\n",
      " 'causes of pain should be considered  a wet prep of vaginal fluid also can '\n",
      " 'detect the presence of  concomitant infections eg bv or trichomoniasis '\n",
      " 'treatment pid treatment regimens should provide empiric broad spectrum '\n",
      " 'coverage of likely pathogens multiple parenteral and  oral antimicrobial '\n",
      " 'regimens have been effective in achieving  clinical and microbiologic cure '\n",
      " 'in randomized clinical trials  with shortterm followup 1171–1173 however '\n",
      " 'only  a limited number of studies have assessed and compared  these regimens '\n",
      " 'with regard to infection elimination in the  endometrium and fallopian tubes '\n",
      " 'or determined the incidence  of longterm complications eg tubal infertility '\n",
      " 'and ectopic  pregnancy after antimicrobial regimens 115911641174  the '\n",
      " 'optimal treatment regimen and longterm outcome of  early treatment of women '\n",
      " 'with subclinical pid are unknown  all regimens used to treat pid should also '\n",
      " 'be effective against  n gonorrhoeae and c trachomatis because negative '\n",
      " 'endocervical  screening for these organisms does not rule out upper genital  '\n",
      " 'tract infection anaerobic bacteria have been isolated from the  upper '\n",
      " 'genital tract of women who have pid and data from in  vitro studies have '\n",
      " 'revealed that some anaerobes eg bacteroides  fragilis can cause tubal and '\n",
      " 'epithelial destruction bv is often  present among women who have pid '\n",
      " '22116011611175  recommendations and reports 96 mmwr  july 23 2021  vol 70  '\n",
      " 'no 4 us department of health and human servicescenters for disease control '\n",
      " 'and prevention addition of metronidazole to im or oral pid regimens more  '\n",
      " 'effectively eradicates anaerobic organisms from the upper  genital tract '\n",
      " '1160 until treatment regimens that do not  cover anaerobic microbes have '\n",
      " 'been demonstrated to prevent  longterm sequelae eg infertility and ectopic '\n",
      " 'pregnancy  as successfully as the regimens that are effective against these  '\n",
      " 'microbes using regimens with anaerobic activity should  be considered '\n",
      " 'treatment should be initiated as soon as the  presumptive diagnosis has been '\n",
      " 'made because prevention of  longterm sequelae is dependent on early '\n",
      " 'administration of  recommended antimicrobials for women with pid of mild or  '\n",
      " 'moderate clinical severity parenteral and oral regimens appear  to have '\n",
      " 'similar efficacy the decision of whether hospitalization  is necessary '\n",
      " 'should be based on provider judgment and whether  the woman meets any of the '\n",
      " 'following criteria • surgical emergencies eg appendicitis cannot be  '\n",
      " 'excluded • tuboovarian abscess • pregnancy • severe illness nausea and '\n",
      " 'vomiting or oral temperature  385°c 101°f • unable to follow or tolerate an '\n",
      " 'outpatient oral regimen • no clinical response to oral antimicrobial therapy '\n",
      " 'no evidence is available to indicate that adolescents have  improved '\n",
      " 'outcomes from hospitalization for treatment of pid  and the clinical '\n",
      " 'response to outpatient treatment is similar  among younger and older women '\n",
      " 'the decision to hospitalize  adolescents with acute pid should be based on '\n",
      " 'the same criteria  used for older women parenteral treatment randomized '\n",
      " 'trials have demonstrated the efficacy of  parenteral regimens '\n",
      " '1160117111721176 clinical  experience should guide decisions regarding '\n",
      " 'transition to oral  therapy which usually can be initiated within 24–48 '\n",
      " 'hours of  clinical improvement for women with tuboovarian abscesses  24 '\n",
      " 'hours of inpatient observation is recommended recommended parenteral '\n",
      " 'regimens for pelvic inflammatory  disease ceftriaxone 1 g by every 24 hours '\n",
      " 'plus doxycycline 100 mg orally or iv every 12 hours plus metronidazole 500 '\n",
      " 'mg orally or iv every 12 hours or cefotetan 2 g iv every 12 hours plus '\n",
      " 'doxycycline 100 mg orally or iv every 12 hours or cefoxitin 2 g iv every 6 '\n",
      " 'hours plus doxycycline 100 mg orally or iv every 12 hours because of the '\n",
      " 'pain associated with iv infusion doxycycline  should be administered orally '\n",
      " 'when possible oral and iv  administration of doxycycline and metronidazole '\n",
      " 'provide  similar bioavailability oral metronidazole is well absorbed  and '\n",
      " 'can be considered instead of iv for women without severe  illness or '\n",
      " 'tuboovarian abscess when possible after clinical  improvement with '\n",
      " 'parenteral therapy transition to oral therapy  with doxycycline 100 mg 2 '\n",
      " 'timesday and metronidazole  500 mg 2 timesday is recommended to complete 14 '\n",
      " 'days of  antimicrobial therapy alternative parenteral regimens only limited '\n",
      " 'data are available to support using other  parenteral second or third '\n",
      " 'generation cephalosporins eg  ceftizoxime or cefotaxime because these '\n",
      " 'cephalosporins are  less active than cefotetan or cefoxitin against '\n",
      " 'anaerobic bacteria  the addition of metronidazole should be considered '\n",
      " 'ampicillinsulbactam plus doxycycline has been investigated  in at least one '\n",
      " 'clinical trial and has broadspectrum coverage  1177 ampicillinsulbactam plus '\n",
      " 'doxycycline is effective  against c trachomatis n gonorrhoeae and anaerobes '\n",
      " 'for  women with tuboovarian abscess another trial demonstrated  shortterm '\n",
      " 'clinical cure rates with azithromycin monotherapy  or combined with '\n",
      " 'metronidazole 1178 when using the clindamycin and gentamicin alternative  '\n",
      " 'parenteral regimen women with clinical improvement after  24–28 hours can be '\n",
      " 'transitioned to clindamycin 450 mg orally  4 timesday or doxycycline 100 mg '\n",
      " 'orally 2 timesday to  complete the 14day therapy however when tuboovarian  '\n",
      " 'abscess is present clindamycin 450 mg orally 4 timesday or  metronidazole '\n",
      " '500 mg orally 2 timesday should be used to  complete 14 days of therapy with '\n",
      " 'oral doxycycline to provide  more effective anaerobic coverage alternative '\n",
      " 'parenteral regimens ampicillinsulbactam 3 g iv every 6 hours plus '\n",
      " 'doxycycline 100 mg orally or iv every 12 hours or clindamycin 900 mg iv '\n",
      " 'every 8 hours plus gentamicin loading dose iv or im 2 mgkg body weight '\n",
      " 'followed by a  maintenance dose 15 mgkg body weight every 8 hours single '\n",
      " 'daily  dosing 3–5 mgkg body weight can be substituted intramuscular or oral '\n",
      " 'treatment im or oral therapy can be considered for women with mild '\n",
      " 'tomoderate acute pid because the clinical outcomes among  women treated with '\n",
      " 'these regimens are similar to those treated  with iv therapy 1158 women who '\n",
      " 'do not respond to im or  recommendations and reports mmwr  july 23 2021  vol '\n",
      " '70  no 4 97us department of health and human servicescenters for disease '\n",
      " 'control and prevention oral therapy within 72 hours should be reevaluated to '\n",
      " 'confirm  the diagnosis and be administered therapy iv recommended '\n",
      " 'intramuscular or oral regimens for pelvic  inflammatory disease ceftriaxone '\n",
      " '500 mg im in a single dose plus doxycycline 100 mg orally 2 timesday for 14 '\n",
      " 'days with metronidazole  500 mg orally 2 timesday for 14 days or cefoxitin 2 '\n",
      " 'g im in a single dose and probenecid 1 g orally administered  concurrently '\n",
      " 'in a single dose plus doxycycline 100 mg orally 2 timesday for 14 days with '\n",
      " 'metronidazole  500 mg orally 2 timesday for 14 days or other parenteral '\n",
      " 'thirdgeneration cephalosporin eg ceftizoxime or  cefotaxime plus doxycycline '\n",
      " '100 mg orally 2 timesday for 14 days with metronidazole  500 mg orally 2 '\n",
      " 'timesday for 14 days  for persons weighing ≥150 kg 1 g of ceftriaxone should '\n",
      " 'be administered these regimens provide coverage against frequent etiologic  '\n",
      " 'agents of pid however the optimal choice of a cephalosporin  is unclear '\n",
      " 'cefoxitin a secondgeneration cephalosporin has  better anaerobic coverage '\n",
      " 'than ceftriaxone and in combination  with probenecid and doxycycline has '\n",
      " 'been effective in short term clinical response among women with pid '\n",
      " 'ceftriaxone  has better coverage against n gonorrhoeae the addition of  '\n",
      " 'metronidazole to these regimens provides extended coverage  against '\n",
      " 'anaerobic organisms and will also effectively treat bv  which is frequently '\n",
      " 'associated with pid alternative intramuscular or oral regimens no data have '\n",
      " 'been published regarding use of oral  cephalosporins for treating pid as a '\n",
      " 'result of the emergence  of quinoloneresistant n gonorrhoeae regimens that '\n",
      " 'include  a quinolone agent are not recommended for pid treatment  however if '\n",
      " 'the patient has cephalosporin allergy the  community prevalence and '\n",
      " 'individual risk for gonorrhea  are low and followup is likely alternative '\n",
      " 'therapy can be  considered use of either levofloxacin 500 mg orally once '\n",
      " 'daily  or moxifloxacin 400 mg orally once daily with metronidazole  500 mg '\n",
      " 'orally 2 timesday for 14 days 1179–1181 or  azithromycin 500 mg iv daily for '\n",
      " '1–2 doses followed by  250 mg orally daily in combination with '\n",
      " 'metronidazole  500 mg 2 timesday for 12–14 days 1178 can be considered  '\n",
      " 'moxifloxacin is the preferred quinolone antimicrobial for  m genitalium '\n",
      " 'infections however the importance of providing  coverage for m genitalium is '\n",
      " 'unknown diagnostic tests for  gonorrhea should be obtained before starting '\n",
      " 'therapy and  persons should be managed as follows • if a culture for '\n",
      " 'gonorrhea is positive treatment should be  based on results of antimicrobial '\n",
      " 'susceptibility testing • if the isolate is determined to be '\n",
      " 'quinoloneresistant  n gonorrhoeae or if antimicrobial susceptibility cannot '\n",
      " 'be  assessed eg if only naat testing is available consultation  with an '\n",
      " 'infectious disease specialist is recommended other management considerations '\n",
      " 'to minimize disease transmission women should be  instructed to abstain from '\n",
      " 'sexual intercourse until therapy is  complete symptoms have resolved and sex '\n",
      " 'partners have been  treated see chlamydial infections gonococcal infections  '\n",
      " 'all women who receive a diagnosis of pid should be tested  for gonorrhea '\n",
      " 'chlamydia hiv and syphilis the value of  testing women with pid for m '\n",
      " 'genitalium is unknown see  mycoplasma genitalium all contraceptive methods '\n",
      " 'can be  continued during treatment  followup women should demonstrate '\n",
      " 'clinical improvement eg  defervescence reduction in direct or rebound '\n",
      " 'abdominal  tenderness and reduction in uterine adnexal and cervical  motion '\n",
      " 'tenderness 3 days after therapy initiation if no  clinical improvement has '\n",
      " 'occurred 72 hours after outpatient  im or oral therapy then hospitalization '\n",
      " 'assessment of the  antimicrobial regimen and additional diagnostics '\n",
      " 'including  consideration of diagnostic laparoscopy for alternative  '\n",
      " 'diagnoses are recommended all women who have received a  diagnosis of '\n",
      " 'chlamydial or gonococcal pid should be retested  3 months after treatment '\n",
      " 'regardless of whether their sex  partners have been treated 753 if retesting '\n",
      " 'at 3 months is  not possible these women should be retested whenever they  '\n",
      " 'next seek medical care 12 months after treatment management of sex partners '\n",
      " 'persons who have had sexual contact with a partner with  pid during the 60 '\n",
      " 'days preceding symptom onset should be  evaluated tested and presumptively '\n",
      " 'treated for chlamydia  and gonorrhea regardless of the pid etiology or '\n",
      " 'pathogens  isolated if the last sexual intercourse was 60 days before  '\n",
      " 'symptom onset or diagnosis the most recent sex partner should  be treated '\n",
      " 'sex partners of persons who have pid caused by  c trachomatis or n '\n",
      " 'gonorrhoeae frequently are asymptomatic  arrangements should be made to link '\n",
      " 'sex partners to care if  linkage is delayed or unlikely ept is an '\n",
      " 'alternative approach  to treating sex partners who have chlamydial or '\n",
      " 'gonococcal  infection 125126 see partner services partners should  be '\n",
      " 'instructed to abstain from sexual intercourse until they  recommendations '\n",
      " 'and reports 98 mmwr  july 23 2021  vol 70  no 4 us department of health and '\n",
      " 'human servicescenters for disease control and prevention and their sex '\n",
      " 'partners have been treated ie until therapy is  completed and symptoms have '\n",
      " 'resolved if originally present special considerations drug allergy '\n",
      " 'intolerance and adverse reactions the risk for penicillin crossreactivity is '\n",
      " 'highest with first generation cephalosporins but is negligible between the  '\n",
      " 'majority of secondgeneration eg cefoxitin and all third generation eg '\n",
      " 'ceftriaxone cephalosporins 619631653656  see management of persons who have '\n",
      " 'a history of  penicillin allergy pregnancy pregnant women suspected of '\n",
      " 'having pid are at high risk  for maternal morbidity and preterm delivery '\n",
      " 'these women  should be hospitalized and treated with iv antimicrobials in  '\n",
      " 'consultation with an infectious disease specialist hiv infection differences '\n",
      " 'in pid clinical manifestations among women  with hiv infection and those '\n",
      " 'without have not been well  delineated 1182 in early observational studies '\n",
      " 'women  with hiv infection and pid were more likely to require  surgical '\n",
      " 'intervention more comprehensive observational  and controlled studies have '\n",
      " 'demonstrated that women with  hiv infection and pid coinfection have similar '\n",
      " 'symptoms  compared with women without hiv 1183–1185 except  they are more '\n",
      " 'likely to have a tuboovarian abscess women  with hiv responded equally well '\n",
      " 'to recommended parenteral  and im or oral antibiotic regimens as women '\n",
      " 'without hiv  the microbiologic findings for women with hiv and women  '\n",
      " 'without hiv were similar except women with hiv had  higher rates of '\n",
      " 'concomitant m hominis and streptococcal  infections these data are '\n",
      " 'insufficient for determining whether  women with hiv infection and pid '\n",
      " 'coinfection require  more aggressive management eg hospitalization or iv  '\n",
      " 'antimicrobial regimens intrauterine devices iuds are one of the most '\n",
      " 'effective contraceptive methods  coppercontaining and '\n",
      " 'levonorgestrelreleasing iuds are  available in the united states the risk '\n",
      " 'for pid associated with  iud use is primarily confined to the first 3 weeks '\n",
      " 'after insertion  1186–1188 if an iud user receives a diagnosis of pid  the '\n",
      " 'iud does not need to be removed 591189 however  the woman should receive '\n",
      " 'treatment according to these  recommendations and should have close clinical '\n",
      " 'followup  if no clinical improvement occurs within 48–72 hours of  '\n",
      " 'initiating treatment providers should consider removing  the iud a '\n",
      " 'systematic review of evidence demonstrated that  treatment outcomes did not '\n",
      " 'differ between women with pid  who retained the iud and those who had the '\n",
      " 'iud removed  1190 these studies primarily included women using copper '\n",
      " 'containing or other nonhormonal iuds no studies are  available regarding '\n",
      " 'treatment outcomes among women using  levonorgestrelreleasing iuds '\n",
      " 'epididymitis acute epididymitis is a clinical syndrome causing pain  '\n",
      " 'swelling and inflammation of the epididymis and lasting  6 weeks 1191 '\n",
      " 'sometimes a testicle is also involved a  condition referred to as '\n",
      " 'epididymoorchitis a high index  of suspicion for spermatic cord testicular '\n",
      " 'torsion should  be maintained among men who have a sudden onset of  symptoms '\n",
      " 'associated with epididymitis because this condition  is a surgical emergency '\n",
      " 'acute epididymitis can be caused by stis eg c trachomatis  n gonorrhoeae or '\n",
      " 'm genitalium or enteric organisms ie  escherichia coli 1192 acute '\n",
      " 'epididymitis caused by an  sti is usually accompanied by urethritis which is '\n",
      " 'frequently  asymptomatic acute epididymitis caused by sexually  transmitted '\n",
      " 'enteric organisms might also occur among men  who are the insertive partner '\n",
      " 'during anal sex nonsexually  transmitted acute epididymitis caused by '\n",
      " 'genitourinary  pathogens typically occurs with bacteriuria secondary to  '\n",
      " 'bladder outlet obstruction eg benign prostatic hyperplasia  1193 among older '\n",
      " 'men nonsexually transmitted  acute epididymitis is also associated with '\n",
      " 'prostate biopsy  urinary tract instrumentation or surgery systemic disease  '\n",
      " 'or immunosuppression uncommon infectious causes of  nonsexually transmitted '\n",
      " 'acute epididymitis eg fournier’s  gangrene should be managed in consultation '\n",
      " 'with a urologist chronic epididymitis is characterized by a ≥6week history  '\n",
      " 'of symptoms of discomfort or pain in the scrotum testicle or  epididymis '\n",
      " 'chronic infectious epididymitis is most frequently  observed with conditions '\n",
      " 'associated with a granulomatous  reaction mycobacterium tuberculosis tb is '\n",
      " 'the most common  granulomatous disease affecting the epididymis and should '\n",
      " 'be  suspected especially among men with a known history of or recent  '\n",
      " 'exposure to tb the differential diagnosis of chronic noninfectious  '\n",
      " 'epididymitis sometimes termed orchialgia or epididymalgia is  broad eg '\n",
      " 'trauma cancer autoimmune conditions or idiopathic  conditions men with this '\n",
      " 'diagnosis should be referred to a  urologist for clinical management '\n",
      " '11911192 recommendations and reports mmwr  july 23 2021  vol 70  no 4 99us '\n",
      " 'department of health and human servicescenters for disease control and '\n",
      " 'prevention diagnostic considerations men who have acute epididymitis '\n",
      " 'typically have unilateral  testicular pain and tenderness hydrocele and '\n",
      " 'palpable swelling  of the epididymis although inflammation and swelling  '\n",
      " 'usually begin in the tail of the epididymis it can spread to  the rest of '\n",
      " 'the epididymis and testicle the spermatic cord  is usually tender and '\n",
      " 'swollen spermatic cord testicular  torsion a surgical emergency should be '\n",
      " 'considered in all cases  however it occurs more frequently among adolescents '\n",
      " 'and  men without evidence of inflammation or infection for men  with severe '\n",
      " 'unilateral pain with sudden onset those whose  test results do not support a '\n",
      " 'diagnosis of urethritis or urinary  tract infection or for whom diagnosis of '\n",
      " 'acute epididymitis is  questionable immediate referral to a urologist for '\n",
      " 'evaluation  for testicular torsion is vital because testicular viability '\n",
      " 'might  be compromised bilateral symptoms should increase suspicion of other '\n",
      " 'causes  of testicular pain radionuclide scanning of the scrotum is the  most '\n",
      " 'accurate method for diagnosing epididymitis but it is  not routinely '\n",
      " 'available ultrasound should be used primarily  for ruling out torsion of the '\n",
      " 'spermatic cord in cases of acute  unilateral painful scrotal swelling '\n",
      " 'however because partial  spermatic cord torsion can mimic epididymitis on '\n",
      " 'scrotal  ultrasound differentiation between spermatic cord torsion  and '\n",
      " 'epididymitis when torsion is not ruled out by ultrasound  should be made on '\n",
      " 'the basis of clinical evaluation although  ultrasound can demonstrate '\n",
      " 'epididymal hyperemia and  swelling associated with epididymitis it provides '\n",
      " 'minimal  diagnostic usefulness for men with a clinical presentation  '\n",
      " 'consistent with epididymitis a negative ultrasound does  not rule out '\n",
      " 'epididymitis and thus does not alter clinical  management ultrasound should '\n",
      " 'be reserved for men if torsion  of the spermatic cord is suspected or for '\n",
      " 'those with scrotal pain  who cannot receive an accurate diagnosis by history '\n",
      " 'physical  examination and objective laboratory findings all suspected cases '\n",
      " 'of acute epididymitis should be evaluated  for objective evidence of '\n",
      " 'inflammation by one of the following  poc tests • gram mb or gv stain of '\n",
      " 'urethral secretions demonstrating  ≥2 wbcs per oil immersion field 737 see '\n",
      " 'urethritis  these stains are preferred poc diagnostic tests for  evaluating '\n",
      " 'urethritis because they are highly sensitive and  specific for documenting '\n",
      " 'both urethral inflammation and  presence or absence of gonococcal infection '\n",
      " 'gonococcal  infection is established by documenting the presence of  '\n",
      " 'wbccontaining intracellular gramnegative or purple  diplococci on urethral '\n",
      " 'gram mb or gv stain respectively • positive leukocyte esterase test on '\n",
      " 'firstvoid urine • microscopic examination of sediment from a spun first void '\n",
      " 'urine demonstrating ≥10 wbcshpf all suspected cases of acute epididymitis '\n",
      " 'should be tested  for c trachomatis and n gonorrhoeae by naat urine is  the '\n",
      " 'preferred specimen for naat for men 553 urine  cultures for chlamydial and '\n",
      " 'gonococcal epididymitis are  insensitive and are not recommended urine '\n",
      " 'bacterial  cultures should also be performed for all men to evaluate for  '\n",
      " 'the presence of genitourinary organisms and to determine  antibiotic '\n",
      " 'susceptibility treatment to prevent complications and transmission of stis  '\n",
      " 'presumptive therapy for all sexually active men is indicated  at the time of '\n",
      " 'the visit before all laboratory test results are  available selection of '\n",
      " 'presumptive therapy is based on risk for  chlamydial and gonococcal '\n",
      " 'infections or enteric organisms  treatment goals for acute epididymitis are '\n",
      " '1 microbiologic  infection cure 2 improvement of signs and symptoms  3 '\n",
      " 'prevention of transmission of chlamydia and gonorrhea to  others and 4 '\n",
      " 'decreased potential for chlamydial or gonococcal  epididymitis complications '\n",
      " 'eg infertility or chronic pain  although the majority of men with acute '\n",
      " 'epididymitis can  be treated on an outpatient basis referral to a specialist '\n",
      " 'and  hospitalization should be considered when severe pain or fever  '\n",
      " 'indicates other diagnoses eg torsion testicular infarction  abscess or '\n",
      " 'necrotizing fasciitis or when men are unable to  comply with an '\n",
      " 'antimicrobial regimen age history of diabetes  fever and elevated creactive '\n",
      " 'protein can indicate more severe  disease requiring hospitalization 1193 '\n",
      " 'recommended regimens for epididymitis for acute epididymitis most likely '\n",
      " 'caused by chlamydia or gonorrhea  ceftriaxone 500 mg im in a single dose '\n",
      " 'plus doxycycline 100 mg orally 2 timesday for 10 days for acute epididymitis '\n",
      " 'most likely caused by chlamydia gonorrhea  or enteric organisms men who '\n",
      " 'practice insertive anal sex  ceftriaxone 500 mg im in a single dose plus '\n",
      " 'levofloxacin 500 mg orally once daily for 10 days for acute epididymitis '\n",
      " 'most likely caused by enteric organisms only  levofloxacin 500 mg orally '\n",
      " 'once daily for 10 days  for persons weighing ≥150 kg 1 g of ceftriaxone '\n",
      " 'should be administered levofloxacin monotherapy should be considered if the  '\n",
      " 'infection is most likely caused by enteric organisms only and  gonorrhea has '\n",
      " 'been ruled out by gram mb or gv stain this  includes men who have undergone '\n",
      " 'prostate biopsy vasectomy  and other urinary tract instrumentation '\n",
      " 'procedures treatment  recommendations and reports 100 mmwr  july 23 2021  '\n",
      " 'vol 70  no 4 us department of health and human servicescenters for disease '\n",
      " 'control and prevention should be guided by bacterial cultures and '\n",
      " 'antimicrobial  susceptibilities as an adjunct to therapy bed rest scrotal  '\n",
      " 'elevation and nonsteroidal antiinflammatory drugs are  recommended until '\n",
      " 'fever and local inflammation have  subsided complete resolution of '\n",
      " 'discomfort might not occur  for a few weeks after completion of the '\n",
      " 'antibiotic regimen other management considerations men who have acute '\n",
      " 'epididymitis confirmed or suspected to  be caused by n gonorrhoeae or c '\n",
      " 'trachomatis should be advised  to abstain from sexual intercourse until they '\n",
      " 'and their partners  have been treated and symptoms have resolved all men '\n",
      " 'with  acute epididymitis should be tested for hiv and syphilis followup men '\n",
      " 'should be instructed to return to their health care  providers if their '\n",
      " 'symptoms do not improve 72 hours after  treatment signs and symptoms of '\n",
      " 'epididymitis that do not  subside in 3 days require reevaluation of the '\n",
      " 'diagnosis and  therapy men who experience swelling and tenderness that  '\n",
      " 'persist after completion of antimicrobial therapy should be  evaluated for '\n",
      " 'alternative diagnoses including tumor abscess  infarction testicular cancer '\n",
      " 'tb and fungal epididymitis management of sex partners men who have acute '\n",
      " 'sexually transmitted epididymitis  confirmed or suspected to be caused by n '\n",
      " 'gonorrhoeae or  c trachomatis should be instructed to refer all sex '\n",
      " 'partners  during the previous 60 days before symptom onset for  evaluation '\n",
      " 'testing and presumptive treatment see chlamydial  infections gonococcal '\n",
      " 'infections if the last sexual intercourse  was 60 days before onset of '\n",
      " 'symptoms or diagnosis the  most recent sex partner should be evaluated and '\n",
      " 'treated  arrangements should be made to link sex partners to care ept  is an '\n",
      " 'effective strategy for treating sex partners of men who  have or are '\n",
      " 'suspected of having chlamydia or gonorrhea for  whom linkage to care is '\n",
      " 'anticipated to be delayed 125126  see partner services partners should be '\n",
      " 'instructed to abstain  from sexual intercourse until they and their sex '\n",
      " 'partners are  treated and symptoms have resolved special considerations drug '\n",
      " 'allergy intolerance and adverse reactions the risk for penicillin '\n",
      " 'crossreactivity is negligible between all  thirdgeneration cephalosporins eg '\n",
      " 'ceftriaxone 658681  see management of persons who have a history of '\n",
      " 'penicillin  allergy alternative regimens have not been studied therefore  '\n",
      " 'clinicians should consult an infectious disease specialist if such  regimens '\n",
      " 'are required hiv infection men with hiv infection who have uncomplicated '\n",
      " 'acute  epididymitis should receive the same treatment regimen as  those who '\n",
      " 'do not have hiv other etiologic agents have  been implicated in acute '\n",
      " 'epididymitis among men with hiv  including cmv salmonella toxoplasmosis u '\n",
      " 'urealyticum  corynebacterium species mycoplasma species and mima  polymorpha '\n",
      " '1192 human papillomavirus infections approximately 150 types of hpv have '\n",
      " 'been identified at  least 40 of which infect the genital area 1194 the '\n",
      " 'majority  of hpv infections are selflimited and are asymptomatic or  '\n",
      " 'unrecognized sexually active persons are usually exposed to  hpv during '\n",
      " 'their lifetime 83811951196 oncogenic  highrisk hpv infection eg hpv types 16 '\n",
      " 'and 18 causes the  majority of cervical penile vulvar vaginal anal and '\n",
      " 'oropharyngeal  cancers and precancers 1197 whereas other hpv infection  eg '\n",
      " 'hpv types 6 and 11 causes genital warts and recurrent  respiratory '\n",
      " 'papillomatosis persistent oncogenic hpv infection  is the strongest risk '\n",
      " 'factor for development of hpvattributable  precancers and cancers a '\n",
      " 'substantial proportion of cancers and  anogenital warts are attributable to '\n",
      " 'hpv in the united states  an estimated 34800 new hpvattributable cancers '\n",
      " 'occurred  every year during 2012–2016 1198 before hpv vaccines were  '\n",
      " 'introduced approximately 355000 new cases of anogenital warts  occurred '\n",
      " 'every year 1199 prevention hpv vaccines three hpv vaccines are licensed in '\n",
      " 'the united states  ceravrix a 2valent vaccine 2vhpv that targets hpv types  '\n",
      " '16 and 18 gardasil a 4valent vaccine 4vhpv that targets  hpv types 6 11 16 '\n",
      " 'and 18 and gardasil 9 a 9valent  vaccine 9vhpv that targets hpv types 6 11 '\n",
      " '16 18 31  33 45 52 and 58 types 16 and 18 account for 66 of all  cervical '\n",
      " 'cancers whereas the five additional types targeted by  the 9valent vaccine '\n",
      " 'account for 15 types 6 and 11 cause  90 of genital warts only 9vhpv vaccine '\n",
      " 'is available in  the united states acip recommendations for hpv vaccination '\n",
      " 'httpswww cdcgovvaccineshcpaciprecsvaccspecifichpvhtml include  the following '\n",
      " 'httpswwwcdcgovvaccineshcpaciprecsvaccspecifichpvhtml '\n",
      " 'httpswwwcdcgovvaccineshcpaciprecsvaccspecifichpvhtml recommendations and '\n",
      " 'reports mmwr  july 23 2021  vol 70  no 4 101us department of health and '\n",
      " 'human servicescenters for disease control and prevention • routine hpv '\n",
      " 'vaccination for all adolescents at age 11 or  12 years • administering '\n",
      " 'vaccine starting at age 9 years • catchup vaccination through age 26 years '\n",
      " 'for those not  vaccinated previously • not using hpv vaccination for all '\n",
      " 'adults aged 26 years  instead shared clinical decisionmaking between a '\n",
      " 'patient  and a provider regarding hpv vaccination is recommended  for '\n",
      " 'certain adults aged 27–45 years not vaccinated previously • a 2dose vaccine '\n",
      " 'schedule at 0 and 6–12month  intervals is recommended for persons who '\n",
      " 'initiate  vaccination before their 15th birthday • a 3dose vaccine schedule '\n",
      " 'at 0 1–2 and 6month  intervals for immunocompromised persons regardless of  '\n",
      " 'age of initiation hpv vaccines are not recommended for use in pregnant  '\n",
      " 'women hpv vaccines can be administered regardless of  history of anogenital '\n",
      " 'warts abnormal pap test or hpv test or  anogenital precancer women who have '\n",
      " 'received hpv vaccine  should continue routine cervical cancer screening see '\n",
      " 'cervical  cancer hpv vaccine is available for eligible children and  '\n",
      " 'adolescents aged 19 years through the vaccines for children  vfc program '\n",
      " 'additional information is available at https '\n",
      " 'wwwcdcgovvaccinesprogramsvfcindexhtml or by calling  cdc info 8002324636 for '\n",
      " 'uninsured persons aged  19 years patient assistance programs are available '\n",
      " 'from the  vaccine manufacturers prelicensure and postlicensure safety  '\n",
      " 'evaluations have determined that the vaccine is well tolerated  with 120 '\n",
      " 'million doses of hpv vaccines distributed in the  united states robust data '\n",
      " 'demonstrate that hpv vaccines are  safe httpswwwcdcgovvaccinesafety '\n",
      " 'impactmonitoring  studies in the united states have demonstrated reductions  '\n",
      " 'of genital warts as well as the hpv types contained within  the quadrivalent '\n",
      " 'vaccine 1200–1203 settings that provide  sti services should either '\n",
      " 'administer the vaccine to eligible  clients within the routine and catchup '\n",
      " 'age groups through  age 26 years who have not started or completed the '\n",
      " 'vaccine  series or link these persons to another facility equipped to  '\n",
      " 'provide the vaccine clinicians providing services to children  adolescents '\n",
      " 'and young adults should be knowledgeable about  hpv and the vaccine '\n",
      " 'httpswwwcdcgovvaccineswho teensforhcphpvresourceshtml hpv vaccination has '\n",
      " 'not  been associated with initiation of sexual activity or sexual risk  '\n",
      " 'behaviors 12041205 abstaining from sexual activity is the most reliable '\n",
      " 'method  for preventing genital hpv infection persons can decrease  their '\n",
      " 'chances of infection by practicing consistent and correct  condom use and '\n",
      " 'limiting their number of sex partners although  these interventions might '\n",
      " 'not fully protect against hpv they  can decrease the chances of hpv '\n",
      " 'acquisition and transmission diagnostic considerations hpv tests are '\n",
      " 'available for detecting oncogenic types of hpv  infection and are used in '\n",
      " 'the context of cervical cancer screening  and management or followup of '\n",
      " 'abnormal cervical cytology or  histology see cervical cancer these tests '\n",
      " 'should not be used  for male partners of women with hpv or women aged 25 '\n",
      " 'years  for diagnosis of genital warts or as a general sti test application '\n",
      " 'of 3–5 acetic acid which might cause  affected areas to turn white has been '\n",
      " 'used by certain providers  to detect genital mucosa infected with hpv the '\n",
      " 'routine use  of this procedure to detect mucosal changes attributed to  hpv '\n",
      " 'infection is not recommended because the results do  not influence clinical '\n",
      " 'management treatment treatment is directed to the macroscopic eg genital '\n",
      " 'warts  or pathologic precancerous lesions caused by hpv subclinical  genital '\n",
      " 'hpv infection typically clears spontaneously therefore  specific antiviral '\n",
      " 'therapy is not recommended to eradicate hpv  infection precancerous lesions '\n",
      " 'are detected through cervical  cancer screening hpvrelated precancer should '\n",
      " 'be managed  on the basis of existing guidance see cervical cancer counseling '\n",
      " 'key messages for persons with human  papillomavirus infection when '\n",
      " 'counseling persons with anogenital hpv infection  the provider should '\n",
      " 'discuss the following • anogenital hpv infection is common it usually '\n",
      " 'infects  the anogenital area but can infect other areas including  the mouth '\n",
      " 'and throat the majority of sexually active  persons get hpv at some time '\n",
      " 'during their lifetime  although most never know it • partners tend to share '\n",
      " 'hpv and it is not possible to  determine which partner transmitted the '\n",
      " 'original  infection having hpv does not mean that a person or  his or her '\n",
      " 'partner is having sex outside the relationship • persons who acquire hpv '\n",
      " 'usually clear the infection  spontaneously meaning that hpv becomes '\n",
      " 'undetectable  with no associated health problems • if hpv infection persists '\n",
      " 'genital warts precancers and  cancers of the cervix anus penis vulva vagina '\n",
      " 'head or  neck might develop • discussion of tobacco use and provision of '\n",
      " 'cessation  counseling is important because of its contribution to the  '\n",
      " 'progression of precancer and cancer • the types of hpv that cause genital '\n",
      " 'warts are different  from the types that can cause cancer '\n",
      " 'httpswwwcdcgovvaccinesprogramsvfcindexhtml '\n",
      " 'httpswwwcdcgovvaccinesprogramsvfcindexhtml httpswwwcdcgovvaccinesafety '\n",
      " 'httpswwwcdcgovvaccineswhoteensforhcphpvresourceshtml '\n",
      " 'httpswwwcdcgovvaccineswhoteensforhcphpvresourceshtml recommendations and '\n",
      " 'reports 102 mmwr  july 23 2021  vol 70  no 4 us department of health and '\n",
      " 'human servicescenters for disease control and prevention • many types of hpv '\n",
      " 'are sexually transmitted through  anogenital contact mainly during vaginal '\n",
      " 'and anal sex hpv  also might be transmitted during oral sex and '\n",
      " 'genitaltogenital  contact without penetration in rare cases a pregnant '\n",
      " 'woman  can transmit hpv to an infant during delivery • treatments are '\n",
      " 'available for the conditions caused by hpv  but not for the virus itself • '\n",
      " 'having hpv does not make it harder for a woman to get  pregnant or carry a '\n",
      " 'pregnancy to term however certain  precancers or cancers that hpv can cause '\n",
      " 'and the surgical  procedures needed to treat them can affect a woman’s  '\n",
      " 'ability to get pregnant or carry a pregnancy to term • no hpv test can '\n",
      " 'determine which hpv infection will  become undetectable and which will '\n",
      " 'persist or progress to  disease however in certain circumstances hpv tests '\n",
      " 'can  determine whether a woman is at increased risk for cervical  cancer '\n",
      " 'these tests are not for detecting other hpvrelated  problems nor are they '\n",
      " 'useful for women aged25 years  or men of any age prevention • three hpv '\n",
      " 'vaccines can prevent diseases and cancers  caused by hpv the 2vhpv 4vhpv and '\n",
      " '9vhpv vaccines  protect against the majority of cervical cancer cases  '\n",
      " 'although the 4vhpv and 9vhpv vaccines also protect  against the majority of '\n",
      " 'genital warts only 9vhpv vaccine  is available in the united states hpv '\n",
      " 'vaccines are safe  and effective and are recommended routinely for  '\n",
      " 'adolescents aged 11–12 years catchup vaccination is also  recommended for '\n",
      " 'older adolescents and young adults  through age 26 years '\n",
      " 'httpswwwcdcgovhpvhcp indexhtml shared clinical decisionmaking is  '\n",
      " 'recommended regarding hpv vaccination for certain  adults aged 27–45 years '\n",
      " 'who are not adequately vaccinated  per guidance httpswwwcdcgovmmwrvolumes68 '\n",
      " 'wrpdfsmm6832a3hpdf  • condoms used consistently and correctly can lower the  '\n",
      " 'chances of acquiring and transmitting hpv and  developing hpvrelated '\n",
      " 'diseases eg genital warts or  cervical cancer however because hpv can infect '\n",
      " 'areas  not covered by a condom condoms might not fully protect  against hpv '\n",
      " '• limiting the number of sex partners can reduce the risk  for hpv however '\n",
      " 'even persons with only one lifetime  sex partner can get hpv • abstaining '\n",
      " 'from sexual activity is the most reliable method  for preventing genital hpv '\n",
      " 'infection anogenital warts anogenital warts are a common disease and 90 are '\n",
      " 'caused  by nononcogenic hpv types 6 or 11 these types can be  commonly '\n",
      " 'identified before or at the same time anogenital  warts are detected 1206 '\n",
      " 'hpv types 16 18 31 33 and 35  also are occasionally identified in anogenital '\n",
      " 'warts usually  as infections with hpv 6 or 11 and can be associated with  '\n",
      " 'foci of highgrade squamous intraepithelial lesion hsil  particularly among '\n",
      " 'persons who have hiv infection in  addition to anogenital warts hpv types 6 '\n",
      " 'and 11 have been  associated with conjunctival nasal oral and laryngeal '\n",
      " 'warts anogenital warts are usually asymptomatic however  depending on the '\n",
      " 'size and anatomic location they can  be painful or pruritic they are usually '\n",
      " 'flat papular or  pedunculated growths on the genital mucosa anogenital '\n",
      " 'warts  occur commonly at certain anatomic sites including around  the '\n",
      " 'vaginal introitus under the foreskin of the uncircumcised  penis and on the '\n",
      " 'shaft of the circumcised penis warts can  also occur at multiple sites in '\n",
      " 'the anogenital epithelium or  within the anogenital tract eg cervix vagina '\n",
      " 'urethra  perineum perianal skin anus or scrotum intraanal warts  are '\n",
      " 'observed predominantly in persons who have had receptive  anal intercourse '\n",
      " 'however they also can occur among men and  women who have not had a history '\n",
      " 'of anal sexual contact prevention anogenital warts have decreased among '\n",
      " 'adolescents  young women and heterosexual men with use of hpv  vaccination '\n",
      " 'in multiple countries including the united states  12031207–1216 diagnostic '\n",
      " 'considerations diagnosis of anogenital warts is usually made by visual  '\n",
      " 'inspection but can be confirmed by biopsy which is indicated  if lesions are '\n",
      " 'atypical eg pigmented indurated affixed to  underlying tissue bleeding or '\n",
      " 'ulcerated lesions biopsy might  also be indicated in the following '\n",
      " 'circumstances particularly  if the patient is immunocompromised including '\n",
      " 'those with  hiv infection the diagnosis is uncertain the lesions do not  '\n",
      " 'respond to standard therapy or the disease worsens during  therapy hpv '\n",
      " 'testing is not recommended for anogenital wart  diagnosis because test '\n",
      " 'results are not confirmatory and do not  guide genital wart management some '\n",
      " 'anogenital lesions can  resemble anogenital warts condyloma accuminata but '\n",
      " 'do  not respond to anogenital wart treatment condyloma lata  a manifestation '\n",
      " 'of secondary syphilis can be diagnosed by  serologic tests or through direct '\n",
      " 'detection from serous fluid  from the lesions see syphilis diagnostic '\n",
      " 'considerations httpswwwcdcgovhpvhcpindexhtml httpswwwcdcgovhpvhcpindexhtml '\n",
      " 'httpswwwcdcgovmmwrvolumes68wrpdfsmm6832a3hpdf '\n",
      " 'httpswwwcdcgovmmwrvolumes68wrpdfsmm6832a3hpdf recommendations and reports '\n",
      " 'mmwr  july 23 2021  vol 70  no 4 103us department of health and human '\n",
      " 'servicescenters for disease control and prevention treatment the aim of '\n",
      " 'treatment is removal of the warts and amelioration  of symptoms if present '\n",
      " 'the appearance of warts also can result  in considerable psychosocial '\n",
      " 'distress and removal can relieve  cosmetic concerns for most patients '\n",
      " 'treatment results in  resolution of the warts if left untreated anogenital '\n",
      " 'warts can  resolve spontaneously remain unchanged or increase in size or  '\n",
      " 'number because warts might spontaneously resolve in 1 year  an acceptable '\n",
      " 'alternative for certain persons is to forego treatment  and wait for '\n",
      " 'spontaneous resolution available therapies for  anogenital warts might '\n",
      " 'reduce but probably do not eradicate  hpv infectivity whether reduction in '\n",
      " 'hpv viral dna resulting  from treatment reduces future transmission remains '\n",
      " 'unknown treatment of anogenital warts should be guided by wart size  number '\n",
      " 'and anatomic site patient preference cost of treatment  convenience adverse '\n",
      " 'effects and provider experience no  definitive evidence indicates that any '\n",
      " 'one recommended treatment  is superior to another and no single treatment is '\n",
      " 'ideal for all  patients or all warts shared clinical decisionmaking between  '\n",
      " 'a patient and a provider regarding treatment algorithms has  been associated '\n",
      " 'with improved clinical outcomes and should be  encouraged because all '\n",
      " 'available treatments have shortcomings  clinicians sometimes use combination '\n",
      " 'therapy eg provider administered cryotherapy with patientapplied topical '\n",
      " 'therapy  between visits to the provider however limited data exist  '\n",
      " 'regarding the efficacy or risk for complications associated with  '\n",
      " 'combination therapy treatment regimens are classified as either  '\n",
      " 'patientapplied or provideradministered modalities patient applied modalities '\n",
      " 'are preferred by certain persons because they  can be administered in the '\n",
      " 'privacy of their home to ensure  that patientapplied modalities are '\n",
      " 'effective instructions should  be provided to patients while in the clinic '\n",
      " 'and all anogenital  warts should be accessible and identified during the '\n",
      " 'clinic visit  followup visits after weeks of therapy enable providers to '\n",
      " 'answer  any questions about use of the medication address any side effects  '\n",
      " 'experienced and facilitate assessment of the response to treatment '\n",
      " 'recommended regimens for external anogenital warts ie  penis groin scrotum '\n",
      " 'vulva perineum external anus or  perianus patientapplied imiquimod 375 or 5 '\n",
      " 'cream† or podofilox 05 solution or gel or sinecatechins 15 ointment† '\n",
      " 'provideradministered cryotherapy with liquid nitrogen or cryoprobe or '\n",
      " 'surgical removal by tangential scissor excision tangential shave  excision '\n",
      " 'curettage laser or electrosurgery or trichloroacetic acid tca or '\n",
      " 'bichloroacetic acid bca   80–90 solution  persons with external anal or '\n",
      " 'perianal warts might also have intraanal  warts thus persons with external '\n",
      " 'anal warts might benefit from an  inspection of the anal canal by digital '\n",
      " 'examination standard anoscopy  or highresolution anoscopy † might weaken '\n",
      " 'condoms and vaginal diaphragms imiquimod is a patientapplied topically '\n",
      " 'active immune  enhancer that stimulates production of interferon and other  '\n",
      " 'cytokines imiquimod 5 cream should be applied once  at bedtime 3 timesweek '\n",
      " 'for 16 weeks 1217 similarly  imiquimod 375 cream should be applied once at '\n",
      " 'bedtime  every night for 8 weeks 1218 with either formulation the  treatment '\n",
      " 'area should be washed with soap and water 6–10 hours  after the application '\n",
      " 'local inflammatory reactions including  redness irritation induration '\n",
      " 'ulceration or erosion and vesicles  might occur with using imiquimod and '\n",
      " 'hypopigmentation has  also been described 1219 limited case reports '\n",
      " 'demonstrate  an association between treatment with imiquimod cream and  '\n",
      " 'worsened inflammatory or autoimmune skin diseases eg  psoriasis vitiligo or '\n",
      " 'lichenoid dermatoses 1220–1222 data  from studies of human participants are '\n",
      " 'limited regarding use of  imiquimod during pregnancy however animal data '\n",
      " 'indicate  that this therapy poses low risk 431 podofilox podophyllotoxin is '\n",
      " 'a patientapplied antimitotic  drug that causes wart necrosis podofilox '\n",
      " 'solution using a  cotton swab or podofilox gel using a finger should be '\n",
      " 'applied  to anogenital warts 2 timesday for 3 days followed by 4 days  of no '\n",
      " 'therapy this cycle can be repeated as necessary for up  to four cycles the '\n",
      " 'total wart area treated should not exceed  10 cm2 and the total volume of '\n",
      " 'podofilox should be limited to  05 mlday if possible the health care '\n",
      " 'provider should apply the  initial treatment to demonstrate proper '\n",
      " 'application technique  and identify which warts should be treated mild to '\n",
      " 'moderate  pain or local irritation might develop after treatment after each  '\n",
      " 'treatment the gel or solution should be allowed to dry patients  should wash '\n",
      " 'their hands before and after each application  podofilox is contraindicated '\n",
      " 'during pregnancy 431 sinecatechins is a patientapplied greentea extract with '\n",
      " 'an  active product catechins sinecatechins 15 ointment should  be applied 3 '\n",
      " 'timesday 05cm strand of ointment to each wart  by using a finger to ensure '\n",
      " 'coverage with a thin layer of ointment  until complete clearance of warts is '\n",
      " 'achieved this product should  not be continued for 16 weeks 1223–1225 the '\n",
      " 'medication  should not be washed off after use genital anal and oral sexual  '\n",
      " 'contact should be avoided while the ointment is on the skin the  most common '\n",
      " 'side effects of sinecatechins are erythema pruritus  or burning pain '\n",
      " 'ulceration edema induration and vesicular  recommendations and reports 104 '\n",
      " 'mmwr  july 23 2021  vol 70  no 4 us department of health and human '\n",
      " 'servicescenters for disease control and prevention rash this medication is '\n",
      " 'not recommended for persons with hiv  infection other immunocompromised '\n",
      " 'conditions or genital herpes  because the safety and efficacy of therapy has '\n",
      " 'not been evaluated  the safety of sinecatechins during pregnancy is unknown '\n",
      " 'cryotherapy is a provideradministered therapy that destroys  warts by '\n",
      " 'thermalinduced cytolysis health care providers  should be trained on the '\n",
      " 'correct use of this therapy because  overtreatment or undertreatment can '\n",
      " 'result in complications  or low efficacy pain during and after application '\n",
      " 'of the liquid  nitrogen followed by necrosis and sometimes blistering is  '\n",
      " 'common local anesthesia topical or injected might facilitate  therapy if '\n",
      " 'warts are present in many areas or if the area of warts  is large surgical '\n",
      " 'therapy has the advantage of eliminating the  majority of warts at a single '\n",
      " 'visit although recurrence can  occur surgical removal requires substantial '\n",
      " 'clinical training  additional equipment and sometimes a longer office visit '\n",
      " 'after  local anesthesia is applied anogenital warts can be physically  '\n",
      " 'destroyed by electrocautery in which case no additional  hemostasis is '\n",
      " 'required care should be taken to control the  depth of electrocautery to '\n",
      " 'prevent scarring alternatively the  warts can be removed either by '\n",
      " 'tangential excision with a pair of  fine scissors or a scalpel by co2 laser '\n",
      " 'or by curettage because  most warts are exophytic this procedure can be '\n",
      " 'accomplished  with a resulting wound that only extends into the upper '\n",
      " 'dermis  hemostasis can be achieved with an electrocautery unit or in  cases '\n",
      " 'of minor bleeding a chemical styptic eg an aluminum  chloride solution '\n",
      " 'suturing is neither required nor indicated  in the majority of cases for '\n",
      " 'patients with large or extensive  warts surgical therapy including co2 laser '\n",
      " 'might be most  beneficial such therapy might also be useful for '\n",
      " 'intraurethral  warts particularly for those persons whose warts have not  '\n",
      " 'responded to other treatments treatment of anogenital and  oral warts should '\n",
      " 'be performed in a ventilated room by using  standard precautions '\n",
      " 'httpswwwcdcgovinfectioncontrol '\n",
      " 'guidelinesisolationindexhtmlisolation2007pdfpage and  local exhaust '\n",
      " 'ventilation eg a smoke evacuator 1226 trichloroacetic acid tca and '\n",
      " 'bichloroacetic acid bca  are provideradministered caustic agents that '\n",
      " 'destroy warts by  chemical coagulation of proteins although these '\n",
      " 'preparations  are widely used they have not been investigated thoroughly  '\n",
      " 'tca solution has a low viscosity comparable with that of  water and can '\n",
      " 'spread rapidly and damage adjacent tissues if  applied excessively a small '\n",
      " 'amount should be applied only  to the warts and allowed to dry ie develop '\n",
      " 'white frost on  tissue before the patient sits or stands if pain is intense '\n",
      " 'or an  excess amount of acid is applied the area can be covered with  sodium '\n",
      " 'bicarbonate ie baking soda washed with liquid  soap preparations or be '\n",
      " 'powdered with talc to neutralize the  acid or remove unreacted acid tca or '\n",
      " 'bca treatment can be  repeated weekly if necessary alternative regimens for '\n",
      " 'external genital warts fewer data are available regarding the efficacy of '\n",
      " 'alternative  regimens for treating anogenital warts which include  '\n",
      " 'podophyllin resin intralesional interferon photodynamic  therapy and topical '\n",
      " 'cidofovir shared clinical decision making between the patient and provider '\n",
      " 'regarding benefits  and risks of these regimens should be provided in '\n",
      " 'addition  alternative regimens might be associated with more side  effects '\n",
      " 'podophyllin resin is no longer a recommended regimen  because of the number '\n",
      " 'of safer regimens available and severe  systemic toxicity has been reported '\n",
      " 'when podophyllin resin  was applied to large areas of friable tissue and was '\n",
      " 'not washed  off within 4 hours 1227–1229 podophyllin resin 10–25  in a '\n",
      " 'compound tincture of benzoin might be considered for  provideradministered '\n",
      " 'treatment under conditions of strict  adherence to recommendations '\n",
      " 'podophyllin should be applied  to each wart and then allowed to air dry '\n",
      " 'before the treated area  comes into contact with clothing overapplication or '\n",
      " 'failure  to air dry can result in local irritation caused by spread of the  '\n",
      " 'compound to adjacent areas and possible systemic toxicity the  treatment can '\n",
      " 'be repeated weekly if necessary to avoid the  possibility of complications '\n",
      " 'associated with systemic absorption  and toxicity application should be '\n",
      " 'limited to 05 ml of  podophyllin or an area of 10 cm2 of warts per session '\n",
      " 'the  area to which treatment is administered should not contain  any open '\n",
      " 'lesions wounds or friable tissue and the preparation  should be thoroughly '\n",
      " 'washed off 1–4 hours after application  podophyllin resin preparations '\n",
      " 'differ in the concentration of  active components and contaminants shelf '\n",
      " 'life and stability  of podophyllin preparations are unknown the safety of  '\n",
      " 'podophyllin during pregnancy has not been established recommended regimens '\n",
      " 'for urethral meatus warts cryotherapy with liquid nitrogen or surgical '\n",
      " 'removal recommended regimens for vaginal warts cryotherapy with liquid '\n",
      " 'nitrogen the use of a cryoprobe in the vagina is not recommended because of  '\n",
      " 'the risk for vaginal perforation and fistula formation or surgical removal '\n",
      " 'or trichloracetic acid tca or bichloroacetic acid bca 80–90  solution '\n",
      " 'recommended regimens for cervical warts cryotherapy with liquid nitrogen '\n",
      " 'httpswwwcdcgovinfectioncontrolguidelinesisolationindexhtmlisolation2007pdfpage '\n",
      " 'httpswwwcdcgovinfectioncontrolguidelinesisolationindexhtmlisolation2007pdfpage '\n",
      " 'recommendations and reports mmwr  july 23 2021  vol 70  no 4 105us '\n",
      " 'department of health and human servicescenters for disease control and '\n",
      " 'prevention or surgical removal or trichloracetic acid tca or bichloroacetic '\n",
      " 'acid bca 80–90  solution management of cervical warts should include '\n",
      " 'consultation with a specialist for women who have exophytic cervical warts a '\n",
      " 'biopsy evaluation to  exclude hsil should be performed before treatment is '\n",
      " 'initiated recommended regimens for intraanal warts cryotherapy with liquid '\n",
      " 'nitrogen or surgical removal or trichloracetic acid tca or bichloroacetic '\n",
      " 'acid bca 80–90  solution management of intraanal warts should include '\n",
      " 'consultation with a  colorectal specialist followup anogenital warts '\n",
      " 'typically respond within 3 months of  therapy factors that might affect '\n",
      " 'response to therapy include  immunosuppression and treatment compliance '\n",
      " 'warts  located on moist surfaces or in intertriginous areas respond  best to '\n",
      " 'topical treatment a new treatment modality should  be selected when no '\n",
      " 'substantial improvement is observed  after a complete course of treatment or '\n",
      " 'in the event of severe  side effects treatment response and '\n",
      " 'therapyassociated side  effects should be evaluated throughout the therapy '\n",
      " 'course  complications occur rarely when treatment is administered  correctly '\n",
      " 'persistent hypopigmentation or hyperpigmentation  can occur with ablative '\n",
      " 'modalities eg cryotherapy and  electrocautery and have been described with '\n",
      " 'immune  modulating therapies eg imiquimod cream depressed or  hypertrophic '\n",
      " 'scars are uncommon but can occur especially  if patients have insufficient '\n",
      " 'time to heal between treatments  rarely treatment can result in chronic pain '\n",
      " 'syndromes eg  vulvodynia and hyperesthesia of the treatment site or in the  '\n",
      " 'case of anal warts painful defecation or fistulas counseling when counseling '\n",
      " 'persons with anogenital warts the provider  should discuss the following • '\n",
      " 'if left untreated genital warts might resolve stay the same  or increase in '\n",
      " 'size or number the types of hpv that cause  genital warts are different from '\n",
      " 'the types that can cause cancer • women with genital warts do not need pap '\n",
      " 'tests more  often than other women • time of hpv acquisition cannot be '\n",
      " 'definitively  determined genital warts can develop months or years  after '\n",
      " 'acquiring hpv • hpv types that cause genital warts can be passed on to  '\n",
      " 'another person even without visible signs of warts sex  partners tend to '\n",
      " 'share hpv even though signs of hpv  eg warts might occur in only one or '\n",
      " 'neither partner • although genital warts are common and benign certain  '\n",
      " 'persons might experience considerable psychosocial impact  after receiving '\n",
      " 'this diagnosis • although genital warts can be treated such treatment does  '\n",
      " 'not cure the virus itself for this reason genital warts often  recur after '\n",
      " 'treatment especially during the first 3 months • because genital warts can '\n",
      " 'be sexually transmitted persons  with genital warts benefit from testing for '\n",
      " 'other stis  hpv might remain present and can still be transmitted  to '\n",
      " 'partners even after the warts are gone • condoms might lower the chances of '\n",
      " 'transmitting genital  warts if used consistently and correctly however hpv  '\n",
      " 'can infect areas that are not covered by a condom and  might not fully '\n",
      " 'protect against hpv • a vaccine is available for males and females to '\n",
      " 'prevent  genital warts gardasil 9 but it will not treat existing hpv  or '\n",
      " 'genital warts this vaccine can prevent the majority of  cases of genital '\n",
      " 'warts among persons who have not yet  been exposed to wartcausing types of '\n",
      " 'hpv management of sex partners persons should inform current partners about '\n",
      " 'having genital  warts because the types of hpv that cause warts can be '\n",
      " 'passed  on to partners partners should be counseled that they might  already '\n",
      " 'have hpv despite no visible signs of warts therefore  hpv testing of sex '\n",
      " 'partners of persons with genital warts is  not recommended partners might '\n",
      " 'benefit from a physical  examination to detect genital warts and tests for '\n",
      " 'other stis no  recommendations can be made regarding informing future sex  '\n",
      " 'partners about a diagnosis of genital warts because the duration  of viral '\n",
      " 'persistence after warts have resolved is unknown special considerations '\n",
      " 'pregnancy podofilox podophyllin and sinecatechins should not be  used during '\n",
      " 'pregnancy imiquimod appears to pose low risk  but should be avoided until '\n",
      " 'more data are available anogenital  warts can proliferate and become friable '\n",
      " 'during pregnancy  although removal of warts during pregnancy can be '\n",
      " 'considered  resolution might be incomplete or poor until pregnancy is  '\n",
      " 'complete rarely hpv types 6 and 11 can cause respiratory  papillomatosis '\n",
      " 'among infants and children although the route  of transmission ie '\n",
      " 'transplacental perinatal or postnatal is  not completely understood whether '\n",
      " 'cesarean delivery prevents  respiratory papillomatosis among infants and '\n",
      " 'children also  recommendations and reports 106 mmwr  july 23 2021  vol 70  '\n",
      " 'no 4 us department of health and human servicescenters for disease control '\n",
      " 'and prevention is unclear 1230 therefore cesarean delivery should not be  '\n",
      " 'performed solely to prevent transmission of hpv infection to  the newborn '\n",
      " 'cesarean delivery is indicated for women with  anogenital warts if the '\n",
      " 'pelvic outlet is obstructed or if vaginal  delivery would result in '\n",
      " 'excessive bleeding pregnant women  with anogenital warts should be counseled '\n",
      " 'about the low risk  for warts on the larynx of their infants or children '\n",
      " 'recurrent  respiratory papillomatosis hiv and other causes of '\n",
      " 'immunosuppression persons with hiv infection or who are otherwise  '\n",
      " 'immunosuppressed are more likely to develop anogenital  warts than those who '\n",
      " 'do not have hiv 1231 moreover  such persons can have larger or more numerous '\n",
      " 'lesions  might not respond to therapy as well as those who are  '\n",
      " 'immunocompetent and might have more frequent recurrences  after treatment '\n",
      " '12311232–1234 despite these factors data  do not support altered approaches '\n",
      " 'to treatment for persons  with hiv infection squamous cell carcinomas '\n",
      " 'arising in or  resembling anogenital warts might occur more frequently  '\n",
      " 'among immunosuppressed persons therefore requiring biopsy  for confirmation '\n",
      " 'of diagnosis for suspicious cases 1235–1237 highgrade squamous '\n",
      " 'intraepithelial lesions biopsy of an atypical wart might reveal hsil or '\n",
      " 'cancer of  the anogenital tract in this instance referral to a specialist '\n",
      " 'for  treatment is recommended cancers and precancers associated with human  '\n",
      " 'papillomavirus persistent infection with highrisk oncogenic types of hpv  '\n",
      " 'has a causal role in approximately all cervical cancers and in  certain '\n",
      " 'vulvar vaginal penile anal and oropharyngeal cancers  1238 however cervical '\n",
      " 'cancer is the only hpvassociated  cancer for which routine screening is '\n",
      " 'recommended cervical cancer screening recommendations recommendations for '\n",
      " 'cervical cancer screening in the  united states are based on systematic '\n",
      " 'evidence reviews  by major medical and advocacy organizations including  '\n",
      " 'uspstf 174 acs 177 and acog 175 over time  general alignment across these '\n",
      " 'organizations has emerged as  to when to start and end cervical cancer '\n",
      " 'screening as well as  the periodicity of screening although no single '\n",
      " 'guideline  universally guides screening practices in the united states the  '\n",
      " 'patient protection and affordable care act required medicaid  and new '\n",
      " 'private health insurance plans to provide coverage for  preventive services '\n",
      " 'graded a or b by uspstf which includes  cervical cancer screening in '\n",
      " 'addition the national center for  quality assurance provides a set of '\n",
      " 'measures the healthcare  effectiveness data and information set hedis for '\n",
      " 'upto date cervical cancer screening that aligns with uspstf  recommendations '\n",
      " 'httpswwwncqaorghedismeasures cervicalcancerscreening the center for medicaid '\n",
      " 'and  medicare services uses the same measure as hedis to measure  cervical '\n",
      " 'cancer screening performance uspstf screening recommendations apply to '\n",
      " 'persons with  a cervix at average risk defined as those with no previous  '\n",
      " 'cervical cancer or highgrade precancer not currently  under close followup '\n",
      " 'for a recent abnormal result not  immunocompromised eg persons with hiv and '\n",
      " 'who  had no exposure to diethylstilbestrol in utero among these  persons '\n",
      " 'screening should be performed starting at age 21 years  and continue through '\n",
      " 'age 65 years testing can be performed  using either conventional or '\n",
      " 'liquidbased cytologic tests ie  pap tests for persons aged ≥30 years '\n",
      " 'screening can include  fdacleared tests for highrisk oncogenic types of hpv  '\n",
      " 'for cytopathologic testing clinics should use cliacertified  laboratories '\n",
      " 'using acceptable terminology bethesda 2001 or  last terminology 1239 annual '\n",
      " 'cervical cancer screening is not recommended for  persons at average risk '\n",
      " 'instead cytology testing is recommended  every 3 years for persons aged '\n",
      " '21–29 years for persons aged  30–65 years a cytology test every 3 years an '\n",
      " 'hpv test alone  every 5 years or a cytology test plus an hpv test cotest '\n",
      " 'every  5 years is recommended cotesting can be done by either  collecting '\n",
      " 'one sample for the cytology test and another for the  hpv test or by using '\n",
      " 'the remaining liquid cytology material  for the hpv test cervical screening '\n",
      " 'programs should screen  those who have received hpv vaccination in the same '\n",
      " 'manner  as those that are unvaccinated screening is not recommended  before '\n",
      " 'age 21 years among those at average risk for those aged  30–65 years '\n",
      " 'cytology alone or primary hpv testing is preferred  by uspstf however '\n",
      " 'cotesting can be used as an alternative  approach acog 1240 acs 177 and '\n",
      " 'uspstf 174 each  have screening recommendations 1241 table 1 clinics should '\n",
      " 'weigh the benefits of each screening strategy  as well as their resources '\n",
      " 'such as time and cost in deciding on  which of the three possible screening '\n",
      " 'strategies to implement  decision analytic models 1242 estimating the '\n",
      " 'benefits harms  and costs 1243 of several different strategies might be '\n",
      " 'useful  in making this determination 17412441245 adopting  recommended '\n",
      " 'screening and followup procedures including  screening methods results '\n",
      " 'provision and followup can lead to  success in implementing cervical cancer '\n",
      " 'screening in clinics 1246 patients should be provided a copy of their test '\n",
      " 'results  those with normal results should be provided information  on '\n",
      " 'followup visits and the importance of continued cervical  '\n",
      " 'httpswwwncqaorghedismeasurescervicalcancerscreening '\n",
      " 'httpswwwncqaorghedismeasurescervicalcancerscreening recommendations and '\n",
      " 'reports mmwr  july 23 2021  vol 70  no 4 107us department of health and '\n",
      " 'human servicescenters for disease control and prevention table 1 cervical '\n",
      " 'cancer screening and surveillance recommendations  population  screening '\n",
      " 'specifics guideline group yr of recommendation uspstf 2018 acog 2016 acs '\n",
      " '2020 persons at average risk age to start screening 21 yrs 21 yrs 25 yrs age '\n",
      " 'to end screening 65 yrs 65 yrs 65 yrs if three consecutive negative cytology '\n",
      " 'tests or two negative cytology plus hpv tests or two  negative hpv tests acs '\n",
      " 'with the most recent within the previous 5 yrs and no abnormal tests  within '\n",
      " 'the previous 10 yrs acs and no cin 2 or cin 3 within the previous 25 yrs '\n",
      " 'screening test options  and intervals aged 21–65 yrs cytology alone every 3 '\n",
      " 'yrs  or  aged 21–29 yrs cytology alone every 3 yrs  aged 30–65 yrs cytology '\n",
      " 'plus hpv testing every 5 yrs  or  aged 21–29 yrs cytology alone every 3 yrs  '\n",
      " 'aged 30–65 hpv testing alone every 5 yrs hpv testing alone every 5 yrs  or  '\n",
      " 'cytology plus hpv testing every  5 yrs  or  cytology alone every 3 yrs '\n",
      " 'preferred strategies cytology alone every 3 yrs  and hpv testing alone '\n",
      " 'every  5 yrs equally preferred cytology plus hpv testing every   5 yrs  hpv '\n",
      " 'testing alone every 5 yrs previous hysterectomy  with removal of cervix '\n",
      " 'screening not recommended after hysterectomy for benign indications  '\n",
      " 'surveillance testing recommended for previous diagnosis of highgrade '\n",
      " 'precancer ais or cancer persons with an  immunocompromising medical  '\n",
      " 'condition† eg hiv infection or  solid organ transplantation age to start '\n",
      " 'screening no specific   recommendation within 1 yr of onset of sexual '\n",
      " 'activity or if already sexually active  within the first year after hiv or '\n",
      " 'other immunocompromising  medical condition diagnosis but no later than age '\n",
      " '21 yrs age to end screening none lifelong screening recommended screening '\n",
      " 'test options  and intervals aged 21–65 yrs cytology every year after three '\n",
      " 'consecutive annual  normal cytology test results screening can be every 3 '\n",
      " 'yrs  or  aged 21–29 yrs cytology every year  aged 30–65 yrs cytology plus '\n",
      " 'hpv testing every 3 yrs previous hysterectomy  with removal of cervix not '\n",
      " 'specified persons with in utero exposure to  diethylstilbestrol§ age to '\n",
      " 'start screening no specific   recommendation not specified no specific '\n",
      " 'recommendation age to end screening not specified screening test options  '\n",
      " 'and intervals cytology alone annually previous hysterectomy  with removal of '\n",
      " 'cervix not specified persons who have received hpv  vaccination no changes '\n",
      " 'to the screening approaches above asccp 2019 and acog 2020 persons with a '\n",
      " 'diagnosis of cin 2   or cin 3 histologic hsil¶   within the previous 25 yrs '\n",
      " 'age to start screening not applicable age to end screening may end at age 65 '\n",
      " 'yrs if cin diagnosis ≥25 yrs ago and criteria for ending screening met '\n",
      " 'otherwise  continue screening past age 65 yrs  continued screening for ≥25 '\n",
      " 'yrs after diagnosis is acceptable if patient is in good health screening '\n",
      " 'test options  and intervals initial surveillance  hpv testing alone or '\n",
      " 'cytology plus hpv testing at 6 18 and 30 mos  or  cytology at 6 12 18 24 and '\n",
      " '30 mos longterm surveillance  hpv testing alone or cytology plus hpv testing '\n",
      " 'every 3 yrs  or  cytology alone annually  continue for ≥25 yrs from the '\n",
      " 'initial cin diagnosis even if extends past age 65 yrs  routine screening can '\n",
      " 'resume after the posttreatment surveillance period previous hysterectomy  '\n",
      " 'with removal of cervix hpv testing alone or cytology plus hpv testing every '\n",
      " '3 yrs  or  cytology alone annually  continue for ≥25 yrs from the initial '\n",
      " 'cin diagnosis even if extends past age 65 yrs source perkins r guido r '\n",
      " 'saraiya m et al summary of current guidelines for cervical cancer screening '\n",
      " 'and management of abnormal test results 2016–2020 j  womens health larchmt '\n",
      " '2021305–13 abbreviations acs  american cancer society acog  american college '\n",
      " 'of obstetricians and gynecologists ais  adenocarcinoma in situ asccp  '\n",
      " 'american  society for colposcopy and cervical pathology cin  cervical '\n",
      " 'intraepithelial neoplasia hpv  human papillomavirus hsil  highgrade squamous '\n",
      " 'intraepithelial  lesion uspstf  us preventive services task force  '\n",
      " 'considered an alternative screening strategy by acog † panel for '\n",
      " 'opportunistic infections acog 2016 § acog 2016 ¶ either by cytology or by '\n",
      " 'histology includes a persistent cytologic diagnosis of atypical squamous '\n",
      " 'cells cannot rule out hsil recommendations and reports 108 mmwr  july 23 '\n",
      " '2021  vol 70  no 4 us department of health and human servicescenters for '\n",
      " 'disease control and prevention cancer screening if applicable those with '\n",
      " 'abnormal screening  tests should be managed per published guidelines '\n",
      " 'national  consensus guidelines are available for the management of  abnormal '\n",
      " 'cervical cancer screening tests 1247 hpv testing  or cotesting is preferred '\n",
      " 'to cytology alone for surveillance  after an abnormal screening test result '\n",
      " 'these guidelines base  management recommendations on casebycase assessment  '\n",
      " 'of risk considering past screening history and current results  see followup '\n",
      " 'patients with abnormal cervical cancer  screening test results should be '\n",
      " 'counseled about those results  see counseling messages the following '\n",
      " 'additional management considerations are  associated with performing pap '\n",
      " 'tests and hpv tests • cytology pap tests and hpv tests should not be  '\n",
      " 'considered screening tests for stis • all persons with a cervix should '\n",
      " 'receive cervical cancer  screening regardless of sexual orientation or '\n",
      " 'gender  identity ie those who identify as lesbian bisexual  heterosexual or '\n",
      " 'transgender • a conventional cytology test in which the sample is  smeared '\n",
      " 'onto a dry slide should ideally be scheduled for  10–20 days after the first '\n",
      " 'day of menses liquidbased  cytology can be performed at any time during the  '\n",
      " 'menstrual cycle • if specific infections other than hpv eg chlamydia or  '\n",
      " 'gonorrhea are identified at the visit a repeat cytology test  after '\n",
      " 'appropriate treatment for those infections might be  indicated however in '\n",
      " 'most instances even in the  presence of certain severe cervical infections '\n",
      " 'cytology  tests will be reported as satisfactory for evaluation and  '\n",
      " 'reliable final reports can be produced without the need to  repeat the '\n",
      " 'cytology test after treatment • the presence of a mucopurulent discharge '\n",
      " 'should not  postpone cytology testing the test can be performed after  '\n",
      " 'removal of the discharge with a salinesoaked cotton swab • hpv testing can '\n",
      " 'be performed either as a separate test or  by using material from the '\n",
      " 'liquidbased cytology specimen • in the absence of other indications the '\n",
      " 'presence of external  genital warts does not warrant more frequent cervical  '\n",
      " 'cancer screening • the sequence of cytology testing in relation to '\n",
      " 'collection  of other endocervical specimens does not influence pap test  '\n",
      " 'results or their interpretation 600 typically vaginal  specimens are '\n",
      " 'preferred for chlamydia and gonorrhea  screening however during a pelvic '\n",
      " 'examination endocervical  specimens for sti testing can be collected first • '\n",
      " 'persons who have had a total hysterectomy with removal  of the cervix do not '\n",
      " 'require screening unless cervical  intraepithelial neoplasia cin 2 cin 3 or '\n",
      " 'adenocarcinoma  in situ was diagnosed within the previous 20 years  1751247 '\n",
      " 'if the cervix remains intact after a supracervical  hysterectomy regularly '\n",
      " 'scheduled pap tests should be  performed as indicated 1248–1250 • health '\n",
      " 'care facilities that train providers on cytology test  collection and use '\n",
      " 'simple quality assurance measures are  more likely to obtain satisfactory '\n",
      " 'test results as determined  by the laboratory • the use of instruments '\n",
      " 'designed to sample the cervical  transformation zone eg cytobrushes improves '\n",
      " 'the  accuracy of cytology tests 1251 • both liquidbased and conventional '\n",
      " 'cytology are acceptable  because they have similar testperformance '\n",
      " 'characteristics • at an initial visit providers should ask patients about '\n",
      " 'their  recent cytology test and hpv results and any history of  evaluation '\n",
      " 'and treatment eg loop electrosurgical  excision procedure and colposcopy to '\n",
      " 'assist with  management effort should be made to obtain copies of  recent '\n",
      " 'results the importance and frequency of screening  should be reinforced '\n",
      " 'counseling persons might believe the cytology pap test or hpv test  screens '\n",
      " 'for conditions other than cervical cancer or they  might be confused by '\n",
      " 'abnormal results 1252–1254 health  care providers as trusted sources of '\n",
      " 'information about hpv  infections and abnormal cytology test results have an '\n",
      " 'important  role in educating persons about hpv and can moderate the  '\n",
      " 'psychosocial impact of abnormal results 12551256 persons  should be '\n",
      " 'counseled on the risks uncertainties and benefits  of screening 1741257 an '\n",
      " 'abnormal cytology test or a positive hpv test can  cause shortterm anxiety '\n",
      " 'stress fear and confusion possibly  decreasing the patient’s ability to '\n",
      " 'absorb and retain information  and acting as a barrier to followup care '\n",
      " '1258–1261 a  positive hpv test might elicit concerns about partners worries  '\n",
      " 'about disclosure and feelings of guilt anger and stigmatization  1260 '\n",
      " 'providers should frame hpv positivity in a neutral  nonstigmatizing context '\n",
      " 'and emphasize its common  asymptomatic and transient nature providers also '\n",
      " 'should  emphasize that hpv infections often are shared between  partners but '\n",
      " 'it is often not possible to know the origin of an  hpv infection hpv tests '\n",
      " 'might become positive many years  after initial exposure due to reactivation '\n",
      " 'of latent infections  in both male and female partners having an hpv '\n",
      " 'infection  should not raise concerns about a male partner’s health 1262  '\n",
      " 'providers should communicate the meaning of both the  cytology and hpv test '\n",
      " 'results to patients at screening providers also should screen for tobacco '\n",
      " 'use and  perform cessation counseling wwwacogorgclinical '\n",
      " 'clinicalguidancecommitteeopinionarticles201109 '\n",
      " 'httpswwwacogorgclinicalclinicalguidancecommitteeopinionarticles201109tobaccouseandwomenshealth '\n",
      " 'httpswwwacogorgclinicalclinicalguidancecommitteeopinionarticles201109tobaccouseandwomenshealth '\n",
      " 'recommendations and reports mmwr  july 23 2021  vol 70  no 4 109us '\n",
      " 'department of health and human servicescenters for disease control and '\n",
      " 'prevention tobaccouseandwomenshealth smoking contributes to  the progression '\n",
      " 'of cin with both active and passive smoking  associated with squamous cell '\n",
      " 'carcinoma of the cervix in  women with hpv 16 or 18 infection 1263–1266 '\n",
      " 'promoting cervical cancer screening clinics can use the evidencebased '\n",
      " 'interventions in the  community preventive services task force guidelines '\n",
      " 'to  promote cervical cancer screening in their communities  '\n",
      " 'httpswwwthecommunityguideorgfindingscancer '\n",
      " 'screeningmulticomponentinterventionscervicalcancer  implementing '\n",
      " 'interventions that increase community demand  for screening 1266 eg client '\n",
      " 'reminders client incentives  media group education or oneonone education '\n",
      " 'together  with those that increase community access to screening eg  '\n",
      " 'reducing structural barriers and reducing client outofpocket  costs is '\n",
      " 'effective in increasing cervical cancer screening  coverage these '\n",
      " 'interventions are more effective if they are  implemented with interventions '\n",
      " 'to increase provider delivery  of screening services eg provider assessment '\n",
      " 'and feedback  provider incentives and provider reminders print materials  '\n",
      " 'and online resources are available at httpswwwcdcgov '\n",
      " 'cancercervicalbasicinfoscreeninghtm and httpswww '\n",
      " 'cdcgovstdhpvfactsbrochureshtm patient navigators can  be effective in '\n",
      " 'improving both screening and followup after  abnormal results 1267 key '\n",
      " 'messages about cervical cancer screening when counseling persons about '\n",
      " 'cervical cancer screening  the provider should discuss the following • '\n",
      " 'cervical cancer can be prevented with regular screening tests  like the pap '\n",
      " 'test cytology and hpv tests those at average  risk should start getting '\n",
      " 'cytology tests at age 21 years • the cytology test can find abnormal '\n",
      " 'cervical cells which  could lead to cervical cancer over time and an hpv '\n",
      " 'test  detects hpv infection of the cervix the hpv test can be  used alone '\n",
      " 'for cervical cancer screening or at the same time  as the cytology test '\n",
      " 'known as cotesting for those aged  ≥30 years to 65 years the hpv test is '\n",
      " 'also used after a  cytology test result of atypical squamous cells of  '\n",
      " 'undetermined significance ascus among persons aged  25 years known as reflex '\n",
      " 'hpv testing • positive cytology and hpv tests are markers of cervical  '\n",
      " 'precancerous lesions which often do not cause symptoms  until they become '\n",
      " 'invasive appropriate followup is  essential to ensure that cervical cancer '\n",
      " 'does not develop • hpv is a common infection and is often controlled by  the '\n",
      " 'body without any medical interventions a positive  hpv test does not mean '\n",
      " 'that a person has cancer • providers should emphasize that hpv infections '\n",
      " 'often are  shared between partners and it is often not possible to know  the '\n",
      " 'origin of an hpv infection hpv tests might become  positive many years after '\n",
      " 'initial exposure due to reactivation  of latent infections in both male and '\n",
      " 'female partners management of sex partners the benefit of disclosing a '\n",
      " 'positive hpv test to current  and future sex partners is unclear the '\n",
      " 'following counseling  messages can be communicated to sex partners • sex '\n",
      " 'partners do not need to be tested for hpv • sex partners tend to share hpv '\n",
      " 'sex partners of persons  with hpv infection also are likely have an hpv '\n",
      " 'infection • female sex partners of men who disclose they had a previous  '\n",
      " 'female partner with hpv should be screened at the same  intervals as women '\n",
      " 'with average risk no data are available  to suggest that more frequent '\n",
      " 'screening is of benefit • when used correctly and consistently condoms '\n",
      " 'might  lower the risk for hpv infection and might decrease the  time to '\n",
      " 'clear in those with hpv infection however hpv  can infect areas not covered '\n",
      " 'by the condom and condoms  might not fully protect against hpv 2425 '\n",
      " 'additional messages for partners include the messages for persons  with hpv '\n",
      " 'see cervical cancer screening counseling messages screening recommendations '\n",
      " 'in special  populations pregnancy persons who are pregnant should be '\n",
      " 'screened at the same  intervals as those who are not a swab ayre’s spatula '\n",
      " 'or  cytobrush can be used for obtaining cytology test samples  during '\n",
      " 'pregnancy 1268–1270 hiv infection several studies have documented an '\n",
      " 'increased risk for cervical  precancers and cancers in individuals with hiv '\n",
      " 'infection  1271–1273 adolescents with hiv should be screened 1 year  after '\n",
      " 'onset of sexual activity but no later than age 21 years  sexually active '\n",
      " 'persons should be screened at the time of the  initial hiv diagnosis '\n",
      " 'conventional or liquidbased cytology  pap test should be used as primary hpv '\n",
      " 'testing and is not  recommended in individuals with hiv cotesting cytology  '\n",
      " 'and hpv test can be done in individuals aged ≥30 years with  hiv annual '\n",
      " 'screening is recommended for persons with hiv  infection after 3 years of '\n",
      " 'consecutive normal cytology results  or normal cotest normal cytology and '\n",
      " 'negative hpv test the  screening interval can be increased to every 3 years '\n",
      " 'lifelong  screening is recommended among persons with hiv infection '\n",
      " 'httpswwwacogorgclinicalclinicalguidancecommitteeopinionarticles201109tobaccouseandwomenshealth '\n",
      " 'httpswwwthecommunityguideorgfindingscancerscreeningmulticomponentinterventionscervicalcancer '\n",
      " 'httpswwwthecommunityguideorgfindingscancerscreeningmulticomponentinterventionscervicalcancer '\n",
      " 'httpswwwcdcgovcancercervicalbasicinfoscreeninghtm '\n",
      " 'httpswwwcdcgovcancercervicalbasicinfoscreeninghtm '\n",
      " 'httpswwwcdcgovstdhpvfactsbrochureshtm httpswwwcdcgovstdhpvfactsbrochureshtm '\n",
      " 'recommendations and reports 110 mmwr  july 23 2021  vol 70  no 4 us '\n",
      " 'department of health and human servicescenters for disease control and '\n",
      " 'prevention providers should defer to existing guidelines for the prevention  '\n",
      " 'and treatment of opportunistic infections in adults and  adolescents with '\n",
      " 'hiv for guidance on cervical cancer screening  and management of results in '\n",
      " 'persons with hiv 98 adolescents prevalence of hpv infection is high among '\n",
      " 'those aged  21 years 174 however hpv infections and squamous  '\n",
      " 'intraepithelial lesions caused by hpv in adolescents are more  likely to '\n",
      " 'regress than those in older persons for these reasons  cervical cancer '\n",
      " 'screening and hpv testing are not recommended  in immunocompetent '\n",
      " 'adolescents however for adolescents  with hiv infection providers should '\n",
      " 'screen 1 year after onset of  sexual activity regardless of age or mode of '\n",
      " 'hiv acquisition eg  perinatally acquired or sexually acquired 98 such '\n",
      " 'screening  is warranted because of the reported high rate of progression of  '\n",
      " 'abnormal cytology in adolescents with hiv human papillomavirus tests for '\n",
      " 'cervical  cancer screening clinical tests for hpv are used for the following '\n",
      " 'cervical  cancer screening as a primary test cervical cancer screening  with '\n",
      " 'a cytology test triage of some abnormal cervical  cytology results followup '\n",
      " 'after abnormal screening test  results followup after a colposcopy in which '\n",
      " 'no cin 2 or  cin 3 is found and followup after treatment of cervical  '\n",
      " 'precancers these tests are only fda cleared for use with  cervical specimens '\n",
      " 'not oral or anal specimens testing  for nononcogenic hpv types eg types 6 '\n",
      " 'and 11 is not  recommended httpswwwasccporgguidelines fdacleared hpv tests '\n",
      " 'detect viral dna or messenger  rna several fdacleared tests for hpv are '\n",
      " 'available for  use in the united states the cobas 4800 hpv test roche  '\n",
      " 'molecular diagnostics and the onclarity hpv test becton  dickinson can '\n",
      " 'detect the presence of 14 oncogenic hpv types  types 16 18 31 33 35 39 45 51 '\n",
      " '52 56 58 59 66 and  68 as well as individual types 16 and 18 and are cleared '\n",
      " 'for  primary cervical cancer screening other hpv tests are cleared for use '\n",
      " 'in conjunction with  a cytology test or to triage some abnormal cervical '\n",
      " 'cytology  results they should not be used for primary hpv testing  because '\n",
      " 'they are not cleared for this purpose these tests  include the hybrid '\n",
      " 'capture 2 highrisk hpv dna test  qiagen the cervista hpv highrisk dna and '\n",
      " 'hpv 1618  dna tests hologics and the aptima hr hpv gen  probe test all hpv '\n",
      " 'assays should be fda cleared and used  only for the appropriate indications '\n",
      " 'httpswwwfdagov media122799download 158 hpv testing should not be performed '\n",
      " 'in the following situations • deciding whether to vaccinate against hpv • '\n",
      " 'conducting hpv tests for lowrisk nononcogenic hpv  types eg types 6 and 11 • '\n",
      " 'providing care to persons with genital warts or their partners • testing '\n",
      " 'persons aged 25 years as part of routine cervical  cancer screening • '\n",
      " 'testing oral or anal specimens unlike cytology samples for hpv testing have '\n",
      " 'the potential  to be collected by the patient and mailed to health programs  '\n",
      " 'for analysis thus selfcollection might be one strategy for  increasing '\n",
      " 'screening rates among populations where screening  rates are low '\n",
      " 'selfcollection for hpv testing is not cleared by  fda or recommended by us '\n",
      " 'medical organizations 174 followup of abnormal cytology and human  '\n",
      " 'papillomavirus test results if the result of the cytology pap test is '\n",
      " 'abnormal followup  care should be provided according to the 2019 asccp risk '\n",
      " 'based management consensus guidelines for abnormal cervical  cancer '\n",
      " 'screening tests and cancer precursors 158 clinics that  serve clients who '\n",
      " 'might have difficulty adhering to followup  recommendations and for whom '\n",
      " 'linkage to care is unlikely should  consider offering inhouse colposcopy and '\n",
      " 'biopsy services consensus guidelines for management of abnormal  cervical '\n",
      " 'cancer screening tests combine patientlevel risk  data with clinical action '\n",
      " 'thresholds to generate personalized  management recommendations table 2 this '\n",
      " 'framework  allows management on the basis of risk for cin 3 not specific  '\n",
      " 'test results the guidelines were designed to identify persons at  high risk '\n",
      " 'who require colposcopy or expedited treatment and  persons at low risk who '\n",
      " 'might be able to safely defer invasive  diagnostic procedures the riskbased '\n",
      " 'framework was designed  to easily incorporate future revisions such as the '\n",
      " 'inclusion of  new technologies for screening and management use of the  '\n",
      " 'guidelines can be facilitated by electronic technology that is  continually '\n",
      " 'updated such as a smartphone application or the  website '\n",
      " 'httpswwwasccporgdefaultaspx  the following are highlights of the new '\n",
      " 'management guidelines • colposcopy can be deferred for patients at low risk  '\n",
      " 'ű if a patient has a minimally abnormal test result ie  negative for '\n",
      " 'intraepithelial lesion or malignancy hpv  positive ascus hpv positive lsil '\n",
      " 'or hpv positive  that was preceded by a negative screening hpv test or  '\n",
      " 'cotest within the past 5 years followup in 1 year instead  of colposcopy is '\n",
      " 'recommended a negative hpv test or  cotest performed during followup of '\n",
      " 'abnormal results  would not similarly reduce risk  ű referral to colposcopy '\n",
      " 'is recommended if cytology test  results are abnormal or the hpv test is '\n",
      " 'positive at the  1year followup visit • treatment can be expedited for '\n",
      " 'highrisk patients httpswwwasccporgguidelines '\n",
      " 'httpswwwfdagovmedia122799download httpswwwfdagovmedia122799download '\n",
      " 'httpswwwasccporgdefaultaspx recommendations and reports mmwr  july 23 2021  '\n",
      " 'vol 70  no 4 111us department of health and human servicescenters for '\n",
      " 'disease control and prevention  ű if a patient has a highgrade cytology pap '\n",
      " 'test result  ie hsil and an hpv test that is positive for hpv  type 16 then '\n",
      " 'treatment with a loop electrosurgical  excision procedure leep is preferred '\n",
      " 'a colposcopy  with biopsy is not necessary to confirm the diagnosis first  ű '\n",
      " 'if a patient who has not been screened in more than  5 years ie rarely '\n",
      " 'screened has an hsil cytology result  and a positive hpv test regardless of '\n",
      " 'type then  treatment with leep is preferred a colposcopy with  biopsy is not '\n",
      " 'necessary to confirm the diagnosis first  ű when considering treatment '\n",
      " 'without confirmatory  biopsy shared decisionmaking with the patient is  '\n",
      " 'important considerations include age concern about  cancer ability to follow '\n",
      " 'up financial concerns and  concerns about the potential effect of treatment '\n",
      " 'on a  future pregnancy • when primary hpv testing is used for screening '\n",
      " 'cytology  testing should be performed for all positive hpv test  results to '\n",
      " 'help determine the next steps in management  ű ideally cytology testing '\n",
      " 'should be performed by the  laboratory as a reflex test from the same '\n",
      " 'specimen so the  patient does not need to return to the clinic colposcopy  '\n",
      " 'is recommended if hpv genotyping is positive for types  16 or 18 and it can '\n",
      " 'be considered if it is infeasible for  the patient to return for cytology '\n",
      " 'alone 1274  ű hpv 16 is the highestrisk hpv type expedited  treatment should '\n",
      " 'be considered for hsil cytology  results and colposcopy is recommended in '\n",
      " 'all other  cases even if the cytology test is normal table 2 comparison of '\n",
      " '2012 and 2019 consensus recommendations for management of common '\n",
      " 'abnormalities — american society for  colposcopy and cervical pathology '\n",
      " 'current hpv result current pap   test result previous result management by '\n",
      " '2012  guidelines management by 2019  guidelines negative ascus unknown or '\n",
      " 'hpv negative repeat pap plus hpv testing   in 3 yrs repeat hpv test with or '\n",
      " 'without  concurrent pap test in 3 yrs negative lsil unknown or hpv negative '\n",
      " 'repeat pap plus hpv testing   in 1 yr preferred colposcopy  acceptable '\n",
      " 'repeat hpv test with or without  concurrent pap test in 1 yr negative asch '\n",
      " 'noncontributory colposcopy colposcopy noncontributory agc noncontributory '\n",
      " 'colposcopy colposcopy  positive nilm unknown or hpv negative repeat pap plus '\n",
      " 'hpv testing   in 1 yr repeat hpv test with or without  concurrent pap test '\n",
      " 'in 1 yr positive nilm hpv positive† colposcopy colposcopy positive for '\n",
      " 'genotype hpv 16  hpv 18 or both nilm noncontributory colposcopy colposcopy '\n",
      " 'positive for genotype hpv 16  hpv 18 or both ascus or lsil noncontributory '\n",
      " 'not applicable genotyping   not recommended for   ascus or lsil in 2012 '\n",
      " 'colposcopy positive ascus or lsil unknown or hpv positive colposcopy '\n",
      " 'colposcopy positive ascus or lsil negative screening results with  hpv '\n",
      " 'testing or hpv plus pap  testing within the previous 5 yrs colposcopy repeat '\n",
      " 'hpv test with or without  concurrent pap test in 1 yr§ positive ascus or '\n",
      " 'lsil colposcopy confirming the absence  of highgrade lesion within the  past '\n",
      " 'yr colposcopy repeat hpv test with or without  concurrent pap test in 1 yr§ '\n",
      " 'positive asch noncontributory colposcopy colposcopy or expedited  treatment '\n",
      " 'positive untyped positive for  genotype other than hpv 16  or negative hsil '\n",
      " 'noncontributory colposcopy or expedited  treatment colposcopy or expedited  '\n",
      " 'treatment positive for genotype hpv 16 hsil noncontributory colposcopy or '\n",
      " 'expedited  treatment expedited treatment¶ sources massad ls einstein mh huh '\n",
      " 'wk et al 2012 asccp consensus guidelines conference 2012 updated consensus '\n",
      " 'guidelines for the management of abnormal  cervical cancer screening tests '\n",
      " 'and cancer precursors obstet gynecol 2013121829–46 perkins rb guido rs '\n",
      " 'castle pe et al 2019 asccp riskbased management  consensus guidelines '\n",
      " 'committee 2019 asccp riskbased management consensus guidelines for abnormal '\n",
      " 'cervical cancer screening tests and cancer precursors  j low genit tract dis '\n",
      " '202024102–31 perkins r guido r saraiya m et al summary of current guidelines '\n",
      " 'for cervical cancer screening and management of abnormal  test results '\n",
      " '2016–2020 j womens health larchmt 2021305–13 abbreviations agc  atypical '\n",
      " 'glandular cells ais  adenocarcinoma in situ asch  atypical squamous cells '\n",
      " 'cannot exclude highgrade squamous intraepithelial  lesion ascus  atypical '\n",
      " 'squamous cells of undetermined significance cin  cervical intraepithelial '\n",
      " 'neoplasia hpv  human papillomavirus hsil  highgrade  squamous '\n",
      " 'intraepithelial lesion lsil  lowgrade squamous intraepithelial lesion nilm  '\n",
      " 'negative for intraepithelial lesion or malignancy pap  papanicolaou  '\n",
      " 'colposcopy may be warranted for patients with a history of highgrade lesions '\n",
      " 'cin 2 or cin 3 histologic or cytologic hsil asch agc or ais † previous pap '\n",
      " 'test results do not modify the recommendation colposcopy is always '\n",
      " 'recommended for two consecutive hpvpositive tests § negative hpv test or '\n",
      " 'cotest hpv plus pap test results only reduce risk sufficiently to defer '\n",
      " 'colposcopy if performed for screening purposes within the last 5 years  '\n",
      " 'colposcopy is still warranted if negative hpv test or cotest results '\n",
      " 'occurred in the context of surveillance for a previous abnormal result  ¶ '\n",
      " 'expedited treatment is preferred for nonpregnant patients aged ≥25 years '\n",
      " 'colposcopy with biopsy is an acceptable option if desired by patient after '\n",
      " 'shared  decisionmaking recommendations and reports 112 mmwr  july 23 2021  '\n",
      " 'vol 70  no 4 us department of health and human servicescenters for disease '\n",
      " 'control and prevention  ű hpv 18 has a relatively high association with '\n",
      " 'cancer  and colposcopy is recommended in all cases even if the  cytology '\n",
      " 'test is normal because of the association of  hpv 18 with adenocarcinoma '\n",
      " 'endocervical sampling  is acceptable at the time of colposcopy  ű if the hpv '\n",
      " 'type is not hpv 16 or 18 and the cytology test  is normal return in 1 year '\n",
      " 'is recommended in most cases • hpv testing or cotesting is preferred to '\n",
      " 'cytology testing  alone for followup after an abnormal test result  ű '\n",
      " 'negative hpv testing or cotesting is less likely to miss  disease than '\n",
      " 'normal cytology testing alone therefore  cytology testing is recommended '\n",
      " 'more often than hpv  testing or cotesting for followup of abnormal results  '\n",
      " 'specifically cytology testing is recommended annually  when hpv testing or '\n",
      " 'cotesting is recommended at  3year intervals and cytology testing is '\n",
      " 'recommended  at 6month intervals when hpv testing or cotesting is  '\n",
      " 'recommended annually •  after treatment for a highgrade precancer moderate '\n",
      " 'or  severe dysplasia surveillance should continue for at least  25 years  ű '\n",
      " 'initial testing includes an hpv test or cotest at 6 18  and 30 months if '\n",
      " 'cytology alone is used testing should  occur at 6 12 18 24 and 30 months  ű '\n",
      " 'after completing initial testing longterm surveillance  includes testing at '\n",
      " '3year intervals if using hpv testing or  cotesting or annual testing if '\n",
      " 'using cytology testing alone  ű surveillance should continue for at least 25 '\n",
      " 'years after  the initial treatment even if this extends beyond age  65 years '\n",
      " 'if a woman undergoes hysterectomy during the  surveillance period vaginal '\n",
      " 'screening should continue anal cancer anal cancer is rare in the general '\n",
      " 'population 1–2 cases per  100000 personyears however incidence is '\n",
      " 'substantially  higher among specific populations including msm with hiv  '\n",
      " 'infection 80–131 cases per 100000 personyears men with  hiv infection 40–60 '\n",
      " 'cases per 100000 personyears women  with hiv infection 20–30 cases per '\n",
      " '100000 personyears  and msm without hiv infection 14 cases per 100000  '\n",
      " 'personyears 1275–1279 incidence is variable among  women with previous '\n",
      " 'hpvrelated gynecologic dysplasia and  cancer 6–63 cases per 100000 '\n",
      " 'personyears 12801281  persistent hpv infection might be a risk factor for '\n",
      " 'preventable  hpvassociated second primary cancers among survivors of  '\n",
      " 'hpvassociated cancers 1282 data are insufficient to recommend routine anal '\n",
      " 'cancer  screening with anal cytology in persons with hiv infection  msm '\n",
      " 'without hiv infection and the general population an  annual digital '\n",
      " 'anorectal examination dare might be useful  to detect masses on palpation in '\n",
      " 'persons with hiv infection  and possibly in msm without hiv with a history '\n",
      " 'of receptive  anal intercourse 98 more evidence is needed concerning  the '\n",
      " 'natural history of anal intraepithelial neoplasia the best  screening '\n",
      " 'methods and target populations the safety and  response to treatments and '\n",
      " 'other programmatic considerations  before screening can be routinely '\n",
      " 'recommended populations at high risk and digital anorectal  examination '\n",
      " 'providers should discuss anal cancer risk with their patients  among '\n",
      " 'specific populations to guide management according  to the hiv opportunistic '\n",
      " 'infection guidelines and the  international anal neoplasia society a dare '\n",
      " 'should be  performed to detect early anal cancer in persons with hiv  '\n",
      " 'infection and msm without hiv with a history of receptive  anal intercourse '\n",
      " '981283 dare is acceptable to patients and  has a low risk for adverse '\n",
      " 'outcomes 12841285 data are insufficient to guide initiation of dare at a '\n",
      " 'defined  age or optimal intervals for examination whereas anal hsil  is '\n",
      " 'observed among young adults cancer incidence begins  to increase after the '\n",
      " 'early 30s and continues to increase as a  function of age populations at '\n",
      " 'high risk and anal cytology data are insufficient to recommend routine anal '\n",
      " 'cancer  screening with anal cytology among populations at risk for  anal '\n",
      " 'cancer certain clinical centers perform anal cytology to  screen for anal '\n",
      " 'cancer among populations at high risk eg  persons with hiv infection msm and '\n",
      " 'those having receptive  anal intercourse followed by highresolution anoscopy '\n",
      " 'hra  for those with abnormal cytologic results eg acsus lsil  or hsil '\n",
      " 'sensitivity and specificity of anal cytology to detect  hsil are limited '\n",
      " 'sensitivity 55–89 and specificity 40– 67 1286–1291 health centers that '\n",
      " 'initiate a cytology based screening program should only do so if referrals '\n",
      " 'to hra  and biopsy are available hra can be used for diagnosis of hsil to '\n",
      " 'monitor response  to therapy or to conduct surveillance of hsil for evidence '\n",
      " 'of  progression hra is the primary method used for diagnosis of  '\n",
      " 'superficially invasive squamous carcinoma a very early form of  anal cancer '\n",
      " 'that is not palpable on dare however data are  insufficient to conclude '\n",
      " 'whether use of hra leads to reductions  in anal cancer incidence or improves '\n",
      " 'anal cancer morbidity and  mortality an ongoing clinical trial is '\n",
      " 'investigating whether  treatment of hsil is effective in reducing the '\n",
      " 'incidence of anal  cancer among persons with hiv infection nct02135419 human '\n",
      " 'papillomavirus testing hpv tests using highrisk hpv types are not '\n",
      " 'clinically  useful for anal cancer screening because of a high prevalence  '\n",
      " 'recommendations and reports mmwr  july 23 2021  vol 70  no 4 113us '\n",
      " 'department of health and human servicescenters for disease control and '\n",
      " 'prevention of anal hpv infection among populations at high risk  '\n",
      " 'particularly msm 127812891290 no standard hpvbased  algorithms exist for '\n",
      " 'anal cancer screening due to the high  prevalence of highrisk hpv infection '\n",
      " 'among groups at risk treatment of anal highgrade squamous  intraepithelial '\n",
      " 'lesion multiple officebased treatments exist for anal hsil  including '\n",
      " 'ablative methods eg laser electrocautery or  infrared coagulation and '\n",
      " 'topical patientapplied therapies  eg imiquimod recurrence rates with both '\n",
      " 'provider applied and patientapplied treatments are high ranging  from '\n",
      " 'approximately 50 at 1 year to 77 after 3 years  128912921293 in addition '\n",
      " 'evidence exists that hsil  might spontaneously regress without treatment '\n",
      " '12941295  shared decisionmaking about treatment for anal hsil is  '\n",
      " 'recommended because of limited data on the natural history  of anal hsil '\n",
      " 'including factors related to progression or  regression of lesions viral '\n",
      " 'hepatitis hepatitis a virus infection hav infection has an incubation period '\n",
      " 'of approximately  28 days range 15–50 days 1296 hav replicates in the liver  '\n",
      " 'and is shed in high concentrations in feces from 2–3 weeks  before to 1 week '\n",
      " 'after the onset of clinical illness hav infection  produces a selflimited '\n",
      " 'disease that does not result in chronic  infection or chronic liver disease '\n",
      " 'however approximately  10 of patients experience a relapse of symptoms '\n",
      " 'during  the 6 months after acute illness acute liver failure from  hepatitis '\n",
      " 'a is rare overall casefatality rate 05 the risk  for symptomatic infection '\n",
      " 'is directly related to age with  approximately 70 of adults having symptoms '\n",
      " 'compatible  with acute viral hepatitis and the majority of children having  '\n",
      " 'either asymptomatic or unrecognized infection antibody  produced in response '\n",
      " 'to hav infection persists for life and  confers protection against '\n",
      " 'reinfection 1297 hav infection is primarily transmitted by the fecaloral '\n",
      " 'route  by either persontoperson contact or through consumption  of '\n",
      " 'contaminated food or water 1298 transmission of hav  during sexual activity '\n",
      " 'probably results from fecaloral contact  although viremia occurs early '\n",
      " 'during infection and can persist  for weeks after symptom onset bloodborne '\n",
      " 'transmission of  hav is uncommon 1299 transmission by saliva has not  been '\n",
      " 'demonstrated in the united states of the hepatitis a cases accompanied by  '\n",
      " 'risk information a particular risk was identified among only  238 13372 '\n",
      " 'among cases with a risk factor identified a  recognized foodborne or '\n",
      " 'waterborne outbreak was the most  commonly identified risk 496 other '\n",
      " 'infection sources  identified in the united states include msm persons who  '\n",
      " 'use injecting drugs sexual and household contacts those  experiencing '\n",
      " 'homelessness international travelers those with  children attending a '\n",
      " 'nursery childcare or preschool and  persons working in such settings 13372 '\n",
      " 'diagnostic considerations diagnosis of hav infection cannot be made on a '\n",
      " 'clinical  basis alone but requires serologic testing presence of igm  '\n",
      " 'antibody to hav is diagnostic of acute hav infection a  positive test for '\n",
      " 'total antihav indicates immunity to hav  infection but does not '\n",
      " 'differentiate current from previous hav  infection although usually not '\n",
      " 'sensitive enough to detect the  low level of protective antibody after '\n",
      " 'vaccination antihav  tests also might be positive after hepatitis a '\n",
      " 'vaccination treatment patients with acute hav infection usually require '\n",
      " 'only  supportive care with no restrictions in diet or activity  '\n",
      " 'hospitalization might be necessary for patients who become  dehydrated '\n",
      " 'because of nausea and vomiting and is crucial  for patients with signs or '\n",
      " 'symptoms of acute liver failure  medications that might cause liver damage '\n",
      " 'or are metabolized  by the liver should be used with caution among persons '\n",
      " 'with  hav infection prevention vaccination is the most effective means of '\n",
      " 'preventing hav  transmission among persons at risk for infection eg msm  '\n",
      " 'injecting drug users and persons with chronic liver disease  who did not '\n",
      " 'receive hepatitis a vaccination during childhood  hepatitis a vaccines are '\n",
      " 'prepared from formalininactivated  cellculture–derived hav two monovalent '\n",
      " 'vaccines havrix  and vaqta are approved by fda for persons aged ≥12 months  '\n",
      " 'table 3 these vaccines are available for eligible children  and adolescents '\n",
      " 'aged 19 years through the vfc program  '\n",
      " 'httpswwwcdcgovvaccinesprogramsvfcindexhtml  administered im in a 2dose '\n",
      " 'series at 0 and 6–12 months  hepatitis a vaccines induce protective antibody '\n",
      " 'levels among  virtually all adults by 1 month after the first dose 94–100  '\n",
      " 'of adults have protective antibody levels and after a second  dose 100 '\n",
      " 'achieve protective levels 129713001301  kinetic models of antibody decrease '\n",
      " 'among adults indicate that  protective levels persist for 40 years 1302–1304 '\n",
      " 'a study of  alaska natives demonstrated that seropositivity for hepatitis  a '\n",
      " 'persists for 20 years after completing 2dose vaccination at  age 12–21 '\n",
      " 'months 1302 antihav persistence of 20 years  was demonstrated among '\n",
      " 'immunocompetent adults vaccinated  '\n",
      " 'httpswwwcdcgovvaccinesprogramsvfcindexhtml recommendations and reports 114 '\n",
      " 'mmwr  july 23 2021  vol 70  no 4 us department of health and human '\n",
      " 'servicescenters for disease control and prevention with a 2dose hepatitis a '\n",
      " 'schedule as adults 13031305 a  combined hepatitis a and hepatitis b vaccine '\n",
      " 'twinrix has  been developed and licensed for use as a 3dose series for  '\n",
      " 'adults aged ≥18 years at risk for hav or hbv infections  when administered '\n",
      " 'im on a 0 1 and 6month schedule  the vaccine has equivalent immunogenicity '\n",
      " 'to that of the  monovalent hepatitis a vaccines preexposure vaccination '\n",
      " 'persons at risk for hav infection box 5 1297 should be  offered vaccine '\n",
      " 'table 3 if persons are at risk for both hav  and hbv the combined vaccine '\n",
      " 'can be considered prevaccination serologic testing among usborn adults aged '\n",
      " '20 years hav susceptibility  prevalence ie total antibody to hav was '\n",
      " 'negative was  741 95 ci\\xa0729–753 during 2007–2016 1306 prevaccination '\n",
      " 'serologic testing for hav immunity before  vaccination is not routinely '\n",
      " 'recommended however it can be  considered in specific settings to reduce '\n",
      " 'costs by not vaccinating  persons who are already immune prevaccination '\n",
      " 'serologic  testing should not be a barrier to vaccination of susceptible  '\n",
      " 'persons especially for populations that are difficult to access if  '\n",
      " 'prevaccination testing is performed commercially available tests  for total '\n",
      " 'antihav or igg antihav should be used 1297 box 5 populations recommended for '\n",
      " 'hepatitis a vaccination — advisory committee on immunization practices 2020 '\n",
      " 'children • all children aged 12–23 months • unvaccinated children and '\n",
      " 'adolescents aged 2–18 years persons at increased risk for hepatitis a virus '\n",
      " 'hav  infection • international travelers • men who have sex with men • '\n",
      " 'persons who use injecting or noninjecting drugs ie  all those who use '\n",
      " 'illegal drugs • persons with occupational risk for exposure • persons who '\n",
      " 'anticipate close personal contact with an  international adoptee • persons '\n",
      " 'experiencing homelessness persons at increased risk for severe disease from  '\n",
      " 'hav infection • persons with chronic liver disease • persons with hiv '\n",
      " 'infection other persons recommended for vaccination • pregnant women at risk '\n",
      " 'for hav infection or severe  outcome from hav infection • any persons who '\n",
      " 'requests a vaccine vaccination during outbreaks • unvaccinated persons in '\n",
      " 'outbreak settings who are at  risk for hav infection or at risk for severe '\n",
      " 'disease from  hav implementation strategies for settings providing  services '\n",
      " 'to adults • persons in settings that provide services to adults where  a '\n",
      " 'high proportion of those persons have risk factors for  hav infection '\n",
      " 'hepatitis a vaccination is no longer recommended by  the advisory committee '\n",
      " 'on immunization practices • persons who receive blood products for clotting '\n",
      " 'disorders  eg hemophilia source nelson np weng mk hofmeister mg et al '\n",
      " 'prevention of hepatitis a virus infection in the united states '\n",
      " 'recommendations of the advisory committee  on immunization practices 2020 '\n",
      " 'mmwr recomm rep 202069no rr5 table 3 vaccines for preventing hepatitis a '\n",
      " 'infection vaccine trade name manufacturer age group yrs dose route schedule '\n",
      " 'booster hep a inactivated   2 doses havrix glaxosmithkline 1–18 05 ml 720 '\n",
      " 'elisa units inactivated hav im 0 6–12 mos none ≥19 1 ml 1440 elisa units '\n",
      " 'inactivated hav im 0 6–12 mos none hep a inactivated   2 doses vaqta merck '\n",
      " '1–18 05 ml 25 units hav antigen im 0 6–18 mos none ≥19 1 ml 50 units hav '\n",
      " 'antigen im 0 6–18 mos none combined hep a   and hep b   3 doses twinrix '\n",
      " 'glaxosmithkline ≥18 primary 1 ml 720 elisa units inactivated plus   20 µg '\n",
      " 'hbsag im 0 1 6 mos none ≥18 accelerated 1 ml 720 elisa units inactivated '\n",
      " 'plus   20 µg hbsag im 0 7 21–30 days 12 mos source nelson np weng mk '\n",
      " 'hofmeister mg et al prevention of hepatitis a virus infection in the united '\n",
      " 'states recommendations of the advisory committee on  immunization practices '\n",
      " '2020 mmwr recomm rep 202069no rr5 abbreviations elisa  enzymelinked '\n",
      " 'immunosorbent assay hav  hepatitis a virus hbsag  hepatitis b surface '\n",
      " 'antigen hep a  hepatitis a hep b  hepatitis b  im intramuscular  combined '\n",
      " 'hep a and hep b vaccine twinrix should not be used as postexposure '\n",
      " 'prophylaxis recommendations and reports mmwr  july 23 2021  vol 70  no 4 '\n",
      " '115us department of health and human servicescenters for disease control and '\n",
      " 'prevention persons for whom prevaccination testing will likely be most  '\n",
      " 'costeffective include adults who were either born in or lived for  extensive '\n",
      " 'periods in geographic areas where hav endemicity is  high or intermediate '\n",
      " '1297 prevaccination serologic testing  of children is not indicated because '\n",
      " 'of the low prevalence of  infection among that age group for populations who '\n",
      " 'are expected to have high rates of previous  hav infection vaccination '\n",
      " 'history should be obtained when  feasible before testing or vaccination '\n",
      " 'vaccination should not be  postponed if vaccination history cannot be '\n",
      " 'obtained records are  unavailable or prevaccination testing is infeasible '\n",
      " 'vaccinating  persons immune from natural infection carries no known risk '\n",
      " 'nor  does giving extra doses of hepatitis a vaccine 1307 vaccination  of a '\n",
      " 'person who is already immune is not harmful persons who  have a documented '\n",
      " 'history of ≥2 doses of hepatitis a vaccine do  not need further vaccination '\n",
      " 'or serologic testing postvaccination serologic testing serologic testing for '\n",
      " 'immunity is unnecessary after routine  vaccination of infants children or '\n",
      " 'adults 1297 testing  for antihav antibody after vaccination is recommended  '\n",
      " 'for persons whose subsequent clinical management depends  on knowledge of '\n",
      " 'their immune status and persons for whom  revaccination might be indicated '\n",
      " 'eg persons with hiv  infection and other immunocompromising conditions '\n",
      " 'postexposure prophylaxis persons who recently have been exposed to hav and '\n",
      " 'who  previously have not received hepatitis a vaccine should be  '\n",
      " 'administered a single dose of monovalent hepatitis a vaccine  or '\n",
      " 'immunoglobulin ig 01 mlkg body weight as soon as  possible ideally 2 weeks '\n",
      " 'after exposure because the efficacy  of vaccine or ig when administered 2 '\n",
      " 'weeks after exposure  has not been established 1297 in most cases '\n",
      " 'monovalent  hepatitis a vaccine at the ageappropriate dose is preferred  '\n",
      " 'over ig for pep advantages of hepatitis a vaccine for pep  include induction '\n",
      " 'of active immunity longerterm protection  ease of administration and better '\n",
      " 'acceptability and availability  decisions to use vaccine versus ig should be '\n",
      " 'guided by patient  characteristics associated with more severe '\n",
      " 'manifestations  of hav infection eg older age immunocompromising  conditions '\n",
      " 'and chronic liver disease and the magnitude of the  risk for hav '\n",
      " 'transmission resulting from the exposure 1297 ig should be used for children '\n",
      " 'aged 6 months  immunocompromised persons persons with chronic liver  disease '\n",
      " 'and persons for whom vaccine is contraindicated ig  can be administered to '\n",
      " 'persons aged 40 years in addition to  hepatitis a vaccine 1297 ig '\n",
      " 'administered im can provide pep against hav table 4  ig is a sterile '\n",
      " 'solution of concentrated immunoglobulins prepared  table 4 recommendations '\n",
      " 'for hepatitis a postexposure prophylaxis and preexposure protection by age '\n",
      " 'group and risk category — advisory  committee on immunization practices 2020 '\n",
      " 'indication and age group risk category and health status hepatitis a vaccine '\n",
      " 'ig postexposure prophylaxis 0–11 mos healthy no 01 mlkg body weight 12 mos '\n",
      " 'to 40 yrs healthy 1 dose† none 40 yrs healthy 1 dose† 01 mlkg body weight§ '\n",
      " '≥12 mos immunocompromised or chronic liver disease 1 dose† 01 mlkg body '\n",
      " 'weight¶ ≥12 mos vaccine contraindicated no 01 mlkg body weight preexposure '\n",
      " 'protection eg travel†† 6 mos healthy no 01–02 mlkg body weight§§ 6–11 mos '\n",
      " 'healthy 1 dose¶¶ none 12 mos to 40 yrs healthy 1 dose none 40 yrs healthy 1 '\n",
      " 'dose 01–02 mlkg body weight§§††† 6 mos immunocompromised or chronic liver '\n",
      " 'disease 1 dose 01–02 mlkg body weight§§††† 6 mos persons who elect not to '\n",
      " 'receive vaccine or for whom  vaccine is contraindicated no 01–02 mlkg body '\n",
      " 'weight§§ source nelson np weng mk hofmeister mg et al prevention of '\n",
      " 'hepatitis a virus infection in the united states recommendations of the '\n",
      " 'advisory committee on  immunization practices 2020 mmwr recomm rep 202069no '\n",
      " 'rr5 abbreviations hav  hepatitis a virus ig  immune globulin   measles mumps '\n",
      " 'and rubella vaccine should not be administered for ≥2 weeks before and 6 '\n",
      " 'months after administration of ig  † a second dose of hepatitis a vaccine is '\n",
      " 'not required for postexposure prophylaxis however for longterm immunity the '\n",
      " 'vaccination series should be completed  with a second dose ≥6 months after '\n",
      " 'the first dose  § the provider’s risk assessment should determine the need '\n",
      " 'for ig administration if the provider’s risk assessment determines that both '\n",
      " 'vaccine and ig are warranted  hepatitis a vaccine and ig should be '\n",
      " 'administered simultaneously at different anatomic sites eg separate limbs  ¶ '\n",
      " 'vaccine and ig should be administered simultaneously at different anatomic '\n",
      " 'sites eg separate limbs   lifethreatening allergic reaction to a previous '\n",
      " 'dose of hepatitis a vaccine or allergy to any vaccine component  †† ig '\n",
      " 'should be considered before travel for persons with special risk factors for '\n",
      " 'either hav infection or severe disease from hav infection  §§ 01 mlkg body '\n",
      " 'weight for travel ≤1 month 02 mlkg body weight for travel ≤2 months 02 mlkg '\n",
      " 'every 2 months for travel of ≥2 months’ duration  ¶¶ this dose should not be '\n",
      " 'counted toward the routine 2dose series which should be initiated at age 12 '\n",
      " 'months   for persons not previously vaccinated with hepatitis a vaccine '\n",
      " 'administer dose as soon as travel is considered and complete the series '\n",
      " 'according to routine  schedule if the next dose is needed before travel  ††† '\n",
      " 'can be administered on the basis of the provider’s risk assessment '\n",
      " 'recommendations and reports 116 mmwr  july 23 2021  vol 70  no 4 us '\n",
      " 'department of health and human servicescenters for disease control and '\n",
      " 'prevention from pooled human plasma processed by cold ethanol  fractionation '\n",
      " 'in the united states ig is produced only from  plasma that has tested '\n",
      " 'negative for hbsag antibodies to hiv  and hcv and hiv and hcv rna in '\n",
      " 'addition the process  used to manufacture ig inactivates viruses eg hbv hcv  '\n",
      " 'and hiv when administered im 2 weeks after exposure to  hav ig is 85 '\n",
      " 'effective in preventing hav infection 1308 if ig is administered to persons '\n",
      " 'for whom hepatitis a vaccine  also is recommended a dose of vaccine should '\n",
      " 'be provided  simultaneously with ig in different anatomic sites eg  '\n",
      " 'different limbs as soon as possible and the second vaccine dose  should be '\n",
      " 'administered according to the licensed schedule to  complete the series the '\n",
      " 'combined vaccine can be considered  for persons among whom both hepatitis a '\n",
      " 'and hepatitis b  vaccine is recommended 1312971302–1304 special '\n",
      " 'considerations for persons with hiv infection antibody response can be  '\n",
      " 'directly related to cd4 tcell levels although persons with  hiv who have '\n",
      " 'lower cd4 tcell counts or percentages might  have a weaker response to the '\n",
      " 'vaccine vaccination should  not be delayed for the cd4 tcell count to exceed '\n",
      " 'a certain  threshold because of the prolonged risk for hav exposure  created '\n",
      " 'by missed opportunities to vaccinate hepatitis b virus infection the '\n",
      " 'incubation period for hbv infection from time of  exposure to symptom onset '\n",
      " 'ranges from 6 weeks to 6 months  the highest concentrations of hbv are '\n",
      " 'located in blood with  lower concentrations in other body fluids including '\n",
      " 'wound  exudates semen vaginal secretions and saliva 13091310  hbv is more '\n",
      " 'infectious and more stable in the environment  than other bloodborne '\n",
      " 'pathogens eg hcv or hiv hbv infection can be either selflimited or chronic  '\n",
      " 'among adults approximately half of newly acquired hbv  infections are '\n",
      " 'symptomatic and approximately 1 of reported  cases result in acute liver '\n",
      " 'failure and death 1311 risk for  chronic infection is inversely related to '\n",
      " 'age at acquisition  approximately 90 of infected infants and 30 of infected  '\n",
      " 'children aged 5 years become chronically infected compared  with 2–6 of '\n",
      " 'persons who become infected as adults 1312  among persons with chronic hbv '\n",
      " 'infection the risk for  premature death from cirrhosis or hepatocellular '\n",
      " 'carcinoma  is 15–25 1313 hbv is efficiently transmitted by percutaneous or '\n",
      " 'mucous  membrane exposure to hbvinfected blood or body fluids  that contain '\n",
      " 'hbv the primary risk factors associated with  infection among adolescents '\n",
      " 'and adults are unprotected sex  with an infected partner having multiple '\n",
      " 'partners men having  sex with men having history of other stis and injecting '\n",
      " 'drug  use 233 in addition studies have demonstrated other modes  of hbv '\n",
      " 'transmission including premastication and lapses  in health care infection '\n",
      " 'control procedures as less common  sources of transmission 1314–1317 cdc’s '\n",
      " 'national strategy for eliminating transmission of hbv  infection includes '\n",
      " 'prevention of perinatal infection through  routine screening of all pregnant '\n",
      " 'women for hbsag and  immunoprophylaxis of infants born to mothers with '\n",
      " 'hbsag  or mothers whose hbsag status is unknown routine infant  vaccination '\n",
      " 'vaccination of previously unvaccinated children  and adolescents through age '\n",
      " '18 years and vaccination of  previously unvaccinated adults at increased '\n",
      " 'risk for infection  12 high vaccination coverage rates with subsequent  '\n",
      " 'decreases in acute hbv infection incidence have been achieved  among infants '\n",
      " 'and adolescents 1318 the vaccination of  persons as children and adolescents '\n",
      " 'likely has led to improved  vaccination coverage among adults aged 30 years '\n",
      " '1319 and  corresponding lower rates of acute hbv infection among this  group '\n",
      " 'in contrast vaccination coverage among the majority  of adult populations at '\n",
      " 'high risk aged ≥30 years eg persons  with multiple sex partners msm and '\n",
      " 'injecting drug users  has remained low 13201321 these groups account for '\n",
      " 'the  highest rates of preventable acute infections 1213191322  std clinics '\n",
      " 'and other health care settings providing sti  services to adults at high '\n",
      " 'risk for infection should administer  hepatitis b vaccine to those who are '\n",
      " 'unvaccinated diagnosis diagnosis of acute or chronic hbv infection requires  '\n",
      " 'serologic testing table 5 because hbsag is present in both  acute and '\n",
      " 'chronic infection presence of igm antibody to  hepatitis b core antigen igm '\n",
      " 'antihbc is diagnostic of acute  or recently acquired hbv infection antibody '\n",
      " 'to hbsag  antihbs is produced after a resolved infection and is the  only '\n",
      " 'hbv antibody marker present after vaccination the  presence of hbsag and '\n",
      " 'antihbc with a negative test for igm  antihbc indicates chronic hbv '\n",
      " 'infection the presence of  total antihbc alone might indicate acute resolved '\n",
      " 'or chronic  infection or a falsepositive result treatment no specific '\n",
      " 'therapy is available for persons with acute hbv  infection treatment is '\n",
      " 'supportive persons with chronic  hbv infection should be referred for '\n",
      " 'evaluation to a provider  experienced in managing such infections '\n",
      " 'therapeutic agents  approved by fda for treatment of chronic hbv infection  '\n",
      " 'can achieve sustained suppression of hbv replication and  remission of liver '\n",
      " 'disease 1323 recommendations and reports mmwr  july 23 2021  vol 70  no 4 '\n",
      " '117us department of health and human servicescenters for disease control and '\n",
      " 'prevention prevention two products have been approved for hbv prevention  '\n",
      " 'hepatitis b immune globulin hbig for pep and hepatitis  b vaccine 12 hbig '\n",
      " 'provides temporary ie 3–6 months  protection from hbv infection and is '\n",
      " 'typically used as  pep as an adjunct to hepatitis b vaccination for '\n",
      " 'previously  unvaccinated persons or for persons who have not responded to  '\n",
      " 'vaccination hbig is prepared from plasma known to contain  high '\n",
      " 'concentrations of antihbs the recommended dose of  hbig is 006 mlkg body '\n",
      " 'weight hepatitis b vaccine contains hbsag produced in yeast by  recombinant '\n",
      " 'dna technology and provides protection from  hbv infection when used for '\n",
      " 'both preexposure vaccination  and pep the three available monovalent '\n",
      " 'hepatitis b vaccines  for use in the united states are recombivax hb '\n",
      " 'engerixb  and heplisavb a combination hepatitis a and hepatitis b  vaccine '\n",
      " 'for use among persons aged ≥18 years twinrix also  is available when '\n",
      " 'selecting a hepatitis b vaccination schedule health care  providers should '\n",
      " 'consider the need to achieve completion of  the vaccine series the '\n",
      " 'recommended hbv dose and schedule  varies by product and age of recipient '\n",
      " 'table 6 three different  3dose schedules for adolescents and adults have '\n",
      " 'been approved  for both monovalent hepatitis b vaccines ie engerixb and  '\n",
      " 'recombivax hb these vaccines can be administered at 0 1  and 6 months 0 1 '\n",
      " 'and 4 months or 0 2 and 4 months  a 4dose schedule of engerixb at 0 1 2 and '\n",
      " '12 months is  licensed for all age groups a 2dose schedule of recombivax  hb '\n",
      " 'adult formulation 10 µg is licensed for adolescents  aged 11–15 years with a '\n",
      " '4month minimal interval between  doses when scheduled to receive the second '\n",
      " 'dose adolescents  aged 16–19 years should be switched to a 3dose series '\n",
      " 'with  doses 2 and 3 consisting of the pediatric formulation 5 µg  '\n",
      " 'administered on a recommended schedule heplisavb is a  new singleantigen '\n",
      " 'recombinant hepatitis b vaccine with a  novel cytosinephosphateguanine 1018 '\n",
      " 'oligodeoxynucleotide  adjuvant for prevention of hbv infection among '\n",
      " 'persons  aged ≥18 years administered as a 2dose series at 0 and  1 month 4 '\n",
      " 'weeks apart 156 twinrix is a 3dose schedule  administered at 0 1 and 6 '\n",
      " 'months to persons aged ≥18 years  at risk for both hav and hbv infections '\n",
      " 'hepatitis b vaccine should be administered im in the deltoid  muscle and can '\n",
      " 'be administered simultaneously with other  vaccines if the vaccine series is '\n",
      " 'interrupted after the first or  second dose of vaccine the missed dose '\n",
      " 'should be administered  as soon as possible the series does not need to be '\n",
      " 'restarted after  a missed dose hbv vaccination is available for eligible '\n",
      " 'children  and adolescents aged 19 years through the vfc program  '\n",
      " 'httpswwwcdcgovvaccinesprogramsvfccontactsstate html when feasible the same '\n",
      " 'manufacturer’s vaccines should  be used to complete the series however '\n",
      " 'vaccination should  not be deferred when the manufacturer of the previously  '\n",
      " 'administered vaccine is unknown or when the vaccine from  the same '\n",
      " 'manufacturer is unavailable 1324 among adolescents and healthy adults aged '\n",
      " '40 years  approximately 30–55 achieve a protective antibody response  ie '\n",
      " 'antihbs ≥10 miuml after the first singleantigen  vaccine dose 75 after the '\n",
      " 'second and 90 after the third  recent clinical trials reported a protective '\n",
      " 'antibody response  achieved among approximately 90 of participants '\n",
      " 'receiving  heplisavb compared with 705–902 of participants  receiving '\n",
      " 'engerixb 12 vaccineinduced immune memory  has been demonstrated to persist '\n",
      " 'for 30 years 1325–1327  table 5 interpretation of serologic test results for '\n",
      " 'hepatitis b virus infection serologic marker interpretationhbsag total '\n",
      " 'antihbc igm antihbc antihbs − − − − never infected † − − − early acute '\n",
      " 'infection transient ≤18 days after vaccination    − acute infection −   − '\n",
      " 'acute resolving infection −  −  recovered from past infection and immune   − '\n",
      " '− chronic infection −  − − past infection lowlevel chronic infection§ '\n",
      " 'passive transfer to infant born to hbsag positive mother false positive no '\n",
      " 'infection − − −  immune if concentration is 10 miuml after vaccination '\n",
      " 'passive transfer after hbig  administration source adapted from schillie s '\n",
      " 'vellozzi c reingold a et al prevention of hepatitis b virus infection in the '\n",
      " 'united states recommendations of the advisory committee  on immunization '\n",
      " 'practices mmwr recomm rep 201867no rr1 abbreviations antihbc  antibody to '\n",
      " 'hepatitis b core antigen antihbs  antibody to hepatitis b surface antigen '\n",
      " 'hbig  hepatitis b immune globulin hbsag   hepatitis b surface antigen igm  '\n",
      " 'immunoglobulin m  −  negative test result   positive test result † to ensure '\n",
      " 'that an hbsagpositive test result is not false positive samples with '\n",
      " 'repeatedly reactive hbsag results should be tested with a neutralizing '\n",
      " 'confirmatory  test cleared by the food and drug administration § persons '\n",
      " 'positive for only antihbc are unlikely to be infectious except under unusual '\n",
      " 'circumstances involving direct percutaneous exposure to large quantities of  '\n",
      " 'blood eg blood transfusion or organ transplantation or mutant hbsagrelated '\n",
      " 'infection httpswwwcdcgovvaccinesprogramsvfccontactsstatehtml '\n",
      " 'httpswwwcdcgovvaccinesprogramsvfccontactsstatehtml recommendations and '\n",
      " 'reports 118 mmwr  july 23 2021  vol 70  no 4 us department of health and '\n",
      " 'human servicescenters for disease control and prevention periodic testing to '\n",
      " 'determine antibody levels after routine  vaccination among immunocompetent '\n",
      " 'persons is unnecessary  and booster doses of vaccine are not recommended '\n",
      " 'hepatitis b vaccination is usually well tolerated by the  majority of '\n",
      " 'recipients pain at the injection site and lowgrade  fever are reported by a '\n",
      " 'minority of recipients for children  and adolescents a causal association '\n",
      " 'exists between receipt of  hepatitis b vaccination and anaphylaxis for each '\n",
      " '11 million  doses of vaccine administered approximately one recipient will  '\n",
      " 'experience this type of reaction 1328 however no deaths have  been reported '\n",
      " 'among these patients 13181328 vaccine is  contraindicated for persons with a '\n",
      " 'history of anaphylaxis after a  previous dose of hepatitis b vaccine and '\n",
      " 'persons with a known  anaphylactic reaction to any vaccine component 1329 '\n",
      " 'no  other adverse events after administration of hepatitis b vaccine  have '\n",
      " 'been demonstrated preexposure vaccination hepatitis b vaccination is '\n",
      " 'recommended for all unvaccinated  children and adolescents all unvaccinated '\n",
      " 'adults at risk for hbv  infection especially injecting drug users msm adults '\n",
      " 'with  multiple sex partners sex partners needlesharing contacts  or '\n",
      " 'household contacts of persons with chronic hepatitis b  and persons with '\n",
      " 'diabetes and all adults seeking protection  from hbv infection 1318 for '\n",
      " 'adults acknowledgment of  a specific risk factor is not a requirement for '\n",
      " 'vaccination hepatitis b vaccine should be routinely offered to all  '\n",
      " 'unvaccinated persons attending std clinics and to all  unvaccinated persons '\n",
      " 'seeking evaluation or treatment for stis  in other settings especially '\n",
      " 'correctional facilities facilities  providing substance misuse treatment and '\n",
      " 'prevention services  federally qualified health centers and settings serving '\n",
      " 'msm  eg hiv infection care and prevention settings if hepatitis  b vaccine '\n",
      " 'is unavailable at a particular facility persons should  be linked to a '\n",
      " 'setting where they can receive vaccine persons  with a reliable vaccination '\n",
      " 'history ie a written dated record  of each dose of a complete series or '\n",
      " 'reliable history of hepatitis  b infection ie a written record of infection '\n",
      " 'and serologic  results providing evidence of previous infection do not '\n",
      " 'require  vaccination in all settings vaccination should be initiated  at the '\n",
      " 'initial visit even if concerns about completion of the  vaccine series exist '\n",
      " 'prevaccination serologic testing conducting prevaccination serologic testing '\n",
      " 'for susceptibility  just before the initial vaccine dose is administered '\n",
      " 'can  be considered for identifying persons with chronic hbv  infection and '\n",
      " 'potentially reducing the cost of completing the  vaccination series for '\n",
      " 'adult populations that have an expected  high prevalence 20–30 of hbv '\n",
      " 'infection eg injecting  drug users and msm especially those among older age '\n",
      " 'groups  or persons born where hbv endemicity is moderate to  high in '\n",
      " 'addition prevaccination testing for susceptibility is  table 6 recommended '\n",
      " 'doses of licensed formulations of hepatitis b vaccines age group yrs '\n",
      " 'singleantigen vaccine combination vaccine recombivax hb engerixb heplisavb '\n",
      " 'twinrix† dose μg§ volume ml dose μg§ volume ml dose μg§ volume ml dose μg§ '\n",
      " 'volume ml infants 1 5 05 10 05 —¶ —¶ na na children 1–10 5 05 10 05 —¶ —¶ na '\n",
      " 'na adolescents 11–15 10 10 na na —¶ —¶ na na adolescents 11–19 5 05 10 05 —¶ '\n",
      " '—¶ na na adults ≥18 —†† —†† —†† —†† 20 05 20† 1 adults ≥20 10 10 20 10 20† '\n",
      " '05 20† 1 hemodialysis patients and other  immunocompromised persons 20§§ 5 '\n",
      " '05 10 05 20 05 na na hemodialysis patients and other  immunocompromised '\n",
      " 'persons ≥20 40¶¶ 10 40 20 20 05 na na source adapted from schillie s '\n",
      " 'vellozzi c reingold a et al prevention of hepatitis b virus infection in the '\n",
      " 'united states recommendations of the advisory committee  on immunization '\n",
      " 'practices mmwr recomm rep 201867no rr1 abbreviation na  not applicable   '\n",
      " 'administered on a 2dose schedule  † combined hepatitis a and b vaccines this '\n",
      " 'vaccine is recommended for persons aged ≥18 years who are at increased risk '\n",
      " 'for both hepatitis b and hepatitis a virus  infections  § recombinant '\n",
      " 'hepatitis b surface antigen protein dose  ¶ heplisavb should not be used for '\n",
      " 'vaccination of infants children or adolescents because the safety and '\n",
      " 'effectiveness of heplisavb has not been established in  persons aged 8 years '\n",
      " 'and is not approved for use in these populations   adult formulation '\n",
      " 'administered on a 2dose schedule  †† engerixb and recombivax hb are approved '\n",
      " 'for use in persons of all ages  §§ higher doses might be more immunogenic '\n",
      " 'however no specific recommendations have been made  ¶¶ dialysis formulation '\n",
      " 'administered on a 3dose schedule at 0 1 and 6 months   two 10ml doses '\n",
      " 'administered at one site on a 4dose schedule at 0 1 2 and 6 months '\n",
      " 'recommendations and reports mmwr  july 23 2021  vol 70  no 4 119us '\n",
      " 'department of health and human servicescenters for disease control and '\n",
      " 'prevention recommended for unvaccinated household sexual and needle sharing '\n",
      " 'contacts of hbsagpositive persons 1318 serologic  testing should not be a '\n",
      " 'barrier to vaccination the first vaccine  dose should be administered '\n",
      " 'immediately after collection of the  blood sample for serologic testing '\n",
      " 'vaccination of persons who  are immune to hbv infection because of current '\n",
      " 'or previous  infection or vaccination is not harmful and does not increase  '\n",
      " 'the risk for adverse events prevaccination testing should be performed with '\n",
      " 'hbsag  antihbs and total antihbc to define patients’ hbv clinical  status '\n",
      " 'and deliver recommended care 1330 persons who  test hbsag positive should '\n",
      " 'receive prevention counseling and  evaluation for antiviral treatment see '\n",
      " 'management of persons  who are hbsag positive persons who test total '\n",
      " 'antihbc  positive and antihbs positive should be counseled that they  have '\n",
      " 'had previous hbv infection and are immune those  persons with isolated '\n",
      " 'antihbc ie negative hbsag and  antihbs need further assessment to rule out '\n",
      " 'occult hbv  infection and they are at higher risk for reactivation if '\n",
      " 'exposed  to immunosuppressants persons who test negative to all three  hbv '\n",
      " 'seromarkers should receive the complete vaccination  series with the first '\n",
      " 'vaccine dose administered immediately postvaccination serologic testing for '\n",
      " 'response postvaccination serologic testing for immunity is unnecessary  '\n",
      " 'after routine vaccination of adolescents or adults however  such testing is '\n",
      " 'recommended for persons whose subsequent  clinical management depends on '\n",
      " 'knowledge of their immune  status persons recommended to receive '\n",
      " 'postvaccination  serologic testing include health care personnel and public '\n",
      " 'safety  workers persons with hiv infection sex and needlesharing  partners '\n",
      " 'of hbsagpositive persons hemodialysis patients  and others who might require '\n",
      " 'outpatient hemodialysis eg  predialysis peritoneal dialysis or home dialysis '\n",
      " 'and other  immunocompromised persons eg hematopoietic stemcell  transplant '\n",
      " 'recipients or persons receiving chemotherapy 1318 if indicated antihbs '\n",
      " 'testing should be performed  1–2 months after administration of the last '\n",
      " 'dose of the  vaccine series persons determined to have antihbs levels  of 10 '\n",
      " 'miuml after the primary vaccine series should be  revaccinated with a 3dose '\n",
      " 'series and tested again for antihbs  1–2 months after the third dose persons '\n",
      " 'who do not respond to  revaccination should be tested for hbsag and hbc if '\n",
      " 'hbsag  positive persons should receive recommended management  see '\n",
      " 'management of persons who are hbsag positive if  hbsag negative persons '\n",
      " 'should be considered susceptible to  hbv infection and counseled about '\n",
      " 'precautions for preventing  hbv infection and the need for hbig pep for any '\n",
      " 'known  exposure if isolated antihbc positive ie negative hbsag  and antihbs '\n",
      " 'persons will need further assessment to rule out  occult hbv infection and '\n",
      " 'are at higher risk for reactivation if  exposed to immunosuppressants '\n",
      " 'postexposure prophylaxis both passive and active pep simultaneous '\n",
      " 'administration of  hbig ie 006 mlkg body weight and hepatitis b vaccine  at '\n",
      " 'separate anatomic sites and active pep administration of  hepatitis b '\n",
      " 'vaccination alone have been demonstrated to be  highly effective in '\n",
      " 'preventing transmission after exposure to  hbv 12 hbig alone also has been '\n",
      " 'demonstrated to be  effective in preventing hbv transmission however with '\n",
      " 'the  availability of hepatitis b vaccine hbig typically is used as  an '\n",
      " 'adjunct to vaccination exposure to a source who is hbsag positive '\n",
      " 'unvaccinated persons or persons known not to have  responded to a complete '\n",
      " 'hepatitis b vaccine series should  receive both hbig and hepatitis vaccine '\n",
      " 'as soon as possible  preferably ≤24 hours after a discrete identifiable '\n",
      " 'exposure  to blood or body fluids that contain blood from a person with  '\n",
      " 'hbsag table 7 hepatitis b vaccine should be administered  simultaneously '\n",
      " 'with hbig at a separate anatomic site and the  vaccine series should be '\n",
      " 'completed by using the ageappropriate  vaccine dose and schedule table 6 '\n",
      " 'exposed persons who  are not fully vaccinated because they have not '\n",
      " 'completed the  vaccine series should receive hbig ie 006 mlkg body  weight '\n",
      " 'and complete the vaccine series persons who have  written documentation of a '\n",
      " 'complete hepatitis b vaccine series  who did not receive postvaccination '\n",
      " 'testing should receive a  single vaccine booster dose exposed persons who '\n",
      " 'are known  to have responded to vaccination by postvaccination testing  are '\n",
      " 'considered protected therefore they need no additional  doses of vaccine or '\n",
      " 'hbig all persons with an occupational  exposure to blood or body fluids that '\n",
      " 'contain hbv should be  managed according to guidelines 12 exposure to a '\n",
      " 'source with unknown hbsag status unvaccinated persons and persons with '\n",
      " 'previous nonresponse  to hepatitis b vaccination who have a discrete '\n",
      " 'identifiable  exposure to blood or body fluids containing blood from  a '\n",
      " 'person with unknown hbsag status should receive the  hepatitis b vaccine '\n",
      " 'series with the first dose initiated as soon  as possible after exposure '\n",
      " 'preferably 24 hours and the series  completed according to the '\n",
      " 'ageappropriate dose and schedule  exposed persons who are not fully '\n",
      " 'vaccinated but started the  series should complete the vaccine series '\n",
      " 'exposed persons  with written documentation of a complete hepatitis b '\n",
      " 'vaccine  series who did not receive postvaccination testing require no  '\n",
      " 'further treatment recommendations and reports 120 mmwr  july 23 2021  vol '\n",
      " '70  no 4 us department of health and human servicescenters for disease '\n",
      " 'control and prevention other management considerations all persons with hbv '\n",
      " 'infection should be tested for hiv  syphilis gonorrhea and chlamydia '\n",
      " 'management of persons who are hbsag positive recommendations for management '\n",
      " 'of all persons with  hbsag include the following • all persons with hbsag '\n",
      " 'documented on laboratory results  should be reported to the state or local '\n",
      " 'health department • to verify the presence of chronic hbv infection persons  '\n",
      " 'with hbsag should be retested the absence of igm anti hbc or the persistence '\n",
      " 'of hbsag for ≥6 months indicates  chronic hbv infection • persons with '\n",
      " 'chronic hbv infection should be referred  for evaluation to a specialist '\n",
      " 'experienced in managing  chronic hepatitis b infection • household sexual '\n",
      " 'and needlesharing contacts of persons  with chronic infection should be '\n",
      " 'evaluated unvaccinated  sex partners and household and needlesharing '\n",
      " 'contacts  should be tested for susceptibility to hbv infection and  receive '\n",
      " 'the first dose of hepatitis b vaccine immediately  after collection of the '\n",
      " 'blood sample for serologic testing  see prevaccination serologic testing '\n",
      " 'susceptible persons  should complete the vaccine series by using an age '\n",
      " 'appropriate vaccine dose and schedule • sex partners of persons with hbsag '\n",
      " 'should be counseled  to use latex condoms 1331 to protect themselves from  '\n",
      " 'sexual exposure to infectious body fluids eg semen and  vaginal secretions '\n",
      " 'unless they have been demonstrated  to be immune after vaccination antihbs '\n",
      " '≥10 miuml  or previously infected antihbc positive • to prevent or reduce '\n",
      " 'the risk for transmission to others in  addition to vaccination persons with '\n",
      " 'hbsag also should  be advised to  ű use methods eg condoms to protect '\n",
      " 'nonimmune sex  partners from acquiring hbv infection from sexual  activity '\n",
      " 'until the partner can be vaccinated and  immunity documented  ű cover cuts '\n",
      " 'and skin lesions to prevent spread by  infectious secretions or blood  ű '\n",
      " 'refrain from donating blood plasma body organs other  tissue or semen and  ű '\n",
      " 'refrain from sharing household articles eg  toothbrushes razors or personal '\n",
      " 'injecting equipment  that could become contaminated with blood and refrain  '\n",
      " 'from premastication of food • to protect the liver from further harm persons '\n",
      " 'with  hbsag should be advised to table 7 guidelines for postexposure '\n",
      " 'prophylaxis of persons with nonoccupational exposure† to blood or body '\n",
      " 'fluids that contain blood by  exposure type and hepatitis b vaccination '\n",
      " 'status source of exposure unvaccinated person§ previously vaccinated person¶ '\n",
      " 'hbsagpositive source  percutaneous eg bite or needlestick or mucosal  '\n",
      " 'exposure to hbsagpositive blood or body fluids  or  sex or needlesharing '\n",
      " 'contact with an hbsag positive person  or  victim of sexual assault or abuse '\n",
      " 'by an assailant  who is hbsag positive administer hepatitis b vaccine series '\n",
      " 'and hbig complete hepatitis b vaccine series and hbig if  vaccine series not '\n",
      " 'completed  or  administer hepatitis b vaccine booster dose if  previous '\n",
      " 'vaccination without testing source with unknown hbsag status  percutaneous '\n",
      " 'eg bite or needlestick or mucosal  exposure to potentially infectious blood '\n",
      " 'or body  fluids from a source with unknown hbsag status  or  sex or '\n",
      " 'needlesharing contact with person with  unknown hbsag status  or  victim of '\n",
      " 'sexual assault or abuse by a perpetrator  with unknown hbsag status '\n",
      " 'administer hepatitis b vaccine series complete hepatitis b vaccine series '\n",
      " 'sources cdc cdc guidance for evaluating healthcare personnel for hepatitis b '\n",
      " 'virus protection and for administering postexposure management mmwr recomm  '\n",
      " 'rep 201362no rr10 cdc postexposure prophylaxis to prevent hepatitis b virus '\n",
      " 'infection mmwr recomm rep 200655no rr16 abbreviations hbig  hepatitis b '\n",
      " 'immune globulin hbsag  hepatitis b surface antigen   when indicated '\n",
      " 'immunoprophylaxis should be initiated as soon as possible preferably within '\n",
      " '24 hours studies are limited regarding the maximum interval after  exposure '\n",
      " 'during which postexposure prophylaxis is effective but the interval is '\n",
      " 'unlikely to exceed 7 days for percutaneous exposures or 14 days for sexual '\n",
      " 'exposures  the hepatitis b vaccine series should be completed these '\n",
      " 'guidelines apply to nonoccupational exposures  † these guidelines apply to '\n",
      " 'nonoccupational exposures  § a person who is in the process of being '\n",
      " 'vaccinated but who has not completed the vaccine series should complete the '\n",
      " 'series and receive treatment for hepatitis  b as indicated  ¶ a person who '\n",
      " 'has written documentation of a complete hepatitis b vaccine series and who '\n",
      " 'did not receive postvaccination testing   no booster dose is needed for '\n",
      " 'persons who have written documentation of hepatitis b vaccine series with '\n",
      " 'serologic response recommendations and reports mmwr  july 23 2021  vol 70  '\n",
      " 'no 4 121us department of health and human servicescenters for disease '\n",
      " 'control and prevention  ű avoid or limit alcohol consumption because of the '\n",
      " 'effects  of alcohol on the liver  ű refrain from starting any new medicines '\n",
      " 'including over thecounter and herbal medicines without checking  with their '\n",
      " 'health care provider and  ű obtain vaccination against hepatitis a when '\n",
      " 'seeking medical or dental care persons who are  hbsag positive should be '\n",
      " 'advised to inform their health care  providers of their hbsag status so that '\n",
      " 'they can be evaluated  and managed the following are key counseling messages '\n",
      " 'for  persons with hbsag • hbv is not usually spread by hugging coughing food '\n",
      " 'or water  sharing eating utensils or drinking glasses or casual contact • '\n",
      " 'persons should not be excluded from work school play  childcare or other '\n",
      " 'settings because they are infected with hbv • involvement with a support '\n",
      " 'group might help patients  cope with chronic hbv infection • hbv infection '\n",
      " 'is a chronic condition that can be treated  and patients should receive '\n",
      " 'prevention counseling and be  evaluated for antiviral treatment special '\n",
      " 'considerations pregnancy regardless of whether they have been previously '\n",
      " 'tested or  vaccinated all pregnant women should be tested for hbsag  at the '\n",
      " 'first prenatal visit and again at delivery if at high  risk for hbv '\n",
      " 'infection see sti detection among special  populations pregnant women at '\n",
      " 'risk for hbv infection and  without documentation of a complete hepatitis b '\n",
      " 'vaccine series  should receive hepatitis b vaccination all pregnant women  '\n",
      " 'with hbsag should be reported to state and local perinatal  hepatitis b '\n",
      " 'prevention programs and referred to a specialist  information about '\n",
      " 'management of pregnant women with  hbsag and their infants is available at '\n",
      " 'httpswwwcdcgov hepatitishbvperinatalxmtnhtm hiv infection hiv infection can '\n",
      " 'impair the response to hepatitis b  vaccination persons with hiv should be '\n",
      " 'tested for antihbs  1–2 months after the third vaccine dose see '\n",
      " 'postvaccination  serologic testing modified dosing regimens including a  '\n",
      " 'doubling of the standard antigen dose and administration of  additional '\n",
      " 'doses might increase the response rate and should be  managed in '\n",
      " 'consultation with an infectious disease specialist  additional '\n",
      " 'recommendations for management of persons with  hbsag and hiv infection are '\n",
      " 'available 98 hepatitis c virus infection hcv infection is the most common '\n",
      " 'chronic bloodborne  infection in the united states with an estimated 24 '\n",
      " 'million  persons living with chronic infection 1332 hcv is not  efficiently '\n",
      " 'transmitted through sex 1333–1335 studies of  hcv transmission between '\n",
      " 'heterosexual couples and msm  have yielded mixed results however studies '\n",
      " 'have reported  either no or minimally increased rates of hcv infection  '\n",
      " 'among partners of persons with hcv infection compared  with partners of '\n",
      " 'those without hcv 13341336–1338  however data indicate that sexual '\n",
      " 'transmission of hcv  can occur especially among persons with hiv infection  '\n",
      " 'increasing incidence of acute hcv infection among msm  with hiv infection '\n",
      " 'has been reported in multiple us  962362391339 and european cities '\n",
      " '2371340–1342 a  recent systematic review reported an hcv incidence of 635  '\n",
      " 'per 1000 person years among msm with hiv infection  1343 an association '\n",
      " 'exists with highrisk and traumatic  sexual practices eg condomless receptive '\n",
      " 'anal intercourse  or receptive fisting and concurrent genital ulcerative '\n",
      " 'disease  or stirelated proctitis 2371342 hcv transmission among  msm with '\n",
      " 'hiv infection has also been associated with group  sex and chemsex ie using '\n",
      " 'recreational drugs in a sexual  context 1344–1348 shedding of hcv in the '\n",
      " 'semen and in  the rectum of men with hiv infection has been documented  '\n",
      " '13491350 certain studies have revealed that risk increases  commensurate '\n",
      " 'with increasing numbers of sex partners among  heterosexual persons '\n",
      " '133713381351–1353 and msm with  hiv infection 13491354–1357 especially if '\n",
      " 'their partners are  also coinfected with hiv 23713401354–13561358 more  '\n",
      " 'recently acute hcv infections have been reported among msm  on prep '\n",
      " 'increasing concerns that certain msm might be at  increased risk for '\n",
      " 'incident hcv infection through condomless  sexual intercourse with msm with '\n",
      " 'hcv infection 13591360 persons newly infected with hcv typically are either  '\n",
      " 'asymptomatic or have a mild clinical illness hcv rna can  be detected in '\n",
      " 'blood within 1–3 weeks after exposure the  average time from exposure to '\n",
      " 'antibody to hcv antihcv  seroconversion is 4−10 weeks and antihcv can be '\n",
      " 'detected  among approximately 97 of persons by 6 months after  exposure '\n",
      " '1361–1364 httpswwwcdcgovhepatitishcv hcvfaqhtmsection3 chronic hcv infection '\n",
      " 'develops among 75–85 of  persons with hcv infection 13651366 and 10–20 of  '\n",
      " 'persons with chronic infection develop cirrhosis in 20–30 years  of active '\n",
      " 'liver disease 1367 the majority of infected persons  remain unaware of their '\n",
      " 'infection because they are not clinically  '\n",
      " 'httpswwwcdcgovhepatitishbvperinatalxmtnhtm '\n",
      " 'httpswwwcdcgovhepatitishbvperinatalxmtnhtm '\n",
      " 'httpswwwcdcgovhepatitishcvhcvfaqhtmsection3 '\n",
      " 'httpswwwcdcgovhepatitishcvhcvfaqhtmsection3 recommendations and reports 122 '\n",
      " 'mmwr  july 23 2021  vol 70  no 4 us department of health and human '\n",
      " 'servicescenters for disease control and prevention ill however infected '\n",
      " 'persons are a source of transmission to  others and are at risk for '\n",
      " 'cirrhosis and hepatocellular carcinoma  decades after infection hcv is '\n",
      " 'primarily transmitted parenterally usually through  shared druginjecting '\n",
      " 'needles and paraphernalia hcv also  can be transmitted through exposures in '\n",
      " 'health care settings  as a consequence of inadequate infection control '\n",
      " 'practices  1314 transmission after receipt of blood from donors and  from '\n",
      " 'transplantation of tissues and organs with hcv infection  has occurred only '\n",
      " 'rarely since 1992 when routine screening  of these donated products was '\n",
      " 'mandated in the united  states 13671369 tattoos applied in regulated '\n",
      " 'settings  have not been associated with hcv transmission although  those '\n",
      " 'obtained in certain settings have been linked to such  transmission 1336 '\n",
      " 'occupational and perinatal exposures also  can result in transmission of hcv '\n",
      " 'however such transmission  is uncommon acute hcv infection is a reportable '\n",
      " 'condition in 49 states  matching viral hepatitis and hiv surveillance '\n",
      " 'registries and  molecular epidemiologic assessments can facilitate early  '\n",
      " 'detection of social networks of hcv transmission among  msm with hiv '\n",
      " 'infection cdc recommends hepatitis c screening at least once in a  lifetime '\n",
      " 'for all adults aged ≥18 years and for all women during  each pregnancy '\n",
      " 'except in settings where the prevalence of  hcv infection is 01 156 onetime '\n",
      " 'hepatitis c testing  is also recommended regardless of age setting or '\n",
      " 'recognized  conditions or exposures eg hiv infection history of  injecting '\n",
      " 'drug use or children born to women with hcv  infection routine periodic hcv '\n",
      " 'testing is recommended  for persons with ongoing risk factors eg injecting '\n",
      " 'drug use  or hemodialysis diagnosis testing for hcv infection should include '\n",
      " 'use of an fda cleared test for antibody to hcv ie immunoassay eia or  '\n",
      " 'enhanced cia and if recommended a supplemental antibody  test followed by '\n",
      " 'naat to detect hcv rna for those with a  positive antibody result 1370 '\n",
      " 'persons with hiv infection with  low cd4 tcell count might require further '\n",
      " 'testing by naat  because of the potential for a falsenegative antibody assay '\n",
      " 'persons determined to have hcv infection ie positive  for hcv rna should be '\n",
      " 'evaluated for treatment antibody  to hcv remains positive after '\n",
      " 'spontaneously resolving or  successful treatment therefore subsequent '\n",
      " 'testing for hcv  reinfection among persons with ongoing risk factors should  '\n",
      " 'be limited to hcv rna persons who have spontaneous  resolution or who have '\n",
      " 'undergone successful treatment are  not immune to reinfection treatment hcv '\n",
      " 'infection is curable and persons with diagnosed hcv  infection should be '\n",
      " 'linked to care and treatment providers  should consult existing guidelines '\n",
      " 'to learn about the latest  advances in treating hcv infection '\n",
      " 'httpswwwhcvguidelines org and with hepatitis specialists as needed persons '\n",
      " 'at high  risk for transmitting hcv to others should be treated both for  '\n",
      " 'individual benefit and to prevent hcv transmission management of sex '\n",
      " 'partners because incident hcv has not been demonstrated to  occur among '\n",
      " 'heterosexual couples followed over time  13341371–1373 condom use might not '\n",
      " 'be necessary in  such circumstances persons with hcv infection with one  '\n",
      " 'longterm steady sex partner do not need to change their  sexual practices '\n",
      " 'however they should discuss the risk for  transmission with their partner '\n",
      " 'and discuss the need for  testing 234 httpswwwcdcgovhepatitishcvindexhtm  '\n",
      " 'heterosexual persons and msm with hcv infection and  more than one partner '\n",
      " 'especially those with concurrent hiv  infection should protect their '\n",
      " 'partners against hcv and hiv  acquisition by using external latex condoms '\n",
      " '23713581374  and hiv prep partners of persons with hcv and hiv should  be '\n",
      " 'tested for both infections other management considerations all persons with '\n",
      " 'hcv infection for whom hiv and  hbv infection status is unknown should be '\n",
      " 'tested for these  infections those who have hiv or hbv infection should be  '\n",
      " 'referred for or provided with recommended care and treatment  persons '\n",
      " 'without previous exposure to hav or hbv should  be vaccinated prevention '\n",
      " 'reducing the burden of hcv infection and disease in  the united states '\n",
      " 'requires implementing both primary and  secondary prevention activities '\n",
      " 'primary prevention reduces or  eliminates hcv transmission whereas secondary '\n",
      " 'prevention  identifies persons through screening and then provides  '\n",
      " 'treatment to reduce chronic liver disease and other chronic  diseases and '\n",
      " 'hcv transmission no vaccine for hepatitis  c is available and prophylaxis '\n",
      " 'with ig is not effective in  preventing hcv infection after exposure pep '\n",
      " 'using direct acting antivirals is not recommended persons with hcv infection '\n",
      " 'should be provided information  about how to protect their liver from '\n",
      " 'further harm ie  hepatotoxic agents for instance persons with hcv infection  '\n",
      " 'should be advised to avoid drinking alcohol and taking any new  medicines '\n",
      " 'including overthecounter or herbal medications  without checking with their '\n",
      " 'clinician in addition a need for  httpswwwhcvguidelinesorg '\n",
      " 'httpswwwhcvguidelinesorg httpswwwcdcgovhepatitishcvindexhtm recommendations '\n",
      " 'and reports mmwr  july 23 2021  vol 70  no 4 123us department of health and '\n",
      " 'human servicescenters for disease control and prevention hepatitis a and b '\n",
      " 'vaccination should be determined persons  who are not immune should be '\n",
      " 'vaccinated to reduce the risk for transmission to others persons with hcv  '\n",
      " 'infection should be advised not to donate blood body organs  other tissue or '\n",
      " 'semen not to share any personal items that might  have blood on them eg '\n",
      " 'toothbrushes or razors and to cover  cuts and sores on the skin to keep the '\n",
      " 'virus from spreading by  blood or secretions women with hcv infection do not '\n",
      " 'need  to avoid pregnancy or breastfeeding although children born to  women '\n",
      " 'with hcv also should be tested for hcv persons who use or inject drugs '\n",
      " 'should be counseled about  the importance of prevention and provided access '\n",
      " 'to substance  misuse treatment including medicationassisted treatment  if '\n",
      " 'indicated persons who inject drugs should be encouraged  to take the '\n",
      " 'following additional steps to reduce personal and  public health risks • '\n",
      " 'never reuse or share syringes water or drug preparation  equipment • only '\n",
      " 'use syringes obtained from a reliable source eg a  syringe services program '\n",
      " 'or a pharmacy • use a new sterile syringe to prepare and inject drugs each '\n",
      " 'time • if possible use sterile water to prepare drugs otherwise  use clean '\n",
      " 'water from a reliable source eg fresh tap water • use a new or disinfected '\n",
      " 'container ie cooker and a new  filter ie cotton to prepare drugs • clean the '\n",
      " 'injection site with a new alcohol swab before  injection • safely dispose of '\n",
      " 'syringes after one use postexposure followup no pep has been demonstrated to '\n",
      " 'be effective against hcv  infection testing for hcv is recommended for '\n",
      " 'health care  workers after percutaneous or perimucosal exposures to hcv '\n",
      " 'positive blood prompt identification of acute infection is vital  because '\n",
      " 'outcomes are improved when treatment is initiated  early during the illness '\n",
      " 'course special considerations pregnancy all pregnant women should be '\n",
      " 'screened with each pregnancy  for hcv antibodies at the first prenatal visit '\n",
      " 'in settings  where the hcv prevalence is 01 httpswwwcdcgov '\n",
      " 'hepatitishcvindexhtm 154155 although the rate of  transmission is highly '\n",
      " 'variable more than six of every 100  infants born to women with hcv '\n",
      " 'infection become infected  this infection occurs predominantly during or '\n",
      " 'near delivery  and no treatment or delivery method eg cesarean delivery  has '\n",
      " 'been demonstrated to decrease this risk 1375 however  the risk is increased '\n",
      " 'by the presence of maternal hcv viremia  at delivery and is twofold to '\n",
      " 'threefold greater if the woman has  hiv infection although no '\n",
      " 'recommendations are available  for hcv treatment during pregnancy discussion '\n",
      " 'about the  individual risks and benefits of postpartum treatment can be  '\n",
      " 'considered in accordance with existing guidance httpswww '\n",
      " 'hcvguidelinesorguniquepopulationspregnancy hcv has not been reported to be '\n",
      " 'transmitted through breast  milk although mothers with hcv infection should '\n",
      " 'consider  abstaining from breastfeeding if their nipples are cracked or  '\n",
      " 'bleeding infants born to mothers with hcv infection should  be tested for '\n",
      " 'hcv infection children should be tested for  antihcv no sooner than age 18 '\n",
      " 'months because antihcv  from the mother might last until that age if '\n",
      " 'diagnosis is desired  before the child reaches age 18 months testing for '\n",
      " 'hcv  rna can be performed at or after the infant’s first wellchild  visit at '\n",
      " 'age 1–2 months hcv rna testing can be repeated  at a subsequent visit '\n",
      " 'independent of the initial hcv rna  test result 1376 '\n",
      " 'httpswwwcdcgovhepatitishcvhcvfaq htmsection3 hiv infection all persons with '\n",
      " 'hiv infection should undergo serologic  screening for hcv at initial '\n",
      " 'evaluation 98 httpswww hcvguidelinesorg providers should be aware of the '\n",
      " 'likelihood  that msm with hiv infection can acquire hcv after initial  '\n",
      " 'screening because acute hcv infection acquisition among  persons with hiv '\n",
      " 'infection can occur especially among  msm and regular screening of those '\n",
      " 'with hiv is cost effective 2382391377 periodic hcv screening should be  '\n",
      " 'conducted 1378–1380 for persons with hiv infection  hepatitis c screening '\n",
      " 'with hcv antibody assays followed  by hcv rna if antibody positive can be '\n",
      " 'considered at least  yearly for those at high risk for infection and more '\n",
      " 'frequently  depending on specific circumstances eg community hcv  infection '\n",
      " 'prevalence and incidence highrisk sexual behavior  and concomitant '\n",
      " 'ulcerative stis and proctitis antibody to  hcv remains positive after '\n",
      " 'spontaneously resolved infection  or successful treatment therefore '\n",
      " 'subsequent testing for  potential hcv reinfection among persons with ongoing '\n",
      " 'risk  should be limited to hcv rna testing only indirect testing  eg alanine '\n",
      " 'aminotransferase alt is not recommended  for detecting incident hcv '\n",
      " 'infections because such testing  especially if performed once a year can '\n",
      " 'miss persons who have  reverted after acute hcv infection to a normal alt '\n",
      " 'level at  the time of testing 239 httpswwwhcvguidelinesorg  conversely alt '\n",
      " 'can be elevated by antiretroviral and other  medications alcohol and toxins '\n",
      " 'if alt levels are being  monitored persons with hiv infection who experience '\n",
      " 'new  or unexplained increases in alt should be tested for acute  '\n",
      " 'httpswwwcdcgovhepatitishcvindexhtm httpswwwcdcgovhepatitishcvindexhtm '\n",
      " 'httpswwwcdcgovhepatitishcvhcvfaqhtmsection3 '\n",
      " 'httpswwwcdcgovhepatitishcvhcvfaqhtmsection3 httpswwwhcvguidelinesorg '\n",
      " 'httpswwwhcvguidelinesorg httpswwwhcvguidelinesorg recommendations and '\n",
      " 'reports 124 mmwr  july 23 2021  vol 70  no 4 us department of health and '\n",
      " 'human servicescenters for disease control and prevention hcv infection and '\n",
      " 'evaluated for possible medication toxicity  or excessive alcohol use '\n",
      " 'continued unprotected sexual contact between partners  with hiv can '\n",
      " 'facilitate spread of hcv infection because  the virus can be recovered from '\n",
      " 'the semen of men with hiv  infection 13491381 specific prevention practices '\n",
      " 'eg  barrier precautions that limit contact with body fluids during  sexual '\n",
      " 'contact with other msm should be discussed because a minimal percentage of '\n",
      " 'persons with hiv infection  do not develop hcv antibodies hcv rna testing '\n",
      " 'should  be performed for persons with hiv infection and unexplained  liver '\n",
      " 'disease who are antihcv negative the course of liver  disease is more rapid '\n",
      " 'among persons with hiv and hcv and  the risk for cirrhosis is higher than '\n",
      " 'that for persons with hcv  infection alone proctitis proctocolitis and '\n",
      " 'enteritis sexually transmitted gastrointestinal syndromes include  proctitis '\n",
      " 'proctocolitis and enteritis evaluation for these  syndromes should include '\n",
      " 'recommended diagnostic  procedures including anoscopy or sigmoidoscopy '\n",
      " 'stool  examination for wbcs and microbiologic workup eg  gonorrhea chlamydia '\n",
      " 'lgv pcr if available herpes simplex  naat and syphilis serology for those '\n",
      " 'with enteritis stool  culture or lgv pcr also is recommended proctitis is '\n",
      " 'inflammation of the rectum ie the distal  10–12 cm that can be associated '\n",
      " 'with anorectal pain  tenesmus or rectal discharge fecal leukocytes are '\n",
      " 'common  proctitis occurs predominantly among persons who have  receptive '\n",
      " 'anal exposures oralanal digitalanal or genital anal n gonorrhoeae c '\n",
      " 'trachomatis including lgv serovars  hsv and t pallidum are the most common '\n",
      " 'sti pathogens  genital hsv and lgv proctitis are more prevalent among  '\n",
      " 'persons with hiv infection 5455561382 m genitalium  has been detected in '\n",
      " 'certain cases of proctitis and might be  more common among persons with hiv '\n",
      " 'infection 9371382  n meningitidis has been identified as an etiology of '\n",
      " 'proctitis  among msm with hiv infection 1383 proctocolitis is associated '\n",
      " 'with symptoms of proctitis  diarrhea or abdominal cramps and inflammation of '\n",
      " 'the colonic  mucosa extending to 12 cm above the anus fecal leukocytes  '\n",
      " 'might be detected on stool examination depending on the  pathogen '\n",
      " 'proctocolitis can be acquired through receptive anal  intercourse or by '\n",
      " 'oralanal contact depending on the pathogen pathogenic organisms include '\n",
      " 'campylobacter species  shigella species e histolytica lgv serovars of c '\n",
      " 'trachomatis  and t pallidum among immunosuppressed persons with  hiv '\n",
      " 'infection cmv or other opportunistic agents should  be considered the '\n",
      " 'clinical presentation can be mistaken for  inflammatory bowel disease or '\n",
      " 'malignancy resulting in a  delayed diagnosis 13841385 enteritis usually '\n",
      " 'results in diarrhea and abdominal cramping  without signs of proctitis or '\n",
      " 'proctocolitis fecal leukocytes  might be detected on stool examination '\n",
      " 'depending on the  pathogen when outbreaks of gastrointestinal illness occur  '\n",
      " 'among social or sexual networks of msm clinicians should  consider sexual '\n",
      " 'transmission as a mode of spread and provide  counseling accordingly sexual '\n",
      " 'practices that can facilitate  transmission of enteric pathogens include '\n",
      " 'oralanal contact or  in certain instances direct genitalanal contact g '\n",
      " 'lamblia is the  most frequently implicated parasite and bacterial pathogens  '\n",
      " 'include shigella species salmonella e coli campylobacter  species and '\n",
      " 'cryptosporidium outbreaks of shigella species  campylobacter cryptosporidium '\n",
      " 'and microsporidiosis have  been reported among msm 25927413861387 multiple  '\n",
      " 'enteric pathogens and concurrent stis have also been reported  among '\n",
      " 'immunosuppressed persons with hiv infection cmv  or other opportunistic '\n",
      " 'pathogens should be considered diagnostic and treatment considerations  for '\n",
      " 'acute proctitis diagnosis persons with symptoms of acute proctitis should be '\n",
      " 'examined  by anoscopy a gramstained smear of any anorectal exudate  from '\n",
      " 'anoscopic or anal examination should be examined for  polymorphonuclear '\n",
      " 'leukocytes all persons should be evaluated  for herpes simplex preferably by '\n",
      " 'naat of rectal lesions  n gonorrhoeae naat or culture c trachomatis naat  '\n",
      " 'and t pallidum darkfield of lesion if available and serologic  testing if '\n",
      " 'the c trachomatis naat test is positive on a rectal  swab and severe '\n",
      " 'symptoms associated with lgv are present  including rectal ulcers anal '\n",
      " 'discharge bleeding ≥10 wbcs  on gram stain and tenesmus patients should be '\n",
      " 'treated  empirically for lgv molecular testing for lgv is not widely  '\n",
      " 'available or not fda cleared and results are not typically  available in '\n",
      " 'time for clinical decisionmaking however if  available molecular pcr testing '\n",
      " 'for c trachomatis serovars  l1 l2 or l3 can be considered for confirming lgv '\n",
      " '553 the pathogenic role of m genitalium in proctitis is unclear  for persons '\n",
      " 'with persistent symptoms after standard treatment  providers should consider '\n",
      " 'testing for m genitalium with naat  and treat if positive see mycoplasma '\n",
      " 'genitalium treatment  acute proctitis among persons who have anal exposure  '\n",
      " 'through oral genital or digital contact is usually sexually  acquired '\n",
      " '13821388 presumptive therapy should be  recommendations and reports mmwr  '\n",
      " 'july 23 2021  vol 70  no 4 125us department of health and human '\n",
      " 'servicescenters for disease control and prevention initiated while awaiting '\n",
      " 'results of laboratory tests for  persons with anorectal exudate detected on '\n",
      " 'examination or  polymorphonuclear leukocytes detected on a gramstained  '\n",
      " 'smear of anorectal exudate or secretions such therapy also  should be '\n",
      " 'initiated when anoscopy or gram stain is not  available and the clinical '\n",
      " 'presentation is consistent with acute  proctitis for persons reporting '\n",
      " 'receptive anal exposures recommended regimen for acute proctitis ceftriaxone '\n",
      " '500 mg im in a single dose plus doxycycline 100 mg orally 2 timesday for 7 '\n",
      " 'days†  for persons weighing ≥150 kg 1 g of ceftriaxone should be '\n",
      " 'administered † doxycycline course should be extended to 100 mg orally 2 '\n",
      " 'timesday for  21 days in the presence of bloody discharge perianal or '\n",
      " 'mucosal ulcers  or tenesmus and a positive rectal chlamydia test bloody '\n",
      " 'discharge perianal ulcers or mucosal ulcers among  persons with acute '\n",
      " 'proctitis and rectal chlamydia naat  should receive presumptive treatment '\n",
      " 'for lgv with an  extended course of doxycycline 100 mg orally 2 timesday '\n",
      " 'for  3 weeks 13891390 see lymphogranuloma venereum if  painful perianal '\n",
      " 'ulcers are present or mucosal ulcers are  detected on anoscopy presumptive '\n",
      " 'therapy should also include  a regimen for genital herpes see genital herpes '\n",
      " 'diagnostic and treatment considerations  for proctocolitis or enteritis '\n",
      " 'treatment for proctocolitis or enteritis should be directed  to the specific '\n",
      " 'enteric pathogen identified multiple stool  examinations might be necessary '\n",
      " 'for detecting giardia  and special stool preparations are required for '\n",
      " 'diagnosing  cryptosporidiosis and microsporidiosis diagnostic and  treatment '\n",
      " 'recommendations for all enteric infections are beyond  the scope of these '\n",
      " 'guidelines providers should be aware of the  potential for '\n",
      " 'antimicrobialresistant pathogens particularly  during outbreaks of shigella '\n",
      " 'and campylobacter among sexual  networks of msm where increased resistance '\n",
      " 'to azithromycin  fluoroquinolones and isolates resistant to multiple '\n",
      " 'antibiotics  have been described 26627227313911392 other management '\n",
      " 'considerations to minimize transmission and reinfection patients treated  '\n",
      " 'for acute proctitis should be instructed to abstain from sexual  intercourse '\n",
      " 'until they and their partners have been treated  ie until completion of a '\n",
      " '7day regimen and symptoms  have resolved studies have reported that '\n",
      " 'behaviors that  facilitate enteric pathogen transmission might be '\n",
      " 'associated  with acquisition of other stis including hiv infection  all '\n",
      " 'persons with acute proctitis and concern for sexually  transmitted '\n",
      " 'proctocolitis or enteritis should be tested for hiv  syphilis gonorrhea and '\n",
      " 'chlamydia at other exposed sites  pep should be considered for exposures '\n",
      " 'that present a risk for  hiv acquisition for ongoing risk for hiv '\n",
      " 'acquisition prep  should be considered evidencebased interventions for '\n",
      " 'preventing acquisition  of sexually transmitted enteric pathogens are not '\n",
      " 'available  however extrapolating from general infection control practices  '\n",
      " 'for communicable diseases and established sti prevention  practices '\n",
      " 'recommendations include avoiding contact with  feces during sex using '\n",
      " 'barriers and washing hands after  handing materials that have been in '\n",
      " 'contact with the anal  area ie barriers and sex toys and after touching the '\n",
      " 'anus  or rectal area followup followup should be based on specific etiology '\n",
      " 'and severity  of clinical symptoms for proctitis associated with gonorrhea  '\n",
      " 'or chlamydia retesting for the respective pathogen should be  performed 3 '\n",
      " 'months after treatment management of sex partners partners who have had '\n",
      " 'sexual contact with persons treated  for gonorrhea or chlamydia 60 days '\n",
      " 'before the onset of  the persons symptoms should be evaluated tested and  '\n",
      " 'presumptively treated for the respective infection partners  of persons with '\n",
      " 'proctitis should be evaluated for any diseases  diagnosed in the index '\n",
      " 'partner sex partners should abstain  from sexual contact until they and '\n",
      " 'their partners are treated  no specific recommendations are available for '\n",
      " 'screening  or treating sex partners of persons with diagnosed sexually  '\n",
      " 'transmitted enteric pathogens however partners should seek  care if '\n",
      " 'symptomatic special considerations drug allergy intolerance and adverse '\n",
      " 'reactions allergic reactions with thirdgeneration cephalosporins eg  '\n",
      " 'ceftriaxone are uncommon among persons with a history of  penicillin allergy '\n",
      " '620631658896 hiv infection  persons with hiv infection and acute proctitis '\n",
      " 'might present  with bloody discharge painful perianal ulcers or mucosal  '\n",
      " 'ulcers and lgv and herpes proctitis are more prevalent among  this '\n",
      " 'population presumptive treatment in such cases should  include a regimen for '\n",
      " 'genital herpes and lgv recommendations and reports 126 mmwr  july 23 2021  '\n",
      " 'vol 70  no 4 us department of health and human servicescenters for disease '\n",
      " 'control and prevention ectoparasitic infections pediculosis pubis persons '\n",
      " 'who have pediculosis pubis ie pubic lice usually  seek medical attention '\n",
      " 'because of pruritus or because they  notice lice or nits on their pubic hair '\n",
      " 'pediculosis pubis is  caused by the parasite phthirus pubis and is usually '\n",
      " 'transmitted  by sexual contact 1393 diagnosis the clinical diagnosis is '\n",
      " 'based on typical symptoms of itching  in the pubic region lice and nits can '\n",
      " 'be observed on pubic hair treatment recommended regimens for pediculosis '\n",
      " 'pubis permethrin 1 cream rinse applied to affected areas and washed off  '\n",
      " 'after 10 minutes or pyrethrin with piperonyl butoxide applied to the '\n",
      " 'affected area and  washed off after 10 minutes alternative regimens '\n",
      " 'malathion 05 lotion applied to affected areas and washed off after  8–12 '\n",
      " 'hours or ivermectin 250 µgkg body weight orally repeated in 7–14 days '\n",
      " 'reported resistance to pediculcides permethrin and  pyrethrin has been '\n",
      " 'increasing and is widespread 13941395  malathion can be used when treatment '\n",
      " 'failure is believed to  have occurred as a result of resistance the odor and '\n",
      " 'longer  duration of application associated with malathion therapy  make it a '\n",
      " 'less attractive alternative compared with the  recommended pediculicides '\n",
      " 'ivermectin has limited ovicidal  activity 1396 ivermectin might not prevent '\n",
      " 'recurrences  from eggs at the time of treatment and therefore treatment  '\n",
      " 'should be repeated in 7–14 days 13971398 ivermectin  should be taken with '\n",
      " 'food because bioavailability is increased  thus increasing penetration of '\n",
      " 'the drug into the epidermis  adjustment of ivermectin dosage is not required '\n",
      " 'for persons  with renal impairment however the safety of multiple doses  '\n",
      " 'among persons with severe liver disease is unknown lindane  is not '\n",
      " 'recommended for treatment of pediculosis because of  toxicity '\n",
      " 'contraindications for certain populations pregnant  and breastfeeding women '\n",
      " 'children aged 10 years and those  with extensive dermatitis and complexity '\n",
      " 'of administration other management considerations the recommended regimens '\n",
      " 'should not be applied to the  eyes pediculosis of the eyelashes should be '\n",
      " 'treated by applying  occlusive ophthalmic ointment or petroleum jelly to the '\n",
      " 'eyelid  margins 2 timesday for 10 days bedding and clothing should  be '\n",
      " 'decontaminated ie machine washed and dried by using  the heat cycle or dry '\n",
      " 'cleaned or removed from body contact  for at least 72 hours fumigation of '\n",
      " 'living areas is unnecessary  pubic hair removal has been associated with '\n",
      " 'atypical patterns  of pubic lice infestation and decreasing incidence of '\n",
      " 'infection  5371399 persons with pediculosis pubis should be evaluated  for '\n",
      " 'hiv syphilis chlamydia and gonorrhea followup evaluation should be performed '\n",
      " 'after 1 week if symptoms  persist retreatment might be necessary if lice are '\n",
      " 'found or  if eggs are observed at the hairskin junction if no clinical  '\n",
      " 'response is achieved to one of the recommended regimens  retreatment with an '\n",
      " 'alternative regimen is recommended management of sex partners sex partners '\n",
      " 'within the previous month should be treated  sexual contact should be '\n",
      " 'avoided until patients and partners  have been treated bedding and clothing '\n",
      " 'decontaminated and  reevaluation performed to rule out persistent infection '\n",
      " 'special considerations pregnancy existing data from human participants '\n",
      " 'demonstrate that  pregnant and lactating women should be treated with '\n",
      " 'either  permethrin or pyrethrin with piperonyl butoxide because no  '\n",
      " 'teratogenicity or toxicity attributable to ivermectin has been  observed '\n",
      " 'during human pregnancy experience ivermectin is  classified as “human data '\n",
      " 'suggest low risk” during pregnancy  and probably compatible with '\n",
      " 'breastfeeding 431 hiv infection persons who have pediculosis pubis and hiv '\n",
      " 'infection  should receive the same treatment regimen as those who do  not '\n",
      " 'have hiv scabies scabies is a skin infestation caused by the mite sarcoptes  '\n",
      " 'scabiei which causes pruritus sensitization to s scabiei occurs  before '\n",
      " 'pruritus begins the first time a person is infested with  s scabiei '\n",
      " 'sensitization takes weeks to develop however  pruritus might occur 24 hours '\n",
      " 'after a subsequent reinfestation  scabies among adults frequently is '\n",
      " 'sexually acquired although  scabies among children usually is not 1400–1402 '\n",
      " 'diagnosis scabies diagnosis is made by identifying burrows mites eggs  or '\n",
      " 'the mites’ feces from affected areas skin scrapings can be  examined under '\n",
      " 'the microscope to identify organisms although  recommendations and reports '\n",
      " 'mmwr  july 23 2021  vol 70  no 4 127us department of health and human '\n",
      " 'servicescenters for disease control and prevention this method has low '\n",
      " 'sensitivity and is time consuming 1403  alternatively noninvasive '\n",
      " 'examination of the affected skin by  using videodermatoscopy videomicroscopy '\n",
      " 'or dermoscopy  can be used each of which has high sensitivity and '\n",
      " 'specificity  particularly when performed by experienced operators 1404  '\n",
      " 'lowtechnology strategies include the burrow ink test and the  adhesive tape '\n",
      " 'test treatment recommended regimens for scabies permethrin 5 cream applied '\n",
      " 'to all areas of the body from the neck  down and washed off after 8–14 hours '\n",
      " 'or ivermectin 200 ugkg body weight orally repeated in 14 days or ivermectin '\n",
      " '1 lotion applied to all areas of the body from the neck  down and washed off '\n",
      " 'after 8–14 hours repeat treatment in 1 week if  symptoms persist  oral '\n",
      " 'ivermectin has limited ovicidal activity a second dose is required  for '\n",
      " 'eradication alternative regimen lindane 1 1 oz of lotion or 30 g of cream '\n",
      " 'applied in a thin layer to all  areas of the body from the neck down and '\n",
      " 'thoroughly washed off after  8 hours  infants and children aged 10 years '\n",
      " 'should not be treated with lindane topical permethrin and oral and topical '\n",
      " 'ivermectin have  similar efficacy for cure of scabies 1405–1410 choice of  '\n",
      " 'treatment might be based on patient preference for topical  versus oral '\n",
      " 'therapy drug interactions with ivermectin eg  azithromycin '\n",
      " 'trimethoprimsulfamethoxazole bactrim or  cetirizine zytrec and cost '\n",
      " 'permethrin is safe and effective  with a single application 1411 ivermectin '\n",
      " 'has limited ovicidal  activity and might not prevent recurrences of eggs at '\n",
      " 'the time  of treatment therefore a second dose of ivermectin should be  '\n",
      " 'administered 14 days after the first dose 1412 ivermectin  should be taken '\n",
      " 'with food because bioavailability is increased  thereby increasing '\n",
      " 'penetration of the drug into the epidermis  adjustments to ivermectin dosing '\n",
      " 'are not required for patients  with renal impairment however the safety of '\n",
      " 'multiple doses  among patients with severe liver disease is unknown lindane '\n",
      " 'is an alternative regimen because it can cause toxicity  1413 it should be '\n",
      " 'used only if the patient cannot tolerate  the recommended therapies or if '\n",
      " 'these therapies have failed  1414–1416 lindane is not recommended for '\n",
      " 'pregnant and  breastfeeding women children aged 10 years and persons  with '\n",
      " 'extensive dermatitis seizures have occurred when lindane  was applied after '\n",
      " 'a bath or used by patients who had extensive  dermatitis aplastic anemia '\n",
      " 'after lindane use also has been  reported 1413 lindane resistance has been '\n",
      " 'reported in some  areas of the world including parts of the united states '\n",
      " '1413 other management considerations bedding and clothing should be '\n",
      " 'decontaminated ie  either machine washed and dried by using the heat cycle '\n",
      " 'or  dry cleaned or removed from body contact for 72 hours  fumigation of '\n",
      " 'living areas is unnecessary persons with scabies  should be advised to keep '\n",
      " 'fingernails closely trimmed to reduce  injury from excessive scratching 1417 '\n",
      " 'crusted scabies crusted scabies is an aggressive infestation that usually  '\n",
      " 'occurs among immunodeficient debilitated or malnourished  persons including '\n",
      " 'persons receiving systemic or potent topical  glucocorticoids organ '\n",
      " 'transplant recipients persons with hiv  infection or human tlymphotrophic '\n",
      " 'virus1 infection and  persons with hematologic malignancies crusted scabies '\n",
      " 'is  transmitted more easily than scabies 1418 no controlled  therapeutic '\n",
      " 'studies for crusted scabies have been conducted  and a recommended treatment '\n",
      " 'remains unclear substantial  treatment failure might occur with a singledose '\n",
      " 'topical  scabicide or with oral ivermectin treatment combination  treatment '\n",
      " 'is recommended with a topical scabicide either 5  topical permethrin cream '\n",
      " 'fullbody application to be repeated  daily for 7 days then 2 timesweek until '\n",
      " 'cure or 25 topical  benzyl benzoate and oral ivermectin 200 ugkg body weight '\n",
      " 'on  days 1 2 8 9 and 15 additional ivermectin treatment on days  22 and 29 '\n",
      " 'might be required for severe cases 1419 lindane  should be avoided because '\n",
      " 'of the risks for neurotoxicity with  heavy applications on denuded skin '\n",
      " 'followup the rash and pruritus of scabies might persist for 2 weeks  after '\n",
      " 'treatment symptoms or signs persisting for 2 weeks  can be attributed to '\n",
      " 'multiple factors treatment failure  can occur as a result of resistance to '\n",
      " 'medication or faulty  application of topical scabicides these medications do '\n",
      " 'not  easily penetrate into thick scaly skin of persons with crusted  scabies '\n",
      " 'perpetuating the harboring of mites in these difficult topenetrate layers in '\n",
      " 'the absence of recommended contact  treatment and decontamination of bedding '\n",
      " 'and clothing  persisting symptoms can be attributed to reinfection by '\n",
      " 'family  members or fomites finally other household mites can cause  symptoms '\n",
      " 'to persist as a result of crossreactivity between  antigens even when '\n",
      " 'treatment is successful reinfection is  avoided and crossreactivity does not '\n",
      " 'occur symptoms can  persist or worsen as a result of allergic dermatitis '\n",
      " 'retreatment 2 weeks after the initial treatment regimen can  be considered '\n",
      " 'for those persons who are still symptomatic or  when live mites are observed '\n",
      " 'use of an alternative regimen is  recommended for those persons who do not '\n",
      " 'respond initially  to the recommended treatment recommendations and reports '\n",
      " '128 mmwr  july 23 2021  vol 70  no 4 us department of health and human '\n",
      " 'servicescenters for disease control and prevention management of sex '\n",
      " 'partners and  household contacts persons who have had sexual close personal '\n",
      " 'or household  contact with the patient within the month preceding scabies  '\n",
      " 'infestation should be examined those identified as being  infested should be '\n",
      " 'provided treatment management of outbreaks in communities  nursing homes and '\n",
      " 'other institutional settings scabies epidemics frequently occur in nursing '\n",
      " 'homes  hospitals residential facilities and other communities  14201421 '\n",
      " 'control of an epidemic can only be achieved  by treating the entire '\n",
      " 'population at risk ivermectin can be  considered in these settings '\n",
      " 'especially if treatment with topical  scabicides fails mass treatment with '\n",
      " 'oral ivermectin is highly  effective in decreasing prevalence in settings '\n",
      " 'where scabies is  endemic 1422 epidemics should be managed in consultation  '\n",
      " 'with a specialist special considerations infants young children and pregnant '\n",
      " 'or  lactating women infants and young children should be treated with  '\n",
      " 'permethrin the safety of ivermectin for children weighing  15 kg has not '\n",
      " 'been determined infants and children aged  10 years should not be treated '\n",
      " 'with lindane ivermectin likely  poses a low risk to pregnant women and is '\n",
      " 'likely compatible  with breastfeeding however because of limited data '\n",
      " 'regarding  ivermectin use for pregnant and lactating women permethrin  is '\n",
      " 'the preferred treatment 431 see pediculosis pubis hiv infection persons with '\n",
      " 'hiv infection who have uncomplicated scabies  should receive the same '\n",
      " 'treatment regimens as those who do  not have hiv persons with hiv infection '\n",
      " 'and others who are  immunosuppressed are at increased risk for crusted '\n",
      " 'scabies and  should be managed in consultation with a specialist sexual '\n",
      " 'assault and abuse and stis adolescents and adults these guidelines are '\n",
      " 'primarily limited to the identification  prophylaxis and treatment of stis '\n",
      " 'and conditions among  adolescent and adult female sexual assault survivors '\n",
      " 'however  some of the following guidelines might still apply to male  sexual '\n",
      " 'assault survivors documentation of findings collection  of nonmicrobiologic '\n",
      " 'specimens for forensic purposes  and management of potential pregnancy or '\n",
      " 'physical and  psychological trauma are beyond the scope of these guidelines  '\n",
      " 'examinations of survivors of sexual assault should be  conducted by an '\n",
      " 'experienced clinician in a way that minimizes  further trauma to the person '\n",
      " 'the decision to obtain genital  or other specimens for sti diagnosis should '\n",
      " 'be made on an  individual basis care systems for survivors should be '\n",
      " 'designed  to ensure continuity including timely review of test results  '\n",
      " 'support adherence and monitoring for adverse reactions to  any prescribed '\n",
      " 'therapeutic or prophylactic regimens laws in  all 50 states limit the '\n",
      " 'evidentiary use of a survivor’s previous  sexual history including evidence '\n",
      " 'of previously acquired stis  as part of an effort to undermine the '\n",
      " 'credibility of the survivor’s  testimony evidentiary privilege against '\n",
      " 'revealing any aspect of  the examination or treatment also is enforced in '\n",
      " 'most states  although it rarely occurs sti diagnoses might later be '\n",
      " 'accessed  and the survivor and clinician might opt to defer testing for '\n",
      " 'this  reason although collection of specimens at initial examination  for '\n",
      " 'laboratory sti diagnosis gives the survivor and clinician  the option of '\n",
      " 'deferring empiric prophylactic antimicrobial  treatment compliance with '\n",
      " 'followup visits is typically poor  1423–1425 among sexually active adults '\n",
      " 'identification  of an sti might represent an infection acquired before the  '\n",
      " 'assault and therefore might be more important for the medical  management of '\n",
      " 'the patient than for legal purposes trichomoniasis bv gonorrhea and '\n",
      " 'chlamydia are the  most frequently diagnosed infections among women who  '\n",
      " 'have been sexually assaulted such conditions are prevalent  among the '\n",
      " 'population and detection of these infections  after an assault does not '\n",
      " 'necessarily imply acquisition during  the assault however a postassault '\n",
      " 'examination presents an  important opportunity for identifying or preventing '\n",
      " 'an sti  chlamydial and gonococcal infections among women are  of particular '\n",
      " 'concern because of the possibility of ascending  infection in addition hbv '\n",
      " 'infection can be prevented  through postexposure vaccination see hepatitis b '\n",
      " 'virus  infection because persons who have been sexually assaulted  also are '\n",
      " 'at risk for acquiring hpv infection and the efficacy  of the hpv vaccine is '\n",
      " 'high 14261427 hpv vaccination is  also recommended for females and males '\n",
      " 'through age 26 years  httpswwwcdcgovvaccineshcpaciprecsvaccspecific hpvhtml '\n",
      " '11 reproductiveaged female survivors should be  evaluated for pregnancy and '\n",
      " 'offered emergency contraception evaluating adolescents and adults for stis '\n",
      " 'initial examination decisions to perform the following tests should be made '\n",
      " 'on  an individual basis an initial examination after a sexual assault  might '\n",
      " 'include the following httpswwwcdcgovvaccineshcpaciprecsvaccspecifichpvhtml '\n",
      " 'httpswwwcdcgovvaccineshcpaciprecsvaccspecifichpvhtml recommendations and '\n",
      " 'reports mmwr  july 23 2021  vol 70  no 4 129us department of health and '\n",
      " 'human servicescenters for disease control and prevention • naats for c '\n",
      " 'trachomatis and n gonorrhoeae at the sites  of penetration or attempted '\n",
      " 'penetration should be  performed 553 these tests are preferred for '\n",
      " 'diagnostic  evaluation of adolescent or adult sexual assault survivors • '\n",
      " 'females should be offered naat testing for t vaginalis  from a urine or '\n",
      " 'vaginal specimen poc or wet mount with  measurement of vaginal ph and koh '\n",
      " 'application for the  whiff test from vaginal secretions should be performed '\n",
      " 'for  evidence of bv and candidiasis especially if vaginal  discharge malodor '\n",
      " 'or itching is present • msm should be offered screening for c trachomatis '\n",
      " 'and  n gonorrhoeae if they report receptive oral or anal sex  during the '\n",
      " 'preceding year regardless of whether sexual  contact occurred at these '\n",
      " 'anatomic sites during the assault  anoscopy should be considered in '\n",
      " 'instances of reported  anal penetration • a serum sample should be performed '\n",
      " 'for hiv hbv and  syphilis infection treatment compliance with followup '\n",
      " 'visits is poor among survivors  of sexual assault 1423–1425 consequently the '\n",
      " 'following  routine presumptive treatments after a sexual assault are  '\n",
      " 'recommended • an empiric antimicrobial regimen for chlamydia  gonorrhea and '\n",
      " 'trichomonas for women and chlamydia  and gonorrhea for men • emergency '\n",
      " 'contraception should be considered when the  assault could result in '\n",
      " 'pregnancy see emergency  contraception • postexposure hepatitis b '\n",
      " 'vaccination without hbig if  the hepatitis status of the assailant is '\n",
      " 'unknown and the  survivor has not been previously vaccinated if the '\n",
      " 'assailant  is known to be hbsag positive unvaccinated survivors  should '\n",
      " 'receive both hepatitis b vaccine and hbig the  vaccine and hbig if indicated '\n",
      " 'should be administered  to sexual assault survivors at the time of the '\n",
      " 'initial  examination and followup doses of vaccine should be  administered '\n",
      " '1–2 and 4–6 months after the first dose  survivors who were previously '\n",
      " 'vaccinated but did not  receive postvaccination testing should receive a '\n",
      " 'single  vaccine booster dose see hepatitis b virus infection • hpv '\n",
      " 'vaccination for female and male survivors aged  9–26 years who have not been '\n",
      " 'vaccinated or are  incompletely vaccinated 11 httpswwwcdcgov '\n",
      " 'vaccineshcpaciprecsvaccspecifichpvhtml the  vaccine should be administered '\n",
      " 'to sexual assault survivors  at the time of the initial examination and '\n",
      " 'followup doses  should be administered at 1–2 months and 6 months after  the '\n",
      " 'first dose a 2dose schedule 0 and 6–12 months is  recommended for persons '\n",
      " 'initiating vaccination before  age 15 years • recommendations for hiv pep '\n",
      " 'are made on a caseby case basis according to risk see risk for acquiring '\n",
      " 'hiv  infection recommendations for postexposure hiv risk  assessment of '\n",
      " 'adolescents and adults 72 hours after  sexual assault  recommended regimen '\n",
      " 'for adolescent and adult female  sexual assault survivors ceftriaxone 500 mg '\n",
      " 'im in a single dose plus doxycycline 100 mg 2 timesday orally for 7 days '\n",
      " 'plus metronidazole 500 mg 2 timesday orally for 7 days  for persons weighing '\n",
      " '≥150 kg 1 g of ceftriaxone should be administered recommended regimen for '\n",
      " 'adolescent and adult male sexual  assault survivors ceftriaxone 500 mg im in '\n",
      " 'a single dose plus doxycycline 100 mg 2 timesday orally for 7 days  for '\n",
      " 'persons weighing ≥150 kg 1 g of ceftriaxone should be administered '\n",
      " 'clinicians should counsel persons regarding the possible  benefits and '\n",
      " 'toxicities associated with these treatment regimens  gastrointestinal side '\n",
      " 'effects can occur with this combination  the efficacy of these regimens in '\n",
      " 'preventing infections after  sexual assault has not been evaluated for those '\n",
      " 'requiring  alternative treatments refer to the specific sections in this  '\n",
      " 'report relevant to the specific organisms other management considerations at '\n",
      " 'the initial examination and if indicated at followup  examinations patients '\n",
      " 'should be counseled regarding  symptoms of stis and the need for immediate '\n",
      " 'examination if  symptoms occur further they should be instructed to abstain  '\n",
      " 'from sexual intercourse until sti prophylactic treatment  is completed '\n",
      " 'followup after the initial postassault examination followup  examinations '\n",
      " 'provide an opportunity to detect new infections  acquired during or after '\n",
      " 'the assault complete hepatitis b  and hpv vaccinations if indicated complete '\n",
      " 'counseling  and treatment for other stis and monitor side effects and  '\n",
      " 'adherence to pep if prescribed if initial testing was performed  followup '\n",
      " 'evaluation should be conducted in 1 week to ensure  that results of positive '\n",
      " 'tests can be discussed promptly with  the survivor treatment is provided if '\n",
      " 'not administered at the  initial visit and any followup for infections can '\n",
      " 'be arranged  if initial tests are negative and treatment was not provided  '\n",
      " 'httpswwwcdcgovvaccineshcpaciprecsvaccspecifichpvhtml '\n",
      " 'httpswwwcdcgovvaccineshcpaciprecsvaccspecifichpvhtml recommendations and '\n",
      " 'reports 130 mmwr  july 23 2021  vol 70  no 4 us department of health and '\n",
      " 'human servicescenters for disease control and prevention examination for '\n",
      " 'stis can be repeated 1–2 weeks after the  assault repeat testing detects '\n",
      " 'infectious organisms that might  not have reached sufficient concentrations '\n",
      " 'to produce positive  test results at the time of initial examination for '\n",
      " 'survivors who  are treated during the initial visit regardless of whether '\n",
      " 'testing  was performed posttreatment testing should be conducted  only if '\n",
      " 'the person reports having symptoms if initial test results  were negative '\n",
      " 'and infection in the assailant cannot be ruled  out serologic tests for '\n",
      " 'syphilis can be repeated at 4–6 weeks  and 3 months hiv testing can be '\n",
      " 'repeated at 6 weeks and at  3 months by using methods to identify acute hiv '\n",
      " 'infection risk for acquiring hiv infection hiv seroconversion has occurred '\n",
      " 'among persons whose only  known risk factor was sexual assault or sexual '\n",
      " 'abuse however  the frequency of this occurrence likely is low 14281429 in  '\n",
      " 'consensual sex the peract risk for hiv transmission from  vaginal '\n",
      " 'intercourse is 008 and for receptive anal intercourse  138 192 the peract '\n",
      " 'risk for hiv transmission from  oral sex is substantially lower specific '\n",
      " 'circumstances of an  assault eg bleeding which often accompanies trauma  '\n",
      " 'might increase risk for hiv transmission in cases involving  vaginal anal or '\n",
      " 'oral penetration site of exposure to ejaculate  viral load in ejaculate and '\n",
      " 'the presence of an sti or genital  lesions in the assailant or survivor also '\n",
      " 'might increase risk for  hiv acquisition pep with a 28day course of '\n",
      " 'zidovudine was associated with  an 81 reduction in risk for acquiring hiv in '\n",
      " 'a study of health  care workers who had percutaneous exposures to '\n",
      " 'hivinfected  blood 1430 on the basis of these results and results from  '\n",
      " 'animal studies pep has been recommended for health care  workers who have '\n",
      " 'occupational exposures to hiv 1431  these findings have been extrapolated to '\n",
      " 'nonoccupational  injecting drug and sexual hiv exposures including sexual  '\n",
      " 'assault the possibility of hiv exposure from the assault should  be assessed '\n",
      " 'at the initial examination survivors determined  to be at risk for acquiring '\n",
      " 'hiv should be informed about the  possible benefit of pep in preventing hiv '\n",
      " 'infection initiation  of pep as soon as possible after the exposure '\n",
      " 'increases the  likelihood of prophylactic benefit multiple factors affect '\n",
      " 'the medical recommendation for  pep and affect the assault survivor’s '\n",
      " 'acceptance of that  recommendation these factors include the likelihood of '\n",
      " 'the  assailant having hiv any exposure characteristics that might  increase '\n",
      " 'the risk for hiv transmission the time elapsed after  the event and the '\n",
      " 'potential benefits and risks associated  with pep 1431 determination of the '\n",
      " 'assailant’s hiv  status at the time of the postassault examination is '\n",
      " 'usually  not possible therefore health care providers should assess  any '\n",
      " 'available information concerning the characteristics and  hiv risk behaviors '\n",
      " 'of the assailant eg being an msm or  using injecting drugs local '\n",
      " 'epidemiology of hivaids and  exposure characteristics of the assault when an '\n",
      " 'assailant’s  hiv status is unknown determinations about risk for hiv  '\n",
      " 'transmission to the survivor should be based on whether vaginal  or anal '\n",
      " 'penetration occurred whether ejaculation occurred on  mucous membranes '\n",
      " 'whether multiple assailants were involved  whether mucosal lesions were '\n",
      " 'present in the assailant or  survivor and any other characteristics of the '\n",
      " 'assault survivor  or assailant that might increase risk for hiv transmission '\n",
      " 'if pep is offered the following information should be  discussed with the '\n",
      " 'survivor the necessity of early initiation  of pep to optimize potential '\n",
      " 'benefits ie as soon as possible  after and 72 hours after the assault the '\n",
      " 'importance of close  followup the benefit of adherence to recommended '\n",
      " 'dosing  and potential adverse effects of antiretroviral medications  '\n",
      " 'providers should emphasize that severe adverse effects are  rare from pep '\n",
      " '1431–1435 clinical management of the  survivor should be implemented '\n",
      " 'according to the hiv pep  guidelines and in collaboration with specialists '\n",
      " '1436 health  care providers should provide an initial course of 3–7 days of  '\n",
      " 'medication ie a starter pack with a prescription for the  remainder of the '\n",
      " 'course or if starter packs are unavailable  they should provide a '\n",
      " 'prescription for an entire 28day  course provision of the entire 28day pep '\n",
      " 'medication supply  at the initial visit has been reported to increase '\n",
      " 'likelihood of  adherence especially when patients have difficulty returning  '\n",
      " 'for multiple followup visits 1437 routinely providing  starter packs or the '\n",
      " 'entire 28day course requires that health  care providers stock pep drugs in '\n",
      " 'their practice setting or have  an established agreement with a pharmacy to '\n",
      " 'stock package  and urgently dispense pep drugs with required administration  '\n",
      " 'instructions uninsured patients or those with high copayments  can be '\n",
      " 'enrolled in a patientassistance program to ensure  access to pep medications '\n",
      " 'an early followup visit should be  scheduled at which health care providers '\n",
      " 'can discuss the results  of hiv and sti testing provide additional '\n",
      " 'counseling and  support provide indicated vaccines not administered at the  '\n",
      " 'initial evaluation assess medication side effects and adherence  or provide '\n",
      " 'an altered pep medication regimen if indicated by  side effects or '\n",
      " 'laboratory test results recommendations for postexposure hiv risk  '\n",
      " 'assessment of adolescents and adults 72 hours  after sexual assault health '\n",
      " 'care providers should do the following • assess risk for hiv infection in '\n",
      " 'the assailant and test that  person for hiv whenever possible • use the '\n",
      " 'algorithm to evaluate the survivor for the need for  hiv pep figure 1436 '\n",
      " 'recommendations and reports mmwr  july 23 2021  vol 70  no 4 131us '\n",
      " 'department of health and human servicescenters for disease control and '\n",
      " 'prevention • consult with a specialist in hiv treatment if pep is being  '\n",
      " 'considered • if the survivor appears to be at risk for acquiring hiv from  '\n",
      " 'the assault discuss pep including benefits and risks • if the survivor '\n",
      " 'chooses to start pep provide an initial  course of 3–7 days of medication ie '\n",
      " 'a starter pack with  a prescription for the remainder of the course or '\n",
      " 'provide  a prescription for an entire 28day course schedule an  early '\n",
      " 'followup visit to discuss test results and provide  additional counseling '\n",
      " '1438 • if pep is started obtain serum creatinine ast and alanine  '\n",
      " 'aminotransferase at baseline • perform an hiv antibody test at original '\n",
      " 'assessment  repeat at 6 weeks and 3 months • counsel the survivor regarding '\n",
      " 'ongoing risk for hiv  acquisition and about hiv prep and provide referrals '\n",
      " 'to  a prep provider assistance with peprelated decisions can be obtained by  '\n",
      " 'calling the national clinician’s post exposure prophylaxis  hotline pep line '\n",
      " 'telephone 8884484911 sexual assault or abuse of children these guidelines '\n",
      " 'are limited to the identification and  treatment of stis in prepubertal '\n",
      " 'children management of  the psychosocial or legal aspects of the sexual '\n",
      " 'assault or abuse  of children is beyond the scope of these guidelines '\n",
      " 'identification of stis in children past the neonatal period  strongly '\n",
      " 'indicates sexual abuse 1438 the importance of  figure algorithm to evaluate '\n",
      " 'the need for nonoccupational hiv postexposure prophylaxis among adult and '\n",
      " 'adolescent survivors of sexual assault  substantial exposure risk 72 hours '\n",
      " 'since exposure source patient known to be hiv positive pep recommended '\n",
      " 'source patient of unknown hiv status casebycase determination pep not '\n",
      " 'recommended ≥72 hours since exposure negligible exposure risk substantial '\n",
      " 'risk for hiv acquisition exposure of vagina rectum eye mouth or other mucous '\n",
      " 'membrane nonintact skin or  percutaneous contact with blood semen vaginal '\n",
      " 'secretions rectal secretions breast milk or any body  �uid that is visibly '\n",
      " 'contaminated with blood when the source is known to be hiv positive '\n",
      " 'negligible risk for hiv acquisition exposure of vagina rectum eye mouth or '\n",
      " 'other mucous  membrane intact or nonintact skin or  percutaneous contact '\n",
      " 'with urine nasal secretions saliva sweat or tears if  not visibly '\n",
      " 'contaminated with blood regardless of the known or suspected hiv status of  '\n",
      " 'the source source adapted from announcement updated guidelines for '\n",
      " 'antiretroviral postexposure prophylaxis after sexual injectiondrug use or '\n",
      " 'other nonoccupational  exposure to hiv—united states 2016 mmwr morb mortal '\n",
      " 'wkly rep 201665458  abbreviation pep  postexposure prophylaxis '\n",
      " 'recommendations and reports 132 mmwr  july 23 2021  vol 70  no 4 us '\n",
      " 'department of health and human servicescenters for disease control and '\n",
      " 'prevention identifying a sexually transmitted organism for such children  as '\n",
      " 'evidence of possible child sexual abuse varies by pathogen  postnatally '\n",
      " 'acquired gonorrhea syphilis chlamydia and  t vaginalis infection and '\n",
      " 'nontransfusion nonperinatally  acquired hiv infection are indicative of '\n",
      " 'sexual abuse  sexual abuse should be suspected when anogenital herpes or  '\n",
      " 'anogenital warts are diagnosed investigation of sexual abuse  among children '\n",
      " 'who have an infection that might have been  transmitted sexually should be '\n",
      " 'conducted in compliance with  recommendations by clinicians who have '\n",
      " 'experience and  training in all elements of the evaluation of child abuse '\n",
      " 'neglect  and assault the social significance of an infection that might  '\n",
      " 'have been acquired sexually varies by the specific organism as  does the '\n",
      " 'threshold for reporting suspected child sexual abuse  table 8 when any sti '\n",
      " 'has been diagnosed in a child efforts  should be made in consultation with a '\n",
      " 'specialist to evaluate  the possibility of sexual abuse including conducting '\n",
      " 'a history  and physical examination for evidence of abuse and diagnostic  '\n",
      " 'testing for other commonly occurring stis 1439–1441 the general rule that '\n",
      " 'stis beyond the neonatal period are  evidence of sexual abuse has exceptions '\n",
      " 'for example genital  infection with t vaginalis 1442 or rectal or genital '\n",
      " 'infection  with c trachomatis among young children might be the result  of '\n",
      " 'perinatally acquired infection and has in certain cases  of chlamydial '\n",
      " 'infection persisted for as long as 2–3 years  1443–1445 although perinatal '\n",
      " 'chlamydial infection is now  uncommon because of prenatal screening and '\n",
      " 'treatment of  pregnant women genital warts have been diagnosed among  '\n",
      " 'children who have been sexually abused 1426 but also  among children who '\n",
      " 'have no other evidence of sexual abuse  14461447 lesions appearing for the '\n",
      " 'first time in a child  aged 5 years are more likely to have been caused by '\n",
      " 'sexual  transmission 1448 bv has been diagnosed among children  who have '\n",
      " 'been abused but its presence alone does not prove  sexual abuse the majority '\n",
      " 'of hbv infections among children  result from household exposure to persons '\n",
      " 'who have chronic  hbv infection rather than sexual abuse reporting all us '\n",
      " 'states and territories have laws that require reporting  of child abuse '\n",
      " 'although the exact requirements differ by state  or territory if a health '\n",
      " 'care provider has reasonable cause to  suspect child abuse a report must be '\n",
      " 'made 1448 health care  providers should contact their state or local child '\n",
      " 'protection  service agency regarding child abuse reporting requirements '\n",
      " 'evaluating children for stis evaluating children for sexual assault or abuse '\n",
      " 'should be  conducted in a manner designed to minimize pain and trauma  to '\n",
      " 'the child examinations and collection of vaginal specimens  in prepubertal '\n",
      " 'girls can be extremely uncomfortable and should  be performed by an '\n",
      " 'experienced clinician to avoid psychological  and physical trauma to the '\n",
      " 'child the decision to obtain genital  or other specimens from a child to '\n",
      " 'evaluate for stis should be  made on an individual basis however children '\n",
      " 'who received  a diagnosis of one sti should be screened for other stis  '\n",
      " 'history and reported type of sexual contact might not be a  reliable '\n",
      " 'indicator and urogenital pharyngeal and rectal testing  should be considered '\n",
      " 'for preverbal children and children who  cannot verbalize details of the '\n",
      " 'assault 14381449 factors that  should lead the physician to consider testing '\n",
      " 'for stis include  the following 1449 • the child has experienced penetration '\n",
      " 'or has evidence of  recent or healed penetrative injury to the genitals '\n",
      " 'anus  or oropharynx • the child has been abused by a stranger table 8 '\n",
      " 'implications of commonly encountered sexually transmitted or sexually '\n",
      " 'associated infections for diagnosis and reporting of sexual  abuse among '\n",
      " 'infants and prepubertal children infection evidence for sexual abuse '\n",
      " 'recommended action gonorrhea diagnostic report† syphilis diagnostic report† '\n",
      " 'hiv§ diagnostic report† chlamydia trachomatis diagnostic report† trichomonas '\n",
      " 'vaginalis diagnostic report† anogenital herpes suspicious consider report†¶ '\n",
      " 'condylomata acuminata anogenital warts suspicious consider report†¶ '\n",
      " 'anogenital molluscum contagiosum inconclusive medical followup bacterial '\n",
      " 'vaginosis inconclusive medical followup sources adapted from kellogg n '\n",
      " 'american academy of pediatrics committee on child abuse and neglect the '\n",
      " 'evaluation of child abuse in children pediatrics  200516506–12 adams ja '\n",
      " 'farst kj kellogg nd interpretation of medical findings in suspected child '\n",
      " 'abuse an update for 2018 j pediatr adolesc gynecol  201831225–31   if '\n",
      " 'unlikely to have been perinatally acquired and vertical transmission which '\n",
      " 'is rare is excluded  † reports should be made to the local or state agency '\n",
      " 'mandated to receive reports of suspected child abuse or neglect  § if '\n",
      " 'unlikely to have been acquired perinatally or through transfusion  ¶ unless '\n",
      " 'a clear history of autoinoculation exists   report if evidence exists to '\n",
      " 'suspect abuse including history physical examination or other identified '\n",
      " 'infections lesions appearing for the first time in a child aged  5 years are '\n",
      " 'more likely to have been caused by sexual transmission recommendations and '\n",
      " 'reports mmwr  july 23 2021  vol 70  no 4 133us department of health and '\n",
      " 'human servicescenters for disease control and prevention • the child has '\n",
      " 'been abused by an assailant known to be  infected with an sti or at high '\n",
      " 'risk for stis eg injecting  drug user msm person with multiple sex partners '\n",
      " 'or  person with a history of stis • the child has a sibling other relative '\n",
      " 'or another person  in the household with an sti • the child lives in an area '\n",
      " 'with a high rate of stis in the  community • the child has signs or symptoms '\n",
      " 'of stis eg vaginal  discharge or pain genital itching or odor urinary  '\n",
      " 'symptoms or genital lesions or ulcers • the child or parent requests sti '\n",
      " 'testing • the child is unable to verbalize details of the assault if a child '\n",
      " 'has symptoms signs or evidence of an infection  that might be sexually '\n",
      " 'transmitted the child should be tested  for common stis before initiation of '\n",
      " 'any treatment that might  interfere with diagnosing other stis because of '\n",
      " 'the legal and  psychosocial consequences of a falsepositive diagnosis only  '\n",
      " 'tests with high specificities should be used the potential  benefit to the '\n",
      " 'child of a reliable sti diagnosis justifies deferring  presumptive treatment '\n",
      " 'until specimens for highly specific tests  are obtained by providers with '\n",
      " 'experience in evaluating sexually  abused and assaulted children evaluations '\n",
      " 'should be performed on a casebycase basis  according to history of assault '\n",
      " 'or abuse and in a manner  that minimizes the possibility for psychological '\n",
      " 'trauma and  social stigma if the initial exposure was recent the infectious  '\n",
      " 'organisms acquired through the exposure might not have  produced sufficient '\n",
      " 'concentrations to result in positive test  results or examination findings '\n",
      " '1450 alternatively positive  test results after a recent exposure might '\n",
      " 'represent the assailant’s  secretions but would nonetheless be an indication '\n",
      " 'for  treatment of the child a second visit approximately 2–6 weeks  after '\n",
      " 'the most recent sexual exposure should be scheduled  to include a repeat '\n",
      " 'physical examination and collection of  additional specimens to identify any '\n",
      " 'infection that might not  have been detected at the time of initial '\n",
      " 'evaluation a single  evaluation might be sufficient if the child was abused '\n",
      " 'for an  extended period and if a substantial amount of time elapsed  between '\n",
      " 'the last suspected episode of abuse and the medical  evaluation compliance '\n",
      " 'with followup appointments might be  improved when law enforcement personnel '\n",
      " 'or child protective  services are involved initial examination visual '\n",
      " 'inspection of the genital perianal and oral areas  for genital discharge '\n",
      " 'odor bleeding irritation warts  and ulcerative lesions should be performed '\n",
      " 'during initial  examination the clinical manifestations of certain stis are  '\n",
      " 'different for children than for adults for example typical  vesicular '\n",
      " 'lesions might be absent even in the presence of hsv  infection the following '\n",
      " 'should be performed during the initial  examination if sti testing is '\n",
      " 'indicated • testing for n gonorrhoeae and c trachomatis can be  performed '\n",
      " 'from specimens collected from the pharynx  and rectum as well as the vagina '\n",
      " 'for girls and urine for  boys cervical specimens are not recommended for  '\n",
      " 'prepubertal girls for boys with a urethral discharge a  meatal specimen '\n",
      " 'discharge is an adequate substitute for  an intraurethral swab specimen '\n",
      " 'culture or naat can be  used to test for n gonorrhoeae and c trachomatis  '\n",
      " 'although data regarding naat for children are more  limited and performance '\n",
      " 'is test dependent 553 no  evidence demonstrates that performance of naat '\n",
      " 'for  detection of n gonorrhoea or c trachomatis among  children differs from '\n",
      " 'that among adults only fdacleared  naat assays should be used consultation '\n",
      " 'with an expert  is necessary before using naat in this context both to  '\n",
      " 'minimize the possibility of crossreaction with  nongonococcal neisseria '\n",
      " 'species and other commensals  eg n meningitidis n sicca n lactamica n '\n",
      " 'cinerea  or m catarrhalis and to ensure correct interpretation of  results '\n",
      " 'because of the implications of a diagnosis of  n gonorrhoeae or c '\n",
      " 'trachomatis infection in a child only  cliavalidated fdacleared naats should '\n",
      " 'be used  837 if culture for the isolation of n gonorrhoeae or  c trachomatis '\n",
      " 'is performed only standard culture  procedures should be followed specimens '\n",
      " 'from the vagina  urethra pharynx or rectum should be streaked onto  '\n",
      " 'selective media for isolation of n gonorrhoeae and all  presumptive isolates '\n",
      " 'of n gonorrhoeae should be identified  definitively by at least two tests '\n",
      " 'that involve different  approaches eg biochemical enzyme substrate or  '\n",
      " 'molecular probes gram stains are inadequate for  evaluating prepubertal '\n",
      " 'children for gonorrhea and should  not be used to diagnose or exclude '\n",
      " 'gonorrhea specimens  either naat or culture including any isolates obtained  '\n",
      " 'before treatment should be preserved for further validation  if needed when '\n",
      " 'a specimen is positive the result should  be confirmed either by retesting '\n",
      " 'the original specimen or  obtaining another because of the overall low '\n",
      " 'prevalence  of n gonorrhoeae and c trachomatis among children  falsepositive '\n",
      " 'results can occur and all specimens that are  initially positive should be '\n",
      " 'confirmed • testing for t vaginalis should not be limited to girls with  '\n",
      " 'vaginal discharge if other indications for vaginal testing  exist because '\n",
      " 'evidence indicates that asymptomatic sexually  abused children might be '\n",
      " 'infected with t vaginalis and  might benefit from treatment 14511452 naat '\n",
      " 'can  be used as an alternative or in addition to culture and wet  '\n",
      " 'recommendations and reports 134 mmwr  july 23 2021  vol 70  no 4 us '\n",
      " 'department of health and human servicescenters for disease control and '\n",
      " 'prevention mount especially in settings where culture and wet mount  of '\n",
      " 'vaginal swab specimens are not obtainable data  regarding use of naats for '\n",
      " 'detection of t vaginalis among  children are limited however no evidence '\n",
      " 'indicates that  performance of naat for detection of t vaginalis for  '\n",
      " 'children would differ from that for adults consultation  with an expert is '\n",
      " 'necessary before using naat in this  context to ensure correct '\n",
      " 'interpretation of results because  of the implications of a diagnosis of t '\n",
      " 'vaginalis infection in  a child only cliavalidated fdacleared naats should  '\n",
      " 'be used 837 poc tests for t vaginalis have not been  validated for '\n",
      " 'prepubertal children and should not be used  in the case of a positive '\n",
      " 'specimen the result should be  confirmed either by retesting the original '\n",
      " 'specimen or  obtaining another because of the overall low prevalence of  t '\n",
      " 'vaginalis among children falsepositive results can occur  and all specimens '\n",
      " 'that are initially positive should  be confirmed • hsv can be indicative of '\n",
      " 'sexual abuse therefore  specimens should be obtained from all vesicular or  '\n",
      " 'ulcerative genital or perianal lesions and sent for naat  or viral culture • '\n",
      " 'wet mount can be used for a vaginal swab specimen for  bv if discharge is '\n",
      " 'present • collection of serum samples should be evaluated preserved  for '\n",
      " 'subsequent analysis and used as a baseline for  comparison with followup '\n",
      " 'serologic tests sera can be tested  for antibodies to t pallidum hiv and hbv '\n",
      " 'decisions  regarding the infectious agents for which to perform  serologic '\n",
      " 'tests should be made on a casebycase basis treatment the risk for a child '\n",
      " 'acquiring an sti as a result of sexual  abuse or assault has not been well '\n",
      " 'studied presumptive  treatment for children who have been sexually assaulted '\n",
      " 'or  abused is not recommended because the incidence of most  stis among '\n",
      " 'children is low after abuse or assault prepubertal  girls appear to be at '\n",
      " 'lower risk for ascending infection than  adolescent or adult women and '\n",
      " 'regular followup of children  usually can be ensured however certain '\n",
      " 'children or their  parent or guardian might be concerned about the '\n",
      " 'possibility  of infection with an sti even if the health care provider  has '\n",
      " 'perceived the risk to be low such concerns might be an  indication for '\n",
      " 'presumptive treatment in certain settings and  might be considered after all '\n",
      " 'relevant specimens for diagnostic  tests have been collected other '\n",
      " 'management considerations children who are survivors of sexual assault or '\n",
      " 'abuse are at  increased risk for future unsafe sexual practices that have '\n",
      " 'been  linked to higher risk for hpv acquisition 14261453 and  are more '\n",
      " 'likely to engage in these behaviors at an earlier age  therefore acip '\n",
      " 'recommends vaccination of these children  at age ≥9 years if they have not '\n",
      " 'initiated or completed hpv  vaccination see human papillomavirus infections '\n",
      " 'prevention  httpswwwcdcgovvaccineshcpaciprecsvaccspecific hpvhtml although '\n",
      " 'hpv vaccine will not protect against  progression of infection already '\n",
      " 'acquired or promote clearance  of the infection the vaccine protects against '\n",
      " 'hpv types not  yet acquired followup if no infections were identified at the '\n",
      " 'initial examination  after the last suspected sexual exposure and if this '\n",
      " 'exposure  was recent a followup evaluation approximately 2 weeks  after the '\n",
      " 'last exposure can be considered likewise if no  physical examination or '\n",
      " 'diagnostic testing was performed  at the initial visit a complete '\n",
      " 'examination can be scheduled  approximately 2 weeks after the last exposure '\n",
      " 'to identify any  evidence of stis in circumstances in which transmission of  '\n",
      " 'syphilis hiv hbv or hpv is a concern but baseline tests  for syphilis hiv '\n",
      " 'and hbv are negative and examinations  for genital warts are negative '\n",
      " 'followup serologic testing and  examination approximately 6 weeks and 3 '\n",
      " 'months after the  last suspected sexual exposure is recommended to allow '\n",
      " 'time  for antibodies to develop and signs of infection to appear  in '\n",
      " 'addition results of hbsag testing should be interpreted  carefully because '\n",
      " 'hbv can be transmitted nonsexually  decisions regarding which tests should '\n",
      " 'be performed should  be made on a casebycase basis risk for acquiring hiv '\n",
      " 'infection hiv has been reported among children for whom sexual  abuse was '\n",
      " 'the only known risk factor serologic testing for hiv  should be considered '\n",
      " 'for sexually abused children the decision  to test for hiv should involve '\n",
      " 'the family if possible and be  made on a casebycase basis depending on the '\n",
      " 'likelihood  of infection in the assailant 14481454 although data are  '\n",
      " 'insufficient concerning the efficacy of pep among children  treatment is '\n",
      " 'well tolerated by infants and children with and  without hiv and children '\n",
      " 'have a minimal risk for serious  adverse reactions because of the short '\n",
      " 'period recommended  for prophylaxis 1455 recommendations for postexposure '\n",
      " 'hiv risk  assessment of children 72 hours after  sexual assault providers '\n",
      " 'should do the following • review local hiv epidemiology assess risk for hiv '\n",
      " 'in the  assailant and test for hiv '\n",
      " 'httpswwwcdcgovvaccineshcpaciprecsvaccspecifichpvhtml '\n",
      " 'httpswwwcdcgovvaccineshcpaciprecsvaccspecifichpvhtml recommendations and '\n",
      " 'reports mmwr  july 23 2021  vol 70  no 4 135us department of health and '\n",
      " 'human servicescenters for disease control and prevention • evaluate the '\n",
      " 'circumstances of the assault or abuse that  might affect risk for hiv '\n",
      " 'transmission • perform hiv antigen or antibody testing or antibody  testing '\n",
      " 'if antigen or antibody testing is unavailable during  the original '\n",
      " 'assessment and again at followup visits in  accordance with cdc guidelines '\n",
      " 'httpsstackscdcgov viewcdc38856 in considering whether to offer pep  health '\n",
      " 'care providers should consider whether the child  can be treated soon after '\n",
      " 'the sexual exposure ie  72 hours the likelihood that the assailant has hiv  '\n",
      " 'infection and the likelihood of high compliance with the  prophylactic '\n",
      " 'regimen 1436 potential benefit of treating  a sexually abused child should '\n",
      " 'be weighed against the risk  for adverse reactions • consult with a provider '\n",
      " 'specializing in evaluating or  treating children with hiv infection to '\n",
      " 'determine age appropriate dosing and regimens and baseline laboratory  '\n",
      " 'testing if pep is being considered • discuss pep with the caregivers '\n",
      " 'including its toxicity  unknown efficacy and possible benefits for children  '\n",
      " 'determined to be at risk for hiv transmission from the  assault or abuse • '\n",
      " 'provided adequate doses of medication if pep is begun  to last until the '\n",
      " 'followup visit 3–7 days after the initial  assessment at which time the '\n",
      " 'child should be reevaluated  and tolerance of medication assessed 139 '\n",
      " 'conflicts of interest all authors have completed and submitted the '\n",
      " 'international  committee of medical journal editors form for disclosure of  '\n",
      " 'potential conflicts of interest christina muzny reports other support  from '\n",
      " 'cdc during the conduct of the study grants from the national  institutes of '\n",
      " 'healthnational institute of allergy and infectious  diseases and lupin '\n",
      " 'pharmaceuticals personal fees from lupin  pharmaceuticals phagomed cepheid '\n",
      " 'and beckton dickinson and  personal fees and other support from roche '\n",
      " 'diagnostics abbott  molecular and biofire diagnostics outside the submitted '\n",
      " 'work  hilary reno reports grants from hologic outside the submitted  work '\n",
      " 'christine johnston reports other support from cdc during  the conduct of the '\n",
      " 'study received research funding from sanofi pasteur royalties from uptodate '\n",
      " 'and personal fees from medpace  gilead abbvie and uptodate outside the '\n",
      " 'submitted work references  1 workowski ka bolan ga cdc sexually transmitted '\n",
      " 'diseases  treatment guidelines 2015 mmwr recomm rep 201564no rr3  '\n",
      " 'pmid26042815  2 barrow ry ahmed f bolan ga workowski ka recommendations  for '\n",
      " 'providing quality sexually transmitted diseases clinical services 2020  mmwr '\n",
      " 'recomm rep 202068no rr5 pmid31899459 https doiorg1015585mmwrrr6805a1  3 cdc '\n",
      " 'a guide to taking a sexual history atlanta ga us department  of health and '\n",
      " 'human services cdc httpswwwcdcgovstd treatmentsexualhistorypdf  4 henderson '\n",
      " 'jt senger ca henninger m bean si redmond n  o’connor ea behavioral '\n",
      " 'counseling interventions to prevent sexually  transmitted infections updated '\n",
      " 'evidence report and systematic review  for the us preventive services task '\n",
      " 'force jama 2020324682–99  pmid32809007 httpsdoiorg101001jama202010371  5 '\n",
      " 'kamb ml fishbein m douglas jm jr et al project respect study  group efficacy '\n",
      " 'of riskreduction counseling to prevent human  immunodeficiency virus and '\n",
      " 'sexually transmitted diseases a randomized  controlled trial jama '\n",
      " '19982801161–7 pmid9777816 httpsdoi org101001jama280131161  6 metsch lr '\n",
      " 'feaster dj gooden l et al effect of riskreduction  counseling with rapid hiv '\n",
      " 'testing on risk of acquiring sexually  transmitted infections the aware '\n",
      " 'randomized clinical trial jama  20133101701–10 pmid24150466 '\n",
      " 'httpsdoiorg101001 jama2013280034  7 brookmeyer ka hogben m kinsey j the role '\n",
      " 'of behavioral counseling  in sexually transmitted disease prevention program '\n",
      " 'settings sex transm  dis 201643suppl 1s102–12 pmid26779681 httpsdoi '\n",
      " 'org101097olq0000000000000327  8 patel p bush t mayer k et al sun study '\n",
      " 'investigators routine brief  riskreduction counseling with biannual std '\n",
      " 'testing reduces std  incidence among hivinfected men who have sex with men '\n",
      " 'in care sex  transm dis 201239470–4 pmid22592834 httpsdoiorg101097 '\n",
      " 'olq0b013e31824b3110  9 warner l klausner jd rietmeijer ca et al safe in the '\n",
      " 'city study  group effect of a brief video intervention on incident infection '\n",
      " 'among  patients attending sexually transmitted disease clinics plos med  '\n",
      " '20085e135 pmid18578564 httpsdoiorg101371journal pmed0050135  10 mustanski b '\n",
      " 'parsons jt sullivan ps madkins k rosenberg e swann  g biomedical and '\n",
      " 'behavioral outcomes of keep it up an ehealth hiv  prevention program rct am '\n",
      " 'j prev med 201855151–8  pmid29937115 httpsdoiorg101016jamepre201804026  11 '\n",
      " 'meites e szilagyi pg chesson hw unger er romero jr markowitz  le human '\n",
      " 'papillomavirus vaccination for adults updated  recommendations of the '\n",
      " 'advisory committee on immunization  practices mmwr morb mortal wkly rep '\n",
      " '201968698–702  pmid31415491 httpsdoiorg1015585mmwrmm6832a3  12 schillie s '\n",
      " 'vellozzi c reingold a et al prevention of hepatitis b virus  infection in '\n",
      " 'the united states recommendations of the advisory  committee on immunization '\n",
      " 'practices mmwr recomm rep  201867no rr1 pmid29939980 httpsdoiorg1015585mmwr '\n",
      " 'rr6701a1  13 doshani m weng m moore kl romero jr nelson np  recommendations '\n",
      " 'of the advisory committee on immunization  practices for use of hepatitis a '\n",
      " 'vaccine for persons experiencing  homelessness mmwr morb mortal wkly rep '\n",
      " '201968153–6  pmid30763295 httpsdoiorg1015585mmwrmm6806a6  14 weller s davis '\n",
      " 'k condom effectiveness in reducing heterosexual hiv  transmission cochrane '\n",
      " 'database syst rev 20021cd003255  pmid11869658 '\n",
      " 'httpsdoiorg10100214651858cd003255  15 giannou fk tsiara cg nikolopoulos gk '\n",
      " 'et al condom effectiveness  in reducing heterosexual hiv transmission a '\n",
      " 'systematic review and  metaanalysis of studies on hiv serodiscordant couples '\n",
      " 'expert rev  pharmacoecon outcomes res 201616489–99 pmid26488070  '\n",
      " 'httpsdoiorg1015861473716720161102635  16 smith dk herbst jh zhang x rose ce '\n",
      " 'condom effectiveness for  hiv prevention by consistency of use among men who '\n",
      " 'have sex with  men in the united states j acquir immune defic syndr '\n",
      " '201568337–44  pmid25469526 httpsdoiorg101097qai0000000000000461 '\n",
      " 'httpsstackscdcgovviewcdc38856 httpsstackscdcgovviewcdc38856 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids26042815doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids26042815doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids31899459doptabstract '\n",
      " 'httpsdoiorg1015585mmwrrr6805a1 httpsdoiorg1015585mmwrrr6805a1 '\n",
      " 'httpswwwcdcgovstdtreatmentsexualhistorypdf '\n",
      " 'httpswwwcdcgovstdtreatmentsexualhistorypdf '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids32809007doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids32809007doptabstract '\n",
      " 'httpsdoiorg101001jama202010371 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids9777816doptabstract '\n",
      " 'httpsdoiorg101001jama280131161 httpsdoiorg101001jama280131161 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids24150466doptabstract '\n",
      " 'httpsdoiorg101001jama2013280034 httpsdoiorg101001jama2013280034 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids26779681doptabstract '\n",
      " 'httpsdoiorg101097olq0000000000000327 httpsdoiorg101097olq0000000000000327 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids22592834doptabstract '\n",
      " 'httpsdoiorg101097olq0b013e31824b3110 httpsdoiorg101097olq0b013e31824b3110 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids18578564doptabstract '\n",
      " 'httpsdoiorg101371journalpmed0050135 httpsdoiorg101371journalpmed0050135 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29937115doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29937115doptabstract '\n",
      " 'httpsdoiorg101016jamepre201804026 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids31415491doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids31415491doptabstract '\n",
      " 'httpsdoiorg1015585mmwrmm6832a3 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29939980doptabstract '\n",
      " 'httpsdoiorg1015585mmwrrr6701a1 httpsdoiorg1015585mmwrrr6701a1 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30763295doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30763295doptabstract '\n",
      " 'httpsdoiorg1015585mmwrmm6806a6 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids11869658doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids11869658doptabstract '\n",
      " 'httpsdoiorg10100214651858cd003255 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids26488070doptabstract '\n",
      " 'httpsdoiorg1015861473716720161102635 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids25469526doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids25469526doptabstract '\n",
      " 'httpsdoiorg101097qai0000000000000461 recommendations and reports 136 mmwr  '\n",
      " 'july 23 2021  vol 70  no 4 us department of health and human servicescenters '\n",
      " 'for disease control and prevention  17 johnson wd o’leary a flores sa '\n",
      " 'perpartner condom effectiveness  against hiv for men who have sex with men '\n",
      " 'aids 2018321499–505  pmid29794493 httpsdoiorg101097qad0000000000001832  18 '\n",
      " 'crosby ra charnigo ra weathers c caliendo am shrier la  condom effectiveness '\n",
      " 'against nonviral sexually transmitted infections  a prospective study using '\n",
      " 'electronic daily diaries sex transm infect  201288484–9 pmid23002192 '\n",
      " 'httpsdoiorg101136 sextrans2012050618  19 holmes kk levine r weaver m '\n",
      " 'effectiveness of condoms in  preventing sexually transmitted infections bull '\n",
      " 'world health organ  200482454–61 pmid15356939  20 warner l stone km macaluso '\n",
      " 'm buehler jw austin hd condom  use and risk of gonorrhea and chlamydia a '\n",
      " 'systematic review of design  and measurement factors assessed in '\n",
      " 'epidemiologic studies sex transm  dis 20063336–51 pmid16385221 '\n",
      " 'httpsdoiorg10109701 olq000018790842622fd  21 bernabeortiz a carcamo cp scott '\n",
      " 'jd hughes jp garcia pj holmes  kk hbv infection in relation to consistent '\n",
      " 'condom use a population based study in peru plos one 20116e24721 '\n",
      " 'pmid21931828  httpsdoiorg101371journalpone0024721  22 ness rb hillier sl kip '\n",
      " 'ke et al bacterial vaginosis and risk of pelvic  inflammatory disease obstet '\n",
      " 'gynecol 2004104761–9 pmid15458899  httpsdoiorg10109701aog00001395123758217  '\n",
      " '23 martin ie gu w yang y tsang rs macrolide resistance and molecular  types '\n",
      " 'of treponema pallidum causing primary syphilis in shanghai china  clin '\n",
      " 'infect dis 200949515–21 pmid19583516 httpsdoi org101086600878  24 winer rl '\n",
      " 'hughes jp feng q et al condom use and the risk of genital  human '\n",
      " 'papillomavirus infection in young women n engl j med  20063542645–54 '\n",
      " 'pmid16790697 httpsdoiorg101056 nejmoa053284  25 bleeker mc hogewoning cj '\n",
      " 'voorhorst fj et al condom use promotes  regression of human '\n",
      " 'papillomavirusassociated penile lesions in male  sexual partners of women '\n",
      " 'with cervical intraepithelial neoplasia int  j cancer 2003107804–10 '\n",
      " 'pmid14566831 httpsdoiorg101002 ijc11473  26 hogewoning cj bleeker mc van den '\n",
      " 'brule aj et al condom use  promotes regression of cervical intraepithelial '\n",
      " 'neoplasia and clearance  of human papillomavirus a randomized clinical trial '\n",
      " 'int j cancer  2003107811–6 pmid14566832 httpsdoiorg101002ijc11474  27 koss '\n",
      " 'ca dunne ef warner l a systematic review of epidemiologic  studies assessing '\n",
      " 'condom use and risk of syphilis sex transm dis  200936401–5 pmid19455075 '\n",
      " 'httpsdoiorg101097 olq0b013e3181a396eb  28 hernándezromieu ac siegler aj '\n",
      " 'sullivan ps crosby r rosenberg  es how often do condoms fail a '\n",
      " 'crosssectional study exploring  incomplete use of condoms condom failures '\n",
      " 'and other condom  problems among black and white msm in southern usa sex '\n",
      " 'transm  infect 201490602–7 pmid25080511 httpsdoiorg101136 '\n",
      " 'sextrans2014051581  29 d’anna lh margolis ad warner l et al safe city study '\n",
      " 'group  condom use problems during anal sex among men who have sex with  men '\n",
      " 'msm findings from the safe in the city study aids care  2012241028–38 '\n",
      " 'pmid22519680 httpsdoiorg101080095401 212012668285  30 steiner mj cates w jr '\n",
      " 'warner l the real problem with male condoms  is nonuse sex transm dis '\n",
      " '199926459–62 pmid10494937 https doiorg1010970000743519990900000007  31 kowal '\n",
      " 'd hatcher ra nelson al et al eds contraceptive technology  21st ed atlanta '\n",
      " 'ga managing contraception 2017  32 gallo mf kilbournebrook m coffey ps a '\n",
      " 'review of the effectiveness  and acceptability of the female condom for dual '\n",
      " 'protection sex health  2012918–26 pmid22348629 httpsdoiorg101071sh11037  33 '\n",
      " 'mantell je kelvin ea exner tm hoffman s needham s stein za  anal use of the '\n",
      " 'female condom does uncertainty justify provider  inaction aids care '\n",
      " '2009211185–94 pmid20024779 httpsdoi org10108009540120902730005  34 rosenberg '\n",
      " 'mj davidson aj chen jh judson fn douglas jm barrier  contraceptives and '\n",
      " 'sexually transmitted diseases in women a comparison  of femaledependent '\n",
      " 'methods and condoms am j public health  199282669–74 pmid1566944 '\n",
      " 'httpsdoiorg102105 ajph825669  35 de bruyn g shiboski s van der straten a et '\n",
      " 'al mira team the  effect of the vaginal diaphragm and lubricant gel on '\n",
      " 'acquisition of  hsv2 sex transm infect 201187301–5 pmid21447515 https '\n",
      " 'doiorg101136sti2010047142  36 ramjee g van der straten a chipato t et al '\n",
      " 'mira team the  diaphragm and lubricant gel for prevention of cervical '\n",
      " 'sexually  transmitted infections results of a randomized controlled trial '\n",
      " 'plos  one 20083e3488 pmid18941533 httpsdoiorg101371journal pone0003488  37 '\n",
      " 'lustinarasimhan m merialdi m holt b multipurpose prevention  technologies '\n",
      " 'maximising positive synergies bjog 2014121251  pmid24393212 '\n",
      " 'httpsdoiorg1011111471052812606  38 ahmed k baeten jm beksinska m et al '\n",
      " 'evidence for contraceptive  options and hiv outcomes echo trial consortium '\n",
      " 'hiv incidence  among women using intramuscular depot medroxyprogesterone '\n",
      " 'acetate  a copper intrauterine device or a levonorgestrel implant for  '\n",
      " 'contraception a randomised multicentre openlabel trial lancet  2019394303–13 '\n",
      " 'pmid31204114 httpsdoiorg101016 s0140673619312887  39 young holt b dellplain '\n",
      " 'l creinin md peine kj romano j  hemmerling a a strategic action framework '\n",
      " 'for multipurpose  prevention technologies combining contraceptive hormones '\n",
      " 'and  antiretroviral drugs to prevent pregnancy and hiv eur j contracept  '\n",
      " 'reprod health care 201823326–34 pmid30247084 httpsdoi '\n",
      " 'org1010801362518720181508650  40 wilkinson d tholandi m ramjee g rutherford '\n",
      " 'gw nonoxynol9  spermicide for prevention of vaginally acquired hiv and other '\n",
      " 'sexually  transmitted infections systematic review and metaanalysis of  '\n",
      " 'randomised controlled trials including more than 5000 women lancet  infect '\n",
      " 'dis 20022613–7 pmid12383611 httpsdoiorg101016 s1473309902003961  41 '\n",
      " 'mccormack s ramjee g kamali a et al pro2000 vaginal gel for  prevention of '\n",
      " 'hiv1 infection microbicides development programme  301 a phase 3 randomised '\n",
      " 'doubleblind parallelgroup trial lancet  20103761329–37 pmid20851460 '\n",
      " 'httpsdoiorg101016 s0140673610610860  42 skolerkarpoff s ramjee g ahmed k et '\n",
      " 'al efficacy of carraguard for  prevention of hiv infection in women in south '\n",
      " 'africa a randomised  doubleblind placebocontrolled trial lancet '\n",
      " '20083721977–87  pmid19059048 httpsdoiorg101016s0140673608618425  43 van '\n",
      " 'damme l govinden r mirembe fm et al cs study group  lack of effectiveness of '\n",
      " 'cellulose sulfate gel for the prevention of vaginal  hiv transmission n engl '\n",
      " 'j med 2008359463–72 pmid18669425  httpsdoiorg101056nejmoa0707957  44 '\n",
      " 'feldblum pj adeiga a bakare r et al savvy vaginal gel c31g for  prevention '\n",
      " 'of hiv infection a randomized controlled trial in nigeria  plos one '\n",
      " '20083e1474 pmid18213382 httpsdoiorg101371 journalpone0001474  45 cottrell ml '\n",
      " 'kashuba ad topical microbicides and hiv prevention  in the female genital '\n",
      " 'tract j clin pharmacol 201454603–15  pmid24664786 httpsdoiorg101002jcph292  '\n",
      " '46 abdool karim ss abdool karim q kharsany abm et al caprisa  004 trial '\n",
      " 'group tenofovir gel for the prevention of herpes simplex virus  type 2 '\n",
      " 'infection n engl j med 2015373530–9 pmid26244306  '\n",
      " 'httpsdoiorg101056nejmoa1410649 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29794493doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29794493doptabstract '\n",
      " 'httpsdoiorg101097qad0000000000001832 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids23002192doptabstract '\n",
      " 'httpsdoiorg101136sextrans2012050618 httpsdoiorg101136sextrans2012050618 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids15356939doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids16385221doptabstract '\n",
      " 'httpsdoiorg10109701olq000018790842622fd '\n",
      " 'httpsdoiorg10109701olq000018790842622fd httpsdoiorg101371journalpone0024721 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids15458899doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids19583516doptabstract '\n",
      " 'httpsdoiorg101086600878 httpsdoiorg101086600878 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids16790697doptabstract '\n",
      " 'httpsdoiorg101056nejmoa053284 httpsdoiorg101056nejmoa053284 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids14566831doptabstract '\n",
      " 'httpsdoiorg101002ijc11473 httpsdoiorg101002ijc11473 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids14566832doptabstract '\n",
      " 'httpsdoiorg101002ijc11474 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids19455075doptabstract '\n",
      " 'httpsdoiorg101097olq0b013e3181a396eb httpsdoiorg101097olq0b013e3181a396eb '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids25080511doptabstract '\n",
      " 'httpsdoiorg101136sextrans2014051581 httpsdoiorg101136sextrans2014051581 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids22519680doptabstract '\n",
      " 'httpsdoiorg101080095401212012668285 httpsdoiorg101080095401212012668285 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids10494937doptabstract '\n",
      " 'httpsdoiorg1010970000743519990900000007 '\n",
      " 'httpsdoiorg1010970000743519990900000007 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids22348629doptabstract '\n",
      " 'httpsdoiorg101071sh11037 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids20024779doptabstract '\n",
      " 'httpsdoiorg10108009540120902730005 httpsdoiorg10108009540120902730005 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids1566944doptabstract '\n",
      " 'httpsdoiorg102105ajph825669 httpsdoiorg102105ajph825669 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids21447515doptabstract '\n",
      " 'httpsdoiorg101136sti2010047142 httpsdoiorg101136sti2010047142 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids18941533doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids24393212doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids24393212doptabstract '\n",
      " 'httpsdoiorg1011111471052812606 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids31204114doptabstract '\n",
      " 'httpsdoiorg101016s0140673619312887 httpsdoiorg101016s0140673619312887 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30247084doptabstract '\n",
      " 'httpsdoiorg1010801362518720181508650 httpsdoiorg1010801362518720181508650 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids12383611doptabstract '\n",
      " 'httpsdoiorg101016s1473309902003961 httpsdoiorg101016s1473309902003961 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids20851460doptabstract '\n",
      " 'httpsdoiorg101016s0140673610610860 httpsdoiorg101016s0140673610610860 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids19059048doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids19059048doptabstract '\n",
      " 'httpsdoiorg101016s0140673608618425 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids18669425doptabstract '\n",
      " 'httpsdoiorg101056nejmoa0707957 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids18213382doptabstract '\n",
      " 'httpsdoiorg101371journalpone0001474 httpsdoiorg101371journalpone0001474 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids24664786doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids24664786doptabstract '\n",
      " 'httpsdoiorg101002jcph292 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids26244306doptabstract '\n",
      " 'httpsdoiorg101056nejmoa1410649 recommendations and reports mmwr  july 23 '\n",
      " '2021  vol 70  no 4 137us department of health and human servicescenters for '\n",
      " 'disease control and prevention  47 abdool karim q abdool karim ss frohlich '\n",
      " 'ja et al caprisa 004  trial group effectiveness and safety of tenofovir gel '\n",
      " 'an antiretroviral  microbicide for the prevention of hiv infection in women '\n",
      " 'science  20103291168–74 erratum in science 2011333524 pmid20643915  '\n",
      " 'httpsdoiorg101126science1193748  48 marrazzo jm ramjee g richardson ba et al '\n",
      " 'voice study team  tenofovirbased preexposure prophylaxis for hiv infection '\n",
      " 'among  african women n engl j med 2015372509–18 pmid25651245  '\n",
      " 'httpsdoiorg101056nejmoa1402269  49 delanymoretlwe s lombard c baron d et al '\n",
      " 'tenofovir 1 vaginal  gel for prevention of hiv1 infection in women in south '\n",
      " 'africa  facts001 a phase 3 randomised doubleblind placebocontrolled  trial '\n",
      " 'lancet infect dis 2018181241–50 pmid30507409 https '\n",
      " 'doiorg101016s1473309918304286  50 baeten jm palaneephillips t brown er et al '\n",
      " 'mtn020–aspire  study team use of a vaginal ring containing dapivirine for '\n",
      " 'hiv1  prevention in women n engl j med 20163752121–32  pmid26900902 '\n",
      " 'httpsdoiorg101056nejmoa1506110  51 nel a van niekerk n kapiga s et al ring '\n",
      " 'study team safety and  efficacy of a dapivirine vaginal ring for hiv '\n",
      " 'prevention in women n  engl j med 20163752133–43 pmid27959766 httpsdoi '\n",
      " 'org101056nejmoa1602046  52 cranston rd lama jr richardson ba et al mtn017 '\n",
      " 'protocol  team mtn017 a rectal phase 2 extended safety and acceptability  '\n",
      " 'study of tenofovir reducedglycerin 1 gel clin infect dis  201764614–20 '\n",
      " 'pmid27986684  53 hooton tm roberts pl stamm we effects of recent sexual '\n",
      " 'activity  and use of a diaphragm on the vaginal microflora clin infect dis  '\n",
      " '199419274–8 pmid7986899 httpsdoiorg101093 clinids192274  54 fihn sd boyko ej '\n",
      " 'normand eh et al association between use of  spermicidecoated condoms and '\n",
      " 'escherichia coli urinary tract infection  in young women am j epidemiol '\n",
      " '1996144512–20 pmid8781467  httpsdoiorg101093oxfordjournalsajea008958  55 '\n",
      " 'polis cb curtis km hannaford pc et al an updated systematic review  of '\n",
      " 'epidemiological evidence on hormonal contraceptive methods and  hiv '\n",
      " 'acquisition in women aids 2016302665–83 pmid27500670  '\n",
      " 'httpsdoiorg101097qad0000000000001228  56 kiweewa fm brown e mishra a et al '\n",
      " 'mtn020aspire study  team acquisition of sexually transmitted infections '\n",
      " 'among women  using a variety of contraceptive options a prospective study '\n",
      " 'among  highrisk african women j int aids soc 201922e25257  pmid30816632 '\n",
      " 'httpsdoiorg101002jia225257  57 mccarthy kj gollub el ralph l van de wijgert '\n",
      " 'j jones he  hormonal contraceptives and the acquisition of sexually '\n",
      " 'transmitted  infections an updated systematic review sex transm dis '\n",
      " '201946290–6  pmid30628946 httpsdoiorg101097olq0000000000000975  58 curtis km '\n",
      " 'tepper nk jatlaoui tc et al us medical eligibility criteria  for '\n",
      " 'contraceptive use 2016 mmwr recomm rep 201665no rr3  pmid27467196 '\n",
      " 'httpsdoiorg1015585mmwrrr6503a1  59 curtis km jatlaoui tc tepper nk et al us '\n",
      " 'selected practice  recommendations for contraceptive use 2016 mmwr recomm '\n",
      " 'rep  201665no rr4 pmid27467319 httpsdoiorg1015585mmwr rr6504a1  60 cleland k '\n",
      " 'zhu h goldstuck n cheng l trussell j the efficacy of  intrauterine devices '\n",
      " 'for emergency contraception a systematic review  of 35 years of experience '\n",
      " 'hum reprod 2012271994–2000  pmid22570193 httpsdoiorg101093humrepdes140  61 '\n",
      " 'shen j che y showell e chen k cheng l interventions for emergency  '\n",
      " 'contraception cochrane database syst rev 20191cd001324  pmid30661244  62 '\n",
      " 'marcell av waks ab rutkow l mckenna r rompalo a hogan mt  what do we know '\n",
      " 'about males and emergency contraception a synthesis  of the literature '\n",
      " 'perspect sex reprod health 201244184–93  pmid22958663 '\n",
      " 'httpsdoiorg1013634418412  63 gray rh kigozi g serwadda d et al male '\n",
      " 'circumcision for hiv  prevention in men in rakai uganda a randomised trial '\n",
      " 'lancet  2007369657–66 pmid17321311 httpsdoiorg101016 s0140673607603134  64 '\n",
      " 'bailey rc moses s parker cb et al male circumcision for hiv  prevention in '\n",
      " 'young men in kisumu kenya a randomised controlled  trial lancet '\n",
      " '2007369643–56 pmid17321310 httpsdoi org101016s0140673607603122  65 auvert b '\n",
      " 'taljaard d lagarde e sobngwitambekou j sitta r puren  a randomized '\n",
      " 'controlled intervention trial of male circumcision for  reduction of hiv '\n",
      " 'infection risk the anrs 1265 trial plos med  20052e298 erratum in plos med '\n",
      " '20063298 pmid16231970  httpsdoiorg101371journalpmed0020298  66 tobian aa '\n",
      " 'serwadda d quinn tc et al male circumcision for the  prevention of hsv2 and '\n",
      " 'hpv infections and syphilis n engl j med  20093601298–309 pmid19321868 '\n",
      " 'httpsdoiorg101056 nejmoa0802556  67 auvert b sobngwitambekou j cutler e et '\n",
      " 'al effect of male  circumcision on the prevalence of highrisk human '\n",
      " 'papillomavirus in  young men results of a randomized controlled trial '\n",
      " 'conducted in orange  farm south africa j infect dis 200919914–9 '\n",
      " 'pmid19086814  httpsdoiorg101086595566  68 sobngwitambekou j taljaard d '\n",
      " 'lissouba p et al effect of hsv2  serostatus on acquisition of hiv by young '\n",
      " 'men results of a longitudinal  study in orange farm south africa j infect '\n",
      " 'dis 2009199958–64  pmid19220143 httpsdoiorg101086597208  69 gray r kigozi g '\n",
      " 'kong x et al the effectiveness of male circumcision  for hiv prevention and '\n",
      " 'effects on risk behaviors in a posttrial followup  study aids 201226609–15 '\n",
      " 'pmid22210632 httpsdoi org101097qad0b013e3283504a3f  70 mehta sd moses s '\n",
      " 'parker cb agot k maclean i bailey rc  circumcision status and incident '\n",
      " 'herpes simplex virus type 2 infection  genital ulcer disease and hiv '\n",
      " 'infection aids 2012261141–9  pmid22382150 '\n",
      " 'httpsdoiorg101097qad0b013e328352d116  71 world health organizationunaids new '\n",
      " 'data on male circumcision  and hiv prevention policy and programme '\n",
      " 'implications internet  geneva switzerland whounaids technical consultation '\n",
      " 'on male  circumcision and hiv prevention research implications for policy  '\n",
      " 'and programming  2007  https  wwwwho inthivpub '\n",
      " 'malecircumcisionresearchimplicationsen  72 american urological association '\n",
      " 'circumcision policy statement  internet linthicum md american urological '\n",
      " 'association 2017  httpswwwauanetorgguidelinesguidelinescircumcision  73 yuan '\n",
      " 't fitzpatrick t ko ny et al circumcision to prevent hiv and  other sexually '\n",
      " 'transmitted infections in men who have sex with men a  systematic review and '\n",
      " 'metaanalysis of global data lancet glob health  20197e436–47 pmid30879508 '\n",
      " 'httpsdoiorg101016 s2214109x18305679  74 grohskopf la chillag kl gvetadze r '\n",
      " 'et al randomized trial of  clinical safety of daily oral tenofovir '\n",
      " 'disoproxil fumarate among hiv uninfected men who have sex with men in the '\n",
      " 'united states j acquir  immune defic syndr 20136479–86 pmid23466649 httpsdoi '\n",
      " 'org101097qai0b013e31828ece33  75 grant rm lama jr anderson pl et al iprex '\n",
      " 'study team preexposure  chemoprophylaxis for hiv prevention in men who have '\n",
      " 'sex with men  n engl j med 20103632587–99 pmid21091279 httpsdoi '\n",
      " 'org101056nejmoa1011205  76 baeten jm donnell d ndase p et al partners prep '\n",
      " 'study team  antiretroviral prophylaxis for hiv prevention in heterosexual '\n",
      " 'men and  women n engl j med 2012367399–410 pmid22784037 https '\n",
      " 'doiorg101056nejmoa1108524  77 thigpen mc kebaabetswe pm paxton la et al tdf2 '\n",
      " 'study group  antiretroviral preexposure prophylaxis for heterosexual hiv '\n",
      " 'transmission  in botswana n engl j med 2012367423–34 pmid22784038 https '\n",
      " 'doiorg101056nejmoa1110711 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids20643915doptabstract '\n",
      " 'httpsdoiorg101126science1193748 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids25651245doptabstract '\n",
      " 'httpsdoiorg101056nejmoa1402269 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30507409doptabstract '\n",
      " 'httpsdoiorg101016s1473309918304286 httpsdoiorg101016s1473309918304286 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids26900902doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids26900902doptabstract '\n",
      " 'httpsdoiorg101056nejmoa1506110 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids27959766doptabstract '\n",
      " 'httpsdoiorg101056nejmoa1602046 httpsdoiorg101056nejmoa1602046 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids27986684doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids7986899doptabstract '\n",
      " 'httpsdoiorg101093clinids192274 httpsdoiorg101093clinids192274 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids8781467doptabstract '\n",
      " 'httpsdoiorg101093oxfordjournalsajea008958 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids27500670doptabstract '\n",
      " 'httpsdoiorg101097qad0000000000001228 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30816632doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30816632doptabstract '\n",
      " 'httpsdoiorg101002jia225257 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30628946doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30628946doptabstract '\n",
      " 'httpsdoiorg101097olq0000000000000975 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids27467196doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids27467196doptabstract '\n",
      " 'httpsdoiorg1015585mmwrrr6503a1 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids27467319doptabstract '\n",
      " 'httpsdoiorg1015585mmwrrr6504a1 httpsdoiorg1015585mmwrrr6504a1 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids22570193doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids22570193doptabstract '\n",
      " 'httpsdoiorg101093humrepdes140 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30661244doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30661244doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids22958663doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids22958663doptabstract '\n",
      " 'httpsdoiorg1013634418412 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids17321311doptabstract '\n",
      " 'httpsdoiorg101016s0140673607603134 httpsdoiorg101016s0140673607603134 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids17321310doptabstract '\n",
      " 'httpsdoiorg101016s0140673607603122 httpsdoiorg101016s0140673607603122 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids16231970doptabstract '\n",
      " 'httpsdoiorg101371journalpmed0020298 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids19321868doptabstract '\n",
      " 'httpsdoiorg101056nejmoa0802556 httpsdoiorg101056nejmoa0802556 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids19086814doptabstract '\n",
      " 'httpsdoiorg101086595566 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids19220143doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids19220143doptabstract '\n",
      " 'httpsdoiorg101086597208 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids22210632doptabstract '\n",
      " 'httpsdoiorg101097qad0b013e3283504a3f httpsdoiorg101097qad0b013e3283504a3f '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids22382150doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids22382150doptabstract '\n",
      " 'httpsdoiorg101097qad0b013e328352d116 '\n",
      " 'httpswwwwhointhivpubmalecircumcisionresearchimplicationsen '\n",
      " 'httpswwwwhointhivpubmalecircumcisionresearchimplicationsen '\n",
      " 'httpswwwauanetorgguidelinesguidelinescircumcision '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30879508doptabstract '\n",
      " 'httpsdoiorg101016s2214109x18305679 httpsdoiorg101016s2214109x18305679 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids23466649doptabstract '\n",
      " 'httpsdoiorg101097qai0b013e31828ece33 httpsdoiorg101097qai0b013e31828ece33 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids21091279doptabstract '\n",
      " 'httpsdoiorg101056nejmoa1011205 httpsdoiorg101056nejmoa1011205 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids22784037doptabstract '\n",
      " 'httpsdoiorg101056nejmoa1108524 httpsdoiorg101056nejmoa1108524 '\n",
      " 'httpsdoiorg101056nejmoa1110711 httpsdoiorg101056nejmoa1110711 '\n",
      " 'recommendations and reports 138 mmwr  july 23 2021  vol 70  no 4 us '\n",
      " 'department of health and human servicescenters for disease control and '\n",
      " 'prevention  78 choopanya k martin m suntharasamai p et al bangkok tenofovir  '\n",
      " 'study group antiretroviral prophylaxis for hiv infection in injecting  drug '\n",
      " 'users in bangkok thailand the bangkok tenofovir study a  randomised '\n",
      " 'doubleblind placebocontrolled phase 3 trial lancet  20133812083–90 '\n",
      " 'pmid23769234 httpsdoiorg101016 s0140673613611277  79 molina jm charreau i '\n",
      " 'spire b et al anrs ipergay study group  efficacy safety and effect on sexual '\n",
      " 'behaviour of ondemand pre exposure prophylaxis for hiv in men who have sex '\n",
      " 'with men an  observational cohort study lancet hiv 20174e402–10  '\n",
      " 'pmid28747274 httpsdoiorg101016s2352301817300899  80 cdc preexposure '\n",
      " 'prophylaxis for the prevention of hiv infection in the  united states—2017 '\n",
      " 'update a clinical practice guideline atlanta ga  us department of health and '\n",
      " 'human services cdc 2018 https '\n",
      " 'wwwcdcgovhivpdfriskprepcdchivprepguidelines2017pdf  81 jones j weiss k '\n",
      " 'mermin j et al proportion of incident human  immunodeficiency virus cases '\n",
      " 'among men who have sex with men  attributable to gonorrhea and chlamydia a '\n",
      " 'modeling analysis sex transm  dis 201946357–63 pmid31095100 '\n",
      " 'httpsdoiorg101097 olq0000000000000980  82 pathela p braunstein sl blank s '\n",
      " 'schillinger ja hiv incidence among  men with and those without sexually '\n",
      " 'transmitted rectal infections  estimates from matching against an hiv case '\n",
      " 'registry clin infect dis  2013571203–9 pmid23800942 '\n",
      " 'httpsdoiorg101093cidcit437  83 pathela p braunstein sl blank s shepard c '\n",
      " 'schillinger ja the high  risk of an hiv diagnosis following a diagnosis of '\n",
      " 'syphilis a population level analysis of new york city men clin infect dis '\n",
      " '201561281–7  pmid25870333 httpsdoiorg101093cidciv289  84 chou r evans c '\n",
      " 'hoverman a et al preexposure prophylaxis for the  prevention of hiv '\n",
      " 'infection evidence report and systematic review for  the us preventive '\n",
      " 'services task force jama 20193212214–30  pmid31184746 '\n",
      " 'httpsdoiorg101001jama20192591  85 liu ay cohen se vittinghoff e et al '\n",
      " 'preexposure prophylaxis for hiv  infection integrated with municipal and '\n",
      " 'communitybased sexual health  services jama intern med 201617675–84 '\n",
      " 'pmid26571482 https doiorg101001jamainternmed20154683  86 mccormack s dunn dt '\n",
      " 'desai m et al preexposure prophylaxis to  prevent the acquisition of hiv1 '\n",
      " 'infection proud effectiveness  results from the pilot phase of a pragmatic '\n",
      " 'openlabel randomised trial  lancet 201638753–60 pmid26364263 '\n",
      " 'httpsdoiorg101016 s0140673615000562  87 volk je marcus jl phengrasamy t et '\n",
      " 'al no new hiv infections with  increasing use of hiv preexposure prophylaxis '\n",
      " 'in a clinical practice  setting clin infect dis 2015611601–3 pmid26334052 '\n",
      " 'httpsdoi org101093cidciv778  88 celum c wald a lingappa jr et al partners in '\n",
      " 'prevention hsv hiv transmission study team acyclovir and transmission of '\n",
      " 'hiv1  from persons infected with hiv1 and hsv2 n engl j med  2010362427–39 '\n",
      " 'pmid20089951 httpsdoiorg101056 nejmoa0904849  89 celum c wald a hughes j et '\n",
      " 'al hptn 039 protocol team effect  of aciclovir on hiv1 acquisition in herpes '\n",
      " 'simplex virus 2 seropositive  women and men who have sex with men a '\n",
      " 'randomised doubleblind  placebocontrolled trial lancet 20083712109–19 '\n",
      " 'pmid18572080  httpsdoiorg101016s0140673608609204  90 bolan rk beymer mr '\n",
      " 'weiss re flynn rp leibowitz aa klausner  jd doxycycline prophylaxis to '\n",
      " 'reduce incident syphilis among hiv infected men who have sex with men who '\n",
      " 'continue to engage in highrisk  sex a randomized controlled pilot study sex '\n",
      " 'transm dis 20154298–103  pmid25585069 httpsdoiorg101097olq0000000000000216  '\n",
      " '91 grant js stafylis c celum c et al doxycycline prophylaxis for bacterial  '\n",
      " 'sexually transmitted infections clin infect dis 2020701247–53  pmid31504345 '\n",
      " 'httpsdoiorg101093cidciz866  92 myer l kuhn l stein za wright tc jr denny l '\n",
      " 'intravaginal  practices bacterial vaginosis and women’s susceptibility to '\n",
      " 'hiv  infection epidemiological evidence and biological mechanisms lancet  '\n",
      " 'infect dis 20055786–94 pmid16310150 httpsdoiorg101016 s147330990570298x  93 '\n",
      " 'molina jm charreau i chidiac c et al anrs ipergay study group  postexposure '\n",
      " 'prophylaxis with doxycycline to prevent sexually  transmitted infections in '\n",
      " 'men who have sex with men an openlabel  randomised substudy of the anrs '\n",
      " 'ipergay trial lancet infect dis  201818308–17 pmid29229440 httpsdoiorg101016 '\n",
      " 's1473309917307259  94 cohen ms chen yq mccauley m et al hptn 052 study team  '\n",
      " 'prevention of hiv1 infection with early antiretroviral therapy n engl  j med '\n",
      " '2011365493–505 pmid21767103 httpsdoiorg101056 nejmoa1105243  95 rodger aj '\n",
      " 'cambiano v bruun t et al partner study group  sexual activity without '\n",
      " 'condoms and risk of hiv transmission in  serodifferent couples when the '\n",
      " 'hivpositive partner is using suppressive  antiretroviral therapy jama '\n",
      " '2016316171–81 pmid27404185  httpsdoiorg101001jama20165148  96 bavinton br '\n",
      " 'pinto an phanuphak n et al opposites attract study  group viral suppression '\n",
      " 'and hiv transmission in serodiscordant male  couples an international '\n",
      " 'prospective observational cohort study lancet  hiv 20185e438–47 pmid30025681 '\n",
      " 'httpsdoiorg101016 s2352301818301322  97 rodger aj cambiano v bruun t et al '\n",
      " 'partner study group risk  of hiv transmission through condomless sex in '\n",
      " 'serodifferent gay couples  with the hivpositive partner taking suppressive '\n",
      " 'antiretroviral therapy  partner final results of a multicentre prospective '\n",
      " 'observational  study lancet 20193932428–38 pmid31056293 httpsdoi '\n",
      " 'org101016s0140673619304180  98 panel on antiretroviral guidelines for adults '\n",
      " 'and adolescents guidelines  for the use of antiretroviral agents in adults '\n",
      " 'and adolescents with hiv  bethesda md us department of health and human '\n",
      " 'services national  institutes of health aidsinfo '\n",
      " 'httpsclinicalinfohivgovsitesdefault filesinlinefilesadultandadolescentglpdf  '\n",
      " '99 golden mr kerani rp stenger m et al effect of expedited partner  therapy '\n",
      " 'ept on chlamydial prevalence the washington state  communitylevel trial '\n",
      " 'presented at the std prevention conference  minneapolis mn march 12–15 2012 '\n",
      " '100 philip ss yu x donnell d vittinghoff e buchbinder s serosorting  is '\n",
      " 'associated with a decreased risk of hiv seroconversion in the  explore study '\n",
      " 'cohort plos one 20105e12662 pmid20844744  '\n",
      " 'httpsdoiorg101371journalpone0012662  101 vallabhaneni s li x vittinghoff e '\n",
      " 'donnell d pilcher cd  buchbinder sp seroadaptive practices association with '\n",
      " 'hiv acquisition  among hivnegative men who have sex with men plos one  '\n",
      " '20127e45718 pmid23056215 httpsdoiorg101371journal pone0045718  102 jin f '\n",
      " 'prestage gp templeton dj et al the impact of hiv seroadaptive  behaviors on '\n",
      " 'sexually transmissible infections in hivnegative  homosexual men in sydney '\n",
      " 'australia sex transm dis 201239191–4  pmid22337105 '\n",
      " 'httpsdoiorg101097olq0b013e3182401a2f  103 hotton al gratzer b mehta sd '\n",
      " 'association between serosorting  and bacterial sexually transmitted '\n",
      " 'infection among hivnegative men  who have sex with men at an urban lesbian '\n",
      " 'gay bisexual and  transgender health center sex transm dis 201239959–64  '\n",
      " 'pmid23191950 httpsdoiorg101097olq0b013e31826e870d  104 anderson c gallo mf '\n",
      " 'hyltonkong t et al randomized controlled  trial on the effectiveness of '\n",
      " 'counseling messages for avoiding  unprotected sexual intercourse during '\n",
      " 'sexually transmitted infection  and reproductive tract infection treatment '\n",
      " 'among female sexually  transmitted infection clinic patients sex transm dis '\n",
      " '201340105–10  pmid23321990 httpsdoiorg101097olq0b013e31827938a1 '\n",
      " 'httpsdoiorg101016s0140673613611277 httpsdoiorg101016s0140673613611277 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28747274doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28747274doptabstract '\n",
      " 'httpsdoiorg101016s2352301817300899 '\n",
      " 'httpswwwcdcgovhivpdfriskprepcdchivprepguidelines2017pdf '\n",
      " 'httpswwwcdcgovhivpdfriskprepcdchivprepguidelines2017pdf '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids31095100doptabstract '\n",
      " 'httpsdoiorg101097olq0000000000000980 httpsdoiorg101097olq0000000000000980 '\n",
      " 'httpsdoiorg101093cidcit437 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids25870333doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids25870333doptabstract '\n",
      " 'httpsdoiorg101093cidciv289 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids31184746doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids31184746doptabstract '\n",
      " 'httpsdoiorg101001jama20192591 httpsdoiorg101001jamainternmed20154683 '\n",
      " 'httpsdoiorg101001jamainternmed20154683 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids26364263doptabstract '\n",
      " 'httpsdoiorg101016s0140673615000562 httpsdoiorg101016s0140673615000562 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids26334052doptabstract '\n",
      " 'httpsdoiorg101093cidciv778 httpsdoiorg101093cidciv778 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids20089951doptabstract '\n",
      " 'httpsdoiorg101056nejmoa0904849 httpsdoiorg101056nejmoa0904849 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids18572080doptabstract '\n",
      " 'httpsdoiorg101016s0140673608609204 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids25585069doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids25585069doptabstract '\n",
      " 'httpsdoiorg101097olq0000000000000216 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids31504345doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids31504345doptabstract '\n",
      " 'httpsdoiorg101093cidciz866 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids16310150doptabstract '\n",
      " 'httpsdoiorg101016s147330990570298x httpsdoiorg101016s147330990570298x '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29229440doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids21767103doptabstract '\n",
      " 'httpsdoiorg101056nejmoa1105243 httpsdoiorg101056nejmoa1105243 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids27404185doptabstract '\n",
      " 'httpsdoiorg101001jama20165148 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30025681doptabstract '\n",
      " 'httpsdoiorg101016s2352301818301322 httpsdoiorg101016s2352301818301322 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids31056293doptabstract '\n",
      " 'httpsdoiorg101016s0140673619304180 httpsdoiorg101016s0140673619304180 '\n",
      " 'httpsclinicalinfohivgovsitesdefaultfilesinlinefilesadultandadolescentglpdf '\n",
      " 'httpsclinicalinfohivgovsitesdefaultfilesinlinefilesadultandadolescentglpdf '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids20844744doptabstract '\n",
      " 'httpsdoiorg101371journalpone0012662 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids23056215doptabstract '\n",
      " 'httpsdoiorg101371journalpone0045718 httpsdoiorg101371journalpone0045718 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids22337105doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids22337105doptabstract '\n",
      " 'httpsdoiorg101097olq0b013e3182401a2f '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids23191950doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids23191950doptabstract '\n",
      " 'httpsdoiorg101097olq0b013e31826e870d '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids23321990doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids23321990doptabstract '\n",
      " 'httpsdoiorg101097olq0b013e31827938a1 recommendations and reports mmwr  july '\n",
      " '23 2021  vol 70  no 4 139us department of health and human servicescenters '\n",
      " 'for disease control and prevention  105 golden mr hogben m handsfield hh st '\n",
      " 'lawrence js potterat jj  holmes kk partner notification for hiv and std in '\n",
      " 'the united  states low coverage for gonorrhea chlamydial infection and hiv '\n",
      " 'sex  transm dis 200330490–6 pmid12782949 httpsdoi '\n",
      " 'org1010970000743520030600000004  106 katz da dombrowski jc kerani rp et al '\n",
      " 'integrating hiv testing  as an outcome of std partner services for men who '\n",
      " 'have sex with  men aids patient care stds 201630208–14 pmid27158848  '\n",
      " 'httpsdoiorg101089apc20160027  107 katz da dombrowski jc barry m spellman d '\n",
      " 'bell tr golden  mr std partner services to monitor and promote hiv '\n",
      " 'preexposure  prophylaxis use among men who have sex with men j acquir '\n",
      " 'immune  defic syndr 201980533–41 pmid30649032 httpsdoi '\n",
      " 'org101097qai0000000000001952  108 bocour a renaud tc udeagu cc shepard cw '\n",
      " 'hiv partner services  are associated with timely linkage to hiv medical care '\n",
      " 'aids  2013272961–3 pmid24189585 httpsdoiorg101097 qad0000000000000031  109 '\n",
      " 'tesoriero jm johnson bl hartmalloy r et al improving retention  in hiv care '\n",
      " 'through new york’s expanded partner services datato care pilot j public '\n",
      " 'health manag pract 201723255–63  pmid27902561 '\n",
      " 'httpsdoiorg101097phh0000000000000483  110 trelle s shang a nartey l cassell '\n",
      " 'ja low n improved effectiveness  of partner notification for patients with '\n",
      " 'sexually transmitted infections  systematic review bmj 2007334354 '\n",
      " 'pmid17237298 httpsdoi org101136bmj390794607417c  111 cdc recommendations for '\n",
      " 'partner services programs for hiv  infection syphilis gonorrhea and '\n",
      " 'chlamydial infection mmwr  recomm rep 200857no rr9 pmid18987617  112 thurman '\n",
      " 'ar shain rn holden ae champion jd perdue st piper  jm partner notification '\n",
      " 'of sexually transmitted infections a large  cohort of mexican american and '\n",
      " 'african american women sex transm  dis 200835136–40 pmid17898679 '\n",
      " 'httpsdoiorg101097 olq0b013e318151498f  113 kissinger pj niccolai lm magnus m '\n",
      " 'et al partner notification for  hiv and syphilis effects on sexual behaviors '\n",
      " 'and relationship stability  sex transm dis 20033075–82 pmid12514447 httpsdoi '\n",
      " 'org1010970000743520030100000015  114 smith sg zhang x basile kc et al the '\n",
      " 'national intimate partner  and sexual violence survey 2015 data '\n",
      " 'brief—updated release atlanta  ga us department of health and human services '\n",
      " 'cdc national  center for injury prevention and control 2018 httpswwwcdcgov '\n",
      " 'violencepreventionpdf2015databrief508pdf  115 wilson te hogben m malka es et '\n",
      " 'al a randomized controlled trial  for reducing risks for sexually '\n",
      " 'transmitted infections through enhanced  patientbased partner notification '\n",
      " 'am j public health 200999suppl  1 s104–10 pmid18556619 httpsdoi org102105 '\n",
      " 'ajph2007112128  116 yu yy frasurewilliams ja dunne ef bolan g markowitz l '\n",
      " 'bauer  hm chlamydia partner services for females in california family  '\n",
      " 'planning clinics sex transm dis 201138913–8 pmid21934563  '\n",
      " 'httpsdoiorg101097olq0b013e3182240366  117 mickiewicz t altayyib a thrun m '\n",
      " 'rietmeijer c implementation  and effectiveness of an expedited partner '\n",
      " 'therapy program in an urban  clinic sex transm dis 201239923–9 pmid23169171 '\n",
      " 'httpsdoi org101097olq0b013e3182756f20  118 kachur r strona fv kinsey j '\n",
      " 'collins d introducing technology  into partner services a toolkit for '\n",
      " 'programs atlanta ga us  department of health and human services cdc 2015 '\n",
      " 'httpswww cdcgovstdprogramipsipstoolkit12282015pdf  119 kachur r hall w coor '\n",
      " 'a kinsey j collins d strona fv the use  of technology for sexually '\n",
      " 'transmitted disease partner services in the  united states a structured '\n",
      " 'review sex transm dis 201845707–12  pmid29771868 '\n",
      " 'httpsdoiorg101097olq0000000000000864  120 pellowski j mathews c kalichman mo '\n",
      " 'dewing s lurie mn  kalichman sc advancing partner notification through '\n",
      " 'electronic  communication technology a review of acceptability and '\n",
      " 'utilization  research j health commun 201621629–37 pmid27144318  '\n",
      " 'httpsdoiorg1010801081073020151128020  121 borchardt ln pickett ml tan kt '\n",
      " 'visotcky am drendel al  expedited partner therapy pharmacist refusal of '\n",
      " 'legal prescriptions  sex transm dis 201845350–3 pmid29465689 httpsdoi '\n",
      " 'org101097olq0000000000000751  122 qin jz diniz cp coleman js pharmacylevel '\n",
      " 'barriers to implementing  expedited partner therapy in baltimore maryland am '\n",
      " 'j obstet  gynecol 2018218504e1–6 pmid29410060 httpsdoi '\n",
      " 'org101016jajog201801036  123 schillinger j slutsker j tsang l et al do '\n",
      " 'prescriptions for expedited  partner therapy get filled findings from a '\n",
      " 'multijurisdictional  evaluation us 2017–2018 sex transm infect 201995suppl  '\n",
      " '1a107  124 slutsker js tsang lb schillinger ja do prescriptions for '\n",
      " 'expedited  partner therapy for chlamydia get filled findings from a multi '\n",
      " 'jurisdictional evaluation united states 2017–2019 sex transm dis  '\n",
      " '202047376–82 pmid32149956 httpsdoiorg101097 olq0000000000001163  125 golden '\n",
      " 'mr whittington wl handsfield hh et al effect of  expedited treatment of sex '\n",
      " 'partners on recurrent or persistent gonorrhea  or chlamydial infection n '\n",
      " 'engl j med 2005352676–85  pmid15716561 httpsdoiorg101056nejmoa041681  126 '\n",
      " 'schillinger ja kissinger p calvet h et al patientdelivered partner  '\n",
      " 'treatment with azithromycin to prevent repeated chlamydia trachomatis  '\n",
      " 'infection among women a randomized controlled trial sex transm  d i s  2 0 0 '\n",
      " '3  3 0  4 9 – 5 6   p m i d  1 2 5 1 4 4 4 3  h t t p s    d o i  '\n",
      " 'org1010970000743520030100000011  127 kissinger p mohammed h richardsonalston '\n",
      " 'g et al patient delivered partner treatment for male urethritis a randomized '\n",
      " 'controlled  trial clin infect dis 200541623–9 pmid16080084 httpsdoi '\n",
      " 'org101086432476  128 cameron st glasier a scott g et al novel interventions '\n",
      " 'to reduce  reinfection in women with chlamydia a randomized controlled '\n",
      " 'trial  hum reprod 200924888–95 pmid19136481 httpsdoi org101093humrepden475  '\n",
      " '129 kissinger p schmidt n mohammed h et al patientdelivered partner  '\n",
      " 'treatment for trichomonas vaginalis infection a randomized controlled  trial '\n",
      " 'sex transm dis 200633445–50 pmid16531939 httpsdoi '\n",
      " 'org10109701olq0000204511844854c  130 schwebke jr desmond ra a randomized '\n",
      " 'controlled trial of partner  notification methods for prevention of '\n",
      " 'trichomoniasis in women sex  transm dis 201037392–6 pmid20453720 '\n",
      " 'httpsdoiorg101097 olq0b013e3181dd1691  131 stephens sc bernstein kt katz mh '\n",
      " 'philip ss klausner jd the  effectiveness of patientdelivered partner therapy '\n",
      " 'and chlamydial and  gonococcal reinfection in san francisco sex transm dis '\n",
      " '201037525– 9 pmid20502392 httpsdoiorg101097olq0b013e3181d8920f  132 kerani '\n",
      " 'rp fleming m deyoung b golden mr a randomized  controlled trial of inspot '\n",
      " 'and patientdelivered partner therapy for  gonorrhea and chlamydial infection '\n",
      " 'among men who have sex with  men sex transm dis 201138941–6 pmid21934569 '\n",
      " 'httpsdoi org101097olq0b013e318223fcbc  133 stekler j bachmann l brotman rm '\n",
      " 'et al concurrent sexually  transmitted infections stis in sex partners of '\n",
      " 'patients with selected  stis implications for patientdelivered partner '\n",
      " 'therapy clin infect  di s  2 0 0 5  4 0  7 8 7 – 9 3   p m i d  1 5 7 3 6 0 '\n",
      " '0 9  h t t p s    d o i  org101086428043  134 mcnulty a teh mf freedman e '\n",
      " 'patient delivered partner therapy  for chlamydial infection—what would be '\n",
      " 'missed sex transm dis  200835834–6 pmid18580822 httpsdoiorg101097 '\n",
      " 'olq0b013e3181761993 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids12782949doptabstract '\n",
      " 'httpsdoiorg1010970000743520030600000004 '\n",
      " 'httpsdoiorg1010970000743520030600000004 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids27158848doptabstract '\n",
      " 'httpsdoiorg101089apc20160027 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30649032doptabstract '\n",
      " 'httpsdoiorg101097qai0000000000001952 httpsdoiorg101097qai0000000000001952 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids24189585doptabstract '\n",
      " 'httpsdoiorg101097qad0000000000000031 httpsdoiorg101097qad0000000000000031 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids27902561doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids27902561doptabstract '\n",
      " 'httpsdoiorg101097phh0000000000000483 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids17237298doptabstract '\n",
      " 'httpsdoiorg101136bmj390794607417c httpsdoiorg101136bmj390794607417c '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids18987617doptabstract '\n",
      " 'httpsdoiorg101097olq0b013e318151498f httpsdoiorg101097olq0b013e318151498f '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids12514447doptabstract '\n",
      " 'httpsdoiorg1010970000743520030100000015 '\n",
      " 'httpsdoiorg1010970000743520030100000015 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids18556619doptabstract '\n",
      " 'httpsdoiorg102105ajph2007112128 httpsdoiorg102105ajph2007112128 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids21934563doptabstract '\n",
      " 'httpsdoiorg101097olq0b013e3182240366 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids23169171doptabstract '\n",
      " 'httpsdoiorg101097olq0b013e3182756f20 httpsdoiorg101097olq0b013e3182756f20 '\n",
      " 'httpswwwcdcgovstdprogramipsipstoolkit12282015pdf '\n",
      " 'httpswwwcdcgovstdprogramipsipstoolkit12282015pdf '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29771868doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29771868doptabstract '\n",
      " 'httpsdoiorg101097olq0000000000000864 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids27144318doptabstract '\n",
      " 'httpsdoiorg1010801081073020151128020 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29465689doptabstract '\n",
      " 'httpsdoiorg101097olq0000000000000751 httpsdoiorg101097olq0000000000000751 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29410060doptabstract '\n",
      " 'httpsdoiorg101016jajog201801036 httpsdoiorg101016jajog201801036 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids32149956doptabstract '\n",
      " 'httpsdoiorg101097olq0000000000001163 httpsdoiorg101097olq0000000000001163 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids15716561doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids15716561doptabstract '\n",
      " 'httpsdoiorg101056nejmoa041681 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids12514443doptabstract '\n",
      " 'httpsdoiorg1010970000743520030100000011 '\n",
      " 'httpsdoiorg1010970000743520030100000011 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids16080084doptabstract '\n",
      " 'httpsdoiorg101086432476 httpsdoiorg101086432476 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids19136481doptabstract '\n",
      " 'httpsdoiorg101093humrepden475 httpsdoiorg101093humrepden475 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids16531939doptabstract '\n",
      " 'httpsdoiorg10109701olq0000204511844854c '\n",
      " 'httpsdoiorg10109701olq0000204511844854c '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids20453720doptabstract '\n",
      " 'httpsdoiorg101097olq0b013e3181dd1691 httpsdoiorg101097olq0b013e3181dd1691 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids20502392doptabstract '\n",
      " 'httpsdoiorg101097olq0b013e3181d8920f '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids21934569doptabstract '\n",
      " 'httpsdoiorg101097olq0b013e318223fcbc httpsdoiorg101097olq0b013e318223fcbc '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids15736009doptabstract '\n",
      " 'httpsdoiorg101086428043 httpsdoiorg101086428043 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids18580822doptabstract '\n",
      " 'httpsdoiorg101097olq0b013e3181761993 httpsdoiorg101097olq0b013e3181761993 '\n",
      " 'recommendations and reports 140 mmwr  july 23 2021  vol 70  no 4 us '\n",
      " 'department of health and human servicescenters for disease control and '\n",
      " 'prevention  135 schillinger j jamison k slutsker j et al sti and hiv '\n",
      " 'infections  among msm reporting exposure to gonorrhea or chlamydia  '\n",
      " 'implications for expedited partner therapy sex transm infect  2019 95 supp '\n",
      " 'l  1  a107   h t tp   dx do i  o r g 10 1136  sextrans2019sti272  136 turner '\n",
      " 'an feldblum pj hoke th baseline infection with a sexually  transmitted '\n",
      " 'disease is highly predictive of reinfection during followup  in malagasy sex '\n",
      " 'workers sex transm dis 201037559–62  pmid20716996 '\n",
      " 'httpsdoiorg101097olq0b013e3181d70a03  137 peterman ta tian lh metcalf ca et '\n",
      " 'al respect2 study group  high incidence of new sexually transmitted '\n",
      " 'infections in the year  following a sexually transmitted infection a case '\n",
      " 'for rescreening ann  intern med 2006145564–72 pmid17043338 httpsdoi '\n",
      " 'org10732600034819145820061017000005  138 owens dk davidson kw krist ah et al '\n",
      " 'us preventive services  task force screening for hiv infection us preventive '\n",
      " 'services task  force recommendation statement jama 20193212326–36  '\n",
      " 'pmid31184701 httpsdoiorg101001jama20196587  139 health and human services '\n",
      " 'panel on treatment of hivinfected  pregnant women and prevention of '\n",
      " 'perinatal transmission  recommendations for use of antiretroviral drugs in '\n",
      " 'pregnant hiv1 infected women for maternal health and interventions to '\n",
      " 'reduce  perinatal hiv transmission in the united states bethesda md us  '\n",
      " 'department of health and human services national institutes of  health '\n",
      " 'aidsinfo 2014 httpsnpincdcgovpublication '\n",
      " 'recommendationsuseantiretroviraldrugspregnanthiv1infected '\n",
      " 'womenmaternalhealth  140 committee on obstetric practice hiv expert work '\n",
      " 'group acog  committee opinion no 752 prenatal and perinatal human  '\n",
      " 'immunodeficiency virus testing obstet gynecol 2018132e138–42  pmid30134428 '\n",
      " 'httpsdoiorg101097aog0000000000002825  141 cdc sexually transmitted disease '\n",
      " 'surveillance 2019 internet atlanta  ga us department of health and human '\n",
      " 'services cdc 2021  httpswwwcdcgovstdstatistics2019defaulthtm  142 warren hp '\n",
      " 'cramer r kidd s leichliter js state requirements for  prenatal syphilis '\n",
      " 'screening in the united states 2016 matern child  health j 2018221227–32 '\n",
      " 'pmid30019155 httpsdoiorg101007 s1099501825920  143 lin js eder m bean s '\n",
      " 'screening for syphilis infection in pregnant  women a reaffirmation evidence '\n",
      " 'update for the us preventive services  task force evidence synthesis no 167 '\n",
      " 'ahrq publication no  1805238ef1 rockville md agency for healthcare research '\n",
      " 'and  quality 2018  144 neblett fanfair r tao g owusuedusei k gift tl '\n",
      " 'bernstein kt  suboptimal prenatal syphilis testing among commercially '\n",
      " 'insured  women in the united states 2013 sex transm dis 201744219–21  '\n",
      " 'pmid28282647 httpsdoiorg101097olq0000000000000569  145 patel cg huppert js '\n",
      " 'tao g provider adherence to syphilis testing  recommendations for women '\n",
      " 'delivering a stillbirth sex transm dis  201744685–90 pmid28876321 '\n",
      " 'httpsdoiorg101097 olq0000000000000656  146 matthias jm rahman mm newman dr '\n",
      " 'peterman ta effectiveness  of prenatal screening and treatment to prevent '\n",
      " 'congenital syphilis  louisiana and florida 2013–2014 sex transm dis '\n",
      " '201744498–502  pmid28703731 httpsdoiorg101097olq0000000000000638  147 '\n",
      " 'albright cm emerson jb werner ef hughes bl thirdtrimester  prenatal syphilis '\n",
      " 'screening a costeffectiveness analysis obstet gynecol  2015126479–85 '\n",
      " 'pmid26244531 httpsdoiorg101097 aog0000000000000997  148 owens dk davidson kw '\n",
      " 'krist ah et al us preventive services  task force screening for hepatitis b '\n",
      " 'virus infection in pregnant women  us preventive services task force '\n",
      " 'reaffirmation recommendation  statement jama 2019322349–54 pmid31334800 '\n",
      " 'httpsdoi org101001jama20199365  149 lefevre ml us preventive services task '\n",
      " 'force screening for  chlamydia and gonorrhea us preventive services task '\n",
      " 'force  recommendation statement ann intern med 2014161902–10  pmid25243785 '\n",
      " 'httpsdoiorg107326m141981  150 watts t stockman l martin j guilfoyle s '\n",
      " 'vergeront jm increased  risk for mothertoinfant transmission of hepatitis c '\n",
      " 'virus among  medicaid recipients—wisconsin 2011–2015 mmwr morb mortal  wkly '\n",
      " 'rep 2017661136–9 pmid29072864 httpsdoi org1015585mmwrmm6642a3  151 patrick '\n",
      " 'sw bauer am warren md jones tf wester c hepatitis c  virus infection among '\n",
      " 'women giving birth—tennessee and united  states 2009–2014 mmwr morb mortal '\n",
      " 'wkly rep 201766470–3  pmid28493860 httpsdoiorg1015585mmwrmm6618a3  152 '\n",
      " 'chappell ca hillier sl crowe d meyn la bogen dl krans ee  hepatitis c virus '\n",
      " 'screening among children exposed during pregnancy  pediatrics '\n",
      " '2018141e20173273 pmid29720535 httpsdoi org101542peds20173273  153 gowda c '\n",
      " 'kennedy s glover c prasad mr wang l honegger jr  enhanced identification of '\n",
      " 'maternal hepatitis c virus infection using  existing public health '\n",
      " 'surveillance systems paediatr perinat epidemiol  201832401–10 pmid29972246 '\n",
      " 'httpsdoiorg101111 ppe12481  154 waruingi w mhanna mj kumar d abughali n '\n",
      " 'hepatitis c virus  universal screening versus risk based selective screening '\n",
      " 'during  pregnancy j neonatal perinatal med 20158371–8 pmid26836823  '\n",
      " 'httpsdoiorg103233npm15915024  155 boudova s mark k elkamary ss riskbased '\n",
      " 'hepatitis c screening  in pregnancy is less reliable than universal '\n",
      " 'screening a retrospective  chart review open forum infect dis 20185ofy043 '\n",
      " 'pmid29564364  httpsdoiorg101093ofidofy043  156 schillie s wester c osborne m '\n",
      " 'wesolowski l ryerson ab cdc  recommendations for hepatitis c screening among '\n",
      " 'adults—united  states 2020 mmwr recomm rep 202069no rr2  pmid32271723 '\n",
      " 'httpsdoiorg1015585mmwrrr6902a1  157 moyer va us preventive services task '\n",
      " 'force screening for hepatitis c virus  infection in adults us preventive '\n",
      " 'services task force recommendation  statement ann intern med 2013159349–57 '\n",
      " 'pmid23798026  httpsdoiorg10732600034819159520130903000672  158 perkins rb '\n",
      " 'guido rs castle pe et al 2019 asccp riskbased  management consensus '\n",
      " 'guidelines committee 2019 asccp risk based management consensus guidelines '\n",
      " 'for abnormal cervical cancer  screening tests and cancer precursors j low '\n",
      " 'genit tract dis  202024102–31 pmid32243307 httpsdoiorg101097 '\n",
      " 'lgt0000000000000525  159 owens dk davidson kw krist ah et al us preventive '\n",
      " 'services  task force screening for bacterial vaginosis in pregnant persons '\n",
      " 'to  prevent preterm delivery us preventive services task force  '\n",
      " 'recommendation statement  jama 20203231286–92  pmid32259236 '\n",
      " 'httpsdoiorg101001jama20202684  160 american academy of pediatrics committee '\n",
      " 'on fetus and newborn  american college of obstetrics and gynecology '\n",
      " 'committee on obstetric  practice guidelines for perinatal care kilpatrick sj '\n",
      " 'papile la eds 8th  ed itasca il american academy of pediatrics and '\n",
      " 'washington dc  american college of obstetrics and gynecology 2017  161 curry '\n",
      " 'sj krist ah owens dk et al us preventive services task  force screening for '\n",
      " 'syphilis infection in pregnant women us  preventive services task force '\n",
      " 'reaffirmation recommendation  statement jama 2018320911–7 pmid30193283 '\n",
      " 'httpsdoi org101001jama201811785  162 bibbinsdomingo k grossman dc curry sj '\n",
      " 'et al us preventive  services task force serologic screening for genital '\n",
      " 'herpes infection  us preventive services task force recommendation statement '\n",
      " 'jama  20163162525–30 pmid27997659 httpsdoiorg101001 jama201616776 '\n",
      " 'httpdxdoiorg101136sextrans2019sti272 httpdxdoiorg101136sextrans2019sti272 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids20716996doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids20716996doptabstract '\n",
      " 'httpsdoiorg101097olq0b013e3181d70a03 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids17043338doptabstract '\n",
      " 'httpsdoiorg10732600034819145820061017000005 '\n",
      " 'httpsdoiorg10732600034819145820061017000005 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids31184701doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids31184701doptabstract '\n",
      " 'httpsdoiorg101001jama20196587 '\n",
      " 'httpsnpincdcgovpublicationrecommendationsuseantiretroviraldrugspregnanthiv1infectedwomenmaternalhealth '\n",
      " 'httpsnpincdcgovpublicationrecommendationsuseantiretroviraldrugspregnanthiv1infectedwomenmaternalhealth '\n",
      " 'httpsnpincdcgovpublicationrecommendationsuseantiretroviraldrugspregnanthiv1infectedwomenmaternalhealth '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30134428doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30134428doptabstract '\n",
      " 'httpsdoiorg101097aog0000000000002825 '\n",
      " 'httpswwwcdcgovstdstatistics2019defaulthtm '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30019155doptabstract '\n",
      " 'httpsdoiorg101007s1099501825920 httpsdoiorg101007s1099501825920 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28282647doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28282647doptabstract '\n",
      " 'httpsdoiorg101097olq0000000000000569 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28876321doptabstract '\n",
      " 'httpsdoiorg101097olq0000000000000656 httpsdoiorg101097olq0000000000000656 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28703731doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28703731doptabstract '\n",
      " 'httpsdoiorg101097olq0000000000000638 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids26244531doptabstract '\n",
      " 'httpsdoiorg101097aog0000000000000997 httpsdoiorg101097aog0000000000000997 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids31334800doptabstract '\n",
      " 'httpsdoiorg101001jama20199365 httpsdoiorg101001jama20199365 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids25243785doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids25243785doptabstract '\n",
      " 'httpsdoiorg107326m141981 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29072864doptabstract '\n",
      " 'httpsdoiorg1015585mmwrmm6642a3 httpsdoiorg1015585mmwrmm6642a3 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28493860doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28493860doptabstract '\n",
      " 'httpsdoiorg1015585mmwrmm6618a3 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29720535doptabstract '\n",
      " 'httpsdoiorg101542peds20173273 httpsdoiorg101542peds20173273 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29972246doptabstract '\n",
      " 'httpsdoiorg101111ppe12481 httpsdoiorg101111ppe12481 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids26836823doptabstract '\n",
      " 'httpsdoiorg103233npm15915024 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29564364doptabstract '\n",
      " 'httpsdoiorg101093ofidofy043 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids32271723doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids32271723doptabstract '\n",
      " 'httpsdoiorg1015585mmwrrr6902a1 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids23798026doptabstract '\n",
      " 'httpsdoiorg10732600034819159520130903000672 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids32243307doptabstract '\n",
      " 'httpsdoiorg101097lgt0000000000000525 httpsdoiorg101097lgt0000000000000525 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids32259236doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids32259236doptabstract '\n",
      " 'httpsdoiorg101001jama20202684 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30193283doptabstract '\n",
      " 'httpsdoiorg101001jama201811785 httpsdoiorg101001jama201811785 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids27997659doptabstract '\n",
      " 'httpsdoiorg101001jama201616776 httpsdoiorg101001jama201616776 '\n",
      " 'recommendations and reports mmwr  july 23 2021  vol 70  no 4 141us '\n",
      " 'department of health and human servicescenters for disease control and '\n",
      " 'prevention  163 selph ss bougatsos c dana t grusing s chou r screening for  '\n",
      " 'hiv infection in pregnant women updated evidence report and  systematic '\n",
      " 'review for the us preventive services task force jama  20193212349–60 '\n",
      " 'pmid31184704 httpsdoiorg101001 jama20192593  164 henderson jt webber em bean '\n",
      " 'si screening for hepatitis b  infection in pregnant women updated evidence '\n",
      " 'report and systematic  review for the us preventive services task force jama '\n",
      " '2019322360–2  pmid31334780 httpsdoiorg101001jama20191655  165 leichliter js '\n",
      " 'dittus pj copen ce aral so trends in factors indicating  increased risk for '\n",
      " 'sti among key subpopulations in the united states  2002–2015 sex transm '\n",
      " 'infect 202096121–3 pmid31350378  httpsdoiorg101136sextrans2019054045  166 '\n",
      " 'committee on adolescence council on clinical and information  technology '\n",
      " 'blythe mj del beccaro ma standards for health  information technology to '\n",
      " 'ensure adolescent privacy pediatrics  2012130987–90 pmid23109684 '\n",
      " 'httpsdoiorg101542 peds20122580  167 acog committee opinion no 599 committee '\n",
      " 'on adolescent health  care adolescent confidentiality and electronic health '\n",
      " 'records obstet  gynecol 20141231148–50 pmid24785881 httpsdoi '\n",
      " 'org10109701aog00004468250871598  168 thompson la martinko t budd p mercado r '\n",
      " 'schentrup am  meaningful use of a confidential adolescent patient portal j '\n",
      " 'adolesc  health 201658134–40 pmid26802988 httpsdoiorg101016j '\n",
      " 'jadohealth201510015  169 society for adolescent health and medicine american '\n",
      " 'academy of  pediatrics confidentiality protections for adolescents and young '\n",
      " 'adults  in the health care billing and insurance claims process j adolesc '\n",
      " 'health  201658374–7 pmid26903437 httpsdoiorg101016j jadohealth201512009  170 '\n",
      " 'bamberger dm graham g dennis l gerkovich mm extragenital  gonorrhea and '\n",
      " 'chlamydia among men and women according to type  of sexual exposure sex '\n",
      " 'transm dis 201946329–34 pmid30676485  httpsdoiorg101097olq0000000000000967  '\n",
      " '171 chan pa robinette a montgomery m et al extragenital infections  caused '\n",
      " 'by chlamydia trachomatis and neisseria gonorrhoeae a review of  the '\n",
      " 'literature infect dis obstet gynecol 201620165758387  pmid27366021 '\n",
      " 'httpsdoiorg10115520165758387  172 owusuedusei k jr hoover kw gift tl '\n",
      " 'costeffectiveness of optout  chlamydia testing for highrisk young women in '\n",
      " 'the us am j prev  med 201651216–24 pmid26952078 httpsdoiorg101016j '\n",
      " 'amepre201601007  173 diclemente rj sales jm danner f crosby ra association '\n",
      " 'between  sexually transmitted diseases and young adults’ selfreported '\n",
      " 'abstinence  pediatrics 2011127208–13 pmid21199852 httpsdoi '\n",
      " 'org101542peds20090892  174 curry sj krist ah owens dk et al us preventive '\n",
      " 'services task  force screening for cervical cancer us preventive services '\n",
      " 'task force  recommendat ion s ta tement   jama 2018320674–86  pmid30140884 '\n",
      " 'httpsdoiorg101001jama201810897  175 committee on practice '\n",
      " 'bulletins—gynecology practice bulletin no  157 cervical cancer screening and '\n",
      " 'prevention obstet gynecol  2016127e1–20 pmid26695583 httpsdoiorg101097 '\n",
      " 'aog0000000000001263  176 benard vb watson m castle pe saraiya m cervical '\n",
      " 'carcinoma rates  among young females in the united states obstet gynecol  '\n",
      " '20121201117–23 pmid23090530 httpsdoiorg101097 aog0b013e31826e4609  177 '\n",
      " 'fontham eth wolf amd church tr et al cervical cancer screening  for '\n",
      " 'individuals at average risk 2020 guideline update from the american  cancer '\n",
      " 'society ca cancer j clin 202070321–46 pmid32729638  '\n",
      " 'httpsdoiorg103322caac21628  178 owens dk davidson kw krist ah et al us '\n",
      " 'preventive services  task force preexposure prophylaxis for the prevention '\n",
      " 'of hiv  infection us preventive services task force recommendation  '\n",
      " 'statement jama 20193212203–13 pmid31184747 httpsdoi org101001jama20196390  '\n",
      " '179 mayer kh bekker lg stall r grulich ae colfax g lama jr  comprehensive '\n",
      " 'clinical care for men who have sex with men an  integrated approach lancet '\n",
      " '2012380378–87 pmid22819653  httpsdoiorg101016s0140673612608356  180 '\n",
      " 'buchbinder sp vittinghoff e heagerty pj et al sexual risk nitrite  inhalant '\n",
      " 'use and lack of circumcision associated with hiv  seroconversion in men who '\n",
      " 'have sex with men in the united states  j acquir immune defic syndr '\n",
      " '20053982–9 pmid15851918  httpsdoiorg10109701qai000013474041585f4  181 '\n",
      " 'pazbailey g mendoza mc finlayson t et al nhbs study group  trends in condom '\n",
      " 'use among msm in the united states the role of  antiretroviral therapy and '\n",
      " 'seroadaptive strategies aids  2016301985–90 pmid27149088 httpsdoiorg101097 '\n",
      " 'qad0000000000001139  182 spicknall ih gift tl bernstein kt aral so sexual '\n",
      " 'networks and  infection transmission networks among men who have sex with '\n",
      " 'men  as causes of disparity and targets of prevention sex transm infect  '\n",
      " '201793307–8 pmid28389442 httpsdoiorg101136 sextrans2016052676  183 glick sn '\n",
      " 'morris m foxman b et al a comparison of sexual behavior  patterns among men '\n",
      " 'who have sex with men and heterosexual men  and women j acquir immune defic '\n",
      " 'syndr 20126083–90  pmid22522237 httpsdoiorg101097qai0b013e318247925e  184 '\n",
      " 'goodreau sm golden mr biological and demographic causes of  high hiv and '\n",
      " 'sexually transmitted disease prevalence in men who have  sex with men sex '\n",
      " 'transm infect 200783458–62 pmid17855487  httpsdoiorg101136sti2007025627  185 '\n",
      " 'chew ng ra samuel mc lo t et al sex drugs methamphetamines  and the internet '\n",
      " 'increasing syphilis among men who have sex with  men in california 2004–2008 '\n",
      " 'am j public health 20131031450–6  pmid23153138 '\n",
      " 'httpsdoiorg102105ajph2012300808  186 bernstein kt stephens sc strona fv kohn '\n",
      " 'rp philip ss  epidemiologic characteristics of an ongoing syphilis epidemic '\n",
      " 'among  men who have sex with men san francisco sex transm dis  20134011–7 '\n",
      " 'pmid23254114 httpsdoiorg101097 olq0b013e31827763ea  187 cohen se chew ng ra '\n",
      " 'katz ka et al repeat syphilis among men  who have sex with men in california '\n",
      " '2002–2006 implications for  syphilis elimination efforts am j public health '\n",
      " '2012102e1–8  pmid22095364 httpsdoiorg102105ajph2011300383  188 kirkcaldy rd '\n",
      " 'harvey a papp jr et al neisseria gonorrhoeae  antimicrobial susceptibility '\n",
      " 'surveillance—the gonococcal isolate  surveillance project 27 sites united '\n",
      " 'states 2014 mmwr surveill  summ 201665no ss7 pmid27414503 httpsdoiorg1015585 '\n",
      " 'mmwrss6507a1  189 kirkcaldy rd zaidi a hook ew 3rd et al   neisseria  '\n",
      " 'gonorrhoeae antimicrobial resistance among men who have sex  with men and '\n",
      " 'men who have sex exclusively with women  the gonococcal isolate surveillance '\n",
      " 'project 2005–2010 ann  intern med 2013158321–8 pmid23460055 httpsdoi '\n",
      " 'org10732600034819158520130305000004  190 newman lm dowell d bernstein k et '\n",
      " 'al a tale of two gonorrhea  epidemics results from the std surveillance '\n",
      " 'network public health  rep  2012 127 282–92   pmid22547859 h t tp s   do i  '\n",
      " 'org101177003335491212700308  191 hess kl hu x lansky a mermin j hall hi '\n",
      " 'lifetime risk of a  diagnosis of hiv infection in the united states ann '\n",
      " 'epidemiol  201727238–43 pmid28325538 httpsdoiorg101016j annepidem201702003 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids31184704doptabstract '\n",
      " 'httpsdoiorg101001jama20192593 httpsdoiorg101001jama20192593 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids31334780doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids31334780doptabstract '\n",
      " 'httpsdoiorg101001jama20191655 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids31350378doptabstract '\n",
      " 'httpsdoiorg101136sextrans2019054045 httpsdoiorg101542peds20122580 '\n",
      " 'httpsdoiorg101542peds20122580 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids24785881doptabstract '\n",
      " 'httpsdoiorg10109701aog00004468250871598 '\n",
      " 'httpsdoiorg10109701aog00004468250871598 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids26802988doptabstract '\n",
      " 'httpsdoiorg101016jjadohealth201510015 httpsdoiorg101016jjadohealth201510015 '\n",
      " 'httpsdoiorg101016jjadohealth201512009 httpsdoiorg101016jjadohealth201512009 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30676485doptabstract '\n",
      " 'httpsdoiorg101097olq0000000000000967 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids27366021doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids27366021doptabstract '\n",
      " 'httpsdoiorg10115520165758387 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids26952078doptabstract '\n",
      " 'httpsdoiorg101016jamepre201601007 httpsdoiorg101016jamepre201601007 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids21199852doptabstract '\n",
      " 'httpsdoiorg101542peds20090892 httpsdoiorg101542peds20090892 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30140884doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30140884doptabstract '\n",
      " 'httpsdoiorg101001jama201810897 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids26695583doptabstract '\n",
      " 'httpsdoiorg101097aog0000000000001263 httpsdoiorg101097aog0000000000001263 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids23090530doptabstract '\n",
      " 'httpsdoiorg101097aog0b013e31826e4609 httpsdoiorg101097aog0b013e31826e4609 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids32729638doptabstract '\n",
      " 'httpsdoiorg103322caac21628 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids31184747doptabstract '\n",
      " 'httpsdoiorg101001jama20196390 httpsdoiorg101001jama20196390 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids22819653doptabstract '\n",
      " 'httpsdoiorg101016s0140673612608356 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids15851918doptabstract '\n",
      " 'httpsdoiorg10109701qai000013474041585f4 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids27149088doptabstract '\n",
      " 'httpsdoiorg101097qad0000000000001139 httpsdoiorg101097qad0000000000001139 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28389442doptabstract '\n",
      " 'httpsdoiorg101136sextrans2016052676 httpsdoiorg101136sextrans2016052676 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids22522237doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids22522237doptabstract '\n",
      " 'httpsdoiorg101097qai0b013e318247925e '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids17855487doptabstract '\n",
      " 'httpsdoiorg101136sti2007025627 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids23153138doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids23153138doptabstract '\n",
      " 'httpsdoiorg102105ajph2012300808 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids23254114doptabstract '\n",
      " 'httpsdoiorg101097olq0b013e31827763ea httpsdoiorg101097olq0b013e31827763ea '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids22095364doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids22095364doptabstract '\n",
      " 'httpsdoiorg102105ajph2011300383 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids27414503doptabstract '\n",
      " 'httpsdoiorg1015585mmwrss6507a1 httpsdoiorg1015585mmwrss6507a1 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids23460055doptabstract '\n",
      " 'httpsdoiorg10732600034819158520130305000004 '\n",
      " 'httpsdoiorg10732600034819158520130305000004 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids22547859doptabstract '\n",
      " 'httpsdoiorg101177003335491212700308 httpsdoiorg101177003335491212700308 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28325538doptabstract '\n",
      " 'httpsdoiorg101016jannepidem201702003 httpsdoiorg101016jannepidem201702003 '\n",
      " 'recommendations and reports 142 mmwr  july 23 2021  vol 70  no 4 us '\n",
      " 'department of health and human servicescenters for disease control and '\n",
      " 'prevention  192 patel p borkowf cb brooks jt lasry a lansky a mermin j  '\n",
      " 'estimating peract hiv transmission risk a systematic review aids  '\n",
      " '2014281509–19 pmid24809629 httpsdoiorg101097 qad0000000000000298  193 koblin '\n",
      " 'ba husnik mj colfax g et al risk factors for  hiv infection among men who '\n",
      " 'have sex with men aids  200620731–9 pmid16514304 httpsdoiorg10109701 '\n",
      " 'aids00002163746144255  194 ackers ml greenberg ae lin cy et al high and '\n",
      " 'persistent hiv  seroincidence in men who have sex with men across 47 us '\n",
      " 'cities  plos one 20127e34972 pmid22529964 httpsdoiorg101371 '\n",
      " 'journalpone0034972  195 zetola nm bernstein kt wong e louie b klausner jd '\n",
      " 'exploring  the relationship between sexually transmitted diseases and hiv  '\n",
      " 'acquisition by using different study designs j acquir immune defic  syndr '\n",
      " '200950546–51 pmid19367993 httpsdoiorg101097 qai0b013e318195bd2b  196 solomon '\n",
      " 'mm mayer kh glidden dv et al iprex study team  syphilis predicts hiv '\n",
      " 'incidence among men and transgender women  who have sex with men in a '\n",
      " 'preexposure prophylaxis trial clin infect  dis 2014591020–6 pmid24928295 '\n",
      " 'httpsdoiorg101093cid ciu450  197 fleming dt wasserheit jn from '\n",
      " 'epidemiological synergy to public  health policy and practice the '\n",
      " 'contribution of other sexually  transmitted diseases to sexual transmission '\n",
      " 'of hiv infection sex  transm infect 1999753–17 pmid10448335 httpsdoi '\n",
      " 'org101136sti7513  198 freeman ee weiss ha glynn jr cross pl whitworth ja '\n",
      " 'hayes  rj herpes simplex virus 2 infection increases hiv acquisition in men  '\n",
      " 'and women systematic review and metaanalysis of longitudinal studies  aids '\n",
      " '20062073–83 pmid16327322 httpsdoiorg10109701 aids000019808109337a7  199 '\n",
      " 'reynolds sj risbud ar shepherd me et al high rates of syphilis  among sti '\n",
      " 'patients are contributing to the spread of hiv1 in india  sex transm infect '\n",
      " '200682121–6 pmid16581736 httpsdoi org101136sti2005015040  200 hoots be '\n",
      " 'wejnert c martin a et al nhbs study group  undisclosed hiv infection among '\n",
      " 'msm in a behavioral surveillance  study aids 201933913–8 pmid30649053 '\n",
      " 'httpsdoi org101097qad0000000000002147  201 dolling di desai m mcowan a et al '\n",
      " 'proud study group an  analysis of baseline data from the proud study an '\n",
      " 'openlabel  randomised trial of preexposure prophylaxis trials 201617163  '\n",
      " 'pmid27013513 httpsdoiorg101186s1306301612864  202 oldenburg ce nunn as '\n",
      " 'montgomery m et al behavioral changes  following uptake of hiv preexposure '\n",
      " 'prophylaxis among men who  have sex with men in a clinical setting aids '\n",
      " 'behav 2018221075–9  pmid28150120 httpsdoiorg101007s1046101717011  203 '\n",
      " 'montaño ma dombrowski jc dasgupta s et al changes in sexual  behavior and '\n",
      " 'sti diagnoses among msm initiating prep in a clinic  setting aids behav '\n",
      " '201923548–55 pmid30117076 httpsdoi org101007s1046101822529  204 traeger mw '\n",
      " 'schroeder se wright ej et al effects of preexposure  prophylaxis for the '\n",
      " 'prevention of human immunodeficiency virus  infection on sexual risk '\n",
      " 'behavior in men who have sex with men a  systematic review and metaanalysis '\n",
      " 'clin infect dis 201867676–86  pmid29509889 httpsdoiorg101093cidciy182  205 '\n",
      " 'jenness sm weiss km goodreau sm et al incidence of gonorrhea  and chlamydia '\n",
      " 'following human immunodeficiency virus preexposure  prophylaxis among men '\n",
      " 'who have sex with men a modeling study  clin infect dis 201765712–8 '\n",
      " 'pmid28505240 httpsdoi org101093cidcix439  206 tang ec vittinghoff e philip '\n",
      " 'ss et al quarterly screening optimizes  detection of sexually transmitted '\n",
      " 'infections when prescribing hiv  preexposure prophylaxis aids 2020341181–6 '\n",
      " 'pmid32205724  httpsdoiorg101097qad0000000000002522  207 barbee la khosropour '\n",
      " 'cm dombrowksi jc golden mr new  human immunodeficiency virus diagnosis '\n",
      " 'independently associated  with rectal gonorrhea and chlamydia in men who '\n",
      " 'have sex with men  sex transm dis 201744385–9 pmid28608786 httpsdoi '\n",
      " 'org101097olq0000000000000614  208 bernstein kt marcus jl nieri g philip ss '\n",
      " 'klausner jd rectal  gonorrhea and chlamydia reinfection is associated with '\n",
      " 'increased risk  of hiv seroconversion j acquir immune defic syndr '\n",
      " '201053537–43  pmid19935075 httpsdoiorg101097qai0b013e3181c3ef29  209 barbee '\n",
      " 'la khosropour cm dombrowski jc manhart le golden  mr an estimate of the '\n",
      " 'proportion of symptomatic gonococcal  chlamydial and nongonococcal '\n",
      " 'nonchlamydial urethritis attributable  to oral sex among men who have sex '\n",
      " 'with men a casecontrol study  sex transm infect 201692155–60 pmid26297719 '\n",
      " 'httpsdoi org101136sextrans2015052214  210 lafferty we hughes jp handsfield '\n",
      " 'hh sexually transmitted diseases  in men who have sex with men acquisition '\n",
      " 'of gonorrhea and  nongonococcal urethritis by fellatio and implications for '\n",
      " 'stdhiv  prevention sex transm dis 199724272–8 pmid9153736 https '\n",
      " 'doiorg1010970000743519970500000007  211 bernstein kt stephens sc barry pm et '\n",
      " 'al chlamydia trachomatis  and neisseria gonorrhoeae transmission from the '\n",
      " 'oropharynx to the  urethra among men who have sex with men clin infect dis  '\n",
      " '2009491793–7 pmid19911970 httpsdoiorg101086648427  212 patton me kidd s '\n",
      " 'llata e et al extragenital gonorrhea and chlamydia  testing and infection '\n",
      " 'among men who have sex with men—std  surveillance network united states '\n",
      " '2010–2012 clin infect dis  2014581564–70 pmid24647015 httpsdoiorg101093cid '\n",
      " 'ciu184  213 kent ck chaw jk wong w et al prevalence of rectal urethral and  '\n",
      " 'pharyngeal chlamydia and gonorrhea detected in 2 clinical settings  among '\n",
      " 'men who have sex with men san francisco california 2003  clin infect dis '\n",
      " '20054167–74 pmid15937765 httpsdoi org101086430704  214 koedijk fd van bergen '\n",
      " 'je dukersmuijrers nh van leeuwen ap  hoebe cj van der sande ma dutch sti '\n",
      " 'centres the value of testing  multiple anatomic sites for gonorrhoea and '\n",
      " 'chlamydia in sexually  transmitted infection centres in the netherlands '\n",
      " '2006–2010 int j std  aids 201223626–31 pmid23033514 httpsdoiorg101258 '\n",
      " 'ijsa2012011378  215 barbee la dombrowski jc kerani r golden mr effect of '\n",
      " 'nucleic  acid amplification testing on detection of extragenital gonorrhea '\n",
      " 'and  chlamydial infections in men who have sex with men sexually  '\n",
      " 'transmitted disease clinic patients sex transm dis 201441168–72  '\n",
      " 'pmid24521722 httpsdoiorg101097olq0000000000000093  216 danby cs cosentino la '\n",
      " 'rabe lk et al patterns of extragenital  chlamydia and gonorrhea in women and '\n",
      " 'men who have sex with men  reporting a history of receptive anal intercourse '\n",
      " 'sex transm dis  201643105–9 pmid26766527 httpsdoiorg101097 '\n",
      " 'olq0000000000000384  217 van der helm jj hoebe cj van rooijen ms et al high '\n",
      " 'performance  and acceptability of selfcollected rectal swabs for diagnosis '\n",
      " 'of  chlamydia trachomatis and neisseria gonorrhoeae in men who have sex  '\n",
      " 'with men and women sex transm dis 200936493–7 pmid19617869  '\n",
      " 'httpsdoiorg101097olq0b013e3181a44b8c  218 alexander s ison c parry j et al '\n",
      " 'brighton home sampling kits  steering group selftaken pharyngeal and rectal '\n",
      " 'swabs are appropriate  for the detection of chlamydia trachomatis and '\n",
      " 'neisseria gonorrhoeae  in asymptomatic men who have sex with men sex transm '\n",
      " 'infect  200884488–92 pmid19028953 httpsdoiorg101136 sti2008031443 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids24809629doptabstract '\n",
      " 'httpsdoiorg101097qad0000000000000298 httpsdoiorg101097qad0000000000000298 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids16514304doptabstract '\n",
      " 'httpsdoiorg10109701aids00002163746144255 '\n",
      " 'httpsdoiorg10109701aids00002163746144255 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids22529964doptabstract '\n",
      " 'httpsdoiorg101371journalpone0034972 httpsdoiorg101371journalpone0034972 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids19367993doptabstract '\n",
      " 'httpsdoiorg101097qai0b013e318195bd2b httpsdoiorg101097qai0b013e318195bd2b '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids24928295doptabstract '\n",
      " 'httpsdoiorg101093cidciu450 httpsdoiorg101093cidciu450 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids10448335doptabstract '\n",
      " 'httpsdoiorg101136sti7513 httpsdoiorg101136sti7513 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids16327322doptabstract '\n",
      " 'httpsdoiorg10109701aids000019808109337a7 '\n",
      " 'httpsdoiorg10109701aids000019808109337a7 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids16581736doptabstract '\n",
      " 'httpsdoiorg101136sti2005015040 httpsdoiorg101136sti2005015040 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30649053doptabstract '\n",
      " 'httpsdoiorg101097qad0000000000002147 httpsdoiorg101097qad0000000000002147 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids27013513doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids27013513doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28150120doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28150120doptabstract '\n",
      " 'httpsdoiorg101007s1046101717011 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30117076doptabstract '\n",
      " 'httpsdoiorg101007s1046101822529 httpsdoiorg101007s1046101822529 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29509889doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29509889doptabstract '\n",
      " 'httpsdoiorg101093cidciy182 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28505240doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids32205724doptabstract '\n",
      " 'httpsdoiorg101097qad0000000000002522 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28608786doptabstract '\n",
      " 'httpsdoiorg101097olq0000000000000614 httpsdoiorg101097olq0000000000000614 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids19935075doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids19935075doptabstract '\n",
      " 'httpsdoiorg101097qai0b013e3181c3ef29 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids26297719doptabstract '\n",
      " 'httpsdoiorg101136sextrans2015052214 httpsdoiorg101136sextrans2015052214 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids9153736doptabstract '\n",
      " 'httpsdoiorg1010970000743519970500000007 '\n",
      " 'httpsdoiorg1010970000743519970500000007 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids19911970doptabstract '\n",
      " 'httpsdoiorg101086648427 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids24647015doptabstract '\n",
      " 'httpsdoiorg101093cidciu184 httpsdoiorg101093cidciu184 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids15937765doptabstract '\n",
      " 'httpsdoiorg101086430704 httpsdoiorg101086430704 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids23033514doptabstract '\n",
      " 'httpsdoiorg101258ijsa2012011378 httpsdoiorg101258ijsa2012011378 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids24521722doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids24521722doptabstract '\n",
      " 'httpsdoiorg101097olq0000000000000093 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids26766527doptabstract '\n",
      " 'httpsdoiorg101097olq0000000000000384 httpsdoiorg101097olq0000000000000384 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids19617869doptabstract '\n",
      " 'httpsdoiorg101097olq0b013e3181a44b8c '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids19028953doptabstract '\n",
      " 'httpsdoiorg101136sti2008031443 httpsdoiorg101136sti2008031443 '\n",
      " 'recommendations and reports mmwr  july 23 2021  vol 70  no 4 143us '\n",
      " 'department of health and human servicescenters for disease control and '\n",
      " 'prevention  219 freeman ah bernstein kt kohn rp philip s rauch lm klausner  '\n",
      " 'jd evaluation of selfcollected versus cliniciancollected swabs for the  '\n",
      " 'detection of chlamydia trachomatis and neisseria gonorrhoeae pharyngeal  '\n",
      " 'infection among men who have sex with men sex transm dis  2011381036–9 '\n",
      " 'pmid21992980 httpsdoiorg101097 olq0b013e318227713e  220 chesson hw bernstein '\n",
      " 'kt gift tl marcus jl pipkin s kent ck  the costeffectiveness of screening '\n",
      " 'men who have sex with men for  rectal chlamydial and gonococcal infection to '\n",
      " 'prevent hiv infection  sex transm dis 201340366–71 pmid23588125 httpsdoi '\n",
      " 'org101097olq0b013e318284e544  221 jenness sm weiss km prasad p zlotorzynska '\n",
      " 'm sanchez t bacterial  sexually transmitted infection screening rates by '\n",
      " 'symptomatic status  among men who have sex with men in the united states a '\n",
      " 'hierarchical  bayesian analysis sex transm dis 20194625–30 pmid30044334  '\n",
      " 'httpsdoiorg101097olq0000000000000896  222 hoover kw butler m workowski k et '\n",
      " 'al evaluation group for  adherence to std and hepatitis screening std '\n",
      " 'screening of hiv infected msm in hiv clinics sex transm dis 201037771–6  '\n",
      " 'pmid20585275 httpsdoiorg101097olq0b013e3181e50058  223 de voux a bernstein '\n",
      " 'kt bradley h kirkcaldy rd tie y shouse rl  medical monitoring project '\n",
      " 'syphilis testing among sexually active  men who have sex with men and who '\n",
      " 'are receiving medical care for  human immunodeficiency virus in the united '\n",
      " 'states medical  monitoring project 2013–2014 clin infect dis 201968934–9  '\n",
      " 'pmid29985985 httpsdoiorg101093cidciy571  224 gray rt hoare a prestage gp '\n",
      " 'donovan b kaldor jm wilson dp  frequent testing of highly sexually active '\n",
      " 'gay men is required to control  syphilis sex transm dis 201037298–305 '\n",
      " 'pmid20393383 https doiorg101097olq0b013e3181ca3c0a  225 tuite ar fisman dn '\n",
      " 'mishra s screen more or screen more often  using mathematical models to '\n",
      " 'inform syphilis control strategies bmc  public health 201313606 pmid23800206 '\n",
      " 'httpsdoi org1011861471245813606  226 tuite a fisman d go big or go home '\n",
      " 'impact of screening coverage  on syphilis infection dynamics sex transm '\n",
      " 'infect 20169249–54  pmid25954016 httpsdoiorg101136sextrans2014052001  227 '\n",
      " 'tuite ar shaw s reimer jn ross cp fisman dn mishra s can  enhanced screening '\n",
      " 'of men with a history of prior syphilis infection  stem the epidemic in men '\n",
      " 'who have sex with men a mathematical  modelling study sex transm infect '\n",
      " '201894105–10 pmid28705938  httpsdoiorg101136sextrans2017053201  228 raifman '\n",
      " 'jr gebo ka mathews wc et al hiv research network  gonorrhea and chlamydia '\n",
      " 'case detection increased when testing  increased in a multisite us hiv '\n",
      " 'cohort 2004–2014 j acquir immune  defic syndr 201776409–16 pmid28777262 '\n",
      " 'httpsdoi org101097qai0000000000001514  229 barbee la dhanireddy s tat sa '\n",
      " 'marrazzo jm barriers to bacterial  sexually transmitted infection testing of '\n",
      " 'hivinfected men who have  sex with men engaged in hiv primary care sex '\n",
      " 'transm dis  201542590–4 pmid26372931 httpsdoiorg101097 olq0000000000000320  '\n",
      " '230 mcmillan a young h moyes a rectal gonorrhoea in homosexual  men source '\n",
      " 'of infection int j std aids 200011284–7  pmid10824935 '\n",
      " 'httpsdoiorg101177095646240001100502  231 chow ep cornelisse vj read tr chen '\n",
      " 'my bradshaw cs fairley  ck saliva use in sex associations with use of '\n",
      " 'smartphone dating  applications in men who have sex with men int j std aids  '\n",
      " '2 0 1 8  2 9  3 6 2 – 6   p m i d  2 8 8 3 5 1 9 7  h t t p s    d o i  '\n",
      " 'org1011770956462417727669  232 cornelisse vj priest d fairley ck et al the '\n",
      " 'frequency of kissing as  part of sexual activity differs depending on how '\n",
      " 'men meet their male  casual sexual partners int j std aids 201829598–602  '\n",
      " 'pmid29256822 httpsdoiorg1011770956462417748717  233 krist ah davidson kw '\n",
      " 'mangione cm et al us preventive services  task force screening for hepatitis '\n",
      " 'b virus infection in adolescents and  adults us preventive services task '\n",
      " 'force recommendation statement  jama 20203242415–22 pmid33320230 '\n",
      " 'httpsdoiorg101001 jama202022980  234 tohme ra holmberg sd is sexual contact '\n",
      " 'a major mode of hepatitis  c virus transmission hepatology 2010521497–505 '\n",
      " 'pmid20635398  httpsdoiorg101002hep23808  235 wandeler g gsponer t bregenzer '\n",
      " 'a et al swiss hiv cohort study  hepatitis c virus infections in the swiss '\n",
      " 'hiv cohort study a rapidly  evolving epidemic clin infect dis 2012551408–16 '\n",
      " 'pmid22893583  httpsdoiorg101093cidcis694  236 garg s taylor le grasso c '\n",
      " 'mayer kh prevalent and incident  hepatitis c virus infection among '\n",
      " 'hivinfected men who have sex with  men engaged in primary care in a boston '\n",
      " 'community health center  clin infect dis 2013561480–7 pmid23386630 httpsdoi '\n",
      " 'org101093cidcit054  237 urbanus at van de laar tj stolte ig et al hepatitis '\n",
      " 'c virus infections  among hivinfected men who have sex with men an '\n",
      " 'expanding  epidemic aids 200923f1–7 pmid19542864 httpsdoi '\n",
      " 'org101097qad0b013e32832e5631  238 linas bp wong ay schackman br kim ay '\n",
      " 'freedberg ka cost effective screening for acute hepatitis c virus infection '\n",
      " 'in hivinfected  men who have sex with men clin infect dis 201255279–90  '\n",
      " 'pmid22491339 httpsdoiorg101093cidcis382  239 taylor le delong ak maynard ma '\n",
      " 'et al acute hepatitis c virus  in an hiv clinic a screening strategy risk '\n",
      " 'factors and perception of  risk aids patient care stds 201125571–7 '\n",
      " 'pmid21859307  httpsdoiorg101089apc20110106  240 kaul r kimani j nagelkerke '\n",
      " 'nj et al kibera hiv study group  monthly antibiotic chemoprophylaxis and '\n",
      " 'incidence of sexually  transmitted infections and hiv1 infection in kenyan '\n",
      " 'sex workers a  randomized controlled trial   jama 20042912555–62  '\n",
      " 'pmid15173146 httpsdoiorg101001jama291212555  241 ong jj baggaley rc wi te et '\n",
      " 'al global epidemiologic characteristics  of sexually transmitted infections '\n",
      " 'among individuals using preexposure  prophylaxis for the prevention of hiv '\n",
      " 'infection a systematic review and  metaanalysis jama netw open 20192e1917134 '\n",
      " 'pmid31825501  httpsdoiorg101001jamanetworkopen201917134  242 pazbailey g '\n",
      " 'hoots be xia m finlayson t prejean j purcell dw  nhbs study group trends in '\n",
      " 'internet use among men who have sex  with men in the united states j acquir '\n",
      " 'immune defic syndr  201775suppl 3s288–95 pmid28604430 httpsdoiorg101097 '\n",
      " 'qai0000000000001404  243 badal hj stryker je deluca n purcell dw swipe right '\n",
      " 'dating  website and app use among men who have sex with men aids behav  '\n",
      " '2018221265–72 pmid28884248 httpsdoiorg101007 s1046101718827  244 chan pa '\n",
      " 'crowley c rose js et al a network analysis of sexually  transmitted diseases '\n",
      " 'and online hookup sites among men who have sex  with men sex transm dis '\n",
      " '201845462–8 pmid29465663 https doiorg101097olq0000000000000784  245 beymer '\n",
      " 'mr weiss re bolan rk et al sex on demand geosocial  networking phone apps '\n",
      " 'and risk of sexually transmitted infections  among a crosssectional sample '\n",
      " 'of men who have sex with men in los  angeles county sex transm infect '\n",
      " '201490567–72 pmid24926041  httpsdoiorg101136sextrans2013051494  246 medina '\n",
      " 'mm crowley c montgomery mc et al disclosure of hiv  serostatus and '\n",
      " 'preexposure prophylaxis use on internet hookup sites  among men who have sex '\n",
      " 'with men aids behav 2019231681–8  pmid30267365 '\n",
      " 'httpsdoiorg101007s104610182286z  247 chan pa towey c poceta j et al online '\n",
      " 'hookup sites for meeting  sexual partners among men who have sex with men in '\n",
      " 'rhode island  2013 a call for public health action public health rep '\n",
      " '2016131264–71  pmid26957661 httpsdoiorg101177003335491613100210 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids21992980doptabstract '\n",
      " 'httpsdoiorg101097olq0b013e318227713e httpsdoiorg101097olq0b013e318227713e '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids23588125doptabstract '\n",
      " 'httpsdoiorg101097olq0b013e318284e544 httpsdoiorg101097olq0b013e318284e544 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30044334doptabstract '\n",
      " 'httpsdoiorg101097olq0000000000000896 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids20585275doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids20585275doptabstract '\n",
      " 'httpsdoiorg101097olq0b013e3181e50058 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29985985doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29985985doptabstract '\n",
      " 'httpsdoiorg101093cidciy571 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids20393383doptabstract '\n",
      " 'httpsdoiorg101097olq0b013e3181ca3c0a httpsdoiorg101097olq0b013e3181ca3c0a '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids23800206doptabstract '\n",
      " 'httpsdoiorg1011861471245813606 httpsdoiorg1011861471245813606 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids25954016doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids25954016doptabstract '\n",
      " 'httpsdoiorg101136sextrans2014052001 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28705938doptabstract '\n",
      " 'httpsdoiorg101136sextrans2017053201 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28777262doptabstract '\n",
      " 'httpsdoiorg101097qai0000000000001514 httpsdoiorg101097qai0000000000001514 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids26372931doptabstract '\n",
      " 'httpsdoiorg101097olq0000000000000320 httpsdoiorg101097olq0000000000000320 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids10824935doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids10824935doptabstract '\n",
      " 'httpsdoiorg101177095646240001100502 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28835197doptabstract '\n",
      " 'httpsdoiorg1011770956462417727669 httpsdoiorg1011770956462417727669 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29256822doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29256822doptabstract '\n",
      " 'httpsdoiorg1011770956462417748717 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids33320230doptabstract '\n",
      " 'httpsdoiorg101001jama202022980 httpsdoiorg101001jama202022980 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids20635398doptabstract '\n",
      " 'httpsdoiorg101002hep23808 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids22893583doptabstract '\n",
      " 'httpsdoiorg101093cidcis694 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids23386630doptabstract '\n",
      " 'httpsdoiorg101093cidcit054 httpsdoiorg101093cidcit054 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids19542864doptabstract '\n",
      " 'httpsdoiorg101097qad0b013e32832e5631 httpsdoiorg101097qad0b013e32832e5631 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids22491339doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids22491339doptabstract '\n",
      " 'httpsdoiorg101093cidcis382 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids21859307doptabstract '\n",
      " 'httpsdoiorg101089apc20110106 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids15173146doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids15173146doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids31825501doptabstract '\n",
      " 'httpsdoiorg101001jamanetworkopen201917134 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28604430doptabstract '\n",
      " 'httpsdoiorg101097qai0000000000001404 httpsdoiorg101097qai0000000000001404 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28884248doptabstract '\n",
      " 'httpsdoiorg101007s1046101718827 httpsdoiorg101007s1046101718827 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29465663doptabstract '\n",
      " 'httpsdoiorg101097olq0000000000000784 httpsdoiorg101097olq0000000000000784 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids24926041doptabstract '\n",
      " 'httpsdoiorg101136sextrans2013051494 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30267365doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30267365doptabstract '\n",
      " 'httpsdoiorg101007s104610182286z '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids26957661doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids26957661doptabstract '\n",
      " 'httpsdoiorg101177003335491613100210 recommendations and reports 144 mmwr  '\n",
      " 'july 23 2021  vol 70  no 4 us department of health and human servicescenters '\n",
      " 'for disease control and prevention  248 lampkin d crawley a lopez tp mejia '\n",
      " 'cm yuen w levy v  reaching suburban men who have sex with men for std and '\n",
      " 'hiv  services through online social networking outreach a public health  '\n",
      " 'approach j acquir immune defic syndr 20167273–8  pmid27097365 '\n",
      " 'httpsdoiorg101097qai0000000000000930  249 sun cj stowers j miller c bachmann '\n",
      " 'lh rhodes sd acceptability  and feasibility of using established geosocial '\n",
      " 'and sexual networking  mobile applications to promote hiv and std testing '\n",
      " 'among men  who have sex with men aids behav 201519543–52 pmid25381563  '\n",
      " 'httpsdoiorg101007s1046101409425  250 dritz sk back af letter shigella '\n",
      " 'enteritis venereally transmitted  n engl j med 19742911194 pmid4608062 '\n",
      " 'httpsdoi org101056nejm197411282912223  251 aragón tj vugia dj shallow s et '\n",
      " 'al casecontrol study of shigellosis  in san francisco the role of sexual '\n",
      " 'transmission and hiv infection  clin infect dis 200744327–34 pmid17205436 '\n",
      " 'httpsdoi org101086510593  252 simms i field n jenkins c et al intensified '\n",
      " 'shigellosis epidemic  associated with sexual transmission in men who have '\n",
      " 'sex with men— shigella flexneri and s sonnei in england 2004 to end of '\n",
      " 'february  2015 euro surveill 20152021097 pmid25953129 httpsdoi '\n",
      " 'org10280715607917es2015201521097  253 gilbart vl simms i jenkins c et al sex '\n",
      " 'drugs and smart phone  applications findings from semistructured interviews '\n",
      " 'with men who  have sex with men diagnosed with shigella flexneri 3a in '\n",
      " 'england and  wales sex transm infect 201591598–602 pmid25921020 https '\n",
      " 'doiorg101136sextrans2015052014  254 narayan s galanis e bc stei group are '\n",
      " 'enteric infections sexually  transmitted in british columbia can commun dis '\n",
      " 'rep 20164224–9  pmid29770000 httpsdoiorg1014745ccdrv42i02a01  255 mohan k '\n",
      " 'hibbert m rooney g et al what is the overlap between  hiv and shigellosis '\n",
      " 'epidemics in england further evidence of msm  transmission sex transm infect '\n",
      " '20189467–71 pmid28490580  httpsdoiorg101136sextrans2016052962  256 hughes g '\n",
      " 'silalang p were j et al prevalence and characteristics of  gastrointestinal '\n",
      " 'infections in men who have sex with men diagnosed  with rectal chlamydia '\n",
      " 'infection in the uk an ‘unlinked anonymous’  crosssectional study sex transm '\n",
      " 'infect 201894518–21  pmid28360379 httpsdoiorg101136sextrans2016053057  257 '\n",
      " 'o’sullivan b delpech v pontivivo g et al shigellosis linked to sex  venues '\n",
      " 'australia emerg infect dis 20028862–4 pmid12141976  '\n",
      " 'httpsdoiorg103201eid0808010534  258 marcus u zucs p bremer v et al '\n",
      " 'shigellosis—a reemerging sexually  transmitted infection outbreak in men '\n",
      " 'having sex with men in berlin  int j std aids 200415533–7 pmid15307964 '\n",
      " 'httpsdoi org1012580956462041558221  259 danila rn eikmeier dl robinson tj la '\n",
      " 'pointe a devries as two  concurrent enteric disease outbreaks among men who '\n",
      " 'have sex with  men minneapolisst paul area clin infect dis 201459987–9  '\n",
      " 'pmid24944234 httpsdoiorg101093cidciu478  260 okame m adachi e sato h et al '\n",
      " 'shigella sonnei outbreak among  men who have sex with men in tokyo jpn j '\n",
      " 'infect dis 201265277–8  pmid22627317 httpsdoiorg107883yoken65277  261 wilmer '\n",
      " 'a romney mg gustafson r et al shigella flexneri serotype  1 infections in '\n",
      " 'men who have sex with men in vancouver canada  hiv med 201516168–75 '\n",
      " 'pmid25656740 httpsdoiorg101111 hiv12191  262 cdc shigella sonnei outbreak '\n",
      " 'among men who have sex with men— san francisco california 2000–2001 mmwr '\n",
      " 'morb mortal wkly  rep 200150922–6 pmid11699845  263 baer jt vugia dj '\n",
      " 'reingold al aragon t angulo fj bradford wz  hiv infection as a risk factor '\n",
      " 'for shigellosis emerg infect dis  19995820–3 pmid10603219 httpsdoiorg103201 '\n",
      " 'eid0506990614  264 simms i gilbart vl byrne l et al identification of '\n",
      " 'verocytotoxin producing escherichia coli o117h7 in men who have sex with '\n",
      " 'men  england november 2013 to august 2014 euro surveill 20141920946  '\n",
      " 'pmid25375900 ht tps   do i o rg 10 280715607917 es2014194320946  265 quinn '\n",
      " 'tc goodell se fennell c et al infections with campylobacter  jejuni and '\n",
      " 'campylobacterlike organisms in homosexual men ann  intern med 1984101187–92 '\n",
      " 'pmid6547580 httpsdoi org107326000348191012187  266 gaudreau c pilon pa '\n",
      " 'sylvestre jl boucher f bekal s multidrug resistant campylobacter coli in men '\n",
      " 'who have sex with men quebec  canada 2015 emerg infect dis 2016221661–3 '\n",
      " 'pmid27533504  httpsdoiorg103201eid2209151695  267 chen gj lin ky hung cc '\n",
      " 'chang sc hepatitis a outbreak among  men who have sex with men in a country '\n",
      " 'of low endemicity of hepatitis  a infection j infect dis 20172151339–40 '\n",
      " 'pmid28329351 https doiorg101093infdisjix123  268 lo yc ji dd hung cc '\n",
      " 'prevalent and incident hiv diagnoses among  entamoeba histolyticainfected '\n",
      " 'adult males a changing epidemiology  associated with sexual '\n",
      " 'transmission—taiwan 2006–2013 plos negl  trop dis 20148e3222 pmid25299178 '\n",
      " 'httpsdoiorg101371 journalpntd0003222  269 stark d van hal sj matthews g '\n",
      " 'harkness j marriott d invasive  amebiasis in men who have sex with men '\n",
      " 'australia emerg infect dis  2008141141–3 pmid18598643 httpsdoiorg103201 '\n",
      " 'eid1407080017  270 mitchell h hughes g recent epidemiology of sexually '\n",
      " 'transmissible  enteric infections in men who have sex with men curr opin '\n",
      " 'infect  dis 20183150–6 pmid29251673 httpsdoiorg101097 qco0000000000000423  '\n",
      " '271 weatherburn p hickson f reid d torresrueda s bourne a  motivations and '\n",
      " 'values associated with combining sex and illicit drugs  ‘chemsex’ among gay '\n",
      " 'men in south london findings from a  qualitative study sex transm infect '\n",
      " '201793203–6 pmid27519259  httpsdoiorg101136sextrans2016052695  272 baker ks '\n",
      " 'dallman tj ashton pm et al intercontinental dissemination  of '\n",
      " 'azithromycinresistant shigellosis through sexual transmission a  '\n",
      " 'crosssectional study lancet infect dis 201515913–21  pmid25936611 '\n",
      " 'httpsdoiorg101016s147330991500002x  273 bowen a grass j bicknese a campbell '\n",
      " 'd hurd j kirkcaldy rd  elevated risk for antimicrobial drugresistant '\n",
      " 'shigella infection among  men who have sex with men united states 2011–2015 '\n",
      " 'emerg infect  dis 2016221613–6 pmid27533624 httpsdoiorg103201 eid2209160624  '\n",
      " '274 gaudreau c rodriguescoutlée s pilon pa coutlée f bekal s long lasting '\n",
      " 'outbreak of erythromycin and ciprofloxacinresistant  campylobacter jejuni '\n",
      " 'subspecies jejuni from 2003 to 2013 in men who  have sex with men quebec '\n",
      " 'canada clin infect dis 2015611549–52  pmid26187024 '\n",
      " 'httpsdoiorg101093cidciv570  275 muzny ca sunesara ir martin dh mena la '\n",
      " 'sexually transmitted  infections and risk behaviors among african american '\n",
      " 'women who  have sex with women does sex with men make a difference sex '\n",
      " 'transm  dis 2011381118–25 pmid22082722 httpsdoiorg101097 '\n",
      " 'olq0b013e31822e6179  276 eisenberg m differences in sexual risk behaviors '\n",
      " 'between college  students with samesex and oppositesex experience results '\n",
      " 'from a  national survey arch sex behav 200130575–89 pmid11725456  '\n",
      " 'httpsdoiorg101023a1011958816438  277 koh as gómez ca shade s rowley e sexual '\n",
      " 'risk factors among  selfidentified lesbians bisexual women and heterosexual '\n",
      " 'women  accessing primary care settings sex transm dis 200532563–9  p m i d  '\n",
      " '1 6 1 1 8 6 0 5  h t t p s    d o i  o r g  1 0  1 0 9 7  0 1  '\n",
      " 'olq00001754171707821 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids27097365doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids27097365doptabstract '\n",
      " 'httpsdoiorg101097qai0000000000000930 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids25381563doptabstract '\n",
      " 'httpsdoiorg101007s1046101409425 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids4608062doptabstract '\n",
      " 'httpsdoiorg101056nejm197411282912223 httpsdoiorg101056nejm197411282912223 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids17205436doptabstract '\n",
      " 'httpsdoiorg101086510593 httpsdoiorg101086510593 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids25953129doptabstract '\n",
      " 'httpsdoiorg10280715607917es2015201521097 '\n",
      " 'httpsdoiorg10280715607917es2015201521097 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids25921020doptabstract '\n",
      " 'httpsdoiorg101136sextrans2015052014 httpsdoiorg101136sextrans2015052014 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29770000doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29770000doptabstract '\n",
      " 'httpsdoiorg1014745ccdrv42i02a01 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28490580doptabstract '\n",
      " 'httpsdoiorg101136sextrans2016052962 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28360379doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28360379doptabstract '\n",
      " 'httpsdoiorg101136sextrans2016053057 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids12141976doptabstract '\n",
      " 'httpsdoiorg103201eid0808010534 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids15307964doptabstract '\n",
      " 'httpsdoiorg1012580956462041558221 httpsdoiorg1012580956462041558221 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids24944234doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids24944234doptabstract '\n",
      " 'httpsdoiorg101093cidciu478 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids22627317doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids22627317doptabstract '\n",
      " 'httpsdoiorg107883yoken65277 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids25656740doptabstract '\n",
      " 'httpsdoiorg101111hiv12191 httpsdoiorg101111hiv12191 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids11699845doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids10603219doptabstract '\n",
      " 'httpsdoiorg103201eid0506990614 httpsdoiorg103201eid0506990614 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids25375900doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids25375900doptabstract '\n",
      " 'httpsdoiorg10280715607917es2014194320946 '\n",
      " 'httpsdoiorg10280715607917es2014194320946 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids6547580doptabstract '\n",
      " 'httpsdoiorg107326000348191012187 httpsdoiorg107326000348191012187 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids27533504doptabstract '\n",
      " 'httpsdoiorg103201eid2209151695 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28329351doptabstract '\n",
      " 'httpsdoiorg101093infdisjix123 httpsdoiorg101093infdisjix123 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids25299178doptabstract '\n",
      " 'httpsdoiorg101371journalpntd0003222 httpsdoiorg101371journalpntd0003222 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids18598643doptabstract '\n",
      " 'httpsdoiorg103201eid1407080017 httpsdoiorg103201eid1407080017 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29251673doptabstract '\n",
      " 'httpsdoiorg101097qco0000000000000423 httpsdoiorg101097qco0000000000000423 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids27519259doptabstract '\n",
      " 'httpsdoiorg101136sextrans2016052695 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids25936611doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids25936611doptabstract '\n",
      " 'httpsdoiorg101016s147330991500002x '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids27533624doptabstract '\n",
      " 'httpsdoiorg103201eid2209160624 httpsdoiorg103201eid2209160624 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids26187024doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids26187024doptabstract '\n",
      " 'httpsdoiorg101093cidciv570 httpsdoiorg101097olq0b013e31822e6179 '\n",
      " 'httpsdoiorg101097olq0b013e31822e6179 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids11725456doptabstract '\n",
      " 'httpsdoiorg101023a1011958816438 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids16118605doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids16118605doptabstract '\n",
      " 'httpsdoiorg10109701olq00001754171707821 '\n",
      " 'httpsdoiorg10109701olq00001754171707821 recommendations and reports mmwr  '\n",
      " 'july 23 2021  vol 70  no 4 145us department of health and human '\n",
      " 'servicescenters for disease control and prevention  278 goodenow c szalacha '\n",
      " 'la robin le westheimer k dimensions of  sexual orientation and hivrelated '\n",
      " 'risk among adolescent females  evidence from a statewide survey am j public '\n",
      " 'health 2008981051–8  pmid18445809 httpsdoiorg102105ajph2005080531  279 muzny '\n",
      " 'ca austin el harbison hs hook ew 3rd sexual  partnership characteristics of '\n",
      " 'african american women who have sex  with women impact on sexually '\n",
      " 'transmitted infection risk sex transm  dis 201441611–7 pmid25211257 '\n",
      " 'httpsdoiorg101097 olq0000000000000194  280 riskind rg tornello sl younger bc '\n",
      " 'patterson cj sexual identity  partner gender and sexual health among '\n",
      " 'adolescent girls in the united  states am j public health 20141041957–63 '\n",
      " 'pmid25121821  httpsdoiorg102105ajph2014302037  281 schick v rosenberger jg '\n",
      " 'herbenick d reece m sexual behaviour  and risk reduction strategies among a '\n",
      " 'multinational sample of women  who have sex with women sex transm infect '\n",
      " '201288407–12  pmid22563015 httpsdoiorg101136sextrans2011050404  282 richters '\n",
      " 'j prestage g schneider k clayton s do women use dental  dams safer sex '\n",
      " 'practices of lesbians and other women who have sex  with women sex health '\n",
      " '20107165–9 pmid20465981 httpsdoi org101071sh09072  283 rowen ts breyer bn '\n",
      " 'lin tc li cs robertson pa shindel aw  use of barrier protection for sexual '\n",
      " 'activity among women who have  sex with women int j gynaecol obstet '\n",
      " '201312042–5  pmid23106842 httpsdoiorg101016jijgo201208011  284 lindley ll '\n",
      " 'friedman db struble c becoming visible assessing the  availability of online '\n",
      " 'sexual health information for lesbians health  promot pract 201213472–80 '\n",
      " 'pmid21677116 httpsdoi org1011771524839910390314  285 chetcuti n beltzer n '\n",
      " 'methy n laborde c velter a bajos n csf  group preventive care’s forgotten '\n",
      " 'women life course sexuality and  sexual health among homosexually and '\n",
      " 'bisexually active women in  france j sex res 201350587–97 pmid22497621 '\n",
      " 'httpsdoiorg 101080002244992012657264  286 logie ch navia d loutfy mr '\n",
      " 'correlates of a lifetime history of  sexually transmitted infections among '\n",
      " 'women who have sex with  women in toronto canada results from a '\n",
      " 'crosssectional internet based survey sex transm infect 201591278–83 '\n",
      " 'pmid25477474  httpsdoiorg101136sextrans2014051745  287 muzny ca kapil r '\n",
      " 'austin el hook ew geisler wm lower sexually  transmissible infection '\n",
      " 'prevalence among lifetime exclusive women  who have sex with women compared '\n",
      " 'with women who have sex with  women and men sex health 201411592–3 '\n",
      " 'pmid25435197  httpsdoiorg101071sh14181  288 muzny ca harbison hs pembleton '\n",
      " 'es austin el sexual behaviors  perception of sexually transmitted infection '\n",
      " 'risk and practice of safe  sex among southern african american women who '\n",
      " 'have sex with  women sex transm dis 201340395–400 pmid23588129 https '\n",
      " 'doiorg101097olq0b013e31828caf34  289 przedworski jm mcalpine dd karacamandic '\n",
      " 'p vankim na health  and health risks among sexual minority women an '\n",
      " 'examination of 3  subgroups am j public health 20141041045–7 pmid24825204  '\n",
      " 'httpsdoiorg102105ajph2013301733  290 brenick a romano k kegler c eaton la '\n",
      " 'understanding the  influence of stigma and medical mistrust on engagement in '\n",
      " 'routine  healthcare among black women who have sex with women lgbt  health '\n",
      " '201744–10 pmid28113005 httpsdoiorg101089 lgbt20160083  291 fethers k marks c '\n",
      " 'mindel a estcourt cs sexually transmitted  infections and risk behaviours in '\n",
      " 'women who have sex with women  sex transm infect 200076345–9 pmid11141849 '\n",
      " 'httpsdoi org101136sti765345  292 marrazzo jm koutsky la eschenbach da agnew '\n",
      " 'k stine k hillier  sl characterization of vaginal flora and bacterial '\n",
      " 'vaginosis in women  who have sex with women j infect dis 20021851307–13  '\n",
      " 'pmid12001048 httpsdoiorg101086339884  293 kellock d o’mahony cp sexually '\n",
      " 'acquired metronidazoleresistant  trichomoniasis in a lesbian couple '\n",
      " 'genitourin med 19967260–1  pmid8655171 httpsdoiorg101136sti72160  294 muzny '\n",
      " 'ca rivers ca mena la schwebke jr genotypic  characterization of trichomonas '\n",
      " 'vaginalis isolates among women who  have sex with women in sexual '\n",
      " 'partnerships sex transm dis  201239556–8 pmid22706219 httpsdoiorg101097 '\n",
      " 'olq0b013e31824f1c49  295 chan sk thornton lr chronister kj et al cdc likely '\n",
      " 'female tofemale sexual transmission of hiv—texas 2012 mmwr morb  mortal wkly '\n",
      " 'rep 201463209–12 pmid24622284  296 kwakwa ha ghobrial mw femaletofemale '\n",
      " 'transmission of human  immunodeficiency virus clin infect dis 200336e40–1  '\n",
      " 'pmid12539088 httpsdoiorg101086345462  297 marrazzo jm handsfield hh '\n",
      " 'whittington wl predicting chlamydial  and gonococcal cervical infection '\n",
      " 'implications for management of  cervicitis obstet gynecol 2002100579–84 '\n",
      " 'pmid12220782 https doiorg1010970000625020020900000029  298 diamant al '\n",
      " 'schuster ma mcguigan k lever j lesbians’ sexual  history with men '\n",
      " 'implications for taking a sexual history arch intern  med 19991592730–6 '\n",
      " 'pmid10597764 httpsdoiorg101001 archinte159222730  299 xu f sternberg mr '\n",
      " 'markowitz le women who have sex with women  in the united states prevalence '\n",
      " 'sexual behavior and prevalence of  herpes simplex virus type 2 '\n",
      " 'infection—results from national health and  nutrition examination survey '\n",
      " '2001–2006 sex transm dis  201037407–13 pmid20531032 httpsdoiorg101097 '\n",
      " 'olq0b013e3181db2e18  300 everett bg higgins ja haider s carpenter e do '\n",
      " 'sexual minorities  receive appropriate sexual and reproductive health care '\n",
      " 'and counseling  j womens health larchmt 20192853–62 pmid30372369 https '\n",
      " 'doiorg101089jwh20176866  301 marrazzo jm koutsky la stine kl et al genital '\n",
      " 'human  papillomavirus infection in women who have sex with women j infect  '\n",
      " 'di s  1 9 9 8  1 7 8  1 6 0 4 – 9   p m i d  9 8 1 5 2 1 1  h t t p s    d o '\n",
      " 'i  org101086314494  302 marrazzo jm koutsky la kiviat nb kuypers jm stine k  '\n",
      " 'papanicolaou test screening and prevalence of genital human  papillomavirus '\n",
      " 'among women who have sex with women am j public  health 200191947–52 '\n",
      " 'pmid11392939 httpsdoiorg102105 ajph916947  303 bailey jv kavanagh j owen c '\n",
      " 'mclean ka skinner cj lesbians  and cervical screening br j gen pract '\n",
      " '200050481–2 pmid10962789  304 anderson ta schick v herbenick d dodge b '\n",
      " 'fortenberry jd a  study of human papillomavirus on vaginally inserted sex '\n",
      " 'toys before  and after cleaning among women who have sex with women and men  '\n",
      " 'sex transm infect 201490529–31 pmid24739872 httpsdoi '\n",
      " 'org101136sextrans2014051558  305 marrazzo jm stine k wald a prevalence and '\n",
      " 'risk factors for infection  with herpes simplex virus type1 and 2 among '\n",
      " 'lesbians sex transm  dis 200330890–5 pmid14646636 httpsdoiorg10109701 '\n",
      " 'olq000009115152656e5  306 muzny ca schwebke jr the clinical spectrum of '\n",
      " 'trichomonas  vaginalis infection and challenges to management sex transm '\n",
      " 'infect  201389423–5 pmid23543252 httpsdoiorg101136 sextrans2012050893  307 '\n",
      " 'muzny ca blackburn rj sinsky rj austin el schwebke jr added  benefit of '\n",
      " 'nucleic acid amplification testing for the diagnosis of  trichomonas '\n",
      " 'vaginalis among men and women attending a sexually  transmitted diseases '\n",
      " 'clinic clin infect dis 201459834–41  pmid24928292 httpsdoiorg101093cidciu446 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids18445809doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids18445809doptabstract '\n",
      " 'httpsdoiorg102105ajph2005080531 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids25211257doptabstract '\n",
      " 'httpsdoiorg101097olq0000000000000194 httpsdoiorg101097olq0000000000000194 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids25121821doptabstract '\n",
      " 'httpsdoiorg102105ajph2014302037 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids22563015doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids22563015doptabstract '\n",
      " 'httpsdoiorg101136sextrans2011050404 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids20465981doptabstract '\n",
      " 'httpsdoiorg101071sh09072 httpsdoiorg101071sh09072 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids23106842doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids23106842doptabstract '\n",
      " 'httpsdoiorg101016jijgo201208011 httpsdoiorg1011771524839910390314 '\n",
      " 'httpsdoiorg1011771524839910390314 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids22497621doptabstract '\n",
      " 'httpsdoiorg101080002244992012657264 httpsdoiorg101080002244992012657264 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids25477474doptabstract '\n",
      " 'httpsdoiorg101136sextrans2014051745 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids25435197doptabstract '\n",
      " 'httpsdoiorg101071sh14181 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids23588129doptabstract '\n",
      " 'httpsdoiorg101097olq0b013e31828caf34 httpsdoiorg101097olq0b013e31828caf34 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids24825204doptabstract '\n",
      " 'httpsdoiorg102105ajph2013301733 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28113005doptabstract '\n",
      " 'httpsdoiorg101089lgbt20160083 httpsdoiorg101089lgbt20160083 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids11141849doptabstract '\n",
      " 'httpsdoiorg101136sti765345 httpsdoiorg101136sti765345 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids12001048doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids12001048doptabstract '\n",
      " 'httpsdoiorg101086339884 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids8655171doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids8655171doptabstract '\n",
      " 'httpsdoiorg101136sti72160 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids22706219doptabstract '\n",
      " 'httpsdoiorg101097olq0b013e31824f1c49 httpsdoiorg101097olq0b013e31824f1c49 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids24622284doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids12539088doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids12539088doptabstract '\n",
      " 'httpsdoiorg101086345462 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids12220782doptabstract '\n",
      " 'httpsdoiorg1010970000625020020900000029 '\n",
      " 'httpsdoiorg1010970000625020020900000029 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids10597764doptabstract '\n",
      " 'httpsdoiorg101001archinte159222730 httpsdoiorg101001archinte159222730 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids20531032doptabstract '\n",
      " 'httpsdoiorg101097olq0b013e3181db2e18 httpsdoiorg101097olq0b013e3181db2e18 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30372369doptabstract '\n",
      " 'httpsdoiorg101089jwh20176866 httpsdoiorg101089jwh20176866 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids9815211doptabstract '\n",
      " 'httpsdoiorg101086314494 httpsdoiorg101086314494 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids11392939doptabstract '\n",
      " 'httpsdoiorg102105ajph916947 httpsdoiorg102105ajph916947 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids10962789doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids24739872doptabstract '\n",
      " 'httpsdoiorg101136sextrans2014051558 httpsdoiorg101136sextrans2014051558 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids14646636doptabstract '\n",
      " 'httpsdoiorg10109701olq000009115152656e5 '\n",
      " 'httpsdoiorg10109701olq000009115152656e5 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids23543252doptabstract '\n",
      " 'httpsdoiorg101136sextrans2012050893 httpsdoiorg101136sextrans2012050893 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids24928292doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids24928292doptabstract '\n",
      " 'httpsdoiorg101093cidciu446 recommendations and reports 146 mmwr  july 23 '\n",
      " '2021  vol 70  no 4 us department of health and human servicescenters for '\n",
      " 'disease control and prevention  308 singh d fine dn marrazzo jm chlamydia '\n",
      " 'trachomatis infection  among women reporting sexual activity with women '\n",
      " 'screened in family  planning clinics in the pacific northwest 1997 to 2005 '\n",
      " 'am j public  health 20111011284–90 pmid20724697 httpsdoiorg102105 '\n",
      " 'ajph2009169631  309 muzny ca kapil r austin el brown l hook ew 3rd geisler '\n",
      " 'wm  chlamydia trachomatis infection in african american women who  '\n",
      " 'exclusively have sex with women int j std aids 201627978–83  pmid26384942 '\n",
      " 'httpsdoiorg1011770956462415604092  310 koumans eh sternberg m bruce c et al '\n",
      " 'the prevalence of bacterial  vaginosis in the united states 2001–2004 '\n",
      " 'associations with symptoms  sexual behaviors and reproductive health sex '\n",
      " 'transm dis  200734864–9 pmid17621244 httpsdoiorg101097 olq0b013e318074e565  '\n",
      " '311 evans al scally aj wellard sj wilson jd prevalence of bacterial  '\n",
      " 'vaginosis in lesbians and heterosexual women in a community setting  sex '\n",
      " 'transm infect 200783470–5 pmid17611235 httpsdoi org101136sti2006022277  312 '\n",
      " 'olson km boohaker lj schwebke jr aslibekyan s muzny ca  comparisons of '\n",
      " 'vaginal flora patterns among sexual behaviour groups  of women implications '\n",
      " 'for the pathogenesis of bacterial vaginosis sex  health 20181561–7 '\n",
      " 'pmid29212588 httpsdoiorg101071 sh17087  313 muzny ca lensing sy aaron kj '\n",
      " 'schwebke jr incubation period  and risk factors support sexual transmission '\n",
      " 'of bacterial vaginosis in  women who have sex with women sex transm infect '\n",
      " '201995511–5  pmid30872415 httpsdoiorg101136sextrans2018053824  314 bradshaw '\n",
      " 'cs walker sm vodstrcil la et al the influence of behaviors  and '\n",
      " 'relationships on the vaginal microbiota of women and their female  partners '\n",
      " 'the wow health study j infect dis 20142091562–72  pmid24285846 '\n",
      " 'httpsdoiorg101093infdisjit664  315 marrazzo jm antonio m agnew k hillier sl '\n",
      " 'distribution of genital  lactobacillus strains shared by female sex partners '\n",
      " 'j infect dis  2009199680–3 pmid19199538 httpsdoiorg101086596632  316 '\n",
      " 'marrazzo jm fiedler tl srinivasan s et al extravaginal reservoirs of  '\n",
      " 'vaginal bacteria as risk factors for incident bacterial vaginosis j infect  '\n",
      " 'dis 20122051580–8 pmid22448002 httpsdoiorg101093 infdisjis242  317 mitchell '\n",
      " 'c manhart le thomas k fiedler t fredricks dn marrazzo  j behavioral '\n",
      " 'predictors of colonization with lactobacillus crispatus or  lactobacillus '\n",
      " 'jensenii after treatment for bacterial vaginosis a cohort  study infect dis '\n",
      " 'obstet gynecol 20122012706540 epub may 30  2012 pmid22693410 '\n",
      " 'httpsdoiorg1011552012706540  318 mitchell c manhart le thomas kk agnew k '\n",
      " 'marrazzo jm effect  of sexual activity on vaginal colonization with hydrogen '\n",
      " 'peroxide producing lactobacilli and gardnerella vaginalis sex transm dis  '\n",
      " '2011381137–44 pmid22082725 httpsdoiorg101097 olq0b013e31822e6121  319 '\n",
      " 'fethers k twin j fairley ck et al bacterial vaginosis bv candidate  bacteria '\n",
      " 'associations with bv and behavioural practices in sexually experienced and '\n",
      " 'inexperienced women plos one 20127e30633  pmid22363457 '\n",
      " 'httpsdoiorg101371journalpone0030633  320 bradshaw cs vodstrcil la hocking js '\n",
      " 'et al recurrence of bacterial  vaginosis is significantly associated with '\n",
      " 'posttreatment sexual activities  and hormonal contraceptive use clin infect '\n",
      " 'dis 201356777–86  pmid23243173 httpsdoiorg101093cidcis1030  321 marrazzo jm '\n",
      " 'thomas kk fiedler tl ringwood k fredricks dn  risks for acquisition of '\n",
      " 'bacterial vaginosis among women who report  sex with women a cohort study '\n",
      " 'plos one 20105e11139  pmid20559445 httpsdoiorg101371journalpone0011139  322 '\n",
      " 'vodstrcil la walker sm hocking js et al incident bacterial vaginosis  bv in '\n",
      " 'women who have sex with women is associated with behaviors  that suggest '\n",
      " 'sexual transmission of bv clin infect dis 2015601042–53  pmid25516188 '\n",
      " 'httpsdoiorg101093cidciu1130  323 muzny ca blanchard e taylor cm et al '\n",
      " 'identification of key bacteria  involved in the induction of incident '\n",
      " 'bacterial vaginosis a prospective  study j infect dis 2018218966–78 '\n",
      " 'pmid29718358 httpsdoi org101093infdisjiy243  324 marrazzo jm thomas kk '\n",
      " 'ringwood k a behavioural intervention  to reduce persistence of bacterial '\n",
      " 'vaginosis among women who report  sex with women results of a randomised '\n",
      " 'trial sex transm infect  201187399–405 pmid21653935 httpsdoiorg101136 '\n",
      " 'sti2011049213  325 bradshaw cs walker j fairley ck et al prevalent and '\n",
      " 'incident  bacterial vaginosis are associated with sexual and contraceptive  '\n",
      " 'behaviours in young australian women plos one 20138e57688  pmid23472099 '\n",
      " 'httpsdoiorg101371journalpone0057688  326 poteat t reisner sl radix a hiv '\n",
      " 'epidemics among transgender  women curr opin hiv aids 20149168–73 '\n",
      " 'pmid24322537  httpsdoiorg101097coh0000000000000030  327 white hughto jm '\n",
      " 'reisner sl pachankis je transgender stigma and  health a critical review of '\n",
      " 'stigma determinants mechanisms and  interventions soc sci med 2015147222–31 '\n",
      " 'pmid26599625  httpsdoiorg101016jsocscimed201511010  328 radix ae '\n",
      " 'lelutiuweinberger c gamarel ke satisfaction and  healthcare utilization of '\n",
      " 'transgender and gender nonconforming  individuals in nyc a communitybased '\n",
      " 'participatory study lgbt  health 20141302–8 pmid26789858 httpsdoiorg101089 '\n",
      " 'lgbt20130042  329 rapues j wilson ec packer t colfax gn raymond hf '\n",
      " 'correlates  of hiv infection among transfemales san francisco 2010 results  '\n",
      " 'from a respondentdriven sampling study am j public health  20131031485–92 '\n",
      " 'pmid23763398 httpsdoiorg102105 ajph2012301109  330 sevelius jm patouhas e '\n",
      " 'keatley jg johnson mo barriers and  facilitators to engagement and retention '\n",
      " 'in care among transgender  women living with human immunodeficiency virus '\n",
      " 'ann behav med  2014475–16 pmid24317955 httpsdoiorg101007 s1216001395658  331 '\n",
      " 'sevelius jm gender affirmation a framework for conceptualizing risk  '\n",
      " 'behavior among transgender women of color sex roles 201368675–89  '\n",
      " 'pmid23729971 httpsdoiorg101007s1119901202165  332 reisner sl white hughto jm '\n",
      " 'pardee d sevelius j syndemics and  gender affirmation hiv sexual risk in '\n",
      " 'femaletomale trans masculine  adults reporting sexual contact with cisgender '\n",
      " 'males int j std aids  2 0 1 6  2 7  9 5 5 – 6 6   p m i d  2 6 3 8 4 9 4 6  '\n",
      " 'h t t p s    d o i  org1011770956462415602418  333 coleman e bockting w '\n",
      " 'botzer m et al standards of care for the  health of transsexual transgender '\n",
      " 'and gendernonconforming people  version 7 int j transgenderism 201213165–232 '\n",
      " 'httpsdoiorg10 1080155327392011700873  334 winter s diamond m green j et al '\n",
      " 'transgender people health at  the margins of society lancet 2016388390–400 '\n",
      " 'pmid27323925  httpsdoiorg101016s0140673616006838  335 cahill s singal r '\n",
      " 'grasso c et al do ask do tell high levels of  acceptability by patients of '\n",
      " 'routine collection of sexual orientation and  gender identity data in four '\n",
      " 'diverse american community health  centers plos one 20149e107104 '\n",
      " 'pmid25198577 httpsdoi org101371journalpone0107104  336 cahill sr baker k '\n",
      " 'deutsch mb keatley j makadon hj inclusion  of sexual orientation and gender '\n",
      " 'identity in stage 3 meaningful use  guidelines a huge step forward for lgbt '\n",
      " 'health lgbt health  20163100–2 pmid26698386 httpsdoiorg101089 lgbt20150136  '\n",
      " '337 tordoff dm morgan j dombrowski jc golden mr barbee la  increased '\n",
      " 'ascertainment of transgender and nonbinary patients using  a 2step versus '\n",
      " '1step gender identity intake question in an std clinic  setting sex transm '\n",
      " 'dis 201946254–9 pmid30516726 httpsdoi org101097olq0000000000000952 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids20724697doptabstract '\n",
      " 'httpsdoiorg102105ajph2009169631 httpsdoiorg102105ajph2009169631 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids26384942doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids26384942doptabstract '\n",
      " 'httpsdoiorg1011770956462415604092 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids17621244doptabstract '\n",
      " 'httpsdoiorg101097olq0b013e318074e565 httpsdoiorg101097olq0b013e318074e565 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids17611235doptabstract '\n",
      " 'httpsdoiorg101136sti2006022277 httpsdoiorg101136sti2006022277 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29212588doptabstract '\n",
      " 'httpsdoiorg101071sh17087 httpsdoiorg101071sh17087 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30872415doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30872415doptabstract '\n",
      " 'httpsdoiorg101136sextrans2018053824 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids24285846doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids24285846doptabstract '\n",
      " 'httpsdoiorg101093infdisjit664 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids19199538doptabstract '\n",
      " 'httpsdoiorg101086596632 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids22448002doptabstract '\n",
      " 'httpsdoiorg101093infdisjis242 httpsdoiorg101093infdisjis242 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids22693410doptabstract '\n",
      " 'httpsdoiorg1011552012706540 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids22082725doptabstract '\n",
      " 'httpsdoiorg101097olq0b013e31822e6121 httpsdoiorg101097olq0b013e31822e6121 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids22363457doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids22363457doptabstract '\n",
      " 'httpsdoiorg101371journalpone0030633 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids23243173doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids23243173doptabstract '\n",
      " 'httpsdoiorg101093cidcis1030 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids20559445doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids20559445doptabstract '\n",
      " 'httpsdoiorg101371journalpone0011139 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids25516188doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids25516188doptabstract '\n",
      " 'httpsdoiorg101093cidciu1130 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29718358doptabstract '\n",
      " 'httpsdoiorg101093infdisjiy243 httpsdoiorg101093infdisjiy243 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids21653935doptabstract '\n",
      " 'httpsdoiorg101136sti2011049213 httpsdoiorg101136sti2011049213 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids23472099doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids23472099doptabstract '\n",
      " 'httpsdoiorg101371journalpone0057688 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids24322537doptabstract '\n",
      " 'httpsdoiorg101097coh0000000000000030 httpsdoiorg101016jsocscimed201511010 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids26789858doptabstract '\n",
      " 'httpsdoiorg101089lgbt20130042 httpsdoiorg101089lgbt20130042 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids23763398doptabstract '\n",
      " 'httpsdoiorg102105ajph2012301109 httpsdoiorg102105ajph2012301109 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids24317955doptabstract '\n",
      " 'httpsdoiorg101007s1216001395658 httpsdoiorg101007s1216001395658 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids23729971doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids23729971doptabstract '\n",
      " 'httpsdoiorg101007s1119901202165 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids26384946doptabstract '\n",
      " 'httpsdoiorg1011770956462415602418 httpsdoiorg1011770956462415602418 '\n",
      " 'httpsdoiorg101080155327392011700873 httpsdoiorg101080155327392011700873 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids27323925doptabstract '\n",
      " 'httpsdoiorg101016s0140673616006838 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids25198577doptabstract '\n",
      " 'httpsdoiorg101371journalpone0107104 httpsdoiorg101371journalpone0107104 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids26698386doptabstract '\n",
      " 'httpsdoiorg101089lgbt20150136 httpsdoiorg101089lgbt20150136 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30516726doptabstract '\n",
      " 'httpsdoiorg101097olq0000000000000952 httpsdoiorg101097olq0000000000000952 '\n",
      " 'recommendations and reports mmwr  july 23 2021  vol 70  no 4 147us '\n",
      " 'department of health and human servicescenters for disease control and '\n",
      " 'prevention  338 grant jm mottet la tanis j national transgender '\n",
      " 'discrimination  survey report on health and health care washington dc '\n",
      " 'national  center for transgender equality and the national gay and lesbian  '\n",
      " 'task force 2010 httpscancernetworkorgwpcontent '\n",
      " 'uploads201702nationaltransgenderdiscriminationsurvey '\n",
      " 'reportonhealthandhealthcarepdf  339 jaffee kd shires da stroumsa d '\n",
      " 'discrimination and delayed health  care among transgender women and men '\n",
      " 'implications for improving  medical education and health care delivery med '\n",
      " 'care 2016541010–6  pmid27314263 httpsdoiorg101097mlr0000000000000583  340 '\n",
      " 'glick jl theall kp andrinopoulos km kendall c the role of  discrimination in '\n",
      " 'care postponement among transfeminine individuals  in the us national '\n",
      " 'transgender discrimination survey lgbt health  20185171–9 pmid29589995 '\n",
      " 'httpsdoiorg101089 lgbt20170093  341 callander d cook t cornelisse v et al '\n",
      " 'trans and gender diverse  people’s experiences of sexual health care are '\n",
      " 'associated with sexual  health screening uptake sex transm infect '\n",
      " '201995suppl 1a64  httpsstibmjcomcontentsextrans95suppl1tocpdf   342 casey ls '\n",
      " 'reisner sl findling mg et al discrimination in the united  states '\n",
      " 'experiences of lesbian gay bisexual transgender and queer  americans health '\n",
      " 'serv res 201954suppl 21454–66  pmid31659745 httpsdoiorg1011111475677313229  '\n",
      " '343 potter j peitzmeier sm bernstein i et al cervical cancer screening  for '\n",
      " 'patients on the femaletomale spectrum a narrative review and  guide for '\n",
      " 'clinicians j gen intern med 2015301857–64  pmid26160483 '\n",
      " 'httpsdoiorg101007s1160601534628  344 becasen js denard cl mullins mm higa dh '\n",
      " 'sipe ta estimating  the prevalence of hiv and sexual behaviors among the us '\n",
      " 'transgender  population a systematic review and metaanalysis 2006–2017 am j  '\n",
      " 'public health 2019109e1–8 pmid30496000 httpsdoi org102105ajph2018304727  345 '\n",
      " 'baral sd poteat t strömdahl s wirtz al guadamuz te beyrer c  worldwide '\n",
      " 'burden of hiv in transgender women a systematic review  and metaanalysis '\n",
      " 'lancet infect dis 201313214–22 pmid23260128  '\n",
      " 'httpsdoiorg101016s1473309912703158  346 allanblitz lt konda ka calvo gm et '\n",
      " 'al high incidence of extra genital gonorrheal and chlamydial infections '\n",
      " 'among highrisk men  who have sex with men and transgender women in peru int '\n",
      " 'j std  aids 201829 568–76  pmid29183269 ht tps   do i  '\n",
      " 'org1011770956462417744098  347 hiransuthikul a janamnuaysook r sungsing t et '\n",
      " 'al high burden  of chlamydia and gonorrhoea in pharyngeal rectal and '\n",
      " 'urethral sites  among thai transgender women implications for anatomical '\n",
      " 'site  selection for the screening of sti sex transm infect 201995534–9  '\n",
      " 'pmid30982000 httpsdoiorg101136sextrans2018053835  348 kojima n park h konda '\n",
      " 'ka et al the picasso cohort baseline  characteristics of a cohort of men who '\n",
      " 'have sex with men and male tofemale transgender women at high risk for '\n",
      " 'syphilis infection in lima  peru bmc infect dis 201717255 pmid28399798 '\n",
      " 'httpsdoi org101186s128790172332x  349 pitasi ma kerani rp kohn r et al '\n",
      " 'chlamydia gonorrhea and human  immunodeficiency virus infection among '\n",
      " 'transgender women and  transgender men attending clinics that provide '\n",
      " 'sexually transmitted  disease services in six us cities results from the '\n",
      " 'sexually transmitted  disease surveillance network sex transm dis '\n",
      " '201946112–7  pmid30278030 httpsdoiorg101097olq0000000000000917  350 james s '\n",
      " 'herman jl rankin s keisling m mottet l anafi m the  report of the 2015 us '\n",
      " 'transgender survey washington dc national  center for transgender equality '\n",
      " '2016 httpstransequalityorgsites defaultfilesdocsustsustsfullreportdec17pdf  '\n",
      " '351 hadjmoussa m ohl da kuzon wm jr feminizing genital gender confirmation '\n",
      " 'surgery sex med rev 20186457–468e2  pmid29454634 '\n",
      " 'httpsdoiorg101016jsxmr201711005  352 salgado cj nugent a kuhn j janette m '\n",
      " 'bahna h primary sigmoid  vaginoplasty in transwomen technique and outcomes '\n",
      " 'biomed res  int  201820184907208  pmid29862275 https   doi  '\n",
      " 'org10115520184907208  353 radix ae harris ab belkind u ting j goldstein zg '\n",
      " 'chlamydia  trachomatis infection of the neovagina in transgender women open  '\n",
      " 'forum infect dis 20196ofz470 pmid32395566 httpsdoi org101093ofidofz470  354 '\n",
      " 'elfering l van der sluis wb mermans jf buncamper me herpes  neolabialis '\n",
      " 'herpes simplex virus type 1 infection of the neolabia in a  transgender '\n",
      " 'woman int j std aids 201728841–3 pmid28632111  '\n",
      " 'httpsdoiorg1011770956462416685658  355 van der sluis wb buncamper me bouman '\n",
      " 'mb et al prevalence of  neovaginal highrisk human papillomavirus among '\n",
      " 'transgender women  in the netherlands sex transm dis 201643503–5 '\n",
      " 'pmid27414682  httpsdoiorg101097olq0000000000000476  356 yang c liu s xu k '\n",
      " 'xiang q yang s zhang x condylomata gigantea  in a male transsexual int j std '\n",
      " 'aids 200920211–2 pmid19255276  httpsdoiorg101258ijsa2008008213  357 matsuki '\n",
      " 's kusatake k hein kz anraku k morita e condylomata  acuminata in the '\n",
      " 'neovagina after maletofemale reassignment treated  with co2 laser and '\n",
      " 'imiquimod int j std aids 201526509–11  pmid24970474 '\n",
      " 'httpsdoiorg1011770956462414542476  358 bodsworth nj price r davies sc '\n",
      " 'gonococcal infection of the  neovagina in a maletofemale transsexual sex '\n",
      " 'transm dis  1 9 9 4  2 1  2 1 1 – 2   p m i d  7 9 7 4 0 7 1  h t t p s    d '\n",
      " 'o i  org1010970000743519940700000005  359 haustein uf pruritus of the '\n",
      " 'artificial vagina of a transsexual patient  caused by gonococcal infection '\n",
      " 'german hautarzt 199546858–9  pmid8567271 httpsdoiorg101007s001050050354  360 '\n",
      " 'yamada k shida d kato t yoshida h yoshinaga s kanemitsu y  adenocarcinoma '\n",
      " 'arising in sigmoid colon neovagina 53\\xa0 years after  construction world j '\n",
      " 'surg oncol 20181688 pmid29703260  httpsdoiorg101186s129570181372z  361 hiroi '\n",
      " 'h yasugi t matsumoto k et al mucinous adenocarcinoma  arising in a neovagina '\n",
      " 'using the sigmoid colon thirty years after  operation a case report j surg '\n",
      " 'oncol 20017761–4 pmid11344485  httpsdoiorg101002jso1067  362 heller ds '\n",
      " 'lesions of the neovagina—a review j low genit tract dis  201519267–70 '\n",
      " 'pmid26111041 httpsdoiorg101097 lgt0000000000000110  363 scheim ai bauer gr '\n",
      " 'travers r hivrelated sexual risk among  transgender men who are gay bisexual '\n",
      " 'or have sex with men j acquir  immune defic syndr 201774e89–96 pmid27798432 '\n",
      " 'httpsdoi org101097qai0000000000001222  364 sevelius j “there’s no pamphlet '\n",
      " 'for the kind of sex i have” hivrelated  risk factors and protective '\n",
      " 'behaviors among transgender men who have  sex with nontransgender men j '\n",
      " 'assoc nurses aids care  200920398–410 pmid19732698 httpsdoiorg101016j '\n",
      " 'jana200906001  365 pitasi ma oraka e clark h town m dinenno ea hiv testing  '\n",
      " 'among transgender women and men—27 states and guam 2014– 2015 mmwr morb '\n",
      " 'mortal wkly rep 201766883–7  pmid28837547 httpsdoiorg1015585mmwrmm6633a3  '\n",
      " '366 reisner sl perkovich b mimiaga mj a mixed methods study of the  sexual '\n",
      " 'health needs of new england transmen who have sex with  nontransgender men '\n",
      " 'aids patient care stds 201024501–13  pmid20666586 '\n",
      " 'httpsdoiorg101089apc20100059  367 hembree wc cohenkettenis pt gooren l et al '\n",
      " 'endocrine  treatment of genderdysphoricgenderincongruent persons an  '\n",
      " 'endocrine society clinical practice guideline j clin endocrinol metab  '\n",
      " '20171023869–903 pmid28945902 httpsdoiorg101210 jc201701658 '\n",
      " 'httpscancernetworkorgwpcontentuploads201702nationaltransgenderdiscriminationsurveyreportonhealthandhealthcarepdf '\n",
      " 'httpscancernetworkorgwpcontentuploads201702nationaltransgenderdiscriminationsurveyreportonhealthandhealthcarepdf '\n",
      " 'httpscancernetworkorgwpcontentuploads201702nationaltransgenderdiscriminationsurveyreportonhealthandhealthcarepdf '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids27314263doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids27314263doptabstract '\n",
      " 'httpsdoiorg101097mlr0000000000000583 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29589995doptabstract '\n",
      " 'httpsdoiorg101089lgbt20170093 httpsdoiorg101089lgbt20170093 '\n",
      " 'httpsstibmjcomcontentsextrans95suppl1tocpdf '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids31659745doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids31659745doptabstract '\n",
      " 'httpsdoiorg1011111475677313229 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids26160483doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids26160483doptabstract '\n",
      " 'httpsdoiorg101007s1160601534628 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30496000doptabstract '\n",
      " 'httpsdoiorg102105ajph2018304727 httpsdoiorg102105ajph2018304727 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids23260128doptabstract '\n",
      " 'httpsdoiorg101016s1473309912703158 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29183269doptabstract '\n",
      " 'httpsdoiorg1011770956462417744098 httpsdoiorg1011770956462417744098 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30982000doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30982000doptabstract '\n",
      " 'httpsdoiorg101136sextrans2018053835 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28399798doptabstract '\n",
      " 'httpsdoiorg101186s128790172332x httpsdoiorg101186s128790172332x '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30278030doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30278030doptabstract '\n",
      " 'httpsdoiorg101097olq0000000000000917 '\n",
      " 'httpstransequalityorgsitesdefaultfilesdocsustsustsfullreportdec17pdf '\n",
      " 'httpstransequalityorgsitesdefaultfilesdocsustsustsfullreportdec17pdf '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29454634doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29454634doptabstract '\n",
      " 'httpsdoiorg101016jsxmr201711005 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29862275doptabstract '\n",
      " 'httpsdoiorg10115520184907208 httpsdoiorg10115520184907208 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids32395566doptabstract '\n",
      " 'httpsdoiorg101093ofidofz470 httpsdoiorg101093ofidofz470 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28632111doptabstract '\n",
      " 'httpsdoiorg1011770956462416685658 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids27414682doptabstract '\n",
      " 'httpsdoiorg101097olq0000000000000476 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids19255276doptabstract '\n",
      " 'httpsdoiorg101258ijsa2008008213 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids24970474doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids24970474doptabstract '\n",
      " 'httpsdoiorg1011770956462414542476 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids7974071doptabstract '\n",
      " 'httpsdoiorg1010970000743519940700000005 '\n",
      " 'httpsdoiorg1010970000743519940700000005 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids8567271doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids8567271doptabstract '\n",
      " 'httpsdoiorg101007s001050050354 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29703260doptabstract '\n",
      " 'httpsdoiorg101186s129570181372z '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids11344485doptabstract '\n",
      " 'httpsdoiorg101002jso1067 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids26111041doptabstract '\n",
      " 'httpsdoiorg101097lgt0000000000000110 httpsdoiorg101097lgt0000000000000110 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids27798432doptabstract '\n",
      " 'httpsdoiorg101097qai0000000000001222 httpsdoiorg101097qai0000000000001222 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids19732698doptabstract '\n",
      " 'httpsdoiorg101016jjana200906001 httpsdoiorg101016jjana200906001 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28837547doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28837547doptabstract '\n",
      " 'httpsdoiorg1015585mmwrmm6633a3 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids20666586doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids20666586doptabstract '\n",
      " 'httpsdoiorg101089apc20100059 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28945902doptabstract '\n",
      " 'httpsdoiorg101210jc201701658 httpsdoiorg101210jc201701658 recommendations '\n",
      " 'and reports 148 mmwr  july 23 2021  vol 70  no 4 us department of health and '\n",
      " 'human servicescenters for disease control and prevention  368 deutsch m ed '\n",
      " 'guidelines for the primary and genderaffirming care  of transgender and '\n",
      " 'gender nonbinary people san francisco ca  university of california san '\n",
      " 'francisco department of family and  community medicine center of excellence '\n",
      " 'for transgender care  2016 httpstranscareucsfedusitestranscareucsfedufiles '\n",
      " 'transgenderpgacg61716pdf  369 peitzmeier sm reisner sl harigopal p potter j '\n",
      " 'femaletomale  patients have high prevalence of unsatisfactory paps compared '\n",
      " 'to non transgender females implications for cervical cancer screening j gen  '\n",
      " 'intern med 201429778–84 pmid24424775 httpsdoi org101007s1160601327531  370 '\n",
      " 'peitzmeier sm khullar k reisner sl potter j pap test use is lower  among '\n",
      " 'femaletomale patients than nontransgender women am j  prev med 201447808–12 '\n",
      " 'pmid25455121 httpsdoi org101016jamepre201407031  371 reisner sl deutsch mb '\n",
      " 'peitzmeier sm et al test performance and  acceptability of self versus '\n",
      " 'providercollected swabs for highrisk hpv  dna testing in femaletomale trans '\n",
      " 'masculine patients plos one  201813e0190172 pmid29538411 '\n",
      " 'httpsdoiorg101371journal pone0190172  372 cdc surveillance for viral '\n",
      " 'hepatitis—united states 2017 atlanta  ga us department of health and human '\n",
      " 'services cdc 2019  httpswwwcdcgovhepatitisstatistics2017surveillance '\n",
      " 'pdfs2017hepsurveillancerptpdf  373 kouyoumdjian fg leto d john s henein h '\n",
      " 'bondy s a systematic  review and metaanalysis of the prevalence of chlamydia '\n",
      " 'gonorrhoea  and syphilis in incarcerated persons int j std aids '\n",
      " '201223248–54  pmid22581947 httpsdoiorg101258ijsa2011011194  374 cdc '\n",
      " 'evaluation of large jail std screening programs 2008–2009  atlanta ga us '\n",
      " 'department of health and human services cdc  2011 '\n",
      " 'httpswwwcdcgovstdpublicationsjailscreening2011pdf  375 pathela p hennessy rr '\n",
      " 'blank s parvez f franklin w schillinger ja  the contribution of a urinebased '\n",
      " 'jail screening program to citywide  male chlamydia and gonorrhea case rates '\n",
      " 'in new york city sex transm  dis 200936suppls58–61 pmid17989586 httpsdoi '\n",
      " 'org101097olq0b013e31815615bb  376 joesoef mr weinstock hs kent ck et al '\n",
      " 'corrections std  prevalence monitoring group sex and age correlates of '\n",
      " 'chlamydia  prevalence in adolescents and adults entering correctional '\n",
      " 'facilities  2005 implications for screening policy sex transm dis  '\n",
      " '200936suppls67–71 pmid19125147 httpsdoiorg101097 olq0b013e31815d6de8  377 '\n",
      " 'blank s mcdonnell dd rubin sr et al new approaches to syphilis  control '\n",
      " 'finding opportunities for syphilis treatment and congenital  syphilis '\n",
      " 'prevention in a women’s correctional setting sex transm dis  1 9 9 7  2 4  2 '\n",
      " '1 8 – 2 6   p m i d  9 1 0 1 6 3 3  h t t p s    d o i  '\n",
      " 'org1010970000743519970400000006  378 owusuedusei k jr gift tl chesson hw '\n",
      " 'kent ck investigating  the potential public health benefit of jailbased '\n",
      " 'screening and treatment  programs for chlamydia am j epidemiol '\n",
      " '2013177463–73  pmid23403986 httpsdoiorg101093ajekws240  379 spaulding ac '\n",
      " 'miller j trigg bg et al screening for sexually  transmitted diseases in '\n",
      " 'shortterm correctional institutions summary  of evidence reviewed for the '\n",
      " '2010 centers for disease control and  prevention sexually transmitted '\n",
      " 'diseases treatment guidelines sex  transm dis 201340679–84 pmid23945422 '\n",
      " 'httpsdoi org10109701olq000043135388464ab  380 cdc male chlamydia screening '\n",
      " 'consultation march 28–29 2006  meeting report atlanta ga us department of '\n",
      " 'health and human  services cdc 2007 httpswwwcdcgovstdchlamydia '\n",
      " 'chlamydiascreeningmalespdf  381 cole j hotton a zawitz c kessler h optout '\n",
      " 'screening for  chlamydia trachomatis and neisseria gonorrhoeae in female '\n",
      " 'detainees at  cook county jail in chicago il sex transm dis 201441161–5  '\n",
      " 'pmid24521720 httpsdoiorg101097olq0000000000000106  382 shaikh ra simonsen ka '\n",
      " 'o’keefe a et al comparison of optin  versus optout testing for sexually '\n",
      " 'transmitted infections among inmates  in a county jail j correct health care '\n",
      " '201521408–16  pmid26285597 httpsdoiorg1011771078345815600447  383 spaulding '\n",
      " 'ac kim mj corpening kt carpenter t watlington p  bowden cj establishing an '\n",
      " 'hiv screening program led by staff nurses  in a county jail j public health '\n",
      " 'manag pract 201521538–45  pmid25427254 httpsdoiorg101097phh0000000000000183  '\n",
      " '384 rosen dl wohl da golin ce et al comparing hiv case detection  in prison '\n",
      " 'during optin vs optout testing policies j acquir immune  defic syndr '\n",
      " '201671e85–8 pmid26536318 httpsdoi org101097qai0000000000000889  385 gratrix '\n",
      " 'j smyczek p bertholet l et al a crosssectional evaluation of  optin testing '\n",
      " 'for sexually transmitted and bloodborne infections in  three canadian '\n",
      " 'provincial correctional facilities a missed opportunity  for public health '\n",
      " 'int j prison health 201915273–81 pmid31329036  '\n",
      " 'httpsdoiorg101108ijph0720180043  386 sutcliffe s newman sb hardick a gaydos '\n",
      " 'ca prevalence and  correlates of trichomonas vaginalis infection among '\n",
      " 'female us federal  prison inmates sex transm dis 201037585–90 pmid20803782  '\n",
      " 'httpsdoiorg101097olq0b013e3181de4113  387 freeman ah katz ka pandori mw et '\n",
      " 'al prevalence and correlates  of trichomonas vaginalis among incarcerated '\n",
      " 'persons assessed using a  highly sensitive molecular assay sex transm dis '\n",
      " '201037165–8  pmid20023598 httpsdoiorg101097olq0b013e3181bcd3fc  388 sosman j '\n",
      " 'macgowan r margolis a et al project start biologics  study group sexually '\n",
      " 'transmitted infections and hepatitis in men with  a history of incarceration '\n",
      " 'sex transm dis 201138634–9  pmid21844713 '\n",
      " 'httpsdoiorg101097olq0b013e31820bc86c  389 javanbakht m stirland a stahlman s '\n",
      " 'et al prevalence and factors  associated with trichomonas vaginalis '\n",
      " 'infection among highrisk women  in los angeles sex transm dis 201340804–7 '\n",
      " 'pmid24275733  httpsdoiorg101097olq0000000000000026  390 nijhawan ae chapin '\n",
      " 'kc salloway r et al prevalence and predictors  of trichomonas infection in '\n",
      " 'newly incarcerated women sex transm  dis 201239973–8 pmid23191953 '\n",
      " 'httpsdoiorg101097 olq0b013e31826e8847  391 nijhawan ae delong ak celentano '\n",
      " 'dd et al the association  between trichomonas infection and incarceration in '\n",
      " 'hivseropositive  and atr i sk hivseronegat ive  women  sex transm dis  '\n",
      " '2011381094–100 pmid22082718 httpsdoiorg101097 olq0b013e31822ea147  392 '\n",
      " 'willers dm peipert jf allsworth je stein md rose js clarke jg  prevalence '\n",
      " 'and predictors of sexually transmitted infection among  newly incarcerated '\n",
      " 'females sex transm dis 20083568–72  pmid18090178 '\n",
      " 'httpsdoiorg101097olq0b013e318154bdb2  393 nijhawan ae salloway r nunn as '\n",
      " 'poshkus m clarke jg preventive  healthcare for underserved women results of '\n",
      " 'a prison survey j womens  health larchmt 20101917–22 pmid20088654 httpsdoi '\n",
      " 'org101089jwh20091469  394 binswanger ia white mc pérezstable ej goldenson j '\n",
      " 'tulsky jp  cancer screening among jail inmates frequency knowledge and  '\n",
      " 'willingness am j public health 2005951781–7 pmid16186455  '\n",
      " 'httpsdoiorg102105ajph2004052498  395 brinkleyrubinstein l peterson m arnold '\n",
      " 't et al knowledge interest  and anticipated barriers of preexposure '\n",
      " 'prophylaxis uptake and  adherence among gay bisexual and men who have sex '\n",
      " 'with men who  are incarcerated plos one 201813e0205593 pmid30532275  '\n",
      " 'httpsdoiorg101371journalpone0205593  396 brinkleyrubinstein l dauria e '\n",
      " 'toloushams m et al the path to  implementation of hiv preexposure '\n",
      " 'prophylaxis for people involved  in criminal justice systems curr hivaids '\n",
      " 'rep 20181593–5  pmid29516265 httpsdoiorg101007s1190401803899 '\n",
      " 'httpstranscareucsfedusitestranscareucsfedufilestransgenderpgacg61716pdf '\n",
      " 'httpstranscareucsfedusitestranscareucsfedufilestransgenderpgacg61716pdf '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids24424775doptabstract '\n",
      " 'httpsdoiorg101007s1160601327531 httpsdoiorg101007s1160601327531 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids25455121doptabstract '\n",
      " 'httpsdoiorg101016jamepre201407031 httpsdoiorg101016jamepre201407031 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29538411doptabstract '\n",
      " 'httpsdoiorg101371journalpone0190172 httpsdoiorg101371journalpone0190172 '\n",
      " 'httpswwwcdcgovhepatitisstatistics2017surveillancepdfs2017hepsurveillancerptpdf '\n",
      " 'httpswwwcdcgovhepatitisstatistics2017surveillancepdfs2017hepsurveillancerptpdf '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids22581947doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids22581947doptabstract '\n",
      " 'httpsdoiorg101258ijsa2011011194 '\n",
      " 'httpswwwcdcgovstdpublicationsjailscreening2011pdf '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids17989586doptabstract '\n",
      " 'httpsdoiorg101097olq0b013e31815615bb httpsdoiorg101097olq0b013e31815615bb '\n",
      " 'httpsdoiorg101097olq0b013e31815d6de8 httpsdoiorg101097olq0b013e31815d6de8 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids9101633doptabstract '\n",
      " 'httpsdoiorg1010970000743519970400000006 '\n",
      " 'httpsdoiorg1010970000743519970400000006 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids23403986doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids23403986doptabstract '\n",
      " 'httpsdoiorg101093ajekws240 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids23945422doptabstract '\n",
      " 'httpsdoiorg10109701olq000043135388464ab '\n",
      " 'httpsdoiorg10109701olq000043135388464ab '\n",
      " 'httpswwwcdcgovstdchlamydiachlamydiascreeningmalespdf '\n",
      " 'httpswwwcdcgovstdchlamydiachlamydiascreeningmalespdf '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids24521720doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids24521720doptabstract '\n",
      " 'httpsdoiorg101097olq0000000000000106 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids26285597doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids26285597doptabstract '\n",
      " 'httpsdoiorg1011771078345815600447 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids25427254doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids25427254doptabstract '\n",
      " 'httpsdoiorg101097phh0000000000000183 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids26536318doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids31329036doptabstract '\n",
      " 'httpsdoiorg101108ijph0720180043 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids20803782doptabstract '\n",
      " 'httpsdoiorg101097olq0b013e3181de4113 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids20023598doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids20023598doptabstract '\n",
      " 'httpsdoiorg101097olq0b013e3181bcd3fc '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids21844713doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids21844713doptabstract '\n",
      " 'httpsdoiorg101097olq0b013e31820bc86c '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids24275733doptabstract '\n",
      " 'httpsdoiorg101097olq0000000000000026 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids23191953doptabstract '\n",
      " 'httpsdoiorg101097olq0b013e31826e8847 httpsdoiorg101097olq0b013e31826e8847 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids22082718doptabstract '\n",
      " 'httpsdoiorg101097olq0b013e31822ea147 httpsdoiorg101097olq0b013e31822ea147 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids18090178doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids18090178doptabstract '\n",
      " 'httpsdoiorg101097olq0b013e318154bdb2 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids20088654doptabstract '\n",
      " 'httpsdoiorg101089jwh20091469 httpsdoiorg101089jwh20091469 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids16186455doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30532275doptabstract '\n",
      " 'httpsdoiorg101371journalpone0205593 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29516265doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29516265doptabstract '\n",
      " 'httpsdoiorg101007s1190401803899 recommendations and reports mmwr  july 23 '\n",
      " '2021  vol 70  no 4 149us department of health and human servicescenters for '\n",
      " 'disease control and prevention  397 morrow km project start study group hiv '\n",
      " 'std and hepatitis  risk behaviors of young men before and after '\n",
      " 'incarceration aids care  2 0 0 9  2 1  2 3 5 – 4 3   p m i d  1 9 2 2 9 6 9 '\n",
      " '4  h t t p s    d o i  org10108009540120802017586  398 bryan ad magnan re '\n",
      " 'gillman as et al effect of including alcohol  and cannabis content in a '\n",
      " 'sexual riskreduction intervention on the  incidence of sexually transmitted '\n",
      " 'infections in adolescents a cluster  randomized clinical trial jama pediatr '\n",
      " '2018172e175621  pmid29435591 httpsdoiorg101001jamapediatrics20175621  399 '\n",
      " 'diclemente rj davis tl swartzendruber a et al efficacy of an  hivsti sexual '\n",
      " 'riskreduction intervention for african american  adolescent girls in '\n",
      " 'juvenile detention centers a randomized controlled  trial women health '\n",
      " '201454726–49 pmid25190056 httpsdoi org101080036302422014932893  400 fogel ci '\n",
      " 'crandell jl neevel am et al efficacy of an adapted hiv  and sexually '\n",
      " 'transmitted infection prevention intervention for  incarcerated women a '\n",
      " 'randomized controlled trial am j public health  2015105802–9 pmid25211714 '\n",
      " 'httpsdoiorg102105 ajph2014302105  401 son j miller wm tossone k butcher f '\n",
      " 'kuo k the effect of  interprofessional studentled reproductive health '\n",
      " 'education on youths  in juvenile detention j pediatr adolesc gynecol '\n",
      " '201730370–5  pmid27871918 httpsdoiorg101016jjpag201611002  402 costumbrado j '\n",
      " 'stirland a cox g et al implementation of a hepatitis  ab vaccination program '\n",
      " 'using an accelerated schedule among highrisk  inmates  los angeles county '\n",
      " 'jai l   2007–2010 vaccine  2012306878–82 pmid22989688 httpsdoiorg101016j '\n",
      " 'vaccine201209006  403 allison m musser b satterwhite c ault k kelly p '\n",
      " 'ramaswamy m  human papillomavirus vaccine knowledge and intention among '\n",
      " 'adult  inmates in kansas 2016–2017 am j public health 20181081000–2  '\n",
      " 'pmid29927651 httpsdoiorg102105ajph2018304499  404 lucas kd miller jl eckert '\n",
      " 'v horne rl samuel mc mohleboetani  jc risk feasibility and cost evaluation '\n",
      " 'of a prisoner condom access  pilot program in one california state prison j '\n",
      " 'correct health care  2 0 1 4  2 0  1 8 4 – 9 4   p m i d  2 4 9 3 4 8 3 6  h '\n",
      " 't t p s    d o i  org1011771078345814530869  405 scott n mcbryde e kirwan a '\n",
      " 'stoové m modelling the impact of  condom distribution on the incidence and '\n",
      " 'prevalence of sexually  transmitted infections in an adult male prison '\n",
      " 'system plos one  201510e0144869 pmid26658518 httpsdoiorg101371journal '\n",
      " 'pone0144869  406 schacker t collier ac hughes j shea t corey l clinical and  '\n",
      " 'epidemiologic features of primary hiv infection ann intern med  1 9 9 6  1 2 '\n",
      " '5  2 5 7 – 6 4   p m i d  8 6 7 8 3 8 7  h t t p s    d o i  '\n",
      " 'org10732600034819125419960815000001  407 henn a flateau c gallien s primary '\n",
      " 'hiv infection clinical  presentation testing and treatment curr infect dis '\n",
      " 'rep 20171937  pmid28884279 httpsdoiorg101007s1190801705883  408 robb ml '\n",
      " 'eller la kibuuka h et al rv 217 study team prospective  study of acute hiv1 '\n",
      " 'infection in adults in east africa and thailand  n engl j med 20163742120–30 '\n",
      " 'pmid27192360 httpsdoi org101056nejmoa1508952  409 hoenigl m green n camacho '\n",
      " 'm et al signs or symptoms of acute  hiv infection in a cohort undergoing '\n",
      " 'communitybased screening  emerg infect dis 201622532–4 pmid26890854 httpsdoi '\n",
      " 'org103201eid2203151607  410 legarth ra ahlström mg kronborg g et al longterm '\n",
      " 'mortality  in hivinfected individuals 50 years or older a nationwide '\n",
      " 'population based cohort study j acquir immune defic syndr 201671213–8  '\n",
      " 'pmid26334734 httpsdoiorg101097qai0000000000000825  411 marcus jl chao cr '\n",
      " 'leyden wa et al narrowing the gap in life  expectancy between hivinfected '\n",
      " 'and hivuninfected individuals  with access to care j acquir immune defic '\n",
      " 'syndr 20167339–46  pmid27028501 httpsdoiorg101097qai0000000000001014  412 '\n",
      " 'cohen ms chen yq mccauley m et al hptn 052 study team  antiretroviral '\n",
      " 'therapy for the prevention of hiv1 transmission n engl  j med 2016375830–9 '\n",
      " 'pmid27424812 httpsdoiorg101056 nejmoa1600693  413 saag ms benson ca gandhi '\n",
      " 'rt et al antiretroviral drugs for  treatment and prevention of hiv infection '\n",
      " 'in adults 2018  recommendations of the international antiviral societyusa '\n",
      " 'panel  jama 2018320379–96 pmid30043070 httpsdoiorg101001 jama20188431  414 '\n",
      " 'seth p wang g sizemore e hogben m hiv testing and hiv service  delivery to '\n",
      " 'populations at high risk attending sexually transmitted  disease clinics in '\n",
      " 'the united states 2011–2013 am j public health  20151052374–81 pmid26378854 '\n",
      " 'httpsdoiorg102105 ajph2015302778  415 benton s smith j wang f heitgerd j '\n",
      " 'belcher l patel h hiv testing  diagnosis and linkage to care among persons '\n",
      " 'tested in select cdc funded health care and nonhealth care settings '\n",
      " '2012–2017 presented  at the national hiv prevention conference atlanta ga '\n",
      " 'march  18–21 2019  416 pathela p braunstein sl schillinger ja shepard c '\n",
      " 'sweeney m blank  s men who have sex with men have a 140fold higher risk for '\n",
      " 'newly  diagnosed hiv and syphilis compared with heterosexual men in new  '\n",
      " 'york city j acquir immune defic syndr 201158408–16  pmid21857351 '\n",
      " 'httpsdoiorg101097qai0b013e318230e1ca  417 chou r selph s dana t et al '\n",
      " 'screening for hiv systematic review  to update the 2005 us preventive '\n",
      " 'services task force recommendation  ann intern med 2012157706–18 '\n",
      " 'pmid23165662 httpsdoi org107326000348191571020121120000007  418 branson bm '\n",
      " 'handsfield hh lampe ma et al cdc revised  recommendations for hiv testing of '\n",
      " 'adults adolescents and pregnant  women in healthcare settings mmwr recomm '\n",
      " 'rep 200655no  rr14 pmid16988643  419 dinenno ea prejean j irwin k et al '\n",
      " 'recommendations for hiv  screening of gay bisexual and other men who have '\n",
      " 'sex with men— united states 2017 mmwr morb mortal wkly rep 201766830–2  '\n",
      " 'pmid28796758 httpsdoiorg1015585mmwrmm6631a3  420 cdc hiv2 infection '\n",
      " 'surveillance—united states 1987–2009  mmwr morb mortal wkly rep 201160985–8 '\n",
      " 'pmid21796096  421 wawer mj gray rh sewankambo nk et al rates of hiv1  '\n",
      " 'transmission per coital act by stage of hiv1 infection in rakai  uganda j '\n",
      " 'infect dis 20051911403–9 pmid15809897 httpsdoi org101086429411  422 pilcher '\n",
      " 'cd eron jj jr vemazza pl et al sexual transmission during  the incubation '\n",
      " 'period of primary hiv infection jama  20012861713–4 pmid11594895 '\n",
      " 'httpsdoiorg101001 jama286141713  423 calabrese sk mayer kh providers should '\n",
      " 'discuss uu with all  patients living with hiv lancet hiv 20196e211–3 '\n",
      " 'pmid30772420  httpsdoiorg101016s235230181930030x  424 gilbert p ciccarone d '\n",
      " 'gansky sa et al interactive “video doctor”  counseling reduces drug and '\n",
      " 'sexual risk behaviors among hivpositive  patients in diverse outpatient '\n",
      " 'settings plos one 20083e1988  pmid18431475 '\n",
      " 'httpsdoiorg101371journalpone0001988  425 aberg ja gallant je ghanem kg '\n",
      " 'emmanuel p zingman bs horberg  ma infectious diseases society of america '\n",
      " 'primary care guidelines  for the management of persons infected with hiv '\n",
      " '2013 update by  the hiv medicine association of the infectious diseases '\n",
      " 'society of  america clin infect dis 201458e1–34 pmid24235263 https '\n",
      " 'doiorg101093cidcit665  426 dicarlo rp martin dh the clinical diagnosis of '\n",
      " 'genital ulcer disease  in men clin infect dis 199725292–8 pmid9332527 '\n",
      " 'httpsdoi org101086514548  427 lockett ae dance da mabey dc drasar bs '\n",
      " 'serumfree media for  isolation of haemophilus ducreyi lancet 1991338326 '\n",
      " 'pmid1677152  httpsdoiorg1010160140673691904733 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids19229694doptabstract '\n",
      " 'httpsdoiorg10108009540120802017586 httpsdoiorg10108009540120802017586 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29435591doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29435591doptabstract '\n",
      " 'httpsdoiorg101001jamapediatrics20175621 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids25190056doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids25211714doptabstract '\n",
      " 'httpsdoiorg102105ajph2014302105 httpsdoiorg102105ajph2014302105 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids27871918doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids27871918doptabstract '\n",
      " 'httpsdoiorg101016jjpag201611002 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids22989688doptabstract '\n",
      " 'httpsdoiorg101016jvaccine201209006 httpsdoiorg101016jvaccine201209006 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29927651doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29927651doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids24934836doptabstract '\n",
      " 'httpsdoiorg1011771078345814530869 httpsdoiorg1011771078345814530869 '\n",
      " 'httpsdoiorg101371journalpone0144869 httpsdoiorg101371journalpone0144869 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids8678387doptabstract '\n",
      " 'httpsdoiorg10732600034819125419960815000001 '\n",
      " 'httpsdoiorg10732600034819125419960815000001 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28884279doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28884279doptabstract '\n",
      " 'httpsdoiorg101007s1190801705883 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids27192360doptabstract '\n",
      " 'httpsdoiorg101056nejmoa1508952 httpsdoiorg101056nejmoa1508952 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids26890854doptabstract '\n",
      " 'httpsdoiorg103201eid2203151607 httpsdoiorg103201eid2203151607 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids26334734doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids26334734doptabstract '\n",
      " 'httpsdoiorg101097qai0000000000000825 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids27028501doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids27028501doptabstract '\n",
      " 'httpsdoiorg101097qai0000000000001014 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids27424812doptabstract '\n",
      " 'httpsdoiorg101056nejmoa1600693 httpsdoiorg101056nejmoa1600693 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30043070doptabstract '\n",
      " 'httpsdoiorg101001jama20188431 httpsdoiorg101001jama20188431 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids26378854doptabstract '\n",
      " 'httpsdoiorg102105ajph2015302778 httpsdoiorg102105ajph2015302778 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids21857351doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids21857351doptabstract '\n",
      " 'httpsdoiorg101097qai0b013e318230e1ca '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids23165662doptabstract '\n",
      " 'httpsdoiorg107326000348191571020121120000007 '\n",
      " 'httpsdoiorg107326000348191571020121120000007 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids16988643doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28796758doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28796758doptabstract '\n",
      " 'httpsdoiorg1015585mmwrmm6631a3 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids21796096doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids15809897doptabstract '\n",
      " 'httpsdoiorg101086429411 httpsdoiorg101086429411 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids11594895doptabstract '\n",
      " 'httpsdoiorg101001jama286141713 httpsdoiorg101001jama286141713 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30772420doptabstract '\n",
      " 'httpsdoiorg101016s235230181930030x '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids18431475doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids18431475doptabstract '\n",
      " 'httpsdoiorg101371journalpone0001988 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids24235263doptabstract '\n",
      " 'httpsdoiorg101093cidcit665 httpsdoiorg101093cidcit665 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids9332527doptabstract '\n",
      " 'httpsdoiorg101086514548 httpsdoiorg101086514548 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids1677152doptabstract '\n",
      " 'httpsdoiorg1010160140673691904733 recommendations and reports 150 mmwr  july '\n",
      " '23 2021  vol 70  no 4 us department of health and human servicescenters for '\n",
      " 'disease control and prevention  428 lewis da mitjà o haemophilus ducreyi '\n",
      " 'from sexually transmitted  infection to skin ulcer pathogen curr opin infect '\n",
      " 'dis 20162952–7  pmid26658654 httpsdoiorg101097qco0000000000000226  429 '\n",
      " 'romero l huerfano c grilloardila cf macrolides for treatment of  haemophilus '\n",
      " 'ducreyi infection in sexually active adults cochrane  database syst rev '\n",
      " '201712cd012492 pmid29226307 httpsdoi org10100214651858cd012492pub2  430 '\n",
      " 'jessamine pg plummer fa ndinya achola jo et al human  immunodeficiency virus '\n",
      " 'genital ulcers and the male foreskin synergism  in hiv1 transmission scand j '\n",
      " 'infect dis suppl 199069181–6  pmid2263893  431 briggs gc drugs in pregnancy '\n",
      " 'and lactation a reference guide to fetal  and neonatal risk 11th ed '\n",
      " 'philadelphia pa wolters kluwer 2017  432 lewis da epidemiology clinical '\n",
      " 'features diagnosis and treatment of  haemophilus ducreyi—a disappearing '\n",
      " 'pathogen expert rev anti infect  ther 201412687–96 pmid24597521 '\n",
      " 'httpsdoiorg10158614 7872102014892414  433 mitjà o lukehart sa pokowas g et '\n",
      " 'al haemophilus ducreyi as a  cause of skin ulcers in children from a '\n",
      " 'yawsendemic area of papua  new guinea a prospective cohort study lancet glob '\n",
      " 'health  20142e235–41 pmid25103064 httpsdoiorg101016 s2214109x14700191  434 '\n",
      " 'marks m chi kh vahi v et al haemophilus ducreyi associated with  skin ulcers '\n",
      " 'among children solomon islands emerg infect dis  2014201705–7 pmid25271477 '\n",
      " 'httpsdoiorg103201 eid2010140573  435 ghinai r elduah p chi kh et al a '\n",
      " 'crosssectional study of ‘yaws’  in districts of ghana which have previously '\n",
      " 'undertaken azithromycin  mass drug administration for trachoma control plos '\n",
      " 'negl trop dis  20159e0003496 pmid25632942 httpsdoiorg101371journal '\n",
      " 'pntd0003496  436 mcquillan g kruszonmoran d flagg ew pauloseram r  '\n",
      " 'prevalence of herpes simplex virus type 1 and type 2 in persons aged  14–49 '\n",
      " 'united states 2015–2016 nchs data brief 20183041–8  pmid29442994  437 ryder '\n",
      " 'n jin f mcnulty am grulich ae donovan b increasing role  of herpes simplex '\n",
      " 'virus type 1 in firstepisode anogenital herpes in  heterosexual women and '\n",
      " 'younger men who have sex with men  1992–2006 sex transm infect 200985416–9 '\n",
      " 'pmid19273479  httpsdoiorg101136sti2008033902  438 roberts cm pfister jr '\n",
      " 'spear sj increasing proportion of herpes  simplex virus type 1 as a cause of '\n",
      " 'genital herpes infection in college  students sex transm dis 200330797–800 '\n",
      " 'pmid14520181 https doiorg10109701olq000009238758746c7  439 benedetti j corey '\n",
      " 'l ashley r recurrence rates in genital  herpes  a f ter  symptomatic  f i r '\n",
      " 's t episode infect ion  ann  intern med 1994121847–54 pmid7978697 httpsdoi '\n",
      " 'org107326000348191211119941201000004  440 engelberg r carrell d krantz e '\n",
      " 'corey l wald a natural  history of genital herpes simplex virus type 1 '\n",
      " 'infection sex  transm dis 200330174–7 pmid12567178 httpsdoi '\n",
      " 'org1010970000743520030200000015  441 masese l baeten jm richardson ba et al '\n",
      " 'changes in the contribution  of genital tract infections to hiv acquisition '\n",
      " 'among kenyan highrisk  women from 1993 to 2012 aids 2015291077–85 '\n",
      " 'pmid26125141  httpsdoiorg101097qad0000000000000646  442 sam ss caliendo am '\n",
      " 'ingersoll j abdulali d kraft cs performance  evaluation of the aptima hsv1 '\n",
      " 'and 2 assay for the detection of hsv  in cutaneous and mucocutaneous lesion '\n",
      " 'specimens j clin virol  2018991001–4 pmid29253834 httpsdoiorg101016j '\n",
      " 'jcv201712006  443 wald a huang ml carrell d selke s corey l polymerase '\n",
      " 'chain  reaction for detection of herpes simplex virus hsv dna on mucosal  '\n",
      " 'surfaces comparison with hsv isolation in cell culture j infect dis  '\n",
      " '20031881345–51 pmid14593592 httpsdoiorg101086379043  444 van der pol b '\n",
      " 'warren t taylor sn et al typespecific identification  of anogenital herpes '\n",
      " 'simplex virus infections by use of a commercially  available nucleic acid '\n",
      " 'amplification test j clin microbiol 2012503466– 71 pmid22875892 '\n",
      " 'httpsdoiorg101128jcm0168512  445 binnicker mj espy mj duresko b irish c '\n",
      " 'mandrekar j automated  processing extraction and detection of herpes simplex '\n",
      " 'virus types 1  and 2 a comparative evaluation of three commercial platforms '\n",
      " 'using  clinical specimens j clin virol 20178930–3 pmid28226272  '\n",
      " 'httpsdoiorg101016jjcv201702006  446 teo jw chiang d jureen r lin rt clinical '\n",
      " 'evaluation of a helicase dependant amplification hdabased commercial assay '\n",
      " 'for the  simultaneous detection of hsv1 and hsv2 diagn microbiol infect  dis '\n",
      " '201583261–2 pmid26302856 httpsdoiorg101016j diagmicrobio201507018  447 '\n",
      " 'gitman mr ferguson d landry ml comparison of simplexa hsv 1   2 pcr with '\n",
      " 'culture immunofluorescence and laboratorydeveloped  taqman pcr for detection '\n",
      " 'of herpes simplex virus in swab specimens  j clin microbiol 2013513765–9 '\n",
      " 'pmid24006008 httpsdoi org101128jcm0141313  448 corey l holmes kk genital '\n",
      " 'herpes simplex virus infections  current concepts in diagnosis therapy and '\n",
      " 'prevention ann  intern med 198398973–83 pmid6344713 httpsdoi '\n",
      " 'org10732600034819986958  449 caviness ac oelze ll saz ue greer jm '\n",
      " 'demmlerharrison gj  direct immunofluorescence assay compared to cell culture '\n",
      " 'for the  diagnosis of mucocutaneous herpes simplex virus infections in '\n",
      " 'children  j clin virol 20104958–60 pmid20620099 httpsdoi '\n",
      " 'org101016jjcv201006006  450 song b dwyer de mindel a hsv type specific '\n",
      " 'serology in sexual  health clinics use benefits and who gets tested sex '\n",
      " 'transm infect  200480113–7 pmid15054171 httpsdoiorg101136 sti2003006783  451 '\n",
      " 'whittington wl celum cl cent a ashley rl use of a glycoprotein  gbased '\n",
      " 'typespecific assay to detect antibodies to herpes simplex virus  type 2 '\n",
      " 'among persons attending sexually transmitted disease clinics  sex transm dis '\n",
      " '20012899–104 pmid11234793 httpsdoi org1010970000743520010200000007  452 '\n",
      " 'zimet gd rosenthal sl fortenberry jd et al factors predicting  the '\n",
      " 'acceptance of herpes simplex virus type 2 antibody testing among  '\n",
      " 'adolescents and young adults sex transm dis 200431665–9  pmid15502674 '\n",
      " 'httpsdoiorg10109701olq000014308977493c2  453 turner kr wong eh kent ck '\n",
      " 'klausner jd serologic herpes  testing in the real world validation of new '\n",
      " 'typespecific serologic  herpes simplex virus tests in a public health '\n",
      " 'laboratory sex  transm dis 200229422–5 pmid12170133 httpsdoi '\n",
      " 'org1010970000743520020700000011  454 eing br lippelt l lorentzen eu et al '\n",
      " 'evaluation of confirmatory  strategies for detection of typespecific '\n",
      " 'antibodies against herpes simplex  virus type 2 j clin microbiol '\n",
      " '200240407–13 pmid11825950  httpsdoiorg101128jcm4024074132002  455 golden mr '\n",
      " 'ashleymorrow r swenson p hogrefe wr handsfield  hh wald a herpes simplex '\n",
      " 'virus type 2 hsv2 western blot  confirmatory testing among men testing '\n",
      " 'positive for hsv2 using the  focus enzymelinked immunosorbent assay in a '\n",
      " 'sexually transmitted  disease clinic sex transm dis 200532771–7 '\n",
      " 'pmid16314775  httpsdoiorg10109701olq000017537788358f3  456 morrow ra '\n",
      " 'friedrich d meier a corey l use of “biokit hsv2  rapid assay” to improve the '\n",
      " 'positive predictive value of focus  herpeselect hsv2 elisa bmc infect dis '\n",
      " '2005584  pmid16225691 httpsdoiorg10118614712334584  457 ngo td laeyendecker '\n",
      " 'o la h hogrefe w morrow ra quinn tc  use of commercial enzyme immunoassays '\n",
      " 'to detect antibodies to the  herpes simplex virus type 2 glycoprotein g in a '\n",
      " 'lowrisk population in  hanoi vietnam clin vaccine immunol 200815382–4  '\n",
      " 'pmid18077617 httpsdoiorg101128cvi0043706 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids26658654doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids26658654doptabstract '\n",
      " 'httpsdoiorg101097qco0000000000000226 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29226307doptabstract '\n",
      " 'httpsdoiorg10100214651858cd012492pub2 httpsdoiorg10100214651858cd012492pub2 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids24597521doptabstract '\n",
      " 'httpsdoiorg101586147872102014892414 httpsdoiorg101586147872102014892414 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids25103064doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids25271477doptabstract '\n",
      " 'httpsdoiorg103201eid2010140573 httpsdoiorg103201eid2010140573 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids25632942doptabstract '\n",
      " 'httpsdoiorg101371journalpntd0003496 httpsdoiorg101371journalpntd0003496 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29442994doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29442994doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids19273479doptabstract '\n",
      " 'httpsdoiorg101136sti2008033902 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids14520181doptabstract '\n",
      " 'httpsdoiorg10109701olq000009238758746c7 '\n",
      " 'httpsdoiorg10109701olq000009238758746c7 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids7978697doptabstract '\n",
      " 'httpsdoiorg107326000348191211119941201000004 '\n",
      " 'httpsdoiorg107326000348191211119941201000004 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids12567178doptabstract '\n",
      " 'httpsdoiorg1010970000743520030200000015 '\n",
      " 'httpsdoiorg1010970000743520030200000015 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids26125141doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29253834doptabstract '\n",
      " 'httpsdoiorg101016jjcv201712006 httpsdoiorg101016jjcv201712006 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids14593592doptabstract '\n",
      " 'httpsdoiorg101086379043 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids22875892doptabstract '\n",
      " 'httpsdoiorg101128jcm0168512 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28226272doptabstract '\n",
      " 'httpsdoiorg101016jjcv201702006 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids26302856doptabstract '\n",
      " 'httpsdoiorg101016jdiagmicrobio201507018 '\n",
      " 'httpsdoiorg101016jdiagmicrobio201507018 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids24006008doptabstract '\n",
      " 'httpsdoiorg101128jcm0141313 httpsdoiorg101128jcm0141313 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids6344713doptabstract '\n",
      " 'httpsdoiorg10732600034819986958 httpsdoiorg10732600034819986958 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids20620099doptabstract '\n",
      " 'httpsdoiorg101016jjcv201006006 httpsdoiorg101016jjcv201006006 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids15054171doptabstract '\n",
      " 'httpsdoiorg101136sti2003006783 httpsdoiorg101136sti2003006783 '\n",
      " 'httpsdoiorg1010970000743520010200000007 '\n",
      " 'httpsdoiorg1010970000743520010200000007 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids15502674doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids15502674doptabstract '\n",
      " 'httpsdoiorg10109701olq000014308977493c2 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids12170133doptabstract '\n",
      " 'httpsdoiorg1010970000743520020700000011 '\n",
      " 'httpsdoiorg1010970000743520020700000011 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids11825950doptabstract '\n",
      " 'httpsdoiorg101128jcm4024074132002 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids16314775doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids16225691doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids16225691doptabstract '\n",
      " 'httpsdoiorg10118614712334584 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids18077617doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids18077617doptabstract '\n",
      " 'httpsdoiorg101128cvi0043706 recommendations and reports mmwr  july 23 2021  '\n",
      " 'vol 70  no 4 151us department of health and human servicescenters for '\n",
      " 'disease control and prevention  458 agyemang e le qa warren t et al '\n",
      " 'performance of commercial  enzymelinked immunoassays for diagnosis of herpes '\n",
      " 'simplex virus1  and herpes simplex virus2 infection in a clinical setting '\n",
      " 'sex transm  dis 201744763–7 pmid28876290 httpsdoiorg101097 '\n",
      " 'olq0000000000000689  459 morrow r friedrich d performance of a novel test '\n",
      " 'for igm and  igg antibodies in subjects with culturedocumented genital '\n",
      " 'herpes  simplex virus1 or 2 infection clin microbiol infect 200612463–9  '\n",
      " 'pmid16643524 httpsdoiorg101111j14690691200601370x  460 ameli n bacchetti p '\n",
      " 'morrow ra et al herpes simplex virus infection  in women in the wihs '\n",
      " 'epidemiology and effect of antiretroviral therapy  on clinical '\n",
      " 'manifestations aids 2006201051–8 pmid16603858  '\n",
      " 'httpsdoiorg10109701aids00002220787586777  461 bradley h markowitz le gibson '\n",
      " 't mcquillan gm seroprevalence of  herpes simplex virus types 1 and 2—united '\n",
      " 'states 1999–2010 j infect  dis 2014209325–33 pmid24136792 httpsdoiorg101093 '\n",
      " 'infdisjit458  462 bernstein di bellamy ar hook ew 3rd et al epidemiology '\n",
      " 'clinical  presentation and antibody response to primary infection with '\n",
      " 'herpes  simplex virus type 1 and type 2 in young women clin infect dis  '\n",
      " '201356344–51 pmid23087395 httpsdoiorg101093cid cis891  463 leone pa trottier '\n",
      " 's miller jm valacyclovir for episodic treatment of  genital herpes a shorter '\n",
      " '3day treatment course compared with 5day  treatment clin infect dis '\n",
      " '200234958–62 pmid11880962 https doiorg101086339326  464 wald a carrell d '\n",
      " 'remington m kexel e zeh j corey l two day regimen of acyclovir for treatment '\n",
      " 'of recurrent genital herpes  simplex virus type 2 infection clin infect dis '\n",
      " '200234944–8  pmid11880960 httpsdoiorg101086339325  465 aoki fy tyring s '\n",
      " 'diazmitoma f gross g gao j hamed k single day patientinitiated famciclovir '\n",
      " 'therapy for recurrent genital herpes  a randomized doubleblind '\n",
      " 'placebocontrolled trial clin infect dis  2006428–13 pmid16323085 '\n",
      " 'httpsdoiorg101086498521  466 chosidow o drouault y leconteveyriac f et al '\n",
      " 'famciclovir vs  aciclovir in immunocompetent patients with recurrent genital '\n",
      " 'herpes  infections a parallelgroups randomized doubleblind clinical trial  '\n",
      " 'br j dermatol 2001144818–24 pmid11298543 httpsdoi '\n",
      " 'org101046j13652133200104139x  467 bodsworth nj crooks rj borelli s et al '\n",
      " 'international valaciclovir  hsv study group valaciclovir versus aciclovir in '\n",
      " 'patient initiated  treatment of recurrent genital herpes a randomised double '\n",
      " 'blind  clinical trial genitourin med 199773110–6 pmid9215092  468 fife kh '\n",
      " 'barbarash ra rudolph t degregorio b roth r the  valaciclovir international '\n",
      " 'herpes simplex virus study group valaciclovir  versus acyclovir in the '\n",
      " 'treatment of firstepisode genital herpes infection  results of an '\n",
      " 'international multicenter doubleblind randomized  clinical trial sex transm '\n",
      " 'dis 199724481–6 pmid9293612 https doiorg1010970000743519970900000007  469 '\n",
      " 'diazmitoma f sibbald rg shafran sd boon r saltzman rl  collaborative '\n",
      " 'famciclovir genital herpes research group oral  famciclovir for the '\n",
      " 'suppression of recurrent genital herpes a randomized  controlled trial jama '\n",
      " '1998280887–92 pmid9739972 httpsdoi org101001jama28010887  470 mertz gj '\n",
      " 'loveless mo levin mj et al collaborative famciclovir  genital herpes '\n",
      " 'research group oral famciclovir for suppression  of recurrent genital herpes '\n",
      " 'simplex virus infection in women a  multicenter doubleblind '\n",
      " 'placebocontrolled trial arch intern  med 1997157343–9 pmid9040303 '\n",
      " 'httpsdoiorg101001 archinte199700440240109016  471 reitano m tyring s lang w '\n",
      " 'et al international valaciclovir hsv  study group valaciclovir for the '\n",
      " 'suppression of recurrent genital herpes  simplex virus infection a '\n",
      " 'largescale dose rangefinding study j infect  di s  1 9 9 8  1 7 8  6 0 3 – 1 '\n",
      " '0   p m i d  9 7 2 8 5 2 6  h t t p s    d o i  org101086515385  472 '\n",
      " 'romanowski b marina rb roberts jn valtrex hs230017 study  group patients’ '\n",
      " 'preference of valacyclovir oncedaily suppressive  therapy versus twicedaily '\n",
      " 'episodic therapy for recurrent genital herpes a  randomized study sex transm '\n",
      " 'dis 200330226–31 pmid12616141  httpsdoiorg1010970000743520030300000010  473 '\n",
      " 'corey l wald a patel r et al valacyclovir hsv transmission study  group '\n",
      " 'oncedaily valacyclovir to reduce the risk of transmission of  genital herpes '\n",
      " 'n engl j med 200435011–20 pmid14702423  httpsdoiorg101056nejmoa035144  474 '\n",
      " 'tyring sk baker d snowden w valacyclovir for herpes simplex  virus infection '\n",
      " 'longterm safety and sustained efficacy after 20 years’  experience with '\n",
      " 'acyclovir j infect dis 2002186suppl 1s40–6  pmid12353186 '\n",
      " 'httpsdoiorg101086342966  475 bartlett bl tyring sk fife k et al famciclovir '\n",
      " 'treatment options  for patients with frequent outbreaks of recurrent genital '\n",
      " 'herpes the  relief trial j clin virol 200843190–5 pmid18621575 https '\n",
      " 'doiorg101016jjcv200806004  476 tronstein e johnston c huang ml et al genital '\n",
      " 'shedding of herpes  simplex virus among symptomatic and asymptomatic persons '\n",
      " 'with  hsv2 infection jama 20113051441–9 pmid21486977 https '\n",
      " 'doiorg101001jama2011420  477 bender ignacio ra perti t magaret as et al oral '\n",
      " 'and vaginal tenofovir  for genital herpes simplex virus type 2 shedding in '\n",
      " 'immunocompetent  women a doubleblind randomized crossover trial j infect '\n",
      " 'dis  20152121949–56 pmid26044291 httpsdoiorg101093infdis jiv317  478 wald a '\n",
      " 'selke s warren t et al comparative efficacy of famciclovir  and valacyclovir '\n",
      " 'for suppression of recurrent genital herpes and viral  shedding sex transm '\n",
      " 'dis 200633529–33 pmid16540883 https doiorg10109701olq00002047231576591  479 '\n",
      " 'johnston c magaret a stern m et al natural history of genital and  oral '\n",
      " 'herpes simplex virus1 hsv1 shedding after first episode genital  hsv1 '\n",
      " 'infection sex transm infect 201995a42  480 tang yw cleavinger pj li h '\n",
      " 'mitchell ps smith tf persing dh  analysis of candidatehost immunogenetic '\n",
      " 'determinants in herpes  simplex virusassociated mollaret’s meningitis clin '\n",
      " 'infect dis  200030176–8 pmid10619748 httpsdoiorg101086313616  481 shalabi m '\n",
      " 'whitley rj recurrent benign lymphocytic meningitis  clin infect dis '\n",
      " '2006431194–7 pmid17029141 httpsdoi org101086508281  482 landry ml greenwold '\n",
      " 'j vikram hr herpes simplex type2  meningitis presentation and lack of '\n",
      " 'standardized therapy am j med  2009122688–91 pmid19559173 httpsdoiorg101016j '\n",
      " 'amjmed200902017  483 aurelius e franzenröhl e glimåker m et al hsv2 '\n",
      " 'meningitis  study group longterm valacyclovir suppressive treatment after '\n",
      " 'herpes  simplex virus type 2 meningitis a doubleblind randomized controlled  '\n",
      " 'trial clin infect dis 2012541304–13 pmid22460966 httpsdoi '\n",
      " 'org101093cidcis031  484 magawa s tanaka h furuhashi f et al a literature '\n",
      " 'review of herpes  simplex virus hepatitis in pregnancy j matern fetal '\n",
      " 'neonatal med  2020331774–9 pmid30235956 httpsdoiorg101080147670 '\n",
      " '5820181527311  485 masadeh m shen h lee y et al a fatal case of herpes '\n",
      " 'simplex virus  hepatitis in a pregnant patient intractable rare dis res '\n",
      " '20176124–7  pmid28580213 httpsdoiorg105582irdr201701013  486 martin et '\n",
      " 'krantz e gottlieb sl et al a pooled analysis of the  effect of condoms in '\n",
      " 'preventing hsv2 acquisition arch intern  med 20091691233–40 pmid19597073 '\n",
      " 'httpsdoiorg101001 archinternmed2009177  487 wald a langenberg ag krantz e et '\n",
      " 'al the relationship  between condom use and herpes simplex virus acquisition '\n",
      " 'ann  intern med 2005143707–13 pmid16287791 httpsdoi '\n",
      " 'org107326000348191431020051115000007 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28876290doptabstract '\n",
      " 'httpsdoiorg101097olq0000000000000689 httpsdoiorg101097olq0000000000000689 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids16643524doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids16643524doptabstract '\n",
      " 'httpsdoiorg101111j14690691200601370x '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids16603858doptabstract '\n",
      " 'httpsdoiorg10109701aids00002220787586777 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids24136792doptabstract '\n",
      " 'httpsdoiorg101093infdisjit458 httpsdoiorg101093infdisjit458 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids23087395doptabstract '\n",
      " 'httpsdoiorg101093cidcis891 httpsdoiorg101093cidcis891 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids11880962doptabstract '\n",
      " 'httpsdoiorg101086339326 httpsdoiorg101086339326 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids11880960doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids11880960doptabstract '\n",
      " 'httpsdoiorg101086339325 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids16323085doptabstract '\n",
      " 'httpsdoiorg101086498521 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids11298543doptabstract '\n",
      " 'httpsdoiorg101046j13652133200104139x httpsdoiorg101046j13652133200104139x '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids9215092doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids9293612doptabstract '\n",
      " 'httpsdoiorg1010970000743519970900000007 '\n",
      " 'httpsdoiorg1010970000743519970900000007 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids9739972doptabstract '\n",
      " 'httpsdoiorg101001jama28010887 httpsdoiorg101001jama28010887 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids9040303doptabstract '\n",
      " 'httpsdoiorg101001archinte199700440240109016 '\n",
      " 'httpsdoiorg101001archinte199700440240109016 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids9728526doptabstract '\n",
      " 'httpsdoiorg101086515385 httpsdoiorg101086515385 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids12616141doptabstract '\n",
      " 'httpsdoiorg1010970000743520030300000010 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids14702423doptabstract '\n",
      " 'httpsdoiorg101056nejmoa035144 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids12353186doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids12353186doptabstract '\n",
      " 'httpsdoiorg101086342966 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids18621575doptabstract '\n",
      " 'httpsdoiorg101016jjcv200806004 httpsdoiorg101016jjcv200806004 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids21486977doptabstract '\n",
      " 'httpsdoiorg101001jama2011420 httpsdoiorg101001jama2011420 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids26044291doptabstract '\n",
      " 'httpsdoiorg101093infdisjiv317 httpsdoiorg101093infdisjiv317 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids16540883doptabstract '\n",
      " 'httpsdoiorg10109701olq00002047231576591 '\n",
      " 'httpsdoiorg10109701olq00002047231576591 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids10619748doptabstract '\n",
      " 'httpsdoiorg101086313616 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids17029141doptabstract '\n",
      " 'httpsdoiorg101086508281 httpsdoiorg101086508281 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids19559173doptabstract '\n",
      " 'httpsdoiorg101016jamjmed200902017 httpsdoiorg101016jamjmed200902017 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids22460966doptabstract '\n",
      " 'httpsdoiorg101093cidcis031 httpsdoiorg101093cidcis031 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30235956doptabstract '\n",
      " 'httpsdoiorg1010801476705820181527311 httpsdoiorg1010801476705820181527311 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28580213doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28580213doptabstract '\n",
      " 'httpsdoiorg105582irdr201701013 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids19597073doptabstract '\n",
      " 'httpsdoiorg101001archinternmed2009177 httpsdoiorg101001archinternmed2009177 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids16287791doptabstract '\n",
      " 'httpsdoiorg107326000348191431020051115000007 '\n",
      " 'httpsdoiorg107326000348191431020051115000007 recommendations and reports 152 '\n",
      " 'mmwr  july 23 2021  vol 70  no 4 us department of health and human '\n",
      " 'servicescenters for disease control and prevention  488 wald a langenberg ag '\n",
      " 'link k et al effect of condoms on reducing  the transmission of herpes '\n",
      " 'simplex virus type 2 from men to women  jama 20012853100–6 pmid11427138 '\n",
      " 'httpsdoiorg101001 jama285243100  489 magaret as mujugira a hughes jp et al '\n",
      " 'partners in prevention  hsvhiv transmission study team effect of condom use '\n",
      " 'on peract  hsv2 transmission risk in hiv1 hsv2discordant couples clin  '\n",
      " 'infect dis 201662456–61 pmid26578538  490 mehta sd moses s agot k et al '\n",
      " 'medical male circumcision and  herpes simplex virus 2 acquisition posttrial '\n",
      " 'surveillance in kisumu  kenya j infect dis 20132081869–76 pmid23901089 '\n",
      " 'httpsdoi org101093infdisjit371  491 grund jm bryant ts jackson i et al '\n",
      " 'association between male  circumcision and women’s biomedical health '\n",
      " 'outcomes a systematic  review lancet glob health 20175e1113–22 pmid29025633  '\n",
      " 'httpsdoiorg101016s2214109x17303698  492 celum c morrow ra donnell d et al '\n",
      " 'partners prep study team  daily oral tenofovir and emtricitabinetenofovir '\n",
      " 'preexposure  prophylaxis reduces herpes simplex virus type 2 acquisition '\n",
      " 'among  heterosexual hiv1uninfected men and women a subgroup analysis  of a '\n",
      " 'randomized trial ann intern med 201416111–9 pmid24979446  '\n",
      " 'httpsdoiorg107326m132471  493 abdool karim ss abdool karim q gengiah tn '\n",
      " 'tenofovir gel to  prevent hsv2 infection n engl j med 20153731980–1  '\n",
      " 'pmid26559584 httpsdoiorg101056nejmoa1410649  494 marcus jl glidden dv '\n",
      " 'mcmahan v et al daily oral emtricitabine tenofovir preexposure prophylaxis '\n",
      " 'and herpes simplex virus type 2  among men who have sex with men plos one '\n",
      " '20149e91513  pmid24637511 httpsdoiorg101371journalpone0091513  495 celum c '\n",
      " 'hong t cent a et al actg pearlsa5175 team  herpes simplex virus type 2 '\n",
      " 'acquisition among hiv1infected adults  treated with tenofovir disoproxyl '\n",
      " 'fumarate as part of combination  antiretroviral therapy results from the '\n",
      " 'actg a5175 pearls study  j infect dis 2017215907–10 pmid28453835 httpsdoi '\n",
      " 'org101093infdisjix029  496 gilbert lk wyand f genital herpes education and '\n",
      " 'counselling testing  a onepage ‘faq’ intervention herpes 20091551–6 '\n",
      " 'pmid19306603  497 rosenthal sl zimet gd leichliter js et al the psychosocial '\n",
      " 'impact  of serological diagnosis of asymptomatic herpes simplex virus type '\n",
      " '2  infection sex transm infect 200682154–7 discussion 157–8  pmid16581745 '\n",
      " 'httpsdoiorg101136sti2005016311  498 miyai t turner kr kent ck klausner j the '\n",
      " 'psychosocial impact  of testing individuals with no history of genital '\n",
      " 'herpes for herpes simplex  virus type 2 sex transm dis 200431517–21 '\n",
      " 'pmid15480111  httpsdoiorg10109701olq0000137901712846b  499 ross k johnston c '\n",
      " 'wald a herpes simplex virus type 2 serological  testing and psychosocial '\n",
      " 'harm a systematic review sex transm infect  201187594–600 pmid21903980 '\n",
      " 'httpsdoiorg101136 sextrans2011050099  500 henry re wegmann ja hartle je '\n",
      " 'christopher gw successful oral  acyclovir desensitization ann allergy '\n",
      " '199370386–8 pmid8498729  501 leeyaphan c surawan tm chirachanakul p et al '\n",
      " 'clinical  characteristics of hypertrophic herpes simplex genitalis and '\n",
      " 'treatment  outcomes of imiquimod a retrospective observational study int j '\n",
      " 'infect  dis 201533165–70 pmid25660091 httpsdoiorg101016j ijid201502002  502 '\n",
      " 'keller mj huber a espinoza l et al impact of herpes simplex virus  type 2 '\n",
      " 'and human immunodeficiency virus dual infection on female  genital tract '\n",
      " 'mucosal immunity and the vaginal microbiome j infect  dis 2019220852–61 '\n",
      " 'pmid31111902 httpsdoiorg101093 infdisjiz203  503 posavad cm wald a kuntz s '\n",
      " 'et al frequent reactivation of herpes  simplex virus among hiv1infected '\n",
      " 'patients treated with highly active  antiretroviral therapy j infect dis '\n",
      " '2004190693–6 pmid15272395  httpsdoiorg101086422755  504 tobian aa grabowski '\n",
      " 'mk serwadda d et al rakai health sciences  program reactivation of herpes '\n",
      " 'simplex virus type 2 after initiation  of antiretroviral therapy j infect '\n",
      " 'dis 2013208839–46  pmid23812240 httpsdoiorg101093infdisjit252  505 mujugira '\n",
      " 'a magaret as celum c et al partners in prevention hsv hiv transmission study '\n",
      " 'team daily acyclovir to decrease herpes simplex  virus type 2 hsv2 '\n",
      " 'transmission from hsv2hiv1 coinfected  persons a randomized controlled trial '\n",
      " 'j infect dis 20132081366–74  pmid23901094 httpsdoiorg101093infdisjit333  506 '\n",
      " 'van wagoner n geisler wm bachmann lh hook ew the effect  of valacyclovir on '\n",
      " 'hiv and hsv2 in hivinfected persons on  antiretroviral therapy with '\n",
      " 'previously unrecognised hsv2 int j std  aids 201526 574–81  pmid25147236 ht '\n",
      " 'tps   do i  org1011770956462414546504  507 reyes m shaik ns graber jm et al '\n",
      " 'task force on herpes simplex  virus resistance acyclovirresistant genital '\n",
      " 'herpes among persons  attending sexually transmitted disease and human '\n",
      " 'immunodeficiency  virus clinics arch intern med 200316376–80 pmid12523920  '\n",
      " 'httpsdoiorg101001archinte163176  508 safrin s crumpacker c chatis p et al '\n",
      " 'the aids clinical trials  group a controlled trial comparing foscarnet with '\n",
      " 'vidarabine for  acyclovirresistant mucocutaneous herpes simplex in the '\n",
      " 'acquired  immunodeficiency syndrome n engl j med 1991325551–5  pmid1649971 '\n",
      " 'httpsdoiorg101056nejm199108223250805  509 levin mj bacon th leary jj '\n",
      " 'resistance of herpes simplex virus  infections to nucleoside analogues in '\n",
      " 'hivinfected patients clin infect  dis 200439suppl 5s248–57 pmid15494896 '\n",
      " 'httpsdoi org101086422364  510 tandon s singh j sinha s sharma dp '\n",
      " 'recalcitrant hypertrophic  herpes genitalis in hivinfected patient '\n",
      " 'successfully treated with topical  imiquimod dermatol ther heidelb  '\n",
      " '201730e12479  pmid28261899 httpsdoiorg101111dth12479  511 perkins n nisbet m '\n",
      " 'thomas m topical imiquimod treatment of  aciclovirresistant herpes simplex '\n",
      " 'disease case series and literature  review sex transm infect 201187292–5 '\n",
      " 'pmid21406577 https doiorg101136sti2010047431  512 mcelhiney lf topical '\n",
      " 'cidofovir for treatment of resistant viral  infections int j pharm compd '\n",
      " '200610324–8 pmid23974309  513 erard v wald a corey l leisenring wm boeckh m '\n",
      " 'use of long term suppressive acyclovir after hematopoietic stemcell '\n",
      " 'transplantation  impact on herpes simplex virus hsv disease and '\n",
      " 'drugresistant hsv  disease j infect dis 2007196266–70 pmid17570114 httpsdoi '\n",
      " 'org101086518938  514 brown za selke s zeh j et al the acquisition of herpes '\n",
      " 'simplex virus  during pregnancy n engl j med 1997337509–15 pmid9262493  '\n",
      " 'httpsdoiorg101056nejm199708213370801  515 pinninti sg kimberlin dw maternal '\n",
      " 'and neonatal herpes simplex  virus infections am j perinatol 201330113–9 '\n",
      " 'pmid23303485  httpsdoiorg101055s00321332802  516 brown za benedetti j ashley '\n",
      " 'r et al neonatal herpes simplex virus  infection in relation to asymptomatic '\n",
      " 'maternal infection at the time  of labor n engl j med 19913241247–52 '\n",
      " 'pmid1849612 https doiorg101056nejm199105023241804  517 brown za wald a '\n",
      " 'morrow ra selke s zeh j corey l effect of  serologic status and cesarean '\n",
      " 'delivery on transmission rates of herpes  simplex virus from mother to '\n",
      " 'infant jama 2003289203–9  pmid12517231 httpsdoiorg101001jama2892203  518 '\n",
      " 'ahrens ka anderka mt feldkamp ml canfield ma mitchell aa  werler mm national '\n",
      " 'birth defects prevention study antiherpetic  medication use and the risk of '\n",
      " 'gastroschisis findings from the national  birth defects prevention study '\n",
      " '1997–2007 paediatr perinat epidemiol  201327340–5 pmid23772935 '\n",
      " 'httpsdoiorg101111ppe12064 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids11427138doptabstract '\n",
      " 'httpsdoiorg101001jama285243100 httpsdoiorg101001jama285243100 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids26578538doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids23901089doptabstract '\n",
      " 'httpsdoiorg101093infdisjit371 httpsdoiorg101093infdisjit371 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29025633doptabstract '\n",
      " 'httpsdoiorg101016s2214109x17303698 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids24979446doptabstract '\n",
      " 'httpsdoiorg107326m132471 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids26559584doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids26559584doptabstract '\n",
      " 'httpsdoiorg101056nejmoa1410649 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids24637511doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids24637511doptabstract '\n",
      " 'httpsdoiorg101371journalpone0091513 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28453835doptabstract '\n",
      " 'httpsdoiorg101093infdisjix029 httpsdoiorg101093infdisjix029 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids19306603doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids16581745doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids16581745doptabstract '\n",
      " 'httpsdoiorg101136sti2005016311 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids15480111doptabstract '\n",
      " 'httpsdoiorg10109701olq0000137901712846b '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids21903980doptabstract '\n",
      " 'httpsdoiorg101136sextrans2011050099 httpsdoiorg101136sextrans2011050099 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids8498729doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids25660091doptabstract '\n",
      " 'httpsdoiorg101016jijid201502002 httpsdoiorg101016jijid201502002 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids31111902doptabstract '\n",
      " 'httpsdoiorg101093infdisjiz203 httpsdoiorg101093infdisjiz203 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids15272395doptabstract '\n",
      " 'httpsdoiorg101086422755 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids23812240doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids23812240doptabstract '\n",
      " 'httpsdoiorg101093infdisjit252 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids23901094doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids23901094doptabstract '\n",
      " 'httpsdoiorg101093infdisjit333 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids25147236doptabstract '\n",
      " 'httpsdoiorg1011770956462414546504 httpsdoiorg1011770956462414546504 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids12523920doptabstract '\n",
      " 'httpsdoiorg101001archinte163176 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids1649971doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids1649971doptabstract '\n",
      " 'httpsdoiorg101056nejm199108223250805 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids15494896doptabstract '\n",
      " 'httpsdoiorg101086422364 httpsdoiorg101086422364 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28261899doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28261899doptabstract '\n",
      " 'httpsdoiorg101111dth12479 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids21406577doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids23974309doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids17570114doptabstract '\n",
      " 'httpsdoiorg101086518938 httpsdoiorg101086518938 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids9262493doptabstract '\n",
      " 'httpsdoiorg101056nejm199708213370801 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids23303485doptabstract '\n",
      " 'httpsdoiorg101055s00321332802 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids1849612doptabstract '\n",
      " 'httpsdoiorg101056nejm199105023241804 httpsdoiorg101056nejm199105023241804 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids12517231doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids12517231doptabstract '\n",
      " 'httpsdoiorg101001jama2892203 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids23772935doptabstract '\n",
      " 'httpsdoiorg101111ppe12064 recommendations and reports mmwr  july 23 2021  '\n",
      " 'vol 70  no 4 153us department of health and human servicescenters for '\n",
      " 'disease control and prevention  519 stone km reiffeldridge r white ad et al '\n",
      " 'pregnancy outcomes  following systemic prenatal acyclovir exposure '\n",
      " 'conclusions from the  international acyclovir pregnancy registry 1984–1999 '\n",
      " 'birth defects  res a clin mol teratol 200470201–7 pmid15108247 httpsdoi '\n",
      " 'org101002bdra20013  520 pasternak b hviid a use of acyclovir valacyclovir '\n",
      " 'and famciclovir in  the first trimester of pregnancy and the risk of birth '\n",
      " 'defects jama  2010304859–66 pmid20736469 httpsdoiorg101001 jama20101206  521 '\n",
      " 'sheffield js sánchez pj wendel gd jr et al placental histopathology  of '\n",
      " 'congenital syphilis obstet gynecol 2002100126–33  pmid12100814  522 watts dh '\n",
      " 'brown za money d et al a doubleblind randomized  placebocontrolled trial of '\n",
      " 'acyclovir in late pregnancy for the reduction  of herpes simplex virus '\n",
      " 'shedding and cesarean delivery am j obstet  gynecol 2003188836–43 '\n",
      " 'pmid12634667 httpsdoiorg101067 mob2003185  523 scott ll hollier lm mcintire '\n",
      " 'd sanchez pj jackson gl wendel  gd jr acyclovir suppression to prevent '\n",
      " 'recurrent genital herpes at  delivery infect dis obstet gynecol 20021071–7 '\n",
      " 'pmid12530483  httpsdoiorg101155s1064744902000054  524 pinninti sg angara r '\n",
      " 'feja kn et al neonatal herpes disease following  maternal antenatal '\n",
      " 'antiviral suppressive therapy a multicenter case  series j pediatr '\n",
      " '2012161134–8e13 pmid22336576 httpsdoi org101016jjpeds201112053  525 acog '\n",
      " 'committee on practice bulletins acog practice bulletin  clinical management '\n",
      " 'guidelines for obstetriciangynecologists no 82  june 2007 management of '\n",
      " 'herpes in pregnancy obstet gynecol  20071091489–98 pmid17569194 '\n",
      " 'httpsdoiorg10109701 aog0000263902319533e  526 winer rl hughes jp feng q et '\n",
      " 'al early natural history of incident  typespecific human papillomavirus '\n",
      " 'infections in newly sexually active  young women cancer epidemiol biomarkers '\n",
      " 'prev 201120699–707  pmid21173170 httpsdoiorg10115810559965epi101108  527 '\n",
      " 'ahmed n pillay a lawler m bobat r archary m donovanosis  causing '\n",
      " 'lymphadenitis mastoiditis and meningitis in a child lancet  20153852644 '\n",
      " 'pmid26122163 httpsdoiorg101016 s0140673615609928  528 arora ak kumaran ms '\n",
      " 'narang t saikia un handa s donovanosis  and squamous cell carcinoma the '\n",
      " 'relationship conundrum int j std  aids  2017 28 411–4   pmid27535727  h t tp '\n",
      " 's   do i  org1011770956462416665996  529 liverani ca lattuada d mangano s et '\n",
      " 'al hypertrophic donavanosis  in a young pregnant woman j pediatr adolesc '\n",
      " 'gynecol 201225e81–3  pmid22840941 httpsdoiorg101016jjpag201110002  530 '\n",
      " 'magalhães bm veasey jv mayor sas lellis rf donovanosis in a  child victim of '\n",
      " 'sexual abuse response to doxycycline treatment an  bras dermatol 201893592–4 '\n",
      " 'httpsdoiorg101590 abd1806484120187948  531 marfatia ys menon ds jose s patel '\n",
      " 'bk nonhealing genital ulcer  in aids a diagnostic dilemma indian j sex '\n",
      " 'transm dis aids  2 0 1 6  3 7  1 9 7 – 2 0 0   p m i d  2 7 8 9 0 9 5 8  h t '\n",
      " 't p s    d o i  org10410302537184192130  532 narang t kanwar aj genital '\n",
      " 'elephantiasis due to donovanosis  forgotten but not gone yet int j std aids '\n",
      " '201223835–6  pmid23155109 httpsdoiorg101258ijsa2012012096  533 pi lani  a  '\n",
      " 'vora r  anjaneyan g granuloma inguinale  mimicking as squamous cell '\n",
      " 'carcinoma of penis indian j sex  transm dis aids 20143556–8 pmid24958990 '\n",
      " 'httpsdoi org10410302537184132433  534 ramdial pk sing y ramburan a et al '\n",
      " 'infantile donovanosis  presenting as external auditory canal polyps a '\n",
      " 'diagnostic trap am j  dermatopathol 201234818–21 pmid23169417 httpsdoi '\n",
      " 'org101097dad0b013e3182540ccb  535 wahal sp tuli d donovanosis an incidental '\n",
      " 'finding on pap  test j cytol 201330217–8 pmid24130421 httpsdoi '\n",
      " 'org10410309709371117638  536 bowden fj national donovanosis eradication '\n",
      " 'advisory committee  donovanosis in australia going going sex transm infect  '\n",
      " '200581365–6 pmid16199732 httpsdoiorg101136 sti2004013227  537 bright a '\n",
      " 'national notifiable diseases surveillance system surveillance  report '\n",
      " 'sexually transmissible infections in aboriginal and torres strait  islander '\n",
      " 'people commun dis intell q rep 201539e584–9  pmid26779731  538 o’farrell n '\n",
      " 'donovanosis sex transm infect 200278452–7  pmid12473810 '\n",
      " 'httpsdoiorg101136sti786452  539 mabey d peeling rw lymphogranuloma venereum '\n",
      " 'sex transm  infect 20027890–2 pmid12081191 httpsdoiorg101136 sti78290  540 '\n",
      " 'white ja manifestations and management of lymphogranuloma  venereum curr '\n",
      " 'opin infect dis 20092257–66 pmid19532081  '\n",
      " 'httpsdoiorg101097qco0b013e328320a8ae  541 de vries hj zingoni a white ja '\n",
      " 'ross jd kreuter a 2013  european guideline on the management of proctitis '\n",
      " 'proctocolitis  and enteritis caused by sexually transmissible pathogens int  '\n",
      " 'j std aids 201425465–74 pmid24352129 httpsdoi org1011770956462413516100  542 '\n",
      " 'ward h martin i macdonald n et al lymphogranuloma venereum  in the united '\n",
      " 'kingdom clin infect dis 20074426–32  pmid17143811 httpsdoiorg101086509922  '\n",
      " '543 martiniguacel r llibre jm nielsen h et al lymphogranuloma  venereum '\n",
      " 'proctocolitis a silent endemic disease in men who have sex  with men in '\n",
      " 'industrialised countries eur j clin microbiol infect dis  201029917–25 '\n",
      " 'pmid20509036 httpsdoiorg101007 s1009601009592  544 de voux a kent jb '\n",
      " 'macomber k et al notes from the field cluster  of lymphogranuloma venereum '\n",
      " 'cases among men who have sex with  men—michigan august 2015–april 2016 mmwr '\n",
      " 'morb mortal  wkly rep 201665920–1 pmid27583686 httpsdoiorg1015585 '\n",
      " 'mmwrmm6534a6  545 pallawela sn sullivan ak macdonald n et al clinical '\n",
      " 'predictors of  rectal lymphogranuloma venereum infection results from a '\n",
      " 'multicentre  casecontrol study in the uk sex transm infect 201490269–74  '\n",
      " 'pmid24687130 httpsdoiorg101136sextrans2013051401  546 de vrieze nh de vries '\n",
      " 'hj lymphogranuloma venereum among men  who have sex with men an '\n",
      " 'epidemiological and clinical review expert  rev anti infect ther '\n",
      " '201412697–704 pmid24655220 httpsdoi org101586147872102014901169  547 koper '\n",
      " 'ne van der sande ma gotz hm koedijk fd dutch sti  clinics lymphogranuloma '\n",
      " 'venereum among men who have sex with  men in the netherlands regional '\n",
      " 'differences in testing rates lead to  underestimation of the incidence '\n",
      " '2006–2012 euro surveill  20131820561 pmid23987831 httpsdoiorg1028071560 '\n",
      " '7917es2013183420561  548 haar k dudarevavizule s wisplinghoff h et al '\n",
      " 'lymphogranuloma  venereum in men screened for pharyngeal and rectal '\n",
      " 'infection  germany emerg infect dis 201319488–92 pmid23621949  '\n",
      " 'httpsdoiorg103201eid1903121028  549 rieramonroig j fuertes de vega i '\n",
      " 'lymphogranuloma venereum  presenting as an ulcer on the tongue sex transm '\n",
      " 'infect 201995169–70  pmid30554142 httpsdoiorg101136sextrans2018053787  550 '\n",
      " 'andrada mt dhar jk wilde h oral lymphogranuloma venereum  and cervical '\n",
      " 'lymphadenopathy case report mil med 197413999–101  pmid4204816 '\n",
      " 'httpsdoiorg101093milmed139299  551 ilyas s richmond d burns g et al '\n",
      " 'orolabial lymphogranuloma  venereum michigan usa emerg infect dis '\n",
      " '2019252112–4  pmid31625852 httpsdoiorg103201eid2511190819 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids15108247doptabstract '\n",
      " 'httpsdoiorg101002bdra20013 httpsdoiorg101002bdra20013 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids20736469doptabstract '\n",
      " 'httpsdoiorg101001jama20101206 httpsdoiorg101001jama20101206 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids12100814doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids12100814doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids12634667doptabstract '\n",
      " 'httpsdoiorg101067mob2003185 httpsdoiorg101067mob2003185 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids12530483doptabstract '\n",
      " 'httpsdoiorg101155s1064744902000054 httpspubmedncbinlmnihgov22336576 '\n",
      " 'httpsdoiorg101016jjpeds201112053 httpsdoiorg101016jjpeds201112053 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids17569194doptabstract '\n",
      " 'httpsdoiorg10109701aog0000263902319533e '\n",
      " 'httpsdoiorg10109701aog0000263902319533e '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids21173170doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids21173170doptabstract '\n",
      " 'httpsdoiorg10115810559965epi101108 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids26122163doptabstract '\n",
      " 'httpsdoiorg101016s0140673615609928 httpsdoiorg101016s0140673615609928 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids27535727doptabstract '\n",
      " 'httpsdoiorg1011770956462416665996 httpsdoiorg1011770956462416665996 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids22840941doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids22840941doptabstract '\n",
      " 'httpsdoiorg101016jjpag201110002 httpsdoiorg101590abd1806484120187948 '\n",
      " 'httpsdoiorg101590abd1806484120187948 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids27890958doptabstract '\n",
      " 'httpsdoiorg10410302537184192130 httpsdoiorg10410302537184192130 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids23155109doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids23155109doptabstract '\n",
      " 'httpsdoiorg101258ijsa2012012096 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids24958990doptabstract '\n",
      " 'httpsdoiorg10410302537184132433 httpsdoiorg10410302537184132433 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids23169417doptabstract '\n",
      " 'httpsdoiorg101097dad0b013e3182540ccb httpsdoiorg101097dad0b013e3182540ccb '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids24130421doptabstract '\n",
      " 'httpsdoiorg10410309709371117638 httpsdoiorg10410309709371117638 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids16199732doptabstract '\n",
      " 'httpsdoiorg101136sti2004013227 httpsdoiorg101136sti2004013227 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids26779731doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids26779731doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids12473810doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids12473810doptabstract '\n",
      " 'httpsdoiorg101136sti786452 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids12081191doptabstract '\n",
      " 'httpsdoiorg101136sti78290 httpsdoiorg101136sti78290 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids19532081doptabstract '\n",
      " 'httpsdoiorg101097qco0b013e328320a8ae '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids24352129doptabstract '\n",
      " 'httpsdoiorg1011770956462413516100 httpsdoiorg1011770956462413516100 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids17143811doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids17143811doptabstract '\n",
      " 'httpsdoiorg101086509922 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids20509036doptabstract '\n",
      " 'httpsdoiorg101007s1009601009592 httpsdoiorg101007s1009601009592 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids27583686doptabstract '\n",
      " 'httpsdoiorg1015585mmwrmm6534a6 httpsdoiorg1015585mmwrmm6534a6 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids24687130doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids24687130doptabstract '\n",
      " 'httpsdoiorg101136sextrans2013051401 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids24655220doptabstract '\n",
      " 'httpsdoiorg101586147872102014901169 httpsdoiorg101586147872102014901169 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids23987831doptabstract '\n",
      " 'httpsdoiorg10280715607917es2013183420561 '\n",
      " 'httpsdoiorg10280715607917es2013183420561 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids23621949doptabstract '\n",
      " 'httpsdoiorg103201eid1903121028 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30554142doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30554142doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids4204816doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids4204816doptabstract '\n",
      " 'httpsdoiorg101093milmed139299 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids31625852doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids31625852doptabstract '\n",
      " 'httpsdoiorg103201eid2511190819 recommendations and reports 154 mmwr  july 23 '\n",
      " '2021  vol 70  no 4 us department of health and human servicescenters for '\n",
      " 'disease control and prevention  552 kersh en pillay a de voux a chen c '\n",
      " 'laboratory processes for  confirmation of lymphogranuloma venereum infection '\n",
      " 'during a 2015  investigation of a cluster of cases in the united states sex '\n",
      " 'transm dis  201744691–4 pmid28876314 httpsdoiorg101097 olq0000000000000667  '\n",
      " '553 cdc recommendations for the laboratorybased detection of  chlamydia '\n",
      " 'trachomatis and neisseria gonorrhoeae—2014 mmwr  recomm rep 201463no rr2 '\n",
      " 'pmid24622331  554 pathela p jamison k kornblum j quinlan t halse ta '\n",
      " 'schillinger  ja lymphogranuloma venereum an increasingly common anorectal  '\n",
      " 'infection among men who have sex with men attending new york city  sexual '\n",
      " 'health clinics sex transm dis 201946e14–7 pmid30278027  '\n",
      " 'httpsdoiorg101097olq0000000000000921  555 cohen s brosnan h kohn r et al '\n",
      " 'p494 diagnosis and management  of lymphogranuloma venereum lgv in a '\n",
      " 'municipal std clinic san  francisco 2016–18 sex transm infect 201995suppl '\n",
      " '1a229  556 leeyaphan c ong jj chow ep et al systematic review and meta '\n",
      " 'analysis of doxycycline efficacy for rectal lymphogranuloma venereum  in men '\n",
      " 'who have sex with men emerg infect dis 2016221778–84  pmid27513890 '\n",
      " 'httpsdoiorg103201eid2210160986  557 cabello úbeda a fernández roblas r '\n",
      " 'garcía delgado r et al  anorectal lymphogranuloma venereum in madrid a '\n",
      " 'persistent  emerging problem in men who have sex with men sex transm dis  '\n",
      " '201643414–9 pmid27322040 httpsdoiorg101097 olq0000000000000459  558 simons r '\n",
      " 'candfield s french p white ja observed treatment  responses to shortcourse '\n",
      " 'doxycycline therapy for rectal  lymphogranuloma venereum in men who have sex '\n",
      " 'with men sex  transm dis 201845406–8 pmid29465660 httpsdoiorg101097 '\n",
      " 'olq0000000000000772  559 vallmayans m isaksson j caballero e sallés b '\n",
      " 'herrmann b bubonic  lymphogranuloma venereum with multidrug treatment '\n",
      " 'failure int j  std aids 201425306–8 pmid24216037 httpsdoi '\n",
      " 'org1011770956462413501158  560 blanco jl fuertes i bosch j et al effective '\n",
      " 'treatment of  lymphogranuloma venereum lgv with 1g azithormycin '\n",
      " 'administered  weekly for 3 weeks in hivinfected population presented at the  '\n",
      " 'conference on retroviruses and opportunist infections seattle wa  february '\n",
      " '23–26 2015  561 kong fy rupasinghe tw simpson ja et al pharmacokinetics of '\n",
      " 'a  single 1g dose of azithromycin in rectal tissue in men plos one  '\n",
      " '201712e0174372 pmid28350806 httpsdoiorg101371journal pone0174372  562 '\n",
      " 'elgalib a alexander s tong cy white ja seven days of doxycycline  is an '\n",
      " 'effective treatment for asymptomatic rectal chlamydia trachomatis  infection '\n",
      " 'int j std aids 201122474–7 pmid21764781 https doiorg101258ijsa2011011134  '\n",
      " '563 wormser gp wormser rp strle f myers r cunha ba how safe is  doxycycline '\n",
      " 'for young children or for pregnant or breastfeeding women  diagn microbiol '\n",
      " 'infect dis 201993238–42 pmid30442509  '\n",
      " 'httpsdoiorg101016jdiagmicrobio201809015  564 towns jm leslie de denham i '\n",
      " 'azzato f fairley ck chen m  painful and multiple anogenital lesions are '\n",
      " 'common in men with  treponema pallidum pcrpositive primary syphilis without '\n",
      " 'herpes  simplex virus coinfection a crosssectional clinicbased study sex  '\n",
      " 'transm infect 201692110–5 pmid26378262 httpsdoi org101136sextrans2015052219  '\n",
      " '565 theel es katz ss pillay a molecular and direct detection tests for  '\n",
      " 'treponema pallidum subspecies pallidum a review of the literature  1964–2017 '\n",
      " 'clin infect dis 202071suppl 1s4–12 pmid32578865  '\n",
      " 'httpsdoiorg101093cidciaa176  566 tuddenham s katz ss ghanem kg syphilis '\n",
      " 'laboratory guidelines  performance characteristics of nontreponemal antibody '\n",
      " 'tests clin  infect dis 202071suppl 1s21–42 pmid32578862 httpsdoi '\n",
      " 'org101093cidciaa306  567 park iu tran a pereira l fakile y sensitivity and '\n",
      " 'specificity of  treponemalspecific tests for the diagnosis of syphilis clin '\n",
      " 'infect dis  202071suppl 1s13–20 pmid32578866 httpsdoiorg101093 cidciaa349  '\n",
      " '568 bristow cc klausner jd tran a clinical test performance of a rapid  '\n",
      " 'pointofcare syphilis treponemal antibody test a systematic review  and '\n",
      " 'metaanalysis clin infect dis 202071suppl 1s52–7  pmid32578863 '\n",
      " 'httpsdoiorg101093cidciaa350  569 nandwani r evans dt are you sure it’s '\n",
      " 'syphilis a review of false  positive serology int j std aids 19956241–8 '\n",
      " 'pmid7548285  httpsdoiorg101177095646249500600404  570 romanowski b '\n",
      " 'sutherland r fick gh mooney d love  ej serologic response to treatment of '\n",
      " 'infectious syphilis ann  intern med 19911141005–9 pmid2029095 httpsdoi '\n",
      " 'org10732600034819114121005  571 cdc syphilis testing algorithms using '\n",
      " 'treponemal tests for initial  screening—four laboratories new york city '\n",
      " '2005–2006 mmwr  morb mortal wkly rep 200857872–5 pmid18701877  572 cdc '\n",
      " 'discordant results from reverse sequence syphilis screening—five  '\n",
      " 'laboratories united states 2006–2010 mmwr morb mortal wkly  rep 201160133–7 '\n",
      " 'pmid21307823  573 ortizlopez n diez m diaz o simon f diaz a epidemiological  '\n",
      " 'surveillance of congenital syphilis in spain 2000–2010 pediatr infect  dis j '\n",
      " '201231988–90 pmid22572752 httpsdoiorg101097 inf0b013e31825d3152  574 ortiz '\n",
      " 'da shukla mr loeffelholz mj the traditional or reverse  algorithm for '\n",
      " 'diagnosis of syphilis pros and cons clin infect dis  202071suppl 1s43–51 '\n",
      " 'pmid32578864 httpsdoiorg101093 cidciaa307  575 berry gj loeffelholz mj use '\n",
      " 'of treponemal screening assay strength  of signal to avoid unnecessary '\n",
      " 'confirmatory testing sex transm  dis 201643737–40 pmid27835625 '\n",
      " 'httpsdoiorg101097 olq0000000000000524  576 park iu chow jm bolan g stanley m '\n",
      " 'shieh j schapiro jm  screening for syphilis with the treponemal immunoassay '\n",
      " 'analysis of  discordant serology results and implications for clinical '\n",
      " 'management  j infect dis 20112041297–304 pmid21930610 httpsdoi '\n",
      " 'org101093infdisjir524  577 loeffelholz mj wen t patel ja analysis of bioplex '\n",
      " 'syphilis igg  quantitative results in different patient populations clin '\n",
      " 'vaccine  immunol 2011182005–6 pmid21880852 httpsdoiorg101128 cvi0533511  578 '\n",
      " 'fakile yf jost h hoover kw et al correlation of treponemal  immunoassay '\n",
      " 'signal strength values with reactivity of confirmatory  treponemal testing j '\n",
      " 'clin microbiol 201756e0116517  pmid29046410 httpsdoiorg101128jcm0116517  579 '\n",
      " 'wong eh klausner jd caguingrygiel g et al evaluation of an igm igg sensitive '\n",
      " 'enzyme immunoassay and the utility of index values for  the screening of '\n",
      " 'syphilis infection in a highrisk population sex transm  dis 201138528–32 '\n",
      " 'pmid21233789 httpsdoiorg101097 olq0b013e318205491a  580 dai s chi p lin y et '\n",
      " 'al improved reverse screening algorithm  for treponema pallidum antibody '\n",
      " 'using signaltocutoff ratios  from chemiluminescence microparticle '\n",
      " 'immunoassay sex transm  dis 20144129–34 pmid24326578 httpsdoiorg101097 '\n",
      " 'olq0000000000000066  581 li z feng z liu p yan c screening for antibodies '\n",
      " 'against treponema  pallidum with chemiluminescent microparticle immunoassay '\n",
      " 'analysis  of discordant serology results and clinical characterization ann '\n",
      " 'clin  biochem 201653588–92 pmid26680646 httpsdoi org1011770004563215623806  '\n",
      " '582 yenlieberman b daniel j means c waletzky j daly tm  identification of '\n",
      " 'falsepositive syphilis antibody results using a  semiquantitative algorithm '\n",
      " 'clin vaccine immunol 2011181038–40  pmid21508162 httpsdoiorg101128cvi0506611 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28876314doptabstract '\n",
      " 'httpsdoiorg101097olq0000000000000667 httpsdoiorg101097olq0000000000000667 '\n",
      " 'httpspubmedncbinlmnihgov24622331 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30278027doptabstract '\n",
      " 'httpsdoiorg101097olq0000000000000921 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids27513890doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids27513890doptabstract '\n",
      " 'httpsdoiorg103201eid2210160986 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids27322040doptabstract '\n",
      " 'httpsdoiorg101097olq0000000000000459 httpsdoiorg101097olq0000000000000459 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29465660doptabstract '\n",
      " 'httpsdoiorg101097olq0000000000000772 httpsdoiorg101097olq0000000000000772 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids24216037doptabstract '\n",
      " 'httpsdoiorg1011770956462413501158 httpsdoiorg1011770956462413501158 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28350806doptabstract '\n",
      " 'httpsdoiorg101371journalpone0174372 httpsdoiorg101371journalpone0174372 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids21764781doptabstract '\n",
      " 'httpsdoiorg101258ijsa2011011134 httpsdoiorg101258ijsa2011011134 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30442509doptabstract '\n",
      " 'httpsdoiorg101016jdiagmicrobio201809015 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids26378262doptabstract '\n",
      " 'httpsdoiorg101136sextrans2015052219 httpsdoiorg101136sextrans2015052219 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids32578865doptabstract '\n",
      " 'httpsdoiorg101093cidciaa176 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids32578862doptabstract '\n",
      " 'httpsdoiorg101093cidciaa306 httpsdoiorg101093cidciaa306 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids32578866doptabstract '\n",
      " 'httpsdoiorg101093cidciaa349 httpsdoiorg101093cidciaa349 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids32578863doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids32578863doptabstract '\n",
      " 'httpsdoiorg101093cidciaa350 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids7548285doptabstract '\n",
      " 'httpsdoiorg101177095646249500600404 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids2029095doptabstract '\n",
      " 'httpsdoiorg10732600034819114121005 httpsdoiorg10732600034819114121005 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids18701877doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids21307823doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids22572752doptabstract '\n",
      " 'httpsdoiorg101097inf0b013e31825d3152 httpsdoiorg101097inf0b013e31825d3152 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids32578864doptabstract '\n",
      " 'httpsdoiorg101093cidciaa307 httpsdoiorg101093cidciaa307 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids27835625doptabstract '\n",
      " 'httpsdoiorg101097olq0000000000000524 httpsdoiorg101097olq0000000000000524 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids21930610doptabstract '\n",
      " 'httpsdoiorg101093infdisjir524 httpsdoiorg101093infdisjir524 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids21880852doptabstract '\n",
      " 'httpsdoiorg101128cvi0533511 httpsdoiorg101128cvi0533511 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29046410doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29046410doptabstract '\n",
      " 'httpsdoiorg101128jcm0116517 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids21233789doptabstract '\n",
      " 'httpsdoiorg101097olq0b013e318205491a httpsdoiorg101097olq0b013e318205491a '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids24326578doptabstract '\n",
      " 'httpsdoiorg101097olq0000000000000066 httpsdoiorg101097olq0000000000000066 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids26680646doptabstract '\n",
      " 'httpsdoiorg1011770004563215623806 httpsdoiorg1011770004563215623806 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids21508162doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids21508162doptabstract '\n",
      " 'httpsdoiorg101128cvi0506611 recommendations and reports mmwr  july 23 2021  '\n",
      " 'vol 70  no 4 155us department of health and human servicescenters for '\n",
      " 'disease control and prevention  583 yimtae k srirompotong s lertsukprasert k '\n",
      " 'otosyphilis a review of  85 cases otolaryngol head neck surg 200713667–71  '\n",
      " 'pmid17210336 httpsdoiorg101016jotohns200608026  584 gleich ll linstrom cj '\n",
      " 'kimmelman cp otosyphilis a diagnostic and  therapeutic dilemma laryngoscope '\n",
      " '19921021255–9 pmid1307698  httpsdoiorg1012880000553719921100000010  585 '\n",
      " 'lukehart sa hook ew 3rd bakerzander sa collier ac critchlow  cw handsfield '\n",
      " 'hh invasion of the central nervous system by  treponema pallidum '\n",
      " 'implications for diagnosis and treatment ann  intern med 1988109855–62 '\n",
      " 'pmid3056164 httpsdoi org1073260003481910911855  586 harding as ghanem kg the '\n",
      " 'performance of cerebrospinal fluid  treponemalspecific antibody tests in '\n",
      " 'neurosyphilis a systematic  review sex transm dis 201239291–7 pmid22421696 '\n",
      " 'httpsdoi org101097olq0b013e31824c0e62  587 jaffe hw larsen sa peters m jove '\n",
      " 'df lopez b schroeter  al tests for treponemal antibody in csf arch intern '\n",
      " 'med  1978138252–5 pmid343742 httpsdoiorg101001 archinte197803630260050016  '\n",
      " '588 marra cm maxwell cl smith sl et al cerebrospinal fluid  abnormalities in '\n",
      " 'patients with syphilis association with clinical and  laboratory features j '\n",
      " 'infect dis 2004189369–76 pmid14745693  httpsdoiorg101086381227  589 cdc '\n",
      " 'inadvertent use of bicillin cr to treat syphilis infection—los  angeles '\n",
      " 'california 1999–2004 mmwr morb mortal wkly rep  200554217–9 pmid15758893  '\n",
      " '590 butler t the jarischherxheimer reaction after antibiotic treatment of  '\n",
      " 'spirochetal infections a review of recent cases and our understanding of  '\n",
      " 'pathogenesis am j trop med hyg 20179646–52 pmid28077740  '\n",
      " 'httpsdoiorg104269ajtmh160434  591 rolfs rt joesoef mr hendershot ef et al '\n",
      " 'the syphilis and hiv  study group a randomized trial of enhanced therapy for '\n",
      " 'early  syphilis in patients with and without human immunodeficiency virus  '\n",
      " 'infection n engl j med 1997337307–14 pmid9235493 https '\n",
      " 'doiorg101056nejm199707313370504  592 yang cj lee ny chen tc et al one dose '\n",
      " 'versus three weekly doses  of benzathine penicillin g for patients '\n",
      " 'coinfected with hiv and early  syphilis a multicenter prospective '\n",
      " 'observational study plos one  20149e109667 pmid25286091 '\n",
      " 'httpsdoiorg101371journal pone0109667  593 ganesan a mesner o okulicz jf et '\n",
      " 'al infectious disease clinical  research program hivsti working group a '\n",
      " 'single dose of  benzathine penicillin g is as effective as multiple doses of '\n",
      " 'benzathine  penicillin g for the treatment of hivinfected persons with '\n",
      " 'early  syphilis clin infect dis 201560653–60 pmid25389249 https '\n",
      " 'doiorg101093cidciu888  594 ghanem kg erbelding ej wiener zs rompalo am '\n",
      " 'serological  response to syphilis treatment in hivpositive and hivnegative  '\n",
      " 'patients attending sexually transmitted diseases clinics sex transm  infect '\n",
      " '20078397–101 pmid16943224 httpsdoiorg101136 sti2006021402  595 seña ac wolff '\n",
      " 'm martin dh et al predictors of serological cure  and serofast state after '\n",
      " 'treatment in hivnegative persons with early  syphilis clin infect dis '\n",
      " '2011531092–9 pmid21998287 https doiorg101093cidcir671  596 zhang rl wang qq '\n",
      " 'zhang jp yang lj molecular subtyping of  treponema pallidum and associated '\n",
      " 'factors of serofast status in early  syphilis patients identified novel '\n",
      " 'genotype and cytokine marker plos  one 201712e0175477 pmid28410389 '\n",
      " 'httpsdoiorg101371 journalpone0175477  597 seña ac zhang xh li t et al a '\n",
      " 'systematic review of syphilis  serological treatment outcomes in hivinfected '\n",
      " 'and hivuninfected  persons rethinking the significance of serological '\n",
      " 'nonresponsiveness  and the serofast state after therapy bmc infect dis '\n",
      " '201515479  pmid26511465 httpsdoiorg101186s1287901512090  598 tong ml lin lr '\n",
      " 'liu gl et al factors associated with serological  cure and the serofast '\n",
      " 'state of hivnegative patients with primary  secondary latent and tertiary '\n",
      " 'syphilis plos one 20138e70102  pmid23894598 '\n",
      " 'httpsdoiorg101371journalpone0070102  599 seña ac wolff m behets f et al '\n",
      " 'response to therapy following  retreatment of serofast early syphilis '\n",
      " 'patients with benzathine penicillin  clin infect dis 201356420–2 '\n",
      " 'pmid23118269 httpsdoi org101093cidcis918  600 ghanem kg erbelding ej cheng '\n",
      " 'ww rompalo am doxycycline  compared with benzathine penicillin for the '\n",
      " 'treatment of early  syphilis clin infect dis 200642e45–9 pmid16477545 https '\n",
      " 'doiorg101086500406  601 wong t singh ae de p primary syphilis serological '\n",
      " 'treatment  response to doxycyclinetetracycline versus benzathine penicillin '\n",
      " 'am  j med 2008121903–8 pmid18823862 httpsdoiorg101016j amjmed200804042  602 '\n",
      " 'hook ew 3rd martin dh stephens j smith bs smith k  a randomized comparative '\n",
      " 'pilot study of azithromycin versus  benzathine penicillin g for treatment of '\n",
      " 'early syphilis sex  transm dis 200229486–90 pmid12172535 httpsdoi '\n",
      " 'org1010970000743520020800000010  603 cao y su x wang q et al a multicenter '\n",
      " 'study evaluating ceftriaxone  and benzathine penicillin g as treatment '\n",
      " 'agents for early syphilis in  jiangsu china clin infect dis 2017651683–8 '\n",
      " 'pmid29020150  httpsdoiorg101093cidcix611  604 riedner g rusizoka m todd j et '\n",
      " 'al singledose azithromycin versus  penicillin g benzathine for the treatment '\n",
      " 'of early syphilis n engl j  med 20053531236–44 pmid16177249 '\n",
      " 'httpsdoiorg101056 nejmoa044284  605 hook ew 3rd behets f van damme k et al a '\n",
      " 'phase iii equivalence  trial of azithromycin versus benzathine penicillin '\n",
      " 'for treatment of early  syphilis j infect dis 20102011729–35 pmid20402591 '\n",
      " 'httpsdoi org101086652239  606 lukehart sa godornes c molini bj et al '\n",
      " 'macrolide resistance  in treponema pallidum in the united states and ireland '\n",
      " 'n engl j  med 2004351154–8 pmid15247355 httpsdoiorg101056 nejmoa040216  607 '\n",
      " 'mitchell sj engelman j kent ck lukehart sa godornes c klausner  jd '\n",
      " 'azithromycinresistant syphilis infection san francisco california  2000–2004 '\n",
      " 'clin infect dis 200642337–45 pmid16392078  httpsdoiorg101086498899  608 '\n",
      " 'a2058g prevalence workgroup prevalence of the 23s rrna a2058g  point '\n",
      " 'mutation and molecular subtypes in treponema pallidum in the  united states '\n",
      " '2007 to 2009 sex transm dis 201239794–8  pmid23001267  609 rolfs rt joesoef '\n",
      " 'mr hendershot ef et al the syphilis and hiv  study group a randomized trial '\n",
      " 'of enhanced therapy for early syphilis  in patients with and without human '\n",
      " 'immunodeficiency virus infection  n engl j med 1997337307–14 pmid9235493 '\n",
      " 'httpsdoi org101056nejm199707313370504  610 collart p poitevin m milovanovic '\n",
      " 'a herlin a durel j kinetic study  of serum penicillin concentrations after '\n",
      " 'single doses of benzathine and  benethamine penicillins in young and old '\n",
      " 'people br j vener dis  198056355–62 pmid7448577 httpsdoiorg101136 sti566355  '\n",
      " '611 hagdrup hk lange wantzin g secher l rosdahl vt penicillin  '\n",
      " 'concentrations in serum following weekly injections of benzathine  '\n",
      " 'penicillin g chemotherapy 19863299–101 pmid3698728 https '\n",
      " 'doiorg101159000238397  612 frentz g nielsen pb espersen f czartoryski a '\n",
      " 'aastrup h penicillin  concentrations in blood and spinal fluid after a '\n",
      " 'single intramuscular  injection of penicillin g benzathine eur j clin '\n",
      " 'microbiol  19843147–9 pmid6723638 httpsdoiorg101007bf02014334 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids17210336doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids17210336doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids1307698doptabstract '\n",
      " 'httpsdoiorg1012880000553719921100000010 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids3056164doptabstract '\n",
      " 'httpsdoiorg1073260003481910911855 httpsdoiorg1073260003481910911855 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids22421696doptabstract '\n",
      " 'httpsdoiorg101097olq0b013e31824c0e62 httpsdoiorg101097olq0b013e31824c0e62 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids343742doptabstract '\n",
      " 'httpsdoiorg101001archinte197803630260050016 '\n",
      " 'httpsdoiorg101001archinte197803630260050016 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids14745693doptabstract '\n",
      " 'httpsdoiorg101086381227 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids15758893doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28077740doptabstract '\n",
      " 'httpsdoiorg104269ajtmh160434 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids9235493doptabstract '\n",
      " 'httpsdoiorg101056nejm199707313370504 httpsdoiorg101056nejm199707313370504 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids25286091doptabstract '\n",
      " 'httpsdoiorg101371journalpone0109667 httpsdoiorg101371journalpone0109667 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids25389249doptabstract '\n",
      " 'httpsdoiorg101093cidciu888 httpsdoiorg101093cidciu888 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids16943224doptabstract '\n",
      " 'httpsdoiorg101136sti2006021402 httpsdoiorg101136sti2006021402 '\n",
      " 'httpsdoiorg101093cidcir671 httpsdoiorg101093cidcir671 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28410389doptabstract '\n",
      " 'httpsdoiorg101371journalpone0175477 httpsdoiorg101371journalpone0175477 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids26511465doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids26511465doptabstract '\n",
      " 'httpsdoiorg101186s1287901512090 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids23894598doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids23894598doptabstract '\n",
      " 'httpsdoiorg101371journalpone0070102 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids23118269doptabstract '\n",
      " 'httpsdoiorg101093cidcis918 httpsdoiorg101093cidcis918 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids16477545doptabstract '\n",
      " 'httpsdoiorg101086500406 httpsdoiorg101086500406 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids18823862doptabstract '\n",
      " 'httpsdoiorg101016jamjmed200804042 httpsdoiorg101016jamjmed200804042 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids12172535doptabstract '\n",
      " 'httpsdoiorg1010970000743520020800000010 '\n",
      " 'httpsdoiorg1010970000743520020800000010 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29020150doptabstract '\n",
      " 'httpsdoiorg101093cidcix611 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids16177249doptabstract '\n",
      " 'httpsdoiorg101056nejmoa044284 httpsdoiorg101056nejmoa044284 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids20402591doptabstract '\n",
      " 'httpsdoiorg101086652239 httpsdoiorg101086652239 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids15247355doptabstract '\n",
      " 'httpsdoiorg101056nejmoa040216 httpsdoiorg101056nejmoa040216 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids16392078doptabstract '\n",
      " 'httpsdoiorg101086498899 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids23001267doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids23001267doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids9235493doptabstract '\n",
      " 'httpsdoiorg101056nejm199707313370504 httpsdoiorg101056nejm199707313370504 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids7448577doptabstract '\n",
      " 'httpsdoiorg101136sti566355 httpsdoiorg101136sti566355 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids3698728doptabstract '\n",
      " 'httpsdoiorg101159000238397 httpsdoiorg101159000238397 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids6723638doptabstract '\n",
      " 'httpsdoiorg101007bf02014334 recommendations and reports 156 mmwr  july 23 '\n",
      " '2021  vol 70  no 4 us department of health and human servicescenters for '\n",
      " 'disease control and prevention  613 nathan l bawdon re sidawi je stettler rw '\n",
      " 'mcintire dm wendel  gd jr penicillin levels following the administration of '\n",
      " 'benzathine  penicillin g in pregnancy obstet gynecol 199382338–42  '\n",
      " 'pmid8355931  614 marra cm maxwell cl tantalo lc sahi sk lukehart sa  '\n",
      " 'normalization of serum rapid plasma reagin titer predicts normalization  of '\n",
      " 'cerebrospinal fluid and clinical abnormalities after treatment of  '\n",
      " 'neurosyphilis clin infect dis 200847893–9 pmid18715154  '\n",
      " 'httpsdoiorg101086591534  615 xiao y tong ml lin lr et al serological '\n",
      " 'response predicts  normalization of cerebrospinal fluid abnormalities at six '\n",
      " 'months after  treatment in hivnegative neurosyphilis patients sci rep '\n",
      " '201779911  pmid28855625 httpsdoiorg101038s4159801710387x  616 hook ew 3rd '\n",
      " 'bakerzander sa moskovitz bl lukehart sa handsfield  hh ceftriaxone therapy '\n",
      " 'for asymptomatic neurosyphilis case report  and western blot analysis of '\n",
      " 'serum and cerebrospinal fluid igg response  to therapy sex transm dis '\n",
      " '198613suppl185–8 pmid3764632  httpsdoiorg1010970000743519860700000018  617 '\n",
      " 'shann s wilson j treatment of neurosyphilis with ceftriaxone  sex transm '\n",
      " 'infect 200379415–6 pmid14573840 httpsdoi org101136sti795415  618 ahmed ka '\n",
      " 'fox sj frigas e park ma clinical outcome in the use  of cephalosporins in '\n",
      " 'pediatric patients with a history of penicillin  allergy int arch allergy '\n",
      " 'immunol 2012158405–10 pmid22487723  httpsdoiorg101159000333553  619 park ma '\n",
      " 'koch ca klemawesch p joshi a li jt increased adverse drug  reactions to '\n",
      " 'cephalosporins in penicillin allergy patients with positive  penicillin skin '\n",
      " 'test int arch allergy immunol 2010153268–73  pmid20484925 '\n",
      " 'httpsdoiorg101159000314367  620 novalbos a sastre j cuesta j et al lack of '\n",
      " 'allergic crossreactivity  to cephalosporins among patients allergic to '\n",
      " 'penicillins clin  exp allergy 200131438–43 pmid11260156 httpsdoi '\n",
      " 'org101046j13652222200100992x  621 pichichero me casey jr safe use of '\n",
      " 'selected cephalosporins in  penicillinallergic patients a metaanalysis '\n",
      " 'otolaryngol head neck  surg 2007136340–7 pmid17321857 httpsdoiorg101016j '\n",
      " 'otohns200610007  622 kingston aa vujevich j shapiro m et al seronegative '\n",
      " 'secondary  syphilis in 2 patients coinfected with human immunodeficiency  '\n",
      " 'virus arch dermatol 2005141431–3 pmid15837859 httpsdoi '\n",
      " 'org101001archderm1414431  623 cdc symptomatic early neurosyphilis among '\n",
      " 'hivpositive men who  have sex with men—four cities united states january '\n",
      " '2002–june 2004  mmwr morb mortal wkly rep 200756625–8 pmid17597693  624 '\n",
      " 'ghanem kg moore rd rompalo am erbelding ej zenilman jm  gebo ka '\n",
      " 'neurosyphilis in a clinical cohort of hiv1infected patients  aids '\n",
      " '2008221145–51 pmid18525260 httpsdoiorg101097 qad0b013e32830184df  625 ghanem '\n",
      " 'kg moore rd rompalo am erbelding ej zenilman jm  gebo ka antiretroviral '\n",
      " 'therapy is associated with reduced serologic  failure rates for syphilis '\n",
      " 'among hivinfected patients clin infect dis  200847258–65 pmid18532887 '\n",
      " 'httpsdoiorg101086589295  626 tomkins a ahmad s cousins de thng cm vilar fj '\n",
      " 'higgins  sp screening for asymptomatic neurosyphilis in hiv patients after  '\n",
      " 'treatment of early syphilis an observational study sex transm  infect '\n",
      " '201894337–9 pmid28196838 httpsdoiorg101136 sextrans2016052938  627 yang cj '\n",
      " 'chang sy hung cc sensitivity and specificity of lumbar  puncture in '\n",
      " 'hivinfected patients with syphilis and no neurologic  symptoms clin infect '\n",
      " 'dis 200949162–3 author reply 162–3  pmid19500029 httpsdoiorg101086599616  '\n",
      " '628 marra cm boutin p mcarthur jc et al a pilot study evaluating  '\n",
      " 'ceftriaxone and penicillin g as treatment agents for neurosyphilis in  human '\n",
      " 'immunodeficiency virusinfected individuals clin infect dis  200030540–4 '\n",
      " 'pmid10722441 httpsdoiorg101086313725  629 dowell me ross pg musher dm cate '\n",
      " 'tr baughn re response of  latent syphilis or neurosyphilis to ceftriaxone '\n",
      " 'therapy in persons infected  with human immunodeficiency virus am j med '\n",
      " '199293481–8  pmid1442850 httpsdoiorg101016000293439290574u  630 smith nh '\n",
      " 'musher dm huang db et al response of hivinfected  patients with asymptomatic '\n",
      " 'syphilis to intensive intramuscular therapy  with ceftriaxone or procaine '\n",
      " 'penicillin int j std aids 200415328–32  pmid15117503 '\n",
      " 'httpsdoiorg101177095646240401500511  631 ahmed ka fox sj frigas e park ma '\n",
      " 'clinical outcome in the use  of cephalosporins in pediatric patients with a '\n",
      " 'history of penicillin  allergy int arch allergy immunol 2012158405–10 '\n",
      " 'pmid22487723  httpsdoiorg101159000333553  632 trivedi s williams c torrone e '\n",
      " 'kidd s national trends and reported  risk factors among pregnant women with '\n",
      " 'syphilis in the united states  2012–2016 obstet gynecol 201913327–32 '\n",
      " 'pmid30531570  httpsdoiorg101097aog0000000000003000  633 biswas hh chew ng ra '\n",
      " 'murray el et al characteristics associated  with delivery of an infant with '\n",
      " 'congenital syphilis and missed  opportunities for prevention—california 2012 '\n",
      " 'to 2014 sex transm  dis 201845435–41 pmid29465666 httpsdoiorg101097 '\n",
      " 'olq0000000000000782  634 slutsker js hennessy rr schillinger ja factors '\n",
      " 'contributing to  congenital syphilis cases—new york city 2010–2016 mmwr '\n",
      " 'morb  mortal wkly rep 2018671088–93 pmid30286056 httpsdoi '\n",
      " 'org1015585mmwrmm6739a3  635 diorio d kroeger k ross a social vulnerability '\n",
      " 'in congenital  syphilis case mothers qualitative assessment of cases in '\n",
      " 'indiana 2014  to 2016 sex transm dis 201845447–51 pmid29465662 https '\n",
      " 'doiorg101097olq0000000000000783  636 kimball a torrone e miele k et al '\n",
      " 'missed opportunities for  prevention of congenital syphilis—united states '\n",
      " '2018 mmwr  morb mortal wkly rep 202069661–5 pmid32497029 https '\n",
      " 'doiorg1015585mmwrmm6922a1  637 park iu chow jm bolan g stanley m shieh j '\n",
      " 'schapiro jm  screening for syphilis with the treponemal immunoassay analysis '\n",
      " 'of  discordant serology results and implications for clinical management  j '\n",
      " 'infect dis 20112041297–304 pmid21930610 httpsdoi org101093infdisjir524  638 '\n",
      " 'mmeje o chow jm davidson l shieh j schapiro jm park  iu discordant syphilis '\n",
      " 'immunoassays in pregnancy perinatal  outcomes and implications for clinical '\n",
      " 'management clin infect dis  2015611049–53 pmid26063719 httpsdoiorg101093cid '\n",
      " 'civ445  639 alexander jm sheffield js sanchez pj mayfield j wendel gd  jr '\n",
      " 'efficacy of treatment for syphilis in pregnancy obstet gynecol  1999935–8 '\n",
      " 'pmid9916946  640 walker gj antibiotics for syphilis diagnosed during '\n",
      " 'pregnancy  cochrane database syst rev 20013cd001143 pmid11686978  641 wendel '\n",
      " 'gd jr sheffield js hollier lm hill jb ramsey ps sánchez  pj treatment of '\n",
      " 'syphilis in pregnancy and prevention of congenital  syphilis clin infect dis '\n",
      " '200235suppl 2s200–9 pmid12353207  httpsdoiorg101086342108  642 zhu l qin m '\n",
      " 'du l xie rh wong t wen sw maternal and  congenital syphilis in shanghai '\n",
      " 'china 2002 to 2006 int j infect dis  201014suppl 3e45–8 pmid20137991 '\n",
      " 'httpsdoiorg101016j ijid200909009  643 hawkes s matin n broutet n low n '\n",
      " 'effectiveness of interventions  to improve screening for syphilis in '\n",
      " 'pregnancy a systematic review and  metaanalysis lancet infect dis '\n",
      " '201111684–91 pmid21683653  httpsdoiorg101016s1473309911701049  644 hollier '\n",
      " 'lm harstad tw sanchez pj twickler dm wendel gd jr  fetal syphilis clinical '\n",
      " 'and laboratory characteristics obstet gynecol  200197947–53 pmid11384701 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids8355931doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids8355931doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids18715154doptabstract '\n",
      " 'httpsdoiorg101086591534 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28855625doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28855625doptabstract '\n",
      " 'httpsdoiorg101038s4159801710387x '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids3764632doptabstract '\n",
      " 'httpsdoiorg1010970000743519860700000018 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids14573840doptabstract '\n",
      " 'httpsdoiorg101136sti795415 httpsdoiorg101136sti795415 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids22487723doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids20484925doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids20484925doptabstract '\n",
      " 'httpsdoiorg101159000314367 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids11260156doptabstract '\n",
      " 'httpsdoiorg101046j13652222200100992x httpsdoiorg101046j13652222200100992x '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids17321857doptabstract '\n",
      " 'httpsdoiorg101016jotohns200610007 httpsdoiorg101016jotohns200610007 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids15837859doptabstract '\n",
      " 'httpsdoiorg101001archderm1414431 httpsdoiorg101001archderm1414431 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids17597693doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids18525260doptabstract '\n",
      " 'httpsdoiorg101097qad0b013e32830184df httpsdoiorg101097qad0b013e32830184df '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids18532887doptabstract '\n",
      " 'httpsdoiorg101086589295 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28196838doptabstract '\n",
      " 'httpsdoiorg101136sextrans2016052938 httpsdoiorg101136sextrans2016052938 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids19500029doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids19500029doptabstract '\n",
      " 'httpsdoiorg101086599616 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids10722441doptabstract '\n",
      " 'httpsdoiorg101086313725 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids1442850doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids1442850doptabstract '\n",
      " 'httpsdoiorg101016000293439290574u '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids15117503doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids15117503doptabstract '\n",
      " 'httpsdoiorg101177095646240401500511 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids22487723doptabstract '\n",
      " 'httpsdoiorg101159000333553 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30531570doptabstract '\n",
      " 'httpsdoiorg101097aog0000000000003000 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29465666doptabstract '\n",
      " 'httpsdoiorg101097olq0000000000000782 httpsdoiorg101097olq0000000000000782 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30286056doptabstract '\n",
      " 'httpsdoiorg1015585mmwrmm6739a3 httpsdoiorg1015585mmwrmm6739a3 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29465662doptabstract '\n",
      " 'httpsdoiorg101097olq0000000000000783 httpsdoiorg101097olq0000000000000783 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids32497029doptabstract '\n",
      " 'httpsdoiorg1015585mmwrmm6922a1 httpsdoiorg1015585mmwrmm6922a1 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids21930610doptabstract '\n",
      " 'httpsdoiorg101093infdisjir524 httpsdoiorg101093infdisjir524 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids26063719doptabstract '\n",
      " 'httpsdoiorg101093cidciv445 httpsdoiorg101093cidciv445 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids9916946doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids11686978doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids12353207doptabstract '\n",
      " 'httpsdoiorg101086342108 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids20137991doptabstract '\n",
      " 'httpsdoiorg101016jijid200909009 httpsdoiorg101016jijid200909009 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids21683653doptabstract '\n",
      " 'httpsdoiorg101016s1473309911701049 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids11384701doptabstract '\n",
      " 'recommendations and reports mmwr  july 23 2021  vol 70  no 4 157us '\n",
      " 'department of health and human servicescenters for disease control and '\n",
      " 'prevention  645 rac mw bryant sn mcintire dd et al progression of '\n",
      " 'ultrasound  findings of fetal syphilis after maternal treatment am j obstet '\n",
      " 'gynecol  2014211426e1–6 pmid24907700 httpsdoiorg101016j ajog201405049  646 '\n",
      " 'zhou p gu z xu j wang x liao k a study evaluating ceftriaxone  as a '\n",
      " 'treatment agent for primary and secondary syphilis in pregnancy  sex transm '\n",
      " 'dis 200532495–8 pmid16041252 httpsdoi org10109701olq000017044370739cd  647 '\n",
      " 'katanami y hashimoto t takaya s et al amoxicillin and ceftriaxone  as '\n",
      " 'treatment alternatives to penicillin for maternal syphilis emerg  infect dis '\n",
      " '201723827–9 pmid28418316 httpsdoiorg103201 eid2305161936  648 kestenbaum la '\n",
      " 'ebberson j zorc jj hodinka rl shah ss defining  cerebrospinal fluid white '\n",
      " 'blood cell count reference values in neonates  and young infants pediatrics '\n",
      " '2010125257–64 pmid20064869  httpsdoiorg101542peds20091181  649 shah ss '\n",
      " 'ebberson j kestenbaum la hodinka rl zorc jj age specific reference values '\n",
      " 'for cerebrospinal fluid protein concentration  in neonates and young infants '\n",
      " 'j hosp med 2011622–7  pmid20629018 httpsdoiorg101002jhm711  650 thomson j '\n",
      " 'sucharew h cruz at et al pediatric emergency medicine  collaborative '\n",
      " 'research committee pem crc hsv study group  cerebrospinal fluid reference '\n",
      " 'values for young infants undergoing  lumbar puncture pediatrics '\n",
      " '2018141e20173405 pmid29437883  httpsdoiorg101542peds20173405  651 kimberlin '\n",
      " 'dw brady mt jackson ma long ss eds red book  2018 report of the committee on '\n",
      " 'infectious diseases 31st ed itasca  il american academy of pediatrics 2018  '\n",
      " '652 macy e contreras r adverse reactions associated with oral and  '\n",
      " 'parenteral use of cephalosporins a retrospective populationbased  analysis   '\n",
      " 'j  allergy clin immunol 2015135745–52e5  pmid25262461 '\n",
      " 'httpsdoiorg101016jjaci201407062  653 macy e vyles d who needs penicillin '\n",
      " 'allergy testing ann allergy  asthma immunol 2018121523–9 pmid30092265 '\n",
      " 'httpsdoi org101016janai201807041  654 annè s reisman re risk of '\n",
      " 'administering cephalosporin antibiotics  to patients with histories of '\n",
      " 'penicillin allergy ann allergy asthma  immunol 199574167–70 pmid7697478  655 '\n",
      " 'albin s agarwal s prevalence and characteristics of reported penicillin  '\n",
      " 'allergy in an urban outpatient adult population allergy asthma proc  '\n",
      " '201435489–94 pmid25584917 httpsdoiorg102500 aap2014353791  656 blumenthal kg '\n",
      " 'peter jg trubiano ja phillips ej antibiotic allergy  lancet 2019393183–98 '\n",
      " 'pmid30558872 httpsdoiorg101016 s0140673618322189  657 macy e poon ky t '\n",
      " 'selfreported antibiotic allergy incidence and  prevalence age and sex '\n",
      " 'effects am j med 2009122778e1–7  pmid19635279 '\n",
      " 'httpsdoiorg101016jamjmed200901034  658 shenoy es macy e rowe t blumenthal kg '\n",
      " 'evaluation and  management of penicillin allergy a review jama '\n",
      " '2019321188–99  pmid30644987 httpsdoiorg101001jama201819283  659 gadde j '\n",
      " 'spence m wheeler b adkinson nf jr clinical experience  with penicillin skin '\n",
      " 'testing in a large innercity std clinic jama  19932702456–63 pmid8230623 '\n",
      " 'httpsdoiorg101001 jama199303510200062033  660 macy e ngor ew safely '\n",
      " 'diagnosing clinically significant penicillin  allergy using only '\n",
      " 'penicilloylpolylysine penicillin and oral  amoxicillin j allergy clin '\n",
      " 'immunol pract 20131258–63  pmid24565482 httpsdoiorg101016jjaip201302002  661 '\n",
      " 'jares ej sánchezborges m cardonavilla r et al latin america  drug allergy '\n",
      " 'interest group multinational experience with  hypersensitivity drug '\n",
      " 'reactions in latin america ann allergy asthma  immunol 2014113282–9 '\n",
      " 'pmid25065979 httpsdoi org101016janai201406019  662 macy e contreras r health '\n",
      " 'care use and serious infection prevalence  associated with penicillin '\n",
      " '“allergy” in hospitalized patients a cohort  study j allergy clin immunol '\n",
      " '2014133790–6 pmid24188976  httpsdoiorg101016jjaci201309021  663 blumenthal '\n",
      " 'kg lu n zhang y li y walensky rp choi hk risk  of meticillin resistant '\n",
      " 'staphylococcus aureus and clostridium difficile in  patients with a '\n",
      " 'documented penicillin allergy population based  matched cohort study bmj '\n",
      " '2018361k2400 pmid29950489  httpsdoiorg101136bmjk2400  664 blumenthal kg ryan '\n",
      " 'ee li y lee h kuhlen jl shenoy es the  impact of a reported penicillin '\n",
      " 'allergy on surgical site infection risk  clin infect dis 201866329–36 '\n",
      " 'pmid29361015 httpsdoi org101093cidcix794  665 tucker mh lomas cm ramchandar '\n",
      " 'n waldram jd amoxicillin  challenge without penicillin skin testing in '\n",
      " 'evaluation of penicillin  allergy in a cohort of marine recruits j allergy '\n",
      " 'clin immunol pract  20175813–5 pmid28341170 httpsdoiorg101016j '\n",
      " 'jaip201701023  666 goldberg a confinocohen r skin testing and oral '\n",
      " 'penicillin  challenge in patients with a history of remote penicillin '\n",
      " 'allergy ann  allergy asthma immunol 200810037–43 pmid18254480 https '\n",
      " 'doiorg101016s1081120610604024  667 iammatteo m alvarez arango s ferastraoaru '\n",
      " 'd et al safety and  outcomes of oral graded challenges to amoxicillin '\n",
      " 'without prior skin  testing j allergy clin immunol pract 20197236–43 '\n",
      " 'pmid29802906  httpsdoiorg101016jjaip201805008  668 cook dj barbara dw singh '\n",
      " 'ke dearani ja penicillin skin testing  in cardiac surgery j thorac '\n",
      " 'cardiovasc surg 20141471931–5  pmid24530197 '\n",
      " 'httpsdoiorg101016jjtcvs201401019  669 mcdanel dl azar ae dowden am et al '\n",
      " 'screening for betalactam  allergy in joint arthroplasty patients to improve '\n",
      " 'surgical prophylaxis  practice j arthroplasty 2017329ss101–8 pmid28236547 '\n",
      " 'https doiorg101016jarth201701012  670 trubiano ja thursky ka stewardson aj '\n",
      " 'et al impact of an integrated  antibiotic allergy testing program on '\n",
      " 'antimicrobial stewardship a  multicenter evaluation clin infect dis '\n",
      " '201765166–74  pmid28520865 httpsdoiorg101093cidcix244  671 siew lqc li ph '\n",
      " 'watts tj et al identifying lowrisk betalactam  allergy patients in a uk '\n",
      " 'tertiary centre j allergy clin immunol pract  201972173–2181e1 pmid30922992 '\n",
      " 'httpsdoiorg101016j jaip201903015  672 chen jr tarver sa alvarez ks tran t '\n",
      " 'khan da a proactive  approach to penicillin allergy testing in hospitalized '\n",
      " 'patients j allergy  clin immunol pract 20175686–93 pmid27888034 httpsdoi '\n",
      " 'org101016jjaip201609045  673 leis ja palmay l ho g et al pointofcare βlactam '\n",
      " 'allergy skin  testing by antimicrobial stewardship programs a pragmatic '\n",
      " 'multicenter  prospective evaluation clin infect dis 2017651059–65  '\n",
      " 'pmid28575226 httpsdoiorg101093cidcix512  674 banks ta tucker m macy e '\n",
      " 'evaluating penicillin allergies without  skin testing curr allergy asthma '\n",
      " 'rep 20191927 pmid30903298  httpsdoiorg101007s1188201908546  675 pham mn ho '\n",
      " 'he desai m penicillin desensitization treatment of  syphilis in pregnancy in '\n",
      " 'penicillinallergic patients ann allergy asthma  immunol 2017118537–41 '\n",
      " 'pmid28477786 httpsdoi org101016janai201703013  676 sogn dd evans r 3rd '\n",
      " 'shepherd gm et al results of the national  institute of allergy and '\n",
      " 'infectious diseases collaborative clinical trial  to test the predictive '\n",
      " 'value of skin testing with major and minor  penicillin derivatives in '\n",
      " 'hospitalized adults arch intern med  19921521025–32 pmid1580706 '\n",
      " 'httpsdoiorg101001 archinte199200400170105020 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids24907700doptabstract '\n",
      " 'httpsdoiorg101016jajog201405049 httpsdoiorg101016jajog201405049 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids16041252doptabstract '\n",
      " 'httpsdoiorg10109701olq000017044370739cd '\n",
      " 'httpsdoiorg10109701olq000017044370739cd '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28418316doptabstract '\n",
      " 'httpsdoiorg103201eid2305161936 httpsdoiorg103201eid2305161936 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids20064869doptabstract '\n",
      " 'httpsdoiorg101542peds20091181 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids20629018doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids20629018doptabstract '\n",
      " 'httpsdoiorg101002jhm711 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29437883doptabstract '\n",
      " 'httpsdoiorg101542peds20173405 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids25262461doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids25262461doptabstract '\n",
      " 'httpsdoiorg101016jjaci201407062 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30092265doptabstract '\n",
      " 'httpsdoiorg101016janai201807041 httpsdoiorg101016janai201807041 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids7697478doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids25584917doptabstract '\n",
      " 'httpsdoiorg102500aap2014353791 httpsdoiorg102500aap2014353791 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30558872doptabstract '\n",
      " 'httpsdoiorg101016s0140673618322189 httpsdoiorg101016s0140673618322189 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids19635279doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids19635279doptabstract '\n",
      " 'httpsdoiorg101016jamjmed200901034 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30644987doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30644987doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids8230623doptabstract '\n",
      " 'httpsdoiorg101001jama199303510200062033 '\n",
      " 'httpsdoiorg101001jama199303510200062033 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids24565482doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids24565482doptabstract '\n",
      " 'httpsdoiorg101016jjaip201302002 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids25065979doptabstract '\n",
      " 'httpsdoiorg101016janai201406019 httpsdoiorg101016janai201406019 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids24188976doptabstract '\n",
      " 'httpsdoiorg101016jjaci201309021 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29950489doptabstract '\n",
      " 'httpsdoiorg101136bmjk2400 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29361015doptabstract '\n",
      " 'httpsdoiorg101093cidcix794 httpsdoiorg101093cidcix794 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28341170doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids18254480doptabstract '\n",
      " 'httpsdoiorg101016s1081120610604024 httpsdoiorg101016s1081120610604024 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29802906doptabstract '\n",
      " 'httpsdoiorg101016jjaip201805008 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids24530197doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids24530197doptabstract '\n",
      " 'httpsdoiorg101016jjtcvs201401019 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28236547doptabstract '\n",
      " 'httpsdoiorg101016jarth201701012 httpsdoiorg101016jarth201701012 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28520865doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28520865doptabstract '\n",
      " 'httpsdoiorg101093cidcix244 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30922992doptabstract '\n",
      " 'httpsdoiorg101016jjaip201903015 httpsdoiorg101016jjaip201903015 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids27888034doptabstract '\n",
      " 'httpsdoiorg101016jjaip201609045 httpsdoiorg101016jjaip201609045 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28575226doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28575226doptabstract '\n",
      " 'httpsdoiorg101093cidcix512 httpsdoiorg101007s1188201908546 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28477786doptabstract '\n",
      " 'httpsdoiorg101016janai201703013 httpsdoiorg101016janai201703013 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids1580706doptabstract '\n",
      " 'httpsdoiorg101001archinte199200400170105020 '\n",
      " 'httpsdoiorg101001archinte199200400170105020 recommendations and reports 158 '\n",
      " 'mmwr  july 23 2021  vol 70  no 4 us department of health and human '\n",
      " 'servicescenters for disease control and prevention  677 solensky r jacobs j '\n",
      " 'lester m et al penicillin allergy evaluation a  prospective multicenter '\n",
      " 'openlabel evaluation of a comprehensive  penicillin skin test kit j allergy '\n",
      " 'clin immunol pract 201971876–85 e3 pmid30878711 '\n",
      " 'httpsdoiorg101016jjaip201902040  678 heil el bork jt schmalzle sa et al '\n",
      " 'implementation of an infectious  disease fellowmanaged penicillin allergy '\n",
      " 'skin testing service open  forum infect dis 20163ofw155 pmid27704011 '\n",
      " 'httpsdoi org101093ofidofw155  679 du plessis t walls g jordan a holland dj '\n",
      " 'implementation of a  pharmacistled penicillin allergy delabelling service in '\n",
      " 'a public hospital  j antimicrob chemother 2019741438–46 pmid30753497 https '\n",
      " 'doiorg101093jacdky575  680 macy e blumenthal kg are cephalosporins safe for '\n",
      " 'use in penicillin  allergy without prior allergy evaluation j allergy clin '\n",
      " 'immunol pract  2018682–9 pmid28958745 httpsdoiorg101016j jaip201707033  681 '\n",
      " 'zagursky rj pichichero me crossreactivity in βlactam allergy j  allergy clin '\n",
      " 'immunol pract 2018672–81e1 pmid29017833  httpsdoiorg101016jjaip201708027  '\n",
      " '682 blumenthal kg shenoy es varughese ca hurwitz s hooper dc  banerji a '\n",
      " 'impact of a clinical guideline for prescribing antibiotics to  inpatients '\n",
      " 'reporting penicillin or cephalosporin allergy ann allergy  asthma immunol '\n",
      " '2015115294–300e2 pmid26070805 https doiorg101016janai201505011  683 '\n",
      " 'kuruvilla m wolf f sexton m wiley z thomas j perioperative use  of cefazolin '\n",
      " 'without preliminary skin testing in patients with reported  penicillin '\n",
      " 'allergy surgery 2019165486–96 pmid30001827 https doiorg101016jsurg201805054  '\n",
      " '684 lee p shanson d results of a uk survey of fatal anaphylaxis after oral  '\n",
      " 'amoxici l l in  j  antimicrob chemother 2007601172–3  pmid17761735 '\n",
      " 'httpsdoiorg101093jacdkm315  685 blumenthal kg shenoy es wolfson ar et al '\n",
      " 'addressing inpatient  betalactam allergies a multihospital implementation j '\n",
      " 'allergy clin  immunol pract 20175616–25e7 pmid28483315 httpsdoi '\n",
      " 'org101016jjaip201702019  686 mustafa ss conn k ramsey a comparing direct '\n",
      " 'challenge to  penicillin skin testing for the outpatient evaluation of '\n",
      " 'penicillin allergy  a randomized controlled trial j allergy clin immunol '\n",
      " 'pract  201972163–70 pmid31170542 httpsdoiorg101016j jaip201905037  687 '\n",
      " 'chastain db hutzley vj parekh j alegro jvg antimicrobial  desensitization a '\n",
      " 'review of published protocols pharmacy basel  20197112  pmid31405062 https '\n",
      " 'doi org103390 pharmacy7030112  688 wendel gd jr stark bj jamison rb molina '\n",
      " 'rd sullivan tj  penicillin allergy and desensitization in serious infections '\n",
      " 'during  pregnancy n engl j med 19853121229–32 pmid3921835 https '\n",
      " 'doiorg101056nejm198505093121905  689 borish l tamir r rosenwasser lj '\n",
      " 'intravenous desensitization to  betalactam antibiotics j allergy clin '\n",
      " 'immunol 198780314–9  pmid3040836 httpsdoiorg1010160091674987900376  690 '\n",
      " 'legere hj 3rd palis ri rodriguez bouza t uluer az castells mc  a safe '\n",
      " 'protocol for rapid desensitization in patients with cystic fibrosis  and '\n",
      " 'antibiotic hypersensitivity j cyst fibros 20098418–24  pmid19740711 '\n",
      " 'httpsdoiorg101016jjcf200908002  691 manhart le holmes kk hughes jp houston '\n",
      " 'ls totten pa  mycoplasma genitalium among young adults in the united states '\n",
      " 'an  emerging sexually transmitted infection am j public health  '\n",
      " '2007971118–25 pmid17463380 httpsdoiorg102105 ajph2005074062  692 ross jdc '\n",
      " 'jensen js mycoplasma genitalium as a sexually transmitted  infection '\n",
      " 'implications for screening testing and treatment sex transm  infect '\n",
      " '200682269–71 pmid16877571 httpsdoiorg101136 sti2005017368  693 '\n",
      " 'taylorrobinson d gi lroy cb thomas bj  hay pe  mycoplasma genitalium in '\n",
      " 'chronic nongonococcal urethritis  int j std aids 20041521–5 pmid14769166 '\n",
      " 'httpsdoi org101258095646204322637209  694 dupin n bijaoui g schwarzinger m '\n",
      " 'et al detection and  quantification of mycoplasma genitalium in male '\n",
      " 'patients with  urethritis clin infect dis 200337602–5 pmid12905147 https '\n",
      " 'doiorg101086376990  695 krieger jn riley de roberts mc berger re prokaryotic '\n",
      " 'dna  sequences in patients with chronic idiopathic prostatitis j clin  '\n",
      " 'microbiol 1996343120–8 pmid8940458 httpsdoiorg101128 jcm3412312031281996  '\n",
      " '696 le roux mc hoosen aa quantitative realtime polymerase chain  reaction '\n",
      " 'for the diagnosis of mycoplasma genitalium infection in south  african men '\n",
      " 'with and without symptoms of urethritis sex transm  dis 20174417–20 '\n",
      " 'pmid27898565 httpsdoiorg101097 olq0000000000000540  697 bachmann lh '\n",
      " 'kirkcaldy rd geisler wm et al the magnum  laboratory working group '\n",
      " 'prevalence of mycoplasma genitalium  infection antimicrobial resistance '\n",
      " 'mutations and symptom resolution  following treatment of urethritis clin '\n",
      " 'infect dis 202071e624–32  pmid32185385 httpsdoiorg101093cidciaa293  698 nye '\n",
      " 'mb schwebke jr body ba comparison of aptima  trichomonas vaginalis '\n",
      " 'transcriptionmediated amplification to wet  mount microscopy culture and '\n",
      " 'polymerase chain reaction for  diagnosis of trichomoniasis in men and women '\n",
      " 'am j obstet gynecol  2009200188e1–7 pmid19185101 httpsdoiorg101016j '\n",
      " 'ajog200810005  699 bradshaw cs tabrizi sn read tr et al etiologies of '\n",
      " 'nongonococcal  urethritis bacteria viruses and the association with '\n",
      " 'orogenital  exposure j infect dis 2006193336–45 pmid16388480 https '\n",
      " 'doiorg101086499434  700 dombrowski jc harrington rd golden mr evidence for '\n",
      " 'the long term stability of hiv transmissionassociated sexual behavior after '\n",
      " 'hiv  diagnosis sex transm dis 20134041–5 pmid23254116 https '\n",
      " 'doiorg101097olq0b013e3182753327  701 rane vs fairley ck weerakoon a et al '\n",
      " 'characteristics of acute  nongonococcal urethritis in men differ by sexual '\n",
      " 'preference  j clin microbiol 2014522971–6 pmid24899041 httpsdoi '\n",
      " 'org101128jcm0089914  702 pond mj nori av witney aa lopeman rc butcher pd '\n",
      " 'sadiq  st high prevalence of antibioticresistant mycoplasma genitalium  in '\n",
      " 'nongonococcal urethritis the need for routine testing and  the inadequacy of '\n",
      " 'current treatment options clin infect dis  201458631–7 pmid24280088 '\n",
      " 'httpsdoiorg101093cidcit752  703 khatib n bradbury c chalker v et al '\n",
      " 'prevalence of trichomonas  vaginalis mycoplasma genitalium and ureaplasma '\n",
      " 'urealyticum in  men with urethritis attending an urban sexual health clinic '\n",
      " 'int  j std aids 201526388–92 pmid24925897 httpsdoi '\n",
      " 'org1011770956462414539464  704 cox c mckenna jp watt ap coyle pv ureaplasma '\n",
      " 'parvum and  mycoplasma genitalium are found to be significantly associated '\n",
      " 'with  microscopyconfirmed urethritis in a routine genitourinary medicine  '\n",
      " 'setting int j std aids 201627861–7 pmid26378187 https '\n",
      " 'doiorg1011770956462415597620  705 li y su x le w et al mycoplasma genitalium '\n",
      " 'in symptomatic male  urethritis macrolide use is associated with increased '\n",
      " 'resistance  clin infect dis 202070805–10 pmid30972419 httpsdoi '\n",
      " 'org101093cidciz294  706 ito s hanaoka n shimuta k et al male nongonococcal '\n",
      " 'urethritis  from microbiological etiologies to demographic and clinical '\n",
      " 'features  int j urol 201623325–31 pmid26845624 httpsdoiorg101111 iju13044 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30878711doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids27704011doptabstract '\n",
      " 'httpsdoiorg101093ofidofw155 httpsdoiorg101093ofidofw155 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30753497doptabstract '\n",
      " 'httpsdoiorg101093jacdky575 httpsdoiorg101093jacdky575 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28958745doptabstract '\n",
      " 'httpsdoiorg101016jjaip201707033 httpsdoiorg101016jjaip201707033 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29017833doptabstract '\n",
      " 'httpsdoiorg101016jjaip201708027 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids26070805doptabstract '\n",
      " 'httpsdoiorg101016janai201505011 httpsdoiorg101016janai201505011 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30001827doptabstract '\n",
      " 'httpsdoiorg101016jsurg201805054 httpsdoiorg101016jsurg201805054 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids17761735doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids17761735doptabstract '\n",
      " 'httpsdoiorg101093jacdkm315 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28483315doptabstract '\n",
      " 'httpsdoiorg101016jjaip201702019 httpsdoiorg101016jjaip201702019 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids31170542doptabstract '\n",
      " 'httpsdoiorg101016jjaip201905037 httpsdoiorg101016jjaip201905037 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids31405062doptabstract '\n",
      " 'httpsdoiorg103390pharmacy7030112 httpsdoiorg103390pharmacy7030112 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids3921835doptabstract '\n",
      " 'httpsdoiorg101056nejm198505093121905 httpsdoiorg101056nejm198505093121905 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids3040836doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids3040836doptabstract '\n",
      " 'httpsdoiorg1010160091674987900376 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids19740711doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids19740711doptabstract '\n",
      " 'httpsdoiorg101016jjcf200908002 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids17463380doptabstract '\n",
      " 'httpsdoiorg102105ajph2005074062 httpsdoiorg102105ajph2005074062 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids16877571doptabstract '\n",
      " 'httpsdoiorg101136sti2005017368 httpsdoiorg101136sti2005017368 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids14769166doptabstract '\n",
      " 'httpsdoiorg101258095646204322637209 httpsdoiorg101258095646204322637209 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids12905147doptabstract '\n",
      " 'httpsdoiorg101086376990 httpsdoiorg101086376990 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids8940458doptabstract '\n",
      " 'httpsdoiorg101128jcm3412312031281996 httpsdoiorg101128jcm3412312031281996 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids27898565doptabstract '\n",
      " 'httpsdoiorg101097olq0000000000000540 httpsdoiorg101097olq0000000000000540 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids32185385doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids32185385doptabstract '\n",
      " 'httpsdoiorg101093cidciaa293 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids19185101doptabstract '\n",
      " 'httpsdoiorg101016jajog200810005 httpsdoiorg101016jajog200810005 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids16388480doptabstract '\n",
      " 'httpsdoiorg101086499434 httpsdoiorg101086499434 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids23254116doptabstract '\n",
      " 'httpsdoiorg101097olq0b013e3182753327 httpsdoiorg101097olq0b013e3182753327 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids24899041doptabstract '\n",
      " 'httpsdoiorg101128jcm0089914 httpsdoiorg101128jcm0089914 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids24280088doptabstract '\n",
      " 'httpsdoiorg101093cidcit752 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids24925897doptabstract '\n",
      " 'httpsdoiorg1011770956462414539464 httpsdoiorg1011770956462414539464 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids26378187doptabstract '\n",
      " 'httpsdoiorg1011770956462415597620 httpsdoiorg1011770956462415597620 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30972419doptabstract '\n",
      " 'httpsdoiorg101093cidciz294 httpsdoiorg101093cidciz294 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids26845624doptabstract '\n",
      " 'httpsdoiorg101111iju13044 httpsdoiorg101111iju13044 recommendations and '\n",
      " 'reports mmwr  july 23 2021  vol 70  no 4 159us department of health and '\n",
      " 'human servicescenters for disease control and prevention  707 horner p '\n",
      " 'donders g cusini m gomberg m jensen js unemo m  should we be testing for '\n",
      " 'urogenital mycoplasma hominis ureaplasma  parvum and ureaplasma urealyticum '\n",
      " 'in men and women—a position  statement from the european sti guidelines '\n",
      " 'editorial board j eur  acad dermatol venereol 2018321845–51 pmid29924422 '\n",
      " 'https doiorg101111jdv15146  708 van der veer c van rooijen ms himschoot m de '\n",
      " 'vries hj bruisten  sm trichomonas vaginalis and mycoplasma genitalium '\n",
      " 'agespecific  prevalence and disease burden in men attending a sexually '\n",
      " 'transmitted  infections clinic in amsterdam the netherlands sex transm '\n",
      " 'infect  20169283–5 pmid26283740 httpsdoiorg101136 sextrans2015052118  709 '\n",
      " 'seike k maeda s kubota y tamaki m yasuda m deguchi t  prevalence and '\n",
      " 'morbidity of urethral trichomonas vaginalis in japanese  men with or without '\n",
      " 'urethritis sex transm infect 201389528–30  pmid23349337 '\n",
      " 'httpsdoiorg101136sextrans2012050702  710 napierala m munson e wenten d et al '\n",
      " 'detection of mycoplasma  genitalium from male primary urine specimens an '\n",
      " 'epidemiologic  dichotomy with trichomonas vaginalis diagn microbiol infect '\n",
      " 'dis  201582194–8 pmid25934156 httpsdoiorg101016j diagmicrobio201503016  711 '\n",
      " 'sviben m missoni em meštrović t vojnović g galinović gm  epidemiology and '\n",
      " 'laboratory characteristics of trichomonas vaginalis  infection in croatian '\n",
      " 'men with and without urethritis syndrome a  casecontrol study sex transm '\n",
      " 'infect 201591360–4 pmid25568091  httpsdoiorg101136sextrans2014051771  712 '\n",
      " 'rietmeijer ca mungati m machiha a et al the etiology of male  urethral '\n",
      " 'discharge in zimbabwe results from the zimbabwe sti  etiology study sex '\n",
      " 'transm dis 20184556–60 pmid29240635  httpsdoiorg101097olq0000000000000696  '\n",
      " '713 bazan ja peterson as kirkcaldy rd et al notes from the field  increase '\n",
      " 'in neisseria meningitidisassociated urethritis among men at  two sentinel '\n",
      " 'clinics—columbus ohio and oakland county  michigan 2015 mmwr morb mortal '\n",
      " 'wkly rep 201665550–2  pmid27254649 httpsdoiorg1015585mmwrmm6521a5  714 '\n",
      " 'jannic a mammeri h larcher l et al orogenital transmission of  neisseria '\n",
      " 'meningitidis causing acute urethritis in men who have sex with  men emerg '\n",
      " 'infect dis 201925175–6 pmid30561300 httpsdoi org103201eid2501171102  715 '\n",
      " 'hayakawa k itoda i shimuta k takahashi h ohnishi m urethritis  caused by '\n",
      " 'novel neisseria meningitidis serogroup w in man who has  sex with men japan '\n",
      " 'emerg infect dis 2014201585–7  pmid25154021 httpsdoiorg103201eid2009140349  '\n",
      " '716 bazan ja tzeng yl stephens ds et al repeat episodes of symptomatic  '\n",
      " 'urethritis due to a uropathogenic meningococcal clade sex transm  dis '\n",
      " '202047e1–4 pmid31651709 httpsdoiorg101097 olq0000000000001079  717 ong jj '\n",
      " 'morton an henzell hr et al clinical characteristics of  herpes simplex virus '\n",
      " 'urethritis compared with chlamydial urethritis  among men sex transm dis '\n",
      " '201744121–5 pmid28079748 https doiorg101097olq0000000000000547  718 avolio m '\n",
      " 'de rosa r modolo ml stano p camporese a when  should adenoviral '\n",
      " 'nongonococcal urethritis be suspected two case  reports new microbiol '\n",
      " '201437109–12 pmid24531179  719 you c hamasuna r ogawa m et al the first '\n",
      " 'report an analysis of  bacterial flora of the first voided urine specimens '\n",
      " 'of patients with male  urethritis using the 16s ribosomal rna genebased '\n",
      " 'clone library  method microb pathog 20169595–100 pmid27013259 https '\n",
      " 'doiorg101016jmicpath201602022  720 deguchi t ito s hatazaki k et al '\n",
      " 'antimicrobial susceptibility of  haemophilus influenzae strains isolated '\n",
      " 'from the urethra of men with  acute urethritis andor epididymitis j infect '\n",
      " 'chemother 201723804–7  pmid28619239 httpsdoiorg101016jjiac201705009  721 ito '\n",
      " 's hatazaki k shimuta k et al haemophilus influenzae isolated  from men with '\n",
      " 'acute urethritis its pathogenic roles responses to  antimicrobial '\n",
      " 'chemotherapies and antimicrobial susceptibilities sex  transm dis '\n",
      " '201744205–10 pmid28282645 httpsdoi org101097olq0000000000000573  722 horie k '\n",
      " 'ito s hatazaki k et al ‘haemophilus quentini’ in the urethra  of men '\n",
      " 'complaining of urethritis symptoms j infect chemother  20182471–4 '\n",
      " 'pmid28889986 httpsdoiorg101016j jiac201708007  723 frølund m falk l ahrens p '\n",
      " 'jensen js detection of ureaplasmas and  bacterial vaginosis associated '\n",
      " 'bacteria and their association with non gonococcal urethritis in men plos '\n",
      " 'one 201914e0214425  pmid30946763 httpsdoiorg101371journalpone0214425  724 '\n",
      " 'deza g martinezquerra g gómez j villargarcía j supervia a  pujol rm '\n",
      " 'isolation of haemophilus influenzae and haemophilus  parainfluenzae in '\n",
      " 'urethral exudates from men with acute urethritis a  descriptive study of 52 '\n",
      " 'cases sex transm infect 20169229–31  pmid26139207 '\n",
      " 'httpsdoiorg101136sextrans2015052135  725 magdalenotapial j valenzuelaoñate c '\n",
      " 'giacamanvon der weth  mm et al haemophilus species isolated in urethral '\n",
      " 'exudates as a possible  causative agent in acute urethritis a study of 38 '\n",
      " 'cases actas  dermosifiliogr 201911038–42 pmid30390917 httpsdoi '\n",
      " 'org101016jadengl201811011  726 abdolrasouli a roushan a corynebacterium '\n",
      " 'propinquum associated  with acute nongonococcal urethritis sex transm dis '\n",
      " '201340829–31  pmid24275738 httpsdoiorg101097olq0000000000000027  727 ongrádi '\n",
      " 'j stercz b kövesdi v nagy k chatlynne l isolation of  kurthia gibsonii from '\n",
      " 'nongonorrheal urethritis implications for the  pathomechanism upon surveying '\n",
      " 'the literature acta microbiol  immunol hung 20146179–87 pmid24631755 '\n",
      " 'httpsdoi org101556amicr61201418  728 gherardi g di bonaventura g pompilio a '\n",
      " 'savini v corynebacterium  glucuronolyticum causing genitourinary tract '\n",
      " 'infection case report and  review of the literature idcases 2015256–8 '\n",
      " 'pmid26793456  httpsdoiorg101016jidcr201503001  729 meštrović t a microbial '\n",
      " 'game of whackamole clinical case series of  the urethral uncloaking '\n",
      " 'phenomenon caused by corynebacterium  glucuronolyticum in men treated for '\n",
      " 'chlamydia trachomatis urethritis  infection 201947121–4 pmid30168068 '\n",
      " 'httpsdoiorg101007 s1501001812118  730 frikh m el yaagoubi i lemnouer a '\n",
      " 'elouennass m urethritis due  to corynebacterium striatum an emerging germ '\n",
      " 'tunis med  20159343–4 pmid25955369  731 babaeer aa nader c iacoviello v '\n",
      " 'tomera k necrotizing urethritis  due to aerococcus urinae case rep urol '\n",
      " '20152015136147  pmid26171271 httpsdoiorg1011552015136147  732 grandolfo m '\n",
      " 'vestita m bonamonte d filoni a acute urethritis and  balonoposthitis '\n",
      " 'associated to neisseria elongata sex transm dis  201643778–9 pmid27832027 '\n",
      " 'httpsdoiorg101097 olq0000000000000532  733 frølund m lidbrink p wikström a '\n",
      " 'cowan s ahrens p jensen js  urethritisassociated pathogens in urine from men '\n",
      " 'with nongonococcal  urethritis a casecontrol study acta derm venereol '\n",
      " '201696689–94  pmid26658669 httpsdoiorg102340000155552314  734 chambers lc '\n",
      " 'morgan jl lowens ms et al crosssectional study of  urethral exposures at '\n",
      " 'last sexual episode associated with nongonococcal  urethritis among std '\n",
      " 'clinic patients sex transm infect 201995212–8  pmid30181326 '\n",
      " 'httpsdoiorg101136sextrans2018053634  735 manhart le khosropour cm liu c et '\n",
      " 'al bacterial vaginosis associated bacteria in men association of '\n",
      " 'leptotrichiasneathia spp  with nongonococcal urethritis sex transm dis '\n",
      " '201340944–9  pmid24220356 httpsdoiorg101097olq0000000000000054 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29924422doptabstract '\n",
      " 'httpsdoiorg101111jdv15146 httpsdoiorg101111jdv15146 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids26283740doptabstract '\n",
      " 'httpsdoiorg101136sextrans2015052118 httpsdoiorg101136sextrans2015052118 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids23349337doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids23349337doptabstract '\n",
      " 'httpsdoiorg101136sextrans2012050702 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids25934156doptabstract '\n",
      " 'httpsdoiorg101016jdiagmicrobio201503016 '\n",
      " 'httpsdoiorg101016jdiagmicrobio201503016 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids25568091doptabstract '\n",
      " 'httpsdoiorg101136sextrans2014051771 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29240635doptabstract '\n",
      " 'httpsdoiorg101097olq0000000000000696 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids27254649doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids27254649doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30561300doptabstract '\n",
      " 'httpsdoiorg103201eid2501171102 httpsdoiorg103201eid2501171102 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids25154021doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids25154021doptabstract '\n",
      " 'httpsdoiorg103201eid2009140349 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids31651709doptabstract '\n",
      " 'httpsdoiorg101097olq0000000000001079 httpsdoiorg101097olq0000000000001079 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28079748doptabstract '\n",
      " 'httpsdoiorg101097olq0000000000000547 httpsdoiorg101097olq0000000000000547 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids24531179doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids27013259doptabstract '\n",
      " 'httpsdoiorg101016jmicpath201602022 httpsdoiorg101016jmicpath201602022 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28619239doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28619239doptabstract '\n",
      " 'httpsdoiorg101016jjiac201705009 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28282645doptabstract '\n",
      " 'httpsdoiorg101097olq0000000000000573 httpsdoiorg101097olq0000000000000573 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28889986doptabstract '\n",
      " 'httpsdoiorg101016jjiac201708007 httpsdoiorg101016jjiac201708007 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30946763doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30946763doptabstract '\n",
      " 'httpsdoiorg101371journalpone0214425 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids26139207doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids26139207doptabstract '\n",
      " 'httpsdoiorg101136sextrans2015052135 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30390917doptabstract '\n",
      " 'httpsdoiorg101016jadengl201811011 httpsdoiorg101016jadengl201811011 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids24275738doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids24275738doptabstract '\n",
      " 'httpsdoiorg101097olq0000000000000027 httpsdoiorg101556amicr61201418 '\n",
      " 'httpsdoiorg101556amicr61201418 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids26793456doptabstract '\n",
      " 'httpsdoiorg101016jidcr201503001 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30168068doptabstract '\n",
      " 'httpsdoiorg101007s1501001812118 httpsdoiorg101007s1501001812118 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids25955369doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids26171271doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids26171271doptabstract '\n",
      " 'httpsdoiorg1011552015136147 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids27832027doptabstract '\n",
      " 'httpsdoiorg101097olq0000000000000532 httpsdoiorg101097olq0000000000000532 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids26658669doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids26658669doptabstract '\n",
      " 'httpsdoiorg102340000155552314 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30181326doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30181326doptabstract '\n",
      " 'httpsdoiorg101136sextrans2018053634 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids24220356doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids24220356doptabstract '\n",
      " 'httpsdoiorg101097olq0000000000000054 recommendations and reports 160 mmwr  '\n",
      " 'july 23 2021  vol 70  no 4 us department of health and human servicescenters '\n",
      " 'for disease control and prevention  736 ashraf j radford ar turner a '\n",
      " 'subramaniam r preliminary  experience with instillation of triamcinolone '\n",
      " 'acetonide into the urethra  for idiopathic urethritis a prospective pilot '\n",
      " 'study j laparoendosc adv  surg tech a 2017271217–21 pmid29023188 httpsdoi '\n",
      " 'org101089lap20170064  737 taylor sn dicarlo rp martin dh comparison of '\n",
      " 'methylene blue gentian violet stain to gram’s stain for the rapid diagnosis '\n",
      " 'of gonococcal  urethritis in men sex transm dis 201138995–6 pmid21992973  '\n",
      " 'httpsdoiorg101097olq0b013e318225f7c2  738 rietmeijer ca mettenbrink cj '\n",
      " 'recalibrating the gram stain diagnosis  of male urethritis in the era of '\n",
      " 'nucleic acid amplification testing sex  transm dis 20123918–20 pmid22183839 '\n",
      " 'httpsdoiorg101097 olq0b013e3182354da3  739 geisler wm yu s hook ew 3rd '\n",
      " 'chlamydial and gonococcal infection  in men without polymorphonuclear '\n",
      " 'leukocytes on gram stain  implications for diagnostic approach and '\n",
      " 'management sex transm  dis 200532630–4 pmid16205305 httpsdoiorg10109701 '\n",
      " 'olq000017539045315a1  740 gottesman t yossepowitch o samra z rosenberg s dan '\n",
      " 'm  prevalence of mycoplasma genitalium in men with urethritis and in high  '\n",
      " 'risk asymptomatic males in tel aviv a prospective study int j std  aids '\n",
      " '201728 127–32  pmid26826161 ht tps   do i  org1011770956462416630675  741 '\n",
      " 'kim hj park jk park sc et al the prevalence of causative organisms  of '\n",
      " 'communityacquired urethritis in an age group at high risk for  sexually '\n",
      " 'transmitted infections in korean soldiers j r army med corps  201716320–2 '\n",
      " 'pmid26607860 httpsdoiorg101136 jramc2015000488  742 libois a hallin m '\n",
      " 'crucitti t delforge m de wit s prevalence of  mycoplasma genitalium in men '\n",
      " 'with urethritis in a large public hospital  in brussels belgium an '\n",
      " 'observational crosssectional study plos one  201813e0196217 pmid29698421 '\n",
      " 'httpsdoiorg101371journal pone0196217  743 bachmann lh manhart le martin dh '\n",
      " 'et al advances in the  understanding and treatment of male urethritis clin '\n",
      " 'infect dis  201561suppl 8s763–9 pmid26602615 httpsdoiorg101093 cidciv755  '\n",
      " '744 samaraweera gr garcia k druce j et al characteristics of adenovirus  '\n",
      " 'urethritis among heterosexual men and men who have sex with men  a review of '\n",
      " 'clinical cases sex transm infect 201692172–4  pmid26574571 '\n",
      " 'httpsdoiorg101136sextrans2015052243  745 horner p blee k o’mahony c muir p '\n",
      " 'evans c radcliffe k clinical  effectiveness group of the british association '\n",
      " 'for sexual health and  hiv 2015 uk national guideline on the management of '\n",
      " 'non gonococcal urethritis  int j std aids 20162785–96  pmid26002319 '\n",
      " 'httpsdoiorg1011770956462415586675  746 sarier m sepin n duman i et al '\n",
      " 'microscopy of gramstained urethral  smear in the diagnosis of urethritis '\n",
      " 'which threshold value should be  selected andrologia 201850e13143 '\n",
      " 'pmid30238498 httpsdoi org101111and13143  747 sarier m kukul e classification '\n",
      " 'of nongonococcal urethritis a review  int urol nephrol 201951901–7 '\n",
      " 'pmid30953260 httpsdoi org101007s11255019021402  748 kong fy tabrizi sn law m '\n",
      " 'et al azithromycin versus doxycycline  for the treatment of genital '\n",
      " 'chlamydia infection a metaanalysis of  randomized controlled trials clin '\n",
      " 'infect dis 201459193–205  pmid24729507 httpsdoiorg101093cidciu220  749 '\n",
      " 'páezcanro c alzate jp gonzález lm rubioromero ja lethaby  a gaitán hg '\n",
      " 'antibiotics for treating urogenital chlamydia trachomatis  infection in men '\n",
      " 'and nonpregnant women cochrane database syst  rev  20191 cd010871  '\n",
      " 'pmid30682211 ht tps   doi  org10100214651858cd010871pub2  750 mciver r '\n",
      " 'jalocon d mcnulty a et al men who have sex with men  with mycoplasma '\n",
      " 'genitaliumpositive nongonococcal urethritis are more  likely to have '\n",
      " 'macrolide resistant strains than men with only female  partners a '\n",
      " 'prospective study sex transm dis 201946513–7  pmid31295218 '\n",
      " 'httpsdoiorg101097olq0000000000001009  751 lau a bradshaw cs lewis d et al '\n",
      " 'the efficacy of azithromycin for  the treatment of genital mycoplasma '\n",
      " 'genitalium a systematic review  and metaanalysis clin infect dis '\n",
      " '2015611389–99 pmid26240201  httpsdoiorg101093cidciv644  752 horner p '\n",
      " 'mycoplasma genitalium nongonococcal urethritis is likely to  increase in men '\n",
      " 'who have sex with men who practice unsafe sex what  should we do sex transm '\n",
      " 'dis 201946518–20 pmid31295219  httpsdoiorg101097olq0000000000001030  753 '\n",
      " 'hosenfeld cb workowski ka berman s et al repeat infection with  chlamydia '\n",
      " 'and gonorrhea among females a systematic review of the  literature sex '\n",
      " 'transm dis 200936478–89 pmid19617871 https doiorg101097olq0b013e3181a2a933  '\n",
      " '754 fung m scott kc kent ck klausner jd chlamydial and gonococcal  '\n",
      " 'reinfection among men a systematic review of data to evaluate the  need for '\n",
      " 'retesting sex transm infect 200783304–9 pmid17166889  '\n",
      " 'httpsdoiorg101136sti2006024059  755 kissinger pj white s manhart le et al '\n",
      " 'azithromycin treatment  failure for chlamydia trachomatis among heterosexual '\n",
      " 'men with  nongonococcal urethritis sex transm dis 201643599–602  '\n",
      " 'pmid27631353 httpsdoiorg101097olq0000000000000489  756 schwebke jr rompalo a '\n",
      " 'taylor s et al reevaluating the treatment  of nongonococcal urethritis '\n",
      " 'emphasizing emerging pathogens—a  randomized clinical trial clin infect dis '\n",
      " '201152163–70  pmid21288838 httpsdoiorg101093cidciq074  757 manhart le '\n",
      " 'khosropour cm gillespie cw lowens ms golden  mr totten pa o023 treatment '\n",
      " 'outcomes for persistent mycoplasma  genitaliumassociated ngu evidence of '\n",
      " 'moxifloxacin treatment  failures sex transm infect 201389suppl 1a29 httpsdoi '\n",
      " 'org101136sextrans20130511840091  758 romano ss jensen js lowens ms et al '\n",
      " 'long duration of  asymptomatic mycoplasma genitalium infection after '\n",
      " 'syndromic  treatment for nongonococcal urethritis clin infect dis '\n",
      " '201969113–20  pmid30281079 httpsdoiorg101093cidciy843  759 read trh fairley '\n",
      " 'ck murray gl et al outcomes of resistance guided sequential treatment of '\n",
      " 'mycoplasma genitalium infections a  prospective evaluation clin infect dis '\n",
      " '201968554–60  pmid29873691 httpsdoiorg101093cidciy477  760 dowe g smikle m '\n",
      " 'king sd baum m chout r williams y  symptomatic and asymptomatic chlamydial '\n",
      " 'nongonococcal urethritis  in jamaica the potential for hiv transmission int '\n",
      " 'j std aids  2 0 0 0  1 1  1 8 7 – 9 0   p m i d  1 0 7 2 6 9 4 4  h t t p '\n",
      " 's    d o i  org1012580956462001915507  761 lusk mj garden fl rawlinson wd '\n",
      " 'naing zw cumming rg  konecny p cervicitis aetiology and case definition a '\n",
      " 'study in australian  women attending sexually transmitted infection clinics '\n",
      " 'sex transm  infect 201692175–81 pmid26586777 httpsdoiorg101136 '\n",
      " 'sextrans2015052332  762 lusk mj konecny p cervicitis a review curr opin '\n",
      " 'infect dis  20082149–55 pmid18192786  763 marrazzo jm martin dh management '\n",
      " 'of women with cervicitis  clin infect dis 200744suppl 3s102–10 pmid17342663 '\n",
      " 'https doiorg101086511423  764 manavi k young h clutterbuck d sensitivity of '\n",
      " 'microscopy for the  rapid diagnosis of gonorrhoea in men and women and the '\n",
      " 'role of  gonorrhoea serovars int j std aids 200314390–4 pmid12816666  '\n",
      " 'httpsdoiorg101258095646203765371277  765 lillis ra martin dh nsuami mj '\n",
      " 'mycoplasma genitalium infections  in women attending a sexually transmitted '\n",
      " 'disease clinic in new  orleans clin infect dis 201969459–65 pmid30351348 '\n",
      " 'https doiorg101093cidciy922 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29023188doptabstract '\n",
      " 'httpsdoiorg101089lap20170064 httpsdoiorg101089lap20170064 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids21992973doptabstract '\n",
      " 'httpsdoiorg101097olq0b013e318225f7c2 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids22183839doptabstract '\n",
      " 'httpsdoiorg101097olq0b013e3182354da3 httpsdoiorg101097olq0b013e3182354da3 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids16205305doptabstract '\n",
      " 'httpsdoiorg10109701olq000017539045315a1 '\n",
      " 'httpsdoiorg10109701olq000017539045315a1 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids26826161doptabstract '\n",
      " 'httpsdoiorg1011770956462416630675 httpsdoiorg1011770956462416630675 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids26607860doptabstract '\n",
      " 'httpsdoiorg101136jramc2015000488 httpsdoiorg101136jramc2015000488 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29698421doptabstract '\n",
      " 'httpsdoiorg101371journalpone0196217 httpsdoiorg101371journalpone0196217 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids26602615doptabstract '\n",
      " 'httpsdoiorg101093cidciv755 httpsdoiorg101093cidciv755 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids26574571doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids26574571doptabstract '\n",
      " 'httpsdoiorg101136sextrans2015052243 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids26002319doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids26002319doptabstract '\n",
      " 'httpsdoiorg1011770956462415586675 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30238498doptabstract '\n",
      " 'httpsdoiorg101111and13143 httpsdoiorg101111and13143 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30953260doptabstract '\n",
      " 'httpsdoiorg101007s11255019021402 httpsdoiorg101007s11255019021402 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids24729507doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids24729507doptabstract '\n",
      " 'httpsdoiorg101093cidciu220 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30682211doptabstract '\n",
      " 'httpsdoiorg10100214651858cd010871pub2 httpsdoiorg10100214651858cd010871pub2 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids31295218doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids31295218doptabstract '\n",
      " 'httpsdoiorg101097olq0000000000001009 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids26240201doptabstract '\n",
      " 'httpsdoiorg101093cidciv644 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids31295219doptabstract '\n",
      " 'httpsdoiorg101097olq0000000000001030 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids19617871doptabstract '\n",
      " 'httpsdoiorg101097olq0b013e3181a2a933 httpsdoiorg101097olq0b013e3181a2a933 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids17166889doptabstract '\n",
      " 'httpsdoiorg101136sti2006024059 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids27631353doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids27631353doptabstract '\n",
      " 'httpsdoiorg101097olq0000000000000489 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids21288838doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids21288838doptabstract '\n",
      " 'httpsdoiorg101093cidciq074 httpsdoiorg101136sextrans20130511840091 '\n",
      " 'httpsdoiorg101136sextrans20130511840091 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30281079doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30281079doptabstract '\n",
      " 'httpsdoiorg101093cidciy843 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29873691doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29873691doptabstract '\n",
      " 'httpsdoiorg101093cidciy477 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids10726944doptabstract '\n",
      " 'httpsdoiorg1012580956462001915507 httpsdoiorg1012580956462001915507 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids26586777doptabstract '\n",
      " 'httpsdoiorg101136sextrans2015052332 httpsdoiorg101136sextrans2015052332 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids18192786doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids17342663doptabstract '\n",
      " 'httpsdoiorg101086511423 httpsdoiorg101086511423 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids12816666doptabstract '\n",
      " 'httpsdoiorg101258095646203765371277 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30351348doptabstract '\n",
      " 'httpsdoiorg101093cidciy922 httpsdoiorg101093cidciy922 recommendations and '\n",
      " 'reports mmwr  july 23 2021  vol 70  no 4 161us department of health and '\n",
      " 'human servicescenters for disease control and prevention  766 lis r '\n",
      " 'rowhanirahbar a manhart le mycoplasma genitalium  infection and female '\n",
      " 'reproductive tract disease a metaanalysis clin  infect dis 201561418–26 '\n",
      " 'pmid25900174 httpsdoiorg101093 cidciv312  767 oliphant j azariah s '\n",
      " 'cervicitis limited clinical utility for the detection  of mycoplasma '\n",
      " 'genitalium in a crosssectional study of women attending  a new zealand '\n",
      " 'sexual health clinic sex health 201310263–7  pmid23702105 '\n",
      " 'httpsdoiorg101071sh12168  768 sethi s rajkumari n dhaliwal l roy a p3294 '\n",
      " 'association of  mycoplasma genitalium with cervicitis in north indian women '\n",
      " 'attending  gynecologic clinics sex transm infect 201389suppl 1a240–1  '\n",
      " 'httpsdoiorg101136sextrans20130511840749  769 taylor sn lensing s schwebke j '\n",
      " 'et al prevalence and treatment  outcome of cervicitis of unknown etiology '\n",
      " 'sex transm dis  201340379–85 pmid23588127 httpsdoiorg101097 '\n",
      " 'olq0b013e31828bfcb1  770 mobley vl hobbs mm lau k weinbaum bs getman dk '\n",
      " 'seña  ac mycoplasma genitalium infection in women attending a sexually  '\n",
      " 'transmitted infection clinic diagnostic specimen type coinfections  and '\n",
      " 'predictors sex transm dis 201239706–9 pmid22902666  '\n",
      " 'httpsdoiorg101097olq0b013e318255de03  771 marrazzo jm wiesenfeld hc murray '\n",
      " 'pj et al risk factors for  cervicitis among women with bacterial vaginosis j '\n",
      " 'infect dis  2006193617–24 pmid16453256 httpsdoiorg101086500149  772 gaydos c '\n",
      " 'maldeis ne hardick a hardick j quinn tc mycoplasma  genitalium as a '\n",
      " 'contributor to the multiple etiologies of cervicitis in  women attending '\n",
      " 'sexually transmitted disease clinics sex transm dis  200936598–606 '\n",
      " 'pmid19704398 httpsdoiorg101097 olq0b013e3181b01948  773 clark lr atendido m '\n",
      " 'group b streptococcal vaginitis in postpubertal  adolescent girls j adolesc '\n",
      " 'health 200536437–40 pmid15837348  httpsdoiorg101016jjadohealth200403009  774 '\n",
      " 'hester ee middleman ab a clinical conundrum chronic cervicitis  j pediatr '\n",
      " 'adolesc gynecol 201932342–4 pmid30582974 https doiorg101016jjpag201812004  '\n",
      " '775 liu l cao g zhao z zhao f huang y high bacterial loads of  ureaplasma '\n",
      " 'may be associated with nonspecific cervicitis scand j  infect dis '\n",
      " '201446637–41 pmid25017795 httpsdoiorg1031 09003655482014922696  776 leli c '\n",
      " 'mencacci a latino ma et al prevalence of cervical colonization  by '\n",
      " 'ureaplasma parvum ureaplasma urealyticum mycoplasma hominis  and mycoplasma '\n",
      " 'genitalium in childbearing age women by a  commercially available multiplex '\n",
      " 'realtime pcr an italian observational  multicentre study j microbiol immunol '\n",
      " 'infect 201851220–5  pmid28711440 httpsdoiorg101016jjmii201705004  777 '\n",
      " 'manhart le has the time come to systematically test for mycoplasma  '\n",
      " 'genitalium sex transm dis 200936607–8 pmid19734818 https '\n",
      " 'doiorg101097olq0b013e3181b9d825  778 liu hl chen cm pai lw hwu yj lee hm '\n",
      " 'chung yc  comorbidity profiles among women with postcoital bleeding a  '\n",
      " 'nationwide health insurance database arch gynecol obstet  2017295935–41 '\n",
      " 'pmid28246983 httpsdoiorg101007 s0040401743277  779 coleman js hitti j bukusi '\n",
      " 'ea et al infectious correlates of hiv1  shedding in the female upper and '\n",
      " 'lower genital tracts aids  200721755–9 pmid17413697 httpsdoiorg101097 '\n",
      " 'qad0b013e328012b838  780 johnson lf lewis da the effect of genital tract '\n",
      " 'infections on hiv1  shedding in the genital tract a systematic review and '\n",
      " 'metaanalysis  sex transm dis 200835946–59 pmid18685546 httpsdoi '\n",
      " 'org101097olq0b013e3181812d15  781 mcclelland rs wang cc mandaliya k et al '\n",
      " 'treatment  of cervicitis is associated with decreased cervical shedding of  '\n",
      " 'hiv1 aids 200115105–10 pmid11192850 httpsdoi '\n",
      " 'org1010970000203020010105000015  782 gatski m martin dh theall k et al '\n",
      " 'mycoplasma genitalium infection  among hivpositive women prevalence risk '\n",
      " 'factors and association  with vaginal shedding int j std aids 201122155–9  '\n",
      " 'pmid21464453 httpsdoiorg101258ijsa2010010320  783 gitau rw graham sm masese '\n",
      " 'ln et al effect of acquisition and  treatment of cervical infections on hiv1 '\n",
      " 'shedding in women on  antiretroviral therapy aids 2010242733–7 pmid20871388  '\n",
      " 'httpsdoiorg101097qad0b013e32833f9f43  784 kreisel km weston ej st cyr sb '\n",
      " 'spicknall ih estimates of the  prevalence and incidence of chlamydia and '\n",
      " 'gonorrhea among us men  and women 2018 sex transm dis 202148222–31 '\n",
      " 'pmid33492094  httpsdoiorg101097olq0000000000001382  785 aghaizu a reid f '\n",
      " 'kerry s et al frequency and risk factors for incident  and redetected '\n",
      " 'chlamydia trachomatis infection in sexually active  young multiethnic women '\n",
      " 'a community based cohort study sex  transm infect 201490524–8 pmid25100744 '\n",
      " 'httpsdoi org101136sextrans2014051607  786 scholes d satterwhite cl yu o fine '\n",
      " 'd weinstock h berman s  longterm trends in chlamydia trachomatis infections '\n",
      " 'and related  outcomes in a us managed care population sex transm dis  '\n",
      " '20123981–8 pmid22249294 httpsdoiorg101097 olq0b013e31823e3009  787 kamwendo '\n",
      " 'f forslin l bodin l danielsson d decreasing incidences  of gonorrhea and '\n",
      " 'chlamydiaassociated acute pelvic inflammatory  disease a 25year study from '\n",
      " 'an urban area of central sweden sex  transm dis 199623384–91 pmid8885069 '\n",
      " 'httpsdoi org1010970000743519960900000007  788 rietmeijer ca hopkins e '\n",
      " 'geisler wm orr dp kent ck chlamydia  trachomatis positivity rates among men '\n",
      " 'tested in selected venues in the  united states a review of the recent '\n",
      " 'literature sex transm dis  200835suppls8–18 pmid18449072 httpsdoiorg101097 '\n",
      " 'olq0b013e31816938ba  789 gift tl blake dr gaydos ca marrazzo jm the '\n",
      " 'costeffectiveness  of screening men for chlamydia trachomatis a review of '\n",
      " 'the literature  sex transm dis 200835suppls51–60 pmid18520977 https '\n",
      " 'doiorg101097olq0b013e3181723dba  790 gift tl gaydos ca kent ck et al the '\n",
      " 'program cost and cost effectiveness of screening men for chlamydia to '\n",
      " 'prevent pelvic  inflammatory disease in women sex transm dis '\n",
      " '200835suppls66–75  pmid18830137 httpsdoiorg101097olq0b013e31818b64ac  791 '\n",
      " 'gopalappa c huang yl gift tl owusuedusei k taylor m gales  v '\n",
      " 'costeffectiveness of screening men in maricopa county jails for  chlamydia '\n",
      " 'and gonorrhea to avert infections in women sex transm  dis 201340776–83 '\n",
      " 'pmid24275727 httpsdoiorg101097 olq0000000000000023  792 masek bj arora n '\n",
      " 'quinn n et al performance of three nucleic acid  amplification tests for '\n",
      " 'detection of chlamydia trachomatis and neisseria  gonorrhoeae by use of '\n",
      " 'selfcollected vaginal swabs obtained via an  internetbased screening program '\n",
      " 'j clin microbiol 2009471663–7  pmid19386838 httpsdoiorg101128jcm0238708  793 '\n",
      " 'knox j tabrizi sn miller p et al evaluation of selfcollected samples  in '\n",
      " 'contrast to practitionercollected samples for detection of chlamydia  '\n",
      " 'trachomatis neisseria gonorrhoeae and trichomonas vaginalis by  polymerase '\n",
      " 'chain reaction among women living in remote areas sex  transm dis '\n",
      " '200229647–54 pmid12438900 httpsdoi org1010970000743520021100000006  794 '\n",
      " 'schachter j chernesky ma willis de et al vaginal swabs are  the specimens of '\n",
      " 'choice when screening for chlamydia trachomatis  and neisseria gonorrhoeae '\n",
      " 'results from a multicenter evaluation  of the aptima assays for both '\n",
      " 'infections sex transm dis  200532725–8 pmid16314767 httpsdoiorg10109701 '\n",
      " 'olq00001900925948296  795 doshi js power j allen e acceptability of '\n",
      " 'chlamydia screening using  selftaken vaginal swabs int j std aids '\n",
      " '200819507–9  pmid18663033 httpsdoiorg101258ijsa2008008056 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids25900174doptabstract '\n",
      " 'httpsdoiorg101093cidciv312 httpsdoiorg101093cidciv312 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids23702105doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids23702105doptabstract '\n",
      " 'httpsdoiorg101071sh12168 httpsdoiorg101136sextrans20130511840749 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids23588127doptabstract '\n",
      " 'httpsdoiorg101097olq0b013e31828bfcb1 httpsdoiorg101097olq0b013e31828bfcb1 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids22902666doptabstract '\n",
      " 'httpsdoiorg101097olq0b013e318255de03 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids16453256doptabstract '\n",
      " 'httpsdoiorg101086500149 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids19704398doptabstract '\n",
      " 'httpsdoiorg101097olq0b013e3181b01948 httpsdoiorg101097olq0b013e3181b01948 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids15837348doptabstract '\n",
      " 'httpsdoiorg101016jjadohealth200403009 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30582974doptabstract '\n",
      " 'httpsdoiorg101016jjpag201812004 httpsdoiorg101016jjpag201812004 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids25017795doptabstract '\n",
      " 'httpsdoiorg103109003655482014922696 httpsdoiorg103109003655482014922696 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28711440doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28711440doptabstract '\n",
      " 'httpsdoiorg101016jjmii201705004 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids19734818doptabstract '\n",
      " 'httpsdoiorg101097olq0b013e3181b9d825 httpsdoiorg101097olq0b013e3181b9d825 '\n",
      " 'httpsdoiorg101007s0040401743277 httpsdoiorg101007s0040401743277 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids17413697doptabstract '\n",
      " 'httpsdoiorg101097qad0b013e328012b838 httpsdoiorg101097qad0b013e328012b838 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids18685546doptabstract '\n",
      " 'httpsdoiorg101097olq0b013e3181812d15 httpsdoiorg101097olq0b013e3181812d15 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids11192850doptabstract '\n",
      " 'httpsdoiorg1010970000203020010105000015 '\n",
      " 'httpsdoiorg1010970000203020010105000015 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids21464453doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids21464453doptabstract '\n",
      " 'httpsdoiorg101258ijsa2010010320 httpsdoiorg101097qad0b013e32833f9f43 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids33492094doptabstract '\n",
      " 'httpsdoiorg101097olq0000000000001382 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids25100744doptabstract '\n",
      " 'httpsdoiorg101136sextrans2014051607 httpsdoiorg101136sextrans2014051607 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids22249294doptabstract '\n",
      " 'httpsdoiorg101097olq0b013e31823e3009 httpsdoiorg101097olq0b013e31823e3009 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids8885069doptabstract '\n",
      " 'httpsdoiorg1010970000743519960900000007 '\n",
      " 'httpsdoiorg1010970000743519960900000007 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids18449072doptabstract '\n",
      " 'httpsdoiorg101097olq0b013e31816938ba httpsdoiorg101097olq0b013e31816938ba '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids18520977doptabstract '\n",
      " 'httpsdoiorg101097olq0b013e3181723dba httpsdoiorg101097olq0b013e3181723dba '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids18830137doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids18830137doptabstract '\n",
      " 'httpsdoiorg101097olq0b013e31818b64ac '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids24275727doptabstract '\n",
      " 'httpsdoiorg101097olq0000000000000023 httpsdoiorg101097olq0000000000000023 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids19386838doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids19386838doptabstract '\n",
      " 'httpsdoiorg101128jcm0238708 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids12438900doptabstract '\n",
      " 'httpsdoiorg1010970000743520021100000006 '\n",
      " 'httpsdoiorg1010970000743520021100000006 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids16314767doptabstract '\n",
      " 'httpsdoiorg10109701olq00001900925948296 '\n",
      " 'httpsdoiorg10109701olq00001900925948296 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids18663033doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids18663033doptabstract '\n",
      " 'httpsdoiorg101258ijsa2008008056 recommendations and reports 162 mmwr  july '\n",
      " '23 2021  vol 70  no 4 us department of health and human servicescenters for '\n",
      " 'disease control and prevention  796 chernesky ma jang d portillo e et al '\n",
      " 'selfcollected swabs of the  urinary meatus diagnose more chlamydia '\n",
      " 'trachomatis and neisseria  gonorrhoeae infections than first catch urine '\n",
      " 'from men sex transm  infect 201389102–4 pmid23024224 httpsdoiorg101136 '\n",
      " 'sextrans2012050573  797 dize l barnes p jr barnes m et al performance of '\n",
      " 'selfcollected penile meatal swabs compared to cliniciancollected urethral '\n",
      " 'swabs for the  detection of chlamydia trachomatis neisseria gonorrhoeae '\n",
      " 'trichomonas  vaginalis and mycoplasma genitalium by nucleic acid '\n",
      " 'amplification  assays diagn microbiol infect dis 201686131–5 pmid27497595  '\n",
      " 'httpsdoiorg101016jdiagmicrobio201607018  798 berry l stanley b comparison of '\n",
      " 'selfcollected meatal swabs with  urine specimens for the diagnosis of '\n",
      " 'chlamydia trachomatis and  neisseria gonorrhoeae in men j med microbiol '\n",
      " '201766134–6  pmid28068218 httpsdoiorg101099jmm0000428  799 chernesky m '\n",
      " 'freund gg hook e 3rd leone p d’ascoli p martens  m detection of chlamydia '\n",
      " 'trachomatis and neisseria gonorrhoeae  infections in north american women by '\n",
      " 'testing surepath liquidbased  pap specimens in aptima assays j clin '\n",
      " 'microbiol 2007452434–8  pmid17581931 httpsdoiorg101128jcm0001307  800 '\n",
      " 'schachter j moncada j liska s shayevich c klausner jd nucleic  acid '\n",
      " 'amplification tests in the diagnosis of chlamydial and gonococcal  '\n",
      " 'infections of the oropharynx and rectum in men who have sex with  men sex '\n",
      " 'transm dis 200835637–42 pmid18520976 httpsdoi org101097olq0b013e31817bdd7e  '\n",
      " '801 mimiaga mj mayer kh reisner sl et al asymptomatic gonorrhea  and '\n",
      " 'chlamydial infections detected by nucleic acid amplification  tests among '\n",
      " 'boston area men who have sex with men sex transm  dis 200835495–8 '\n",
      " 'pmid18354345 httpsdoiorg101097 olq0b013e31816471ae  802 bachmann lh johnson '\n",
      " 're cheng h markowitz le papp jr hook  ew 3rd nucleic acid amplification '\n",
      " 'tests for diagnosis of neisseria  gonorrhoeae oropharyngeal infections j '\n",
      " 'clin microbiol 200947902–7  pmid19193848 httpsdoiorg101128jcm0158108  803 '\n",
      " 'bachmann lh johnson re cheng h et al nucleic acid amplification  tests for '\n",
      " 'diagnosis of neisseria gonorrhoeae and chlamydia trachomatis  rectal '\n",
      " 'infections j clin microbiol 2010481827–32 pmid20335410  '\n",
      " 'httpsdoiorg101128jcm0239809  804 cosentino la danby cs rabe lk et al use of '\n",
      " 'nucleic acid  amplification testing for diagnosis of extragenital sexually '\n",
      " 'transmitted  infections j clin microbiol 2017552801–7 pmid28679521  '\n",
      " 'httpsdoiorg101128jcm0061617  805 food and drug administration microbiology '\n",
      " 'devices panel of  the medical devices advisory committee meeting '\n",
      " 'annoucement  internet silver spring md us department of agriculture  food '\n",
      " 'and drug administration 2019 httpswwwfdagov '\n",
      " 'advisorycommitteesadvisorycommitteecalendarmarch82019 '\n",
      " 'microbiologydevicespanelmedicaldevicesadvisorycommittee '\n",
      " 'meetingannouncementeventmaterials  806 sexton me baker jj nakagawa k et al '\n",
      " 'how reliable is selftesting for  gonorrhea and chlamydia among men who have '\n",
      " 'sex with men j fam  pract 20136270–8 pmid23405376  807 herbst de cortina s '\n",
      " 'bristow cc joseph davey d klausner jd a  systematic review of point of care '\n",
      " 'testing for chlamydia trachomatis  neisseria gonorrhoeae and trichomonas '\n",
      " 'vaginalis infect dis obstet  gynecol 201620164386127 epub may 26 2016 '\n",
      " 'pmid27313440  httpsdoiorg10115520164386127  808 rivard kr dumkow le draper '\n",
      " 'hm brandt kl whalen dw  egwuatu ne impact of rapid diagnostic testing for '\n",
      " 'chlamydia  and gonorrhea on appropriate antimicrobial utilization in the  '\n",
      " 'emergency department diagn microbiol infect dis 201787175–9  pmid27836225 '\n",
      " 'httpsdoiorg101016jdiagmicrobio201610019  809 wingrove i mcowan a nwokolo n '\n",
      " 'whitlock g diagnostics within  the clinic to test for gonorrhoea and '\n",
      " 'chlamydia reduces the time to  treatment a service evaluation sex transm '\n",
      " 'infect 201490474  pmid25118322 httpsdoiorg101136sextrans2014051580  810 '\n",
      " 'geisler wm wang c morrison sg black cm bandea ci hook ew  3rd the natural '\n",
      " 'history of untreated chlamydia trachomatis infection in  the interval '\n",
      " 'between screening and returning for treatment sex transm  dis 200835119–23 '\n",
      " 'pmid17898680 httpsdoiorg101097 olq0b013e318151497d  811 dukersmuijrers nhtm '\n",
      " 'wolffs pfg de vries h et al treatment  effectiveness of azithromycin and '\n",
      " 'doxycycline in uncomplicated rectal  and vaginal chlamydia trachomatis '\n",
      " 'infections in women a multicentre  observational study femcure clin infect '\n",
      " 'dis 2019691946–54  pmid30689759 httpsdoiorg101093cidciz050  812 dombrowski '\n",
      " 'jc wierzbicki mr newman lm et al doxycycline  versus azithromycin for the '\n",
      " 'treatment of rectal chlamydia in men who  have sex with men a randomized '\n",
      " 'controlled trial clin infect dis  2021ciab153 pmid33606009 '\n",
      " 'httpsdoiorg101093cidciab153  813 dukersmuijrers nh schachter j van liere ga '\n",
      " 'wolffs pf hoebe cj  what is needed to guide testing for anorectal and '\n",
      " 'pharyngeal chlamydia  trachomatis and neisseria gonorrhoeae in women and men '\n",
      " 'evidence and  opinion bmc infect dis 201515533 pmid26576538 httpsdoi '\n",
      " 'org101186s1287901512806  814 marcus jl kohn rp barry pm philip ss bernstein '\n",
      " 'kt chlamydia  trachomatis and neisseria gonorrhoeae transmission from the '\n",
      " 'female  oropharynx to the male urethra sex transm dis 201138372–3  '\n",
      " 'pmid21183864 httpsdoiorg101097olq0b013e3182029008  815 manavi k '\n",
      " 'hettiarachchi n hodson j comparison of doxycycline  with azithromycin in '\n",
      " 'treatment of pharyngeal chlamydia infection  int j std aids 2016271303–8 '\n",
      " 'pmid26511655 httpsdoi org1011770956462415614723  816 rank rg yeruva l an '\n",
      " 'alternative scenario to explain rectal positivity  in chlamydiainfected '\n",
      " 'individuals clin infect dis 2015601585–6  pmid25648236 '\n",
      " 'httpsdoiorg101093cidciv079  817 geisler wm koltun wd abdelsayed n et al '\n",
      " 'safety and efficacy  of wc2031 versus vibramycin for the treatment of '\n",
      " 'uncomplicated  urogenital chlamydia trachomatis infection a randomized '\n",
      " 'doubleblind  doubledummy activecontrolled multicenter trial clin infect dis  '\n",
      " '20125582–8 pmid22431798 httpsdoiorg101093cidcis291  818 renault ca israelski '\n",
      " 'dm levy v fujikawa bk kellogg ta klausner  jd time to clearance of chlamydia '\n",
      " 'trachomatis ribosomal rna in  women treated for chlamydial infection sex '\n",
      " 'health 2011869–73  pmid21371385 httpsdoiorg101071sh10030  819 lazenby gb '\n",
      " 'korte je tillman s brown fk soper de a  recommendation for timing of repeat '\n",
      " 'chlamydia trachomatis test  following infection and treatment in pregnant '\n",
      " 'and nonpregnant  women int j std aids 201728902–9 pmid27864473 https '\n",
      " 'doiorg1011770956462416680438  820 dunne ef chapin jb rietmeijer ca et al '\n",
      " 'rate and predictors of  repeat chlamydia trachomatis infection among men sex '\n",
      " 'transm dis  200835suppls40–4 pmid18520978 httpsdoiorg101097 '\n",
      " 'olq0b013e31817247b2  821 kjaer ho dimcevski g hoff g olesen f ostergaard l '\n",
      " 'recurrence of  urogenital chlamydia trachomatis infection evaluated by '\n",
      " 'mailed samples  obtained at home 24 weeks’ prospective follow up study sex '\n",
      " 'transm  infect 200076169–72 pmid10961191 httpsdoiorg101136 sti763169  822 '\n",
      " 'whittington wl kent c kissinger p et al determinants  of persistent and '\n",
      " 'recurrent chlamydia trachomatis infection  in young women results of a '\n",
      " 'multicenter cohort study sex  transm dis 200128117–23 pmid11234786 httpsdoi '\n",
      " 'org1010970000743520010200000011 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids23024224doptabstract '\n",
      " 'httpsdoiorg101136sextrans2012050573 httpsdoiorg101136sextrans2012050573 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids27497595doptabstract '\n",
      " 'httpsdoiorg101016jdiagmicrobio201607018 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28068218doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28068218doptabstract '\n",
      " 'httpsdoiorg101099jmm0000428 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids17581931doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids17581931doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids18520976doptabstract '\n",
      " 'httpsdoiorg101097olq0b013e31817bdd7e httpsdoiorg101097olq0b013e31817bdd7e '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids18354345doptabstract '\n",
      " 'httpsdoiorg101097olq0b013e31816471ae httpsdoiorg101097olq0b013e31816471ae '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids19193848doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids19193848doptabstract '\n",
      " 'httpsdoiorg101128jcm0158108 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids20335410doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28679521doptabstract '\n",
      " 'httpsdoiorg101128jcm0061617 '\n",
      " 'httpswwwfdagovadvisorycommitteesadvisorycommitteecalendarmarch82019microbiologydevicespanelmedicaldevicesadvisorycommitteemeetingannouncementeventmaterials '\n",
      " 'httpswwwfdagovadvisorycommitteesadvisorycommitteecalendarmarch82019microbiologydevicespanelmedicaldevicesadvisorycommitteemeetingannouncementeventmaterials '\n",
      " 'httpswwwfdagovadvisorycommitteesadvisorycommitteecalendarmarch82019microbiologydevicespanelmedicaldevicesadvisorycommitteemeetingannouncementeventmaterials '\n",
      " 'httpswwwfdagovadvisorycommitteesadvisorycommitteecalendarmarch82019microbiologydevicespanelmedicaldevicesadvisorycommitteemeetingannouncementeventmaterials '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids23405376doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids27313440doptabstract '\n",
      " 'httpsdoiorg10115520164386127 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids27836225doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids27836225doptabstract '\n",
      " 'httpsdoiorg101016jdiagmicrobio201610019 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids25118322doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids25118322doptabstract '\n",
      " 'httpsdoiorg101136sextrans2014051580 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids17898680doptabstract '\n",
      " 'httpsdoiorg101097olq0b013e318151497d httpsdoiorg101097olq0b013e318151497d '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30689759doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30689759doptabstract '\n",
      " 'httpsdoiorg101093cidciz050 httpspubmedncbinlmnihgov33606009 '\n",
      " 'httpsdoiorg101093cidciab153 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids26576538doptabstract '\n",
      " 'httpsdoiorg101186s1287901512806 httpsdoiorg101186s1287901512806 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids21183864doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids21183864doptabstract '\n",
      " 'httpsdoiorg101097olq0b013e3182029008 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids26511655doptabstract '\n",
      " 'httpsdoiorg1011770956462415614723 httpsdoiorg1011770956462415614723 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids25648236doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids25648236doptabstract '\n",
      " 'httpsdoiorg101093cidciv079 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids22431798doptabstract '\n",
      " 'httpsdoiorg101093cidcis291 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids21371385doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids21371385doptabstract '\n",
      " 'httpsdoiorg101071sh10030 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids27864473doptabstract '\n",
      " 'httpsdoiorg1011770956462416680438 httpsdoiorg1011770956462416680438 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids18520978doptabstract '\n",
      " 'httpsdoiorg101097olq0b013e31817247b2 httpsdoiorg101097olq0b013e31817247b2 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids10961191doptabstract '\n",
      " 'httpsdoiorg101136sti763169 httpsdoiorg101136sti763169 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids11234786doptabstract '\n",
      " 'httpsdoiorg1010970000743520010200000011 '\n",
      " 'httpsdoiorg1010970000743520010200000011 recommendations and reports mmwr  '\n",
      " 'july 23 2021  vol 70  no 4 163us department of health and human '\n",
      " 'servicescenters for disease control and prevention  823 kapil r press cg '\n",
      " 'hwang ml brown l geisler wm investigating  the epidemiology of repeat '\n",
      " 'chlamydia trachomatis detection after  treatment by using c trachomatis ompa '\n",
      " 'genotyping j clin microbiol  201553546–9 pmid25472488 httpsdoiorg101128 '\n",
      " 'jcm0248314  824 jacobson gf autry am kirby rs liverman em motley ru a  '\n",
      " 'randomized controlled trial comparing amoxicillin and azithromycin  for the '\n",
      " 'treatment of chlamydia trachomatis in pregnancy am j obstet  gynecol '\n",
      " '20011841352–6 pmid11408852 httpsdoiorg101067 mob2001115050  825 kacmar j '\n",
      " 'cheh e montagno a peipert jf a randomized trial of  azithromycin versus '\n",
      " 'amoxicillin for the treatment of chlamydia  trachomatis in pregnancy infect '\n",
      " 'dis obstet gynecol 20019197–202  pmid11916175 '\n",
      " 'httpsdoiorg101155s1064744901000321  826 rahangdale l guerry s bauer hm et al '\n",
      " 'an observational cohort  study of chlamydia trachomatis treatment in '\n",
      " 'pregnancy sex transm  dis 200633106–10 pmid16432482 httpsdoiorg10109701 '\n",
      " 'olq000018722632145ea  827 aggarwal a spitzer rf caccia n stephens d '\n",
      " 'johnstone j allen l  repeat screening for sexually transmitted infection in '\n",
      " 'adolescent  obstetric patients j obstet gynaecol can 201032956–61  '\n",
      " 'pmid21176304 httpsdoiorg101016s1701216316346837  828 phillips campbell r '\n",
      " 'kintner j whittimore j schoborg rv chlamydia  muridarum enters a viable but '\n",
      " 'noninfectious state in amoxicillin treated balbc mice microbes infect '\n",
      " '2012141177–85  pmid22943883 httpsdoiorg101016jmicinf201207017  829 wyrick pb '\n",
      " 'chlamydia trachomatis persistence in vitro an overview  j infect dis '\n",
      " '2010201suppl 2s88–95 pmid20470046 httpsdoi org101086652394  830 fan h li l '\n",
      " 'wijlaars l gilbert re associations between use of  macrolide antibiotics '\n",
      " 'during pregnancy and adverse child outcomes a  systematic review and '\n",
      " 'metaanalysis plos one 201914e0212212  pmid30779772 '\n",
      " 'httpsdoiorg101371journalpone0212212  831 fan h gilbert r o’callaghan f li l '\n",
      " 'associations between macrolide  antibiotics prescribing during pregnancy and '\n",
      " 'adverse child outcomes  in the uk population based cohort study bmj '\n",
      " '2020368m331  erratum in bmj 2020368m766 pmid32075790 httpsdoi '\n",
      " 'org101136bmjm331  832 mallah n tohidinik hr etminan m figueiras a takkouche '\n",
      " 'b  prenatal exposure to macrolides and risk of congenital malformations  a '\n",
      " 'metaanalysis drug saf 202043211–21 pmid31721138 https '\n",
      " 'doiorg101007s40264019008845  833 hammerschlag mr cummings c roblin pm '\n",
      " 'williams th delke  i efficacy of neonatal ocular prophylaxis for the '\n",
      " 'prevention of  chlamydial and gonococcal conjunctivitis n engl j med  '\n",
      " '1989320769–72 pmid2922026 httpsdoiorg101056 nejm198903233201204  834 zikic a '\n",
      " 'schünemann h wi t lincetto o broutet n santesso n  treatment of neonatal '\n",
      " 'chlamydial conjunctivitis a systematic review  and metaanalysis j pediatric '\n",
      " 'infect dis soc 20187e107–15  pmid30007329 httpsdoiorg101093jpidspiy060  835 '\n",
      " 'hammerschlag mr chandler jw alexander er english m koutsky  l longitudinal '\n",
      " 'studies on chlamydial infections in the first year of  life pediatr infect '\n",
      " 'dis 19821395–401 pmid7163029 httpsdoi org1010970000645419821100000007  836 '\n",
      " 'beem mo saxon e tipple ma treatment of chlamydial pneumonia  of infancy '\n",
      " 'pediatrics 197963198–203 pmid440807  837 brownell ad shapiro ra hammerschlag '\n",
      " 'mr caution is required  when using nonfood and drug administrationcleared '\n",
      " 'assays to  diagnose sexually transmitted infections in children j pediatr  '\n",
      " '2019206280–2 pmid30466791 httpsdoiorg101016j jpeds201810038  838 kreisel km '\n",
      " 'spicknall ih gargano jw et al sexually transmitted  infections among us '\n",
      " 'women and men prevalence and incidence  estimates 2018 sex transm dis '\n",
      " '202148208–14 pmid33492089  httpsdoiorg101097olq0000000000001355  839 lunny c '\n",
      " 'taylor d hoang l et al selfcollected versus clinician collected sampling for '\n",
      " 'chlamydia and gonorrhea screening a systemic  review and metaanalysis plos '\n",
      " 'one 201510e0132776  pmid26168051 httpsdoiorg101371journalpone0132776  840 '\n",
      " 'schick v van der pol b dodge b baldwin a fortenberry jd a  mixed methods '\n",
      " 'approach to assess the likelihood of testing for sti  using selfcollected '\n",
      " 'samples among behaviourally bisexual women sex  transm infect 201591329–33 '\n",
      " 'pmid25637328 httpsdoi org101136sextrans2014051842  841 mustanski b feinstein '\n",
      " 'ba madkins k sullivan p swann g prevalence  and risk factors for rectal and '\n",
      " 'urethral sexually transmitted infections  from selfcollected samples among '\n",
      " 'young men who have sex with men  participating in the keep it up 20 '\n",
      " 'randomized controlled trial sex  transm dis 201744483–8 pmid28703727 '\n",
      " 'httpsdoiorg101097 olq0000000000000636  842 salow kr cohen ac bristow cc '\n",
      " 'mcgrath mr klausner jd  comparing mailin selfcollected specimens sent via '\n",
      " 'united states  postal service versus cliniccollected specimens for the '\n",
      " 'detection  of chlamydia trachomatis and neisseria gonorrhoeae in '\n",
      " 'extragenital  sites plos one 201712e0189515 pmid29240781 httpsdoi '\n",
      " 'org101371journalpone0189515  843 drake c barenfanger j lawhorn j verhulst s '\n",
      " 'comparison of  easyflow copan liquid stuart’s and starplex swab transport  '\n",
      " 'systems for recovery of fastidious aerobic bacteria j clin microbiol  '\n",
      " '2005431301–3 pmid15750099 httpsdoiorg101128 jcm433130113032005  844 wade jj '\n",
      " 'graver ma survival of six auxotypes of neisseria gonorrhoeae in  transport '\n",
      " 'media j clin microbiol 2003411720–1 pmid12682168  '\n",
      " 'httpsdoiorg101128jcm414172017212003  845 arbique jc forward kr leblanc j '\n",
      " 'evaluation of four commercial  transport media for the survival of neisseria '\n",
      " 'gonorrhoeae diagn  microbiol infect dis 200036163–8 pmid10729658 httpsdoi '\n",
      " 'org101016s0732889399001340  846 hook ew 3rd kirkcaldy rd a brief history of '\n",
      " 'evolving diagnostics and  therapy for gonorrhea lessons learned clin infect '\n",
      " 'dis 2018671294–9  pmid29659749 httpsdoiorg101093cidciy271  847 unemo m '\n",
      " 'shafer wm future treatment of gonorrhea—novel  emerging drugs are essential '\n",
      " 'and in progress expert opin emerg drugs  201520357–60 pmid25907334 '\n",
      " 'httpsdoiorg101517147282 1420151039981  848 sánchezbusó l golparian d '\n",
      " 'corander j et al the impact of  antimicrobials on gonococcal evolution nat '\n",
      " 'microbiol 201941941–50  pmid31358980 httpsdoiorg101038s415640190501y  849 '\n",
      " 'schwarcz sk zenilman jm schnell d et al national surveillance  of '\n",
      " 'antimicrobial resistance in neisseria gonorrhoeae the gonococcal  isolate '\n",
      " 'surveillance project jama 19902641413–7 pmid2144026  '\n",
      " 'httpsdoiorg101001jama199003450110059027  850 cdc update to cdc’s sexually '\n",
      " 'transmitted diseases treatment  guidelines 2006 fluoroquinolones no longer '\n",
      " 'recommended for  treatment of gonococcal infections mmwr morb mortal wkly '\n",
      " 'rep  200756332–6 pmid17431378  851 cdc sexually transmitted disease '\n",
      " 'surveillance 2013 atlanta ga us  department of health and human services cdc '\n",
      " '2014 httpswww cdcgovstdstatsarchivesurv2013printpdf  852 muratani t akasaka '\n",
      " 's kobayashi t et al outbreak of  cefozopran penicillin oral cephems and '\n",
      " 'aztreonamresistant  neisseria gonorrhoeae in japan antimicrob agents '\n",
      " 'chemother  2001453603–6 pmid11709349 httpsdoiorg101128 aac4512360336062001  '\n",
      " '853 yokoi s deguchi t ozawa t et al threat to cefixime treatment for  '\n",
      " 'gonorrhea emerg infect dis 2007131275–7 pmid17953118 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids25472488doptabstract '\n",
      " 'httpsdoiorg101128jcm0248314 httpsdoiorg101128jcm0248314 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids11408852doptabstract '\n",
      " 'httpsdoiorg101067mob2001115050 httpsdoiorg101067mob2001115050 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids11916175doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids11916175doptabstract '\n",
      " 'httpsdoiorg101155s1064744901000321 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids16432482doptabstract '\n",
      " 'httpsdoiorg10109701olq000018722632145ea '\n",
      " 'httpsdoiorg10109701olq000018722632145ea '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids21176304doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids21176304doptabstract '\n",
      " 'httpsdoiorg101016s1701216316346837 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids22943883doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids22943883doptabstract '\n",
      " 'httpsdoiorg101016jmicinf201207017 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids20470046doptabstract '\n",
      " 'httpsdoiorg101086652394 httpsdoiorg101086652394 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30779772doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30779772doptabstract '\n",
      " 'httpsdoiorg101371journalpone0212212 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids32075790doptabstract '\n",
      " 'httpsdoiorg101136bmjm331 httpsdoiorg101136bmjm331 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids31721138doptabstract '\n",
      " 'httpsdoiorg101007s40264019008845 httpsdoiorg101007s40264019008845 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids2922026doptabstract '\n",
      " 'httpsdoiorg101056nejm198903233201204 httpsdoiorg101056nejm198903233201204 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30007329doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30007329doptabstract '\n",
      " 'httpsdoiorg101093jpidspiy060 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids7163029doptabstract '\n",
      " 'httpsdoiorg1010970000645419821100000007 '\n",
      " 'httpsdoiorg1010970000645419821100000007 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids440807doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30466791doptabstract '\n",
      " 'httpsdoiorg101016jjpeds201810038 httpsdoiorg101016jjpeds201810038 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids33492089doptabstract '\n",
      " 'httpsdoiorg101097olq0000000000001355 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids26168051doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids26168051doptabstract '\n",
      " 'httpsdoiorg101371journalpone0132776 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids25637328doptabstract '\n",
      " 'httpsdoiorg101136sextrans2014051842 httpsdoiorg101136sextrans2014051842 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28703727doptabstract '\n",
      " 'httpsdoiorg101097olq0000000000000636 httpsdoiorg101097olq0000000000000636 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29240781doptabstract '\n",
      " 'httpsdoiorg101371journalpone0189515 httpsdoiorg101371journalpone0189515 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids15750099doptabstract '\n",
      " 'httpsdoiorg101128jcm433130113032005 httpsdoiorg101128jcm433130113032005 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids12682168doptabstract '\n",
      " 'httpsdoiorg101128jcm414172017212003 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids10729658doptabstract '\n",
      " 'httpsdoiorg101016s0732889399001340 httpsdoiorg101016s0732889399001340 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29659749doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29659749doptabstract '\n",
      " 'httpsdoiorg101093cidciy271 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids25907334doptabstract '\n",
      " 'httpsdoiorg1015171472821420151039981 httpsdoiorg1015171472821420151039981 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids31358980doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids31358980doptabstract '\n",
      " 'httpsdoiorg101038s415640190501y httpsdoiorg101001jama199003450110059027 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids17431378doptabstract '\n",
      " 'httpswwwcdcgovstdstatsarchivesurv2013printpdf '\n",
      " 'httpswwwcdcgovstdstatsarchivesurv2013printpdf '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids11709349doptabstract '\n",
      " 'httpsdoiorg101128aac4512360336062001 httpsdoiorg101128aac4512360336062001 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids17953118doptabstract '\n",
      " 'recommendations and reports 164 mmwr  july 23 2021  vol 70  no 4 us '\n",
      " 'department of health and human servicescenters for disease control and '\n",
      " 'prevention  854 lo jy ho km leung ao et al ceftibuten resistance and '\n",
      " 'treatment  failure of neisseria gonorrhoeae infection antimicrob agents '\n",
      " 'chemother  2008523564–7 pmid18663018 httpsdoiorg101128 aac0019808  855 '\n",
      " 'deguchi t yasuda m yokoi s et al treatment of uncomplicated  gonococcal '\n",
      " 'urethritis by doubledosing of 200 mg cefixime at a 6h  interval j infect '\n",
      " 'chemother 2003935–9 pmid12673405 https doiorg101007s1015600202048  856 unemo '\n",
      " 'm golparian d hestner a ceftriaxone treatment failure of  pharyngeal '\n",
      " 'gonorrhoea verified by international recommendations  sweden july 2010 euro '\n",
      " 'surveill 20111619792 pmid21329645  857 unemo m golparian d syversen g '\n",
      " 'vestrheim df moi h two cases  of verified clinical failures using '\n",
      " 'internationally recommended firstline  cefixime for gonorrhoea treatment '\n",
      " 'norway 2010 euro surveill  20101519721 pmid21144442 httpsdoiorg102807 '\n",
      " 'ese154719721en  858 unemo m golparian d potočnik m jeverica s treatment '\n",
      " 'failure of  pharyngeal gonorrhoea with internationally recommended '\n",
      " 'firstline  ceftriaxone verified in slovenia september 2011 euro surveill  '\n",
      " '20121720200 pmid22748003  859 ison ca hussey j sankar kn evans j alexander s '\n",
      " 'gonorrhoea  treatment failures to cefixime and azithromycin in england 2010  '\n",
      " 'euro surveill 20111619833 pmid21492528  860 forsyth s penney p rooney g '\n",
      " 'cefiximeresistant neisseria gonorrhoeae  in the uk a time to reflect on '\n",
      " 'practice and recommendations int j  std aids 201122296–7 pmid21571983 '\n",
      " 'httpsdoiorg101258 ijsa2009009191  861 lewis da sriruttan c müller ee et al '\n",
      " 'phenotypic and genetic  characterization of the first two cases of '\n",
      " 'extendedspectrum cephalosporinresistant neisseria gonorrhoeae infection in '\n",
      " 'south africa  and association with cefixime treatment failure j antimicrob  '\n",
      " 'chemother 2013681267–70 pmid23416957 httpsdoi org101093jacdkt034  862 ota kv '\n",
      " 'fisman dn tamari ie et al incidence and treatment  outcomes of pharyngeal '\n",
      " 'neisseria gonorrhoeae and chlamydia  trachomatis infections in men who have '\n",
      " 'sex with men a 13year  retrospective cohort study clin infect dis '\n",
      " '2009481237–43  pmid19323630 httpsdoiorg101086597586  863 allen vg mitterni l '\n",
      " 'seah c et al neisseria gonorrhoeae treatment  failure and susceptibility to '\n",
      " 'cefixime in toronto canada jama  2013309163–70 pmid23299608 '\n",
      " 'httpsdoiorg101001 jama2012176575  864 chen my stevens k tideman r et al '\n",
      " 'failure of 500 mg of ceftriaxone  to eradicate pharyngeal gonorrhoea '\n",
      " 'australia j antimicrob chemother  2013681445–7 pmid23390207 '\n",
      " 'httpsdoiorg101093jac dkt017  865 tapsall j read p carmody c et al two cases '\n",
      " 'of failed ceftriaxone  treatment in pharyngeal gonorrhoea verified by '\n",
      " 'molecular  microbiological methods j med microbiol 200958683–7  pmid19369534 '\n",
      " 'httpsdoiorg101099jmm00076410  866 ohnishi m saika t hoshina s et al '\n",
      " 'ceftriaxoneresistant neisseria  gonorrhoeae japan emerg infect dis '\n",
      " '201117148–9 pmid21192886  httpsdoiorg103201eid1701100397  867 unemo m '\n",
      " 'golparian d nicholas r ohnishi m gallay a sednaoui  p highlevel cefixime and '\n",
      " 'ceftriaxoneresistant neisseria gonorrhoeae  in france novel pena mosaic '\n",
      " 'allele in a successful international clone  causes treatment failure '\n",
      " 'antimicrob agents chemother 2012561273– 80 pmid22155830 '\n",
      " 'httpsdoiorg101128aac0576011  868 cdc update to cdc’s sexually transmitted '\n",
      " 'diseases treatment  guidelines 2010 oral cephalosporins no longer a '\n",
      " 'recommended  treatment for gonococcal infections mmwr morb mortal wkly rep  '\n",
      " '201261590–4 pmid22874837  869 wind cm de vries e schim van der loeff mf et '\n",
      " 'al decreased  azithromycin susceptibility of neisseria gonorrhoeae isolates '\n",
      " 'in patients  recently treated with azithromycin clin infect dis 20176537–45  '\n",
      " 'pmid28510723 httpsdoiorg101093cidcix249  870 kong fys horner p unemo m '\n",
      " 'hocking js pharmacokinetic  considerations regarding the treatment of '\n",
      " 'bacterial sexually transmitted  infections with azithromycin a review j '\n",
      " 'antimicrob chemother  2019741157–66 pmid30649333 httpsdoiorg101093jac '\n",
      " 'dky548  871 cdc antibiotic resistance threats in the united states 2019 '\n",
      " 'atlanta  ga us department of health and human services cdc 2019  '\n",
      " 'httpswwwcdcgovdrugresistancepdfthreatsreport2019ar threatsreport508pdf  872 '\n",
      " 'st cyr s barbee l workowski ka et al update to cdc’s treatment  guidelines '\n",
      " 'for gonococcal infection 2020 mmwr morb mortal wkly  rep 2020691911–6 '\n",
      " 'pmid33332296 httpsdoiorg1015585 mmwrmm6950a6  873 clinical and laboratory '\n",
      " 'standards institute performance standards for  antimicrobial susceptibility '\n",
      " 'testing twentieth informational supplement  clinical and laboratory '\n",
      " 'standards institute document m100s20  wayne pa clinical and laboratory '\n",
      " 'standards institute 2010  874 cdc cephalosporinresistant neisseria '\n",
      " 'gonorrhoeae public health  response plan atlanta ga us department of health '\n",
      " 'and human  services cdc 2012 httpswwwcdcgovstdtreatmentcephr '\n",
      " 'responseplanjuly302012pdf  875 poncin t merimeche m braille a et al two '\n",
      " 'cases of multidrug resistant neisseria gonorrhoeae related to travel in '\n",
      " 'southeastern asia  france june 2019 euro surveill 2019241900528 '\n",
      " 'pmid31507264  httpsdoiorg10280715607917es201924361900528  876 carnicerpont d '\n",
      " 'smithson a finahomar e bastida mt gonococcus  antimicrobial resistance '\n",
      " 'surveillance working group first cases of  neisseria gonorrhoeae resistant '\n",
      " 'to ceftriaxone in catalonia spain may  2011 enferm infecc microbiol clin '\n",
      " '201230218–9 pmid22244992  httpsdoiorg101016jeimc201111010  877 cámara j '\n",
      " 'serra j ayats j et al molecular characterization of two  highlevel '\n",
      " 'ceftriaxoneresistant neisseria gonorrhoeae isolates detected  in catalonia '\n",
      " 'spain j antimicrob chemother 2012671858–60  pmid22566592 '\n",
      " 'httpsdoiorg101093jacdks162  878 eyre dw sanderson nd lord e et al gonorrhoea '\n",
      " 'treatment failure  caused by a neisseria gonorrhoeae strain with combined '\n",
      " 'ceftriaxone and  highlevel azithromycin resistance england february 2018 '\n",
      " 'euro  surveill  2018231800323 pmid29991383 httpsdoi '\n",
      " 'org10280715607917es201823271800323  879 fifer h hughes g whiley d lahra mm '\n",
      " 'lessons learnt from  ceftriaxoneresistant gonorrhoea in the uk and australia '\n",
      " 'lancet infect  dis 202020276–8 pmid32112753 httpsdoiorg101016 '\n",
      " 's1473309920300554  880 chisholm sa mouton jw lewis da nichols t ison ca '\n",
      " 'livermore  dm cephalosporin mic creep among gonococci time for a  '\n",
      " 'pharmacodynamic rethink j antimicrob chemother 2010652141–8  pmid20693173 '\n",
      " 'httpsdoiorg101093jacdkq289  881 connolly kl eakin ae gomez c osborn bl unemo '\n",
      " 'm jerse ae  pharmacokinetic data are predictive of in vivo efficacy for '\n",
      " 'cefixime and  ceftriaxone against susceptible and resistant neisseria '\n",
      " 'gonorrhoeae strains  in the gonorrhea mouse model antimicrob agents '\n",
      " 'chemother  201963e0164418 pmid30642924 httpsdoiorg101128 aac0164418  882 '\n",
      " 'blondeau jm hansen g metzler k hedlin p the role of pkpd  parameters to '\n",
      " 'avoid selection and increase of resistance mutant  prevention concentration '\n",
      " 'j chemother 200416suppl 31–19  pmid15334827 '\n",
      " 'httpsdoiorg1010801120009x200411782371  883 moran js levine wc drugs of '\n",
      " 'choice for the treatment of  uncomplicated gonococcal infections clin infect '\n",
      " 'dis 199520suppl  1s47–65 pmid7795109 httpsdoiorg101093clinids20 '\n",
      " 'supplement1s47 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids18663018doptabstract '\n",
      " 'httpsdoiorg101128aac0019808 httpsdoiorg101128aac0019808 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids12673405doptabstract '\n",
      " 'httpsdoiorg101007s1015600202048 httpsdoiorg101007s1015600202048 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids21329645doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids21144442doptabstract '\n",
      " 'httpsdoiorg102807ese154719721en httpsdoiorg102807ese154719721en '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids22748003doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids21492528doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids21571983doptabstract '\n",
      " 'httpsdoiorg101258ijsa2009009191 httpsdoiorg101258ijsa2009009191 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids23416957doptabstract '\n",
      " 'httpsdoiorg101093jacdkt034 httpsdoiorg101093jacdkt034 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids19323630doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids19323630doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids23299608doptabstract '\n",
      " 'httpsdoiorg101001jama2012176575 httpsdoiorg101001jama2012176575 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids23390207doptabstract '\n",
      " 'httpsdoiorg101093jacdkt017 httpsdoiorg101093jacdkt017 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids19369534doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids19369534doptabstract '\n",
      " 'httpsdoiorg101099jmm00076410 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids21192886doptabstract '\n",
      " 'httpsdoiorg103201eid1701100397 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids22155830doptabstract '\n",
      " 'httpsdoiorg101128aac0576011 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids22874837doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28510723doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28510723doptabstract '\n",
      " 'httpsdoiorg101093cidcix249 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30649333doptabstract '\n",
      " 'httpsdoiorg101093jacdky548 httpsdoiorg101093jacdky548 '\n",
      " 'httpswwwcdcgovdrugresistancepdfthreatsreport2019arthreatsreport508pdf '\n",
      " 'httpswwwcdcgovdrugresistancepdfthreatsreport2019arthreatsreport508pdf '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids33332296doptabstract '\n",
      " 'httpsdoiorg1015585mmwrmm6950a6 httpsdoiorg1015585mmwrmm6950a6 '\n",
      " 'httpswwwcdcgovstdtreatmentcephrresponseplanjuly302012pdf '\n",
      " 'httpswwwcdcgovstdtreatmentcephrresponseplanjuly302012pdf '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids31507264doptabstract '\n",
      " 'httpsdoiorg10280715607917es201924361900528 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids22244992doptabstract '\n",
      " 'httpsdoiorg101016jeimc201111010 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids22566592doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids22566592doptabstract '\n",
      " 'httpsdoiorg101093jacdks162 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29991383doptabstract '\n",
      " 'httpsdoiorg10280715607917es201823271800323 '\n",
      " 'httpsdoiorg10280715607917es201823271800323 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids32112753doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids20693173doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids20693173doptabstract '\n",
      " 'httpsdoiorg101093jacdkq289 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30642924doptabstract '\n",
      " 'httpsdoiorg101128aac0164418 httpsdoiorg101128aac0164418 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids15334827doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids15334827doptabstract '\n",
      " 'httpsdoiorg1010801120009x200411782371 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids7795109doptabstract '\n",
      " 'httpsdoiorg101093clinids20supplement1s47 '\n",
      " 'httpsdoiorg101093clinids20supplement1s47 recommendations and reports mmwr  '\n",
      " 'july 23 2021  vol 70  no 4 165us department of health and human '\n",
      " 'servicescenters for disease control and prevention  884 unemo m golparian d '\n",
      " 'eyre dw antimicrobial resistance  in neisseria gonorrhoeae and treatment of '\n",
      " 'gonorrhea methods  mol biol 2019199737–58 pmid31119616 httpsdoi '\n",
      " 'org10100797814939949603  885 kirkcaldy rd weinstock hs moore pc et al the '\n",
      " 'efficacy and  safety of gentamicin plus azithromycin and gemifloxacin plus  '\n",
      " 'azithromycin as treatment of uncomplicated gonorrhea clin infect  dis '\n",
      " '2014591083–91 pmid25031289 httpsdoiorg101093 cidciu521  886 ross jdc '\n",
      " 'brittain c cole m et al gtog trial team gentamicin  compared with '\n",
      " 'ceftriaxone for the treatment of gonorrhoea gtog  a randomised '\n",
      " 'noninferiority trial lancet 20193932511–20  pmid31056291 '\n",
      " 'httpsdoiorg101016s0140673618328174  887 singh v bala m bhargava a kakran m '\n",
      " 'bhatnagar r in vitro efficacy  of 21 dual antimicrobial combinations '\n",
      " 'comprising novel and currently  recommended combinations for treatment of '\n",
      " 'drug resistant gonorrhoea  in future era plos one 201813e0193678 '\n",
      " 'pmid29509792 https doiorg101371journalpone0193678  888 mayer kh klausner jd '\n",
      " 'handsfield hh intersecting  epidemics and educable moments sexually '\n",
      " 'transmitted disease  risk assessment and screening in men who have sex with '\n",
      " 'men  sex transm dis 200128464–7 pmid11473219 httpsdoi '\n",
      " 'org1010970000743520010800000008  889 linhart y shohat t amitai z et al '\n",
      " 'sexually transmitted infections  among brothelbased sex workers in telaviv '\n",
      " 'area israel high  prevalence of pharyngeal gonorrhoea int j std aids '\n",
      " '200819656–9  pmid18824615 httpsdoiorg101258ijsa2008008127  890 johnson jones '\n",
      " 'ml chapinbardales j bizune d et al national hiv  behavioral surveillance '\n",
      " 'sexually transmitted infection study group  extragenital chlamydia and '\n",
      " 'gonorrhea among community venue attending men who have sex with men—five '\n",
      " 'cities united states 2017  mmwr morb mortal wkly rep 201968321–5 '\n",
      " 'pmid30973847  httpsdoiorg1015585mmwrmm6814a1  891 chow ep williamson da '\n",
      " 'fortune r et al prevalence of genital and  oropharyngeal chlamydia and '\n",
      " 'gonorrhoea among female sex workers  in melbourne australia 2015–2017 need '\n",
      " 'for oropharyngeal testing  sex transm infect 201995398–401 pmid31113904 '\n",
      " 'httpsdoi org101136sextrans2018053957  892 cornelisse vj williamson d zhang l '\n",
      " 'et al evidence for a new  paradigm of gonorrhoea transmission crosssectional '\n",
      " 'analysis of  neisseria gonorrhoeae infections by anatomical site in both '\n",
      " 'partners in  60 male couples sex transm infect 201995437–42 pmid30996106  '\n",
      " 'httpsdoiorg101136sextrans2018053803  893 kissinger pj reilly k taylor sn '\n",
      " 'leichliter js rosenthal s martin  dh early repeat chlamydia trachomatis and '\n",
      " 'neisseria gonorrhoeae  infections among heterosexual men sex transm dis '\n",
      " '200936498–500  pmid19617870 httpsdoiorg101097olq0b013e3181a4d147  894 '\n",
      " 'berenger bm demczuk w gratrix j pabbaraju k smyczek p  martin i genetic '\n",
      " 'characterization and enhanced surveillance of  ceftriaxoneresistant '\n",
      " 'neisseria gonorrhoeae strain alberta canada  2018 emerg infect dis '\n",
      " '2019251660–7 pmid31407661 https doiorg103201eid2509190407  895 rob f '\n",
      " 'klubalová b nyčová e hercogová j unemo m gentamicin  240 mg plus '\n",
      " 'azithromycin 2 g vs ceftriaxone 500 mg plus  azithromycin 2 g for treatment '\n",
      " 'of rectal and pharyngeal gonorrhoea a  randomized controlled trial clin '\n",
      " 'microbiol infect 202026207–12  pmid31419483 httpsdoiorg101016jcmi201908004  '\n",
      " '896 romano a gaeta f valluzzi rl caruso c rumi g bousquet pj  igemediated '\n",
      " 'hypersensitivity to cephalosporins crossreactivity and  tolerability of '\n",
      " 'penicillins monobactams and carbapenems j allergy  clin immunol 2010126994–9 '\n",
      " 'pmid20888035 httpsdoi org101016jjaci201006052  897 american college of '\n",
      " 'obstetricians and gynecologists’ committee  on obstetric practice committee '\n",
      " 'opinion no 717 sulfonamides  nitrofurantoin and risk of birth defects obstet '\n",
      " 'gynecol  2017130e150–2 pmid28832488 httpsdoiorg101097 aog0000000000002300  '\n",
      " '898 ha imov i c i  r   rous s e l  tj   trea tment  o f  gonococca l  '\n",
      " 'conjunctivitis with singledose intramuscular ceftriaxone am  j ophthalmol '\n",
      " '1989107511–4 pmid2496606 httpsdoi org1010160002939489904959  899 bleich at '\n",
      " 'sheffield js wendel gd jr sigman a cunningham  fg disseminated gonococcal '\n",
      " 'infection in women obstet gynecol  2012119597–602 pmid22353959 '\n",
      " 'httpsdoiorg101097 aog0b013e318244eda9  900 belkacem a caumes e ouanich j et '\n",
      " 'al working group fradgi  changing patterns of disseminated gonococcal '\n",
      " 'infection in france  crosssectional data 2009–2011 sex transm infect '\n",
      " '201389613–5  pmid23920397 httpsdoiorg101136sextrans2013051119  901 birrell '\n",
      " 'jm gunathilake m singleton s williams s krause v  characteristics and impact '\n",
      " 'of disseminated gonococcal infection in  the “top end” of australia am j '\n",
      " 'trop med hyg 2019101753–60  pmid31392956 httpsdoiorg104269ajtmh190288  902 '\n",
      " 'crew pe abara we mcculley l et al disseminated gonococcal  infections in '\n",
      " 'patients receiving eculizumab a case series clin infect  dis 201969596–600 '\n",
      " 'pmid30418536 httpsdoiorg101093cid ciy958  903 curry sj krist ah owens dk et '\n",
      " 'al us preventive services task  force ocular prophylaxis for gonococcal '\n",
      " 'ophthalmia neonatorum  us preventive services task force reaffirmation '\n",
      " 'recommendation  statement jama 2019321394–8 pmid30694327 httpsdoi '\n",
      " 'org101001jama201821367  904 kreisel k weston e braxton j llata e torrone e '\n",
      " 'keeping an eye  on chlamydia and gonorrhea conjunctivitis in infants in the '\n",
      " 'united  states 2010–2015 sex transm dis 201744356–8 pmid28499285  '\n",
      " 'httpsdoiorg101097olq0000000000000613  905 scott wj eck cd povidoneiodine and '\n",
      " 'ophthalmia neonatorum  ophthalmology 2012119653–4 pmid22385492 httpsdoi '\n",
      " 'org101016jophtha201111037  906 david m rumelt s weintraub z efficacy '\n",
      " 'comparison between  povidone iodine 25 and tetracycline 1 in prevention of '\n",
      " 'ophthalmia  neonatorum ophthalmology 20111181454–8 pmid21439642  '\n",
      " 'httpsdoiorg101016jophtha201012003  907 binenbaum g bruno cj forbes bj et al '\n",
      " 'periocular ulcerative  dermatitis associated with gentamicin ointment '\n",
      " 'prophylaxis in  newborns j pediatr 2010156320–1 pmid20105641 httpsdoi '\n",
      " 'org101016jjpeds200911060  908 nathawad r mendez h ahmad a et al severe '\n",
      " 'ocular reactions after  neonatal ocular prophylaxis with gentamicin '\n",
      " 'ophthalmic ointment  pediatr infect dis j 201130175–6 pmid20885334 httpsdoi '\n",
      " 'org101097inf0b013e3181f6c2e5  909 taylorrobinson d jensen js mycoplasma '\n",
      " 'genitalium from chrysalis  to multicolored butterfly clin microbiol rev '\n",
      " '201124498–514  pmid21734246 httpsdoiorg101128cmr0000611  910 seña ac lensing '\n",
      " 's rompalo a et al chlamydia trachomatis  mycoplasma genitalium and '\n",
      " 'trichomonas vaginalis infections in  men with nongonococcal urethritis '\n",
      " 'predictors and persistence after  therapy j infect dis 2012206357–65 '\n",
      " 'pmid22615318 httpsdoi org101093infdisjis356  911 huppert js mortensen je '\n",
      " 'reed jl kahn ja rich kd hobbs mm  mycoplasma genitalium detected by '\n",
      " 'transcriptionmediated amplification  is associated with chlamydia '\n",
      " 'trachomatis in adolescent women sex  transm dis 200835250–4 pmid18490867 '\n",
      " 'httpsdoiorg101097 olq0b013e31815abac6 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids31119616doptabstract '\n",
      " 'httpsdoiorg10100797814939949603 httpsdoiorg10100797814939949603 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids25031289doptabstract '\n",
      " 'httpsdoiorg101093cidciu521 httpsdoiorg101093cidciu521 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids31056291doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids31056291doptabstract '\n",
      " 'httpsdoiorg101016s0140673618328174 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29509792doptabstract '\n",
      " 'httpsdoiorg101371journalpone0193678 httpsdoiorg101371journalpone0193678 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids11473219doptabstract '\n",
      " 'httpsdoiorg1010970000743520010800000008 '\n",
      " 'httpsdoiorg1010970000743520010800000008 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids18824615doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids18824615doptabstract '\n",
      " 'httpsdoiorg101258ijsa2008008127 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30973847doptabstract '\n",
      " 'httpsdoiorg1015585mmwrmm6814a1 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids31113904doptabstract '\n",
      " 'httpsdoiorg101136sextrans2018053957 httpsdoiorg101136sextrans2018053957 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30996106doptabstract '\n",
      " 'httpsdoiorg101136sextrans2018053803 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids19617870doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids19617870doptabstract '\n",
      " 'httpsdoiorg101097olq0b013e3181a4d147 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids31407661doptabstract '\n",
      " 'httpsdoiorg103201eid2509190407 httpsdoiorg103201eid2509190407 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids31419483doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids31419483doptabstract '\n",
      " 'httpsdoiorg101016jcmi201908004 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids20888035doptabstract '\n",
      " 'httpsdoiorg101016jjaci201006052 httpsdoiorg101016jjaci201006052 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28832488doptabstract '\n",
      " 'httpsdoiorg101097aog0000000000002300 httpsdoiorg101097aog0000000000002300 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids2496606doptabstract '\n",
      " 'httpsdoiorg1010160002939489904959 httpsdoiorg1010160002939489904959 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids22353959doptabstract '\n",
      " 'httpsdoiorg101097aog0b013e318244eda9 httpsdoiorg101097aog0b013e318244eda9 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids23920397doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids23920397doptabstract '\n",
      " 'httpsdoiorg101136sextrans2013051119 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids31392956doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids31392956doptabstract '\n",
      " 'httpsdoiorg104269ajtmh190288 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30418536doptabstract '\n",
      " 'httpsdoiorg101093cidciy958 httpsdoiorg101093cidciy958 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30694327doptabstract '\n",
      " 'httpsdoiorg101001jama201821367 httpsdoiorg101001jama201821367 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28499285doptabstract '\n",
      " 'httpsdoiorg101097olq0000000000000613 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids22385492doptabstract '\n",
      " 'httpsdoiorg101016jophtha201111037 httpsdoiorg101016jophtha201111037 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids21439642doptabstract '\n",
      " 'httpsdoiorg101016jophtha201012003 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids20105641doptabstract '\n",
      " 'httpsdoiorg101016jjpeds200911060 httpsdoiorg101016jjpeds200911060 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids20885334doptabstract '\n",
      " 'httpsdoiorg101097inf0b013e3181f6c2e5 httpsdoiorg101097inf0b013e3181f6c2e5 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids21734246doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids21734246doptabstract '\n",
      " 'httpsdoiorg101128cmr0000611 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids22615318doptabstract '\n",
      " 'httpsdoiorg101093infdisjis356 httpsdoiorg101093infdisjis356 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids18490867doptabstract '\n",
      " 'httpsdoiorg101097olq0b013e31815abac6 httpsdoiorg101097olq0b013e31815abac6 '\n",
      " 'recommendations and reports 166 mmwr  july 23 2021  vol 70  no 4 us '\n",
      " 'department of health and human servicescenters for disease control and '\n",
      " 'prevention  912 mena l wang x mroczkowski tf martin dh mycoplasma '\n",
      " 'genitalium  infections in asymptomatic men and men with urethritis attending '\n",
      " 'a  sexually transmitted diseases clinic in new orleans clin infect dis  '\n",
      " '2002351167–73 pmid12410476 httpsdoiorg101086343829  913 falk l the overall '\n",
      " 'agreement of proposed definitions of mucopurulent  cervicitis in women at '\n",
      " 'high risk of chlamydia infection acta derm  venereol 201090506–11 '\n",
      " 'pmid20814628 httpsdoi org102340000155550924  914 anagrius c loré b jensen js '\n",
      " 'mycoplasma genitalium prevalence  clinical significance and transmission sex '\n",
      " 'transm infect  200581458–62 pmid16326846 httpsdoiorg101136 sti2004012062  '\n",
      " '915 manhart le critchlow cw holmes kk et al mucopurulent cervicitis  and '\n",
      " 'mycoplasma genitalium j infect dis 2003187650–7  pmid12599082 '\n",
      " 'httpsdoiorg101086367992  916 lusk mj konecny p naing zw garden fl cumming rg '\n",
      " 'rawlinson  wd mycoplasma genitalium is associated with cervicitis and hiv  '\n",
      " 'infection in an urban australian sti clinic population sex transm  infect '\n",
      " '201187107–9 pmid21071566 httpsdoiorg101136 sti2010045138  917 dehon pm '\n",
      " 'mcgowin cl the immunopathogenesis of mycoplasma  genitalium infections in '\n",
      " 'women a narrative review sex transm dis  201744428–32 pmid28608793 '\n",
      " 'httpsdoiorg101097 olq0000000000000621  918 bjartling c osser s persson k the '\n",
      " 'association between mycoplasma  genitalium and pelvic inflammatory disease '\n",
      " 'after termination of  pregnancy bjog 2010117361–4 pmid20015303 httpsdoi '\n",
      " 'org101111j14710528200902455x  919 bjartling c osser s persson k mycoplasma '\n",
      " 'genitalium in cervicitis  and pelvic inflammatory disease among women at a '\n",
      " 'gynecologic  outpatient service am j obstet gynecol 2012206476e1–8  '\n",
      " 'pmid22483084 httpsdoiorg101016jajog201202036  920 taylor bd zheng x '\n",
      " 'o’connell cm wiesenfeld hc hillier sl  darville t risk factors for '\n",
      " 'mycoplasma genitalium endometritis and  incident infection a secondary data '\n",
      " 'analysis of the t cell response  against chlamydia trac study sex transm '\n",
      " 'infect 201894414–20  pmid29563165 httpsdoiorg101136sextrans2017053376  921 '\n",
      " 'cohen cr mugo nr astete sg et al detection of mycoplasma  genitalium in '\n",
      " 'women with laparoscopically diagnosed acute salpingitis  sex transm infect '\n",
      " '200581463–6 pmid16326847 httpsdoi org101136sti2005015701  922 haggerty cl '\n",
      " 'totten pa astete sg ness rb mycoplasma genitalium  among women with '\n",
      " 'nongonococcal nonchlamydial pelvic inflammatory  disease infect dis obstet '\n",
      " 'gynecol 2006200630184 pmid17485798  httpsdoiorg101155idog200630184  923 '\n",
      " 'short vl totten pa ness rb astete sg kelsey sf haggerty cl  clinical '\n",
      " 'presentation of mycoplasma genitalium infection versus neisseria  '\n",
      " 'gonorrhoeae infection among women with pelvic inflammatory disease  clin '\n",
      " 'infect dis 20094841–7 pmid19025498 httpsdoi org101086594123  924 simms i '\n",
      " 'eastick k mallinson h et al associations between  mycoplasma genitalium '\n",
      " 'chlamydia trachomatis and pelvic inflammatory  disease sex transm infect '\n",
      " '200379154–6 pmid12690141 https doiorg101136sti792154  925 oakeshott p '\n",
      " 'aghaizu a hay p et al is mycoplasma genitalium in  women the “new chlamydia” '\n",
      " 'a communitybased prospective cohort  study clin infect dis 2010511160–6 '\n",
      " 'pmid20942656 httpsdoi org101086656739  926 wiesenfeld hc hillier sl meyn l '\n",
      " 'et al mycoplasma genitalium—is  it a pathogen in acute pelvic inflammatory '\n",
      " 'disease pid sex transm  infect  201389suppl 1 a34 httpsdoi org101136 '\n",
      " 'sextrans20130511840106  927 møller br taylorrobinson d furr pm freundt ea '\n",
      " 'acute upper  genitaltract disease in female monkeys provoked experimentally '\n",
      " 'by  mycoplasma genitalium br j exp pathol 198566417–26  pmid4027175  928 '\n",
      " 'wiesenfeld hc manhart le mycoplasma genitalium in women  current knowledge '\n",
      " 'and research priorities for this recently emerged  pathogen j infect dis '\n",
      " '2017216suppl2s389–95  929 clausen hf fedder j drasbek m et al serological '\n",
      " 'investigation of  mycoplasma genitalium  in infertile women hum reprod  '\n",
      " '2001161866–74 pmid11527890 httpsdoiorg101093 humrep1691866  930 svenstrup hf '\n",
      " 'fedder j kristoffersen se trolle b birkelund s  christiansen g mycoplasma '\n",
      " 'genitalium chlamydia trachomatis and  tubal factor infertility—a prospective '\n",
      " 'study fertil steril 200890513–20  pmid17548070 '\n",
      " 'httpsdoiorg101016jfertnstert200612056  931 idahl a jurstrand m olofsson ji '\n",
      " 'fredlund h mycoplasma genitalium  serum antibodies in infertile couples and '\n",
      " 'fertile women sex transm  infect 201591589–91 pmid25921018 httpsdoiorg101136 '\n",
      " 'sextrans2015052011  932 edwards rk ferguson rj reyes l brown m theriaque dw '\n",
      " 'duff  p assessing the relationship between preterm delivery and various  '\n",
      " 'microorganisms recovered from the lower genital tract j matern fetal  '\n",
      " 'neonatal med 200619357–63 pmid16801313 httpsdoi org10108000207170600712071  '\n",
      " '933 vandepitte j bukenya j hughes p et al clinical characteristics  '\n",
      " 'associated with mycoplasma genitalium infection among women at high  risk of '\n",
      " 'hiv and other sti in uganda sex transm dis 201239487–91  pmid22592838 '\n",
      " 'httpsdoiorg101097olq0b013e31824b1cf3  934 rowlands s danielewski ja tabrizi '\n",
      " 'sn walker sp garland sm  microbial invasion of the amniotic cavity in '\n",
      " 'midtrimester pregnancies  using molecular microbiology am j obstet gynecol '\n",
      " '201721771 e1–5 pmid28268197 httpsdoiorg101016jajog201702051  935 jurstrand m '\n",
      " 'jensen js magnuson a kamwendo f fredlund h a  serological study of the role '\n",
      " 'of mycoplasma genitalium in pelvic  inflammatory disease and ectopic '\n",
      " 'pregnancy sex transm infect  200783319–23 pmid17475688 httpsdoiorg101136 '\n",
      " 'sti2007024752  936 ashshi am batwa sa kutbi sy malibary fa batwa m refaat b  '\n",
      " 'prevalence of 7 sexually transmitted organisms by multiplex realtime  pcr in '\n",
      " 'fallopian tube specimens collected from saudi women with  and without '\n",
      " 'ectopic pregnancy bmc infect dis 201515569  pmid26666587 '\n",
      " 'httpsdoiorg101186s1287901513131  937 bissessor m tabrizi sn bradshaw cs et '\n",
      " 'al the contribution of  mycoplasma genitalium to the aetiology of sexually '\n",
      " 'acquired infectious  proctitis in men who have sex with men clin microbiol '\n",
      " 'infect  201622260–5 pmid26686807 httpsdoiorg101016j cmi201511016  938 ong jj '\n",
      " 'aung e read trh et al clinical characteristics of anorectal  mycoplasma '\n",
      " 'genitalium infection and microbial cure in men who have  sex with men sex '\n",
      " 'transm dis 201845522–6 pmid29465653  httpsdoiorg101097olq0000000000000793  '\n",
      " '939 read trh murray gl danielewski ja et al symptoms sites and  significance '\n",
      " 'of mycoplasma genitalium in men who have sex with men  emerg infect dis '\n",
      " '201925719–27 pmid30882306 httpsdoi org103201eid2504181258  940 cina m '\n",
      " 'baumann l egligany d et al mycoplasma genitalium  incidence persistence '\n",
      " 'concordance between partners and progression  systematic review and '\n",
      " 'metaanalysis sex transm infect 201995328–35  pmid31055469 '\n",
      " 'httpsdoiorg101136sextrans2018053823  941 baumann l cina m egligany d et al '\n",
      " 'prevalence of mycoplasma  genitalium in different population groups '\n",
      " 'systematic review andmeta analysis sex transm infect 201894255–62 '\n",
      " 'pmid29440466 https doiorg101136sextrans2017053384 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids12410476doptabstract '\n",
      " 'httpsdoiorg101086343829 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids20814628doptabstract '\n",
      " 'httpsdoiorg102340000155550924 httpsdoiorg102340000155550924 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids16326846doptabstract '\n",
      " 'httpsdoiorg101136sti2004012062 httpsdoiorg101136sti2004012062 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids12599082doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids12599082doptabstract '\n",
      " 'httpsdoiorg101086367992 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids21071566doptabstract '\n",
      " 'httpsdoiorg101136sti2010045138 httpsdoiorg101136sti2010045138 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28608793doptabstract '\n",
      " 'httpsdoiorg101097olq0000000000000621 httpsdoiorg101097olq0000000000000621 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids20015303doptabstract '\n",
      " 'httpsdoiorg101111j14710528200902455x httpsdoiorg101111j14710528200902455x '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids22483084doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids22483084doptabstract '\n",
      " 'httpsdoiorg101016jajog201202036 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29563165doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29563165doptabstract '\n",
      " 'httpsdoiorg101136sextrans2017053376 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids16326847doptabstract '\n",
      " 'httpsdoiorg101136sti2005015701 httpsdoiorg101136sti2005015701 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids17485798doptabstract '\n",
      " 'httpsdoiorg101155idog200630184 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids19025498doptabstract '\n",
      " 'httpsdoiorg101086594123 httpsdoiorg101086594123 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids12690141doptabstract '\n",
      " 'httpsdoiorg101136sti792154 httpsdoiorg101136sti792154 '\n",
      " 'httpsdoiorg101086656739 httpsdoiorg101086656739 '\n",
      " 'httpsdoiorg101136sextrans20130511840106 '\n",
      " 'httpsdoiorg101136sextrans20130511840106 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids4027175doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids4027175doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids11527890doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids17548070doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids17548070doptabstract '\n",
      " 'httpsdoiorg101016jfertnstert200612056 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids25921018doptabstract '\n",
      " 'httpsdoiorg101136sextrans2015052011 httpsdoiorg101136sextrans2015052011 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids16801313doptabstract '\n",
      " 'httpsdoiorg10108000207170600712071 httpsdoiorg10108000207170600712071 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids22592838doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids22592838doptabstract '\n",
      " 'httpsdoiorg101097olq0b013e31824b1cf3 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28268197doptabstract '\n",
      " 'httpsdoiorg101016jajog201702051 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids17475688doptabstract '\n",
      " 'httpsdoiorg101136sti2007024752 httpsdoiorg101136sti2007024752 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids26666587doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids26666587doptabstract '\n",
      " 'httpsdoiorg101186s1287901513131 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids26686807doptabstract '\n",
      " 'httpsdoiorg101016jcmi201511016 httpsdoiorg101016jcmi201511016 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29465653doptabstract '\n",
      " 'httpsdoiorg101097olq0000000000000793 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30882306doptabstract '\n",
      " 'httpsdoiorg103201eid2504181258 httpsdoiorg103201eid2504181258 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids31055469doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids31055469doptabstract '\n",
      " 'httpsdoiorg101136sextrans2018053823 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29440466doptabstract '\n",
      " 'httpsdoiorg101136sextrans2017053384 httpsdoiorg101136sextrans2017053384 '\n",
      " 'recommendations and reports mmwr  july 23 2021  vol 70  no 4 167us '\n",
      " 'department of health and human servicescenters for disease control and '\n",
      " 'prevention  942 vandepitte j weiss ha bukenya j et al association between  '\n",
      " 'mycoplasma genitalium infection and hiv acquisition among female  sex '\n",
      " 'workers in uganda evidence from a nested casecontrol study sex  transm '\n",
      " 'infect 201490545–9 pmid24687129 httpsdoi org101136sextrans2013051467  943 '\n",
      " 'ferré vm ekouevi dk gbeasorkomlanvi fa et al prevalence of  human '\n",
      " 'papillomavirus human immunodeficiency virus and other  sexually transmitted '\n",
      " 'infections among female sex workers in togo a  national crosssectional '\n",
      " 'survey clin microbiol infect 2019251560 e1–7 pmid31051265 '\n",
      " 'httpsdoiorg101016jcmi201904015  944 mavedzenge sn van der pol b weiss ha et '\n",
      " 'al the association  between mycoplasma genitalium and hiv1 acquisition in '\n",
      " 'african  women aids 201226617–24 pmid22210630 httpsdoi '\n",
      " 'org101097qad0b013e32834ff690  945 saladorasmussen k jensen js mycoplasma '\n",
      " 'genitalium testing pattern  and macrolide resistance a danish nationwide '\n",
      " 'retrospective survey  clin infect dis 20145924–30 pmid24729494 httpsdoi '\n",
      " 'org101093cidciu217  946 wold c sorthe j hartgill u olsen ao moghaddam a '\n",
      " 'reinton n  identification of macrolideresistant mycoplasma genitalium using '\n",
      " 'real time pcr j eur acad dermatol venereol 2015291616–20  pmid25622510 '\n",
      " 'httpsdoiorg101111jdv12963  947 gesink d racey cs seah c et al mycoplasma '\n",
      " 'genitalium in toronto  ont estimates of prevalence and macrolide resistance '\n",
      " 'can fam  physician 201662e96–101 pmid27331225  948 kristiansen gq lisby jg '\n",
      " 'schønning k 5’ nuclease genotyping assay  for identification of '\n",
      " 'macrolideresistant mycoplasma genitalium in  clinical specimens j clin '\n",
      " 'microbiol 2016541593–7 pmid27053672  httpsdoiorg101128jcm0001216  949 braam '\n",
      " 'jf slotboom b van marm s et al high prevalence of the  a2058t macrolide '\n",
      " 'resistanceassociated mutation in mycoplasma  genitalium strains from the '\n",
      " 'netherlands j antimicrob chemother  2017721529–30 pmid28158595 '\n",
      " 'httpsdoiorg101093jac dkw584  950 murray gl bradshaw cs bissessor m et al '\n",
      " 'increasing macrolide and  fluoroquinolone resistance in mycoplasma '\n",
      " 'genitalium emerg infect dis  201723809–12 pmid28418319 httpsdoiorg103201 '\n",
      " 'eid2305161745  951 chernesky ma jang d martin i et al canadian mg study '\n",
      " 'group  mycoplasma genitalium antibiotic resistancemediating mutations in  '\n",
      " 'canadian women with or without chlamydia trachomatis infection  sex transm '\n",
      " 'dis 201744433–5 pmid28608794 httpsdoi org101097olq0000000000000617  952 '\n",
      " 'barberá mj fernándezhuerta m jensen js caballero e andreu a  mycoplasma '\n",
      " 'genitalium macrolide and fluoroquinolone resistance  prevalence and risk '\n",
      " 'factors among a 2013–2014 cohort of patients in  barcelona spain sex transm '\n",
      " 'dis 201744457–62 pmid28703723  httpsdoiorg101097olq0000000000000631  953 '\n",
      " 'sweeney el trembizki e bletchly c et al levels of mycoplasma  genitalium '\n",
      " 'antimicrobial resistance differ by both region and gender in  the state of '\n",
      " 'queensland australia implications for treatment  guidelines j clin microbiol '\n",
      " '201957e0155518 pmid30602443  httpsdoiorg101128jcm0155518  954 bissessor m '\n",
      " 'tabrizi sn twin j et al macrolide resistance and  azithromycin failure in a '\n",
      " 'mycoplasma genitaliuminfected cohort and  response of azithromycin failures '\n",
      " 'to alternative antibiotic regimens  clin infect dis 2015601228–36 '\n",
      " 'pmid25537875 httpsdoi org101093cidciu1162  955 piñeiro l idigoras p de la '\n",
      " 'caba i lópezolaizola m cilla g guided  antibiotic therapy for mycoplasma '\n",
      " 'genitalium infections analysis of  mutations associated with resistance to '\n",
      " 'macrolides and fluoroquinolones  spanish enferm infecc microbiol clin '\n",
      " '201937394–7  pmid30396750  956 dionneodom j geisler wm aaron kj et al high '\n",
      " 'prevalence of  multidrugresistant mycoplasma genitalium in human '\n",
      " 'immunodeficiency  virusinfected men who have sex with men in alabama clin '\n",
      " 'infect dis  201866796–8 pmid29028993 httpsdoiorg101093cidcix853  957 pitt r '\n",
      " 'fifer h woodford n alexander s detection of markers  predictive of macrolide '\n",
      " 'and fluoroquinolone resistance in mycoplasma  genitalium from patients '\n",
      " 'attending sexual health services in england  sex transm infect 2018949–13 '\n",
      " 'pmid28717051 httpsdoi org101136sextrans2017053164  958 unemo m '\n",
      " 'saladorasmussen k hansen m et al clinical and  analytical evaluation of the '\n",
      " 'new aptima mycoplasma genitalium assay  with data on m\\xa0genitalium '\n",
      " 'prevalence and antimicrobial resistance in  m\\xa0 genitalium in denmark '\n",
      " 'norway and sweden in 2016 clin  microbiol infect 201824533–9 pmid28923377 '\n",
      " 'httpsdoi org101016jcmi201709006  959 anderson t coughlan e werno a '\n",
      " 'mycoplasma genitalium macrolide  and fluoroquinolone resistance detection '\n",
      " 'and clinical implications in  a selected cohort in new zealand j clin '\n",
      " 'microbiol 2017553242–8  pmid28878004 httpsdoiorg101128jcm0108717  960 '\n",
      " 'shimada y deguchi t nakane k et al emergence of clinical strains  of '\n",
      " 'mycoplasma genitalium harbouring alterations in parc associated  with '\n",
      " 'fluoroquinolone resistance int j antimicrob agents  201036255–8 pmid20580532 '\n",
      " 'httpsdoiorg101016j ijantimicag201005011  961 muller ee mahlangu mp lewis da '\n",
      " 'kularatne rs macrolide and  fluoroquinolone resistanceassociated mutations '\n",
      " 'in mycoplasma  genitalium in johannesburg south africa 2007–2014 bmc infect  '\n",
      " 'dis 201919148 pmid30760230 httpsdoiorg101186 s1287901937976  962 chambers lc '\n",
      " 'jensen js morgan jl et al lack of association between  the s83i parc '\n",
      " 'mutation in mycoplasma genitalium and treatment  outcomes among men who have '\n",
      " 'sex with men with nongonococcal  urethritis sex transm dis 201946805–9 '\n",
      " 'pmid31259853 https doiorg101097olq0000000000001035  963 durukan d read trh '\n",
      " 'murray g et al resistanceguided  antimicrobial therapy using '\n",
      " 'doxycyclinemoxifloxacin and doxycycline 25g azithromycin for the treatment '\n",
      " 'of mycoplasma genitalium infection  efficacy and tolerability clin infect '\n",
      " 'dis 2020711461–8  pmid31629365 httpsdoiorg101093cidciz1031  964 li y le wj '\n",
      " 'li s cao yp su xh metaanalysis of the efficacy of  moxifloxacin in treating '\n",
      " 'mycoplasma genitalium infection int j std  aids 2017281106–14  pmid28118803 '\n",
      " 'https   doi  org1011770956462416688562  965 mondeja ba couri j rodríguez nm '\n",
      " 'blanco o fernández c jensen  js macrolideresistant mycoplasma genitalium '\n",
      " 'infections in cuban  patients an underestimated health problem bmc infect '\n",
      " 'dis  201818601 pmid30486786 httpsdoiorg101186 s1287901835239  966 glaser am '\n",
      " 'geisler wm ratliff ae xiao l waites kb gaisa m two  cases of '\n",
      " 'multidrugresistant genitourinary mycoplasma genitalium  infection '\n",
      " 'successfully eradicated with minocycline int j std aids  2 0 1 9  3 0  5 1 2 '\n",
      " '– 4   p m i d  3 0 9 9 9 8 3 6  h t t p s    d o i  '\n",
      " 'org1011770956462418816757  967 xiao l waites kb van der pol b aaron kj hook '\n",
      " 'ew 3rd geisler  wm mycoplasma genitalium infections with macrolide and  '\n",
      " 'fluoroquinolone resistanceassociated mutations in heterosexual african  '\n",
      " 'american couples in alabama sex transm dis 20194618–24  pmid29979336 '\n",
      " 'httpsdoiorg101097olq0000000000000891  968 slifirski jb vodstrcil la fairley '\n",
      " 'ck et al mycoplasma genitalium  infection in adults reporting sexual contact '\n",
      " 'with infected partners  australia 2008–2016 emerg infect dis 2017231826–33  '\n",
      " 'pmid29047422 httpsdoiorg103201eid2311170998  969 anderson mr klink k '\n",
      " 'cohrssen a evaluation of vaginal complaints  jama 20042911368–79 '\n",
      " 'pmid15026404 httpsdoiorg101001 jama291111368 '\n",
      " 'httpsdoiorg101136sextrans2013051467 httpsdoiorg101136sextrans2013051467 '\n",
      " 'httpsdoiorg101016jcmi201904015 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids22210630doptabstract '\n",
      " 'httpsdoiorg101097qad0b013e32834ff690 httpsdoiorg101097qad0b013e32834ff690 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids24729494doptabstract '\n",
      " 'httpsdoiorg101093cidciu217 httpsdoiorg101093cidciu217 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids25622510doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids25622510doptabstract '\n",
      " 'httpsdoiorg101111jdv12963 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids27331225doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids27053672doptabstract '\n",
      " 'httpsdoiorg101128jcm0001216 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28158595doptabstract '\n",
      " 'httpsdoiorg101093jacdkw584 httpsdoiorg101093jacdkw584 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28418319doptabstract '\n",
      " 'httpsdoiorg103201eid2305161745 httpsdoiorg103201eid2305161745 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28608794doptabstract '\n",
      " 'httpsdoiorg101097olq0000000000000617 httpsdoiorg101097olq0000000000000617 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28703723doptabstract '\n",
      " 'httpsdoiorg101097olq0000000000000631 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30602443doptabstract '\n",
      " 'httpsdoiorg101128jcm0155518 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids25537875doptabstract '\n",
      " 'httpsdoiorg101093cidciu1162 httpsdoiorg101093cidciu1162 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30396750doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30396750doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29028993doptabstract '\n",
      " 'httpsdoiorg101093cidcix853 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28717051doptabstract '\n",
      " 'httpsdoiorg101136sextrans2017053164 httpsdoiorg101136sextrans2017053164 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28923377doptabstract '\n",
      " 'httpsdoiorg101016jcmi201709006 httpsdoiorg101016jcmi201709006 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28878004doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28878004doptabstract '\n",
      " 'httpsdoiorg101128jcm0108717 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids20580532doptabstract '\n",
      " 'httpsdoiorg101016jijantimicag201005011 '\n",
      " 'httpsdoiorg101016jijantimicag201005011 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30760230doptabstract '\n",
      " 'httpsdoiorg101186s1287901937976 httpsdoiorg101186s1287901937976 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids31259853doptabstract '\n",
      " 'httpsdoiorg101097olq0000000000001035 httpsdoiorg101097olq0000000000001035 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids31629365doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids31629365doptabstract '\n",
      " 'httpsdoiorg101093cidciz1031 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28118803doptabstract '\n",
      " 'httpsdoiorg1011770956462416688562 httpsdoiorg1011770956462416688562 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30486786doptabstract '\n",
      " 'httpsdoiorg101186s1287901835239 httpsdoiorg101186s1287901835239 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30999836doptabstract '\n",
      " 'httpsdoiorg1011770956462418816757 httpsdoiorg1011770956462418816757 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29979336doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29979336doptabstract '\n",
      " 'httpsdoiorg101097olq0000000000000891 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29047422doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29047422doptabstract '\n",
      " 'httpsdoiorg103201eid2311170998 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids15026404doptabstract '\n",
      " 'httpsdoiorg101001jama291111368 httpsdoiorg101001jama291111368 '\n",
      " 'recommendations and reports 168 mmwr  july 23 2021  vol 70  no 4 us '\n",
      " 'department of health and human servicescenters for disease control and '\n",
      " 'prevention  970 swidsinski a mendling w loeningbaucke v et al adherent '\n",
      " 'biofilms  in bacterial vaginosis obstet gynecol 20051061013–23  p m i d  1 6 '\n",
      " '2 6 0 5 2 0  h t t p s    d o i  o r g  1 0  1 0 9 7  0 1  '\n",
      " 'aog000018359445524d2  971 brotman rm klebanoff ma nansel tr et al bacterial '\n",
      " 'vaginosis  assessed by gram stain and diminished colonization resistance to  '\n",
      " 'incident gonococcal chlamydial and trichomonal genital infection  j infect '\n",
      " 'dis 20102021907–15 pmid21067371 httpsdoi org101086657320  972 peebles k '\n",
      " 'velloza j balkus je mcclelland rs barnabas rv high  global burden and costs '\n",
      " 'of bacterial vaginosis a systematic review and  metaanalysis sex transm dis '\n",
      " '201946304–11 pmid30624309  httpsdoiorg101097olq0000000000000972  973 kenyon '\n",
      " 'cr buyze j klebanoff m brotman rm association between  bacterial vaginosis '\n",
      " 'and partner concurrency a longitudinal study sex  transm infect 20189475–7 '\n",
      " 'pmid27645157 httpsdoi org101136sextrans2016052652  974 sanchez s garcia pj '\n",
      " 'thomas kk catlin m holmes kk intravaginal  metronidazole gel versus '\n",
      " 'metronidazole plus nystatin ovules for bacterial  vaginosis a randomized '\n",
      " 'controlled trial am j obstet gynecol  20041911898–906 pmid15592270 '\n",
      " 'httpsdoiorg101016j ajog200406089  975 ness rb soper de holley rl et al pid '\n",
      " 'evaluation and clinical  health peach study investigators douching and '\n",
      " 'endometritis  results from the pid evaluation and clinical health peach '\n",
      " 'study  sex transm dis 200128240–5 pmid11318257 httpsdoi '\n",
      " 'org1010970000743520010400000010  976 gondwe t ness r totten pa et al novel '\n",
      " 'bacterial vaginosisassociated  organisms mediate the relationship between '\n",
      " 'vaginal douching and  pelvic inflammatory disease sex transm infect '\n",
      " '202096439–44  pmid31810995 httpsdoiorg101136sextrans2019054191  977 abbai ns '\n",
      " 'reddy t ramjee g prevalent bacterial vaginosis  infection—a risk factor for '\n",
      " 'incident sexually transmitted infections in  women in durban south africa '\n",
      " 'int j std aids 2016271283–8  pmid26538552 httpsdoiorg1011770956462415616038  '\n",
      " '978 morris bj hankins ca banerjee j et al does male circumcision  reduce '\n",
      " 'women’s risk of sexually transmitted infections cervical cancer  and '\n",
      " 'associated conditions front public health 201974  pmid30766863 '\n",
      " 'httpsdoiorg103389fpubh201900004  979 srinivasan s liu c mitchell cm et al '\n",
      " 'temporal variability of human  vaginal bacteria and relationship with '\n",
      " 'bacterial vaginosis plos one  20105e10197 pmid20419168 '\n",
      " 'httpsdoiorg101371journal pone0010197  980 gajer p brotman rm bai g et al '\n",
      " 'temporal dynamics of the human  vaginal microbiota sci transl med '\n",
      " '20124132ra52 pmid22553250  httpsdoiorg101126scitranslmed3003605  981 fethers '\n",
      " 'ka fairley ck morton a et al early sexual experiences and  risk factors for '\n",
      " 'bacterial vaginosis j infect dis 20092001662–70  pmid19863439 '\n",
      " 'httpsdoiorg101086648092  982 achilles sl austin mn meyn la mhlanga f '\n",
      " 'chirenje zm hillier  sl impact of contraceptive initiation on vaginal '\n",
      " 'microbiota am  j obstet gynecol 2018218622e1–10 pmid29505773 httpsdoi '\n",
      " 'org101016jajog201802017  983 vodstrcil la plummer me fairley ck et al '\n",
      " 'combined oral  contraceptive pillexposure alone does not reduce the risk of '\n",
      " 'bacterial  vaginosis recurrence in a pilot randomised controlled trial sci '\n",
      " 'rep  201993555 pmid30837554 httpsdoiorg101038 s41598019398798  984 brooks jp '\n",
      " 'edwards dj blithe dl et al effects of combined oral  contraceptives depot '\n",
      " 'medroxyprogesterone acetate and the  levonorgestrelreleasing intrauterine '\n",
      " 'system on the vaginal microbiome  contraception 201795405–13 pmid27913230 '\n",
      " 'httpsdoi org101016jcontraception201611006  985 moore kr harmon qe baird dd '\n",
      " 'serum 25hydroxyvitamin d and  risk of selfreported bacterial vaginosis in a '\n",
      " 'prospective cohort study  of young african american women j womens health '\n",
      " 'larchmt  2018271278–84 pmid29897832 httpsdoiorg101089 jwh20176804  986 '\n",
      " 'lokken em balkus je kiarie j et al association of recent bacterial  '\n",
      " 'vaginosis with acquisition of mycoplasma genitalium am j epidemiol  '\n",
      " '2017186194–201 pmid28472225 httpsdoiorg101093aje kwx043  987 brusselaers n '\n",
      " 'shrestha s van de wijgert j verstraelen h vaginal  dysbiosis and the risk of '\n",
      " 'human papillomavirus and cervical cancer  systematic review and metaanalysis '\n",
      " 'am j obstet gynecol  20192219–18e8 pmid30550767 httpsdoiorg101016j '\n",
      " 'ajog201812011  988 abbai ns nyirenda m naidoo s ramjee g prevalent herpes '\n",
      " 'simplex  virus2 increases the risk of incident bacterial vaginosis in women  '\n",
      " 'from south africa aids behav 2018222172–80 pmid28956191  '\n",
      " 'httpsdoiorg101007s1046101719241  989 laxmi u agrawal s raghunandan c '\n",
      " 'randhawa vs saili a  association of bacterial vaginosis with adverse '\n",
      " 'fetomaternal outcome  in women with spontaneous preterm labor a prospective '\n",
      " 'cohort study  j matern fetal neonatal med 20122564–7 pmid21557693  '\n",
      " 'httpsdoiorg103109147670582011565390  990 cherpes tl wiesenfeld hc melan ma '\n",
      " 'et al the associations  between pelvic inflammatory disease trichomonas '\n",
      " 'vaginalis infection  and positive herpes simplex virus type 2 serology sex '\n",
      " 'transm dis  200633747–52 pmid16691155 httpsdoiorg10109701 '\n",
      " 'olq000021886952753c7  991 nelson db hanlon a hassan s et al preterm labor '\n",
      " 'and bacterial  vaginosisassociated bacteria among urban women j perinat med  '\n",
      " '200937130–4 pmid18999913 httpsdoiorg101515 jpm2009026  992 atashili j poole '\n",
      " 'c ndumbe pm adimora aa smith js bacterial  vaginosis and hiv acquisition a '\n",
      " 'metaanalysis of published studies  aids 2008221493–501 pmid18614873 '\n",
      " 'httpsdoiorg101097 qad0b013e3283021a37  993 gosmann c anahtar mn handley sa '\n",
      " 'et al lactobacillusdeficient  cervicovaginal bacterial communities are '\n",
      " 'associated with increased  hiv acquisition in young south african women '\n",
      " 'immunity  20174629–37 pmid28087240 httpsdoiorg101016j immuni201612013  994 '\n",
      " 'mcclelland rs lingappa jr srinivasan s et al evaluation of the  association '\n",
      " 'between the concentrations of key vaginal bacteria and  the increased risk '\n",
      " 'of hiv acquisition in african women from five  cohorts a nested casecontrol '\n",
      " 'study lancet infect dis 201818554– 6 4   p m i d  2 9 3 9 6 0 0 6  h t t p '\n",
      " 's    d o i  o r g  1 0  1 0 1 6  s1473309918300586  995 johnston c magaret a '\n",
      " 'srinivasan s et al p239 genital hsv2  suppression is not associated with '\n",
      " 'alterations in the vaginal  microbiome a oneway crossover study sex transm '\n",
      " 'infect  201995suppl 1a148  996 zozaya m ferris mj siren jd et al bacterial '\n",
      " 'communities in penile  skin male urethra and vaginas of heterosexual couples '\n",
      " 'with and  without bacterial vaginosis microbiome 2016416 pmid27090518  '\n",
      " 'httpsdoiorg101186s4016801601616  997 liu cm hungate ba tobian aa et al '\n",
      " 'penile microbiota and female  partner bacterial vaginosis in rakai uganda '\n",
      " 'mbio 20156e00589  pmid26081632 httpsdoiorg101128mbio0058915  998 mehta sd '\n",
      " 'systematic review of randomized trials of treatment of  male sexual partners '\n",
      " 'for improved bacteria vaginosis outcomes in  women sex transm dis '\n",
      " '201239822–30 pmid23007709 https doiorg101097olq0b013e3182631d89 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids16260520doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids16260520doptabstract '\n",
      " 'httpsdoiorg10109701aog000018359445524d2 '\n",
      " 'httpsdoiorg10109701aog000018359445524d2 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids21067371doptabstract '\n",
      " 'httpsdoiorg101086657320 httpsdoiorg101086657320 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30624309doptabstract '\n",
      " 'httpsdoiorg101097olq0000000000000972 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids27645157doptabstract '\n",
      " 'httpsdoiorg101136sextrans2016052652 httpsdoiorg101136sextrans2016052652 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids15592270doptabstract '\n",
      " 'httpsdoiorg101016jajog200406089 httpsdoiorg101016jajog200406089 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids11318257doptabstract '\n",
      " 'httpsdoiorg1010970000743520010400000010 '\n",
      " 'httpsdoiorg1010970000743520010400000010 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids31810995doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids31810995doptabstract '\n",
      " 'httpsdoiorg101136sextrans2019054191 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids26538552doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids26538552doptabstract '\n",
      " 'httpsdoiorg1011770956462415616038 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30766863doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30766863doptabstract '\n",
      " 'httpsdoiorg103389fpubh201900004 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids20419168doptabstract '\n",
      " 'httpsdoiorg101371journalpone0010197 httpsdoiorg101371journalpone0010197 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids22553250doptabstract '\n",
      " 'httpsdoiorg101126scitranslmed3003605 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids19863439doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids19863439doptabstract '\n",
      " 'httpsdoiorg101086648092 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29505773doptabstract '\n",
      " 'httpsdoiorg101016jajog201802017 httpsdoiorg101016jajog201802017 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30837554doptabstract '\n",
      " 'httpsdoiorg101038s41598019398798 httpsdoiorg101038s41598019398798 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids27913230doptabstract '\n",
      " 'httpsdoiorg101016jcontraception201611006 '\n",
      " 'httpsdoiorg101016jcontraception201611006 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29897832doptabstract '\n",
      " 'httpsdoiorg101089jwh20176804 httpsdoiorg101089jwh20176804 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28472225doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30550767doptabstract '\n",
      " 'httpsdoiorg101016jajog201812011 httpsdoiorg101016jajog201812011 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28956191doptabstract '\n",
      " 'httpsdoiorg101007s1046101719241 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids21557693doptabstract '\n",
      " 'httpsdoiorg103109147670582011565390 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids16691155doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids18999913doptabstract '\n",
      " 'httpsdoiorg101515jpm2009026 httpsdoiorg101515jpm2009026 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids18614873doptabstract '\n",
      " 'httpsdoiorg101097qad0b013e3283021a37 httpsdoiorg101097qad0b013e3283021a37 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28087240doptabstract '\n",
      " 'httpsdoiorg101016jimmuni201612013 httpsdoiorg101016jimmuni201612013 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29396006doptabstract '\n",
      " 'httpsdoiorg101016s1473309918300586 httpsdoiorg101016s1473309918300586 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids27090518doptabstract '\n",
      " 'httpsdoiorg101186s4016801601616 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids26081632doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids26081632doptabstract '\n",
      " 'httpsdoiorg101128mbio0058915 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids23007709doptabstract '\n",
      " 'httpsdoiorg101097olq0b013e3182631d89 httpsdoiorg101097olq0b013e3182631d89 '\n",
      " 'recommendations and reports mmwr  july 23 2021  vol 70  no 4 169us '\n",
      " 'department of health and human servicescenters for disease control and '\n",
      " 'prevention  999 amsel r totten pa spiegel ca chen kc eschenbach d holmes  kk '\n",
      " 'nonspecific vaginitis diagnostic criteria and microbial and  epidemiologic '\n",
      " 'associations  am j med 19837414–22  pmid6600371 '\n",
      " 'httpsdoiorg1010160002934383911129 1000 nugent rp krohn ma hillier sl '\n",
      " 'reliability of diagnosing bacterial  vaginosis is improved by a standardized '\n",
      " 'method of gram stain  interpretation j clin microbiol 199129297–301 '\n",
      " 'pmid1706728  httpsdoiorg101128jcm2922973011991 1001 schwebke jr hillier sl '\n",
      " 'sobel jd mcgregor ja sweet rl validity  of the vaginal gram stain for the '\n",
      " 'diagnosis of bacterial vaginosis  obstet gynecol 199688573–6 pmid8841221 '\n",
      " 'httpsdoi org1010160029784496002335 1002 coleman js gaydos ca molecular '\n",
      " 'diagnosis of bacterial vaginosis  an update j clin microbiol 201856e0034218 '\n",
      " 'pmid29769280  httpsdoiorg101128jcm0034218 1003 myziuk l romanowski b johnson '\n",
      " 'sc bvblue test for diagnosis of  bacterial vaginosis j clin microbiol '\n",
      " '2003411925–8 pmid12734228  httpsdoiorg101128jcm415192519282003 1004 bradshaw '\n",
      " 'cs morton an garland sm horvath lb kuzevska  i fairley ck evaluation of a '\n",
      " 'pointofcare test bvblue and  clinical and laboratory criteria for diagnosis '\n",
      " 'of bacterial vaginosis  j clin microbiol 2005431304–8 pmid15750100 httpsdoi '\n",
      " 'org101128jcm433130413082005 1005 west b morison l schim van der loeff m et '\n",
      " 'al evaluation  of a new rapid diagnostic kit femexam for bacterial '\n",
      " 'vaginosis  in patients with vaginal discharge syndrome in the gambia  sex '\n",
      " 'transm dis 200330483–9 pmid12782948 httpsdoi org1010970000743520030600000003 '\n",
      " '1006 fredricks dn fiedler tl thomas kk oakley bb marrazzo jm  targeted pcr '\n",
      " 'for detection of vaginal bacteria associated with bacterial  vaginosis j '\n",
      " 'clin microbiol 2007453270–6 pmid17687006  httpsdoiorg101128jcm0127207 1007 '\n",
      " 'gaydos ca beqaj s schwebke jr et al clinical validation of a  test for the '\n",
      " 'diagnosis of vaginitis obstet gynecol 2017130181–9  pmid28594779 '\n",
      " 'httpsdoiorg101097aog0000000000002090 1008 cartwright cp lembke bd '\n",
      " 'ramachandran k et al development  and validation of a semiquantitative '\n",
      " 'multitarget pcr assay for  diagnosis of bacterial vaginosis j clin microbiol '\n",
      " '2012502321–9  pmid22535982 httpsdoiorg101128jcm0050612 1009 hilbert dw smith '\n",
      " 'wl chadwick sg et al development and  validation of a highly accurate '\n",
      " 'quantitative realtime pcr assay for  diagnosis of bacterial vaginosis j clin '\n",
      " 'microbiol 2016541017–24  erratum in j clin microbiol 2016541930 '\n",
      " 'pmid26818677  httpsdoiorg101128jcm0310415 1010 schwebke jr desmond r a '\n",
      " 'randomized trial of metronidazole  in asymptomatic bacterial vaginosis to '\n",
      " 'prevent the acquisition of  sexually transmitted diseases am j obstet '\n",
      " 'gynecol 2007196517 e1–6 pmid17547876 httpsdoiorg101016jajog200702048 1011 '\n",
      " 'fjeld h raknes g is combining metronidazole and alcohol really  hazardous '\n",
      " 'norwegian tidsskr nor laegeforen 20141341661–3  pmid25223673 '\n",
      " 'httpsdoiorg104045tidsskr140081 1012 hillier sl nyirjesy p waldbaum as et al '\n",
      " 'secnidazole treatment  of bacterial vaginosis a randomized controlled trial '\n",
      " 'obstet gynecol  2017130379–86 pmid28697102 httpsdoiorg101097 '\n",
      " 'aog0000000000002135 1013 schwebke jr morgan fg jr koltun w nyirjesy p a '\n",
      " 'phase3  doubleblind placebocontrolled study of the effectiveness and safety  '\n",
      " 'of single oral doses of secnidazole 2 g for the treatment of women  with '\n",
      " 'bacterial vaginosis am j obstet gynecol 2017217678e1–9  erratum in am j '\n",
      " 'obstet gynecol 2018219110 pmid28867602  httpsdoiorg101016jajog201708017 1014 '\n",
      " 'chavoustie se gersten jk samuel mj schwebke jr a phase 3  multicenter '\n",
      " 'prospective openlabel study to evaluate the safety of  a single dose of '\n",
      " 'secnidazole 2 g for the treatment of women and  postmenarchal adolescent '\n",
      " 'girls with bacterial vaginosis j womens  health larchmt 201827492–7 '\n",
      " 'pmid29323627 httpsdoi org101089jwh20176500 1015 livengood ch 3rd ferris dg '\n",
      " 'wiesenfeld hc et al effectiveness of  two tinidazole regimens in treatment '\n",
      " 'of bacterial vaginosis a randomized  controlled trial obstet gynecol '\n",
      " '2007110302–9 pmid17666604  httpsdoiorg10109701aog0000275282605063d 1016 '\n",
      " 'sobel jd nyirjesy p brown w tinidazole therapy for metronidazole resistant '\n",
      " 'vaginal trichomoniasis clin infect dis 2001331341–6  pmid11565074 '\n",
      " 'httpsdoiorg101086323034 1017 chavoustie se jacobs m reisman ha et al '\n",
      " 'metronidazole vaginal  gel 13 in the treatment of bacterial vaginosis a '\n",
      " 'doseranging study  j low genit tract dis 201519129–34 pmid24983350 https '\n",
      " 'doiorg101097lgt0000000000000062 1018 schwebke jr marrazzo j beelen ap sobel '\n",
      " 'jd a phase 3  multicenter randomized doubleblind vehiclecontrolled study  '\n",
      " 'evaluating the safety and efficacy of metronidazole vaginal gel  13 in the '\n",
      " 'treatment of bacterial vaginosis sex transm dis  201542376–81 pmid26222750 '\n",
      " 'httpsdoiorg101097 olq0000000000000300 1019 faro s skokos ck clindesse '\n",
      " 'investigators group the efficacy and  safety of a single dose of clindesse '\n",
      " 'vaginal cream versus a sevendose  regimen of cleocin vaginal cream in '\n",
      " 'patients with bacterial vaginosis  infect dis obstet gynecol 200513155–60 '\n",
      " 'pmid16240515  httpsdoiorg10108010647440500148321 1020 marrazzo jm dombrowski '\n",
      " 'jc wierzbicki mr et al safety and  efficacy of a novel vaginal antiinfective '\n",
      " 'tol463 in the treatment  of bacterial vaginosis and vulvovaginal candidiasis '\n",
      " 'a randomized  singleblind phase 2 controlled trial clin infect dis '\n",
      " '201968803–9  pmid30184181 httpsdoiorg101093cidciy554 1021 antonio ma meyn la '\n",
      " 'murray pj busse b hillier sl  vaginal colonization by probiotic '\n",
      " 'lactobacillus crispatus ctv 05 is decreased by sexual activity and '\n",
      " 'endogenous lactobacilli  j infect dis 20091991506–13 pmid19331578 httpsdoi '\n",
      " 'org101086598686 1022 senok ac verstraelen h temmerman m botta ga probiotics  '\n",
      " 'for the treatment of bacterial vaginosis cochrane database  syst rev '\n",
      " '20094cd006289 pmid19821358 httpsdoi org10100214651858cd006289pub2 1023 abad '\n",
      " 'cl safdar n the role of lactobacillus probiotics in the  treatment or '\n",
      " 'prevention of urogenital infections—a systematic  review j chemother '\n",
      " '200921243–52 pmid19567343 https doiorg101179joc2009213243 1024 mastromarino '\n",
      " 'p macchia s meggiorini l et al effectiveness  of lactobacilluscontaining '\n",
      " 'vaginal tablets in the treatment  o f  symptomat ic  bac te r i a l  vag '\n",
      " 'inos i s   c l in  microb io l  infec t  20091567–74  pmid19046169 ht tps   '\n",
      " 'doi  org101111j14690691200802112x 1025 hemmerling a harrison w schroeder a '\n",
      " 'et al phase 2a study  assessing colonization efficiency safety and '\n",
      " 'acceptability of  lactobacillus crispatus ctv05 in women with bacterial '\n",
      " 'vaginosis  sex transm dis 201037745–50 pmid20644497 httpsdoi '\n",
      " 'org101097olq0b013e3181e50026 1026 bunge ke beigi rh meyn la hillier sl the '\n",
      " 'efficacy of retreatment  with the same medication for early treatment '\n",
      " 'failure of bacterial  vaginosis sex transm dis 200936711–3 pmid19652628 '\n",
      " 'https doiorg101097olq0b013e3181af6cfd 1027 aguin t akins ra sobel jd '\n",
      " 'highdose vaginal maintenance  metronidazole for recurrent bacterial '\n",
      " 'vaginosis a pilot study  sex transm dis 201441290–1 pmid24722380 httpsdoi '\n",
      " 'org101097olq0000000000000123 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids6600371doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids6600371doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids1706728doptabstract '\n",
      " 'httpsdoiorg101128jcm2922973011991 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids8841221doptabstract '\n",
      " 'httpsdoiorg1010160029784496002335 httpsdoiorg1010160029784496002335 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29769280doptabstract '\n",
      " 'httpsdoiorg101128jcm0034218 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids12734228doptabstract '\n",
      " 'httpsdoiorg101128jcm415192519282003 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids15750100doptabstract '\n",
      " 'httpsdoiorg101128jcm433130413082005 httpsdoiorg101128jcm433130413082005 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids12782948doptabstract '\n",
      " 'httpsdoiorg1010970000743520030600000003 '\n",
      " 'httpsdoiorg1010970000743520030600000003 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids17687006doptabstract '\n",
      " 'httpsdoiorg101128jcm0127207 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28594779doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28594779doptabstract '\n",
      " 'httpsdoiorg101097aog0000000000002090 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids22535982doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids22535982doptabstract '\n",
      " 'httpsdoiorg101128jcm0050612 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids26818677doptabstract '\n",
      " 'httpsdoiorg101128jcm0310415 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids17547876doptabstract '\n",
      " 'httpsdoiorg101016jajog200702048 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids25223673doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids25223673doptabstract '\n",
      " 'httpsdoiorg104045tidsskr140081 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28697102doptabstract '\n",
      " 'httpsdoiorg101097aog0000000000002135 httpsdoiorg101097aog0000000000002135 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28867602doptabstract '\n",
      " 'httpsdoiorg101016jajog201708017 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29323627doptabstract '\n",
      " 'httpsdoiorg101089jwh20176500 httpsdoiorg101089jwh20176500 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids17666604doptabstract '\n",
      " 'httpsdoiorg10109701aog0000275282605063d '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids11565074doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids11565074doptabstract '\n",
      " 'httpsdoiorg101086323034 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids24983350doptabstract '\n",
      " 'httpsdoiorg101097lgt0000000000000062 httpsdoiorg101097lgt0000000000000062 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids26222750doptabstract '\n",
      " 'httpsdoiorg101097olq0000000000000300 httpsdoiorg101097olq0000000000000300 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids16240515doptabstract '\n",
      " 'httpsdoiorg10108010647440500148321 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30184181doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30184181doptabstract '\n",
      " 'httpsdoiorg101093cidciy554 httpsdoiorg101086598686 httpsdoiorg101086598686 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids19821358doptabstract '\n",
      " 'httpsdoiorg10100214651858cd006289pub2 httpsdoiorg10100214651858cd006289pub2 '\n",
      " 'httpsdoiorg101179joc2009213243 httpsdoiorg101179joc2009213243 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids19046169doptabstract '\n",
      " 'httpsdoiorg101111j14690691200802112x httpsdoiorg101111j14690691200802112x '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids20644497doptabstract '\n",
      " 'httpsdoiorg101097olq0b013e3181e50026 httpsdoiorg101097olq0b013e3181e50026 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids19652628doptabstract '\n",
      " 'httpsdoiorg101097olq0b013e3181af6cfd httpsdoiorg101097olq0b013e3181af6cfd '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids24722380doptabstract '\n",
      " 'httpsdoiorg101097olq0000000000000123 httpsdoiorg101097olq0000000000000123 '\n",
      " 'recommendations and reports 170 mmwr  july 23 2021  vol 70  no 4 us '\n",
      " 'department of health and human servicescenters for disease control and '\n",
      " 'prevention 1028 sobel jd ferris d schwebke j et al suppressive antibacterial '\n",
      " 'therapy  with 075 metronidazole vaginal gel to prevent recurrent bacterial  '\n",
      " 'vaginosis am j obstet gynecol 20061941283–9 pmid16647911  '\n",
      " 'httpsdoiorg101016jajog200511041 1029 reichman o akins r sobel jd boric acid '\n",
      " 'addition to suppressive  antimicrobial therapy for recurrent bacterial '\n",
      " 'vaginosis sex transm  dis 200936732–4 pmid19704395 httpsdoiorg101097 '\n",
      " 'olq0b013e3181b08456 1030 mcclelland rs richardson ba hassan wm et al '\n",
      " 'improvement  of vaginal health for kenyan women at risk for acquisition of  '\n",
      " 'human immunodeficiency virus type 1 results of a randomized  trial j infect '\n",
      " 'dis 20081971361–8 pmid18444793 httpsdoi org101086587490 1031 schwebke j '\n",
      " 'carter b waldbaum a et al results of a phase 3  randomized doubleblind '\n",
      " 'placebocontrolled study to evaluate  the efficacy and safety of astodrimer '\n",
      " 'gel for prevention of recurrent  bacterial vaginosis am j obstet gynecol '\n",
      " '2019221672–3 https doiorg101016jajog201910087 1032 cohen cr wierzbicki mr '\n",
      " 'french al et al randomized trial of  lactinv to prevent recurrence of '\n",
      " 'bacterial vaginosis n engl j med  20203821906–15 pmid32402161 '\n",
      " 'httpsdoiorg101056 nejmoa1915254 1033 turner an carr reese p fields ks et al '\n",
      " 'a blinded randomized  controlled trial of highdose vitamin d supplementation '\n",
      " 'to reduce  recurrence of bacterial vaginosis am j obstet gynecol 2014211479 '\n",
      " 'e1–13 pmid24949544 httpsdoiorg101016jajog201406023 1034 plummer el vodstrcil '\n",
      " 'la danielewski ja et al combined oral  and topical antimicrobial therapy for '\n",
      " 'male partners of women with  bacterial vaginosis acceptability tolerability '\n",
      " 'and impact on the genital  microbiota of couples—a pilot study plos one '\n",
      " '201813e0190199  pmid29293559 httpsdoiorg101371journalpone0190199 1035 '\n",
      " 'schwebke jr lensing sy lee j et al treatment of male sexual  partners of '\n",
      " 'women with bacterial vaginosis bv a randomized  doubleblind '\n",
      " 'placebocontrolled trial clin infect dis 2020 epub  december 31 2020 pmid '\n",
      " '33383580 1036 koumans eh kendrick js  cdc bacteria l  vaginosis  working '\n",
      " 'group preventing adverse sequelae of bacterial  vaginosis a public health '\n",
      " 'program and research agenda sex  transm dis 200128292–7 pmid11354269 '\n",
      " 'httpsdoi org1010970000743520010500000011 1037 hauth jc goldenberg rl andrews '\n",
      " 'ww dubard mb copper  rl reduced incidence of preterm delivery with '\n",
      " 'metronidazole  and erythromycin in women with bacterial vaginosis n engl  j '\n",
      " 'med 19953331732–6 pmid7491136 httpsdoiorg101056 nejm199512283332603 1038 '\n",
      " 'morales wj schorr s albritton j effect of metronidazole in  patients with '\n",
      " 'preterm birth in preceding pregnancy and bacterial  vaginosis a '\n",
      " 'placebocontrolled doubleblind study am j obstet  gynecol 1994171345–9 '\n",
      " 'pmid8059811 httpsdoiorg101016 s0002937894700338 1039 yudin mh landers dv '\n",
      " 'meyn l hillier sl clinical and cervical  cytokine response to treatment with '\n",
      " 'oral or vaginal metronidazole  for bacterial vaginosis during pregnancy a '\n",
      " 'randomized trial obstet  gynecol 2003102527–34 pmid12962937 1040 ugwumadu a '\n",
      " 'reid f hay p manyonda i natural history of bacterial  vaginosis and '\n",
      " 'intermediate flora in pregnancy and effect of oral  clindamycin obstet '\n",
      " 'gynecol 2004104114–9 pmid15229009  httpsdoiorg10109701aog0000130068215664e '\n",
      " '1041 burtin p taddio a ariburnu o einarson tr koren g  safety of '\n",
      " 'metronidazole in pregnancy a metaanalysis am  j obstet gynecol 1995172525–9 '\n",
      " 'pmid7856680 httpsdoi org1010160002937895905677 1042 piper jm mitchel ef ray '\n",
      " 'wa prenatal use of metronidazole and  birth defects no association obstet '\n",
      " 'gynecol 199382348–52  pmid8355932 1043 sheehy o santos f ferreira e berard a '\n",
      " 'the use of metronidazole  during pregnancy a review of evidence curr drug '\n",
      " 'saf 201510170–9  pmid25986038 httpsdoiorg1021741574886310021505151 24548 '\n",
      " '1044 lamont rf nhanchang cl sobel jd workowski k conde agudelo a romero r '\n",
      " 'treatment of abnormal vaginal flora in early  pregnancy with clindamycin for '\n",
      " 'the prevention of spontaneous  preterm birth a systematic review and '\n",
      " 'metaanalysis am j obstet  gynecol 2011205177–90 pmid22071048 httpsdoi '\n",
      " 'org101016jajog201103047 1045 odendaal hj popov i schoeman j smith m grové d '\n",
      " 'preterm  labour—is bacterial vaginosis involved s afr med j 200292231–4  '\n",
      " 'pmid12040953 1046 carey jc klebanoff ma hauth jc et al national institute '\n",
      " 'of  child health and human development network of maternal fetal medicine '\n",
      " 'units metronidazole to prevent preterm delivery in  pregnant women with '\n",
      " 'asymptomatic bacterial vaginosis n engl j med  2000342534–40 pmid10684911 '\n",
      " 'httpsdoiorg101056 nejm200002243420802 1047 vermeulen gm bruinse hw '\n",
      " 'prophylactic administration  of clindamycin 2 vaginal cream to reduce the '\n",
      " 'incidence of  spontaneous preterm birth in women with an increased '\n",
      " 'recurrence  risk a randomised placebocontrolled doubleblind trial br j  '\n",
      " 'obstet gynaecol 1999106652–7 pmid10428520 httpsdoi '\n",
      " 'org101111j147105281999tb08363x 1048 mcdonald hm o’loughlin ja vigneswaran r '\n",
      " 'et al impact  of metronidazole therapy on preterm birth in women with  '\n",
      " 'bacterial vaginosis flora gardnerella vaginalis a randomised  placebo '\n",
      " 'controlled trial br j obstet gynaecol 19971041391–7  pmid9422018 '\n",
      " 'httpsdoiorg101111j147105281997 tb11009x 1049 ugwumadu a manyonda i reid f '\n",
      " 'hay p effect of early  oral clindamycin on late miscarriage and preterm '\n",
      " 'delivery in  asymptomatic women with abnormal vaginal flora and bacterial  '\n",
      " 'vaginosis a randomised controlled trial lancet 2003361983–8  pmid12660054 '\n",
      " 'httpsdoiorg101016s0140673603128231 1050 subtil d brabant g tilloy e et al '\n",
      " 'early clindamycin for bacterial  vaginosis in pregnancy premeva a '\n",
      " 'multicentre double blind randomised controlled trial lancet 20183922171–9  '\n",
      " 'pmid30322724 httpsdoiorg101016s0140673618316179 1051 erickson sh oppenheim '\n",
      " 'gl smith gh metronidazole in breast  milk obstet gynecol 19815748–50 '\n",
      " 'pmid7454176 1052 passmore cm mcelnay jc rainey ea d’arcy pf metronidazole  '\n",
      " 'excretion in human milk and its effect on the suckling neonate br  j clin '\n",
      " 'pharmacol 19882645–51 pmid3203060 httpsdoi org101111j136521251988tb03362x '\n",
      " '1053 united kingdom national health service medicines qa  metronidazole—is '\n",
      " 'it safe to use with breastfeeding internet  london england united kingdom '\n",
      " 'national health service uk  medicines information 2012 '\n",
      " 'httpsstudylibnetdoc7341270 metronidazoleinbreastfeedingmothers 1054 jamieson '\n",
      " 'dj duerr a klein rs et al longitudinal analysis of  bacterial vaginosis '\n",
      " 'findings from the hiv epidemiology research  study obstet gynecol '\n",
      " '200198656–63 pmid11576584 https doiorg1010970000625020011000000023 1055 '\n",
      " 'rowley j vander hoorn s korenromp e et al chlamydia  gonorrhoea '\n",
      " 'trichomoniasis and syphilis global prevalence  and incidence estimates 2016 '\n",
      " 'bull world health organ  201997548–562p pmid31384073 httpsdoiorg102471 '\n",
      " 'blt18228486 1056 hoots be peterman ta torrone ea weinstock h meites e bolan  '\n",
      " 'ga a trichy question should trichomonas vaginalis infection be  reportable '\n",
      " 'sex transm dis 201340113–6 pmid23321992 https '\n",
      " 'doiorg101097olq0b013e31827c08c3 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids16647911doptabstract '\n",
      " 'httpsdoiorg101016jajog200511041 httpsdoiorg101097olq0b013e3181b08456 '\n",
      " 'httpsdoiorg101097olq0b013e3181b08456 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids18444793doptabstract '\n",
      " 'httpsdoiorg101086587490 httpsdoiorg101086587490 '\n",
      " 'httpsdoiorg101016jajog201910087 httpsdoiorg101016jajog201910087 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids32402161doptabstract '\n",
      " 'httpsdoiorg101056nejmoa1915254 httpsdoiorg101056nejmoa1915254 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids24949544doptabstract '\n",
      " 'httpsdoiorg101016jajog201406023 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29293559doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29293559doptabstract '\n",
      " 'httpsdoiorg101371journalpone0190199 httpspubmedncbinlmnihgov33383580 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids11354269doptabstract '\n",
      " 'httpsdoiorg1010970000743520010500000011 '\n",
      " 'httpsdoiorg1010970000743520010500000011 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids7491136doptabstract '\n",
      " 'httpsdoiorg101056nejm199512283332603 httpsdoiorg101056nejm199512283332603 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids8059811doptabstract '\n",
      " 'httpsdoiorg101016s0002937894700338 httpsdoiorg101016s0002937894700338 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids12962937doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids15229009doptabstract '\n",
      " 'httpsdoiorg10109701aog0000130068215664e '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids7856680doptabstract '\n",
      " 'httpsdoiorg1010160002937895905677 httpsdoiorg1010160002937895905677 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids8355932doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids8355932doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids25986038doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids25986038doptabstract '\n",
      " 'httpsdoiorg102174157488631002150515124548 '\n",
      " 'httpsdoiorg102174157488631002150515124548 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids22071048doptabstract '\n",
      " 'httpsdoiorg101016jajog201103047 httpsdoiorg101016jajog201103047 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids12040953doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids12040953doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids10684911doptabstract '\n",
      " 'httpsdoiorg101056nejm200002243420802 httpsdoiorg101056nejm200002243420802 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids10428520doptabstract '\n",
      " 'httpsdoiorg101111j147105281999tb08363x '\n",
      " 'httpsdoiorg101111j147105281999tb08363x '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids9422018doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids9422018doptabstract '\n",
      " 'httpsdoiorg101111j147105281997tb11009x '\n",
      " 'httpsdoiorg101111j147105281997tb11009x '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids12660054doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids12660054doptabstract '\n",
      " 'httpsdoiorg101016s0140673603128231 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30322724doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30322724doptabstract '\n",
      " 'httpsdoiorg101016s0140673618316179 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids7454176doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids3203060doptabstract '\n",
      " 'httpsdoiorg101111j136521251988tb03362x '\n",
      " 'httpsdoiorg101111j136521251988tb03362x '\n",
      " 'httpsstudylibnetdoc7341270metronidazoleinbreastfeedingmothers '\n",
      " 'httpsstudylibnetdoc7341270metronidazoleinbreastfeedingmothers '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids11576584doptabstract '\n",
      " 'httpsdoiorg1010970000625020011000000023 '\n",
      " 'httpsdoiorg1010970000625020011000000023 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids31384073doptabstract '\n",
      " 'httpsdoiorg102471blt18228486 httpsdoiorg102471blt18228486 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids23321992doptabstract '\n",
      " 'recommendations and reports mmwr  july 23 2021  vol 70  no 4 171us '\n",
      " 'department of health and human servicescenters for disease control and '\n",
      " 'prevention 1057 flagg ew meites e phillips c papp j torrone ea prevalence  '\n",
      " 'of trichomonas vaginalis among civilian noninstitutionalized male  and '\n",
      " 'female population aged 14 to 59 years united states 2013 to  2016 sex transm '\n",
      " 'dis 201946e93–6 pmid31517807 httpsdoi org101097olq0000000000001013 1058 '\n",
      " 'daugherty m glynn k byler t prevalence of trichomonas vaginalis  infection '\n",
      " 'among us males 2013–2016 clin infect dis 201968460–5  pmid29893808 '\n",
      " 'httpsdoiorg101093cidciy499c 1059 alcaide ml feaster dj duan r et al the '\n",
      " 'incidence of trichomonas  vaginalis infection in women attending nine '\n",
      " 'sexually transmitted  diseases clinics in the usa sex transm infect '\n",
      " '20169258–62  pmid26071390 httpsdoiorg101136sextrans2015052010 1060 muzny ca '\n",
      " 'blackburn rj sinsky rj austin el schwebke jr  added benefit of nucleic acid '\n",
      " 'amplification testing for the diagnosis  of trichomonas vaginalis among men '\n",
      " 'and women attending a  sexually transmitted diseases clinic clin infect dis '\n",
      " '201459834–41  pmid24928292 httpsdoiorg101093cidciu446 1061 meites e llata e '\n",
      " 'braxton j et al trichomonas vaginalis in selected  us sexually transmitted '\n",
      " 'disease clinics testing screening and  prevalence sex transm dis 201340865–9 '\n",
      " 'pmid24113409  httpsdoiorg101097olq0000000000000038 1062 ginocchio cc chapin '\n",
      " 'k smith js et al prevalence of  trichomonas vaginalis and coinfection with '\n",
      " 'chlamydia trachomatis  and neisseria gonorrhoeae in the united states as '\n",
      " 'determined by  the aptima trichomonas vaginalis nucleic acid amplification '\n",
      " 'assay  j clin microbiol 2012502601–8 pmid22622447 httpsdoi '\n",
      " 'org101128jcm0074812 1063 shuter j bell d graham d holbrook ka bellin ey '\n",
      " 'rates of and  risk factors for trichomoniasis among pregnant inmates in new '\n",
      " 'york  city sex transm dis 199825303–7 pmid9662764 httpsdoi '\n",
      " 'org1010970000743519980700000006 1064 sosman jm macgowan rj margolis ad et al '\n",
      " 'project start  study group screening for sexually transmitted diseases and '\n",
      " 'hepatitis  in 18–29yearold men recently released from prison feasibility '\n",
      " 'and  acceptability int j std aids 200516117–22 pmid15825246  '\n",
      " 'httpsdoiorg1012580956462053057594 1065 rogers sm turner cf hobbs m et al '\n",
      " 'epidemiology of undiagnosed  trichomoniasis in a probability sample of urban '\n",
      " 'young adults plos  one 20149e90548 pmid24626058 httpsdoiorg101371 '\n",
      " 'journalpone0090548 1066 mayer kh bush t henry k et al sun investigators '\n",
      " 'ongoing  sexually transmitted disease acquisition and risktaking behavior  '\n",
      " 'among us hivinfected patients in primary care implications  for prevention '\n",
      " 'interventions sex transm dis 2012391–7  pmid22183836 '\n",
      " 'httpsdoiorg101097olq0b013e31823b1922 1067 seña ac miller wc hobbs mm et al '\n",
      " 'trichomonas vaginalis  infection in male sexual partners implications for '\n",
      " 'diagnosis treatment  and prevention clin infect dis 20074413–22 '\n",
      " 'pmid17143809  httpsdoiorg101086511144 1068 kelley cf rosenberg es o’hara bm '\n",
      " 'sanchez t del rio c  sullivan ps prevalence of urethral trichomonas '\n",
      " 'vaginalis in black and  white men who have sex with men sex transm dis '\n",
      " '201239739  pmid22902674 httpsdoiorg101097olq0b013e318264248b 1069 sutton m '\n",
      " 'sternberg m koumans eh mcquillan g berman s  markowitz l the prevalence of '\n",
      " 'trichomonas vaginalis infection  among reproductiveage women in the united '\n",
      " 'states 2001–2004  clin infect dis 2007451319–26 pmid17968828 httpsdoi '\n",
      " 'org101086522532 1070 peterman ta tian lh metcalf ca malotte ck paul sm  '\n",
      " 'douglas jm jr respect2 study group persistent undetected  trichomonas '\n",
      " 'vaginalis infections clin infect dis 200948259–60  pmid19113985 '\n",
      " 'httpsdoiorg101086595706 1071 wølnerhanssen p krieger jn stevens ce et al '\n",
      " 'clinical manifestations  of vaginal trichomoniasis jama 1989261571–6 '\n",
      " 'pmid2783346  httpsdoiorg101001jama198903420040109029 1072 gray rh kigozi g '\n",
      " 'serwadda d et al the effects of male  circumcision on female partners’ '\n",
      " 'genital tract symptoms and  vaginal infections in a randomized trial in '\n",
      " 'rakai uganda am j  obstet gynecol 200920042e1–7 pmid18976733 httpsdoi '\n",
      " 'org101016jajog200807069 1073 sobngwitambekou j taljaard d nieuwoudt m '\n",
      " 'lissouba p  puren a auvert b male circumcision and neisseria gonorrhoeae  '\n",
      " 'chlamydia trachomatis and trichomonas vaginalis observations  after a '\n",
      " 'randomised controlled trial for hiv prevention sex transm  infect '\n",
      " '200985116–20 pmid19074928 httpsdoiorg101136 sti2008032334 1074 tsai cs '\n",
      " 'shepherd be vermund sh does douching increase  risk for sexually transmitted '\n",
      " 'infections a prospective study in  highrisk adolescents am j obstet gynecol '\n",
      " '200920038e1–8  pmid18667177 httpsdoiorg101016jajog200806026 1075 silver bj '\n",
      " 'guy rj kaldor jm jamil ms rumbold ar trichomonas  vaginalis as a cause of '\n",
      " 'perinatal morbidity a systematic review and  metaanalysis sex transm dis '\n",
      " '201441369–76 pmid24825333  httpsdoiorg101097olq0000000000000134 1076 yang s '\n",
      " 'zhao w wang h wang y li j wu x trichomonas vaginalis  infectionassociated '\n",
      " 'risk of cervical cancer a metaanalysis eur j  obstet gynecol reprod biol '\n",
      " '2018228166–73 pmid29980111  httpsdoiorg101016jejogrb201806031 1077 najafi a '\n",
      " 'chaechi nosrati mr ghasemi e et al is there association  between trichomonas '\n",
      " 'vaginalis infection and prostate cancer  risk a systematic review and '\n",
      " 'metaanalysis microb pathog  2019137103752 pmid31539586 httpsdoiorg101016j '\n",
      " 'micpath2019103752 1078 wang cc mcclelland rs reilly m et al the effect of '\n",
      " 'treatment  of vaginal infections on shedding of human immunodeficiency '\n",
      " 'virus  type 1 j infect dis 20011831017–22 pmid11237825 https '\n",
      " 'doiorg101086319287 1079 kissinger p amedee a clark ra et al trichomonas '\n",
      " 'vaginalis treatment  reduces vaginal hiv1 shedding sex transm dis '\n",
      " '20093611–6  pmid19008776 httpsdoiorg101097olq0b013e318186decf 1080 minkoff h '\n",
      " 'grunebaum an schwarz rh et al risk factors  for prematurity and premature '\n",
      " 'rupture of membranes a  prospective study of the vaginal flora in pregnancy '\n",
      " 'am j  obstet gynecol 1984150965–72 pmid6391179 httpsdoi '\n",
      " 'org1010160002937884903922 1081 cotch mf pastorek jg 2nd nugent rp et al the '\n",
      " 'vaginal  infections and prematurity study group trichomonas vaginalis  '\n",
      " 'associated with low birth weight and preterm delivery sex  transm dis '\n",
      " '199724353–60 pmid9243743 httpsdoi org1010970000743519970700000008 1082 '\n",
      " 'moodley p wilkinson d connolly c moodley j sturm aw  trichomonas vaginalis '\n",
      " 'is associated with pelvic inflammatory disease in  women infected with human '\n",
      " 'immunodeficiency virus clin infect dis  200234519–22 pmid11797180 '\n",
      " 'httpsdoiorg101086338399 1083 francis sc kent ck klausner jd et al prevalence '\n",
      " 'of rectal  trichomonas vaginalis and mycoplasma genitalium in male patients  '\n",
      " 'at the san francisco std clinic 2005–2006 sex transm dis  200835797–800 '\n",
      " 'pmid18607317 httpsdoiorg101097 olq0b013e318177ec39 1084 hollman d coupey sm '\n",
      " 'fox as herold bc screening for  trichomonas vaginalis in highrisk adolescent '\n",
      " 'females with a new  transcriptionmediated nucleic acid amplification test '\n",
      " 'naat  associations with ethnicity symptoms and prior and current stis  j '\n",
      " 'pediatr adolesc gynecol 201023312–6 pmid20493735 https '\n",
      " 'doiorg101016jjpag201003004 1085 roth am williams ja ly r et al changing '\n",
      " 'sexually transmitted  infection screening protocol will result in improved '\n",
      " 'case finding  for trichomonas vaginalis among highrisk female populations  '\n",
      " 'sex transm dis 201138398–400 pmid21217417 httpsdoi '\n",
      " 'org101097olq0b013e318203e3ce '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids31517807doptabstract '\n",
      " 'httpsdoiorg101097olq0000000000001013 httpsdoiorg101097olq0000000000001013 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29893808doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29893808doptabstract '\n",
      " 'httpsdoiorg101093cidciy499 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids26071390doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids26071390doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids24928292doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids24928292doptabstract '\n",
      " 'httpsdoiorg101093cidciu446 httpsdoiorg101097olq0000000000000038 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids22622447doptabstract '\n",
      " 'httpsdoiorg101128jcm0074812 httpsdoiorg101128jcm0074812 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids9662764doptabstract '\n",
      " 'httpsdoiorg1010970000743519980700000006 '\n",
      " 'httpsdoiorg1010970000743519980700000006 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids15825246doptabstract '\n",
      " 'httpsdoiorg1012580956462053057594 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids24626058doptabstract '\n",
      " 'httpsdoiorg101371journalpone0090548 httpsdoiorg101371journalpone0090548 '\n",
      " 'httpsdoiorg101097olq0b013e31823b1922 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids17143809doptabstract '\n",
      " 'httpsdoiorg101086511144 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids22902674doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids22902674doptabstract '\n",
      " 'httpsdoiorg101097olq0b013e318264248b '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids17968828doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids19113985doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids19113985doptabstract '\n",
      " 'httpsdoiorg101086595706 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids2783346doptabstract '\n",
      " 'httpsdoiorg101001jama198903420040109029 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids18976733doptabstract '\n",
      " 'httpsdoiorg101016jajog200807069 httpsdoiorg101016jajog200807069 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids19074928doptabstract '\n",
      " 'httpsdoiorg101136sti2008032334 httpsdoiorg101136sti2008032334 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids18667177doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids18667177doptabstract '\n",
      " 'httpsdoiorg101016jajog200806026 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids24825333doptabstract '\n",
      " 'httpsdoiorg101097olq0000000000000134 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29980111doptabstract '\n",
      " 'httpsdoiorg101016jejogrb201806031 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids31539586doptabstract '\n",
      " 'httpsdoiorg101016jmicpath2019103752 httpsdoiorg101016jmicpath2019103752 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids11237825doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids19008776doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids19008776doptabstract '\n",
      " 'httpsdoiorg101097olq0b013e318186decf '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids6391179doptabstract '\n",
      " 'httpsdoiorg1010160002937884903922 httpsdoiorg1010160002937884903922 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids9243743doptabstract '\n",
      " 'httpsdoiorg1010970000743519970700000008 '\n",
      " 'httpsdoiorg1010970000743519970700000008 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids11797180doptabstract '\n",
      " 'httpsdoiorg101086338399 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids18607317doptabstract '\n",
      " 'httpsdoiorg101097olq0b013e318177ec39 httpsdoiorg101097olq0b013e318177ec39 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids20493735doptabstract '\n",
      " 'httpsdoiorg101016jjpag201003004 httpsdoiorg101016jjpag201003004 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids21217417doptabstract '\n",
      " 'httpsdoiorg101097olq0b013e318203e3ce httpsdoiorg101097olq0b013e318203e3ce '\n",
      " 'recommendations and reports 172 mmwr  july 23 2021  vol 70  no 4 us '\n",
      " 'department of health and human servicescenters for disease control and '\n",
      " 'prevention 1086 hobbs mm seña ac modern diagnosis of trichomonas vaginalis  '\n",
      " 'infection sex transm infect 201389434–8 pmid23633669  '\n",
      " 'httpsdoiorg101136sextrans2013051057 1087 kingston ma bansal d carlin em '\n",
      " '‘shelf life’ of trichomonas  vaginalis int j std aids 20031428–9 '\n",
      " 'pmid12590789 https doiorg101258095646203321043228 1088 schwebke jr hobbs mm '\n",
      " 'taylor sn et al molecular testing for  trichomonas vaginalis in women '\n",
      " 'results from a prospective us  clinical trial j clin microbiol 2011494106–11 '\n",
      " 'pmid21940475  httpsdoiorg101128jcm0129111 1089 huppert js mortensen je reed '\n",
      " 'jl et al rapid antigen testing  compares favorably with '\n",
      " 'transcriptionmediated amplification  assay for the detection of trichomonas '\n",
      " 'vaginalis in young women  clin infect dis 200745194–8 pmid17578778 httpsdoi '\n",
      " 'org101086518851 1090 van der pol b williams ja taylor sn et al detection of '\n",
      " 'trichomonas  vaginalis dna by use of selfobtained vaginal swabs with the bd  '\n",
      " 'probetec qx assay on the bd viper system j clin microbiol  201452885–9 '\n",
      " 'pmid24391200 httpsdoiorg101128 jcm0296613 1091 van der pol b williams ja '\n",
      " 'fuller d taylor sn hook ew 3rd  combined testing for chlamydia gonorrhea and '\n",
      " 'trichomonas by  use of the bd max ctgctv assay with genitourinary specimen  '\n",
      " 'types j clin microbiol 201655155–64 pmid27795343 https '\n",
      " 'doiorg101128jcm0176616 1092 schwebke jr gaydos ca davis t et al clinical '\n",
      " 'evaluation of the  cepheid xpert tv assay for detection of trichomonas '\n",
      " 'vaginalis with  prospectively collected specimens from men and women j clin  '\n",
      " 'microbiol 201856e0109117 pmid29167292 httpsdoi org101128jcm0109117 1093 '\n",
      " 'campbell l woods v lloyd t elsayed s church dl evaluation  of the osom '\n",
      " 'trichomonas rapid test versus wet preparation  examination for detection of '\n",
      " 'trichomonas vaginalis vaginitis  in specimens from women with a low '\n",
      " 'prevalence of infection  j clin microbiol 2008463467–9 pmid18685008 httpsdoi '\n",
      " 'org101128jcm0067108 1094 huppert js hesse e kim g et al adolescent women can '\n",
      " 'perform  a pointofcare test for trichomoniasis as accurately as clinicians  '\n",
      " 'sex transm infect 201086514–9 pmid20595142 httpsdoi org101136sti2009042168 '\n",
      " '1095 sheele jm crandall cj arko bl et al the osom® trichomonas  test is '\n",
      " 'unable to accurately diagnose trichomonas vaginalis from urine  in men am j '\n",
      " 'emerg med 2019371002–3 pmid30361151 https doiorg101016jajem201810022 1096 '\n",
      " 'gaydos ca schwebke j dombrowski j et al clinical performance  of the solana® '\n",
      " 'pointofcare trichomonas assay from clinician collected vaginal swabs and '\n",
      " 'urine specimens from symptomatic  and asymptomatic women expert rev mol '\n",
      " 'diagn 201717303–6  pmid28092466 httpsdoiorg1010801473715920171282823 1097 '\n",
      " 'gaydos ca hobbs m marrazzo j et al rapid diagnosis of trichomonas  vaginalis '\n",
      " 'by testing vaginal swabs in an isothermal helicasedependent  amplivue assay '\n",
      " 'sex transm dis 201643369–73 pmid27196258  '\n",
      " 'httpsdoiorg101097olq0000000000000447 1098 patil mj nagamoti jm metgud sc '\n",
      " 'diagnosis of trichomonas  vaginalis from vaginal specimens by wet mount '\n",
      " 'microscopy in  pouch tv culture system and pcr j glob infect dis 2012422–5  '\n",
      " 'pmid22529623 httpsdoiorg1041030974777x93756 1099 lawing lf hedges sr '\n",
      " 'schwebke jr detection of trichomonosis  in vaginal and urine specimens from '\n",
      " 'women by culture and pcr  j clin microbiol 2000383585–8 pmid11015368 '\n",
      " 'httpsdoi org101128jcm3810358535882000 1100 mohamed oa cohen cr kungu d et al '\n",
      " 'urine proves a poor  specimen for culture of trichomonas vaginalis in women '\n",
      " 'sex transm  infect 20017778–9 pmid11158705 httpsdoiorg101136 sti77178 1101 '\n",
      " 'rivers ca muzny ca schwebke jr diagnostic rates differ on  the basis of the '\n",
      " 'number of read days with the use of the inpouch  culture system for '\n",
      " 'trichomonas vaginalis screening j clin microbiol  2013513875–6 pmid24006006 '\n",
      " 'httpsdoiorg101128 jcm0200613 1103 audisio t pigini t de riutort sv et al '\n",
      " 'validity of the papanicolaou  smear in the diagnosis of candida spp '\n",
      " 'trichomonas vaginalis  and bacterial vaginosis j low genit tract dis '\n",
      " '20015223–5  pmid17050980 1104 loo sk tang wy lo kk clinical significance of '\n",
      " 'trichomonas  vaginalis detected in papanicolaou smear a survey in female '\n",
      " 'social  hygiene clinic hong kong med j 20091590–3 pmid19342733 1105 howe k '\n",
      " 'kissinger pj singledose compared with multidose  metronidazole for the '\n",
      " 'treatment of trichomoniasis in women a meta analysis sex transm dis '\n",
      " '20174429–34 pmid27898571 https doiorg101097olq0000000000000537 1105 '\n",
      " 'kissinger p mena l levison j et al a randomized treatment  trial single '\n",
      " 'versus 7day dose of metronidazole for the treatment  of trichomonas '\n",
      " 'vaginalis among hivinfected women j acquir  immune defic syndr 201055565–71 '\n",
      " 'pmid21423852 https doiorg101097qai0b013e3181eda955 1106 wood ba monro am '\n",
      " 'pharmacokinetics of tinidazole and  metronidazole in women after single '\n",
      " 'large oral doses br j vener dis  19755151–3 pmid1092424 '\n",
      " 'httpsdoiorg101136sti51151 1107 viitanen j haataja h männistö pt '\n",
      " 'concentrations of metronidazole  and tinidazole in male genital tissues '\n",
      " 'antimicrob agents chemother  198528812–4 pmid4083864 httpsdoiorg101128 '\n",
      " 'aac286812 1108 gabriel g robertson e thin rn single dose treatment of  '\n",
      " 'trichomoniasis j int med res 198210129–30 pmid7067925  '\n",
      " 'httpsdoiorg101177030006058201000212 1109 mati jk wallace rj the treatment of '\n",
      " 'trichomonal vaginitis using a  single dose of tinidazole by mouth east afr '\n",
      " 'med j 197451883–8  pmid4616829 1110 anjaeyulu r gupte sa desai db singledose '\n",
      " 'treatment of  trichomonal vaginitis a comparison of tinidazole and '\n",
      " 'metronidazole  j int med res 19775438–41 pmid590601 1111 apte vv packard rs '\n",
      " 'tinidazole in the treatment of trichomoniasis  giardiasis and amoebiasis '\n",
      " 'report of a multicentre study  drugs 197815suppl 143–8 pmid657995 httpsdoi '\n",
      " 'org1021650000349519780015100009 1112 oprasertsawat p jetsawangsri t '\n",
      " 'splitdose metronidazole or  singledose tinidazole for the treatment of '\n",
      " 'vaginal trichomoniasis  sex transm dis 199219295–7 pmid1411848 httpsdoi '\n",
      " 'org1010970000743519920900000011 1113 kawamura n metronidazole and tinidazole '\n",
      " 'in a single large dose for  treating urogenital infections with trichomonas '\n",
      " 'vaginalis in men br  j vener dis 19785481–3 pmid305809 httpsdoiorg101136 '\n",
      " 'sti54281 1114 forna f gülmezoglu am interventions for treating '\n",
      " 'trichomoniasis  in women cochrane database syst rev 20032cd000218  '\n",
      " 'pmid12804391 1115 cuuvin s ko h jamieson dj et al hiv epidemiology research  '\n",
      " 'study hers group prevalence incidence and persistence or  recurrence of '\n",
      " 'trichomoniasis among human immunodeficiency  virus hivpositive women and '\n",
      " 'among hivnegative women at  high risk for hiv infection clin infect dis '\n",
      " '2002341406–11  pmid11981738 httpsdoiorg101086340264 1116 schwebke jr '\n",
      " 'barrientes fj prevalence of trichomonas vaginalis  isolates with resistance '\n",
      " 'to metronidazole and tinidazole antimicrob  agents chemother 2006504209–10 '\n",
      " 'pmid17000740 httpsdoi org101128aac0081406 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids23633669doptabstract '\n",
      " 'httpsdoiorg101136sextrans2013051057 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids12590789doptabstract '\n",
      " 'httpsdoiorg101258095646203321043228 httpsdoiorg101258095646203321043228 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids21940475doptabstract '\n",
      " 'httpsdoiorg101128jcm0129111 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids17578778doptabstract '\n",
      " 'httpsdoiorg101086518851 httpsdoiorg101086518851 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids24391200doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids27795343doptabstract '\n",
      " 'httpsdoiorg101128jcm0176616 httpsdoiorg101128jcm0176616 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29167292doptabstract '\n",
      " 'httpsdoiorg101128jcm0109117 httpsdoiorg101128jcm0109117 '\n",
      " 'httpsdoiorg101128jcm0067108 httpsdoiorg101128jcm0067108 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids20595142doptabstract '\n",
      " 'httpsdoiorg101136sti2009042168 httpsdoiorg101136sti2009042168 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30361151doptabstract '\n",
      " 'httpsdoiorg101016jajem201810022 httpsdoiorg101016jajem201810022 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28092466doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28092466doptabstract '\n",
      " 'httpsdoiorg1010801473715920171282823 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids27196258doptabstract '\n",
      " 'httpsdoiorg101097olq0000000000000447 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids22529623doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids22529623doptabstract '\n",
      " 'httpsdoiorg1041030974777x93756 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids11015368doptabstract '\n",
      " 'httpsdoiorg101128jcm3810358535882000 httpsdoiorg101128jcm3810358535882000 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids11158705doptabstract '\n",
      " 'httpsdoiorg101136sti77178 httpsdoiorg101136sti77178 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids24006006doptabstract '\n",
      " 'httpsdoiorg101128jcm0200613 httpsdoiorg101128jcm0200613 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids17050980doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids17050980doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids19342733doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids27898571doptabstract '\n",
      " 'httpsdoiorg101097olq0000000000000537 httpsdoiorg101097olq0000000000000537 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids21423852doptabstract '\n",
      " 'httpsdoiorg101097qai0b013e3181eda955 httpsdoiorg101097qai0b013e3181eda955 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids1092424doptabstract '\n",
      " 'httpsdoiorg101136sti51151 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids4083864doptabstract '\n",
      " 'httpsdoiorg101128aac286812 httpsdoiorg101128aac286812 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids7067925doptabstract '\n",
      " 'httpsdoiorg101177030006058201000212 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids4616829doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids4616829doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids657995doptabstract '\n",
      " 'httpsdoiorg1021650000349519780015100009 '\n",
      " 'httpsdoiorg1021650000349519780015100009 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids1411848doptabstract '\n",
      " 'httpsdoiorg1010970000743519920900000011 '\n",
      " 'httpsdoiorg1010970000743519920900000011 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids305809doptabstract '\n",
      " 'httpsdoiorg101136sti54281 httpsdoiorg101136sti54281 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids12804391doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids12804391doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids11981738doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids11981738doptabstract '\n",
      " 'httpsdoiorg101086340264 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids17000740doptabstract '\n",
      " 'httpsdoiorg101128aac0081406 httpsdoiorg101128aac0081406 recommendations and '\n",
      " 'reports mmwr  july 23 2021  vol 70  no 4 173us department of health and '\n",
      " 'human servicescenters for disease control and prevention 1117 van der pol b '\n",
      " 'williams ja orr dp batteiger be fortenberry  jd prevalence incidence natural '\n",
      " 'history and response to  treatment of trichomonas vaginalis infection among '\n",
      " 'adolescent  women j infect dis 20051922039–44 pmid16288365 https '\n",
      " 'doiorg101086498217 1118 kirkcaldy rd augostini p asbel le et al trichomonas '\n",
      " 'vaginalis  antimicrobial drug resistance in 6 us cities std surveillance  '\n",
      " 'network 2009–2010 emerg infect dis 201218939–43  pmid22608054 '\n",
      " 'httpsdoiorg103201eid1806111590 1119 crowell al sanderslewis ka secor we in '\n",
      " 'vitro metronidazole  and tinidazole activities against '\n",
      " 'metronidazoleresistant strains  of trichomonas vaginalis antimicrob agents '\n",
      " 'chemother  2003471407–9 pmid12654679 httpsdoiorg101128 aac474140714092003 '\n",
      " '1120 muzny ca mena l lillis ra et al a comparison of 2 g singledose  versus '\n",
      " '7day 500 mg twice daily metronidazole for the treatment  trichomoniasis in '\n",
      " 'women by selected clinical factors am j obstet  gynecol 2019221669 '\n",
      " 'httpsdoiorg101016jajog201910079 1121 sobel jd nyirjesy p brown w tinidazole '\n",
      " 'therapy for metronidazole resistant vaginal trichomoniasis clin infect dis '\n",
      " '2001331341–6  pmid11565074 httpsdoiorg101086323034 1122 nyirjesy p gilbert j '\n",
      " 'mulcahy lj resistant trichomoniasis successful  treatment with combination '\n",
      " 'therapy sex transm dis 201138962–3  pmid21934573 '\n",
      " 'httpsdoiorg101097olq0b013e31822037e4 1123 muzny c barnes a mena l '\n",
      " 'symptomatic trichomonas  vaginalis infection in the setting of severe '\n",
      " 'nitroimidazole allergy  successful treatment with boric acid sex health '\n",
      " '20129389–91  pmid22877600 httpsdoiorg101071sh11114 1124 aggarwal a shier rm '\n",
      " 'recalcitrant trichomonas vaginalis infections  successfully treated with '\n",
      " 'vaginal acidification j obstet gynaecol  can 20083055–8 pmid18198069 '\n",
      " 'httpsdoiorg101016 s1701216316327141 1125 dan m sobel jd failure of '\n",
      " 'nitazoxanide to cure trichomoniasis in  three women sex transm dis '\n",
      " '200734813–4 pmid17551415  httpsdoiorg101097nmd0b013e31802f5d9a 1126 seña ac '\n",
      " 'bachmann lh hobbs mm persistent and recurrent  trichomonas vaginalis '\n",
      " 'infections epidemiology treatment and  management considerations expert rev '\n",
      " 'anti infect ther  201412673–85 pmid24555561 httpsdoiorg1015861478 '\n",
      " '72102014887440 1127 helms dj mosure dj secor we workowski ka management  of '\n",
      " 'trichomonas vaginalis in women with suspected metronidazole  '\n",
      " 'hypersensitivity am j obstet gynecol 2008198370e1–7  pmid18221927 '\n",
      " 'httpsdoiorg101016jajog200710795 1128 gendelman sr pien lc gutta rc '\n",
      " 'abouhassan sr modified oral  metronidazole desensitization protocol allergy '\n",
      " 'rhinol providence  2014566–9 pmid24612959 httpsdoiorg102500 ar201450080 1129 '\n",
      " 'nyirjesy p sobel jd weitz mv leaman dj gelone sp difficultto treat '\n",
      " 'trichomoniasis results with paromomycin cream clin infect dis  199826986–8 '\n",
      " 'pmid9564487 httpsdoiorg101086513951 1130 klebanoff ma carey jc hauth jc et '\n",
      " 'al national institute of  child health and human development network of '\n",
      " 'maternalfetal  medicine units failure of metronidazole to prevent preterm '\n",
      " 'delivery  among pregnant women with asymptomatic trichomonas vaginalis  '\n",
      " 'infection n engl j med 2001345487–93 pmid11519502 https '\n",
      " 'doiorg101056nejmoa003329 1131 stringer e read js hoffman i valentine m aboud '\n",
      " 's goldenberg  rl treatment of trichomoniasis in pregnancy in subsaharan '\n",
      " 'africa  does not appear to be associated with low birth weight or preterm  '\n",
      " 'birth s afr med j 201010058–64 pmid20429491 1132 caropatón t carvajal a '\n",
      " 'martin de diego i martinarias  lh alvarez requejo a rodríguez pinilla e is '\n",
      " 'metronidazole  teratogenic a metaanalysis br j clin pharmacol 199744179–82  '\n",
      " 'pmid9278206 httpsdoiorg101046j13652125199700660x 1133 gülmezoglu am '\n",
      " 'interventions for trichomoniasis in pregnancy  cochrane database syst rev '\n",
      " '20023cd000220 pmid12137609 1134 goldenberg rl mwatha a read js et al hptn024 '\n",
      " 'team  the hptn 024 study the efficacy of antibiotics to prevent  '\n",
      " 'chorioamnionitis and preterm birth am j obstet gynecol  2006194650–61 '\n",
      " 'pmid16522393 httpsdoiorg101016j ajog200601004 1135 mann jr mcdermott s zhou '\n",
      " 'l barnes tl hardin j treatment  of trichomoniasis in pregnancy and preterm '\n",
      " 'birth an observational  study j womens health larchmt 200918493–7 '\n",
      " 'pmid19361316  httpsdoiorg101089jwh20080964 1136 carter je whithaus kc '\n",
      " 'neonatal respiratory tract involvement  by trichomonas vaginalis a case '\n",
      " 'report and review of the literature  am j trop med hyg 20087817–9 '\n",
      " 'pmid18187779 httpsdoi org104269ajtmh20087817 1137 trintis j epie n boss r '\n",
      " 'riedel s neonatal trichomonas vaginalis  infection a case report and review '\n",
      " 'of literature int j std aids  201021606–7 pmid20975098 httpsdoiorg101258 '\n",
      " 'ijsa2010010174 1138 miller m liao y wagner m korves c hiv the clustering of '\n",
      " 'sexually  transmitted infections and sex risk among african american women  '\n",
      " 'who use drugs sex transm dis 200835696–702 pmid18418289  '\n",
      " 'httpsdoiorg101097olq0b013e31816b1fb8 1139 anderson bl firnhaber c liu t et '\n",
      " 'al effect of trichomoniasis  therapy on genital hiv viral burden among '\n",
      " 'african women  sex transm dis 201239638–42 pmid22797689 httpsdoi '\n",
      " 'org101097olq0b013e31825725ad 1140 masese ln graham sm gitau r et al a '\n",
      " 'prospective study of vaginal  trichomoniasis and hiv1 shedding in women on '\n",
      " 'antiretroviral  therapy bmc infect dis 201111307 pmid22047086 https '\n",
      " 'doiorg1011861471233411307 1141 balkus je richardson ba mochache v et al a '\n",
      " 'prospective  cohort study comparing the effect of singledose 2 g '\n",
      " 'metronidazole  on trichomonas vaginalis infection in hivseropositive versus  '\n",
      " 'hivseronegative women sex transm dis 201340499–505  pmid23677023 '\n",
      " 'httpsdoiorg101097olq0b013e31828fce34 1142 gumbo fz duri k kandawasvika gq et '\n",
      " 'al risk factors of hiv  vertical transmission in a cohort of women under a '\n",
      " 'pmtct program  at three periurban clinics in a resourcepoor setting j '\n",
      " 'perinatol  201030717–23 pmid20336078 httpsdoiorg101038 jp201031 1143 '\n",
      " 'brüggemann rj alffenaar jw blijlevens nm et al clinical relevance  of the '\n",
      " 'pharmacokinetic interactions of azole antifungal drugs with  other '\n",
      " 'coadministered agents clin infect dis 2009481441–58  pmid19361301 '\n",
      " 'httpsdoiorg101086598327 1144 shahid z sobel jd reduced fluconazole '\n",
      " 'susceptibility of candida  albicans isolates in women with recurrent '\n",
      " 'vulvovaginal candidiasis  effects of longterm fluconazole therapy diagn '\n",
      " 'microbiol infect  dis 200964354–6 pmid19501794 httpsdoiorg101016j '\n",
      " 'diagmicrobio200903021 1145 marchaim d lemanek l bheemreddy s kaye ks sobel '\n",
      " 'jd  fluconazoleresistant candida albicans vulvovaginitis obstet gynecol  '\n",
      " '20121201407–14 pmid23168767 httpsdoiorg101097 aog0b013e31827307b2 1146 '\n",
      " 'denning dw kneale m sobel jd rautemaarichardson r global  burden of '\n",
      " 'recurrent vulvovaginal candidiasis a systematic review  lancet infect dis '\n",
      " '201818e339–47 pmid30078662 httpsdoi org101016s1473309918301038 1147 crouss t '\n",
      " 'sobel jd smith k nyirjesy p longterm outcomes  of women with recurrent '\n",
      " 'vulvovaginal candidiasis after a course  of maintenance antifungal therapy j '\n",
      " 'low genit tract dis  201822382–6 pmid29975334 httpsdoiorg101097 '\n",
      " 'lgt0000000000000413 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids16288365doptabstract '\n",
      " 'httpsdoiorg101086498217 httpsdoiorg101086498217 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids22608054doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids22608054doptabstract '\n",
      " 'httpsdoiorg103201eid1806111590 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids12654679doptabstract '\n",
      " 'httpsdoiorg101128aac474140714092003 httpsdoiorg101128aac474140714092003 '\n",
      " 'httpsdoiorg101016jajog201910079 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids11565074doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids11565074doptabstract '\n",
      " 'httpsdoiorg101086323034 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids21934573doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids21934573doptabstract '\n",
      " 'httpsdoiorg101097olq0b013e31822037e4 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids22877600doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids22877600doptabstract '\n",
      " 'httpsdoiorg101071sh11114 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids18198069doptabstract '\n",
      " 'httpsdoiorg101016s1701216316327141 httpsdoiorg101016s1701216316327141 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids17551415doptabstract '\n",
      " 'httpsdoiorg101097nmd0b013e31802f5d9a '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids24555561doptabstract '\n",
      " 'httpsdoiorg101586147872102014887440 httpsdoiorg101586147872102014887440 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids18221927doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids18221927doptabstract '\n",
      " 'httpsdoiorg101016jajog200710795 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids24612959doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids9564487doptabstract '\n",
      " 'httpsdoiorg101086513951 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids11519502doptabstract '\n",
      " 'httpsdoiorg101056nejmoa003329 httpsdoiorg101056nejmoa003329 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids20429491doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids9278206doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids9278206doptabstract '\n",
      " 'httpsdoiorg101046j13652125199700660x '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids12137609doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids16522393doptabstract '\n",
      " 'httpsdoiorg101016jajog200601004 httpsdoiorg101016jajog200601004 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids19361316doptabstract '\n",
      " 'httpsdoiorg101089jwh20080964 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids18187779doptabstract '\n",
      " 'httpsdoiorg104269ajtmh20087817 httpsdoiorg104269ajtmh20087817 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids20975098doptabstract '\n",
      " 'httpsdoiorg101258ijsa2010010174 httpsdoiorg101258ijsa2010010174 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids18418289doptabstract '\n",
      " 'httpsdoiorg101097olq0b013e31816b1fb8 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids22797689doptabstract '\n",
      " 'httpsdoiorg101097olq0b013e31825725ad httpsdoiorg101097olq0b013e31825725ad '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids22047086doptabstract '\n",
      " 'httpsdoiorg1011861471233411307 httpsdoiorg1011861471233411307 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids23677023doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids23677023doptabstract '\n",
      " 'httpsdoiorg101097olq0b013e31828fce34 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids20336078doptabstract '\n",
      " 'httpsdoiorg101038jp201031 httpsdoiorg101038jp201031 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids19361301doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids19361301doptabstract '\n",
      " 'httpsdoiorg101086598327 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids19501794doptabstract '\n",
      " 'httpsdoiorg101016jdiagmicrobio200903021 '\n",
      " 'httpsdoiorg101016jdiagmicrobio200903021 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids23168767doptabstract '\n",
      " 'httpsdoiorg101097aog0b013e31827307b2 httpsdoiorg101097aog0b013e31827307b2 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30078662doptabstract '\n",
      " 'httpsdoiorg101016s1473309918301038 httpsdoiorg101016s1473309918301038 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29975334doptabstract '\n",
      " 'httpsdoiorg101097lgt0000000000000413 httpsdoiorg101097lgt0000000000000413 '\n",
      " 'recommendations and reports 174 mmwr  july 23 2021  vol 70  no 4 us '\n",
      " 'department of health and human servicescenters for disease control and '\n",
      " 'prevention 1148 kennedy ma sobel jd vulvovaginal candidiasis caused by  '\n",
      " 'nonalbicans candida species new insights curr infect dis rep  201012465–70 '\n",
      " 'pmid21308556 httpsdoiorg101007 s1190801001379 1149 sobel jd chaim w nagappan '\n",
      " 'v leaman d treatment of vaginitis  caused by candida glabrata use of topical '\n",
      " 'boric acid and flucytosine  am j obstet gynecol 20031891297–300 pmid14634557 '\n",
      " 'https doiorg101067s0002937803007269 1150 mølgaardnielsen d svanström h '\n",
      " 'melbye m hviid a pasternak  b association between use of oral fluconazole '\n",
      " 'during pregnancy and  risk of spontaneous abortion and stillbirth jama '\n",
      " '201631558–67  pmid26746458 httpsdoiorg101001jama201517844 1151 bérard a '\n",
      " 'sheehy o zhao jp et al associations between low and  highdose oral '\n",
      " 'fluconazole and pregnancy outcomes 3 nested case control studies cmaj '\n",
      " '2019191e179–87 pmid30782643 https doiorg101503cmaj180963 1152 ohmit se sobel '\n",
      " 'jd schuman p et al hiv epidemiology research  study hers group longitudinal '\n",
      " 'study of mucosal candida species  colonization and candidiasis among human '\n",
      " 'immunodeficiency  virus hivseropositive and atrisk hivseronegative women  j '\n",
      " 'infect dis 2003188118–27 pmid12825180 httpsdoi org101086375746 1153 duerr a '\n",
      " 'heilig cm meikle sf et al her study group  incident and persistent '\n",
      " 'vulvovaginal candidiasis among human  immunodeficiency virusinfected women '\n",
      " 'risk factors and severity  obstet gynecol 2003101548–56 pmid12636961 '\n",
      " 'httpsdoi org1010970000625020030300000022 1154 vazquez ja peng g sobel jd et '\n",
      " 'al evolution of antifungal  susceptibility among candida species isolates '\n",
      " 'recovered from human  immunodeficiency virusinfected women receiving '\n",
      " 'fluconazole  prophylaxis clin infect dis 2001331069–75 pmid11528582  '\n",
      " 'httpsdoiorg101086322641 1155 darville t pelvic inflammatory disease workshop '\n",
      " 'proceedings  committee pelvic inflammatory disease identifying research '\n",
      " 'gaps— proceedings of a workshop sponsored by department of health and  human '\n",
      " 'servicesnational institutes of healthnational institute of  allergy and '\n",
      " 'infectious diseases november 3–4 2011 sex transm  dis 201340761–7 '\n",
      " 'pmid24275724 httpsdoiorg101097 olq0000000000000028 1156 wiesenfeld hc sweet '\n",
      " 'rl ness rb krohn ma amortegui aj  hillier sl comparison of acute and '\n",
      " 'subclinical pelvic inflammatory  disease sex transm dis 200532400–5 '\n",
      " 'pmid15976596 https doiorg10109701olq0000154508265326a 1157 wiesenfeld hc '\n",
      " 'hillier sl meyn la amortegui aj sweet rl  subclinical pelvic inflammatory '\n",
      " 'disease and infertility obstet gynecol  201212037–43 pmid22678036 '\n",
      " 'httpsdoiorg101097 aog0b013e31825a6bc9 1158 ness rb soper de holley rl et al '\n",
      " 'effectiveness of inpatient and  outpatient treatment strategies for women '\n",
      " 'with pelvic inflammatory  disease results from the pelvic inflammatory '\n",
      " 'disease evaluation and  clinical health peach randomized trial am j obstet '\n",
      " 'gynecol  2002186929–37 pmid12015517 httpsdoiorg101067 mob2002121625 1159 '\n",
      " 'burnett am anderson cp zwank md laboratoryconfirmed  gonorrhea andor '\n",
      " 'chlamydia rates in clinically diagnosed pelvic  inflammatory disease and '\n",
      " 'cervicitis am j emerg med 2012301114–7  pmid22030186 '\n",
      " 'httpsdoiorg101016jajem201107014 1160 wiesenfeld hc meyn la darville t macio '\n",
      " 'is hillier sl a  randomized controlled trial of ceftriaxone and doxycycline '\n",
      " 'with or  without metronidazole for the treatment of acute pelvic '\n",
      " 'inflammatory  disease clin infect dis 2021721181–9 pmid32052831 https '\n",
      " 'doiorg101093cidciaa101 1161 ness rb kip ke hillier sl et al a cluster '\n",
      " 'analysis of bacterial  vaginosisassociated microflora and pelvic '\n",
      " 'inflammatory disease  am j epidemiol 2005162585–90 pmid16093289 httpsdoi '\n",
      " 'org101093ajekwi243 1162 scholes d stergachis a heidrich fe andrilla h holmes '\n",
      " 'kk  stamm we prevention of pelvic inflammatory disease by screening  for '\n",
      " 'cervical chlamydial infection n engl j med 19963341362–6  pmid8614421 '\n",
      " 'httpsdoiorg101056nejm199605233342103 1163 oakeshott p kerry s aghaizu a et '\n",
      " 'al randomised controlled trial of  screening for chlamydia trachomatis to '\n",
      " 'prevent pelvic inflammatory  disease the popi prevention of pelvic infection '\n",
      " 'trial bmj  2010340c1642 pmid20378636 httpsdoiorg101136bmj c1642 1164 peipert '\n",
      " 'jf ness rb blume j et al pelvic inflammatory disease  evaluation and '\n",
      " 'clinical health study investigators clinical  predictors of endometritis in '\n",
      " 'women with symptoms and signs of  pelvic inflammatory disease am j obstet '\n",
      " 'gynecol 2001184856–64  pmid11303192 httpsdoiorg101067mob2001113847 1165 '\n",
      " 'gaitán h angel e diaz r parada a sanchez l vargas c accuracy  of five '\n",
      " 'different diagnostic techniques in mildtomoderate pelvic  inflammatory '\n",
      " 'disease infect dis obstet gynecol 200210171–80  pmid12648310 '\n",
      " 'httpsdoiorg101155s1064744902000194 1166 vicetti miguel rd chivukula m '\n",
      " 'krishnamurti u et al  limitations of the criteria used to diagnose '\n",
      " 'histologic endometritis  in epidemiologic pelvic inflammatory disease '\n",
      " 'research pathol res  pract 2011207680–5 pmid21996319 httpsdoiorg101016j '\n",
      " 'prp201108007 1167 jacobson l weström l objectivized diagnosis of acute '\n",
      " 'pelvic  inflammatory disease diagnostic and prognostic value of  routine '\n",
      " 'laparoscopy am j obstet gynecol 19691051088–98  pmid4242830 '\n",
      " 'httpsdoiorg101016000293786990132x 1168 sellors j mahony j goldsmith c et al '\n",
      " 'the accuracy of clinical  findings and laparoscopy in pelvic inflammatory '\n",
      " 'disease am j  obstet gynecol 1991164113–20 pmid1824740 httpsdoi '\n",
      " 'org1010160002937891906399 1169 bevan cd johal bj mumtaz g ridgway gl siddle '\n",
      " 'nc clinical  laparoscopic and microbiological findings in acute salpingitis '\n",
      " 'report  on a united kingdom cohort br j obstet gynaecol 1995102407–14  '\n",
      " 'pmid7612536 httpsdoiorg101111j147105281995 tb11294x 1170 jaiyeoba o soper de '\n",
      " 'a practical approach to the diagnosis of pelvic  inflammatory disease infect '\n",
      " 'dis obstet gynecol 20112011753037  pmid21822367 httpsdoiorg1011552011753037 '\n",
      " '1171 sweet rl treatment of acute pelvic inflammatory disease infect dis  '\n",
      " 'obstet gynecol 20112011561909 pmid22228985 httpsdoi org1011552011561909 1172 '\n",
      " 'smith kj ness rb wiesenfeld hc roberts ms costeffectiveness  of alternative '\n",
      " 'outpatient pelvic inflammatory disease treatment  strategies sex transm dis '\n",
      " '200734960–6 pmid18077847 https doiorg10109701olq00002253216104913 1173 '\n",
      " 'petrina mab cosentino la wiesenfeld hc darville t hillier sl  susceptibility '\n",
      " 'of endometrial isolates recovered from women with  clinical pelvic '\n",
      " 'inflammatory disease or histological endometritis to  antimicrobial agents '\n",
      " 'anaerobe 20195661–5 pmid30753898  httpsdoiorg101016janaerobe201902005 1174 '\n",
      " 'haggerty cl ness rb amortegui a et al endometritis does not  predict '\n",
      " 'reproductive morbidity after pelvic inflammatory disease  am j obstet '\n",
      " 'gynecol 2003188141–8 pmid12548208 https doiorg101067mob200387 1175 haggerty '\n",
      " 'cl totten pa tang g et al identification of novel  microbes associated with '\n",
      " 'pelvic inflammatory disease and infertility  sex transm infect 201692441–6 '\n",
      " 'pmid26825087 httpsdoi org101136sextrans2015052285 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids21308556doptabstract '\n",
      " 'httpsdoiorg101007s1190801001379 httpsdoiorg101007s1190801001379 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids14634557doptabstract '\n",
      " 'httpsdoiorg101067s0002937803007269 httpsdoiorg101067s0002937803007269 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids26746458doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids26746458doptabstract '\n",
      " 'httpsdoiorg101001jama201517844 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30782643doptabstract '\n",
      " 'httpsdoiorg101503cmaj180963 httpsdoiorg101503cmaj180963 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids12825180doptabstract '\n",
      " 'httpsdoiorg101086375746 httpsdoiorg101086375746 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids12636961doptabstract '\n",
      " 'httpsdoiorg1010970000625020030300000022 '\n",
      " 'httpsdoiorg1010970000625020030300000022 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids11528582doptabstract '\n",
      " 'httpsdoiorg101086322641 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids24275724doptabstract '\n",
      " 'httpsdoiorg101097olq0000000000000028 httpsdoiorg101097olq0000000000000028 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids15976596doptabstract '\n",
      " 'httpsdoiorg10109701olq0000154508265326a '\n",
      " 'httpsdoiorg10109701olq0000154508265326a '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids22678036doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids12015517doptabstract '\n",
      " 'httpsdoiorg101067mob2002121625 httpsdoiorg101067mob2002121625 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids22030186doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids22030186doptabstract '\n",
      " 'httpsdoiorg101016jajem201107014 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids32052831doptabstract '\n",
      " 'httpsdoiorg101093cidciaa101 httpsdoiorg101093cidciaa101 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids16093289doptabstract '\n",
      " 'httpsdoiorg101093ajekwi243 httpsdoiorg101093ajekwi243 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids8614421doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids8614421doptabstract '\n",
      " 'httpsdoiorg101056nejm199605233342103 httpsdoiorg101136bmjc1642 '\n",
      " 'httpsdoiorg101136bmjc1642 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids11303192doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids11303192doptabstract '\n",
      " 'httpsdoiorg101067mob2001113847 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids12648310doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids12648310doptabstract '\n",
      " 'httpsdoiorg101155s1064744902000194 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids21996319doptabstract '\n",
      " 'httpsdoiorg101016jprp201108007 httpsdoiorg101016jprp201108007 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids4242830doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids4242830doptabstract '\n",
      " 'httpsdoiorg101016000293786990132x '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids1824740doptabstract '\n",
      " 'httpsdoiorg1010160002937891906399 httpsdoiorg1010160002937891906399 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids7612536doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids7612536doptabstract '\n",
      " 'httpsdoiorg101111j147105281995tb11294x '\n",
      " 'httpsdoiorg101111j147105281995tb11294x '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids21822367doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids21822367doptabstract '\n",
      " 'httpsdoiorg1011552011753037 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids22228985doptabstract '\n",
      " 'httpsdoiorg1011552011561909 httpsdoiorg1011552011561909 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids18077847doptabstract '\n",
      " 'httpsdoiorg10109701olq00002253216104913 '\n",
      " 'httpsdoiorg10109701olq00002253216104913 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30753898doptabstract '\n",
      " 'httpsdoiorg101016janaerobe201902005 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids12548208doptabstract '\n",
      " 'httpsdoiorg101067mob200387 httpsdoiorg101067mob200387 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids26825087doptabstract '\n",
      " 'httpsdoiorg101136sextrans2015052285 httpsdoiorg101136sextrans2015052285 '\n",
      " 'recommendations and reports mmwr  july 23 2021  vol 70  no 4 175us '\n",
      " 'department of health and human servicescenters for disease control and '\n",
      " 'prevention 1176 ness rb randall h richter he et al pelvic inflammatory '\n",
      " 'disease  evaluation and clinical health study investigators condom use and  '\n",
      " 'the risk of recurrent pelvic inflammatory disease chronic pelvic pain  or '\n",
      " 'infertility following an episode of pelvic inflammatory disease  am j public '\n",
      " 'health 2004941327–9 pmid15284036 httpsdoi org102105ajph9481327 1177 mcgregor '\n",
      " 'ja crombleholme wr newton e sweet rl tuomala  r gibbs rs randomized '\n",
      " 'comparison of ampicillinsulbactam  to cefoxitin and doxycycline or '\n",
      " 'clindamycin and gentamicin in  the treatment of pelvic inflammatory disease '\n",
      " 'or endometritis  obstet gynecol 199483998–1004 pmid8190448 httpsdoi '\n",
      " 'org1010970000625019940600000020 1178 bevan cd ridgway gl rothermel cd '\n",
      " 'efficacy and safety of  azithromycin as monotherapy or combined with '\n",
      " 'metronidazole  compared with two standard multidrug regimens for the '\n",
      " 'treatment  of acute pelvic inflammatory disease j int med res 20033145–54  '\n",
      " 'pmid12635534 httpsdoiorg101177147323000303100108 1179 heystek m ross jd pid '\n",
      " 'study group a randomized double blind comparison of moxifloxacin and '\n",
      " 'doxycyclinemetronidazole ciprofloxacin in the treatment of acute '\n",
      " 'uncomplicated pelvic  inflammatory disease int j std aids 200920690–5  '\n",
      " 'pmid19815913 httpsdoiorg101258ijsa2008008495 1180 boothby m page j pryor r '\n",
      " 'ross jd a comparison of treatment  outcomes for moxifloxacin versus '\n",
      " 'ofloxacinmetronidazole for first line treatment of uncomplicated '\n",
      " 'nongonococcal pelvic inflammatory  disease int j std aids 201021195–7 '\n",
      " 'pmid20215625 https doiorg101258ijsa2009009374 1181 judlin p liao q liu z '\n",
      " 'reimnitz p hampel b arvis p efficacy and  safety of moxifloxacin in '\n",
      " 'uncomplicated pelvic inflammatory disease  the monalisa study bjog '\n",
      " '20101171475–84 pmid20716255  httpsdoiorg101111j14710528201002687x 1182 korn '\n",
      " 'ap pelvic inflammatory disease in women infected with hiv  aids patient care '\n",
      " 'stds 199812431–4 pmid11361990 https doiorg101089apc199812431 1183 irwin kl '\n",
      " 'moorman ac o’sullivan mj et al influence of human  immunodeficiency virus '\n",
      " 'infection on pelvic inflammatory disease  obstet gynecol 200095525–34 '\n",
      " 'pmid10725484 1184 bukusi ea cohen cr stevens ce et al effects of human  '\n",
      " 'immunodeficiency virus 1 infection on microbial origins of pelvic  '\n",
      " 'inflammatory disease and on efficacy of ambulatory oral therapy am  j obstet '\n",
      " 'gynecol 19991811374–81 pmid10601915 httpsdoi org101016s0002937899703789 1185 '\n",
      " 'mugo nr kiehlbauch ja nguti r et al effect of human  immunodeficiency virus1 '\n",
      " 'infection on treatment outcome of acute  salpingitis obstet gynecol '\n",
      " '2006107807–12 pmid16582116  httpsdoiorg10109701aog000020759770524e8 1186 '\n",
      " 'grimes da intrauterine device and uppergenitaltract infection  lancet '\n",
      " '20003561013–9 pmid11041414 httpsdoiorg101016 s0140673600026994 1187 viberga '\n",
      " 'i odlind v lazdane g kroica j berglund l olofsson s  microbiology profile in '\n",
      " 'women with pelvic inflammatory disease in  relation to iud use infect dis '\n",
      " 'obstet gynecol 200513183–90  pmid16338777 httpsdoiorg1011552005376830 1188 '\n",
      " 'jatlaoui tc riley hem curtis km the safety of intrauterine  devices among '\n",
      " 'young women a systematic review contraception  20179517–39 pmid27771475 '\n",
      " 'httpsdoiorg101016j contraception201610006 1189 chen mj kim cr whitehouse kc '\n",
      " 'berrybibee e gaffield me  development updates and future directions of the '\n",
      " 'world health  organization selected practice recommendations for '\n",
      " 'contraceptive  use int j gynaecol obstet 2017136113–9 pmid28099730  '\n",
      " 'httpsdoiorg101002ijgo12064 1190 tepper nk steenland mw gaffield me '\n",
      " 'marchbanks pa curtis  km retention of intrauterine devices in women who '\n",
      " 'acquire  pelvic inflammatory disease a systematic review contraception  '\n",
      " '201387655–60 pmid23040135 httpsdoiorg101016j contraception201208011 1191 '\n",
      " 'louette a krahn j caine v ha s lau tty singh ae treatment  of acute '\n",
      " 'epididymitis a systematic review and discussion of the  implications for '\n",
      " 'treatment based on etiology sex transm dis  201845e104–8 pmid30044339 '\n",
      " 'httpsdoiorg101097 olq0000000000000901 1192 pilatz a hossain h kaiser r et al '\n",
      " 'acute epididymitis revisited impact  of molecular diagnostics on etiology '\n",
      " 'and contemporary guideline  recommendations eur urol 201568428–35 '\n",
      " 'pmid25542628  httpsdoiorg101016jeururo201412005 1193 hongo h kikuchi e '\n",
      " 'matsumoto k et al novel algorithm for  management of acute epididymitis int '\n",
      " 'j urol 20172482–7  pmid27714879 httpsdoiorg101111iju13236 1194 de villiers '\n",
      " 'em fauquet c broker tr bernard hu zur hausen  h classification of '\n",
      " 'papillomaviruses virology 200432417–27  pmid15183049 '\n",
      " 'httpsdoiorg101016jvirol200403033 1195 myers er mccrory dc nanda k bastian l '\n",
      " 'matchar  db mathematical model for the natural history of human  '\n",
      " 'papillomavirus infection and cervical carcinogenesis am j epidemiol  '\n",
      " '20001511158–71 pmid10905528 httpsdoiorg101093 oxfordjournalsajea010166 1196 '\n",
      " 'chesson hw dunne ef hariri s markowitz le the estimated  lifetime '\n",
      " 'probability of acquiring human papillomavirus in the united  states sex '\n",
      " 'transm dis 201441660–4 pmid25299412 httpsdoi org101097olq0000000000000193 '\n",
      " '1197 cogliano v baan r straif k grosse y secretan b el ghissassi f  who '\n",
      " 'international agency for research on cancer carcinogenicity of  human '\n",
      " 'papillomaviruses lancet oncol 20056204 pmid15830458  '\n",
      " 'httpsdoiorg101016s1470204505700863 1198 senkomago v henley sj thomas cc mix '\n",
      " 'jm markowitz le  saraiya m human papillomavirusattributable cancers—united  '\n",
      " 'states 2012–2016 mmwr morb mortal wkly rep 201968724–8  pmid31437140 '\n",
      " 'httpsdoiorg1015585mmwrmm6833a3 1199 chesson hw ekwueme du saraiya m watson m '\n",
      " 'lowy dr  markowitz le estimates of the annual direct medical costs of  the '\n",
      " 'prevention and treatment of disease associated with human  papillomavirus in '\n",
      " 'the united states vaccine 2012306016–9  pmid22867718 '\n",
      " 'httpsdoiorg101016jvaccine201207056 1200 markowitz le hariri s lin c et al '\n",
      " 'reduction in human  papillomavirus hpv prevalence among young women '\n",
      " 'following  hpv vaccine introduction in the united states national health  '\n",
      " 'and nutrition examination surveys 2003–2010 j infect dis  2013208385–93 '\n",
      " 'pmid23785124 httpsdoiorg101093infdis jit192 1201 flagg ew schwartz r '\n",
      " 'weinstock h prevalence of anogenital warts  among participants in private '\n",
      " 'health plans in the united states  2003–2010 potential impact of human '\n",
      " 'papillomavirus vaccination  am j public health 20131031428–35 pmid23763409 '\n",
      " 'https doiorg102105ajph2012301182 1202 mcclung nm lewis rm gargano jw querec '\n",
      " 't unger er  markowitz le declines in vaccinetype human papillomavirus  '\n",
      " 'prevalence in females across racialethnic groups data from a national  '\n",
      " 'survey j adolesc health 201965715–22 pmid31515134 https '\n",
      " 'doiorg101016jjadohealth201907003 1203 drolet m bénard é pérez n et al hpv '\n",
      " 'vaccination impact  study group populationlevel impact and herd effects  '\n",
      " 'following the introduction of human papillomavirus vaccination  programmes '\n",
      " 'updated systematic review and metaanalysis lancet  2019394497–509 '\n",
      " 'pmid31255301 httpsdoiorg101016 s0140673619302983 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids15284036doptabstract '\n",
      " 'httpsdoiorg102105ajph9481327 httpsdoiorg102105ajph9481327 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids8190448doptabstract '\n",
      " 'httpsdoiorg1010970000625019940600000020 '\n",
      " 'httpsdoiorg1010970000625019940600000020 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids12635534doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids12635534doptabstract '\n",
      " 'httpsdoiorg101177147323000303100108 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids19815913doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids19815913doptabstract '\n",
      " 'httpsdoiorg101258ijsa2008008495 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids20215625doptabstract '\n",
      " 'httpsdoiorg101258ijsa2009009374 httpsdoiorg101258ijsa2009009374 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids20716255doptabstract '\n",
      " 'httpsdoiorg101111j14710528201002687x '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids11361990doptabstract '\n",
      " 'httpsdoiorg101089apc199812431 httpsdoiorg101089apc199812431 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids10725484doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids10601915doptabstract '\n",
      " 'httpsdoiorg101016s0002937899703789 httpsdoiorg101016s0002937899703789 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids16582116doptabstract '\n",
      " 'httpsdoiorg10109701aog000020759770524e8 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids11041414doptabstract '\n",
      " 'httpsdoiorg101016s0140673600026994 httpsdoiorg101016s0140673600026994 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids16338777doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids16338777doptabstract '\n",
      " 'httpsdoiorg1011552005376830 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids27771475doptabstract '\n",
      " 'httpsdoiorg101016jcontraception201610006 '\n",
      " 'httpsdoiorg101016jcontraception201610006 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28099730doptabstract '\n",
      " 'httpsdoiorg101002ijgo12064 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids23040135doptabstract '\n",
      " 'httpsdoiorg101016jcontraception201208011 '\n",
      " 'httpsdoiorg101016jcontraception201208011 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30044339doptabstract '\n",
      " 'httpsdoiorg101097olq0000000000000901 httpsdoiorg101097olq0000000000000901 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids25542628doptabstract '\n",
      " 'httpsdoiorg101016jeururo201412005 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids27714879doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids27714879doptabstract '\n",
      " 'httpsdoiorg101111iju13236 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids15183049doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids15183049doptabstract '\n",
      " 'httpsdoiorg101016jvirol200403033 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids10905528doptabstract '\n",
      " 'httpsdoiorg101093oxfordjournalsajea010166 '\n",
      " 'httpsdoiorg101093oxfordjournalsajea010166 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids25299412doptabstract '\n",
      " 'httpsdoiorg101097olq0000000000000193 httpsdoiorg101097olq0000000000000193 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids15830458doptabstract '\n",
      " 'httpsdoiorg101016s1470204505700863 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids31437140doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids31437140doptabstract '\n",
      " 'httpsdoiorg1015585mmwrmm6833a3 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids22867718doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids22867718doptabstract '\n",
      " 'httpsdoiorg101016jvaccine201207056 httpsdoiorg101093infdisjit192 '\n",
      " 'httpsdoiorg101093infdisjit192 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids23763409doptabstract '\n",
      " 'httpsdoiorg102105ajph2012301182 httpsdoiorg102105ajph2012301182 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids31515134doptabstract '\n",
      " 'httpsdoiorg101016jjadohealth201907003 httpsdoiorg101016jjadohealth201907003 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids31255301doptabstract '\n",
      " 'httpsdoiorg101016s0140673619302983 httpsdoiorg101016s0140673619302983 '\n",
      " 'recommendations and reports 176 mmwr  july 23 2021  vol 70  no 4 us '\n",
      " 'department of health and human servicescenters for disease control and '\n",
      " 'prevention 1204 mayhew a mullins tl ding l et al risk perceptions and '\n",
      " 'subsequent  sexual behaviors after hpv vaccination in adolescents '\n",
      " 'pediatrics  2014133404–11 pmid24488747 httpsdoiorg101542 peds20132822 1205 '\n",
      " 'brouwer af delinger rl eisenberg mc et al hpv vaccination has  not increased '\n",
      " 'sexual activity or accelerated sexual debut in a college aged cohort of men '\n",
      " 'and women bmc public health 201919821  pmid31238911 '\n",
      " 'httpsdoiorg101186s1288901971341 1206 garland sm steben m sings hl et al '\n",
      " 'natural history of genital  warts analysis of the placebo arm of 2 '\n",
      " 'randomized phase iii trials  of a quadrivalent human papillomavirus types 6 '\n",
      " '11 16 and 18  vaccine j infect dis 2009199805–14 pmid19199546 https '\n",
      " 'doiorg101086597071 1207 flagg ew torrone ea declines in anogenital warts '\n",
      " 'among age groups  most likely to be impacted by human papillomavirus '\n",
      " 'vaccination  united states 2006–2014 am j public health 2018108112–9  '\n",
      " 'pmid29161070 httpsdoiorg102105ajph2017304119 1208 hariri s schuler ms '\n",
      " 'naleway al et al human papillomavirus  vaccine effectiveness against '\n",
      " 'incident genital warts among  female healthplan enrollees united states am j '\n",
      " 'epidemiol  2018187298–305 pmid28641366 httpsdoiorg101093aje kwx253 1209 '\n",
      " 'wangu z hsu kk impact of hpv vaccination on anogenital  warts and '\n",
      " 'respiratory papillomatosis hum vaccin immunother  2016121357–62 pmid27217191 '\n",
      " 'httpsdoiorg101080216 4551520161172754 1210 swedish ka goldstone se '\n",
      " 'prevention of anal condyloma with  quadrivalent human papillomavirus '\n",
      " 'vaccination of older men who  have sex with men plos one 20149e93393 '\n",
      " 'pmid24714693  httpsdoiorg101371journalpone0093393 1211 sandø n kofoed k '\n",
      " 'zachariae c fouchard j a reduced national  incidence of anogenital warts in '\n",
      " 'young danish men and women  after introduction of a national quadrivalent '\n",
      " 'human papillomavirus  vaccination programme for young women—an ecological '\n",
      " 'study  acta derm venereol 201494288–92 pmid24150529 httpsdoi '\n",
      " 'org102340000155551721 1212 herweijer e ploner a sparén p substantially '\n",
      " 'reduced incidence  of genital warts in women and men six years after hpv '\n",
      " 'vaccine  availability in sweden vaccine 2018361917–20 pmid29523448  '\n",
      " 'httpsdoiorg101016jvaccine201802097 1213 harrison c britt h garland s et al '\n",
      " 'decreased management of  genital warts in young women in australian general '\n",
      " 'practice post  introduction of national hpv vaccination program results from '\n",
      " 'a  nationally representative crosssectional general practice study plos  one '\n",
      " '20149e105967 pmid25180698 httpsdoiorg101371 journalpone0105967 1214 canvin m '\n",
      " 'sinka k hughes g mesher d decline in genital  warts diagnoses among young '\n",
      " 'women and young men since the  introduction of the bivalent hpv 1618 '\n",
      " 'vaccination programme  in england an ecological analysis sex transm infect '\n",
      " '201793125–8  pmid27365492 httpsdoiorg101136sextrans2016052626 1215 chow ep '\n",
      " 'read tr wigan r et al ongoing decline in genital  warts among young '\n",
      " 'heterosexuals 7 years after the australian  human papillomavirus hpv '\n",
      " 'vaccination programme sex transm  infect 201591214–9 pmid25305210 '\n",
      " 'httpsdoiorg101136 sextrans2014051813 1216 petrosky ey liu g hariri s '\n",
      " 'markowitz le human papillomavirus  vaccination and age at first sexual '\n",
      " 'activity national health and  nutrition examination survey clin pediatr '\n",
      " 'phila 201756363–70  pmid27609513 httpsdoiorg1011770009922816660541 1217 '\n",
      " 'gotovtseva ep kapadia as smolensky mh lairson dr optimal  frequency of '\n",
      " 'imiquimod aldara 5 cream for the treatment of  external genital warts in '\n",
      " 'immunocompetent adults a metaanalysis  sex transm dis 200835346–51 '\n",
      " 'pmid18360317 httpsdoi org101097olq0b013e31815ea8d1 1218 baker da ferris dg '\n",
      " 'martens mg et al imiquimod 375  cream applied daily to treat anogenital '\n",
      " 'warts combined results from  women in two randomized placebocontrolled '\n",
      " 'studies infect dis  obstet gynecol 20112011806105 pmid21876641 httpsdoi '\n",
      " 'org1011552011806105 1219 mashiah j brenner s possible mechanisms in the '\n",
      " 'induction of vitiligo like hypopigmentation by topical imiquimod clin exp '\n",
      " 'dermatol  20083374–6 pmid17979992 1220 domingues e chaney kc scharf mj wiss '\n",
      " 'k imiquimod reactivation  of lichen planus cutis 201289276–7 283 '\n",
      " 'pmid22838091 1221 patel u mark nm machler bc levine vj imiquimod 5 cream  '\n",
      " 'induced psoriasis a case report summary of the literature and  mechanism br '\n",
      " 'j dermatol 2011164670–2 pmid21062268  httpsdoiorg101111j13652133201010124x '\n",
      " '1222 kumar b narang t local and systemic adverse effects to topical  '\n",
      " 'imiquimod due to systemic immune stimulation sex transm  infect 201187432 '\n",
      " 'pmid21606474 httpsdoiorg101136 sextrans2011050025 1223 stockfleth e beti h '\n",
      " 'orasan r et al topical polyphenon e in  the treatment of external genital '\n",
      " 'and perianal warts a randomized  controlled trial br j dermatol '\n",
      " '20081581329–38 pmid18363746  httpsdoiorg101111j13652133200808520x 1224 gross '\n",
      " 'g meyer kg pres h thielert c tawfik h mescheder a a  randomized doubleblind '\n",
      " 'fourarm parallelgroup placebocontrolled  phase iiiii study to investigate '\n",
      " 'the clinical efficacy of two galenic  formulations of polyphenon e in the '\n",
      " 'treatment of external genital warts  j eur acad dermatol venereol '\n",
      " '2007211404–12 pmid17958849  httpsdoiorg101111j14683083200702441x 1225 tatti '\n",
      " 's swinehart jm thielert c tawfik h mescheder a beutner  kr sinecatechins a '\n",
      " 'defined green tea extract in the treatment  of external anogenital warts a '\n",
      " 'randomized controlled trial  obstet gynecol 20081111371–9 pmid18515521 '\n",
      " 'httpsdoi org101097aog0b013e3181719b60 1226 national institute for '\n",
      " 'occupational safety and health control of  smoke from laserelectric surgical '\n",
      " 'procedures washington dc  us department of health and human services cdc '\n",
      " 'national  institute for occupational safety and health 1996 httpswww '\n",
      " 'cdcgovnioshdocshazardcontrolpdfshc11pdfid1026616 nioshpub96128 1227 filley '\n",
      " 'cm graffrichard nr lacy jr heitner ma earnest mp  neurologic manifestations '\n",
      " 'of podophyllin toxicity neurology  198232308–11 pmid7199647 '\n",
      " 'httpsdoiorg101212 wnl323308 1228 conard pf hanna n rosenblum m gross jb '\n",
      " 'delayed recognition  of podophyllum toxicity in a patient receiving epidural '\n",
      " 'morphine  anesth analg 199071191–3 pmid2375521 httpsdoi '\n",
      " 'org1012130000053919900800000013 1229 karol  md conner cs watanabe as  '\n",
      " 'murphrey kj  podophyllum suspected teratogenicity from topical application  '\n",
      " 'clin toxicol 198016283–6 pmid7398215 httpsdoi org10310915563658008989950 '\n",
      " '1230 silverberg mj thorsen p lindeberg h grant la shah kv  condyloma in '\n",
      " 'pregnancy is strongly predictive of juvenile onset recurrent respiratory '\n",
      " 'papillomatosis obstet gynecol  2003101645–52 pmid12681865 1231 dolev jc '\n",
      " 'maurer t springer g et al incidence and risk factors  for verrucae in women '\n",
      " 'aids 2008221213–9 pmid18525267  httpsdoiorg101097qad0b013e3283021aa3 1232 '\n",
      " 'silverberg mj ahdieh l munoz a et al the impact of hiv infection and  '\n",
      " 'immunodeficiency on human papillomavirus type 6 or 11 infection and  on '\n",
      " 'genital warts sex transm dis 200229427–35 pmid12172526  '\n",
      " 'httpsdoiorg1010970000743520020800000001 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids24488747doptabstract '\n",
      " 'httpsdoiorg101542peds20132822 httpsdoiorg101542peds20132822 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids31238911doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids31238911doptabstract '\n",
      " 'httpsdoiorg101186s1288901971341 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids19199546doptabstract '\n",
      " 'httpsdoiorg101086597071 httpsdoiorg101086597071 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29161070doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29161070doptabstract '\n",
      " 'httpsdoiorg102105ajph2017304119 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28641366doptabstract '\n",
      " 'httpsdoiorg101093ajekwx253 httpsdoiorg101093ajekwx253 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids27217191doptabstract '\n",
      " 'httpsdoiorg1010802164551520161172754 httpsdoiorg1010802164551520161172754 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids24714693doptabstract '\n",
      " 'httpsdoiorg101371journalpone0093393 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids24150529doptabstract '\n",
      " 'httpsdoiorg102340000155551721 httpsdoiorg102340000155551721 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29523448doptabstract '\n",
      " 'httpsdoiorg101016jvaccine201802097 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids25180698doptabstract '\n",
      " 'httpsdoiorg101371journalpone0105967 httpsdoiorg101371journalpone0105967 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids27365492doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids27365492doptabstract '\n",
      " 'httpsdoiorg101136sextrans2016052626 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids25305210doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids27609513doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids27609513doptabstract '\n",
      " 'httpsdoiorg1011770009922816660541 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids18360317doptabstract '\n",
      " 'httpsdoiorg101097olq0b013e31815ea8d1 httpsdoiorg101097olq0b013e31815ea8d1 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids21876641doptabstract '\n",
      " 'httpsdoiorg1011552011806105 httpsdoiorg1011552011806105 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids17979992doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids22838091doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids21062268doptabstract '\n",
      " 'httpsdoiorg101111j13652133201010124x '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids21606474doptabstract '\n",
      " 'httpsdoiorg101136sextrans2011050025 httpsdoiorg101136sextrans2011050025 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids18363746doptabstract '\n",
      " 'httpsdoiorg101111j13652133200808520x '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids17958849doptabstract '\n",
      " 'httpsdoiorg101111j14683083200702441x '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids18515521doptabstract '\n",
      " 'httpsdoiorg101097aog0b013e3181719b60 httpsdoiorg101097aog0b013e3181719b60 '\n",
      " 'httpswwwcdcgovnioshdocshazardcontrolpdfshc11pdfid1026616nioshpub96128 '\n",
      " 'httpswwwcdcgovnioshdocshazardcontrolpdfshc11pdfid1026616nioshpub96128 '\n",
      " 'httpswwwcdcgovnioshdocshazardcontrolpdfshc11pdfid1026616nioshpub96128 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids7199647doptabstract '\n",
      " 'httpsdoiorg101212wnl323308 httpsdoiorg101212wnl323308 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids2375521doptabstract '\n",
      " 'httpsdoiorg1012130000053919900800000013 '\n",
      " 'httpsdoiorg1012130000053919900800000013 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids7398215doptabstract '\n",
      " 'httpsdoiorg10310915563658008989950 httpsdoiorg10310915563658008989950 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids12681865doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids18525267doptabstract '\n",
      " 'httpsdoiorg101097qad0b013e3283021aa3 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids12172526doptabstract '\n",
      " 'httpsdoiorg1010970000743520020800000001 recommendations and reports mmwr  '\n",
      " 'july 23 2021  vol 70  no 4 177us department of health and human '\n",
      " 'servicescenters for disease control and prevention 1233 de panfilis g '\n",
      " 'melzani g mori g ghidini a graifemberghi  s relapses after treatment of '\n",
      " 'external genital warts are more  frequent in hivpositive patients than in '\n",
      " 'hivnegative controls  sex transm dis 200229121–5 pmid11875372 httpsdoi '\n",
      " 'org1010970000743520020300000001 1234 conley lj ellerbrock tv bush tj '\n",
      " 'chiasson ma sawo d  wright tc hiv1 infection and risk of vulvovaginal and '\n",
      " 'perianal  condylomata acuminata and intraepithelial neoplasia a prospective  '\n",
      " 'cohort study lancet 2002359108–13 pmid11809252 https '\n",
      " 'doiorg101016s0140673602073683 1235 schlecht hp fugelso dk murphy rk et al '\n",
      " 'frequency of occult high grade squamous intraepithelial neoplasia and '\n",
      " 'invasive cancer within  anal condylomata in men who have sex with men clin '\n",
      " 'infect dis  201051107–10 pmid20482370 httpsdoiorg101086653426 1236 maniar kp '\n",
      " 'ronnett bm vang r yemelyanova a coexisting  highgrade vulvar intraepithelial '\n",
      " 'neoplasia vin and condyloma  acuminatum independent lesions due to different '\n",
      " 'hpv types  occurring in immunocompromised patients am j surg pathol  '\n",
      " '20133753–60 pmid23026935 httpsdoiorg101097 pas0b013e318263cda6 1237 massad '\n",
      " 'ls xie x darragh t et al women’s interagency hiv study  collaborative study '\n",
      " 'group genital warts and vulvar intraepithelial  neoplasia natural history '\n",
      " 'and effects of treatment and human  immunodeficiency virus infection obstet '\n",
      " 'gynecol 2011118831–9  pmid21934446 httpsdoiorg101097aog0b013e31821a0f4d 1238 '\n",
      " 'forman d de martel c lacey cj et al global burden of human  papillomavirus '\n",
      " 'and related diseases vaccine 201230suppl 5f12–23  pmid23199955 '\n",
      " 'httpsdoiorg101016jvaccine201207055 1239 darragh tm colgan tj cox jt et al '\n",
      " 'members of last project  work groups the lower anogenital squamous '\n",
      " 'terminology  standardization project for hpvassociated lesions background  '\n",
      " 'and consensus recommendations from the college of american  pathologists and '\n",
      " 'the american society for colposcopy and  cervical pathology arch pathol lab '\n",
      " 'med 20121361266–97  pmid22742517 httpsdoiorg105858arpalgt200570 1240 '\n",
      " 'committee on practice bulletins—gynecology practice bulletin  no 168 summary '\n",
      " 'cervical cancer screening and prevention  obstet gynecol 2016128923–5 '\n",
      " 'pmid27661643 httpsdoi org101097aog0000000000001699 1241 perkins rb guido rl '\n",
      " 'saraiya m et al summary of current  guidelines for cervical cancer screening '\n",
      " 'and management of abnormal  test results 2016–2020 j womens health larchmt '\n",
      " '2021305–13  pmid33464997 httpsdoiorg101089jwh20208918 1242 kim jj burger ea '\n",
      " 'regan c sy s screening for cervical cancer  in primary care a decision '\n",
      " 'analysis for the us preventive services  task force jama 2018320706–14 '\n",
      " 'pmid30140882 httpsdoi org101001jama201719872 1243 sawaya gf sanstead e '\n",
      " 'alaridescudero f et al estimated quality  of life and economic outcomes '\n",
      " 'associated with 12 cervical cancer  screening strategies a costeffectiveness '\n",
      " 'analysis jama intern med  2019179867–78 pmid31081851 httpsdoiorg101001 '\n",
      " 'jamainternmed20190299 1244 saslow d solomon d lawson hw et al acsasccpascp  '\n",
      " 'cervical cancer guideline committee american cancer society  american '\n",
      " 'society for colposcopy and cervical pathology and  american society for '\n",
      " 'clinical pathology screening guidelines for  the prevention and early '\n",
      " 'detection of cervical cancer ca cancer  j clin 201262147–72 pmid22422631 '\n",
      " 'httpsdoiorg103322 caac21139 1245 committee on practice bulletins—gynecology '\n",
      " 'acog practice  bulletin no 131 screening for cervical cancer obstet gynecol  '\n",
      " '20121201222–38 pmid23090560 httpsdoiorg101097 aog0b013e318277c92a 1246 '\n",
      " 'meyerson be sayegh ma davis a et al cervical cancer screening in a  sexually '\n",
      " 'transmitted disease clinic screening adoption experiences from  a midwestern '\n",
      " 'clinic am j public health 2015105suppl 2e8–14  pmid25689199 '\n",
      " 'httpsdoiorg102105ajph2014302272 1247 perkins rb guido rs castle pe et al '\n",
      " '2019 asccp riskbased  management consensus guidelines committee 2019 asccp  '\n",
      " 'riskbased management consensus guidelines for abnormal cervical  cancer '\n",
      " 'screening tests and cancer precursors j low genit tract  dis 202024102–31 '\n",
      " 'pmid32243307 httpsdoiorg101097 lgt0000000000000525 1248 saraiya m lee nc '\n",
      " 'blackman d smith mj morrow b mckenna  ma selfreported papanicolaou smears '\n",
      " 'and hysterectomies among  women in the united states obstet gynecol '\n",
      " '200198269–78  pmid11506844 1249 sirovich be welch hg cervical cancer '\n",
      " 'screening among women  without a cervix jama 20042912990–3 pmid15213211 '\n",
      " 'https doiorg101001jama291242990 1250 stokeslampard h wilson s waddell c ryan '\n",
      " 'a holder r  kehoe s vaginal vault smears after hysterectomy for reasons  '\n",
      " 'other than malignancy a systematic review of the literature  bjog '\n",
      " '20061131354–65 pmid17081187 httpsdoi org101111j14710528200601099x 1251 arbyn '\n",
      " 'm herbert a schenck u et al european guidelines for  quality assurance in '\n",
      " 'cervical cancer screening recommendations  for collecting samples for '\n",
      " 'conventional and liquidbased cytology  cytopathology 200718133–9 '\n",
      " 'pmid17573762 httpsdoi org101111j13652303200700464x 1252 daley e perrin k '\n",
      " 'vamos c et al confusion about pap smears lack  of knowledge among highrisk '\n",
      " 'women j womens health larchmt  20132267–74 pmid23215902 httpsdoiorg101089 '\n",
      " 'jwh20123667 1253 drolet m bénard é boily mc et al populationlevel impact  '\n",
      " 'and herd effects following human papillomavirus vaccination  programmes a '\n",
      " 'systematic review and metaanalysis lancet infect  dis 201515565–80 '\n",
      " 'pmid25744474 httpsdoiorg101016 s1473309914710734 1254 ogbechie oa hacker mr '\n",
      " 'dodge le patil mm ricciotti ha  confusion regarding cervical cancer '\n",
      " 'screening and chlamydia  screening among sexually active young women sex '\n",
      " 'transm  infect 20128835–7 pmid22123163 httpsdoiorg101136 sextrans2011050289 '\n",
      " '1255 dunne ef friedman a datta sd markowitz le workowski  ka updates on '\n",
      " 'human papillomavirus and genital warts and  counseling messages from the '\n",
      " '2010 sexually transmitted diseases  treatment guidelines clin infect dis '\n",
      " '201153suppl 3s143–52  pmid22080267 httpsdoiorg101093cidcir703 1256 fry am '\n",
      " 'ferriesrowe ea learman la haas dm pap smear versus  speculum examination can '\n",
      " 'we teach providers to educate patients  j womens health larchmt 2010191715–9 '\n",
      " 'pmid20662627  httpsdoiorg101089jwh20091862 1257 adab p marshall t rouse a '\n",
      " 'randhawa b sangha h bhangoo  n randomised controlled trial of the effect of '\n",
      " 'evidence based  information on women’s willingness to participate in '\n",
      " 'cervical cancer  screening j epidemiol community health 200357589–93  '\n",
      " 'pmid12883063 httpsdoiorg101136jech578589 1258 drolet m brisson m maunsell e '\n",
      " 'et al the psychosocial impact of  an abnormal cervical smear result '\n",
      " 'psychooncology 2012211071–81  pmid21695747 httpsdoiorg101002pon2003 1259 '\n",
      " 'mccaffery kj irwig l turner r et al psychosocial outcomes of three  triage '\n",
      " 'methods for the management of borderline abnormal cervical  smears an open '\n",
      " 'randomised trial bmj 2010340feb23 1b4491  pmid20179125 '\n",
      " 'httpsdoiorg101136bmjb4491 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids11875372doptabstract '\n",
      " 'httpsdoiorg1010970000743520020300000001 '\n",
      " 'httpsdoiorg1010970000743520020300000001 httpsdoiorg101016s0140673602073683 '\n",
      " 'httpsdoiorg101016s0140673602073683 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids20482370doptabstract '\n",
      " 'httpsdoiorg101086653426 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids23026935doptabstract '\n",
      " 'httpsdoiorg101097pas0b013e318263cda6 httpsdoiorg101097pas0b013e318263cda6 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids21934446doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids21934446doptabstract '\n",
      " 'httpsdoiorg101097aog0b013e31821a0f4d '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids23199955doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids23199955doptabstract '\n",
      " 'httpsdoiorg101016jvaccine201207055 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids22742517doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids22742517doptabstract '\n",
      " 'httpsdoiorg105858arpalgt200570 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids27661643doptabstract '\n",
      " 'httpsdoiorg101097aog0000000000001699 httpsdoiorg101097aog0000000000001699 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids33464997doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids33464997doptabstract '\n",
      " 'httpsdoiorg101089jwh20208918 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30140882doptabstract '\n",
      " 'httpsdoiorg101001jama201719872 httpsdoiorg101001jama201719872 '\n",
      " 'httpsdoiorg101001jamainternmed20190299 '\n",
      " 'httpsdoiorg101001jamainternmed20190299 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids22422631doptabstract '\n",
      " 'httpsdoiorg103322caac21139 httpsdoiorg103322caac21139 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids23090560doptabstract '\n",
      " 'httpsdoiorg101097aog0b013e318277c92a httpsdoiorg101097aog0b013e318277c92a '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids25689199doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids25689199doptabstract '\n",
      " 'httpsdoiorg102105ajph2014302272 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids32243307doptabstract '\n",
      " 'httpsdoiorg101097lgt0000000000000525 httpsdoiorg101097lgt0000000000000525 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids11506844doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids11506844doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids15213211doptabstract '\n",
      " 'httpsdoiorg101001jama291242990 httpsdoiorg101001jama291242990 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids17081187doptabstract '\n",
      " 'httpsdoiorg101111j14710528200601099x httpsdoiorg101111j14710528200601099x '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids17573762doptabstract '\n",
      " 'httpsdoiorg101111j13652303200700464x httpsdoiorg101111j13652303200700464x '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids23215902doptabstract '\n",
      " 'httpsdoiorg101089jwh20123667 httpsdoiorg101089jwh20123667 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids25744474doptabstract '\n",
      " 'httpsdoiorg101016s1473309914710734 httpsdoiorg101016s1473309914710734 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids22123163doptabstract '\n",
      " 'httpsdoiorg101136sextrans2011050289 httpsdoiorg101136sextrans2011050289 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids22080267doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids22080267doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids20662627doptabstract '\n",
      " 'httpsdoiorg101089jwh20091862 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids12883063doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids12883063doptabstract '\n",
      " 'httpsdoiorg101136jech578589 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids21695747doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids21695747doptabstract '\n",
      " 'httpsdoiorg101002pon2003 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids20179125doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids20179125doptabstract '\n",
      " 'httpsdoiorg101136bmjb4491 recommendations and reports 178 mmwr  july 23 '\n",
      " '2021  vol 70  no 4 us department of health and human servicescenters for '\n",
      " 'disease control and prevention 1260 daley em perrin km mcdermott rj et al '\n",
      " 'the psychosocial  burden of hpv a mixedmethod study of knowledge attitudes '\n",
      " 'and  behaviors among hpv women j health psychol 201015279–90  pmid20207671 '\n",
      " 'httpsdoiorg1011771359105309351249 1261 pirotta m ung l stein a et al the '\n",
      " 'psychosocial burden of human  papillomavirus related disease and screening '\n",
      " 'interventions sex transm  infect 200985508–13 pmid19703844 httpsdoiorg101136 '\n",
      " 'sti2009037028 1262 lin l benard vb greek a roland kb hawkins na saraiya m  '\n",
      " 'communication practices about hpv testing among providers in  federally '\n",
      " 'qualified health centers prev med rep 20152436–9  pmid26213683 '\n",
      " 'httpsdoiorg101016jpmedr201505006 1263 kapeu as luostarinen t jellum e et al '\n",
      " 'is smoking an independent  risk factor for invasive cervical cancer a nested '\n",
      " 'casecontrol  study within nordic biobanks am j epidemiol 2009169480–8  '\n",
      " 'pmid19074773 httpsdoiorg101093ajekwn354 1264 plummer m herrero r franceschi '\n",
      " 's et al iarc multicentre  cervical cancer study group smoking and cervical '\n",
      " 'cancer pooled  analysis of the iarc multicentric casecontrol study cancer  '\n",
      " 'causes control 200314805–14 pmid14682438 httpsdoi '\n",
      " 'org101023bcaco0000003811982613e 1265 de sanjosé s brotons m pavón ma the '\n",
      " 'natural history of human  papillomavirus infection best pract res clin '\n",
      " 'obstet gynaecol  2018472–13 pmid28964706 httpsdoiorg101016j bpobgyn201708015 '\n",
      " '1266 louie ks castellsague x de sanjose s et al international agency  for '\n",
      " 'research on cancer multicenter cervical cancer study group  smoking and '\n",
      " 'passive smoking in cervical cancer risk pooled analysis  of couples from the '\n",
      " 'iarc multicentric casecontrol studies cancer  epidemiol biomarkers prev '\n",
      " '2011201379–90 pmid21610224  httpsdoiorg10115810559965epi110284 1267 nelson '\n",
      " 'hd cantor a wagner j et al effectiveness of patient  navigation to increase '\n",
      " 'cancer screening in populations adversely  affected by health disparities a '\n",
      " 'metaanalysis j gen intern med  2020353026–35 pmid32700218 httpsdoiorg101007 '\n",
      " 's11606020060209 1268 stillson t knight al elswick rk jr the effectiveness '\n",
      " 'and safety  of two cervical cytologic techniques during pregnancy j fam '\n",
      " 'pract  199745159–63 pmid9267375 1269 foster jc smith hl use of the cytobrush '\n",
      " 'for papanicolaou smear  screens in pregnant women j nurse midwifery '\n",
      " '199641211–7  pmid8708804 httpsdoiorg1010160091218296000134 1270 paraiso mf '\n",
      " 'brady k helmchen r roat tw evaluation of the  endocervical cytobrush and '\n",
      " 'cervexbrush in pregnant women  obstet gynecol 199484539–43 pmid8090390 1271 '\n",
      " 'silverberg mj leyden wa chi a et al human immunodeficiency  virus hiv and '\n",
      " 'nonhivassociated immunosuppression and risk of  cervical neoplasia obstet '\n",
      " 'gynecol 201813147–55 pmid29215531  httpsdoiorg101097aog0000000000002371 1272 '\n",
      " 'videla s tarrats a ornelas a et al incidence of cervical high grade squamous '\n",
      " 'intraepithelial lesions in hiv1infected women  with no history of cervical '\n",
      " 'pathology up to 17 years of followup  int j std aids 20193056–63 '\n",
      " 'pmid30170532 httpsdoi org1011770956462418792653 1273 liu g sharma m tan n '\n",
      " 'barnabas rv hivpositive women have  higher risk of human papilloma virus '\n",
      " 'infection precancerous lesions  and cervical cancer aids 201832795–808 '\n",
      " 'pmid29369827  httpsdoiorg101097qad0000000000001765 1274 sawaya gf lamar r '\n",
      " 'perkins rb managing minimally abnormal  cervical cancer screening test '\n",
      " 'results jama 20203241557  pmid32975557 httpsdoiorg101001jama202012488 1275 '\n",
      " 'silverberg mj lau b justice ac et al north american aids cohort  '\n",
      " 'collaboration on research and design naaccord of iedea  risk of anal cancer '\n",
      " 'in hivinfected and hivuninfected individuals in  north america clin infect '\n",
      " 'dis 2012541026–34 pmid22291097  httpsdoiorg101093cidcir1012 1276 tomassi mj '\n",
      " 'abbas ma klaristenfeld dd expectant management  surveillance for patients at '\n",
      " 'risk for invasive squamous cell carcinoma  of the anus a large us healthcare '\n",
      " 'system experience int j colorectal  dis 20193447–54 pmid30244347 '\n",
      " 'httpsdoiorg101007 s0038401831677 1277 colónlópez v shiels ms machin m et al '\n",
      " 'anal cancer risk  among people with hiv infection in the united states j '\n",
      " 'clin  oncol 20183668–75 pmid29140774 httpsdoiorg101200 jco2017749291 1278 '\n",
      " 'machalek da grulich ae jin f templeton dj poynten im the  epidemiology and '\n",
      " 'natural history of anal human papillomavirus  infection in men who have sex '\n",
      " 'with men sex health 20129527–37  pmid23380235 httpsdoiorg101071sh12043 1279 '\n",
      " 'deshmukh aa suk r shiels ms et al recent trends in squamous cell  carcinoma '\n",
      " 'of the anus incidence and mortality in the united states  2001–2015 j natl '\n",
      " 'cancer inst 2020112829–38 pmid31742639  httpsdoiorg101093jncidjz219 1280 '\n",
      " 'edgren g sparén p risk of anogenital cancer after diagnosis of cervical  '\n",
      " 'intraepithelial neoplasia a prospective populationbased study lancet  oncol '\n",
      " '20078311–6 pmid17395104 httpsdoiorg101016 s1470204507700438 1281 chaturvedi '\n",
      " 'ak engels ea gilbert es et al second cancers among  104760 survivors of '\n",
      " 'cervical cancer evaluation of longterm risk  j natl cancer inst '\n",
      " '2007991634–43 pmid17971527 httpsdoi org101093jncidjm201 1282 suk r mahale p '\n",
      " 'sonawane k et al trends in risks for second primary  cancers associated with '\n",
      " 'index human papillomavirusassociated  cancers jama netw open 20181e181999 '\n",
      " 'pmid30646145  httpsdoiorg101001jamanetworkopen20181999 1283 hillman rj '\n",
      " 'berrylawhorn jm ong jj et al international anal  neoplasia society '\n",
      " 'international anal neoplasia society guidelines  for the practice of digital '\n",
      " 'anal rectal examination j low genit tract  dis 201923138–46 pmid30907777 '\n",
      " 'httpsdoiorg101097 lgt0000000000000458 1284 ong jj grulich a walker s et al '\n",
      " 'baseline findings from the  anal cancer examination ace study screening '\n",
      " 'using digital  anorectal examination in hivpositive men who have sex with  '\n",
      " 'men j med screen 20162370–6 pmid26462726 httpsdoi org1011770969141315604658 '\n",
      " '1285 read tr vodstrcil l grulich ae et al acceptability of digital anal  '\n",
      " 'cancer screening examinations in hivpositive homosexual men hiv  med '\n",
      " '201314491–6 pmid23590621 httpsdoiorg101111 hiv12035 1286 jin f grulich ae '\n",
      " 'poynten im et al spanc study team the  performance of anal cytology as a '\n",
      " 'screening test for anal hsils  in homosexual men cancer cytopathol '\n",
      " '2016124415–24  pmid26915346 httpsdoiorg101002cncy21702 1287 silva m peixoto '\n",
      " 'a sarmento ja coelho r macedo g anal cytology  histopathology and anoscopy '\n",
      " 'in an anal dysplasia screening program  is anal cytology enough rev esp '\n",
      " 'enferm dig 2018110109–14  pmid29168646 httpsdoiorg1017235reed201856782018 '\n",
      " '1288 iribarren díaz m ocampo hermida a gonzálezcarreró fojón  j et al '\n",
      " 'preliminary results of a screening program for anal cancer  and its '\n",
      " 'precursors for hivinfected men who have sex with men  in vigospain spanish '\n",
      " 'rev esp enferm dig 2017109242–9  pmid28229612 '\n",
      " 'httpsdoiorg1017235reed201742742016 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids20207671doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids20207671doptabstract '\n",
      " 'httpsdoiorg1011771359105309351249 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids19703844doptabstract '\n",
      " 'httpsdoiorg101136sti2009037028 httpsdoiorg101136sti2009037028 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids26213683doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids26213683doptabstract '\n",
      " 'httpsdoiorg101016jpmedr201505006 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids19074773doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids19074773doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids14682438doptabstract '\n",
      " 'httpsdoiorg101023bcaco0000003811982613e '\n",
      " 'httpsdoiorg101023bcaco0000003811982613e '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28964706doptabstract '\n",
      " 'httpsdoiorg101016jbpobgyn201708015 httpsdoiorg101016jbpobgyn201708015 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids21610224doptabstract '\n",
      " 'httpsdoiorg10115810559965epi110284 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids32700218doptabstract '\n",
      " 'httpsdoiorg101007s11606020060209 httpsdoiorg101007s11606020060209 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids9267375doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids8708804doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids8708804doptabstract '\n",
      " 'httpsdoiorg1010160091218296000134 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids8090390doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29215531doptabstract '\n",
      " 'httpsdoiorg101097aog0000000000002371 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30170532doptabstract '\n",
      " 'httpsdoiorg1011770956462418792653 httpsdoiorg1011770956462418792653 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29369827doptabstract '\n",
      " 'httpsdoiorg101097qad0000000000001765 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids32975557doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids32975557doptabstract '\n",
      " 'httpsdoiorg101001jama202012488 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids22291097doptabstract '\n",
      " 'httpsdoiorg101093cidcir1012 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30244347doptabstract '\n",
      " 'httpsdoiorg101007s0038401831677 httpsdoiorg101007s0038401831677 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29140774doptabstract '\n",
      " 'httpsdoiorg101200jco2017749291 httpsdoiorg101200jco2017749291 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids23380235doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids23380235doptabstract '\n",
      " 'httpsdoiorg101071sh12043 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids31742639doptabstract '\n",
      " 'httpsdoiorg101093jncidjz219 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids17395104doptabstract '\n",
      " 'httpsdoiorg101016s1470204507700438 httpsdoiorg101016s1470204507700438 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids17971527doptabstract '\n",
      " 'httpsdoiorg101093jncidjm201 httpsdoiorg101093jncidjm201 '\n",
      " 'httpsdoiorg101001jamanetworkopen20181999 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30907777doptabstract '\n",
      " 'httpsdoiorg101097lgt0000000000000458 httpsdoiorg101097lgt0000000000000458 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids26462726doptabstract '\n",
      " 'httpsdoiorg1011770969141315604658 httpsdoiorg1011770969141315604658 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids23590621doptabstract '\n",
      " 'httpsdoiorg101111hiv12035 httpsdoiorg101111hiv12035 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids26915346doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids26915346doptabstract '\n",
      " 'httpsdoiorg101002cncy21702 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29168646doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29168646doptabstract '\n",
      " 'httpsdoiorg1017235reed201856782018 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28229612doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28229612doptabstract '\n",
      " 'httpsdoiorg1017235reed201742742016 recommendations and reports mmwr  july 23 '\n",
      " '2021  vol 70  no 4 179us department of health and human servicescenters for '\n",
      " 'disease control and prevention 1289 burgos j hernándezlosa j landolfi s et '\n",
      " 'al the role of oncogenic  human papillomavirus determination for diagnosis '\n",
      " 'of highgrade  anal intraepithelial neoplasia in hivinfected msm aids  '\n",
      " '2017312227–33 pmid28723712 httpsdoiorg101097 qad0000000000001605 1290 cheng '\n",
      " 'sh wang cc chang sl chu fy hsueh ym oncogenic  human papillomavirus is not '\n",
      " 'helpful for cytology screening of the  precursor lesions of anal cancers in '\n",
      " 'taiwanese men who are infected  with human immunodeficiency virus int j clin '\n",
      " 'oncol 201520943– 51 pmid25712159 httpsdoiorg101007s1014701508049 1291 '\n",
      " 'hidalgotenorio c riverorodriguez m gilanguita c et al the  role of '\n",
      " 'polymerase chain reaction of highrisk human papilloma virus  in the '\n",
      " 'screening of highgrade squamous intraepithelial lesions in the  anal mucosa '\n",
      " 'of human immunodeficiency viruspositive males having  sex with males plos '\n",
      " 'one 201510e0123590 pmid25849412  httpsdoiorg101371journalpone0123590 1292 '\n",
      " 'richel o de vries hj van noesel cj dijkgraaf mg prins jm  comparison of '\n",
      " 'imiquimod topical fluorouracil and electrocautery  for the treatment of anal '\n",
      " 'intraepithelial neoplasia in hivpositive  men who have sex with men an '\n",
      " 'openlabel randomised controlled  trial lancet oncol 201314346–53 '\n",
      " 'pmid23499546 httpsdoi org101016s1470204513700676 1293 goldstone se johnstone '\n",
      " 'aa moshier el longterm outcome  of ablation of anal highgrade squamous '\n",
      " 'intraepithelial lesions  recurrence and incidence of cancer dis colon '\n",
      " 'rectum  201457316–23 pmid24509453 httpsdoiorg101097 dcr0000000000000058 1294 '\n",
      " 'tong ww shepherd k garland s et al study of the prevention  of anal cancer '\n",
      " 'spanc team human papillomavirus 16specific  tcell responses and spontaneous '\n",
      " 'regression of anal highgrade  squamous intraepithelial lesions j infect dis '\n",
      " '2015211405–15  pmid25139018 httpsdoiorg101093infdisjiu461 1295 tong ww jin f '\n",
      " 'mchugh lc et al progression to and spontaneous  regression of highgrade anal '\n",
      " 'squamous intraepithelial lesions  in hivinfected and uninfected men aids '\n",
      " '2013272233–43  pmid24157904 httpsdoiorg101097qad0b013e3283633111 1296 shin '\n",
      " 'ec jeong sh natural history clinical manifestations and  pathogenesis of '\n",
      " 'hepatitis a cold spring harb perspect med  20188a031708 pmid29440324 '\n",
      " 'httpsdoiorg101101 cshperspecta031708 1297 nelson np weng mk hofmeister mg et '\n",
      " 'al prevention of hepatitis  a virus infection in the united states '\n",
      " 'recommendations of the  advisory committee on immunization practices 2020 '\n",
      " 'mmwr  recomm rep 202069no rr5 pmid32614811 httpsdoi org1015585mmwrrr6905a1 '\n",
      " '1298 foster ma hofmeister mg kupronis ba et al increase in hepatitis  a '\n",
      " 'virus infections—united states 2013–2018 mmwr morb  mortal wkly rep '\n",
      " '201968413–5 pmid31071072 httpsdoi org1015585mmwrmm6818a2 1299 bower wa '\n",
      " 'nainan ov han x margolis hs duration of  viremia in hepatitis a virus '\n",
      " 'infection j infect dis 200018212–7  pmid10882576 httpsdoiorg101086315701 '\n",
      " '1300 clemens r safary a hepburn a roche c stanbury wj andré fe  clinical '\n",
      " 'experience with an inactivated hepatitis a vaccine j infect dis  '\n",
      " '1995171suppl 1s44–9 pmid7876648 httpsdoiorg101093 infdis171supplement1s44 '\n",
      " '1301 sharapov um bulkow lr negus se et al persistence of hepatitis  a '\n",
      " 'vaccine induced seropositivity in infants and young children  by maternal '\n",
      " 'antibody status 10year followup hepatology  201256516–22 pmid22371069 '\n",
      " 'httpsdoiorg101002 hep25687 1302 mosites e gounder p snowball m et al '\n",
      " 'hepatitis a vaccine immune  response 22 years after vaccination j med virol '\n",
      " '2018901418–22  pmid29663458 httpsdoiorg101002jmv25197 1303 theeten h van '\n",
      " 'herck k van der meeren o crasta p van  damme p hens n longterm antibody '\n",
      " 'persistence after vaccination  with a 2dose havrix inactivated hepatitis a '\n",
      " 'vaccine 20 years of  observed data and longterm modelbased predictions '\n",
      " 'vaccine  2015335723–7 pmid26190091 httpsdoiorg101016j vaccine201507008 1304 '\n",
      " 'hens n habteab ghebretinsae a hardt k van damme p  van herck k model based '\n",
      " 'estimates of longterm persistence of  inactivated hepatitis a vaccineinduced '\n",
      " 'antibodies in adults vaccine  2014321507–13 pmid24508042 httpsdoiorg101016j '\n",
      " 'vaccine201310088 1305 mosites e seeman s negus s et al immunogenicity of the '\n",
      " 'hepatitis a  vaccine 20\\xa0years after infant immunization vaccine '\n",
      " '2020384940–3  pmid32535018 httpsdoiorg101016jvaccine202005069 1306 yin s '\n",
      " 'barker l ly kn et al susceptibility to hepatitis a virus  infection in the '\n",
      " 'united states 2007–2016 clin infect dis  202071e571–9 pmid32193542 '\n",
      " 'httpsdoiorg101093cid ciaa298 1307 moro pl arana j marquez pl et al is there '\n",
      " 'any harm in  administering extradoses of vaccine to a person excess doses '\n",
      " 'of  vaccine reported to the vaccine adverse event reporting system  vaers '\n",
      " '2007–2017 vaccine 2019373730–4 pmid31155414  '\n",
      " 'httpsdoiorg101016jvaccine201904088 1308 winokur pl stapleton jt '\n",
      " 'immunoglobulin prophylaxis for hepatitis  a clin infect dis 199214580–6 '\n",
      " 'pmid1554845 httpsdoi org101093clinids142580 1309 alter hj purcell rh gerin '\n",
      " 'jl et al transmission of hepatitis b  to chimpanzees by hepatitis b surface '\n",
      " 'antigenpositive saliva and  semen infect immun 197716928–33 pmid892901 '\n",
      " 'httpsdoi org101128iai1639289331977 1310 villarejos vm visoná ka gutiérrez a '\n",
      " 'rodríguez a role of saliva  urine and feces in the transmission of type b '\n",
      " 'hepatitis n engl j  med 19742911375–8 pmid4427641 httpsdoiorg101056 '\n",
      " 'nejm197412262912602 1311 busch k thimme r natural history of chronic '\n",
      " 'hepatitis b  virus infection med microbiol immunol berl 20152045–10  '\n",
      " 'pmid25540037 httpsdoiorg101007s0043001403697 1312 hyams kc risks of '\n",
      " 'chronicity following acute hepatitis b  virus infection a review clin infect '\n",
      " 'dis 199520992–1000  pmid7795104 httpsdoiorg101093clinids204992 1313 '\n",
      " 'goldstein st zhou f hadler sc bell bp mast ee margolis  hs a mathematical '\n",
      " 'model to estimate global hepatitis b disease  burden and vaccination impact '\n",
      " 'int j epidemiol 2005341329–39  pmid16249217 httpsdoiorg101093ijedyi206 1314 '\n",
      " 'thompson nd perz jf moorman ac holmberg sd nonhospital  health '\n",
      " 'careassociated hepatitis b and c virus transmission united  states 1998–2008 '\n",
      " 'ann intern med 200915033–9 pmid19124818  '\n",
      " 'httpsdoiorg10732600034819150120090106000007 1315 davis lg weber dj lemon sm '\n",
      " 'horizontal transmission of  hepatitis b virus lancet 19891889–93 pmid2564960 '\n",
      " 'https doiorg101016s0140673689928766 1316 martinson fe weigle ka royce ra '\n",
      " 'weber dj suchindran cm  lemon sm risk factors for horizontal transmission of '\n",
      " 'hepatitis b  virus in a rural district in ghana am j epidemiol '\n",
      " '1998147478–87  pmid9525535 httpsdoiorg101093oxfordjournalsajea009474 1317 '\n",
      " 'cdc healthcareassociated hepatitis b and c outbreaks ≥2 cases  reported to '\n",
      " 'the cdc 2008–2019 atlanta ga us department of  health and human services cdc '\n",
      " '2019 httpswwwcdcgov hepatitisoutbreakspdfshealthcareinvestigationtablepdf '\n",
      " '1318 schillie s harris a linkgelles r romero j ward j nelson n  '\n",
      " 'recommendations of the advisory committee on immunization  practices for use '\n",
      " 'of a hepatitis b vaccine with a novel adjuvant  mmwr morb mortal wkly rep '\n",
      " '201867455–8 pmid29672472  httpsdoiorg1015585mmwrmm6715a5 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28723712doptabstract '\n",
      " 'httpsdoiorg101097qad0000000000001605 httpsdoiorg101097qad0000000000001605 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids25712159doptabstract '\n",
      " 'httpsdoiorg101007s1014701508049 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids25849412doptabstract '\n",
      " 'httpsdoiorg101371journalpone0123590 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids23499546doptabstract '\n",
      " 'httpsdoiorg101016s1470204513700676 httpsdoiorg101016s1470204513700676 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids24509453doptabstract '\n",
      " 'httpsdoiorg101097dcr0000000000000058 httpsdoiorg101097dcr0000000000000058 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids25139018doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids25139018doptabstract '\n",
      " 'httpsdoiorg101093infdisjiu461 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids24157904doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids24157904doptabstract '\n",
      " 'httpsdoiorg101097qad0b013e3283633111 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29440324doptabstract '\n",
      " 'httpsdoiorg101101cshperspecta031708 httpsdoiorg101101cshperspecta031708 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids32614811doptabstract '\n",
      " 'httpsdoiorg1015585mmwrrr6905a1 httpsdoiorg1015585mmwrrr6905a1 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids31071072doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids10882576doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids10882576doptabstract '\n",
      " 'httpsdoiorg101086315701 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids7876648doptabstract '\n",
      " 'httpsdoiorg101093infdis171supplement1s44 '\n",
      " 'httpsdoiorg101093infdis171supplement1s44 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids22371069doptabstract '\n",
      " 'httpsdoiorg101002hep25687 httpsdoiorg101002hep25687 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29663458doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29663458doptabstract '\n",
      " 'httpsdoiorg101002jmv25197 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids26190091doptabstract '\n",
      " 'httpsdoiorg101016jvaccine201507008 httpsdoiorg101016jvaccine201507008 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids24508042doptabstract '\n",
      " 'httpsdoiorg101016jvaccine201310088 httpsdoiorg101016jvaccine201310088 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids32535018doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids32535018doptabstract '\n",
      " 'httpsdoiorg101016jvaccine202005069 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids32193542doptabstract '\n",
      " 'httpsdoiorg101093cidciaa298 httpsdoiorg101093cidciaa298 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids31155414doptabstract '\n",
      " 'httpsdoiorg101016jvaccine201904088 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids1554845doptabstract '\n",
      " 'httpsdoiorg101093clinids142580 httpsdoiorg101093clinids142580 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids892901doptabstract '\n",
      " 'httpsdoiorg101128iai1639289331977 httpsdoiorg101128iai1639289331977 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids4427641doptabstract '\n",
      " 'httpsdoiorg101056nejm197412262912602 httpsdoiorg101056nejm197412262912602 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids25540037doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids25540037doptabstract '\n",
      " 'httpsdoiorg101007s0043001403697 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids7795104doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids7795104doptabstract '\n",
      " 'httpsdoiorg101093clinids204992 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids16249217doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids16249217doptabstract '\n",
      " 'httpsdoiorg101093ijedyi206 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids19124818doptabstract '\n",
      " 'httpsdoiorg10732600034819150120090106000007 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids2564960doptabstract '\n",
      " 'httpsdoiorg101016s0140673689928766 httpsdoiorg101016s0140673689928766 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids9525535doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids9525535doptabstract '\n",
      " 'httpsdoiorg101093oxfordjournalsajea009474 '\n",
      " 'httpswwwcdcgovhepatitisoutbreakspdfshealthcareinvestigationtablepdf '\n",
      " 'httpswwwcdcgovhepatitisoutbreakspdfshealthcareinvestigationtablepdf '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29672472doptabstract '\n",
      " 'httpsdoiorg1015585mmwrmm6715a5 recommendations and reports 180 mmwr  july 23 '\n",
      " '2021  vol 70  no 4 us department of health and human servicescenters for '\n",
      " 'disease control and prevention 1319 lu pj byrd kk murphy tv weinbaum c '\n",
      " 'hepatitis b vaccination  coverage among highrisk adults 18–49 years us 2009 '\n",
      " 'vaccine  2011297049–57 pmid21782873 httpsdoiorg101016j vaccine201107030 1320 '\n",
      " 'williams ww lu pj o’halloran a et al surveillance of vaccination  coverage '\n",
      " 'among adult populations—united states 2015 mmwr  surveill summ 201766no ss11 '\n",
      " 'pmid28472027 httpsdoi org1015585mmwrss6611a1 1321 cdc hepatitis b '\n",
      " 'vaccination coverage among adults—united  states 2004 mmwr morb mortal wkly '\n",
      " 'rep 200655509–11  pmid16691181 1322 mackellar da valleroy la secura gm et al '\n",
      " 'young men’s  survey study group two decades after vaccine license hepatitis '\n",
      " 'b  immunization and infection among young men who have sex with  men am j '\n",
      " 'public health 200191965–71 pmid11392942 https doiorg102105ajph916965 1323 '\n",
      " 'terrault na lok asf mcmahon bj et al update on prevention  diagnosis and '\n",
      " 'treatment of chronic hepatitis b aasld 2018 hepatitis  b guidance hepatology '\n",
      " '2018671560–99 pmid29405329 https doiorg101002hep29800 1324 ezeanolue e '\n",
      " 'harriman k hunter p kroger a pellegrini c general  best practice guidelines '\n",
      " 'for immunization best practices guidance  of the advisory committee on '\n",
      " 'immunization practices acip  internet atlanta ga us department of health and '\n",
      " 'human  services cdc advisory committee on immunization practices  2020 '\n",
      " 'httpswwwcdcgovvaccineshcpaciprecsgeneralrecs downloadsgeneralrecspdf 1325 '\n",
      " 'bruce mg bruden d hurlburt d et al antibody levels and  protection after '\n",
      " 'hepatitis b vaccine results of a 30year followup  study and response to a '\n",
      " 'booster dose j infect dis 201621416–22  pmid26802139 '\n",
      " 'httpsdoiorg101093infdisjiv748 1326 mcmahon bj bulkow lr singleton rj et al '\n",
      " 'elimination of  hepatocellular carcinoma and acute hepatitis b in children '\n",
      " '25 years  after a hepatitis b newborn and catchup immunization program  '\n",
      " 'hepatology 201154801–7 pmid21618565 httpsdoi org101002hep24442 1327 simons '\n",
      " 'bc spradling pr bruden dj et al a longitudinal hepatitis  b vaccine cohort '\n",
      " 'demonstrates longlasting hepatitis b virus hbv  cellular immunity despite '\n",
      " 'loss of antibody against hbv surface  antigen j infect dis 2016214273–80 '\n",
      " 'pmid27056956 https doiorg101093infdisjiw142 1328 bohlke k davis rl marcy sm '\n",
      " 'et al vaccine safety datalink team  risk of anaphylaxis after vaccination of '\n",
      " 'children and adolescents  pediatrics 2003112815–20 pmid14523172 httpsdoi '\n",
      " 'org101542peds1124815 1329 andré fe summary of safety and efficacy data on a '\n",
      " 'yeastderived  hepatitis b vaccine am j med 1989873a14s–20 pmid2528292  '\n",
      " 'httpsdoiorg1010160002934389905251 1330 abara we qaseem a schillie s mcmahon '\n",
      " 'bj harris am high  value care task force of the american college of '\n",
      " 'physicians and the  centers for disease control and prevention hepatitis b '\n",
      " 'vaccination  screening and linkage to care best practice advice from the '\n",
      " 'american  college of physicians and the centers for disease control and  '\n",
      " 'prevention ann intern med 2017167794–804 pmid29159414  '\n",
      " 'httpsdoiorg107326m171106 1331 minuk gy bohme ce bowen tj et al efficacy of '\n",
      " 'commercial  condoms in the prevention of hepatitis b virus infection  '\n",
      " 'gastroenterology 198793710–4 pmid3040512 httpsdoi org1010160016508587904318 '\n",
      " '1332 hofmeister mg rosenthal em barker lk et al estimating  prevalence of '\n",
      " 'hepatitis c virus infection in the united states 2013– 2016 hepatology '\n",
      " '2019691020–31 pmid30398671 httpsdoi org101002hep30297 1333 lockart i '\n",
      " 'matthews gv danta m sexually transmitted hepatitis c  infection the evolving '\n",
      " 'epidemic in hivpositive and hivnegative  msm curr opin infect dis 20193231–7 '\n",
      " 'pmid30531370 https doiorg101097qco0000000000000515 1334 terrault na dodge jl '\n",
      " 'murphy el et al sexual transmission of  hepatitis c virus among monogamous '\n",
      " 'heterosexual couples the hcv  partners study hepatology 201357881–9 '\n",
      " 'pmid23175457 https doiorg101002hep26164 1335 price jc mckinney je crouch pc '\n",
      " 'et al sexually acquired hepatitis  c infection in hivuninfected men who have '\n",
      " 'sex with men using  preexposure prophylaxis against hiv j infect dis '\n",
      " '20192191373–6  pmid30462305 httpsdoiorg101093infdisjiy670 1336 tohme ra '\n",
      " 'holmberg sd transmission of hepatitis c virus infection  through tattooing '\n",
      " 'and piercing a critical review clin infect dis  2012541167–78 pmid22291098 '\n",
      " 'httpsdoiorg101093cid cir991 1337 brettler db mannucci pm gringeri a et al '\n",
      " 'the low risk of  hepatitis c virus transmission among sexual partners of '\n",
      " 'hepatitis  cinfected hemophilic males an international multicenter study  '\n",
      " 'blood 199280540–3 pmid1627805 httpsdoiorg101182 bloodv802540540 1338 kao jh '\n",
      " 'hwang yt chen pj et al transmission of hepatitis c  virus between spouses '\n",
      " 'the important role of exposure duration am  j gastroenterol 1996912087–90 '\n",
      " 'pmid8855726 1339 fierer ds mullen mp dieterich dt isabel fiel m branch ad '\n",
      " 'early onset liver fibrosis due to primary hepatitis c virus infection is '\n",
      " 'higher  over time in hivinfected men clin infect dis 201255887–8  author '\n",
      " 'reply 888–9 pmid22677713 httpsdoiorg101093cid cis538 1340 van de laar tj van '\n",
      " 'der bij ak prins m et al increase in hcv  incidence among men who have sex '\n",
      " 'with men in amsterdam most  likely caused by sexual transmission j infect '\n",
      " 'dis 2007196230–8  pmid17570110 httpsdoiorg101086518796 1341 nijmeijer bm '\n",
      " 'koopsen j schinkel j prins m geijtenbeek tb  sexually transmitted hepatitis '\n",
      " 'c virus infections current trends and  recent advances in understanding the '\n",
      " 'spread in men who have sex with  men j int aids soc 201922suppl 6e25348 '\n",
      " 'pmid31468692  httpsdoiorg101002jia225348 1342 todesco e day n amiel c et al '\n",
      " 'high clustering of acute hcv  infections and high rate of associated stis '\n",
      " 'among parisian hiv positive male patients int j antimicrob agents '\n",
      " '201953678–81  pmid30742957 httpsdoiorg101016jijantimicag201902002 1343 jin f '\n",
      " 'matthews gv grulich ae sexual transmission of hepatitis c  virus among gay '\n",
      " 'and bisexual men a systematic review sex health  20171428–41 pmid27712618 '\n",
      " 'httpsdoiorg101071sh16141 1344 hegazi a lee mj whittaker w et al chemsex and '\n",
      " 'the city sexualised  substance use in gay bisexual and other men who have '\n",
      " 'sex with men  attending sexual health clinics int j std aids 201728362–6  '\n",
      " 'erratum in int j std aids 201728423 pmid27178067 https '\n",
      " 'doiorg1011770956462416651229 1345 page ee nelson m hepatitis c and sex clin '\n",
      " 'med lond  201616189–92 pmid27037392 httpsdoiorg107861 clinmedicine162189 '\n",
      " '1346 apers l vanden berghe w de wit s et al risk factors for hcv  '\n",
      " 'acquisition among hivpositive msm in belgium j acquir  immune defic syndr '\n",
      " '201568585–93 pmid25763786 https doiorg101097qai0000000000000528 1347 '\n",
      " 'daskalopoulou m rodger aj phillips an et al astra study  group condomless '\n",
      " 'sex in hivdiagnosed men who have sex with  men in the uk prevalence '\n",
      " 'correlates and implications for hiv  transmission sex transm infect '\n",
      " '201793590–8 pmid28679630  httpsdoiorg101136sextrans2016053029 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids21782873doptabstract '\n",
      " 'httpsdoiorg101016jvaccine201107030 httpsdoiorg101016jvaccine201107030 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28472027doptabstract '\n",
      " 'httpsdoiorg1015585mmwrss6611a1 httpsdoiorg1015585mmwrss6611a1 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids16691181doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids16691181doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids11392942doptabstract '\n",
      " 'httpsdoiorg102105ajph916965 httpsdoiorg102105ajph916965 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29405329doptabstract '\n",
      " 'httpsdoiorg101002hep29800 httpsdoiorg101002hep29800 '\n",
      " 'httpswwwcdcgovvaccineshcpaciprecsgeneralrecsdownloadsgeneralrecspdf '\n",
      " 'httpswwwcdcgovvaccineshcpaciprecsgeneralrecsdownloadsgeneralrecspdf '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids26802139doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids26802139doptabstract '\n",
      " 'httpsdoiorg101093infdisjiv748 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids21618565doptabstract '\n",
      " 'httpsdoiorg101002hep24442 httpsdoiorg101002hep24442 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids27056956doptabstract '\n",
      " 'httpsdoiorg101093infdisjiw142 httpsdoiorg101093infdisjiw142 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids14523172doptabstract '\n",
      " 'httpsdoiorg101542peds1124815 httpsdoiorg101542peds1124815 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids2528292doptabstract '\n",
      " 'httpsdoiorg1010160002934389905251 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29159414doptabstract '\n",
      " 'httpsdoiorg107326m171106 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids3040512doptabstract '\n",
      " 'httpsdoiorg1010160016508587904318 httpsdoiorg1010160016508587904318 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30398671doptabstract '\n",
      " 'httpsdoiorg101002hep30297 httpsdoiorg101002hep30297 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30531370doptabstract '\n",
      " 'httpsdoiorg101097qco0000000000000515 httpsdoiorg101097qco0000000000000515 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids23175457doptabstract '\n",
      " 'httpsdoiorg101002hep26164 httpsdoiorg101002hep26164 '\n",
      " 'httpsdoiorg101093infdisjiy670 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids22291098doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids1627805doptabstract '\n",
      " 'httpsdoiorg101182bloodv802540540 httpsdoiorg101182bloodv802540540 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids8855726doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids22677713doptabstract '\n",
      " 'httpsdoiorg101093cidcis538 httpsdoiorg101093cidcis538 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids17570110doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids17570110doptabstract '\n",
      " 'httpsdoiorg101086518796 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids31468692doptabstract '\n",
      " 'httpsdoiorg101002jia225348 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30742957doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30742957doptabstract '\n",
      " 'httpsdoiorg101016jijantimicag201902002 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids27712618doptabstract '\n",
      " 'httpsdoiorg101071sh16141 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids27178067doptabstract '\n",
      " 'httpsdoiorg1011770956462416651229 httpsdoiorg1011770956462416651229 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids27037392doptabstract '\n",
      " 'httpsdoiorg107861clinmedicine162189 httpsdoiorg107861clinmedicine162189 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids25763786doptabstract '\n",
      " 'httpsdoiorg101097qai0000000000000528 httpsdoiorg101097qai0000000000000528 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28679630doptabstract '\n",
      " 'httpsdoiorg101136sextrans2016053029 recommendations and reports mmwr  july '\n",
      " '23 2021  vol 70  no 4 181us department of health and human servicescenters '\n",
      " 'for disease control and prevention 1348 vanhommerig jw lambers fa schinkel j '\n",
      " 'et al mosaic msm  observational study of acute infection with hepatitis c '\n",
      " 'study  group risk factors for sexual transmission of hepatitis c virus '\n",
      " 'among  human immunodeficiency virusinfected men who have sex with  men a '\n",
      " 'casecontrol study open forum infect dis 20152ofv115  pmid26634219 '\n",
      " 'httpsdoiorg101093ofidofv115 1349 turner ss gianella s yip mj et al shedding '\n",
      " 'of hepatitis c virus in  semen of human immunodeficiency virusinfected men '\n",
      " 'open forum  infect dis 20163ofw057 1350 foster al gaisa mm hijdra rm et al '\n",
      " 'shedding of hepatitis c  virus into the rectum of hivinfected men who have '\n",
      " 'sex with men  clin infect dis 201764284–8 pmid28013267 httpsdoi '\n",
      " 'org101093cidciw740 1351 hammer gp kellogg ta mcfarland wc et al low '\n",
      " 'incidence and  prevalence of hepatitis c virus infection among sexually '\n",
      " 'active non intravenous drugusing adults san francisco 1997–2000 sex transm  '\n",
      " 'dis 200330919–24 pmid14646642 httpsdoiorg10109701 olq000009115231366e6 1352 '\n",
      " 'roy km goldberg dj hutchinson s cameron so wilson k  macdonald l hepatitis c '\n",
      " 'virus among self declared noninjecting  sexual partners of injecting drug '\n",
      " 'users j med virol 20047462–6  pmid15258969 httpsdoiorg101002jmv20146 1353 '\n",
      " 'mele a  stroffol ini  t  tost i  me et  a l   heterosexual  t r an smi s s i '\n",
      " 'on  o f  hepa t i t i s  c  in  it a l y  j  med  vi ro l  199957111–3 '\n",
      " 'pmid9892393 httpsdoiorg101002 sici10969071199902572111aidjmv430co2c 1354 '\n",
      " 'rauch a rickenbach m weber r et al swiss hiv cohort study  unsafe sex and '\n",
      " 'increased incidence of hepatitis c virus infection  among hivinfected men '\n",
      " 'who have sex with men the swiss hiv  cohort study clin infect dis '\n",
      " '200541395–402 pmid16007539  httpsdoiorg101086431486 1355 browne r asboe d '\n",
      " 'gilleece y et al increased numbers of acute  hepatitis c infections in hiv '\n",
      " 'positive homosexual men is sexual  transmission feeding the increase sex '\n",
      " 'transm infect 200480326–7  pmid15295139 httpsdoiorg101136sti2003008532 1356 '\n",
      " 'danta m brown d bhagani s et al hiv and acute hcv haac  group recent '\n",
      " 'epidemic of acute hepatitis c virus in hivpositive  men who have sex with '\n",
      " 'men linked to highrisk sexual behaviours  aids 200721983–91 pmid17457092 '\n",
      " 'httpsdoiorg101097 qad0b013e3281053a0c 1357 ghosn j   pierrefrançois  s  '\n",
      " 'thibault  v  et  a l   acute  hepatitis c in hivinfected men who have sex '\n",
      " 'with men  hiv med 20045303–6 pmid15236621 httpsdoi '\n",
      " 'org101111j14681293200400225x 1358 van de laar t pybus o bruisten s et al '\n",
      " 'evidence of a large  international network of hcv transmission in '\n",
      " 'hivpositive men  who have sex with men gastroenterology 20091361609–17  '\n",
      " 'pmid19422083 httpsdoiorg101053jgastro200902006 1359 hoornenborg e '\n",
      " 'achterbergh rca schim van der loeff mf et al  amsterdam prep project team in '\n",
      " 'the hiv transmission elimination  amsterdam initiative mosaic study group '\n",
      " 'msm starting  preexposure prophylaxis are at risk of hepatitis c virus '\n",
      " 'infection  aids 2017311603–10 pmid28657964 httpsdoiorg101097 '\n",
      " 'qad0000000000001522 1360 gras j mahjoub n charreau i et al ipergay study '\n",
      " 'group early  diagnosis and risk factors of acute hepatitis c in highrisk msm '\n",
      " 'on  preexposure prophylaxis aids 20203447–52 pmid31789889  '\n",
      " 'httpsdoiorg101097qad0000000000002364 1361 hoofnagle jh hepatitis c the '\n",
      " 'clinical spectrum of disease  hepatology 199726suppl 115s–20s pmid9305658 '\n",
      " 'https doiorg101002hep510260703 1362 orland jr wright tl cooper s acute '\n",
      " 'hepatitis c hepatology  200133321–7 pmid11172332 httpsdoiorg101053 '\n",
      " 'jhep200122112 1363 alter mj margolis hs krawczynski k et al the natural '\n",
      " 'history of  communityacquired hepatitis c in the united states the sentinel  '\n",
      " 'counties chronic nona nonb hepatitis study team n engl j  med '\n",
      " '19923271899–905 pmid1280771 httpsdoiorg101056 nejm199212313272702 1364 farci '\n",
      " 'p alter hj wong d et al a longterm study of hepatitis  c virus replication '\n",
      " 'in nona nonb hepatitis n engl j med  199132598–104 pmid1646962 '\n",
      " 'httpsdoiorg101056 nejm199107113250205 1365 liang tj rehermann b seeff lb '\n",
      " 'hoofnagle jh pathogenesis  natural history treatment and prevention of '\n",
      " 'hepatitis c ann  intern med 2000132296–305 pmid10681285 httpsdoi '\n",
      " 'org10732600034819132420000215000008 1366 thomas dl seeff lb natural history '\n",
      " 'of hepatitis c clin liver dis  20059383–98 vi pmid16023972 '\n",
      " 'httpsdoiorg101016j cld200505003 1367 westbrook rh dusheiko g natural history '\n",
      " 'of hepatitis c j  hepatol 201461suppls58–68 pmid25443346 httpsdoi '\n",
      " 'org101016jjhep201407012 1368 zou s stramer sl dodd ry donor testing and risk '\n",
      " 'current  prevalence incidence and residual risk of transfusiontransmissible  '\n",
      " 'agents in us allogeneic donations transfus med rev 201226119–28  '\n",
      " 'pmid21871776 httpsdoiorg101016jtmrv201107007 1369 bixler d annambholta p '\n",
      " 'abara we et al hepatitis b and c virus  infections transmitted through organ '\n",
      " 'transplantation investigated by  cdc united states 2014–2017 am j transplant '\n",
      " '2019192570–82  pmid30861300 httpsdoiorg101111ajt15352 1370 cdc testing for '\n",
      " 'hcv infection an update of guidance for clinicians  and laboratorians mmwr '\n",
      " 'morb mortal wkly rep 201362362–5  pmid23657112 1371 marincovich b castilla j '\n",
      " 'del romero j et al absence of hepatitis  c virus transmission in a '\n",
      " 'prospective cohort of heterosexual  serodiscordant couples sex transm infect '\n",
      " '200379160–2  pmid12690143 httpsdoiorg101136sti792160 1372 tahan v karaca c '\n",
      " 'yildirim b et al sexual transmission of hcv between  spouses am j '\n",
      " 'gastroenterol 2005100821–4 pmid15784025  '\n",
      " 'httpsdoiorg101111j15720241200540879x 1373 vandelli c renzo f romanò l et al '\n",
      " 'lack of evidence  of sexual transmission of hepatitis c among monogamous  '\n",
      " 'couples results of a 10year prospective followup study am  j gastroenterol '\n",
      " '200499855–9 pmid15128350 httpsdoi org101111j15720241200404150x 1374 fierer '\n",
      " 'ds uriel aj carriero dc et al liver fibrosis during an  outbreak of acute '\n",
      " 'hepatitis c virus infection in hivinfected  men a prospective cohort study j '\n",
      " 'infect dis 2008198683–6  pmid18627270 httpsdoiorg101086590430 1375 cottrell '\n",
      " 'eb chou r wasson n rahman b guise jm reducing  risk for mothertoinfant '\n",
      " 'transmission of hepatitis c virus a  systematic review for the us preventive '\n",
      " 'services task force ann  intern med 2013158109–13 pmid23437438 httpsdoi '\n",
      " 'org10732600034819158220130115000575 1376 mast ee hwang ly seto ds et al risk '\n",
      " 'factors for perinatal  transmission of hepatitis c virus hcv and the natural '\n",
      " 'history of  hcv infection acquired in infancy j infect dis 20051921880–9  '\n",
      " 'pmid16267758 httpsdoiorg101086497701 1377 barbosa c fraser h hoerger tj et '\n",
      " 'al costeffectiveness of scalingup  hcv prevention and treatment in the '\n",
      " 'united states for people who  inject drugs addiction 20191142267–78 '\n",
      " 'pmid31307116 https doiorg101111add14731 1378 lambers fa prins m thomas x et '\n",
      " 'al mosaic msm  observational study of acute infection with hepatitis c '\n",
      " 'study  group alarming incidence of hepatitis c virus reinfection after  '\n",
      " 'treatment of sexually acquired acute hepatitis c virus infection  in '\n",
      " 'hivinfected msm aids 201125f21–7 pmid21857492  '\n",
      " 'httpsdoiorg101097qad0b013e32834bac44 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids26634219doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids26634219doptabstract '\n",
      " 'httpsdoiorg101093ofidofv115 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28013267doptabstract '\n",
      " 'httpsdoiorg101093cidciw740 httpsdoiorg101093cidciw740 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids14646642doptabstract '\n",
      " 'httpsdoiorg10109701olq000009115231366e6 '\n",
      " 'httpsdoiorg10109701olq000009115231366e6 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids15258969doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids15258969doptabstract '\n",
      " 'httpsdoiorg101002jmv20146 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids9892393doptabstract '\n",
      " 'httpsdoiorg101002sici109690711999025723c111aidjmv43e30co2c '\n",
      " 'httpsdoiorg101002sici109690711999025723c111aidjmv43e30co2c '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids16007539doptabstract '\n",
      " 'httpsdoiorg101086431486 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids15295139doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids15295139doptabstract '\n",
      " 'httpsdoiorg101136sti2003008532 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids17457092doptabstract '\n",
      " 'httpsdoiorg101097qad0b013e3281053a0c httpsdoiorg101097qad0b013e3281053a0c '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids15236621doptabstract '\n",
      " 'httpsdoiorg101111j14681293200400225x httpsdoiorg101111j14681293200400225x '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids19422083doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids19422083doptabstract '\n",
      " 'httpsdoiorg101053jgastro200902006 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28657964doptabstract '\n",
      " 'httpsdoiorg101097qad0000000000001522 httpsdoiorg101097qad0000000000001522 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids31789889doptabstract '\n",
      " 'httpsdoiorg101097qad0000000000002364 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids9305658doptabstract '\n",
      " 'httpsdoiorg101002hep510260703 httpsdoiorg101002hep510260703 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids11172332doptabstract '\n",
      " 'httpsdoiorg101053jhep200122112 httpsdoiorg101053jhep200122112 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids1280771doptabstract '\n",
      " 'httpsdoiorg101056nejm199212313272702 httpsdoiorg101056nejm199212313272702 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids1646962doptabstract '\n",
      " 'httpsdoiorg101056nejm199107113250205 httpsdoiorg101056nejm199107113250205 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids10681285doptabstract '\n",
      " 'httpsdoiorg10732600034819132420000215000008 '\n",
      " 'httpsdoiorg10732600034819132420000215000008 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids16023972doptabstract '\n",
      " 'httpsdoiorg101016jcld200505003 httpsdoiorg101016jcld200505003 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids25443346doptabstract '\n",
      " 'httpsdoiorg101016jjhep201407012 httpsdoiorg101016jjhep201407012 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids21871776doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids21871776doptabstract '\n",
      " 'httpsdoiorg101016jtmrv201107007 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30861300doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30861300doptabstract '\n",
      " 'httpsdoiorg101111ajt15352 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids23657112doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids23657112doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids12690143doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids12690143doptabstract '\n",
      " 'httpsdoiorg101136sti792160 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids15784025doptabstract '\n",
      " 'httpsdoiorg101111j15720241200540879x httpsdoiorg101111j15720241200404150x '\n",
      " 'httpsdoiorg101111j15720241200404150x '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids18627270doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids18627270doptabstract '\n",
      " 'httpsdoiorg101086590430 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids23437438doptabstract '\n",
      " 'httpsdoiorg10732600034819158220130115000575 '\n",
      " 'httpsdoiorg10732600034819158220130115000575 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids16267758doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids16267758doptabstract '\n",
      " 'httpsdoiorg101086497701 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids31307116doptabstract '\n",
      " 'httpsdoiorg101111add14731 httpsdoiorg101111add14731 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids21857492doptabstract '\n",
      " 'httpsdoiorg101097qad0b013e32834bac44 recommendations and reports 182 mmwr  '\n",
      " 'july 23 2021  vol 70  no 4 us department of health and human servicescenters '\n",
      " 'for disease control and prevention 1379 martin tc singh gj mcclure m nelson '\n",
      " 'm hcv reinfection  among hivpositive men who have sex with men a pragmatic  '\n",
      " 'approach hepatology 2015611437 pmid25147047 httpsdoi org101002hep27391 1380 '\n",
      " 'ingiliz p martin tc rodger a et al neat study group hcv  reinfection '\n",
      " 'incidence and spontaneous clearance rates in hiv positive men who have sex '\n",
      " 'with men in western europe j hepatol  201766282–7 pmid27650285 '\n",
      " 'httpsdoiorg101016j jhep201609004 1381 briat a dulioust e galimand j et al '\n",
      " 'hepatitis c virus in the  semen of men coinfected with hiv1 prevalence and '\n",
      " 'origin aids  2005191827–35 pmid16227790 httpsdoiorg10109701 '\n",
      " 'aids0000189847985692d 1382 bissessor m fairley ck read t denham i bradshaw '\n",
      " 'c  chen m the etiology of infectious proctitis in men who have  sex with men '\n",
      " 'differs according to hiv status sex transm dis  201340768–70 pmid24275725 '\n",
      " 'httpsdoiorg101097 olq0000000000000022 1383 gutierrezfernandez j medina v '\n",
      " 'hidalgotenorio c abad r two  cases of neisseria meningitidis proctitis in '\n",
      " 'hivpositive men who have  sex with men emerg infect dis 201723542–3 '\n",
      " 'pmid28221124  httpsdoiorg103201eid2303161039 1384 levy i gefenhalevi s '\n",
      " 'nissan i et al delayed diagnosis of colorectal  sexually transmitted '\n",
      " 'diseases due to their resemblance to inflammatory  bowel diseases int j '\n",
      " 'infect dis 20187534–8 pmid30125691  httpsdoiorg101016jijid201808004 1385 '\n",
      " 'lebari d syphilis presenting as colorectal cancer abstract 34216  sex transm '\n",
      " 'dis 201441suppl 1s4 1386 hines jz pinsent t rees k et al notes from the '\n",
      " 'field shigellosis  outbreak among men who have sex with men and homeless  '\n",
      " 'persons—oregon 2015–2016 mmwr morb mortal wkly rep  201665812–3 pmid27513523 '\n",
      " 'httpsdoiorg1015585mmwr mm6531a5 1387 marchandsenécal x bekal s pilon pa '\n",
      " 'sylvestre jl gaudreau  c campylobacter fetus cluster among men who have sex '\n",
      " 'with  men montreal quebec canada 2014–2016 clin infect dis  2017651751–3 '\n",
      " 'pmid29020280 httpsdoiorg101093cid cix610 1388 klausner jd kohn r kent c '\n",
      " 'etiology of clinical proctitis among  men who have sex with men clin infect '\n",
      " 'dis 200438300–2  pmid14699467 httpsdoiorg101086380838 1389 stoner bp cohen '\n",
      " 'se lymphogranuloma venereum 2015 clinical  presentation diagnosis and '\n",
      " 'treatment clin infect dis 201561suppl  8s865–73 pmid26602624 '\n",
      " 'httpsdoiorg101093cidciv756 1390 mohrmann g noah c sabranski m sahly h '\n",
      " 'stellbrink hj  ongoing epidemic of lymphogranuloma venereum in hivpositive  '\n",
      " 'men who have sex with men how symptoms should guide treatment  j int aids '\n",
      " 'soc 201417suppl 319657 pmid25394161 https doiorg107448ias17419657 1391 '\n",
      " 'hoffmann c sahly h jessen a et al high rates of quinolone resistant strains '\n",
      " 'of shigella sonnei in hivinfected msm infection  201341999–1003 pmid23852945 '\n",
      " 'httpsdoiorg101007 s1501001305014 1392 heiman ke karlsson m grass j et al cdc '\n",
      " 'notes from the field  shigella with decreased susceptibility to azithromycin '\n",
      " 'among men  who have sex with men—united states 2002–2013 mmwr morb  mortal '\n",
      " 'wkly rep 201463132–3 pmid24522098 1393 galiczynski em jr elston dm what’s '\n",
      " 'eating you pubic lice pthirus  pubis cutis 200881109–14 pmid18441761 1394 '\n",
      " 'meinking tl serrano l hard b et al comparative in vitro  pediculicidal '\n",
      " 'efficacy of treatments in a resistant head lice  population in the united '\n",
      " 'states arch dermatol 2002138220–4  pmid11843643 '\n",
      " 'httpsdoiorg101001archderm1382220 1395 yoon ks gao jr lee sh clark jm brown l '\n",
      " 'taplin d permethrin resistant human head lice pediculus capitis and their '\n",
      " 'treatment  arch dermatol 2003139994–1000 pmid12925385 httpsdoi '\n",
      " 'org101001archderm1398994 1396 burkhart cg burkhart cn oral ivermectin for '\n",
      " 'phthirus pubis  j am acad dermatol 2004511037–8 pmid15583618 https '\n",
      " 'doiorg101016jjaad200404041 1397 scott gr chosidow o iustiwho european '\n",
      " 'guideline for  the management of pediculosis pubis 2010 int j std aids  '\n",
      " '201122304–5 pmid21680662 httpsdoiorg101258 ijsa2011011114 1398 goldust m '\n",
      " 'rezaee e raghifar r hemayat s comparing the efficacy  of oral ivermectin vs '\n",
      " 'malathion 05 lotion for the treatment of  scabies skinmed 201412284–7 '\n",
      " 'pmid25632646 1399 veraldi s schianchi r ramoni s nazzaro g pubic hair '\n",
      " 'removal  and phthirus pubis infestation int j std aids 201829103–4  '\n",
      " 'pmid29130406 httpsdoiorg1011770956462417740292 1400 leung akc lam jm leong '\n",
      " 'kf scabies a neglected global disease  curr pediatr rev 20201633–42 '\n",
      " 'pmid31544694 httpsdoiorg 1021741573396315666190717114131 1401 engelman d '\n",
      " 'cantey pt marks m et al the public health control  of scabies priorities for '\n",
      " 'research and action lancet 201939481–92  pmid31178154 '\n",
      " 'httpsdoiorg101016s0140673619311365 1402 shimose l munozprice ls diagnosis '\n",
      " 'prevention and treatment  of scabies curr infect dis rep 201315426–31 '\n",
      " 'pmid23904181  httpsdoiorg101007s1190801303540 1403 walter b heukelbach j '\n",
      " 'fengler g worth c hengge u feldmeier h  comparison of dermoscopy skin '\n",
      " 'scraping and the adhesive tape test  for the diagnosis of scabies in a '\n",
      " 'resourcepoor setting arch dermatol  2011147468–73 pmid21482897 '\n",
      " 'httpsdoiorg101001 archdermatol201151 1404 micali g lacarrubba f verzì ae '\n",
      " 'chosidow o schwartz ra  scabies advances in noninvasive diagnosis plos negl '\n",
      " 'trop dis  201610e0004691 pmid27311065 httpsdoiorg101371 journalpntd0004691 '\n",
      " '1405 strong m johnstone p interventions for treating scabies cochrane  '\n",
      " 'database syst rev 20073cd000320 pmid17636630 1406 abdelraheem ta méabed em '\n",
      " 'nasef ga abdel wahed wy  rohaim rm efficacy acceptability and cost '\n",
      " 'effectiveness of four  therapeutic agents for treatment of scabies j '\n",
      " 'dermatolog treat  201627473–9 pmid27027929 httpsdoiorg10310909546 '\n",
      " '63420161151855 1407 alipour h goldust m the efficacy of oral ivermectin vs '\n",
      " 'sulfur 10  ointment for the treatment of scabies ann parasitol 20156179–84  '\n",
      " 'pmid26342502 1408 al jaff daa amin mhm comparison of the effectiveness of '\n",
      " 'sulphur  ointment permethrin and oral ivermectin in treatment of scabies '\n",
      " 'res  j pharm biol chem sci 20189670–6 1409 goldust m rezaee e raghifar r '\n",
      " 'hemayat s treatment of scabies  the topical ivermectin vs permethrin 25 '\n",
      " 'cream ann parasitol  20135979–84 pmid24171301 1410 ahmad hm abdelazim es '\n",
      " 'abdelaziz rt clinical efficacy and  safety of topical versus oral ivermectin '\n",
      " 'in treatment of uncomplicated  scabies dermatol ther heidelb 20162958–63 '\n",
      " 'pmid26555785  httpsdoiorg101111dth12310 1411 currie bj mccarthy js '\n",
      " 'permethrin and ivermectin for scabies  n engl j med 2010362717–25 '\n",
      " 'pmid20181973 httpsdoi org101056nejmct0910329 1412 chiu s argaez c ivermectin '\n",
      " 'for parasitic skin infections of scabies  a review of comparative clinical '\n",
      " 'effectiveness costeffectiveness  and guidelines ottawa on canadian agency '\n",
      " 'for drugs and  technologies in health 2019 httpswwwncbinlmnihgovbooks '\n",
      " 'nbk545083 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids25147047doptabstract '\n",
      " 'httpsdoiorg101002hep27391 httpsdoiorg101002hep27391 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids27650285doptabstract '\n",
      " 'httpsdoiorg101016jjhep201609004 httpsdoiorg101016jjhep201609004 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids16227790doptabstract '\n",
      " 'httpsdoiorg10109701aids0000189847985692d '\n",
      " 'httpsdoiorg10109701aids0000189847985692d '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids24275725doptabstract '\n",
      " 'httpsdoiorg101097olq0000000000000022 httpsdoiorg101097olq0000000000000022 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28221124doptabstract '\n",
      " 'httpsdoiorg103201eid2303161039 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30125691doptabstract '\n",
      " 'httpsdoiorg101016jijid201808004 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids27513523doptabstract '\n",
      " 'httpsdoiorg1015585mmwrmm6531a5 httpsdoiorg1015585mmwrmm6531a5 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29020280doptabstract '\n",
      " 'httpsdoiorg101093cidcix610 httpsdoiorg101093cidcix610 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids14699467doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids14699467doptabstract '\n",
      " 'httpsdoiorg101086380838 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids26602624doptabstract '\n",
      " 'httpsdoiorg101093cidciv756 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids25394161doptabstract '\n",
      " 'httpsdoiorg107448ias17419657 httpsdoiorg107448ias17419657 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids23852945doptabstract '\n",
      " 'httpsdoiorg101007s1501001305014 httpsdoiorg101007s1501001305014 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids24522098doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids18441761doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids11843643doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids11843643doptabstract '\n",
      " 'httpsdoiorg101001archderm1382220 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids12925385doptabstract '\n",
      " 'httpsdoiorg101001archderm1398994 httpsdoiorg101001archderm1398994 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids15583618doptabstract '\n",
      " 'httpsdoiorg101016jjaad200404041 httpsdoiorg101016jjaad200404041 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids21680662doptabstract '\n",
      " 'httpsdoiorg101258ijsa2011011114 httpsdoiorg101258ijsa2011011114 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids25632646doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29130406doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29130406doptabstract '\n",
      " 'httpsdoiorg1011770956462417740292 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids31544694doptabstract '\n",
      " 'httpsdoiorg1021741573396315666190717114131 '\n",
      " 'httpsdoiorg1021741573396315666190717114131 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids31178154doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids31178154doptabstract '\n",
      " 'httpsdoiorg101016s0140673619311365 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids23904181doptabstract '\n",
      " 'httpsdoiorg101007s1190801303540 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids21482897doptabstract '\n",
      " 'httpsdoiorg101001archdermatol201151 httpsdoiorg101001archdermatol201151 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids27311065doptabstract '\n",
      " 'httpsdoiorg101371journalpntd0004691 httpsdoiorg101371journalpntd0004691 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids17636630doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids27027929doptabstract '\n",
      " 'httpsdoiorg1031090954663420161151855 httpsdoiorg1031090954663420161151855 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids26342502doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids26342502doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids24171301doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids26555785doptabstract '\n",
      " 'httpsdoiorg101111dth12310 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids20181973doptabstract '\n",
      " 'httpsdoiorg101056nejmct0910329 httpsdoiorg101056nejmct0910329 '\n",
      " 'httpswwwncbinlmnihgovbooksnbk545083 httpswwwncbinlmnihgovbooksnbk545083 '\n",
      " 'recommendations and reports mmwr  july 23 2021  vol 70  no 4 183us '\n",
      " 'department of health and human servicescenters for disease control and '\n",
      " 'prevention 1413 nolan  k  kamrath  j   lev i t t  j   l indane  tox i c i '\n",
      " 'ty   a  comprehensive review of the medical literature pediatr  dermatol '\n",
      " '201229141–6 pmid21995612 httpsdoi org101111j15251470201101519x 1414 mounsey '\n",
      " 'ke holt dc mccarthy j currie bj walton sf  scabies molecular perspectives '\n",
      " 'and therapeutic implications in the  face of emerging drug resistance future '\n",
      " 'microbiol 2008357–66  pmid18230034 httpsdoiorg102217174609133157 1415 '\n",
      " 'mounsey ke holt dc mccarthy js currie bj walton sf  longitudinal evidence of '\n",
      " 'increasing in vitro tolerance of scabies  mites to ivermectin in '\n",
      " 'scabiesendemic communities arch dermatol  2009145840–1 pmid19620572 '\n",
      " 'httpsdoiorg101001 archdermatol2009125 1416 mounsey ke mccarthy js walton sf '\n",
      " 'scratching the itch new tools  to advance understanding of scabies trends '\n",
      " 'parasitol 20132935–42  pmid23088958 httpsdoiorg101016jpt201209006 1417 van '\n",
      " 'der linden n van gool k gardner k et al a systematic review of  scabies '\n",
      " 'transmission models and data to evaluate the costeffectiveness  of scabies '\n",
      " 'interventions plos negl trop dis 201913e0007182  pmid30849124 '\n",
      " 'httpsdoiorg101371journalpntd0007182 1418 roberts lj huffam se walton sf '\n",
      " 'currie bj crusted scabies clinical  and immunological findings in '\n",
      " 'seventyeight patients and a review  of the literature j infect 200550375–81 '\n",
      " 'pmid15907543 https doiorg101016jjinf200408033 1419 ortegaloayza ag mccall co '\n",
      " 'nunley jr crusted scabies and  multiple dosages of ivermectin j drugs '\n",
      " 'dermatol 201312584–5  pmid23652958 1420 bouvresse s chosidow o scabies in '\n",
      " 'healthcare settings curr  opin infect dis 201023111–8 pmid20075729 httpsdoi '\n",
      " 'org101097qco0b013e328336821b 1421 marotta m toni f dallolio l toni g leoni e '\n",
      " 'management of a  family outbreak of scabies with high risk of spread to '\n",
      " 'other community  and hospital facilities am j infect control 201846808–13  '\n",
      " 'pmid29397231 httpsdoiorg101016jajic201712004 1422 romani l whitfeld mj '\n",
      " 'koroivueta j et al mass drug administration  for scabies control in a '\n",
      " 'population with endemic disease n engl j med  20153732305–13 pmid26650152 '\n",
      " 'httpsdoiorg101056 nejmoa1500987 1423 ackerman dr sugar nf fine dn eckert lo '\n",
      " 'sexual assault  victims factors associated with followup care am j obstet '\n",
      " 'gynecol  20061941653–9 pmid16635464 httpsdoiorg101016j ajog200603014 1424 '\n",
      " 'parekh v beaumont brown c follow up of patients who have  been recently '\n",
      " 'sexually assaulted sex transm infect 200379349  pmid12902602 '\n",
      " 'httpsdoiorg101136sti794349a 1425 vrees ra evaluation and management of '\n",
      " 'female victims of sexual  assault obstet gynecol surv 20177239–53 '\n",
      " 'pmid28134394  httpsdoiorg101097ogx0000000000000390 1426 unger er fajman nn '\n",
      " 'maloney em et al anogenital human  papillomavirus in sexually abused and '\n",
      " 'nonabused children a  multicenter study pediatrics 2011128e658–65 '\n",
      " 'pmid21844060  httpsdoiorg101542peds20102247 1427 kreimer ar rodriguez ac '\n",
      " 'hildesheim a et al cvt vaccine  group proofofprinciple evaluation of the '\n",
      " 'efficacy of fewer than  three doses of a bivalent hpv1618 vaccine j natl '\n",
      " 'cancer inst  20111031444–51 pmid21908768 httpsdoiorg101093jnci djr319 1428 '\n",
      " 'claydon e murphy s osborne em kitchen v smith jr harris  jr rape and hiv int '\n",
      " 'j std aids 19912200–1 pmid1863649  httpsdoiorg101177095646249100200310 1429 '\n",
      " 'murphy s kitchen v harris jr forster sm rape and subsequent  seroconversion '\n",
      " 'to hiv bmj 1989299718 pmid2508885 https doiorg101136bmj2996701718 1430 cardo '\n",
      " 'dm culver dh ciesielski ca et al cdc needlestick  surveillance group a '\n",
      " 'casecontrol study of hiv seroconversion  in health care workers after '\n",
      " 'percutaneous exposure n engl j med  19973371485–90 pmid9366579 '\n",
      " 'httpsdoiorg101056 nejm199711203372101 1431 kuhar dt henderson dk struble ka '\n",
      " 'et al us public health  service working group updated us public health '\n",
      " 'service  guidelines for the management of occupational exposures to human  '\n",
      " 'immunodeficiency virus and recommendations for postexposure  prophylaxis '\n",
      " 'infect control hosp epidemiol 201334875–92  pmid23917901 '\n",
      " 'httpsdoiorg101086672271 1432 du mont j myhr tl husson h macdonald s rachlis '\n",
      " 'a loutfy  mr hiv postexposure prophylaxis use among ontario female  '\n",
      " 'adolescent sexual assault victims a prospective analysis sex transm  dis '\n",
      " '200835973–8 pmid18836390 1433 neu n heffernanvacca s millery m stimell m '\n",
      " 'brown j  postexposure prophylaxis for hiv in children and adolescents after  '\n",
      " 'sexual assault a prospective observational study in an urban medical  center '\n",
      " 'sex transm dis 20073465–8 pmid16794560 httpsdoi '\n",
      " 'org10109701olq000022532907765d8 1434 loutfy mr macdonald s myhr t et al '\n",
      " 'prospective cohort study of  hiv postexposure prophylaxis for sexual assault '\n",
      " 'survivors antivir  ther 20081387–95 pmid18389902 1435 inciarte a leal l '\n",
      " 'masfarre l et al sexual assault victims study  group postexposure '\n",
      " 'prophylaxis for hiv infection in sexual assault  victims hiv med 20202143–52 '\n",
      " 'pmid31603619 httpsdoi org101111hiv12797 1436 announcement updated guidelines '\n",
      " 'for antiretroviral postexposure  prophylaxis after sexual injectiondrug use '\n",
      " 'or other nonoccupational  exposure to hiv—united states 2016 mmwr morb '\n",
      " 'mortal wkly  rep 201665458 pmid27149423 httpsdoiorg1015585 mmwrmm6517a5 1437 '\n",
      " 'ford n venter f irvine c beanland rl shubber z starter packs  versus full '\n",
      " 'prescription of antiretroviral drugs for postexposure  prophylaxis a '\n",
      " 'systematic review clin infect dis 201560suppl  3s182–6 pmid25972501 '\n",
      " 'httpsdoiorg101093cidciv093 1438 jenny c crawfordjakubiak je committee on '\n",
      " 'child abuse and  neglect american academy of pediatrics the evaluation of '\n",
      " 'children  in the primary care setting when sexual abuse is suspected '\n",
      " 'pediatrics  2013132e558–67 pmid23897912 httpsdoiorg101542 peds20131741 1439 '\n",
      " 'girardet rg lahoti s howard la et al epidemiology of  sexually transmitted '\n",
      " 'infections in suspected child victims of sexual  assault pediatrics '\n",
      " '200912479–86 pmid19564286 httpsdoi org101542peds20082947 1440 black cm '\n",
      " 'driebe em howard la et al multicenter study of nucleic  acid amplification '\n",
      " 'tests for detection of chlamydia trachomatis and  neisseria gonorrhoeae in '\n",
      " 'children being evaluated for sexual abuse  pediatr infect dis j 200928608–13 '\n",
      " 'pmid19451856 httpsdoi org101097inf0b013e31819b592e 1441 trotman ge '\n",
      " 'younganderson c deye kp acute sexual assault in  the pediatric and '\n",
      " 'adolescent population j pediatr adolesc gynecol  201629518–26 pmid26702774 '\n",
      " 'httpsdoiorg101016j jpag201505001 1442 schwandt a williams c beigi rh '\n",
      " 'perinatal transmission of  trichomonas vaginalis a case report j reprod med '\n",
      " '20085359–61  pmid18251366 1443 bell ta stamm we wang sp kuo cc holmes kk '\n",
      " 'grayston  jt chronic chlamydia trachomatis infections in infants jama  '\n",
      " '1992267400–2 pmid1727964 httpsdoiorg101001 jama199203480030078041 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids21995612doptabstract '\n",
      " 'httpsdoiorg101111j15251470201101519x httpsdoiorg101111j15251470201101519x '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids18230034doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids18230034doptabstract '\n",
      " 'httpsdoiorg102217174609133157 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids19620572doptabstract '\n",
      " 'httpsdoiorg101001archdermatol2009125 httpsdoiorg101001archdermatol2009125 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids23088958doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids23088958doptabstract '\n",
      " 'httpsdoiorg101016jpt201209006 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30849124doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids30849124doptabstract '\n",
      " 'httpsdoiorg101371journalpntd0007182 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids15907543doptabstract '\n",
      " 'httpsdoiorg101016jjinf200408033 httpsdoiorg101016jjinf200408033 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids23652958doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids23652958doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids20075729doptabstract '\n",
      " 'httpsdoiorg101097qco0b013e328336821b httpsdoiorg101097qco0b013e328336821b '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29397231doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29397231doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids26650152doptabstract '\n",
      " 'httpsdoiorg101056nejmoa1500987 httpsdoiorg101056nejmoa1500987 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids16635464doptabstract '\n",
      " 'httpsdoiorg101016jajog200603014 httpsdoiorg101016jajog200603014 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids12902602doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids12902602doptabstract '\n",
      " 'httpsdoiorg101136sti794349a '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28134394doptabstract '\n",
      " 'httpsdoiorg101097ogx0000000000000390 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids21844060doptabstract '\n",
      " 'httpsdoiorg101542peds20102247 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids21908768doptabstract '\n",
      " 'httpsdoiorg101093jncidjr319 httpsdoiorg101093jncidjr319 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids1863649doptabstract '\n",
      " 'httpsdoiorg101177095646249100200310 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids2508885doptabstract '\n",
      " 'httpsdoiorg101136bmj2996701718 httpsdoiorg101136bmj2996701718 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids9366579doptabstract '\n",
      " 'httpsdoiorg101056nejm199711203372101 httpsdoiorg101056nejm199711203372101 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids23917901doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids23917901doptabstract '\n",
      " 'httpsdoiorg101086672271 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids18836390doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids16794560doptabstract '\n",
      " 'httpsdoiorg10109701olq000022532907765d8 '\n",
      " 'httpsdoiorg10109701olq000022532907765d8 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids18389902doptabstract '\n",
      " 'httpsdoiorg101111hiv12797 httpsdoiorg101111hiv12797 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids27149423doptabstract '\n",
      " 'httpsdoiorg1015585mmwrmm6517a5 httpsdoiorg1015585mmwrmm6517a5 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids25972501doptabstract '\n",
      " 'httpsdoiorg101093cidciv093 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids23897912doptabstract '\n",
      " 'httpsdoiorg101542peds20131741 httpsdoiorg101542peds20131741 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids19564286doptabstract '\n",
      " 'httpsdoiorg101542peds20082947 httpsdoiorg101542peds20082947 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids19451856doptabstract '\n",
      " 'httpsdoiorg101097inf0b013e31819b592e httpsdoiorg101097inf0b013e31819b592e '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids26702774doptabstract '\n",
      " 'httpsdoiorg101016jjpag201505001 httpsdoiorg101016jjpag201505001 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids18251366doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids18251366doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids1727964doptabstract '\n",
      " 'httpsdoiorg101001jama199203480030078041 '\n",
      " 'httpsdoiorg101001jama199203480030078041 recommendations and reports 184 '\n",
      " 'mmwr  july 23 2021  vol 70  no 4 us department of health and human '\n",
      " 'servicescenters for disease control and prevention 1444 adachi k '\n",
      " 'nielsensaines k klausner jd chlamydia trachomatis  infection in pregnancy '\n",
      " 'the global challenge of preventing adverse  pregnancy and infant outcomes in '\n",
      " 'subsaharan africa and asia  biomed res int 201620169315757 pmid27144177 '\n",
      " 'httpsdoi org10115520169315757 1445 schachter j grossman m sweet rl holt j '\n",
      " 'jordan c bishop e  prospective study of perinatal transmission of chlamydia '\n",
      " 'trachomatis  jama 19862553374–7 pmid3712696 httpsdoiorg101001 '\n",
      " 'jama198603370240044034 1446 smith em swarnavel s ritchie jm wang d haugen th '\n",
      " 'turek  lp prevalence of human papillomavirus in the oral cavityoropharynx  '\n",
      " 'in a large population of children and adolescents pediatr infect  dis j '\n",
      " '200726836–40 pmid17721381 httpsdoiorg101097 inf0b013e318124a4ae 1447 sabeena '\n",
      " 's bhat p kamath v arunkumar g possible nonsexual  modes of transmission of '\n",
      " 'human papilloma virus j obstet gynaecol  res 201743429–35 pmid28165175 '\n",
      " 'httpsdoiorg101111 jog13248 1448 adams ja farst kj kellogg nd interpretation '\n",
      " 'of medical findings  in suspected child sexual abuse an update for 2018 j '\n",
      " 'pediatr  adolesc gynecol 201831225–31 pmid29294380 httpsdoi '\n",
      " 'org101016jjpag201712011 1449 kellogg nd melville jd lukefahr jl nienow sm '\n",
      " 'russell el  genital and extragenital gonorrhea and chlamydia in children  '\n",
      " 'and adolescents evaluated for sexual abuse pediatr emerg care  201834761–6 '\n",
      " 'pmid28072668 httpsdoiorg101097 pec0000000000001014 1450 gavril ar kellogg nd '\n",
      " 'nair p value of followup examinations  of children and adolescents evaluated '\n",
      " 'for sexual abuse and  assault pediatrics 2012129282–9 pmid22291113 httpsdoi '\n",
      " 'org101542peds20110804 1451 bandea ci joseph k secor ew et al development of '\n",
      " 'pcr assays  for detection of trichomonas vaginalis in urine specimens j '\n",
      " 'clin  microbiol 2013511298–300 pmid23390274 httpsdoi org101128jcm0310112 '\n",
      " '1452 gallion hr dupree lj scott ta arnold dh diagnosis of  trichomonas '\n",
      " 'vaginalis in female children and adolescents evaluated  for possible sexual '\n",
      " 'abuse a comparison of the inpouch tv culture  method and wet mount '\n",
      " 'microscopy j pediatr adolesc gynecol  200922300–5 pmid19576816 '\n",
      " 'httpsdoiorg101016j jpag200812006 1453 lalor k mcelvaney r child sexual abuse '\n",
      " 'links to later  sexual exploitationhighrisk sexual behavior and prevention '\n",
      " 'treatment programs trauma violence abuse 201011159–77  pmid20679329 '\n",
      " 'httpsdoiorg1011771524838010378299 1454 girardet rg lemme s biason ta bolton '\n",
      " 'k lahoti s hiv  postexposure prophylaxis in children and adolescents '\n",
      " 'presenting  for reported sexual assault child abuse negl 200933173–8  '\n",
      " 'pmid19324415 httpsdoiorg101016jchiabu200805010 1455 panel on antiretroviral '\n",
      " 'therapy and medical management of hiv infected children guidelines for the '\n",
      " 'use of antiretroviral agents in  pediatric hiv infection washington dc us '\n",
      " 'department of health  and human services national institutes of health '\n",
      " 'aidsinfo 2020  '\n",
      " 'httpsaidsinfonihgovcontentfileslvguidelinespediatricguidelinespdf '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids27144177doptabstract '\n",
      " 'httpsdoiorg10115520169315757 httpsdoiorg10115520169315757 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids3712696doptabstract '\n",
      " 'httpsdoiorg101001jama198603370240044034 '\n",
      " 'httpsdoiorg101001jama198603370240044034 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids17721381doptabstract '\n",
      " 'httpsdoiorg101097inf0b013e318124a4ae httpsdoiorg101097inf0b013e318124a4ae '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28165175doptabstract '\n",
      " 'httpsdoiorg101111jog13248 httpsdoiorg101111jog13248 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids29294380doptabstract '\n",
      " 'httpsdoiorg101016jjpag201712011 httpsdoiorg101016jjpag201712011 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids28072668doptabstract '\n",
      " 'httpsdoiorg101097pec0000000000001014 httpsdoiorg101097pec0000000000001014 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids22291113doptabstract '\n",
      " 'httpsdoiorg101542peds20110804 httpsdoiorg101542peds20110804 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids23390274doptabstract '\n",
      " 'httpsdoiorg101128jcm0310112 httpsdoiorg101128jcm0310112 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids19576816doptabstract '\n",
      " 'httpsdoiorg101016jjpag200812006 httpsdoiorg101016jjpag200812006 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids20679329doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids20679329doptabstract '\n",
      " 'httpsdoiorg1011771524838010378299 '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids19324415doptabstract '\n",
      " 'httpswwwncbinlmnihgoventrezqueryfcgicmdretrievedbpubmedlistuids19324415doptabstract '\n",
      " 'httpsdoiorg101016jchiabu200805010 '\n",
      " 'httpsaidsinfonihgovcontentfileslvguidelinespediatricguidelinespdf '\n",
      " 'recommendations and reports mmwr  july 23 2021  vol 70  no 4 185us '\n",
      " 'department of health and human servicescenters for disease control and '\n",
      " 'prevention sti treatment guidelines 2021 work group members chairperson '\n",
      " 'kimberly a workowski md national center for hivaids viral hepatitis std and '\n",
      " 'tb prevention cdc and emory university  atlanta georgia work group members '\n",
      " 'elizabeth alderman md the children’s hospital at montefiore the pediatric '\n",
      " 'hospital for albert einstein college of medicine  bronx new york lindley '\n",
      " 'barbee md university of washington and public health seattle and king county '\n",
      " 'std clinic seattle washington luis  barroso md wake forest baptist health '\n",
      " 'winstonsalem north carolina gale burstein md erie county department of '\n",
      " 'health buffalo new york  virginia a caine md marion county public health '\n",
      " 'department indiana university indianapolis indiana carla chibwesha md '\n",
      " 'university of north  carolina at chapel hill chapel hill north carolina '\n",
      " 'stephanie cohen md san francisco department of public health san francisco '\n",
      " 'california susan  cuuvin md brown university providence rhode island jodie '\n",
      " 'dionneodom md university of alabama at birmingham birmingham alabama julia  '\n",
      " 'dombrowski md public health seattle and king county university of washington '\n",
      " 'seattle washington carolyn gardella md veterans affairs puget  sound '\n",
      " 'university of washington seattle washington william m geisler md university '\n",
      " 'of alabama at birmingham birmingham alabama khalil g  ghanem md phd johns '\n",
      " 'hopkins university baltimore maryland matthew golden md seattle and king '\n",
      " 'county stdhiv program university of  washington seattle washington margaret '\n",
      " 'r hammerschlag md suny downstate medical center brooklyn new york h hunter '\n",
      " 'handsfield md  university of washington center for aids and std seattle '\n",
      " 'washington king k holmes md phd university of washington seattle washington  '\n",
      " 'edward w hook iii md university of alabama at birmingham birmingham alabama '\n",
      " 'katherine hsu md ratelle stdhiv prevention training  center massachusetts '\n",
      " 'department of public health boston massachusetts christine johnston md '\n",
      " 'university of washington seattle washington patricia  kissinger phd tulane '\n",
      " 'university school of public health and tropical medicine new orleans '\n",
      " 'louisiana jeffrey d klausner md university of california  los angeles los '\n",
      " 'angeles california lisa e manhart phd university of washington seattle '\n",
      " 'washington jeanne marrazzo md university of alabama at  birmingham '\n",
      " 'birmingham alabama david h martin md tulane university louisiana state '\n",
      " 'university health sciences center new orleans louisiana  leslie massad md '\n",
      " 'washington university st louis missouri kenneth h mayer md fenway health the '\n",
      " 'fenway institute harvard medical school  beth israel deaconess hospital '\n",
      " 'boston massachusetts candice mcneil md wake forest baptist health '\n",
      " 'alabamanorth carolina hivstd prevention  training center forsyth county '\n",
      " 'department of public health winstonsalem north carolina leandro mena md '\n",
      " 'university of mississippi medical  center jackson mississippi caroline '\n",
      " 'mitchell md vincent center for reproductive biology boston massachusetts '\n",
      " 'okeoma mmeje md university  of michigan ann arbor michigan annabarbara '\n",
      " 'moscicki md university of california los angeles los angeles california '\n",
      " 'christina a muzny md  university of alabama at birmingham birmingham alabama '\n",
      " 'natalie neu md columbia university new york new york paul nyirjesy md '\n",
      " 'sidney  kimmel medical college at thomas jefferson university philadelphia '\n",
      " 'pennsylvania jeff peipert md phd indiana university indianapolis indiana  '\n",
      " 'rebecca perkins md boston university boston massachusetts susan philip md '\n",
      " 'san francisco department of public health san francisco california  asa '\n",
      " 'radix md phd callenlorde community health center new york new york anne '\n",
      " 'rompalo md johns hopkins university baltimore maryland  sarah rudman md '\n",
      " 'county of santa clara public health department san jose california pablo j '\n",
      " 'sanchez md the ohio state university nationwide  children’s hospital '\n",
      " 'columbus ohio george sawaya md university of san francisco san francisco '\n",
      " 'california arlene seña md university of north  carolina at chapel hill and '\n",
      " 'durham county department of public health durham north carolina jeanne '\n",
      " 'sheffield md johns hopkins university  baltimore maryland jack sobel md '\n",
      " 'wayne state university detroit michigan david soper md medical university of '\n",
      " 'south carolina charleston south  carolina anne spaulding md emory university '\n",
      " 'atlanta georgia bradley stoner md phd washington university st louis '\n",
      " 'missouri stephanie taylor  md louisiana state university crescent care '\n",
      " 'sexual health center new orleans louisiana susan tuddenham md johns hopkins '\n",
      " 'university school  of medicine baltimore maryland karen wendel md denver '\n",
      " 'public health denver colorado harold c wiesenfeld md university of '\n",
      " 'pittsburgh  pittsburgh pennsylvania jonathan zenilman md johns hopkins '\n",
      " 'university baltimore maryland moderators philip chan md brown university '\n",
      " 'providence rhode island edward w hook iii md university of alabama at '\n",
      " 'birmingham birmingham  alabama christine johnston md university of '\n",
      " 'washington seattle washington david h martin md tulane university louisiana '\n",
      " 'state university  health sciences center new orleans louisiana jeanne '\n",
      " 'marrazzo md university of alabama at birmingham birmingham alabama christina '\n",
      " 'a muzny  md university of alabama at birmingham birmingham alabama ina park '\n",
      " 'md university of california san francisco san francisco california hilary  '\n",
      " 'reno md phd washington university st louis missouri jonathan zenilman md '\n",
      " 'johns hopkins university baltimore maryland rapporteurs philip chan md brown '\n",
      " 'university providence rhode island hilary reno md phd washington university '\n",
      " 'st louis missouri christine  johnston md university of washington seattle '\n",
      " 'washington christina a muzny md university of alabama at birmingham '\n",
      " 'birmingham alabama  ina park md university of california san francisco san '\n",
      " 'francisco california jonathan zenilman md johns hopkins university baltimore '\n",
      " 'maryland liaison participants jean anderson md cdchrsa advisory committee on '\n",
      " 'hiv viral hepatitis and std prevention and treatment johns hopkins  '\n",
      " 'university baltimore maryland kevin ault md american college of '\n",
      " 'obstetricians and gynecologists university of kansas lawrence kansas himani  '\n",
      " 'bisht phd food and drug administration silver spring maryland j quentin '\n",
      " 'clemens md american urological association university of michigan ann  arbor '\n",
      " 'michigan gina coleman md public health agency of canada ottawa ontario '\n",
      " 'carolyn deal phd national institute of allergy and infectious  diseases '\n",
      " 'bethesda maryland maeve b mello phd pan american health organizationworld '\n",
      " 'health organization washington dc diane foley md  us department of health '\n",
      " 'and human services washington dc michael ganio pharmd american society of '\n",
      " 'healthsystem pharmacists bethesda  maryland eric garges md us department of '\n",
      " 'defense arlington virginia and uniformed services university bethesda '\n",
      " 'maryland brent gibson md  national commission on correctional health care '\n",
      " 'chicago illinois william a glover ii phd association of public health '\n",
      " 'laboratories silver spring  maryland w david hardy md hiv medical '\n",
      " 'association johns hopkins university baltimore maryland david harvey '\n",
      " 'national coalition of std  directors washington dc letha healey md health '\n",
      " 'resources and services administration hivaids bureau rockville maryland '\n",
      " 'michael huey  md american college health association silver spring maryland '\n",
      " 'and emory university atlanta georgia gal mayer md glma health professionals  '\n",
      " 'advancing lgbtq equality washington dc sumathi nambiar md food and drug '\n",
      " 'administration silver spring maryland seema nayak md national  institutes of '\n",
      " 'health rockville maryland lori newman md national institute of allergy and '\n",
      " 'infectious diseases bethesda maryland samantha ritter  mph national '\n",
      " 'association of county and city health officials washington dc elizabeth '\n",
      " 'ruebush association of state and territorial health officials  arlington '\n",
      " 'virginia bisan salhi md phd american college of emergency physicians irving '\n",
      " 'texas emory university atlanta georgia natasha travis  md national medical '\n",
      " 'association silver spring maryland and johns hopkins university baltimore '\n",
      " 'maryland maria trent md society for adolescent  health and medicine chicago '\n",
      " 'illinois and johns hopkins university baltimore maryland julie vaishampayan '\n",
      " 'md infectious disease society of america  arlington virginia barbara van der '\n",
      " 'pol phd american sexually transmitted diseases association research triangle '\n",
      " 'park north carolina and university  of alabama at birmingham birmingham '\n",
      " 'alabama teodora elvira wi md department of global hiv hepatitis and sti '\n",
      " 'programmes world health  organization geneva switzerland recommendations and '\n",
      " 'reports 186 mmwr  july 23 2021  vol 70  no 4 us department of health and '\n",
      " 'human servicescenters for disease control and prevention cdc and outside cdc '\n",
      " 'consultants sevgi o aral phd laura h bachmann md kyle bernstein phd gail '\n",
      " 'bolan md john brooks md philip chan  md brown university providence rhode '\n",
      " 'island aaron harris md matthew hogben phd christine johnston md university '\n",
      " 'of washington seattle  washington sarah kidd md kristen kreisel phd lauri '\n",
      " 'markowitz md christina muzny md university of alabama at birmingham '\n",
      " 'birmingham  alabama ina park md university of california san francisco san '\n",
      " 'francisco california allan pillay phd laura quilter md hilary reno md phd  '\n",
      " 'washington university st louis missouri sancta st cyr md mona saraiya md '\n",
      " 'julie schillinger md virginia senkomago phd philip spradling  md phoebe '\n",
      " 'thorpe md mark weng md jonathan zenilman md johns hopkins university '\n",
      " 'baltimore maryland cdc division of sexually transmitted disease prevention '\n",
      " 'treatment guidelines 2021 project coordinator kimberly a workowski md '\n",
      " 'national  center for hivaids viral hepatitis std and tb prevention cdc and '\n",
      " 'emory university atlanta georgia cdc support staff alexandra coor mph '\n",
      " 'catherine carter quinn haaga amber herald patricia jackson brenda kelly '\n",
      " 'recommendations and reports mmwr  july 23 2021  vol 70  no 4 187us '\n",
      " 'department of health and human servicescenters for disease control and '\n",
      " 'prevention disclosure of relationships all sti treatment guidelines 2021 '\n",
      " 'work group members have completed and submitted the international committee '\n",
      " 'of medical journal editors form for  disclosure of potential conflicts of '\n",
      " 'interest lindley barbee received research support from hologic and speedx '\n",
      " 'and consults for nabriva christine johnston  received research funding from '\n",
      " 'sanofipasteur royalties from uptodate and personal fees from medpace gilead '\n",
      " 'abbvie and uptodate jeffrey klausner  received research supplies from '\n",
      " 'hologic cepheid and speedx advisory fees from shield diagnostics click '\n",
      " 'diagnostics and speedx and research funding  from abbvie and gilead sciences '\n",
      " 'lisa manhart received research supplies honoraria and research contracts '\n",
      " 'from hologic and served as a consultant to  diagnostic test manufacturers '\n",
      " 'speedx biofire diagnostics roche diagnostics and click diagnostics jeanne '\n",
      " 'marrazzo serves on expert advisory boards for  becton dickinson biofire '\n",
      " 'diagnostics and gilead sciences and has research and grant support and '\n",
      " 'supplies from merck  co and toltec david martin  served as a consultant in '\n",
      " '2019 to hologic which recently gained food and drug administration clearance '\n",
      " 'for a mycoplasma genitalium diagnostic test and  markets diagnostic tests '\n",
      " 'for gonorrhea chlamydia and trichomonas kenneth mayer serves on the '\n",
      " 'scientific advisory boards for gilead sciences and merck   co '\n",
      " 'pharmaceuticals and receives grant funds from gilead sciences leandro mena '\n",
      " 'received research funding through his institution from atlas genetics  '\n",
      " 'merck  co becton dickinson hologic biolytical and roche and received '\n",
      " 'consulting honoraria from roche molecular merck  co gilead sciences and  '\n",
      " 'viiv healthcare and from speaker bureaus for gilead sciences and viiv '\n",
      " 'healthcare caroline mitchell served as a consultant for lupin '\n",
      " 'pharmaceuticals and  scynexis and received grant funding from merck  co '\n",
      " 'christina a muzny served as a consultant and received research support from '\n",
      " 'lupin pharmaceuticals  for a randomized controlled trial of secnidazole '\n",
      " 'versus placebo for treatment of trichomoniasis and grants from the national '\n",
      " 'institutes of healthnational  institute of allergy and infectious diseases '\n",
      " 'was a speaker for abbott molecular cepheid and roche diagnostics on topics '\n",
      " 'related to stis received personal  fees from lupin pharmaceuticals phagomed '\n",
      " 'cepheid and beckton dickinson  and served as a consultant for biofire '\n",
      " 'diagnostics paul nyirjesy received  research support from mycovia '\n",
      " 'pharmaceuticals curatek pharmaceuticals scynexis and hologic and served as a '\n",
      " 'consultant for mycovia pharmaceuticals  hologic scynexis daré bioscience and '\n",
      " 'becton dickinson jeffery pepest serves on advisory boards for cooper '\n",
      " 'surgical and bayer and provides research support  to merck  co susan philip '\n",
      " 'is an unpaid public health advisor to glaxosmithkline anne rompalo serves on '\n",
      " 'the biofire diagnostics advisory board and  has financial ties to uptodate '\n",
      " 'hilary reno is a site principle investigator on a project evaluating the '\n",
      " 'prevalence of m genitalium funded by hologic funds  are allocated via her '\n",
      " 'institution arlene seña serves on a speaker’s bureau and scientific advisory '\n",
      " 'board for m genitalium at hologic works with the gilead  focus grant for '\n",
      " 'hepatitis c testing and linkage to care and mentored sancta st cyr md at the '\n",
      " 'university of north carolina division of infectious diseases  before '\n",
      " 'employment at cdc anne spaulding received consulting fees or honoraria '\n",
      " 'either directly or through third parties from gilead sciences merck   co and '\n",
      " 'abbvie and grants through her institution from gilead sciences and viiv '\n",
      " 'susan tuddenham served as a consultant for biofire diagnostics and roche  '\n",
      " 'molecular diagnostics and received a speaker honorarium from roche molecular '\n",
      " 'diagnostics karen wendel has stock ownership in pfizer issn 10575987 print '\n",
      " 'the morbidity and mortality weekly report mmwr series is prepared by the '\n",
      " 'centers for disease control and prevention cdc and is available free  of '\n",
      " 'charge in electronic format to receive an electronic copy each week visit '\n",
      " 'mmwr at httpswwwcdcgovmmwrindexhtml  readers who have difficulty accessing '\n",
      " 'this pdf file may access the html file at '\n",
      " 'httpswwwcdcgovmmwrvolumes70rrrr7004a1htms cidrr7004a1w address all inquiries '\n",
      " 'about the mmwr series to editorinchief mmwr series mailstop v255 cdc 1600 '\n",
      " 'clifton rd ne  atlanta ga 303294027 or to mmwrqcdcgov all material in the '\n",
      " 'mmwr series is in the public domain and may be used and reprinted without '\n",
      " 'permission citation as to source however is appreciated mmwr and morbidity '\n",
      " 'and mortality weekly report are service marks of the us department of health '\n",
      " 'and human services use of trade names and commercial sources is for '\n",
      " 'identification only and does not imply endorsement by the us department of '\n",
      " 'health and human services references to noncdc sites on the internet are '\n",
      " 'provided as a service to mmwr readers and do not constitute or imply '\n",
      " 'endorsement of these organizations  or their programs by cdc or the us '\n",
      " 'department of health and human services cdc is not responsible for the '\n",
      " 'content of these sites url addresses  listed in mmwr were current as of the '\n",
      " 'date of publication httpswwwcdcgovmmwrindexhtml '\n",
      " 'httpswwwcdcgovmmwrvolumes70rrrr7004a1htmscidrr7004a1w '\n",
      " 'httpswwwcdcgovmmwrvolumes70rrrr7004a1htmscidrr7004a1w mailtommwrqcdcgov \\t'\n",
      " 'sexually transmitted infections treatment guidelines 2021 \\tintroduction \\t'\n",
      " 'methods \\tclinical prevention guidance \\tsti detection among special '\n",
      " 'populations \\thiv infection \\tdiseases characterized by genital anal or '\n",
      " 'perianal ulcers \\tsyphilis \\tmanagement of persons who have a history of '\n",
      " 'penicillin allergy \\tdiseases characterized by urethritis and cervicitis \\t'\n",
      " 'chlamydial infections \\tgonococcal infections \\tmycoplasma genitalium \\t'\n",
      " 'diseases characterized by vulvovaginal itching burning irritation odor or '\n",
      " 'discharge \\tpelvic inflammatory disease \\tepididymitis \\thuman '\n",
      " 'papillomavirus infections \\tviral hepatitis \\tproctitis proctocolitis and '\n",
      " 'enteritis \\tectoparasitic infections \\tsexual assault and abuse and stis \\t'\n",
      " 'references')\n"
     ]
    }
   ],
   "source": [
    "# I can view the output of the STI string by using pprint\n",
    "pprint(sti_str)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Now I can write the text into a text file so that I can use it later-\n",
    "# to train my model\n",
    "with open('sti2021.txt', 'w', encoding=\"utf-8\") as text_file:\n",
    "    text_file.write(sti_str)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Now I will go ahead and train 3 unsupervised fast text models\n",
    "sti_model_10 = fasttext.train_unsupervised('data/sti2021.txt', epoch=10, dim=300)\n",
    "\n",
    "# save the trained model\n",
    "sti_model_10.save_model('sti2021_10.bin')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [],
   "source": [
    "sti_model_20 = fasttext.train_unsupervised('data/sti2021.txt', epoch=20, dim=300)\n",
    "\n",
    "# save the trained model\n",
    "sti_model_20.save_model('sti2021_20.bin')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [],
   "source": [
    "sti_model_50 = fasttext.train_unsupervised('data/sti2021.txt', epoch=50, dim=300)\n",
    "\n",
    "# save the trained model\n",
    "sti_model_50.save_model('sti2021_50.bin')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "C:\\Users\\muntanerl2\\AppData\\Local\\Temp\\1\\ipykernel_19180\\743768043.py:2: DeprecationWarning: Call to deprecated `load_fasttext_format` (use load_facebook_vectors (to use pretrained embeddings) or load_facebook_model (to continue training with the loaded full model, more RAM) instead).\n",
      "  ft_trained_model_10 = FastText.load_fasttext_format('data/sti2021_10.bin')\n",
      "C:\\Users\\muntanerl2\\AppData\\Local\\Temp\\1\\ipykernel_19180\\743768043.py:3: DeprecationWarning: Call to deprecated `load_fasttext_format` (use load_facebook_vectors (to use pretrained embeddings) or load_facebook_model (to continue training with the loaded full model, more RAM) instead).\n",
      "  ft_trained_model_20 = FastText.load_fasttext_format('data/sti2021_20.bin')\n",
      "C:\\Users\\muntanerl2\\AppData\\Local\\Temp\\1\\ipykernel_19180\\743768043.py:4: DeprecationWarning: Call to deprecated `load_fasttext_format` (use load_facebook_vectors (to use pretrained embeddings) or load_facebook_model (to continue training with the loaded full model, more RAM) instead).\n",
      "  ft_trained_model_50 = FastText.load_fasttext_format('data/sti2021_50.bin')\n"
     ]
    }
   ],
   "source": [
    "# Load models using genism's FastText\n",
    "ft_trained_model_10 = FastText.load_fasttext_format('data/sti2021_10.bin')\n",
    "ft_trained_model_20 = FastText.load_fasttext_format('data/sti2021_20.bin')\n",
    "ft_trained_model_50 = FastText.load_fasttext_format('data/sti2021_50.bin')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "For 10 epochs model[('chlamydia', 0.9944021105766296), ('chlamydial', 0.8954966068267822), ('gonorrhea', 0.810062050819397), ('trachomatis', 0.7779380083084106), ('149', 0.7044327259063721)]\n",
      "\n",
      "For 20 epochs model[('chlamydia', 0.9932137131690979), ('chlamydial', 0.8480893969535828), ('gonorrhea', 0.7431206107139587), ('trachomatis', 0.633487343788147), ('gonorrhoea', 0.563438355922699)]\n",
      "\n",
      "For 50 epochs model[('chlamydia', 0.9863393902778625), ('chlamydial', 0.6639330387115479), ('gonorrhea', 0.5729731321334839), ('trachomatis', 0.4673398435115814), ('≤35', 0.3125862777233124)]\n",
      "\n"
     ]
    }
   ],
   "source": [
    "# Now I will use the models to find the top 5 most similar words-\n",
    "# and confidence score to the clinical text\n",
    "print(\"For 10 epochs model{}\\n\" .format(ft_trained_model_10.wv.most_similar([\"Chlamydia\"], topn=5)))\n",
    "print(\"For 20 epochs model{}\\n\" .format(ft_trained_model_20.wv.most_similar([\"Chlamydia\"], topn=5)))\n",
    "print(\"For 50 epochs model{}\\n\" .format(ft_trained_model_50.wv.most_similar([\"Chlamydia\"], topn=5)))\n",
    "\n",
    "# *For chlamydia, there was no significant difference in the predictions of the models.\n",
    "# *All three were able to predict gonorrhea, and trachomatis as similar words. "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "For 10 epochs model[('tetracycline', 0.881211519241333), ('mg', 0.8328772783279419), ('500', 0.7964303493499756), ('800', 0.7955899238586426), ('1g', 0.7763998508453369)]\n",
      "\n",
      "For 20 epochs model[('tetracycline', 0.7427312135696411), ('azithromycin', 0.6004793047904968), ('100', 0.5848250985145569), ('timesday', 0.5741227269172668), ('cefoxitin', 0.5729455947875977)]\n",
      "\n",
      "For 50 epochs model[('tetracycline', 0.5282465815544128), ('100', 0.4659227132797241), ('azithromycin', 0.4103972613811493), ('efficacious', 0.3827889859676361), ('orally', 0.3694431483745575)]\n",
      "\n"
     ]
    }
   ],
   "source": [
    "# For doxycycline, the models predicted tetracycline and this makes sense because-\n",
    "# they belong to the same class of antibiotics and can be substituted in practice.\n",
    "print(\"For 10 epochs model{}\\n\" .format(ft_trained_model_10.wv.most_similar([\"doxycycline\"], topn=5)))\n",
    "print(\"For 20 epochs model{}\\n\" .format(ft_trained_model_20.wv.most_similar([\"doxycycline\"], topn=5)))\n",
    "print(\"For 50 epochs model{}\\n\" .format(ft_trained_model_50.wv.most_similar([\"doxycycline\"], topn=5)))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "For 10 epochs model[('doxycycline', 0.9831497669219971), ('tetracycline', 0.8936043977737427), ('mg', 0.8175896406173706), ('500', 0.7822662591934204), ('800', 0.7731585502624512)]\n",
      "\n",
      "For 20 epochs model[('doxycycline', 0.9771069884300232), ('tetracycline', 0.7636500000953674), ('decline', 0.6026915907859802), ('cefoxitin', 0.5819800496101379), ('azithromycin', 0.5721902847290039)]\n",
      "\n",
      "For 50 epochs model[('doxycycline', 0.9644572138786316), ('tetracycline', 0.6112635135650635), ('decline', 0.5081950426101685), ('100', 0.45984116196632385), ('efficacious', 0.41410011053085327)]\n",
      "\n"
     ]
    }
   ],
   "source": [
    "# Here I mispelled doxycycline and all 3 models were able to predict doxycycline and tetracycline-\n",
    "# as similar words. \n",
    "print(\"For 10 epochs model{}\\n\" .format(ft_trained_model_10.wv.most_similar([\"doxycline\"], topn=5)))\n",
    "print(\"For 20 epochs model{}\\n\" .format(ft_trained_model_20.wv.most_similar([\"doxycline\"], topn=5)))\n",
    "print(\"For 50 epochs model{}\\n\" .format(ft_trained_model_50.wv.most_similar([\"doxycline\"], topn=5)))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "For 10 epochs model azithromycin\n",
      "\n",
      "For 20 epochs model azithromycin\n",
      "\n",
      "For 50 epochs model azithromycin\n",
      "\n"
     ]
    }
   ],
   "source": [
    "# I will also apply the models to decide which word does not match in the series\n",
    "print(\"For 10 epochs model {}\\n\" .format(ft_trained_model_10.wv.doesnt_match([\"doxycycline\", \"tetracycline\", \"azithromycin\"])))\n",
    "print(\"For 20 epochs model {}\\n\" .format(ft_trained_model_20.wv.doesnt_match([\"doxycycline\", \"tetracycline\", \"azithromycin\"])))\n",
    "print(\"For 50 epochs model {}\\n\" .format(ft_trained_model_50.wv.doesnt_match([\"doxycycline\", \"tetracycline\", \"azithromycin\"])))\n",
    "\n",
    "# The model predicted azithromycin as the odd one out. \n",
    "# This is true, even though the 3 medications are antibiotics, azithromycin belongs to a different subclass."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "For 10 epochs model 0.4946211874485016\n",
      "\n",
      "For 20 epochs model 0.4388333559036255\n",
      "\n",
      "For 50 epochs model 0.33636391162872314\n",
      "\n"
     ]
    }
   ],
   "source": [
    "# Fast Text models can also be used to compare similarities with confidence scores\n",
    "print(\"For 10 epochs model {}\\n\" .format(ft_trained_model_10.wv.similarity(w1='drowsiness', w2='headache')))\n",
    "print(\"For 20 epochs model {}\\n\" .format(ft_trained_model_20.wv.similarity(w1='drowsiness', w2='headache')))\n",
    "print(\"For 50 epochs model {}\\n\" .format(ft_trained_model_50.wv.similarity(w1='drowsiness', w2='headache')))\n",
    "\n",
    "# Headache and drowsiness are common symptoms and when compared-\n",
    "# have very similar scores"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "For 10 epochs model 0.7411637306213379\n",
      "\n",
      "For 20 epochs model 0.6067762970924377\n",
      "\n",
      "For 50 epochs model 0.4368440508842468\n",
      "\n"
     ]
    }
   ],
   "source": [
    "# When discharge and itchig were comapred, there is similarity detected.\n",
    "# While the spellings are different, the contextual similarity exists. \n",
    "\n",
    "# If you think of STI's, they may cause itching and discharge\n",
    "print(\"For 10 epochs model {}\\n\" .format(ft_trained_model_10.wv.similarity(w1='discharge', w2='itching')))\n",
    "print(\"For 20 epochs model {}\\n\" .format(ft_trained_model_20.wv.similarity(w1='discharge', w2='itching')))\n",
    "print(\"For 50 epochs model {}\\n\" .format(ft_trained_model_50.wv.similarity(w1='discharge', w2='itching')))"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "base",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.9.15 (main, Nov 24 2022, 14:39:17) [MSC v.1916 64 bit (AMD64)]"
  },
  "orig_nbformat": 4,
  "vscode": {
   "interpreter": {
    "hash": "5e2cdc5d9691bd870c095a6750a79fad7d28161ac50b231754f6b2354bff69f6"
   }
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
